SLBBC PWID 2023 Report Annex

City-level Results: Vinnytsia



Figure A. RDS recruitment tree in Vinnytsia

1. Sociodemographic Information

Table 1.1. Sociodemographic Characteristics

	n	Mean	CI	Median	IQR
Age, years	500	40.9	(40.2–41.6)	40	(36–45)
Age of first non-injecting drug use	476	16.7	(16.3–17.1)	16	(14–18)
Years since the start of non-injecting drug use	476	24.0	(23.2–24.7)	24	(19–29)
Age of first injecting drug use	500	22.1	(21.5–22.7)	20	(18–25)
Years since the start of injecting drug use	500	18.8	(17.9–19.6)	19	(12–25)
Personal monthly income, UAH	473	10,716.1	(9774.7–11657.6)	9,000	(5000–15000)

Table 1.2. Descriptive Statistics for Sociodemographics

	Site	n	%	CI
Sex				
male	Vinnytsia	435	87.1	(83.7–89.9)
female	Vinnytsia	65	12.9	(10.1–16.3)
Age				
<25	Vinnytsia	8	1.6	(0.8–3.3)
25-34	Vinnytsia	75	15.3	(12.3–18.9)
35-44	Vinnytsia	280	55.4	(50.8–59.9)
45+	Vinnytsia	137	27.7	(23.7–32.0)
Family status				
married or living together	Vinnytsia	74	15.9	(12.7–19.7)
married but have another partner	Vinnytsia	30	5.7	(4.0–8.2)
not married but have a partner	Vinnytsia	118	24.4	(20.6–28.7)
married but not living together	Vinnytsia	19	3.6	(2.3–5.7)
not married and do not have a partner	Vinnytsia	259	50.3	(45.8–54.9)
Partnership status				
live alone	Vinnytsia	278	54.0	(49.4–58.5)
live with partner	Vinnytsia	222	46.0	(41.5–50.6)
Education				
incompl. high school	Vinnytsia	50	9.9	(7.5–12.9)
high school	Vinnytsia	172	34.7	(30.4–39.2)
>high school	Vinnytsia	278	55.5	(50.8–60.0)
Current occupation				
school student	Vinnytsia	0	0.0	
college/uni student	Vinnytsia	2	0.4	(0.1–1.7)
permanent job	Vinnytsia	152	31.9	(27.7–36.4)
sporadic jobs	Vinnytsia	239	46.8	(42.2–51.4)
unemployed	Vinnytsia	36	7.3	(5.2–10.1)
housewife	Vinnytsia	20	3.9	(2.5–6.1)
disabled	Vinnytsia	45	8.7	(6.5–11.5)
military	Vinnytsia	2	0.4	(0.1–1.4)
other	Vinnytsia	4	0.7	(0.3–1.9)
Homelessness				
never	Vinnytsia	440	87.4	(83.9–90.2)
yes, 12m+ ago	Vinnytsia	53	10.8	(8.3–14.0)
yes, in the past 12m	Vinnytsia	7	1.8	(0.8–4.0)
Homeless in 12 months (of those ever)				
no	Vinnytsia	53	85.7	(71.9–93.3)
yes	Vinnytsia	7	14.3	(6.7–28.1)
Monthly income category				
<3K	Vinnytsia	54	11.1	(8.5–14.4)
3-10K	Vinnytsia	187	39.5	(35.0–44.2)
10-20K	Vinnytsia	169	35.7	(31.3–40.3)

	Site	n	%	CI
≥20K	Vinnytsia	63	13.7	(10.7–17.4)
Monthly income relative to 2023 subsistence minimum				
<2684	Vinnytsia	47	9.7	(7.2–12.9)
≥2684	Vinnytsia	426	90.3	(87.1–92.8)
Years since the start of injecting drug use				
≤2	Vinnytsia	17	3.5	(2.2–5.6)
3-5	Vinnytsia	20	4.2	(2.7–6.6)
6-10	Vinnytsia	69	13.5	(10.7–16.9)
≥11	Vinnytsia	394	78.8	(74.9–82.3)

Table 1.3. Accommodation in the past 12 months

	Site	n	%	CI
own place	Vinnytsia	265	52.8	(48.2–57.4)
friends or relatives	Vinnytsia	183	36.3	(32.0–40.8)
renting	Vinnytsia	36	7.6	(5.5–10.4)
varying	Vinnytsia	12	2.5	(1.4–4.6)
on the street (homeless)	Vinnytsia	7	1.8	(0.8–4.0)
in a refugee shelter	Vinnytsia	1	0.2	(0.0–1.4)



Figure 1.1. Distribution of Age by Sex (%)



Figure 1.2. Trend in Sex Distribution by Survey Round (%)



Figure 1.3. Trend in Age Groups by Survey Round (%)

2. Drug Use



Figure 2.1. Injecting Drug Use in the Past 12 Months and 30 Days (%)



Figure 2.2. Non-injecting Drug Use in the Past 12 Months (%)



Figure 2.3. Trends in Injecting Drugs Types in the Past 30 Days by Survey Round (%)



Figure 2.4. Trends in Injecting Opioids in the Past 30 Days by Survey Round (%)



Figure 2.5. Trends in Injecting Stimulants in the Past 30 Days by Survey Round (%)



Figure 2.6. Trends in Injecting Other Drugs in the Past 30 Days by Survey Round (%)



Figure 2.7. Injecting Drug Preference (%)

Table 2.1. Types of Injecting Drugs in the Past 30 Days by Sociodemographic Characteristics

			Past 30 days injecting 4 categories								
		N	opioids		stimulants		opi+stimul		other		
			n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total											
	All	500	252	49.9 (45.3–54.5)	123	24.8 (21.1–29.0)	122	24.9 (21.1–29.1)	3	0.4 (0.1–1.2)	1.0000
Sex											
	male	435	216	49.4 (44.5–54.4)	102	23.3 (19.4–27.8)	114	26.7 (22.6–31.4)	3	0.5 (0.1–1.4)	0.0481
	female	65	36	52.9 (40.0–65.3)	21	34.8 (23.6–48.0)	8	12.3 (5.7–24.7)	0	0.0	
Age											
	<25	8	1	11.8 (1.0–63.0)	4	47.0 (13.7–83.2)	3	41.2 (10.5–80.6)	0	0.0	0.0969

	N	Past 30 days injecting 4 categories								
		opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
25-34	75	32	42.2 (31.1–54.2)	25	34.5 (24.0–46.7)	18	23.3 (14.7–34.8)	0	0.0	
35-44	280	146	51.4 (45.3–57.5)	66	23.6 (18.8–29.3)	68	24.9 (19.9–30.7)	0	0.0	
45+	137	73	53.3 (44.4–62.0)	28	20.5 (14.3–28.6)	33	24.7 (17.8–33.4)	3	1.5 (0.5–4.5)	
Years since the start of injecting drug use										
≤2	17	2	11.1 (2.4–38.1)	11	62.9 (36.0–83.6)	4	26.1 (9.2–55.1)	0	0.0	0.0140
3-5	20	9	36.8 (17.9–60.7)	7	42.7 (20.9–67.7)	4	20.6 (7.0–47.1)	0	0.0	
6-10	69	34	49.6 (37.4–61.8)	20	28.2 (18.5–40.4)	15	22.3 (13.4–34.7)	0	0.0	
≥11	394	207	52.4 (47.2–57.5)	85	21.6 (17.6–26.2)	99	25.5 (21.2–30.4)	3	0.5 (0.2–1.6)	
Partnership status										
live alone	278	143	52.9 (46.8–59.0)	66	22.9 (18.2–28.4)	67	23.7 (18.8–29.3)	2	0.5 (0.1–1.9)	0.4796
live with partner	222	109	46.3 (39.6–53.2)	57	27.0 (21.2–33.7)	55	26.3 (20.5–33.1)	1	0.3 (0.0–2.2)	
Current employment status										
full-time	152	66	42.0 (34.0–50.4)	45	28.3 (21.4–36.4)	41	29.7 (22.4–38.3)	0	0.0	0.3146
part-time or temporary	239	128	53.9 (47.2–60.4)	52	22.8 (17.6–28.9)	56	22.5 (17.5–28.5)	3	0.9 (0.3–2.7)	
unemployed	36	18	49.9 (32.6–67.2)	7	19.8 (9.2–37.8)	11	30.3 (16.3–49.3)	0	0.0	
disabled	45	28	62.7 (47.0–76.2)	9	19.0 (9.8–33.6)	8	18.3 (9.0–33.6)	0	0.0	
other	28	12	41.6 (24.3–61.3)	10	38.2 (21.2–58.7)	6	20.2 (8.9–39.7)	0	0.0	
Monthly income category										
<3K	54	32	56.1 (41.6–69.6)	11	21.7 (12.1–35.8)	11	22.2 (12.0–37.3)	0	0.0	0.8436
3-10K	187	92	50.6 (43.2–58.1)	43	24.3 (18.3–31.5)	49	24.0 (18.4–30.8)	3	1.1 (0.3–3.3)	
10-20K	169	80	46.6 (38.8–54.5)	43	24.7 (18.7–32.0)	46	28.7 (21.9–36.5)	0	0.0	
≥20K	63	34	49.7 (36.6–62.8)	17	26.5 (16.4–39.8)	12	23.9 (13.5–38.6)	0	0.0	
Ever incarcerated										
no	317	152	47.5 (41.8–53.3)	83	26.2 (21.4–31.6)	79	25.7 (20.8–31.2)	3	0.6 (0.2–2.0)	0.3753
yes	183	100	54.0 (46.4–61.4)	40	22.4 (16.6–29.5)	43	23.6 (17.7–30.6)	0	0.0	

Table 2.2. Types of Injecting Drugs in the Past 30 Days by Selected Subgroups

	N	Past 30 days injecting 4 categories								
		opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										

		Past 30 days injecting 4 categories								
	N	opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
no	455	233	50.8 (46.0–55.6)	110	24.3 (20.4–28.7)	109	24.5 (20.5–29.0)	3	0.4 (0.1–1.4)	0.5280
yes	45	19	40.2 (26.5–55.7)	13	30.5 (18.2–46.4)	13	29.3 (17.3–45.0)	0	0.0	
Treated with MAT currently (of all)										
no	479	237	48.8 (44.2–53.5)	121	25.5 (21.6–29.9)	118	25.2 (21.3–29.6)	3	0.4 (0.1–1.3)	0.0653
yes	21	15	75.4 (52.4–89.5)	2	7.5 (1.7–27.9)	4	17.1 (6.0–40.1)	0	0.0	
HIV test result										
positive	52	30	55.5 (40.6–69.5)	9	20.0 (10.2–35.4)	13	24.5 (13.9–39.5)	0	0.0	0.7543
negative	448	222	49.2 (44.4–54.0)	114	25.4 (21.4–29.9)	109	24.9 (20.9–29.4)	3	0.5 (0.1–1.4)	
Injecting drug type of choice										
opioids	334	248	73.5 (68.1–78.3)	0	0.0	86	26.5 (21.7–31.9)	0	0.0	0.0000
stimulants	160	2	0.9 (0.2–3.7)	122	76.7 (69.2–82.9)	36	22.3 (16.3–29.8)	0	0.0	
other	6	2	43.4 (7.5–87.8)	1	16.3 (1.1–76.8)	0	0.0	3	40.4 (7.5–84.9)	

Table 2.3. Injecting frequency

	Past 30 days injecting 4 categories								
	opioids		stimulants		opi+stimul		other		
	n	%	n	%	n	%	n	%	p-value
Injecting frequency: last 24 hrs									
0 times	83	33.2	67	55.3	38	30.9	2	65.3	0.0033
1 time	144	56.7	45	36.3	72	58.5	1	34.7	
2-3 times	23	9.2	8	5.9	10	9.4	0	0.0	
4+ times	2	0.9	3	2.5	2	1.3	0	0.0	
N	252		123		122		3		
Injecting frequency: last 24 hrs (among those who did)									
1 time	144	84.9	45	81.2	72	84.6	1	100.0	0.6900
2-3 times	23	13.8	8	13.1	10	13.5	0	0.0	
4+ times	2	1.3	3	5.6	2	1.9	0	0.0	
N	169		56		84		1		
Injecting frequency: last week									
0 times	8	3.3	7	5.9	3	3.2	0	0.0	0.0411
1-6 times	156	62.4	96	78.0	82	67.9	3	100.0	
every day	88	34.3	20	16.0	37	28.9	0	0.0	
N	252		123		122		3		
Injecting frequency: last 30 days									
1-9 times	55	22.1	58	47.2	16	14.5	2	65.3	0.0000
10-19 times	78	31.2	37	30.1	42	33.0	1	34.7	
20-29 times	50	20.1	12	9.3	32	27.4	0	0.0	
every day	69	26.6	16	13.4	32	25.1	0	0.0	
N	252		123		122		3		
Injecting frequency: main drug last 30 days									
0-9 times	54	21.8	57	46.8	14	12.9	2	65.3	0.0000
10-19 times	79	31.6	36	29.2	41	32.4	1	34.7	

	Past 30 days injecting 4 categories								
	opioids		stimulants		opi+stimul		other		
	n	%	n	%	n	%	n	%	p-value
20-29 times	49	19.8	12	9.3	34	28.7	0	0.0	
every day	70	26.9	18	14.8	33	26.0	0	0.0	
N	252		123		122		3		

Table 2.4. Injecting drug type of choice by Income Category

	Injecting drug type of choice					
	opioids		stimulants		other	
	n	%	n	%	n	%
Monthly income category						
<3K	37	11.0	15	10.2	2	43.4
3-10K	127	40.3	57	37.9	3	40.4
10-20K	110	35.2	58	37.3	1	16.3
≥20K	42	13.5	21	14.6	0	0.0
N	316		151		6	

Table 2.5. Sources of drugs by Drug Type of Choice

Total		Injecting drug type of choice						
All		opioids		stimulants		other		
n	%	n	%	n	%	n	%	p-value
prepare myself								
12	2.5	10	3.0	2	1.7	0	0.0	0.7007
prepared by friends								
7	1.6	6	2.0	1	1.0	0	0.0	0.7314
from a dealer								
257	51.1	174	51.2	80	51.1	3	47.4	0.9851
buy on Internet								
329	66.7	216	65.4	109	69.5	4	72.0	0.6171
from a pharmacy								
19	3.5	15	4.4	3	1.4	1	12.3	0.0646
from MAT program								
5	0.9	4	1.2	1	0.5	0	0.0	0.7325
other								
2	0.4	1	0.3	1	0.5	0	0.0	0.9109
N								
631		426		197		8		



Figure 2.8. Change in the price, quality, and access of drugs by Drug Type of Choice (%)

3. Injecting Risk Behavior

Table 3.1. Prevalence of Injection Risk Practices

	n	%	CI
Used clean syringe for last injection			
yes	486	97.0	(95.0–98.2)
Source of syringe for last injection			
bought in pharmacy	433	87.0	(83.7–89.8)
got in pharmacy	0	0.0	
got from NGO	62	11.7	(9.1–14.8)
got from friend	3	0.9	(0.3–3.1)
got used from friend	0	0.0	
used one used by myself	0	0.0	
got pre-loaded	2	0.3	(0.1–1.3)
other	0	0.0	
Used shared syringe in the past 30 days			
yes	12	2.8	(1.5–4.9)
Used pre-filled syringe in the past 30 days			
yes	37	7.3	(5.2–10.0)
Used front-/back-loaded syringe in the past 30 days			
yes	139	28.1	(24.2–32.4)
Used shared container in the past 30 days			
yes	75	15.1	(12.1–18.7)
Used own previously used syringe in the past 30 days			
yes	215	43.0	(38.5–47.6)
Gave someone a used syringe in the past 30 days			
yes	11	2.3	(1.3–4.2)
Any inj. risk (shared syringe, pre-filled, front-/back-load, container) in the past 30 days			
yes	178	36.1	(31.8–40.6)

Table 3.2. Frequency of risky injection practices

	n	%	CI
Frequency of injecting with a syringe used by others in the past 30 days			
always	1	11.4	(1.6–50.2)

	n	%	CI
often	0	0.0	
half	1	7.0	(0.9–37.0)
sometimes	2	18.4	(4.5–51.8)
rarely	6	49.6	(23.4–76.0)
never	2	13.7	(3.2–43.4)
Frequency of injecting with others in the same place in the past 30 days			
always	69	14.2	(11.2–17.8)
often	48	9.3	(7.0–12.3)
half	67	13.0	(10.2–16.3)
sometimes	67	13.7	(10.9–17.2)
rarely	84	16.5	(13.4–20.2)
never	162	33.3	(29.0–37.8)
Number of syringes used repeatedly in the past 30 days			
1-9	184	85.4	(79.7–89.7)
10-29	29	13.8	(9.6–19.4)
30+	2	0.8	(0.2–3.3)
Number of times one syringe used repeatedly in the past 30 days			
1	20	9.9	(6.3–15.2)
2-3	152	71.4	(64.8–77.3)
4-9	32	14.6	(10.4–20.2)
10+	10	4.0	(2.1–7.4)
How the pre-filled syringe was obtained			
from dealer	29	76.4	(59.2–87.9)
from friends	4	10.6	(4.0–25.3)
from stash	4	12.9	(4.9–30.1)
Someone used one syringe for injection before front-/back-loading			
no	462	92.6	(89.7–94.7)
yes	35	7.4	(5.3–10.3)



Figure 3.1. Prevalence of Key Injection Risk Practices (%)



Figure 3.2. Trends in Key Injection Risk Practices by Survey Round (%)



Figure 3.3. With whom injected drugs in the same place (%)



Figure 3.4. With whom injected drugs in the same place by sex (%)



Figure 3.5. With whom injected drugs in the same place by age (%)

Table 3.3. Prevalence of Shared and Pre-filled Syringe Use by Sociodemographic Characteristics

		Used shared syringe in the past 30 days			Used pre-filled syringe in the past 30 days			
		n	% (CI)	p-value	N	n	% (CI)	p-value
Total								
	All	12	2.8 (1.5–4.9)	1.0000	500	37	7.3 (5.2–10.0)	1.0000
Sex								
	male	12	3.2 (1.8–5.6)	0.1794	435	33	7.5 (5.3–10.6)	0.4941
	female	0	0.0		65	4	5.3 (1.9–14.0)	
Age								
	<25	0	0.0	0.7772	8	0	0.0	0.5776

	Used shared syringe in the past 30 days			Used pre-filled syringe in the past 30 days			
	n	% (CI)	p-value	N	n	% (CI)	p-value
25-34	2	2.8 (0.7–10.9)		75	5	6.3 (2.6–14.8)	
35-44	8	3.4 (1.7–6.7)		280	19	6.5 (4.1–10.2)	
45+	2	1.6 (0.4–7.0)		137	13	9.6 (5.5–16.3)	
Years since the start of injecting drug use							
≤2	0	0.0	0.6815	17	1	5.5 (0.7–34.3)	0.2830
3-5	1	5.7 (0.7–34.2)		20	4	17.7 (6.0–41.9)	
6-10	1	1.4 (0.2–9.8)		69	6	8.0 (3.5–17.0)	
≥11	10	3.0 (1.6–5.5)		394	26	6.7 (4.5–9.8)	
Partnership status							
live alone	7	2.7 (1.3–5.7)	0.9450	278	25	9.2 (6.2–13.5)	0.0737
live with partner	5	2.8 (1.2–6.7)		222	12	5.0 (2.8–8.7)	
Current employment status							
full-time	0	0.0	0.0533	152	12	7.4 (4.2–12.8)	0.8650
part-time or temporary	9	4.4 (2.3–8.4)		239	17	7.2 (4.4–11.5)	
unemployed	2	7.0 (1.6–25.6)		36	4	11.0 (3.7–28.3)	
disabled	0	0.0		45	2	4.4 (1.1–16.7)	
other	1	3.6 (0.5–23.0)		28	2	6.5 (1.5–24.2)	
Monthly income category							
<3K	1	1.8 (0.2–12.4)	0.5861	54	5	8.6 (3.5–19.7)	0.1992
3-10K	5	2.7 (1.1–6.4)		187	13	6.5 (3.7–11.1)	
10-20K	4	3.1 (1.2–8.2)		169	13	8.1 (4.7–13.7)	
≥20K	0	0.0		63	1	1.1 (0.1–7.6)	
Ever incarcerated							
no	9	3.5 (1.8–6.7)	0.1687	317	26	8.0 (5.4–11.8)	0.3766
yes	3	1.4 (0.5–4.5)		183	11	5.9 (3.2–10.4)	

Table 3.4. Prevalence of Shared and Pre-filled Syringe Use by Selected Subgroups

	Used shared syringe in the past 30 days			Used pre-filled syringe in the past 30 days			
	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID							
no	11	2.8 (1.5–5.1)	0.8474	455	35	7.5 (5.4–10.4)	0.4829

	Used shared syringe in the past 30 days			Used pre-filled syringe in the past 30 days			
	n	% (CI)	p-value	N	n	% (CI)	p-value
yes	1	2.3 (0.3–15.3)		45	2	4.6 (1.1–17.2)	
Treated with MAT currently (of all)							
no	11	2.6 (1.4–4.8)	0.4137	479	37	7.6 (5.4–10.4)	0.2037
yes	1	6.0 (0.7–35.1)		21	0	0.0	
HIV test result							
positive	0	0.0	0.2217	52	3	5.2 (1.6–15.7)	0.5297
negative	12	3.1 (1.7–5.5)		448	34	7.5 (5.3–10.5)	
Past 30 days injecting 4 categories							
opioids	2	1.1 (0.3–4.4)	0.0402	252	19	8.1 (5.1–12.5)	0.0482
stimulants	2	2.2 (0.5–8.7)		123	4	2.8 (1.0–7.5)	
opi+stimul	8	6.7 (3.3–13.1)		122	13	9.6 (5.5–16.2)	
other	0	0.0		3	1	34.7 (0.3–99.1)	
Injecting drug type of choice							
opioids	5	1.7 (0.7–4.1)	0.1117	334	28	8.2 (5.6–11.8)	0.3497
stimulants	7	5.1 (2.4–10.5)		160	8	5.1 (2.5–10.1)	
other	0	0.0		6	1	14.0 (1.0–73.5)	

Table 3.5. Prevalence of Front-/back-loading and Container Sharing by Sociodemographic Characteristics

		Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	499	139	28.1 (24.2–32.4)	1.0000	500	75	15.1 (12.1–18.7)	1.0000
Sex									
	male	434	126	29.3 (25.0–34.0)	0.1401	435	66	15.6 (12.3–19.6)	0.4090
	female	65	13	20.2 (11.8–32.3)		65	9	11.8 (6.0–21.8)	
Age									
	<25	8	2	24.7 (4.3–70.3)	0.7602	8	1	10.0 (0.9–58.4)	0.8616
	25-34	75	21	29.0 (19.4–41.0)		75	11	13.1 (7.2–22.7)	
	35-44	280	84	29.8 (24.5–35.6)		280	45	16.2 (12.1–21.3)	
	45+	136	32	24.6 (17.6–33.2)		137	18	14.3 (9.0–21.9)	
Years since the start of injecting drug use									

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
≤2	17	3	18.4 (5.4–47.0)	0.6726	17	1	4.6 (0.5–30.3)	0.1400
3-5	20	4	20.4 (7.2–45.9)		20	2	10.2 (2.3–35.6)	
6-10	69	22	30.5 (20.5–42.6)		69	16	23.3 (14.2–35.8)	
≥11	393	110	28.6 (24.1–33.5)		394	56	14.4 (11.1–18.5)	
Partnership status								
live alone	278	76	27.2 (22.1–33.0)	0.6266	278	40	14.2 (10.5–19.1)	0.5749
live with partner	221	63	29.3 (23.3–36.0)		222	35	16.1 (11.6–22.0)	
Current employment status								
full-time	152	29	20.1 (14.1–27.9)	0.1162	152	14	8.6 (5.0–14.5)	0.0800
part-time or temporary	239	76	31.9 (26.0–38.3)		239	43	19.1 (14.3–25.0)	
unemployed	35	11	32.4 (18.0–51.1)		36	5	14.5 (5.6–32.8)	
disabled	45	13	28.6 (16.8–44.2)		45	7	14.3 (6.7–28.1)	
other	28	10	37.0 (20.5–57.2)		28	6	21.1 (9.3–41.0)	
Monthly income category								
<3K	54	14	25.7 (15.3–39.8)	0.8790	54	10	19.0 (10.2–32.8)	0.7831
3-10K	187	55	28.9 (22.7–36.1)		187	29	14.7 (10.2–20.7)	
10-20K	169	46	27.9 (21.4–35.5)		169	22	13.4 (8.7–20.0)	
≥20K	63	15	23.8 (14.2–37.0)		63	8	13.0 (6.4–24.6)	
Ever incarcerated								
no	317	78	24.9 (20.3–30.3)	0.0437	317	48	15.0 (11.3–19.6)	0.9203
yes	182	61	33.8 (27.0–41.3)		183	27	15.3 (10.6–21.7)	

Table 3.6. Prevalence of Front-/back-loading and Container Sharing by Selected Subgroups

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	455	117	25.9 (21.9–30.3)	0.0002	455	60	13.7 (10.6–17.4)	0.0024
yes	44	22	53.4 (38.1–68.1)		45	15	31.0 (19.0–46.3)	
Treated with MAT currently (of all)								
no	478	126	26.6 (22.7–31.0)	0.0003	479	70	14.6 (11.6–18.3)	0.1522

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
yes	21	13	64.0 (40.3–82.5)		21	5	26.7 (11.0–51.9)	
HIV test result								
positive	52	18	33.4 (21.3–48.1)	0.3886	52	11	19.5 (10.5–33.2)	0.3649
negative	447	121	27.5 (23.4–32.0)		448	64	14.6 (11.4–18.4)	
Past 30 days injecting 4 categories								
opioids	251	78	31.8 (26.1–38.1)	0.0002	252	38	15.7 (11.5–21.0)	0.0128
stimulants	123	16	13.4 (8.2–21.1)		123	9	7.4 (3.8–14.0)	
opi+stimul	122	45	36.1 (27.6–45.5)		122	28	21.9 (15.1–30.8)	
other	3	0	0.0		3	0	0.0	
Injecting drug type of choice								
opioids	333	108	32.3 (27.3–37.7)	0.0163	334	56	16.9 (13.1–21.6)	0.2645
stimulants	160	30	19.8 (14.0–27.2)		160	18	11.3 (7.0–17.6)	
other	6	1	19.3 (1.4–80.3)		6	1	19.3 (1.4–80.3)	

4. Sexual Behavior

Table 4.1. Prevalence of Sexual Practice by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had sex: ever										
yes	495	99.7	(98.8–99.9)	65	100.0		430	99.7	(98.7–99.9)	0.5907
N	497			65			432			
Had sex: in the past 12 months										
yes	369	74.6	(70.4–78.5)	51	80.0	(68.3–88.1)	318	73.9	(69.2–78.0)	0.2928
N	495			65			430			
Had sex: in the past 30 days										
yes	246	50.4	(45.7–55.0)	41	66.1	(53.4–76.8)	205	48.0	(43.1–53.0)	0.0078
N	491			65			426			
Had a sex partner in the past 30 days: regular										
yes	224	90.5	(86.3–93.6)	41	100.0		183	88.6	(83.6–92.2)	0.0197
N	250			41			209			
Had a sex partner in the past 30 days: casual										
yes	28	10.2	(7.1–14.6)	0	0.0		28	12.3	(8.5–17.5)	0.0149
N	248			41			207			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	2	0.7	(0.2–2.7)	0	0.0		2	0.8	(0.2–3.2)	0.5283
N	249			41			208			
Used condom during last sex: if ever had sex										
yes	182	37.3	(32.9–41.8)	8	14.4	(6.9–27.6)	174	40.7	(35.9–45.6)	0.0004
N	494			65			429			

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Used condom during last sex: if had sex in 12m										
yes	140	38.2	(33.1–43.5)	5	13.3	(5.3–29.7)	135	42.2	(36.7–48.0)	0.0012
N	369			51			318			
Used condom during last sex: if had sex in 30d										
yes	88	36.2	(30.2–42.7)	5	16.1	(6.5–34.8)	83	40.4	(33.6–47.5)	0.0137
N	246			41			205			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes				0	0.0		0	0.0		
N				41			208			



Figure 4.1. Frequency of sex in the past week by Drug Types Used (%)

Table 4.2. Sex Practices by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had same-sex sexual experience										
yes	9	1.7	(0.9–3.2)	6	9.3	(4.1–19.6)	3	0.5	(0.2–1.7)	0.0000
N	494			65			429			
Provided sex services for money										
yes	17	3.6	(2.1–5.8)	7	9.9	(4.6–20.0)	10	2.6	(1.3–5.0)	0.0052
N	495			65			430			
Paid for sex ever										
yes	85	17.6	(14.3–21.5)	6	7.1	(3.1–15.4)	79	19.2	(15.5–23.5)	0.0091
N	494			65			429			
Had sex with a sex worker in the past 6 months										
yes	9	9.3	(4.8–17.2)	1	13.5	(1.7–58.4)	8	9.0	(4.5–17.3)	0.6963
N	85			6			79			
Type of partner with whom had last sex										
regular	388	80.0	(76.1–83.3)	58	91.5	(82.4–96.1)	330	78.2	(73.9–82.0)	
casual	99	19.1	(15.8–22.9)	6	7.0	(3.0–15.6)	93	20.9	(17.2–25.1)	
com. sex (I paid)	5	1.0	(0.4–2.3)	1	1.5	(0.2–10.2)	4	0.9	(0.3–2.4)	
com. sex (I was paid)	0	0.0		0	0.0		0	0.0		

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
N	492			65			427			
With whom last had sex										
man	62	12.6	(9.9–16.0)	62	97.0	(90.8–99.1)	0	0.0		
woman	432	87.4	(84.0–90.1)	3	3.0	(0.9–9.2)	429	100.0		
men and women	0	0.0		0	0.0		0	0.0		
N	494			65			429			
Type of last sex contact: vaginal										
yes	469	95.0	(92.6–96.6)	65	100.0		404	94.2	(91.5–96.1)	0.0528
N	494			65			429			
Type of last sex contact: anal										
yes	37	7.5	(5.4–10.3)	6	10.2	(4.5–21.5)	31	7.1	(5.0–10.0)	0.4178
N	494			65			429			
Type of last sex contact: oral										
yes	101	20.9	(17.4–25.0)	8	12.7	(6.3–23.9)	93	22.2	(18.3–26.6)	0.0907
N	494			65			429			

Table 4.3. Sex Partners by Sex

	Total			Sex					
	All			female		male			
	n	%	CI	n	%	n	%	CI	p-value
Had a sex partner in the past 30 days: regular									
yes	224	90.5	(86.3–93.6)	41	100.0	183	88.6	(83.6–92.2)	0.0197
N	250			41		209			
Had a sex partner in the past 30 days: casual									
yes	28	10.2	(7.1–14.6)	0	0.0	28	12.3	(8.5–17.5)	0.0149
N	248			41		207			
Had a sex partner in the past 30 days: commercial (buying - I paid)									
yes	2	0.7	(0.2–2.7)	0	0.0	2	0.8	(0.2–3.2)	0.5283
N	249			41		208			
Number of sex partners in the past 30 days: regular									
1	215	99.1	(96.5–99.8)	40	100.0	175	98.9	(95.7–99.7)	
2-4	2	0.9	(0.2–3.5)	0	0.0	2	1.1	(0.3–4.3)	
5+	0	0.0		0	0.0	0	0.0		
N	217			40		177			
Number of sex partners in the past 30 days: casual									
1	20	81.6	(61.9–92.3)	0	0.0	20	81.6	(61.9–92.3)	
2-4	4	14.2	(5.3–33.1)	0	0.0	4	14.2	(5.3–33.1)	
5+	1	4.2	(0.6–24.8)	0	0.0	1	4.2	(0.6–24.8)	
N	25			0		25			
Number of sex partners in the past 30 days: total									
1	232	97.1	(94.2–98.6)	40	100.0	192	96.5	(93.0–98.3)	0.4494
2-4	6	2.1	(0.9–4.8)	0	0.0	6	2.6	(1.1–5.7)	
5+	2	0.8	(0.2–3.1)	0	0.0	2	1.0	(0.2–3.8)	
N	240			40		200			
Had a sex partner in the past 30 days: commercial (selling - I was paid)									
yes				0	0.0	0	0.0		
N				41		208			



Figure 4.2. Condom Use During Last Sexual Encounter by Type of Partner (%)



Figure 4.3. Trends in Condom Use During Last Sexual Encounter by Survey Round (%)

Table 4.4. Condom Use During Last Sexual Encounter by Sociodemographic Characteristics

			Used condom during last sex: if ever had sex				
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
Total							
	All	494	312	62.7 (58.2–67.1)	182	37.3 (32.9–41.8)	1.0000
Sex							
	male	429	255	59.3 (54.4–64.1)	174	40.7 (35.9–45.6)	0.0004
	female	65	57	85.6 (72.4–93.1)	8	14.4 (6.9–27.6)	
Age							
	<25	8	4	45.1 (12.9–82.0)	4	54.9 (18.0–87.1)	0.0101

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
25-34	74	39	53.2 (41.2–64.8)	35	46.8 (35.2–58.8)	
35-44	277	167	60.2 (54.0–66.0)	110	39.8 (34.0–46.0)	
45+	135	102	74.2 (65.5–81.4)	33	25.8 (18.6–34.5)	
Years since the start of injecting drug use						
≤2	17	10	56.0 (30.5–78.7)	7	44.0 (21.3–69.5)	0.2251
3-5	20	16	82.6 (58.5–94.1)	4	17.4 (5.9–41.5)	
6-10	69	40	57.8 (45.3–69.4)	29	42.2 (30.6–54.7)	
≥11	388	246	62.8 (57.6–67.7)	142	37.2 (32.3–42.4)	
Partnership status						
live alone	274	156	56.1 (49.9–62.2)	118	43.9 (37.8–50.1)	0.0020
live with partner	220	156	70.4 (63.7–76.4)	64	29.6 (23.6–36.3)	
Current employment status						
full-time	150	90	59.3 (50.7–67.3)	60	40.7 (32.7–49.3)	0.1146
part-time or temporary	238	145	60.8 (54.1–67.0)	93	39.2 (33.0–45.9)	
unemployed	35	23	68.2 (49.9–82.2)	12	31.8 (17.8–50.1)	
disabled	43	30	67.6 (51.0–80.7)	13	32.4 (19.3–49.0)	
other	28	24	85.5 (65.7–94.8)	4	14.5 (5.2–34.3)	
Monthly income category						
<3K	53	41	76.9 (62.3–87.0)	12	23.1 (13.0–37.7)	0.1647
3-10K	186	114	60.7 (53.1–67.8)	72	39.3 (32.2–46.9)	
10-20K	167	99	59.4 (51.4–66.9)	68	40.6 (33.1–48.6)	
≥20K	63	38	58.8 (45.2–71.2)	25	41.2 (28.8–54.8)	
Ever incarcerated						
no	313	191	60.8 (55.0–66.4)	122	39.2 (33.6–45.0)	0.2724
yes	181	121	66.1 (58.4–72.9)	60	33.9 (27.1–41.6)	

Table 4.5. Condom Use During Last Sexual Encounter by Selected Subgroups

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	450	287	63.2 (58.4–67.8)	163	36.8 (32.2–41.6)	0.4862
yes	44	25	57.7 (42.1–71.9)	19	42.3 (28.1–57.9)	
Treated with MAT currently (of all)						
no	473	297	62.4 (57.7–66.8)	176	37.6 (33.2–42.3)	0.4128
yes	21	15	71.6 (46.8–87.8)	6	28.4 (12.2–53.2)	
HIV test result						
positive	52	29	58.8 (44.0–72.2)	23	41.2 (27.8–56.0)	0.5547
negative	442	283	63.2 (58.4–67.8)	159	36.8 (32.2–41.6)	
Past 30 days injecting 4 categories						
opioids	250	148	58.7 (52.2–64.9)	102	41.3 (35.1–47.8)	0.1353
stimulants	120	85	69.7 (60.2–77.7)	35	30.3 (22.3–39.8)	
opi+stimul	121	76	63.5 (53.9–72.1)	45	36.5 (27.9–46.1)	
other	3	3	100.0	0	0.0	
Injecting drug type of choice						
opioids	331	200	60.7 (55.1–66.1)	131	39.3 (33.9–44.9)	0.1552
stimulants	158	107	66.0 (57.7–73.4)	51	34.0 (26.6–42.3)	
other	5	5	100.0	0	0.0	

Table 4.6. Condom use by type of partner by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Used condom during last sex: regular partner										
yes	74	34.0	(27.7–40.8)	5	16.1	(6.5–34.8)	69	38.1	(31.0–45.7)	0.0245
N	224			41			183			
Used condom during last sex: casual partner										
yes	21	70.2	(51.5–83.9)	0	0.0		21	70.2	(51.5–83.9)	
N	30			0			30			
Used condom during last sex: commercial (I paid) partner										
yes	1	42.0	(4.3–92.1)	0	0.0		1	42.0	(4.3–92.1)	
N	2			0			2			
Condom use frequency: regular partner										
always	47	21.5	(16.3–27.7)	4	14.2	(5.2–33.5)	43	23.1	(17.4–30.1)	0.1151
often	14	6.2	(3.6–10.4)	1	1.9	(0.3–12.8)	13	7.2	(4.1–12.2)	
half	12	5.6	(3.1–10.1)	0	0.0		12	6.9	(3.8–12.3)	
sometimes	6	3.0	(1.3–6.8)	2	6.0	(1.4–22.0)	4	2.4	(0.8–6.4)	
rarely	11	4.6	(2.5–8.2)	1	2.3	(0.3–14.9)	10	5.1	(2.7–9.4)	
never	133	59.1	(52.2–65.7)	33	75.6	(57.4–87.7)	100	55.2	(47.6–62.6)	

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
N	223			41			182			
Condom use frequency: casual partner										
always	12	42.3	(25.6–61.1)	0	0.0		12	42.3	(25.6–61.1)	
often	2	7.3	(1.8–25.0)	0	0.0		2	7.3	(1.8–25.0)	
half	3	8.4	(2.6–23.8)	0	0.0		3	8.4	(2.6–23.8)	
sometimes	1	4.5	(0.6–26.0)	0	0.0		1	4.5	(0.6–26.0)	
rarely	2	6.3	(1.5–22.4)	0	0.0		2	6.3	(1.5–22.4)	
never	9	31.2	(16.9–50.4)	0	0.0		9	31.2	(16.9–50.4)	
N	29			0			29			
Condom use frequency: commercial (I paid) partner										
always	2	63.3	(13.3–95.1)	0	0.0		2	63.3	(13.3–95.1)	
often	0	0.0		0	0.0		0	0.0		
half	0	0.0		0	0.0		0	0.0		
sometimes	1	36.7	(4.9–86.7)	0	0.0		1	36.7	(4.9–86.7)	
rarely	0	0.0		0	0.0		0	0.0		
never	0	0.0		0	0.0		0	0.0		
N	3			0			3			



Figure 4.4. Frequency of condom use by type of partner by Sex (%)



Figure 4.5. Frequency of condom use among men during the last sexual encounter by the riskiest type of partner in the past 30 days (%)

5. HIV, HCV, and Syphilis Testing Results

Table 5.1. HIV Prevalence by Sociodemographic Characteristics

			HIV test result			
	N		positive		negative	
		n	% (CI)	n	% (CI)	p-value
Total						
All	500	52	11.0 (8.4–14.4)	448	89.0 (85.6–91.6)	1.0000
Sex						
male	435	40	9.8 (7.1–13.3)	395	90.2 (86.7–92.9)	0.0265
female	65	12	19.7 (11.2–32.1)	53	80.3 (67.9–88.8)	
Age						
<25	8	0	0.0	8	100.0	0.0196
25-34	75	1	2.1 (0.3–13.5)	74	97.9 (86.5–99.7)	
35-44	280	29	10.8 (7.4–15.4)	251	89.2 (84.6–92.6)	
45+	137	22	17.2 (11.3–25.3)	115	82.8 (74.7–88.7)	
Years since the start of injecting drug use						
≤2	17	0	0.0	17	100.0	0.2695
3-5	20	2	10.2 (2.3–35.6)	18	89.8 (64.4–97.7)	
6-10	69	4	6.4 (2.3–16.6)	65	93.6 (83.4–97.7)	
≥11	394	46	12.4 (9.2–16.4)	348	87.6 (83.6–90.8)	
Partnership status						
live alone	278	31	12.3 (8.6–17.2)	247	87.7 (82.8–91.4)	0.3919

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
live with partner	222	21	9.6 (6.2–14.7)	201	90.4 (85.3–93.8)	
Current employment status						
full-time	152	6	5.4 (2.4–12.0)	146	94.6 (88.0–97.6)	0.0047
part-time or temporary	239	23	10.0 (6.6–14.9)	216	90.0 (85.1–93.4)	
unemployed	36	7	21.5 (9.7–41.3)	29	78.5 (58.7–90.3)	
disabled	45	12	24.8 (14.0–40.1)	33	75.2 (59.9–86.0)	
other	28	4	16.8 (6.2–38.2)	24	83.2 (61.8–93.8)	
Monthly income category						
<3K	54	6	12.4 (5.0–27.3)	48	87.6 (72.7–95.0)	0.0292
3-10K	187	27	15.2 (10.4–21.8)	160	84.8 (78.2–89.6)	
10-20K	169	9	5.4 (2.8–10.1)	160	94.6 (89.9–97.2)	
≥20K	63	4	6.4 (2.2–17.1)	59	93.6 (82.9–97.8)	
Ever incarcerated						
no	317	24	8.0 (5.3–11.9)	293	92.0 (88.1–94.7)	0.0077
yes	183	28	16.4 (11.4–23.2)	155	83.6 (76.8–88.6)	

Table 5.2. HIV Prevalence by Selected Subgroups

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	455	45	10.6 (7.9–14.2)	410	89.4 (85.8–92.1)	0.3504
yes	45	7	15.4 (7.2–29.9)	38	84.6 (70.1–92.8)	
Treated with MAT currently (of all)						
no	479	47	10.5 (7.8–13.9)	432	89.5 (86.1–92.2)	0.0468
yes	21	5	25.0 (10.1–49.8)	16	75.0 (50.2–89.9)	
Past 30 days injecting 4 categories						
opioids	252	30	12.3 (8.6–17.2)	222	87.7 (82.8–91.4)	0.7543
stimulants	123	9	8.9 (4.5–16.9)	114	91.1 (83.1–95.5)	
opi+stimul	122	13	10.9 (6.0–18.8)	109	89.1 (81.2–94.0)	
other	3	0	0.0	3	100.0	
Injecting drug type of choice						

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
opioids	334	40	12.3 (9.0–16.7)	294	87.7 (83.3–91.0)	0.3732
stimulants	160	12	8.7 (4.8–15.1)	148	91.3 (84.9–95.2)	
other	6	0	0.0	6	100.0	



Figure 5.1. HIV Test Result (%)



Figure 5.2. Trends in HIV Prevalence by Survey Round (%)



Figure 5.3. Anti-HCV Testing Coverage In the Survey (%)



Figure 5.4. Anti-HCV Test Results (%)



Figure 5.5. Anti-HCV Test Results by Sex (%)



Figure 5.6. Trends in Anti-HCV Prevalence by Survey Round (%)



Figure 5.7. Syphilis Test Results (%)

6. HIV Prevention

Table 6.1. Being a Client of NGO by Sociodemographic Characteristics

			Client of NGO working with PWID			
		N	no		yes	
			n	% (CI)	n	% (CI)	p-value
Total							
	All	500	455	91.6 (88.9–93.8)	45	8.4 (6.2–11.1)	1.0000
Sex							
	male	435	402	93.1 (90.3–95.1)	33	6.9 (4.9–9.7)	0.0029
	female	65	53	81.9 (70.2–89.7)	12	18.1 (10.3–29.8)	
Age							

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
<25	8	6	75.3 (29.7–95.7)	2	24.7 (4.3–70.3)	0.2691
25-34	75	67	88.8 (78.6–94.5)	8	11.2 (5.5–21.4)	
35-44	280	256	92.2 (88.6–94.8)	24	7.8 (5.2–11.4)	
45+	137	126	92.9 (87.3–96.2)	11	7.1 (3.8–12.7)	
Years since the start of injecting drug use						
≤2	17	15	88.5 (60.2–97.5)	2	11.5 (2.5–39.8)	0.3972
3-5	20	20	100.0	0	0.0	
6-10	69	61	88.4 (77.9–94.2)	8	11.6 (5.8–22.1)	
≥11	394	359	91.9 (88.8–94.2)	35	8.1 (5.8–11.2)	
Partnership status						
live alone	278	257	92.6 (88.8–95.2)	21	7.4 (4.8–11.2)	0.3959
live with partner	222	198	90.5 (86.0–93.7)	24	9.5 (6.3–14.0)	
Current employment status						
full-time	152	141	93.0 (87.5–96.2)	11	7.0 (3.8–12.5)	0.0204
part-time or temporary	239	223	94.1 (90.5–96.4)	16	5.9 (3.6–9.5)	
unemployed	36	31	87.5 (71.8–95.0)	5	12.5 (5.0–28.2)	
disabled	45	37	83.8 (69.9–92.0)	8	16.2 (8.0–30.1)	
other	28	23	79.6 (58.5–91.6)	5	20.4 (8.4–41.5)	
Monthly income category						
<3K	54	50	93.3 (82.9–97.6)	4	6.7 (2.4–17.1)	0.5963
3-10K	187	173	93.3 (88.8–96.1)	14	6.7 (3.9–11.2)	
10-20K	169	156	92.1 (86.6–95.5)	13	7.9 (4.5–13.4)	
≥20K	63	54	88.3 (78.2–94.0)	9	11.7 (6.0–21.8)	
Ever incarcerated						
no	317	293	93.1 (89.8–95.4)	24	6.9 (4.6–10.2)	0.1223
yes	183	162	89.1 (83.6–92.9)	21	10.9 (7.1–16.4)	

Table 6.2. Being a Client of NGO by Selected Subgroups

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Treated with MAT currently (of all)						
no	479	440	92.4 (89.6–94.4)	39	7.6 (5.6–10.4)	0.0025
yes	21	15	73.6 (50.0–88.7)	6	26.4 (11.3–50.0)	
HIV test result						
positive	52	45	88.3 (76.6–94.6)	7	11.7 (5.4–23.4)	0.3504
negative	448	410	92.0 (89.1–94.2)	38	8.0 (5.8–10.9)	
Past 30 days injecting 4 categories						
opioids	252	233	93.2 (89.5–95.7)	19	6.8 (4.3–10.5)	0.5280
stimulants	123	110	89.7 (82.8–94.1)	13	10.3 (5.9–17.2)	
opi+stimul	122	109	90.2 (83.4–94.3)	13	9.8 (5.7–16.6)	
other	3	3	100.0	0	0.0	
Injecting drug type of choice						
opioids	334	309	93.1 (89.8–95.4)	25	6.9 (4.6–10.2)	0.1938
stimulants	160	141	89.0 (83.1–93.0)	19	11.0 (7.0–16.9)	
other	6	5	80.7 (19.7–98.6)	1	19.3 (1.4–80.3)	



Figure 6.1. Injecting and Sex Risk Perception Among HIV-negative PWID (%)



Figure 6.2. Received HIV Prevention Services in the Past 12 Months and 30 days (%)



Figure 6.3. Receiving Package of Prevention Services in the Past 12 Months (%)



Figure 6.4. Trends in Receiving HIV Prevention Services in the Past 12 Months (%)



Figure 6.5. Perceived changes in access to HIV prevention since February 2022 (%)

Table 6.3. Percentage of correct responses to knowledge questions by HIV status

	Total	HIV test result		
	All	negative	positive	
	%	%	%	p-value
HIV knowledge				
HIV may be avoided	90.1	89.9	92.3	0.6036
proper condom use may prevent HIV	56.8	55.0	71.4	0.0325
undetectable=untransmittable	51.8	50.3	64.3	0.0787
PEP reduces the risk of HIV	55.7	54.8	62.8	0.3053
ART should be started immediately	88.7	89.3	84.6	0.3301

	Total	HIV test result		
	All %	negative %	positive %	p-value
ART may be postponed if one feels healthy	63.6	62.5	72.2	0.1879
ART may be stopped if one feels healthy	61.9	61.1	68.5	0.3200
HIV is transmitted through blood and sex	95.1	94.7	97.8	0.3576
HIV is transmitted via air, food, or skin	70.9	70.7	72.6	0.7861
HBV knowledge				
proper condom use may prevent HBV	85.7	85.7	85.2	0.9185
treatment should be started immediately	88.4	87.6	95.0	0.0934
treatment may be postponed if one feels healthy	63.3	63.0	65.7	0.7152
HBV is 100% transmitted from mother to child	5.0	5.2	3.5	0.5829
HBV is transmitted through blood and sex	94.1	94.1	93.9	0.9589
HBV is transmitted via air, food, or skin	56.5	55.6	63.8	0.2829
treatment may be stopped if one feels healthy	65.4	66.2	58.5	0.2878
HCV knowledge				
proper condom use may prevent HCV	5.3	5.5	3.6	0.5637
treatment should be started immediately	88.6	89.0	85.5	0.4588
treatment may be postponed if one feels healthy	64.0	63.5	67.9	0.5536
HCV is 100% transmitted from mother to child	5.7	5.5	6.8	0.7390
HCV is transmitted through blood and sex	95.7	95.5	97.8	0.4533
there is no treatment for HCV	62.1	60.6	74.0	0.0743
HCV is transmitted via air, food, or skin	77.9	77.2	83.4	0.3446
treatment may be stopped if one feels healthy	65.8	66.1	63.3	0.7075

7. HIV Testing

Table 7.1. HIV Testing Knowledge and Uptake

	n	%	CI
Know where to get HIV test			
yes	454	91.0	(88.1–93.3)
Tested for HIV ever			
yes	461	92.6	(89.8–94.6)
Tested for HIV in the past 12 months			
yes	162	35.4	(30.9–40.1)
Tested for HIV in the past 6 months			
yes	100	22.6	(18.8–27.0)
Received the result of HIV test (of those tested)			
yes	453	98.0	(96.0–99.0)
Willing to disclose HIV test result (of those who got result)			
yes	451	99.7	(98.6–99.9)
Self-reported HIV status (of all tested)			
positive	42	9.9	(7.3–13.4)
negative	416	90.1	(86.6–92.7)
HIV testing and status awareness (GAM)			
yes	169	37.2	(32.7–42.0)
Ever did a HIV self-test			
yes	2	0.6	(0.1–2.2)
Regular sex partner tested for HIV			
yes	159	78.6	(72.4–83.8)
Regular sex partner HIV test result			
positive	12	7.7	(4.2–13.6)
negative	146	91.6	(85.5–95.2)
cannot disclose	1	0.7	(0.1–4.9)



Figure 7.1. HIV Testing Uptake (%)



Figure 7.2. Testing for HIV, HCV, syphilis since February 2022 (%)



Figure 7.3. HIV Testing Since February 2022 (%)

Table 7.2. Testing for HIV in the past 12 months (among all) by Sociodemographic Characteristics

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Total						
All	449	287	64.6 (59.9–69.1)	162	35.4 (30.9–40.1)	1.0000
Sex						
male	393	255	65.7 (60.6–70.4)	138	34.3 (29.6–39.4)	0.2185
female	56	32	57.0 (43.0–69.9)	24	43.0 (30.1–57.0)	
Age						
<25	6	3	54.2 (13.9–89.6)	3	45.8 (10.4–86.1)	0.2068
25-34	71	50	69.8 (57.2–80.0)	21	30.2 (20.0–42.8)	
35-44	251	149	60.4 (54.0–66.5)	102	39.6 (33.5–46.0)	
45+	121	85	70.7 (61.4–78.5)	36	29.3 (21.5–38.6)	
Years since the start of injecting drug use						
≤2	13	10	79.7 (49.0–94.1)	3	20.3 (5.9–51.0)	0.4033
3-5	17	14	79.8 (45.6–94.9)	3	20.2 (5.1–54.4)	
6-10	63	40	64.8 (51.8–75.9)	23	35.2 (24.1–48.2)	
≥11	356	223	63.2 (57.9–68.3)	133	36.8 (31.7–42.1)	
Partnership status						
live alone	244	156	63.6 (57.1–69.7)	88	36.4 (30.3–42.9)	0.6552
live with partner	205	131	65.7 (58.7–72.1)	74	34.3 (27.9–41.3)	

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Current employment status						
full-time	142	104	72.9 (64.5–80.0)	38	27.1 (20.0–35.5)	0.0272
part-time or temporary	217	135	63.8 (56.9–70.1)	82	36.2 (29.9–43.1)	
unemployed	32	15	44.8 (27.4–63.5)	17	55.2 (36.5–72.6)	
disabled	34	20	57.2 (39.3–73.4)	14	42.8 (26.6–60.7)	
other	24	13	55.5 (34.7–74.5)	11	44.5 (25.5–65.3)	
Monthly income category						
<3K	45	25	56.5 (40.7–71.1)	20	43.5 (28.9–59.3)	0.1161
3-10K	164	104	63.4 (55.4–70.7)	60	36.6 (29.3–44.6)	
10-20K	158	112	72.3 (64.6–78.9)	46	27.7 (21.1–35.4)	
≥20K	60	34	58.3 (44.5–71.0)	26	41.7 (29.0–55.5)	
Ever incarcerated						
no	277	191	69.7 (63.7–75.0)	86	30.3 (25.0–36.3)	0.0065
yes	172	96	56.4 (48.6–64.0)	76	43.6 (36.0–51.4)	

Table 7.3. Testing for HIV in the past 12 months (among all) by Selected Subgroups

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	407	271	67.0 (62.0–71.6)	136	33.0 (28.4–38.0)	0.0007
yes	42	16	39.5 (25.3–55.9)	26	60.5 (44.1–74.7)	
Treated with MAT currently (of all)						
no	431	282	66.2 (61.4–70.7)	149	33.8 (29.3–38.6)	0.0004
yes	18	5	25.3 (9.9–51.0)	13	74.7 (49.0–90.1)	
HIV test result						
positive	44	16	34.7 (21.2–51.1)	28	65.3 (48.9–78.8)	0.0000
negative	405	271	68.1 (63.3–72.6)	134	31.9 (27.4–36.7)	
Past 30 days injecting 4 categories						
opioids	230	135	59.5 (52.8–65.9)	95	40.5 (34.1–47.2)	0.0976
stimulants	103	76	73.2 (63.2–81.4)	27	26.8 (18.6–36.8)	
opi+stimul	113	74	66.9 (57.0–75.4)	39	33.1 (24.6–43.0)	

	N	Tested for HIV in the past 12 months				
		n	no % (CI)	n	yes % (CI)	p-value
other	3	2	65.3 (0.9–99.7)	1	34.7 (0.3–99.1)	
Injecting drug type of choice						
opioids	307	185	61.4 (55.5–66.9)	122	38.6 (33.1–44.5)	0.0380
stimulants	136	99	72.7 (64.1–79.9)	37	27.3 (20.1–35.9)	
other	6	3	42.6 (8.1–86.2)	3	57.4 (13.8–91.9)	

8. HIV Treatment



Figure 8.1. HIV Status Awareness Among HIV+ (%)



Figure 8.2. HIV Treatment Cascade - Four-stage (%)



Figure 8.3. HIV Treatment Cascade - Conditional (%)



Figure 8.4. HIV Treatment Cascade - Proportions (%)



Figure 8.5. Trends in HIV Treatment Cascade (Conditional, 95-95-95) by Survey Round (%)

Table 8.1. HIV Treatment Cascade (Conditional, 95-95-95) by Sociodemographic Characteristics

		Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
		N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Total											
	All	52	76.7 (63.1–86.4)	1.0000	39	69.3 (51.0–83.1)	1.0000	29	21	73.4 (53.9–86.7)	1.0000
Sex											
	male	40	77.7 (62.1–88.1)	0.7724	30	73.3 (51.0–87.8)	0.3429	24	18	74.3 (52.2–88.4)	0.8214
	female	12	73.5 (41.9–91.5)		9	55.3 (23.7–83.1)		5	3	69.4 (25.8–93.7)	
Age											

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
<25	0	0.0		0	0.0		0	0	0.0	
25-34	1	0.0		0	0.0		0	0	0.0	
35-44	29	77.9 (59.3–89.5)		22	66.9 (42.5–84.6)		16	9	59.8 (34.6–80.7)	
45+	22	80.3 (59.1–92.0)		17	72.3 (43.3–89.9)		13	12	88.7 (49.7–98.4)	
Years since the start of injecting drug use										
≤2	0	0.0		0	0.0		0	0	0.0	
3-5	2	0.0		0	0.0		0	0	0.0	
6-10	4	41.1 (8.4–84.2)		2	45.7 (4.8–93.4)		1	1	100.0	
≥11	46	83.3 (70.0–91.4)		37	70.4 (51.4–84.2)		28	20	72.7 (52.8–86.3)	
Partnership status										
live alone	31	73.1 (54.6–86.0)	0.4583	22	86.4 (56.6–96.8)	0.0283	20	14	70.1 (46.1–86.5)	0.5147
live with partner	21	82.1 (59.6–93.5)		17	46.7 (24.2–70.7)		9	7	81.5 (46.4–95.7)	
Current employment status										
full-time	6	100.0	0.5710	6	73.1 (23.6–96.0)	0.0081	5	3	56.4 (17.0–89.1)	
part-time or temporary	23	70.3 (48.3–85.7)		16	92.7 (62.4–99.0)		15	12	81.9 (54.8–94.4)	
unemployed	7	72.4 (30.6–94.0)		5	23.2 (4.2–67.6)		2	1	53.2 (6.0–95.3)	
disabled	12	76.4 (44.8–92.8)		9	78.4 (41.2–95.0)		7	5	74.2 (33.6–94.2)	
other	4	73.7 (20.7–96.8)		3	0.0		0	0	0.0	
Monthly income category										
<3K	6	100.0	0.3972	6	49.3 (13.2–86.2)	0.6440	4	4	100.0	0.5988
3-10K	27	74.3 (54.6–87.4)		19	75.0 (47.3–90.9)		15	10	68.3 (40.9–87.0)	
10-20K	9	76.2 (39.3–94.0)		7	82.7 (36.0–97.6)		6	4	62.2 (22.7–90.2)	

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
≥20K	4	100.0		4	71.5 (19.1–96.4)		3	2	79.5 (24.3–97.9)	
Ever incarcerated										
no	24	76.2 (54.8–89.4)	0.9351	18	72.6 (44.0–89.9)	0.7271	14	8	57.8 (31.0–80.6)	0.0745
yes	28	77.2 (58.1–89.2)		21	66.6 (42.0–84.7)		15	13	87.7 (60.1–97.1)	

Table 8.2. HIV Treatment Cascade (Conditional, 95-95-95) by Selected Subgroups

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID										
no	45	78.1 (63.6–87.9)	0.5217	34	71.2 (51.2–85.3)	0.4417	26	20	77.3 (56.5–89.9)	0.0523
yes	7	66.5 (26.4–91.6)		5	53.1 (14.8–88.1)		3	1	27.0 (3.0–81.5)	
Treated with MAT currently (of all)										
no	47	74.4 (59.8–85.0)	0.2044	34	74.2 (53.7–87.7)	0.0647	27	20	75.3 (55.1–88.3)	0.3024
yes	5	100.0		5	33.1 (6.7–77.2)		2	1	42.0 (3.6–93.3)	
HIV test result										
positive	52	76.7 (62.8–86.6)		39	69.3 (50.6–83.3)		29	21	73.4 (53.5–86.9)	
negative	0	0.0		0	0.0		0	0	0.0	
Past 30 days injecting 4 categories										
opioids	30	81.6 (62.2–92.2)		25	75.3 (54.3–88.7)		19	15	78.9 (54.4–92.2)	
stimulants	9	72.0 (37.4–91.7)		6	55.6 (17.2–88.3)		4	3	84.2 (34.9–98.2)	
opi+stimul	13	69.6 (41.0–88.3)		8	65.0 (24.4–91.4)		6	3	48.5 (14.2–84.3)	
other	0	0.0		0	0.0		0	0	0.0	
Injecting drug type of choice										
opioids	40	81.0 (65.4–90.6)		32	74.6 (54.4–87.8)		25	18	71.5 (50.0–86.3)	
stimulants	12	64.0 (34.8–85.6)		7	49.6 (16.6–83.0)		4	3	84.2 (35.0–98.1)	
other	0	0.0		0	0.0		0	0	0.0	

Table 8.3. ART adherence (among those on ART)

	n	%	CI
When did you last miss ART dose			
last week	4	13.9	(4.9–33.7)
1-2 weeks ago	2	8.8	(2.2–29.3)
3-4 weeks ago	2	6.9	(1.7–23.9)
1-3 months ago	1	2.2	(0.3–14.4)
never	22	68.1	(48.5–82.9)
What was the reason for missing the last ART dose			
forgot	3	32.0	(9.6–67.7)
did not have meds	1	16.8	(2.4–62.6)
was under influence	1	10.3	(1.4–48.7)
did not want others to see	1	16.8	(2.4–62.6)
other	2	24.2	(5.5–63.8)
Reasons for not taking ART			
not sure it is needed	4	44.7	(16.8–76.5)
no time to visit clinic	4	48.1	(19.0–78.6)
no motivation to visit clinic	4	59.3	(26.1–85.7)
missed a visit, hard to come back	2	16.5	(3.8–49.4)
too sick to visit clinic	2	25.6	(6.0–64.7)
drug use	3	41.5	(12.8–77.4)
side effects or complications	3	41.5	(12.8–77.4)
no understanding of how to take it	1	8.4	(1.1–43.0)
lost or sold all ARVs	2	14.4	(3.2–46.2)
alcohol use	3	34.7	(10.0–71.8)
waited too long and left	2	11.4	(2.5–39.1)
Time on ART			
≤3m	0	0.0	
4-24m	2	18.6	(3.8–56.6)
25-60m	1	4.4	(0.6–26.7)
5y+	9	77.0	(42.2–93.9)

9. PrEP



Figure 9.1. PrEP Uptake in the Past 12 Months (%)



Figure 9.2. Change in PrEP Awareness and Uptake from 2020 to 2023 (%)



Figure 9.3. Change in PrEP Uptake from 2020 to 2023 (%)

Table 9.1. PrEP Awareness by Sociodemographic Characteristics

			PrEP uptake in the past 12 months				
		N	use now		never used		not aware
			n	% (CI)	n	% (CI)	n	% (CI)
Total								
	All	500	2	0.5 (0.1–2.0)	10	2.0 (1.1–3.8)	488	97.5 (95.5–98.6)
Sex								
	male	435	1	0.4 (0.1–2.5)	8	1.9 (0.9–4.0)	426	97.7 (95.5–98.8)
	female	65	1	1.3 (0.2–8.7)	2	2.6 (0.6–10.2)	62	96.2 (88.4–98.8)
Age								
	<25	8	0	0.0	0	0.0	8	100.0
	25-34	75	1	1.1 (0.1–7.4)	0	0.0	74	98.9 (92.6–99.9)

	N	PrEP uptake in the past 12 months					
		use now		never used		not aware	
		n	% (CI)	n	% (CI)	n	% (CI)
35-44	280	1	0.6 (0.1–4.0)	8	2.9 (1.4–5.9)	271	96.6 (93.2–98.3)
45+	137	0	0.0	2	1.6 (0.4–6.1)	135	98.4 (93.9–99.6)
Years since the start of injecting drug use							
≤2	17	0	0.0	0	0.0	17	100.0
3-5	20	0	0.0	0	0.0	20	100.0
6-10	69	1	1.2 (0.2–8.4)	0	0.0	68	98.8 (91.6–99.8)
≥11	394	1	0.4 (0.1–2.8)	10	2.6 (1.3–4.9)	383	97.0 (94.6–98.4)
Partnership status							
live alone	278	0	0.0	4	1.4 (0.5–3.8)	274	98.6 (96.2–99.5)
live with partner	222	2	1.0 (0.2–4.4)	6	2.7 (1.2–6.3)	214	96.2 (92.3–98.2)
Current employment status							
full-time	152	1	1.0 (0.1–6.8)	2	1.4 (0.3–6.1)	149	97.6 (92.3–99.3)
part-time or temporary	239	0	0.0	6	2.7 (1.2–6.0)	233	97.3 (94.0–98.8)
unemployed	36	0	0.0	0	0.0	36	100.0
disabled	45	0	0.0	1	1.6 (0.2–11.2)	44	98.4 (88.8–99.8)
other	28	1	3.0 (0.4–20.0)	1	3.6 (0.5–23.0)	26	93.5 (75.8–98.5)
Monthly income category							
<3K	54	0	0.0	2	4.1 (1.0–15.5)	52	95.9 (84.5–99.0)
3-10K	187	1	0.4 (0.1–3.0)	2	0.9 (0.2–3.6)	184	98.7 (95.9–99.6)
10-20K	169	0	0.0	5	3.2 (1.2–7.9)	164	96.8 (92.1–98.8)
≥20K	63	1	2.4 (0.3–15.7)	1	1.5 (0.2–10.2)	61	96.1 (84.9–99.1)
Ever incarcerated							
no	317	1	0.3 (0.0–1.8)	5	1.3 (0.6–3.2)	311	98.4 (96.4–99.3)
yes	183	1	0.9 (0.1–6.0)	5	3.2 (1.3–7.8)	177	95.9 (90.9–98.2)

Table 9.2. PrEP Current Use by Sociodemographic Characteristics

	N	PrEP uptake in the past 12 months					
		use now		never used		not aware	
		n	% (CI)	n	% (CI)	n	% (CI)
Client of NGO working with PWID							
no	455	2	0.5 (0.1–2.2)	6	1.5 (0.7–3.4)	447	98.0 (95.9–99.0)
yes	45	0	0.0	4	7.6 (2.7–19.2)	41	92.4 (80.8–97.3)
Treated with MAT currently (of all)							
no	479	2	0.5 (0.1–2.1)	9	2.0 (1.0–3.8)	468	97.5 (95.5–98.7)
yes	21	0	0.0	1	3.5 (0.4–23.5)	20	96.5 (76.5–99.6)

	N	PrEP uptake in the past 12 months					
		use now		never used		not aware	
		n	% (CI)	n	% (CI)	n	% (CI)
HIV test result							
positive	52	1	2.8 (0.4–18.3)	1	1.3 (0.2–8.9)	50	95.9 (83.2–99.1)
negative	448	1	0.2 (0.0–1.3)	9	2.1 (1.1–4.1)	438	97.7 (95.7–98.8)
Past 30 days injecting 4 categories							
opioids	252	1	0.3 (0.0–2.3)	4	1.7 (0.6–4.7)	247	97.9 (95.0–99.2)
stimulants	123	0	0.0	2	1.1 (0.3–4.5)	121	98.9 (95.5–99.7)
opi+stimul	122	1	1.3 (0.2–8.6)	4	3.6 (1.3–9.5)	117	95.2 (88.5–98.1)
other	3	0	0.0	0	0.0	3	100.0
Injecting drug type of choice							
opioids	334	2	0.7 (0.2–3.0)	5	1.6 (0.7–4.0)	327	97.6 (95.0–98.9)
stimulants	160	0	0.0	4	2.3 (0.8–6.4)	156	97.7 (93.6–99.2)
other	6	0	0.0	1	19.3 (1.4–80.3)	5	80.7 (19.7–98.6)

Table 9.3. PrEP Awareness and Uptake

	n	%	CI
PrEP uptake in the past 12 months			
use now	2	0.5	(0.1–2.0)
used in the past	0	0.0	
never used	10	2.0	(1.1–3.8)
not aware	488	97.5	(95.5–98.6)
Aware of PrEP			
no	488	97.5	(95.5–98.6)
yes	12	2.5	(1.4–4.5)
PrEP use current			
no	498	99.5	(98.0–99.9)
yes	2	0.5	(0.1–2.0)
PrEP use current (of those aware)			
no	10	81.0	(46.2–95.5)
yes	2	19.0	(4.5–53.8)

10. MAT



Figure 10.1. MAT Awareness (%)



Figure 10.2. MAT Current Uptake (%)



Figure 10.3. Trends in MAT Lifetime and Current Uptake by Survey Round (%)

Table 10.1. MAT experience

	n	%	CI
Reason for MAT discontinuation			
moved to another city	1	5.1	(0.7–28.6)
clinic closed after Feb 2022	0	0.0	
weak or no effect	7	28.4	(13.6–50.1)
side effects	5	20.6	(8.5–41.9)
do not want to visit clinic	6	22.5	(10.0–43.2)
do not want to quit drugs	7	28.7	(13.7–50.5)
hard to get to the clinic	2	7.0	(1.7–24.9)
do not need it	6	26.2	(11.8–48.5)
do not like the attitude of physician	4	18.1	(6.6–41.0)
How did the injection frequency change during MAT			
intensified	1	6.2	(0.9–33.3)
did not change	11	47.4	(27.9–67.8)
decreased	11	46.3	(26.9–66.9)
Whether bought bupr. or methadone while not being a patient in the past 12 months			
yes, methadone	203	40.5	(36.0–45.0)
yes, buprenorphine	7	1.4	(0.6–3.0)
did not buy	289	58.2	(53.6–62.6)
Where bought bupr. or methadone while not being a patient in the past 12 months			
did not buy	289	58.2	(53.6–62.6)
bought from black market	210	41.8	(37.4–46.4)
bought from private clinic	0	0.0	
Way of using bupr. or methaone bought from others			
injecting	203	96.7	(93.1–98.4)
injecting mixed	0	0.0	
swallow or subling.	6	3.0	(1.3–6.6)
snort	1	0.3	(0.0–2.4)

Table 10.2. MAT Awareness and Uptake by Sociodemographic Characteristics

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
Total										
All	500	21	4.0 (2.6–6.2)	18	4.1 (2.6–6.5)	41	7.5 (5.5–10.1)	420	84.4 (80.9–87.4)	1.0000
Sex										
male	435	16	3.5 (2.1–5.7)	13	3.5 (2.0–6.0)	38	7.9 (5.7–10.8)	368	85.1 (81.4–88.2)	0.0967
female	65	5	7.6 (3.1–17.4)	5	8.4 (3.4–19.3)	3	4.4 (1.4–13.4)	52	79.6 (67.4–88.1)	
Age										
<25	8	1	10.0 (0.9–58.4)	0	0.0	1	11.8 (1.0–63.0)	6	78.2 (33.7–96.2)	0.5360
25-34	75	4	5.0 (1.8–13.0)	1	1.1 (0.1–7.4)	5	6.5 (2.6–15.3)	65	87.4 (77.6–93.3)	
35-44	280	11	3.7 (2.0–6.7)	12	4.9 (2.8–8.7)	29	9.4 (6.5–13.3)	228	82.0 (76.9–86.2)	
45+	137	5	3.7 (1.5–9.0)	5	4.4 (1.8–10.4)	6	3.9 (1.7–8.7)	121	88.0 (80.9–92.7)	
Years since the start of injecting drug use										
≤2	17	1	4.6 (0.5–30.3)	0	0.0	1	5.5 (0.7–34.3)	15	89.8 (63.9–97.8)	0.6361
3-5	20	1	3.3 (0.4–22.8)	0	0.0	3	12.8 (3.6–36.3)	16	83.9 (60.8–94.6)	
6-10	69	1	1.2 (0.2–8.4)	1	1.8 (0.2–11.9)	8	10.5 (5.1–20.2)	59	86.5 (76.1–92.8)	
≥11	394	18	4.5 (2.8–7.1)	17	4.9 (3.0–7.9)	29	6.7 (4.7–9.7)	330	83.8 (79.7–87.3)	
Partnership status										
live alone	278	11	3.6 (2.0–6.6)	10	4.4 (2.3–8.1)	25	8.1 (5.4–11.9)	232	83.9 (78.9–87.9)	0.8966
live with partner	222	10	4.4 (2.4–8.2)	8	3.8 (1.8–7.7)	16	6.7 (4.1–10.9)	188	85.0 (79.6–89.3)	
Current employment status										
full-time	152	3	1.6 (0.5–5.1)	5	3.3 (1.3–8.1)	9	5.1 (2.6–9.8)	135	90.0 (84.1–93.9)	0.0411
part-time or temporary	239	12	5.2 (2.9–9.1)	4	2.1 (0.8–5.6)	25	9.6 (6.5–14.0)	198	83.1 (77.7–87.5)	
unemployed	36	0	0.0	2	7.0 (1.6–25.6)	2	5.0 (1.1–19.9)	32	88.0 (70.3–95.8)	
disabled	45	4	7.3 (2.6–18.7)	4	11.4 (4.2–27.3)	3	7.1 (2.2–20.9)	34	74.2 (58.3–85.6)	
other	28	2	8.0 (1.9–28.3)	3	11.0 (3.3–30.5)	2	7.1 (1.7–25.7)	21	73.9 (53.4–87.6)	
Monthly income category										
<3K	54	1	1.8 (0.2–12.4)	3	7.1 (2.2–20.5)	9	15.7 (8.1–28.4)	41	75.3 (61.2–85.6)	0.0949
3-10K	187	12	6.8 (3.8–11.7)	5	3.1 (1.2–7.6)	13	6.3 (3.6–10.8)	157	83.8 (77.5–88.6)	

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
10-20K	169	4	1.8 (0.7–4.7)	8	5.2 (2.6–10.3)	12	6.6 (3.7–11.4)	145	86.5 (80.3–90.9)	
≥20K	63	3	3.4 (1.1–10.3)	2	3.3 (0.8–12.7)	4	5.1 (1.8–13.4)	54	88.2 (78.1–94.0)	
Ever incarcerated										
no	317	10	2.9 (1.5–5.3)	11	3.6 (1.9–6.5)	28	8.0 (5.5–11.4)	268	85.6 (81.2–89.0)	0.3022
yes	183	11	6.0 (3.3–10.8)	7	5.0 (2.4–10.2)	13	6.6 (3.8–11.2)	152	82.4 (75.8–87.5)	

Table 10.3. MAT Awareness and Uptake by Selected Subgroups

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
Client of NGO working with PWID										
no	455	15	3.2 (1.9–5.4)	11	2.9 (1.6–5.2)	38	7.6 (5.5–10.4)	391	86.3 (82.7–89.2)	0.0000
yes	45	6	12.6 (5.5–26.2)	7	17.7 (8.5–33.3)	3	5.7 (1.7–17.1)	29	64.0 (48.3–77.2)	
Treated with MAT currently (of all)										
no	479	0	0.0	18	4.3 (2.7–6.8)	41	7.8 (5.7–10.5)	420	87.9 (84.6–90.6)	0.0000
yes	21	21	100.0	0	0.0	0	0.0	0	0.0	
HIV test result										
positive	52	5	9.1 (3.7–20.8)	4	9.6 (3.5–23.6)	3	5.6 (1.7–16.8)	40	75.7 (61.1–86.1)	0.0434
negative	448	16	3.4 (2.0–5.5)	14	3.4 (2.0–5.8)	38	7.7 (5.6–10.5)	380	85.5 (81.8–88.5)	
Past 30 days injecting 4 categories										
opioids	252	15	6.1 (3.6–10.0)	14	6.9 (4.1–11.4)	20	7.7 (5.0–11.8)	203	79.3 (73.5–84.1)	0.0251
stimulants	123	2	1.2 (0.3–4.8)	2	1.7 (0.4–6.8)	13	8.9 (5.1–15.0)	106	88.2 (81.4–92.7)	
opi+stimul	122	4	2.8 (1.0–7.3)	2	1.0 (0.2–4.0)	8	5.7 (2.8–11.2)	108	90.6 (84.4–94.5)	
other	3	0	0.0	0	0.0	0	0.0	3	100.0	
Injecting drug type of choice										
opioids	334	19	5.5 (3.5–8.7)	13	4.8 (2.8–8.2)	26	7.4 (5.0–10.8)	276	82.2 (77.5–86.1)	0.0486
stimulants	160	2	0.9 (0.2–3.7)	4	2.1 (0.8–5.8)	15	7.9 (4.7–12.9)	139	89.1 (83.5–92.9)	
other	6	0	0.0	1	19.3 (1.4–80.3)	0	0.0	5	80.7 (19.7–98.6)	



Figure 10.4. Buying MAT medications while not being a patient (%)



Figure 10.5. Source of buying MAT medications while not being a patient (%)



Figure 10.6. Route of administration of MAT medications bought from others (%)

11. Overdose and Naloxone



Figure 11.1. Overdose Experience Ever and in the Past 12 Months (%)



Figure 11.2. Trends in Overdose Experience in the Past 12 Months by Survey Round (%)



Figure 11.3. Drugs causing overdoses (if used only one drug) (%)



Figure 11.4. Naloxone Use (%)

Table 11.1. Overdose Experience

	n	%	CI
Experienced overdose ever			
yes	206	40.8	(36.3–45.3)
Number of overdoses in lifetime			
1	65	30.1	(24.1–36.9)
2-4	85	41.1	(34.3–48.3)
5+	56	28.8	(22.7–35.8)
Experienced overdose in the past 12 months			
yes	31	6.3	(4.4–8.9)
Experienced overdose in the past 12 months (of those ever)			
yes	31	15.4	(10.9–21.3)
Number of overdoses in the past 12 months			
1	23	76.3	(58.5–88.0)
2-4	7	21.1	(10.1–38.9)
5+	1	2.6	(0.4–16.4)
Drug overdosed with (if used only one drug)			
methadone	16	59.9	(38.3–78.1)
other opioid	1	3.3	(0.5–20.3)
stimulant	7	36.8	(19.1–59.0)
other	0	0.0	
Drugs overdosed with (if used a combination)			
methadone+stimulant	3	77.7	(26.2–97.1)
methadone+barbit. or dimedr.	1	22.3	(2.9–73.8)
methadone+other	0	0.0	
other	0	0.0	
Drug overdosed with (if combined drug with alcohol)			
methadone	1	29.8	(3.5–83.3)
other opioid	1	48.6	(7.8–91.4)
stimulant	1	21.6	(2.4–75.8)
other	0	0.0	
Naloxone knowledge and experience			
never heard	163	32.4	(28.2–36.8)
aware but not used	278	55.8	(51.2–60.3)
used myself	56	11.2	(8.6–14.4)
my friends used	1	0.2	(0.0–1.4)

	n	%	CI
me and my friends used	2	0.5	(0.1–2.0)

Table 11.2. Overdose Experience in the Past 12 Months by Sociodemographic Characteristics

		Experienced overdose in the past 12 months			
	N	no		yes	
		n	% (CI)	n	% (CI)	p-value
Total						
All	500	469	93.7 (91.1–95.6)	31	6.3 (4.4–8.9)	1.0000
Sex						
male	435	407	93.5 (90.6–95.6)	28	6.5 (4.4–9.4)	0.6210
female	65	62	95.2 (85.7–98.5)	3	4.8 (1.5–14.3)	
Age						
<25	8	6	78.2 (33.7–96.2)	2	21.8 (3.8–66.3)	0.2592
25-34	75	70	93.7 (85.2–97.4)	5	6.3 (2.6–14.8)	
35-44	280	261	93.2 (89.4–95.7)	19	6.8 (4.3–10.6)	
45+	137	132	95.7 (89.6–98.3)	5	4.3 (1.7–10.4)	
Years since the start of injecting drug use						
≤2	17	14	83.0 (55.3–95.0)	3	17.0 (5.0–44.7)	0.1455
3-5	20	20	100.0	0	0.0	
6-10	69	66	96.1 (88.2–98.8)	3	3.9 (1.2–11.8)	
≥11	394	369	93.5 (90.3–95.6)	25	6.5 (4.4–9.7)	
Partnership status						
live alone	278	260	93.7 (90.0–96.0)	18	6.3 (4.0–10.0)	0.9507
live with partner	222	209	93.8 (89.4–96.5)	13	6.2 (3.5–10.6)	
Current employment status						
full-time	152	147	95.9 (90.4–98.3)	5	4.1 (1.7–9.6)	0.3655
part-time or temporary	239	220	92.2 (87.9–95.1)	19	7.8 (4.9–12.1)	
unemployed	36	32	89.5 (73.8–96.2)	4	10.5 (3.8–26.2)	
disabled	45	44	97.8 (85.1–99.7)	1	2.2 (0.3–14.9)	
other	28	26	92.9 (74.3–98.3)	2	7.1 (1.7–25.7)	
Monthly income category						
<3K	54	53	98.2 (87.6–99.8)	1	1.8 (0.2–12.4)	0.5345
3-10K	187	176	93.9 (89.1–96.7)	11	6.1 (3.3–10.9)	

		Experienced overdose in the past 12 months				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
	10-20K	169	157	92.8 (87.4–96.0)	12	7.2 (4.0–12.6)	
	≥20K	63	58	92.1 (81.9–96.8)	5	7.9 (3.2–18.1)	
Ever incarcerated							
	no	317	297	93.7 (90.3–96.0)	20	6.3 (4.0–9.7)	0.9968
	yes	183	172	93.7 (88.8–96.6)	11	6.3 (3.4–11.2)	

Table 11.3. Overdose Experience in the Past 12 Months by Selected Subgroups

		Experienced overdose in the past 12 months				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	455	427	93.7 (91.0–95.7)	28	6.3 (4.3–9.0)	0.9410
yes	45	42	93.5 (81.0–98.0)	3	6.5 (2.0–19.0)	
Treated with MAT currently (of all)						
no	479	450	93.8 (91.1–95.7)	29	6.2 (4.3–8.9)	0.7930
yes	21	19	92.5 (72.1–98.3)	2	7.5 (1.7–27.9)	
HIV test result						
positive	52	50	95.4 (82.4–98.9)	2	4.6 (1.1–17.6)	0.6333
negative	448	419	93.5 (90.7–95.5)	29	6.5 (4.5–9.3)	
Past 30 days injecting 4 categories						
opioids	252	243	96.6 (93.5–98.2)	9	3.4 (1.8–6.5)	0.0015
stimulants	123	118	95.3 (88.7–98.2)	5	4.7 (1.8–11.3)	
opi+stimul	122	105	86.3 (78.6–91.5)	17	13.7 (8.5–21.4)	
other	3	3	100.0	0	0.0	
Injecting drug type of choice						
opioids	334	312	93.5 (90.2–95.8)	22	6.5 (4.2–9.8)	0.8345
stimulants	160	151	93.9 (88.3–96.9)	9	6.1 (3.1–11.7)	
other	6	6	100.0	0	0.0	

Table 11.4. Naloxone Experience by Sociodemographic Characteristics

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total								
All	500	163	32.4 (28.2–36.8)	279	56.0 (51.4–60.5)	58	11.6 (9.0–14.9)	1.0000
Sex								
male	435	142	32.4 (28.0–37.1)	240	55.4 (50.5–60.2)	53	12.2 (9.4–15.8)	0.5587
female	65	21	32.1 (21.3–45.3)	39	60.2 (47.1–72.0)	5	7.6 (3.1–17.7)	
Age								
<25	8	4	57.8 (20.0–88.2)	4	42.2 (11.8–80.0)	0	0.0	0.2058
25-34	75	28	37.5 (26.8–49.6)	43	56.4 (44.3–67.7)	4	6.1 (2.2–15.7)	
35-44	280	86	30.2 (24.9–36.1)	153	55.0 (48.8–61.0)	41	14.8 (10.9–19.7)	
45+	137	45	32.3 (24.6–41.0)	79	58.7 (49.8–67.0)	13	9.1 (5.2–15.3)	
Years since the start of injecting drug use								
≤2	17	7	44.0 (21.3–69.5)	10	56.0 (30.5–78.7)	0	0.0	0.0081
3-5	20	7	30.6 (13.6–55.2)	11	62.0 (37.8–81.4)	2	7.5 (1.6–28.7)	
6-10	69	33	47.1 (35.1–59.4)	35	51.7 (39.5–63.8)	1	1.2 (0.2–8.4)	
≥11	394	116	29.4 (24.9–34.4)	223	56.4 (51.2–61.5)	55	14.1 (10.9–18.1)	
Partnership status								
live alone	278	104	36.3 (30.7–42.3)	142	52.3 (46.1–58.4)	32	11.4 (8.1–15.9)	0.1430
live with partner	222	59	27.8 (21.9–34.4)	137	60.4 (53.4–66.9)	26	11.9 (8.1–17.1)	
Current employment status								
full-time	152	52	34.0 (26.5–42.4)	90	59.3 (50.9–67.3)	10	6.6 (3.5–12.2)	0.5721
part-time or temporary	239	74	30.7 (25.0–37.1)	134	56.0 (49.4–62.4)	31	13.3 (9.4–18.5)	
unemployed	36	11	33.6 (19.0–52.1)	20	53.0 (35.4–69.9)	5	13.5 (5.2–30.6)	
disabled	45	16	34.7 (21.8–50.3)	22	50.8 (35.7–65.7)	7	14.5 (6.7–28.5)	
other	28	10	31.7 (16.9–51.4)	13	48.8 (30.1–67.8)	5	19.5 (8.0–40.3)	
Monthly income category								
<3K	54	17	30.3 (19.1–44.4)	30	56.6 (42.3–69.8)	7	13.2 (6.1–26.2)	0.6805
3-10K	187	60	31.8 (25.2–39.1)	112	60.7 (53.2–67.7)	15	7.5 (4.5–12.3)	
10-20K	169	53	30.4 (23.7–38.0)	95	56.1 (48.2–63.8)	21	13.5 (8.8–20.1)	
≥20K	63	20	34.5 (22.9–48.3)	35	52.8 (39.5–65.8)	8	12.7 (6.2–24.2)	
Ever incarcerated								

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
no	317	111	34.8 (29.5–40.4)	178	56.1 (50.3–61.7)	28	9.2 (6.3–13.2)	0.0614
yes	183	52	28.2 (21.9–35.4)	101	55.9 (48.3–63.2)	30	15.9 (11.2–22.1)	

Table 11.5. Naloxone Experience by Selected Subgroups

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID								
no	455	154	33.5 (29.1–38.1)	254	56.1 (51.2–60.8)	47	10.5 (7.9–13.8)	0.0144
yes	45	9	20.3 (10.5–35.5)	25	55.3 (40.0–69.7)	11	24.4 (13.6–39.8)	
Treated with MAT currently (of all)								
no	479	159	33.1 (28.8–37.6)	264	55.1 (50.4–59.7)	56	11.8 (9.1–15.2)	0.1086
yes	21	4	15.8 (5.5–37.8)	15	76.7 (54.2–90.1)	2	7.5 (1.7–27.9)	
HIV test result								
positive	52	11	19.6 (10.7–33.2)	30	61.8 (47.3–74.5)	11	18.6 (10.1–31.6)	0.0614
negative	448	152	33.9 (29.5–38.7)	249	55.3 (50.4–60.0)	47	10.8 (8.1–14.2)	
Past 30 days injecting 4 categories								
opioids	252	72	28.3 (22.9–34.4)	149	58.9 (52.5–65.0)	31	12.8 (9.0–17.8)	0.0521
stimulants	123	57	44.5 (35.5–53.8)	56	47.6 (38.4–56.9)	10	8.0 (4.2–14.6)	
opi+stimul	122	34	29.0 (21.0–38.4)	71	57.9 (48.3–66.9)	17	13.1 (8.1–20.6)	
other	3	0	0.0	3	100.0	0	0.0	
Injecting drug type of choice								
opioids	334	92	27.6 (22.9–32.9)	199	59.6 (54.0–65.0)	43	12.8 (9.5–17.0)	0.0150
stimulants	160	70	42.8 (35.0–51.0)	76	48.3 (40.2–56.4)	14	8.9 (5.2–14.8)	
other	6	1	16.3 (1.1–76.8)	4	64.4 (15.8–94.6)	1	19.3 (1.4–80.3)	

12. Physical and Mental Health

Table 12.1. Disease and treatment history

		n	%	CI
Had a disease				
	hepatitis B	54	11.1	(8.5–14.4)
	hepatitis C	177	36.5	(32.1–41.1)
	syphilis	7	1.4	(0.6–3.1)

	n	%	CI
gonorrhea	10	2.0	(1.1–3.8)
chlamydia	8	1.5	(0.8–3.1)
herpes	62	13.0	(10.1–16.5)
human papillomavirus	14	2.9	(1.7–4.9)
tuberculosis	31	6.1	(4.3–8.7)
Treated for: hepatitis B			
treated successfully	27	56.2	(42.3–69.2)
treated unsuccessfully	3	4.9	(1.5–14.4)
did not complete	0	0.0	
treated now	2	3.2	(0.8–12.2)
never treated	21	35.7	(23.9–49.7)
Treated for: hepatitis C			
treated successfully	70	41.2	(33.8–49.0)
treated unsuccessfully	9	5.1	(2.6–9.7)
did not complete	8	4.8	(2.3–9.4)
treated now	8	4.5	(2.2–8.9)
never treated	79	44.5	(37.0–52.2)
Treated for: syphilis			
treated successfully	7	100.0	
treated unsuccessfully	0	0.0	
did not complete	0	0.0	
treated now	0	0.0	
never treated	0	0.0	
Treated for: tuberculosis			
treated successfully	30	96.1	(76.7–99.4)
treated unsuccessfully	1	3.9	(0.6–23.3)
did not complete	0	0.0	
treated now	0	0.0	
never treated	0	0.0	

Table 12.2. Mental health screening scores

	n	Mean	CI	Median	IQR
AUDIT-C alcohol risk score ≥5	4,874	1.2	(1.2–1.2)	1	(1–1)
PHQ-9 depression result	5,002	2.2	(2.2–2.3)	2	(1–3)
GAD-7 anxiety result	5,002	1.9	(1.9–1.9)	2	(1–2)

Table 12.3. Health care utilization

	n	%	CI
Had problems with health besides drugs which required medical attention in the past 12 months			
yes	217	43.1	(38.6–47.7)
Referred to a health care facility for treatment in the past 12 months			
yes	190	38.3	(34.0–42.9)
Referred to a health care facility			
primary care	159	83.5	(77.3–88.3)
hospital, HIV clinic	56	30.9	(24.4–38.3)
private clinic	10	5.1	(2.7–9.4)
private lab	19	9.9	(6.2–15.5)
TB dispensary	1	0.6	(0.1–4.3)
drug clinic	4	1.9	(0.7–5.0)
STI clinic	2	0.7	(0.2–2.7)
ambulance	26	13.7	(9.3–19.7)
mobile clinic	0	0.0	

	n	%	CI
other	20	10.2	(6.5–15.5)
Last health care facility referred to			
primary care	149	78.0	(71.2–83.5)
hospital, HIV clinic	17	9.6	(6.0–15.1)
private clinic	8	4.2	(2.1–8.3)
private lab	5	2.4	(1.0–5.8)
TB dispensary	1	0.6	(0.1–4.3)
drug clinic	4	2.1	(0.8–5.9)
STI clinic	0	0.0	
ambulance	3	1.5	(0.5–4.7)
mobile clinic	0	0.0	
other	3	1.5	(0.5–4.9)
Received necessary care in health care facility			
yes	183	97.3	(94.3–98.7)
Signed a declaration with primary care physician			
yes	409	81.3	(77.4–84.7)
How frequently saw the primary care physician			
twice per month or more	17	4.6	(2.8–7.3)
once per month	81	19.2	(15.6–23.5)
3-4 times in 12 months	111	27.8	(23.5–32.6)
only once	199	48.4	(43.4–53.5)



Figure 12.1. Risky alcohol use (AUDIT-C score > 5) (%)



Figure 12.2. Depression symptoms severity (PHQ-9) (%)



Figure 12.3. Anxiety symptoms severity (GAD-7) (%)

Table 12.4. Risky alcohol use (AUDIT-C score > 5) by Sociodemographic Characteristics

			AUDIT-C alcohol risk score ≥5			
		N	no		yes	
			n	% (CI)	n	% (CI)	p-value
Total							
	All	498	443	88.7 (85.4–91.3)	55	11.3 (8.7–14.6)	1.0000
Sex							
	male	433	382	87.8 (84.2–90.7)	51	12.2 (9.3–15.8)	0.0993
	female	65	61	94.5 (85.9–98.0)	4	5.5 (2.0–14.1)	
Age							
	<25	8	7	85.3 (31.4–98.7)	1	14.7 (1.3–68.6)	0.5038

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
25-34	75	67	87.5 (76.4–93.8)	8	12.5 (6.2–23.6)	
35-44	278	243	87.2 (82.5–90.8)	35	12.8 (9.2–17.5)	
45+	137	126	92.4 (86.4–95.9)	11	7.6 (4.1–13.6)	
Years since the start of injecting drug use						
≤2	17	15	87.6 (58.6–97.2)	2	12.4 (2.8–41.4)	0.9330
3-5	20	17	84.1 (58.3–95.3)	3	15.9 (4.7–41.7)	
6-10	69	62	89.0 (78.1–94.9)	7	11.0 (5.1–21.9)	
≥11	392	349	88.9 (85.2–91.8)	43	11.1 (8.2–14.8)	
Partnership status						
live alone	276	242	87.8 (83.2–91.3)	34	12.2 (8.7–16.8)	0.5200
live with partner	222	201	89.7 (84.5–93.3)	21	10.3 (6.7–15.5)	
Current employment status						
full-time	151	139	91.5 (85.5–95.2)	12	8.5 (4.8–14.5)	0.0532
part-time or temporary	239	208	86.3 (81.0–90.3)	31	13.7 (9.7–19.0)	
unemployed	36	32	90.1 (73.7–96.7)	4	9.9 (3.3–26.3)	
disabled	45	43	97.0 (88.1–99.3)	2	3.0 (0.7–11.9)	
other	27	21	76.7 (55.6–89.6)	6	23.3 (10.4–44.4)	
Monthly income category						
<3K	53	44	83.4 (70.0–91.5)	9	16.6 (8.5–30.0)	0.6795
3-10K	187	165	88.2 (82.4–92.3)	22	11.8 (7.7–17.6)	
10-20K	169	151	88.8 (82.7–92.9)	18	11.2 (7.1–17.3)	
≥20K	62	57	91.0 (79.3–96.4)	5	9.0 (3.6–20.7)	
Ever incarcerated						
no	316	281	88.1 (83.8–91.4)	35	11.9 (8.6–16.2)	0.6190
yes	182	162	89.6 (84.1–93.4)	20	10.4 (6.6–15.9)	

Table 12.5. Risky alcohol use (AUDIT-C score > 5) by Selected Subgroups

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
	n		% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	454	404	88.8 (85.3–91.5)	50	11.2 (8.5–14.7)	0.8337
yes	44	39	87.7 (73.0–94.9)	5	12.3 (5.1–27.0)	
Treated with MAT currently (of all)						
no	477	424	88.5 (85.1–91.2)	53	11.5 (8.8–14.9)	0.4623
yes	21	19	93.0 (73.8–98.4)	2	7.0 (1.6–26.2)	
HIV test result						
positive	52	45	88.1 (75.8–94.6)	7	11.9 (5.4–24.2)	0.8986
negative	446	398	88.7 (85.2–91.5)	48	11.3 (8.5–14.8)	
Past 30 days injecting 4 categories						
opioids	252	228	89.8 (85.0–93.2)	24	10.2 (6.8–15.0)	0.7806
stimulants	121	105	86.9 (79.3–92.0)	16	13.1 (8.0–20.7)	
opi+stimul	122	107	88.0 (80.5–92.8)	15	12.0 (7.2–19.5)	
other	3	3	100.0	0	0.0	
Injecting drug type of choice						
opioids	334	300	89.5 (85.5–92.5)	34	10.5 (7.5–14.5)	0.6289
stimulants	158	138	87.1 (80.6–91.7)	20	12.9 (8.3–19.4)	
other	6	5	80.7 (19.7–98.6)	1	19.3 (1.4–80.3)	

Table 12.6. Depression symptoms severity (PHQ-9) by Sociodemographic Characteristics

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	97	20.1 (16.6–24.0)	155	31.1 (27.0–35.5)	109	21.9 (18.3–25.9)	139	27.0 (23.1–31.2)	1.0000
Sex										
male	435	91	21.6 (17.8–26.0)	139	31.9 (27.5–36.6)	89	20.3 (16.7–24.6)	116	26.2 (22.1–30.7)	0.0360
female	65	6	9.4 (4.2–19.9)	16	25.9 (16.2–38.8)	20	32.1 (21.2–45.4)	23	32.5 (22.0–45.3)	
Age										
<25	8	3	43.0 (11.4–81.6)	1	11.8 (1.0–63.0)	0	0.0	4	45.1 (12.9–82.0)	0.0021
25-34	75	23	31.2 (21.2–43.4)	19	26.6 (17.3–38.5)	13	18.1 (10.5–29.5)	20	24.1 (15.7–35.2)	
35-44	280	53	19.4 (15.0–24.7)	103	36.9 (31.2–43.0)	60	21.2 (16.6–26.6)	64	22.5 (17.8–28.1)	
45+	137	18	13.8 (8.7–21.4)	32	23.1 (16.4–31.6)	36	26.6 (19.4–35.2)	51	36.5 (28.4–45.3)	
Years since the start of injecting drug use										

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
≤2	17	6	39.3 (17.8–66.0)	3	17.9 (5.3–46.0)	3	17.0 (5.0–44.7)	5	25.7 (9.9–52.2)	0.1416
3-5	20	8	42.5 (21.0–67.3)	3	17.0 (5.1–43.6)	4	16.3 (5.1–41.3)	5	24.3 (9.5–49.4)	
6-10	69	11	16.3 (9.0–27.5)	22	33.0 (22.5–45.6)	12	17.3 (9.8–28.7)	24	33.4 (22.8–46.0)	
≥11	394	72	18.6 (14.9–23.0)	127	32.1 (27.5–37.1)	90	23.1 (19.0–27.8)	105	26.1 (21.8–30.9)	
Partnership status										
live alone	278	40	15.6 (11.5–20.8)	85	31.1 (25.6–37.1)	60	21.3 (16.7–26.7)	93	32.0 (26.6–37.9)	0.0176
live with partner	222	57	25.2 (19.7–31.7)	70	31.1 (25.1–37.9)	49	22.5 (17.2–28.9)	46	21.1 (15.9–27.4)	
Current employment status										
full-time	152	48	32.2 (24.8–40.5)	48	30.3 (23.2–38.4)	28	20.6 (14.3–28.7)	28	17.0 (11.6–24.0)	0.0094
part-time or temporary	239	37	15.6 (11.4–21.1)	72	30.4 (24.7–36.8)	57	22.8 (17.8–28.7)	73	31.2 (25.4–37.7)	
unemployed	36	6	15.8 (6.9–32.2)	9	29.0 (14.9–48.9)	8	20.8 (10.2–37.9)	13	34.4 (19.8–52.5)	
disabled	45	3	8.6 (2.7–24.4)	18	40.0 (26.2–55.6)	10	21.9 (11.7–37.2)	14	29.5 (17.6–45.0)	
other	28	3	11.0 (3.3–30.5)	8	30.4 (15.4–51.3)	6	22.8 (10.1–43.6)	11	35.8 (19.9–55.6)	
Monthly income category										
<3K	54	5	10.7 (4.2–24.4)	20	39.7 (26.6–54.4)	12	20.7 (11.7–33.8)	17	29.0 (18.1–42.9)	0.0010
3-10K	187	27	14.6 (10.1–20.7)	55	28.8 (22.6–36.0)	43	22.9 (17.2–29.9)	62	33.6 (26.9–41.1)	
10-20K	169	41	25.5 (19.2–33.1)	58	33.6 (26.6–41.4)	32	19.0 (13.6–26.1)	38	21.9 (16.0–29.0)	
≥20K	63	22	34.2 (22.8–47.8)	18	29.6 (18.8–43.3)	17	27.8 (17.3–41.3)	6	8.4 (3.7–18.0)	
Ever incarcerated										
no	317	59	19.3 (15.1–24.4)	94	30.2 (25.2–35.8)	73	22.9 (18.4–28.2)	91	27.5 (22.7–32.9)	0.8196
yes	183	38	21.3 (15.7–28.2)	61	32.6 (26.0–40.1)	36	19.9 (14.5–26.7)	48	26.1 (20.0–33.3)	

Table 12.7. Depression symptoms severity (PHQ-9) by Selected Subgroups

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	97	20.1 (16.6–24.0)	155	31.1 (27.0–35.5)	109	21.9 (18.3–25.9)	139	27.0 (23.1–31.2)	1.0000
Sex										
male	435	91	21.6 (17.8–26.0)	139	31.9 (27.5–36.6)	89	20.3 (16.7–24.6)	116	26.2 (22.1–30.7)	0.0360
female	65	6	9.4 (4.2–19.9)	16	25.9 (16.2–38.8)	20	32.1 (21.2–45.4)	23	32.5 (22.0–45.3)	
Age										
<25	8	3	43.0 (11.4–81.6)	1	11.8 (1.0–63.0)	0	0.0	4	45.1 (12.9–82.0)	0.0021
25-34	75	23	31.2 (21.2–43.4)	19	26.6 (17.3–38.5)	13	18.1 (10.5–29.5)	20	24.1 (15.7–35.2)	
35-44	280	53	19.4 (15.0–24.7)	103	36.9 (31.2–43.0)	60	21.2 (16.6–26.6)	64	22.5 (17.8–28.1)	

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
45+	137	18	13.8 (8.7–21.4)	32	23.1 (16.4–31.6)	36	26.6 (19.4–35.2)	51	36.5 (28.4–45.3)	
Years since the start of injecting drug use										
≤2	17	6	39.3 (17.8–66.0)	3	17.9 (5.3–46.0)	3	17.0 (5.0–44.7)	5	25.7 (9.9–52.2)	0.1416
3-5	20	8	42.5 (21.0–67.3)	3	17.0 (5.1–43.6)	4	16.3 (5.1–41.3)	5	24.3 (9.5–49.4)	
6-10	69	11	16.3 (9.0–27.5)	22	33.0 (22.5–45.6)	12	17.3 (9.8–28.7)	24	33.4 (22.8–46.0)	
≥11	394	72	18.6 (14.9–23.0)	127	32.1 (27.5–37.1)	90	23.1 (19.0–27.8)	105	26.1 (21.8–30.9)	
Partnership status										
live alone	278	40	15.6 (11.5–20.8)	85	31.1 (25.6–37.1)	60	21.3 (16.7–26.7)	93	32.0 (26.6–37.9)	0.0176
live with partner	222	57	25.2 (19.7–31.7)	70	31.1 (25.1–37.9)	49	22.5 (17.2–28.9)	46	21.1 (15.9–27.4)	
Current employment status										
full-time	152	48	32.2 (24.8–40.5)	48	30.3 (23.2–38.4)	28	20.6 (14.3–28.7)	28	17.0 (11.6–24.0)	0.0094
part-time or temporary	239	37	15.6 (11.4–21.1)	72	30.4 (24.7–36.8)	57	22.8 (17.8–28.7)	73	31.2 (25.4–37.7)	
unemployed	36	6	15.8 (6.9–32.2)	9	29.0 (14.9–48.9)	8	20.8 (10.2–37.9)	13	34.4 (19.8–52.5)	
disabled	45	3	8.6 (2.7–24.4)	18	40.0 (26.2–55.6)	10	21.9 (11.7–37.2)	14	29.5 (17.6–45.0)	
other	28	3	11.0 (3.3–30.5)	8	30.4 (15.4–51.3)	6	22.8 (10.1–43.6)	11	35.8 (19.9–55.6)	
Monthly income category										
<3K	54	5	10.7 (4.2–24.4)	20	39.7 (26.6–54.4)	12	20.7 (11.7–33.8)	17	29.0 (18.1–42.9)	0.0010
3-10K	187	27	14.6 (10.1–20.7)	55	28.8 (22.6–36.0)	43	22.9 (17.2–29.9)	62	33.6 (26.9–41.1)	
10-20K	169	41	25.5 (19.2–33.1)	58	33.6 (26.6–41.4)	32	19.0 (13.6–26.1)	38	21.9 (16.0–29.0)	
≥20K	63	22	34.2 (22.8–47.8)	18	29.6 (18.8–43.3)	17	27.8 (17.3–41.3)	6	8.4 (3.7–18.0)	
Ever incarcerated										
no	317	59	19.3 (15.1–24.4)	94	30.2 (25.2–35.8)	73	22.9 (18.4–28.2)	91	27.5 (22.7–32.9)	0.8196
yes	183	38	21.3 (15.7–28.2)	61	32.6 (26.0–40.1)	36	19.9 (14.5–26.7)	48	26.1 (20.0–33.3)	

Table 12.8. Anxiety symptoms severity (GAD-7) by Sociodemographic Characteristics

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	173	35.6 (31.3–40.1)	163	32.6 (28.5–37.1)	91	17.9 (14.7–21.6)	73	13.9 (11.1–17.3)	1.0000
Sex										
male	435	161	37.8 (33.2–42.7)	137	31.5 (27.1–36.3)	77	17.7 (14.2–21.7)	60	13.0 (10.1–16.5)	0.0501
female	65	12	20.2 (11.6–32.7)	26	40.1 (28.3–53.2)	14	19.6 (11.6–31.1)	13	20.1 (11.6–32.4)	
Age										

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
<25	8	2	31.2 (5.9–76.7)	2	21.8 (3.8–66.3)	3	32.3 (7.6–73.4)	1	14.7 (1.3–68.6)	0.3934
25-34	75	31	45.1 (33.5–57.1)	19	24.4 (15.7–35.9)	14	17.6 (10.4–28.1)	11	13.0 (7.1–22.5)	
35-44	280	100	36.0 (30.3–42.0)	97	35.6 (29.9–41.7)	44	15.2 (11.3–20.1)	39	13.3 (9.7–17.9)	
45+	137	40	29.7 (22.2–38.6)	45	31.9 (24.3–40.7)	30	22.7 (16.1–31.0)	22	15.7 (10.3–23.2)	
Years since the start of injecting drug use										
≤2	17	7	46.2 (22.9–71.3)	6	31.9 (13.6–58.2)	3	15.1 (4.3–41.0)	1	6.9 (0.8–39.7)	0.8976
3-5	20	6	34.1 (14.6–60.9)	5	22.6 (8.7–47.4)	5	25.9 (10.1–52.2)	4	17.4 (5.9–41.3)	
6-10	69	19	29.6 (19.5–42.2)	26	38.9 (27.5–51.7)	13	17.2 (10.0–28.1)	11	14.3 (7.8–24.6)	
≥11	394	141	36.2 (31.4–41.3)	126	32.1 (27.5–37.2)	70	17.7 (14.1–22.0)	57	14.0 (10.8–17.9)	
Partnership status										
live alone	278	89	33.8 (28.1–39.9)	86	30.6 (25.2–36.5)	54	19.0 (14.7–24.1)	49	16.7 (12.7–21.7)	0.2048
live with partner	222	84	37.7 (31.2–44.6)	77	35.0 (28.7–41.9)	37	16.7 (12.1–22.5)	24	10.6 (7.1–15.6)	
Current employment status										
full-time	152	69	46.1 (37.8–54.5)	48	33.0 (25.5–41.5)	24	15.3 (10.3–22.1)	11	5.7 (3.1–10.2)	0.0216
part-time or temporary	239	71	30.1 (24.4–36.5)	85	34.6 (28.7–41.2)	44	18.8 (14.2–24.6)	39	16.4 (12.1–21.9)	
unemployed	36	14	38.4 (23.0–56.5)	9	26.1 (13.0–45.3)	6	15.5 (6.6–32.4)	7	20.1 (9.3–38.1)	
disabled	45	11	27.5 (15.6–43.7)	16	33.7 (21.1–49.2)	10	21.8 (11.6–37.1)	8	17.0 (8.3–31.8)	
other	28	8	29.9 (15.0–50.7)	5	20.4 (8.4–41.5)	7	22.2 (10.3–41.6)	8	27.5 (13.7–47.7)	
Monthly income category										
<3K	54	18	34.7 (22.5–49.3)	18	34.7 (22.4–49.6)	12	21.1 (11.9–34.6)	6	9.4 (4.1–20.1)	0.0558
3-10K	187	52	28.5 (22.2–35.8)	67	35.8 (29.0–43.3)	39	20.7 (15.3–27.4)	29	15.0 (10.5–21.1)	
10-20K	169	72	42.8 (35.2–50.7)	48	28.1 (21.5–35.7)	31	18.6 (13.2–25.5)	18	10.6 (6.6–16.5)	
≥20K	63	29	48.7 (35.6–61.9)	23	35.5 (24.0–49.0)	4	6.6 (2.4–17.2)	7	9.2 (4.3–18.7)	
Ever incarcerated										
no	317	109	35.5 (30.2–41.3)	101	32.0 (26.8–37.6)	59	18.2 (14.2–23.1)	48	14.2 (10.8–18.6)	0.9740
yes	183	64	35.6 (28.7–43.2)	62	33.8 (27.0–41.3)	32	17.3 (12.3–23.8)	25	13.3 (9.0–19.3)	

Table 12.9. Anxiety symptoms severity (GAD-7) by Selected Subgroups

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										
no	455	159	35.6 (31.1–40.4)	147	32.4 (28.1–37.1)	84	18.1 (14.7–22.1)	65	13.8 (10.9–17.4)	0.9702
yes	45	14	34.7 (21.5–50.8)	16	34.8 (21.8–50.5)	7	15.7 (7.4–30.1)	8	14.8 (7.2–28.1)	
Treated with MAT currently (of all)										
no	479	166	35.5 (31.1–40.1)	155	32.4 (28.2–37.0)	89	18.3 (15.0–22.2)	69	13.7 (10.9–17.2)	0.6214
yes	21	7	37.3 (18.0–61.6)	8	37.5 (18.7–61.0)	2	7.5 (1.7–27.9)	4	17.7 (6.1–41.5)	
HIV test result										
positive	52	13	23.4 (13.6–37.2)	19	39.0 (25.6–54.3)	8	14.7 (7.1–27.7)	12	23.0 (13.0–37.4)	0.0892
negative	448	160	37.1 (32.5–41.9)	144	31.8 (27.5–36.5)	83	18.3 (14.9–22.3)	61	12.8 (10.0–16.2)	
Past 30 days injecting 4 categories										
opioids	252	82	33.4 (27.6–39.8)	91	36.2 (30.3–42.6)	40	15.5 (11.4–20.6)	39	14.9 (10.9–20.0)	0.1110
stimulants	123	51	42.1 (33.3–51.6)	29	23.4 (16.4–32.2)	22	17.9 (11.9–26.2)	21	16.5 (10.8–24.6)	
opi+stimul	122	40	33.9 (25.5–43.4)	42	34.6 (26.1–44.3)	27	22.0 (15.2–30.6)	13	9.5 (5.5–16.1)	
other	3	0	0.0	1	34.7 (0.3–99.1)	2	65.3 (0.9–99.7)	0	0.0	
Injecting drug type of choice										
opioids	334	105	32.3 (27.2–37.8)	123	37.3 (32.0–42.9)	56	16.3 (12.6–20.7)	50	14.2 (10.8–18.5)	0.0469
stimulants	160	66	42.4 (34.6–50.7)	38	22.8 (16.8–30.3)	33	21.1 (15.2–28.5)	23	13.7 (9.0–20.1)	
other	6	2	35.6 (5.4–84.2)	2	38.0 (5.9–85.8)	2	26.4 (3.6–77.2)	0	0.0	

13. Detention and Incarceration

Table 13.1. Police Detention and Incarceration Experience

	n	%	CI
Detained by police in 2022 for			
drug use	42	8.4	(6.2–11.3)
drug dealing	4	0.8	(0.3–2.0)
drug storing	29	5.8	(4.0–8.2)
Detained by police in 2023 for			
drug use	33	6.7	(4.7–9.3)
drug dealing	4	0.9	(0.3–2.3)
drug storing	20	3.7	(2.4–5.8)
Stopped, detained, or arrested by police ever			
yes	442	88.7	(85.6–91.3)
Ever incarcerated			
yes	183	36.3	(32.1–40.8)
Duration of incarceration			
≤6m	7	3.6	(1.7–7.5)

	n	%	CI
6m-2y	33	17.6	(12.6–24.0)
2-4y	81	44.6	(37.3–52.2)
4y+	62	34.1	(27.4–41.6)
Time since last incarceration			
≤1y	18	9.5	(5.9–14.9)
1-3y	27	14.1	(9.7–20.0)
3-5y	30	16.9	(11.9–23.4)
5-10y	38	21.0	(15.5–27.8)
10y+	70	38.5	(31.4–46.1)
Used injecting drugs during incarceration			
yes	121	64.8	(57.2–71.7)



Figure 13.1. Incarceration Lifetime Experience (%)

14. Negative experience

Table 14.1. Negative experience

	n	%	CI
Felt excluded from family activities due to drug use			
no	237	47.5	(42.9–52.1)
yes, in the past 6m	255	50.9	(46.3–55.5)
yes, but 6m+ ago	7	1.6	(0.8–3.4)
Was scolded because of drug use			
no	175	34.7	(30.5–39.2)
yes, in the past 6m	313	62.6	(58.1–67.0)
yes, but 6m+ ago	11	2.6	(1.4–4.9)
Was blackmailed for drug use			
no	342	68.5	(64.0–72.6)
yes, in the past 6m	152	30.4	(26.3–34.8)
yes, but 6m+ ago	4	1.1	(0.4–3.1)
Negative experience in the past 6 months (GAM 6.5)			
no	180	36.1	(31.8–40.6)
yes	318	63.9	(59.4–68.2)
Ever experienced physical violence			
no	223	44.9	(40.4–49.5)

		n	%	CI
	yes	277	55.1	(50.5–59.6)
Experienced physical violence in the past 12 months (of those who had ever)				
	no	188	68.5	(62.5–73.9)
	yes	89	31.5	(26.1–37.5)
Witnessed physical violence in the past 12 months				
	no	343	69.7	(65.4–73.7)
	yes	157	30.3	(26.3–34.6)



Figure 14.1. Negative Experience Related to Drug Use in the past 6 Months or Physical Violence in the past 12 months (%)

Table 14.2. Negative Experience Related to Drug Use by Sociodemographic Characteristics

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total								
All	498	318	63.9 (59.4–68.2)	1.0000	277	89	31.5 (26.1–37.5)	1.0000
Sex								
male	433	279	64.4 (59.5–69.0)	0.5726	240	69	27.8 (22.3–34.1)	0.0020
female	65	39	60.7 (47.8–72.2)		37	20	54.4 (37.4–70.4)	
Age								
<25	8	4	48.4 (14.4–84.0)	0.3059	5	3	62.2 (15.7–93.6)	0.4252
25-34	75	42	56.0 (44.0–67.4)		33	12	37.8 (22.4–56.1)	
35-44	278	184	66.9 (60.9–72.4)		159	50	30.5 (23.5–38.4)	
45+	137	88	63.3 (54.2–71.5)		80	24	29.1 (19.8–40.5)	
Years since the start of injecting drug use								
≤2	17	11	65.7 (38.8–85.3)	0.8362	10	5	46.5 (18.3–77.1)	0.3053

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
3-5	20	12	59.4 (34.3–80.3)		12	4	31.2 (10.8–63.1)	
6-10	69	41	59.4 (46.9–70.8)		32	14	43.7 (27.0–62.0)	
≥11	392	254	64.8 (59.7–69.6)		223	66	29.1 (23.3–35.8)	
Partnership status								
live alone	278	185	65.4 (59.2–71.0)	0.4876	158	52	32.1 (25.1–40.1)	0.8176
live with partner	220	133	62.2 (55.3–68.6)		119	37	30.8 (22.8–40.1)	
Current employment status								
full-time	150	76	51.1 (42.6–59.5)	0.0000	76	20	24.3 (15.6–35.9)	0.2839
part-time or temporary	239	179	75.5 (69.4–80.7)		141	53	36.1 (28.3–44.7)	
unemployed	36	21	56.4 (38.4–72.9)		22	8	41.2 (21.5–64.0)	
disabled	45	25	54.6 (39.2–69.1)		24	4	19.9 (7.4–43.6)	
other	28	17	63.2 (43.4–79.4)		14	4	31.3 (11.8–60.9)	
Monthly income category								
<3K	54	32	55.8 (41.3–69.4)	0.0218	24	7	30.7 (14.8–52.9)	0.7904
3-10K	186	121	66.1 (58.7–72.8)		101	34	33.9 (25.0–44.1)	
10-20K	168	113	68.4 (60.7–75.2)		98	29	27.0 (19.0–36.8)	
≥20K	63	31	47.5 (34.6–60.7)		36	10	29.2 (15.5–48.0)	
Ever incarcerated								
no	316	189	59.8 (53.9–65.3)	0.0142	166	51	31.1 (24.2–39.0)	0.8675
yes	182	129	71.2 (63.9–77.5)		111	38	32.1 (23.9–41.6)	

Table 14.3. Negative Experience Related to Drug Use by Selected Subgroups

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	454	281	62.0 (57.2–66.6)	0.0023	246	77	30.7 (25.0–37.1)	0.3946
yes	44	37	85.3 (71.1–93.2)		31	12	38.4 (22.6–57.2)	
Treated with MAT currently (of all)								
no	477	300	62.9 (58.2–67.3)	0.0118	264	80	29.8 (24.3–35.9)	0.0029
yes	21	18	88.2 (66.7–96.6)		13	9	70.0 (39.2–89.4)	
HIV test result								

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
positive	52	35	67.3 (52.2–79.5)	0.6082	34	10	31.3 (17.2–50.0)	0.9811
negative	446	283	63.5 (58.7–68.0)		243	79	31.5 (25.8–37.9)	
Past 30 days injecting 4 categories								
opioids	251	165	65.5 (59.2–71.4)	0.2810	140	39	28.3 (21.1–36.7)	0.5702
stimulants	123	67	56.9 (47.6–65.8)		64	27	37.9 (26.5–50.7)	
opi+stimul	121	84	67.6 (57.9–76.0)		70	22	31.9 (21.4–44.6)	
other	3	2	69.5 (1.2–99.8)		3	1	30.5 (0.2–98.8)	
Injecting drug type of choice								
opioids	332	223	66.6 (61.1–71.8)	0.1725	188	52	28.0 (21.7–35.2)	0.1181
stimulants	160	92	58.8 (50.6–66.5)		85	36	39.5 (29.3–50.7)	
other	6	3	47.4 (9.5–88.6)		4	1	20.6 (1.3–83.7)	

15. The Impact of the Full-scale War

Table 15.1. Migration Since February 2022

	n	%	CI
Changed place of residence since Feb 2022			
yes, because of the war	22	4.5	(2.9–6.9)
yes, for other reasons	21	4.4	(2.9–6.9)
no	457	91.1	(88.0–93.4)
Where migrated since Feb 2022			
unknown	0	0.0	
other country	3	12.4	(3.8–33.5)
other oblast	15	72.1	(50.2–86.9)
other city	3	12.4	(3.8–33.5)
other district	1	3.1	(0.4–19.5)
other house	0	0.0	
Where lived before Feb 2022 (if changed residence)			
same oblast	29	68.2	(52.0–80.9)
other oblast	12	28.1	(16.0–44.4)
other country	2	3.7	(0.9–14.1)



Figure 15.1. Change of Residence Since February 2022 (%)



Figure 15.2. Migration Destination by Survey Site (%)



Figure 15.3. Residence Before February 2022 (%)



Figure 15.4. Changes Since February 2022 (%)

City-level Results: Dnipro



Figure A. RDS recruitment tree in Dnipro

1. Sociodemographic Information

Table 1.1. Sociodemographic Characteristics

	n	Mean	CI	Median	IQR
Age, years	500	37.9	(37.1–38.6)	39	(32–43)
Age of first non-injecting drug use	403	17.8	(17.3–18.2)	17	(15–19)
Years since the start of non-injecting drug use	403	19.9	(19.0–20.9)	21	(14–25)
Age of first injecting drug use	496	23.4	(22.9–24.0)	23	(18–27)
Years since the start of injecting drug use	496	14.4	(13.6–15.3)	14	(7–20)
Personal monthly income, UAH	415	12,170.1	(11171.7–13168.5)	10,000	(6000–15000)

Table 1.2. Descriptive Statistics for Sociodemographics

	Site	n	%	CI
Sex				
male	Dnipro	302	58.5	(53.5–63.3)
female	Dnipro	198	41.5	(36.7–46.5)
Age				
<25	Dnipro	23	4.8	(3.1–7.2)
25-34	Dnipro	143	27.8	(23.6–32.3)
35-44	Dnipro	246	49.6	(44.6–54.5)
45+	Dnipro	88	17.9	(14.4–22.1)
Family status				
married or living together	Dnipro	117	23.2	(19.3–27.6)
married but have another partner	Dnipro	28	4.9	(3.3–7.3)
not married but have a partner	Dnipro	121	25.8	(21.6–30.5)
married but not living together	Dnipro	41	7.8	(5.6–10.6)
not married and do not have a partner	Dnipro	193	38.3	(33.6–43.2)
Partnership status				
live alone	Dnipro	234	46.1	(41.2–51.0)
live with partner	Dnipro	266	53.9	(49.0–58.8)
Education				
incompl. high school	Dnipro	63	14.5	(11.1–18.8)
high school	Dnipro	158	31.1	(26.7–35.8)
>high school	Dnipro	279	54.4	(49.4–59.3)
Current occupation				
school student	Dnipro	0	0.0	
college/uni student	Dnipro	4	1.1	(0.3–4.1)
permanent job	Dnipro	192	36.4	(31.9–41.2)
sporadic jobs	Dnipro	175	34.7	(30.2–39.4)
unemployed	Dnipro	64	14.7	(11.3–18.9)
housewife	Dnipro	15	2.9	(1.7–4.9)
disabled	Dnipro	17	3.9	(2.2–7.0)
military	Dnipro	4	0.6	(0.2–1.6)
other	Dnipro	28	5.7	(3.8–8.4)
Homelessness				
never	Dnipro	428	85.5	(81.5–88.8)
yes, 12m+ ago	Dnipro	66	14.3	(11.0–18.2)
yes, in the past 12m	Dnipro	1	0.2	(0.0–1.7)
Homeless in 12 months (of those ever)				
no	Dnipro	66	98.4	(89.3–99.8)
yes	Dnipro	1	1.6	(0.2–10.7)
Monthly income category				
<3K	Dnipro	32	8.2	(5.5–12.0)
3-10K	Dnipro	147	36.0	(31.0–41.4)
10-20K	Dnipro	162	39.8	(34.7–45.2)

	Site	n	%	CI
≥20K	Dnipro	74	15.9	(12.5–20.1)
Monthly income relative to 2023 subsistence minimum				
<2684	Dnipro	32	8.2	(5.5–12.0)
≥2684	Dnipro	383	91.8	(88.0–94.5)
Years since the start of injecting drug use				
≤2	Dnipro	23	5.0	(3.3–7.6)
3-5	Dnipro	65	12.4	(9.6–16.0)
6-10	Dnipro	102	19.4	(16.0–23.3)
≥11	Dnipro	306	63.2	(58.4–67.7)

Table 1.3. Accommodation in the past 12 months

	Site	n	%	CI
own place	Dnipro	292	59.6	(54.7–64.3)
friends or relatives	Dnipro	125	25.5	(21.4–30.1)
renting	Dnipro	71	12.9	(10.1–16.4)
varying	Dnipro	29	5.0	(3.4–7.3)
on the street (homeless)	Dnipro	1	0.2	(0.0–1.6)
in a refugee shelter	Dnipro	1	0.3	(0.0–2.4)



Figure 1.1. Distribution of Age by Sex (%)



Figure 1.2. Trend in Sex Distribution by Survey Round (%)



Figure 1.3. Trend in Age Groups by Survey Round (%)

2. Drug Use



Figure 2.1. Injecting Drug Use in the Past 12 Months and 30 Days (%)



Figure 2.2. Non-injecting Drug Use in the Past 12 Months (%)



Figure 2.3. Trends in Injecting Drugs Types in the Past 30 Days by Survey Round (%)



Figure 2.4. Trends in Injecting Opioids in the Past 30 Days by Survey Round (%)



Figure 2.5. Trends in Injecting Stimulants in the Past 30 Days by Survey Round (%)



Figure 2.6. Trends in Injecting Other Drugs in the Past 30 Days by Survey Round (%)



Figure 2.7. Injecting Drug Preference (%)

Table 2.1. Types of Injecting Drugs in the Past 30 Days by Sociodemographic Characteristics

			Past 30 days injecting 4 categories					
		N	opioids		stimulants		opi+stimul	
			n	% (CI)	n	% (CI)	n	% (CI)
Total								
	All	500	267	53.4 (48.5–58.3)	193	39.4 (34.6–44.4)	40	7.2 (5.2–9.8)
Sex								
	male	302	170	54.7 (48.4–60.9)	114	39.8 (33.7–46.2)	18	5.5 (3.3–8.9)
	female	198	97	51.6 (43.6–59.5)	79	38.9 (31.4–46.9)	22	9.5 (6.1–14.4)
Age								
	<25	23	12	51.6 (30.1–72.5)	9	39.8 (20.7–62.5)	2	8.6 (1.9–30.9)

	N	Past 30 days injecting 4 categories					
		opioids		stimulants		opi+stimul	
		n	% (CI)	n	% (CI)	n	% (CI)
25-34	143	69	47.7 (38.8–56.8)	58	42.3 (33.5–51.6)	16	10.0 (6.0–16.3)
35-44	246	123	53.0 (45.9–59.9)	105	40.7 (34.0–47.8)	18	6.3 (3.9–10.1)
45+	88	63	64.1 (50.7–75.6)	21	31.2 (20.1–45.1)	4	4.7 (1.6–13.0)
Years since the start of injecting drug use							
≤2	23	11	46.9 (26.0–68.8)	10	42.6 (22.7–65.2)	2	10.5 (2.3–37.2)
3-5	65	32	48.2 (34.8–61.8)	29	47.4 (34.0–61.2)	4	4.5 (1.5–12.6)
6-10	102	52	52.7 (42.5–62.8)	42	39.6 (30.1–49.9)	8	7.7 (3.8–15.0)
≥11	306	169	54.9 (48.4–61.2)	111	37.8 (31.6–44.3)	26	7.4 (4.9–10.9)
Partnership status							
live alone	234	125	55.0 (47.8–62.0)	89	37.0 (30.4–44.2)	20	8.0 (5.1–12.4)
live with partner	266	142	52.1 (45.3–58.9)	104	41.4 (34.8–48.4)	20	6.5 (4.0–10.2)
Current employment status							
full-time	192	108	52.4 (44.4–60.2)	75	42.5 (34.7–50.6)	9	5.1 (2.6–9.9)
part-time or temporary	175	92	54.7 (46.6–62.6)	66	37.1 (29.7–45.1)	17	8.2 (5.0–13.3)
unemployed	64	35	63.6 (49.9–75.3)	23	29.9 (19.3–43.2)	6	6.6 (2.8–14.8)
disabled	17	8	31.5 (12.6–59.5)	8	64.0 (35.4–85.2)	1	4.5 (0.5–30.4)
other	51	23	45.6 (30.8–61.3)	21	41.8 (27.1–58.1)	7	12.6 (5.6–26.0)
Monthly income category							
<3K	32	20	55.1 (33.3–75.1)	7	34.0 (15.3–59.6)	5	10.9 (4.2–25.8)
3-10K	147	75	53.4 (44.4–62.2)	57	37.1 (29.0–45.9)	15	9.5 (5.6–15.6)
10-20K	162	86	49.6 (41.1–58.1)	69	45.7 (37.2–54.5)	7	4.7 (2.2–9.9)
≥20K	74	42	62.1 (49.6–73.2)	24	28.1 (18.7–39.9)	8	9.8 (4.5–19.9)
Ever incarcerated							
no	437	232	53.2 (47.8–58.4)	173	40.2 (35.1–45.6)	32	6.6 (4.6–9.4)
yes	63	35	55.5 (42.0–68.3)	20	33.0 (21.6–46.9)	8	11.4 (5.4–22.8)

Table 2.2. Types of Injecting Drugs in the Past 30 Days by Selected Subgroups

	N	Past 30 days injecting 4 categories					
		opioids		stimulants		opi+stimul	
		n	% (CI)	n	% (CI)	n	% (CI)
Client of NGO working with PWID							

	N	Past 30 days injecting 4 categories					
		opioids		stimulants		opi+stimul	
		n	% (CI)	n	% (CI)	n	% (CI)
no	416	219	53.2 (47.7–58.5)	161	39.1 (33.9–44.5)	36	7.8 (5.5–10.9)
yes	83	48	55.4 (43.1–67.1)	31	40.5 (29.1–53.0)	4	4.1 (1.5–10.9)
Treated with MAT currently (of all)							
no	461	235	51.3 (46.2–56.4)	191	41.8 (36.8–46.9)	35	6.9 (4.9–9.7)
yes	35	29	86.6 (71.0–94.5)	1	1.6 (0.2–11.5)	5	11.8 (4.5–27.5)
HIV test result							
positive	85	52	58.8 (45.7–70.7)	24	33.8 (22.2–47.6)	9	7.5 (3.8–14.3)
negative	415	215	52.3 (46.9–57.6)	169	40.6 (35.4–46.0)	31	7.1 (4.9–10.1)
Injecting drug type of choice							
opioids	288	263	92.3 (88.6–94.9)	1	0.2 (0.0–1.3)	24	7.5 (5.0–11.3)
stimulants	210	2	1.2 (0.3–5.2)	192	92.0 (87.1–95.1)	16	6.8 (4.0–11.3)
other	2	2	100.0	0	0.0	0	0.0

Table 2.3. Injecting frequency

	Past 30 days injecting 4 categories							
	opioids		stimulants		opi+stimul		other	
	n	%	n	%	n	%	n	%
Injecting frequency: last 24 hrs								
0 times	84	29.8	61	33.4	8	18.6	0	
1 time	161	61.9	124	63.0	22	59.3	0	
2-3 times	20	7.6	8	3.6	8	18.6	0	
4+ times	2	0.7	0	0.0	2	3.6	0	
N	267		193		40		0	
Injecting frequency: last 24 hrs (among those who did)								
1 time	161	88.3	124	94.6	22	72.8	0	
2-3 times	20	10.8	8	5.4	8	22.8	0	
4+ times	2	0.9	0	0.0	2	4.4	0	
N	183		132		32		0	
Injecting frequency: last week								
0 times	9	2.7	9	5.3	1	2.5	0	
1-6 times	197	75.8	165	85.4	26	73.5	0	
every day	61	21.6	19	9.3	13	24.1	0	
N	267		193		40		0	
Injecting frequency: last 30 days								
1-9 times	65	25.4	64	35.1	8	22.7	0	
10-19 times	91	34.0	67	33.9	12	31.4	0	
20-29 times	62	24.2	49	24.7	8	23.6	0	
every day	49	16.4	13	6.3	12	22.3	0	
N	267		193		40		0	
Injecting frequency: main drug last 30 days								
0-9 times	66	25.9	63	35.1	8	22.7	0	
10-19 times	87	32.0	68	35.4	16	40.7	0	
20-29 times	58	24.3	43	22.4	6	17.9	0	

	Past 30 days injecting 4 categories							
	opioids		stimulants		opi+stimul		other	
	n	%	n	%	n	%	n	%
every day	52	17.8	15	7.2	10	18.7	0	
N	263		189		40		0	

Table 2.4. Injecting drug type of choice by Income Category

	Injecting drug type of choice					
	opioids		stimulants		other	
	n	%	n	%	n	%
Monthly income category						
<3K	23	8.4	9	8.1	0	0.0
3-10K	84	36.3	61	33.9	2	100.0
10-20K	91	36.9	71	44.9	0	0.0
≥20K	45	18.4	29	13.1	0	0.0
N	243		170		2	

Table 2.5. Sources of drugs by Drug Type of Choice

Total		Injecting drug type of choice						
All		opioids		stimulants		other		
n	%	n	%	n	%	n	%	p-value
prepare myself								
106	19.8	73	24.0	33	14.7	0	0.0	0.1463
prepared by friends								
65	12.2	32	10.4	33	14.9	0	0.0	0.4590
from a dealer								
162	33.1	102	34.8	58	29.3	2	100.0	0.0747
buy on Internet								
252	52.7	122	43.9	129	63.8	1	75.2	0.0013
from a pharmacy								
14	3.7	14	6.6	0	0.0	0	0.0	0.0457
from MAT program								
9	1.4	9	2.5	0	0.0	0	0.0	0.2305
other								
18	3.5	8	3.4	10	3.6	0	0.0	0.9304
N								
626		360		263		3		



Figure 2.8. Change in the price, quality, and access of drugs by Drug Type of Choice (%)

3. Injecting Risk Behavior

Table 3.1. Prevalence of Injection Risk Practices

	n	%	CI
Used clean syringe for last injection			
yes	444	88.9	(85.5–91.6)
Source of syringe for last injection			
bought in pharmacy	333	66.0	(61.1–70.6)
got in pharmacy	4	0.8	(0.3–2.0)
got from NGO	59	12.0	(9.1–15.7)
got from friend	47	8.6	(6.3–11.7)
got used from friend	6	1.1	(0.5–2.5)
used one used by myself	30	5.7	(3.9–8.2)
got pre-loaded	19	5.4	(3.2–9.1)
other	2	0.4	(0.1–1.5)
Used shared syringe in the past 30 days			
yes	29	6.2	(4.3–9.1)
Used pre-filled syringe in the past 30 days			
yes	130	26.2	(22.1–30.8)
Used front-/back-loaded syringe in the past 30 days			
yes	195	39.1	(34.4–44.1)
Used shared container in the past 30 days			
yes	244	47.7	(42.8–52.7)
Used own previously used syringe in the past 30 days			
yes	142	26.9	(22.9–31.4)
Gave someone a used syringe in the past 30 days			
yes	36	6.7	(4.8–9.4)
Any inj. risk (shared syringe, pre-filled, front-/back-load, container) in the past 30 days			
yes	325	66.3	(61.4–70.9)

Table 3.2. Frequency of risky injection practices

	n	%	CI
Frequency of injecting with a syringe used by others in the past 30 days			
always	1	2.8	(0.4–17.9)

	n	%	CI
often	4	18.9	(7.3–40.8)
half	6	24.0	(10.9–45.0)
sometimes	8	20.7	(10.1–37.8)
rarely	8	28.4	(14.3–48.6)
never	2	5.1	(1.2–18.8)
Frequency of injecting with others in the same place in the past 30 days			
always	116	25.4	(21.2–30.2)
often	112	21.9	(18.1–26.1)
half	108	22.7	(18.7–27.3)
sometimes	68	13.1	(10.3–16.5)
rarely	48	9.6	(7.0–12.9)
never	44	7.4	(5.4–9.9)
Number of syringes used repeatedly in the past 30 days			
1-9	82	76.9	(67.0–84.5)
10-29	22	21.7	(14.3–31.5)
30+	2	1.5	(0.4–5.9)
Number of times one syringe used repeatedly in the past 30 days			
1	7	7.4	(2.8–18.2)
2-3	71	60.1	(49.2–70.0)
4-9	24	24.1	(15.9–34.6)
10+	8	8.4	(4.2–16.4)
How the pre-filled syringe was obtained			
from dealer	29	22.4	(15.6–31.1)
from friends	57	46.3	(36.7–56.1)
from stash	36	31.3	(22.8–41.4)
Someone used one syringe for injection before front-/back-loading			
no	359	73.3	(68.8–77.3)
yes	137	26.7	(22.7–31.2)



Figure 3.1. Prevalence of Key Injection Risk Practices (%)



Figure 3.2. Trends in Key Injection Risk Practices by Survey Round (%)



Figure 3.3. With whom injected drugs in the same place (%)



Figure 3.4. With whom injected drugs in the same place by sex (%)



Figure 3.5. With whom injected drugs in the same place by age (%)

Table 3.3. Prevalence of Shared and Pre-filled Syringe Use by Sociodemographic Characteristics

		Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	493	29	6.2 (4.3–9.1)	1.0000	495	130	26.2 (22.1–30.8)	1.0000
Sex									
	male	296	20	6.9 (4.3–10.7)	0.5531	298	74	24.8 (19.7–30.6)	0.4352
	female	197	9	5.4 (2.7–10.4)		197	56	28.3 (21.7–36.1)	
Age									
	<25	23	2	11.0 (2.4–38.4)	0.7533	22	5	28.0 (11.4–53.9)	0.9147

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
25-34	139	7	5.2 (2.4–10.9)		142	42	28.6 (21.3–37.2)	
35-44	245	13	6.0 (3.3–10.4)		244	59	25.2 (19.3–32.2)	
45+	86	7	7.4 (3.5–15.2)		87	24	25.0 (16.6–35.8)	
Years since the start of injecting drug use								
≤2	23	2	10.5 (2.3–37.2)	0.7712	22	8	36.4 (17.7–60.3)	0.4091
3-5	64	3	6.3 (1.9–18.8)		62	19	31.9 (20.5–45.9)	
6-10	99	4	4.2 (1.4–11.8)		101	27	28.5 (19.9–39.0)	
≥11	303	19	6.0 (3.8–9.5)		306	75	23.8 (18.8–29.8)	
Partnership status								
live alone	231	10	4.8 (2.5–8.9)	0.2511	230	74	31.7 (25.3–38.9)	0.0241
live with partner	262	19	7.5 (4.7–11.9)		265	56	21.6 (16.6–27.7)	
Current employment status								
full-time	189	10	6.2 (3.2–11.7)	0.9558	190	39	19.0 (13.8–25.5)	0.1214
part-time or temporary	171	11	6.3 (3.4–11.4)		172	49	28.2 (21.3–36.2)	
unemployed	64	5	7.9 (3.0–19.1)		64	20	35.3 (22.5–50.6)	
disabled	17	1	6.0 (0.7–37.1)		17	5	23.1 (7.9–51.1)	
other	51	2	4.0 (0.9–15.3)		51	16	31.8 (19.4–47.4)	
Monthly income category								
<3K	32	2	5.6 (1.2–21.8)	0.0685	32	9	20.7 (9.9–38.3)	0.4799
3-10K	142	14	10.3 (6.0–17.1)		144	42	29.1 (21.5–38.1)	
10-20K	161	6	4.0 (1.7–9.3)		160	35	21.3 (15.3–28.8)	
≥20K	74	2	2.2 (0.5–9.0)		74	14	22.8 (12.7–37.4)	
Ever incarcerated								
no	430	24	6.1 (4.0–9.1)	0.6238	433	115	26.2 (21.8–31.1)	0.9233
yes	63	5	7.7 (3.1–18.2)		62	15	26.8 (16.3–40.7)	

Table 3.4. Prevalence of Shared and Pre-filled Syringe Use by Selected Subgroups

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	410	27	7.2 (4.8–10.5)	0.0377	411	114	27.3 (22.7–32.3)	0.3613

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
yes	82	2	1.8 (0.4–7.1)		83	16	21.5 (12.5–34.3)	
Treated with MAT currently (of all)								
no	454	28	6.6 (4.5–9.6)	0.1583	456	127	27.9 (23.5–32.7)	0.0003
yes	35	0	0.0		35	2	3.9 (0.9–15.3)	
HIV test result								
positive	84	2	2.4 (0.6–9.3)	0.1104	84	21	20.8 (13.3–31.2)	0.2328
negative	409	27	7.1 (4.8–10.4)		411	109	27.4 (22.7–32.5)	
Past 30 days injecting 4 categories								
opioids	262	15	6.2 (3.6–10.3)		262	66	27.6 (21.7–34.5)	
stimulants	191	13	7.1 (4.0–12.3)		193	50	23.0 (17.4–29.8)	
opi+stimul	40	1	2.5 (0.3–16.4)		40	14	33.5 (20.0–50.4)	
other	0	0			0	0		
Injecting drug type of choice								
opioids	283	16	6.2 (3.7–10.1)	0.8928	283	76	29.3 (23.5–35.9)	0.3328
stimulants	208	13	6.5 (3.7–11.3)		210	54	22.8 (17.4–29.3)	
other	2	0	0.0		2	0	0.0	

Table 3.5. Prevalence of Front-/back-loading and Container Sharing by Sociodemographic Characteristics

		Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	497	195	39.1 (34.4–44.1)	1.0000	498	244	47.7 (42.8–52.7)	1.0000
Sex									
	male	299	109	35.7 (29.9–41.9)	0.1065	300	138	46.7 (40.5–53.1)	0.6387
	female	198	86	43.9 (36.1–51.9)		198	106	49.2 (41.3–57.1)	
Age									
	<25	23	5	28.2 (11.7–53.7)	0.0600	22	6	35.6 (16.5–60.9)	0.0628
	25-34	142	55	38.2 (29.7–47.4)		143	71	46.5 (37.7–55.6)	
	35-44	244	93	35.7 (29.4–42.7)		245	117	44.6 (37.8–51.7)	
	45+	88	42	52.7 (40.8–64.3)		88	50	61.4 (49.7–71.9)	
Years since the start of injecting drug use									
	≤2	23	7	33.9 (15.9–58.3)	0.8774	22	7	32.8 (15.1–57.3)	0.0084

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
3-5	65	22	35.8 (23.5–50.4)		65	20	29.4 (18.9–42.6)	
6-10	99	42	41.8 (31.9–52.3)		102	57	55.9 (45.6–65.8)	
≥11	306	121	39.1 (33.0–45.6)		305	157	49.9 (43.4–56.3)	
Partnership status								
live alone	234	89	38.6 (31.8–46.0)	0.8571	232	123	51.1 (43.9–58.3)	0.2150
live with partner	263	106	39.5 (33.1–46.3)		266	121	44.9 (38.2–51.7)	
Current employment status								
full-time	191	67	34.3 (27.2–42.2)	0.5090	192	78	39.3 (31.9–47.2)	0.0095
part-time or temporary	174	71	40.0 (32.3–48.2)		173	94	53.3 (45.0–61.4)	
unemployed	63	31	43.4 (30.2–57.6)		64	38	53.1 (38.6–67.0)	
disabled	17	6	54.9 (26.1–80.8)		17	12	79.3 (52.7–92.9)	
other	51	20	41.8 (27.1–58.2)		51	22	40.6 (26.6–56.4)	
Monthly income category								
<3K	32	15	53.5 (33.0–72.8)	0.4145	32	19	64.6 (44.3–80.7)	0.0169
3-10K	144	57	37.1 (29.0–46.0)		145	74	48.8 (39.8–57.8)	
10-20K	162	61	37.7 (29.8–46.3)		162	70	40.9 (33.0–49.4)	
≥20K	74	25	35.2 (23.6–48.9)		74	23	31.1 (20.8–43.8)	
Ever incarcerated								
no	434	167	37.9 (32.8–43.2)	0.1266	435	207	45.5 (40.3–50.8)	0.0049
yes	63	28	48.7 (35.7–62.0)		63	37	65.0 (52.1–76.0)	

Table 3.6. Prevalence of Front-/back-loading and Container Sharing by Selected Subgroups

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	413	156	36.9 (31.9–42.3)	0.0634	414	197	46.0 (40.7–51.5)	0.1547
yes	83	38	49.2 (37.2–61.2)		83	46	55.6 (43.4–67.3)	
Treated with MAT currently (of all)								
no	458	182	39.3 (34.4–44.5)	0.0669	459	228	47.9 (42.8–53.0)	0.1678
yes	35	9	23.4 (11.8–41.0)		35	12	35.0 (20.1–53.6)	
HIV test result								

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
positive	85	40	49.6 (37.2–62.0)	0.0610	85	50	62.0 (49.6–73.1)	0.0107
negative	412	155	36.9 (31.9–42.2)		413	194	44.7 (39.5–50.0)	
Past 30 days injecting 4 categories								
opioids	266	99	35.6 (29.6–42.2)		266	125	43.8 (37.4–50.5)	
stimulants	191	74	41.7 (33.7–50.0)		192	100	52.6 (44.5–60.6)	
opi+stimul	40	22	51.2 (34.7–67.5)		40	19	50.1 (33.7–66.5)	
other	0	0			0	0		
Injecting drug type of choice								
opioids	287	110	37.1 (31.2–43.4)	0.5628	287	134	44.2 (38.0–50.6)	0.2148
stimulants	208	84	42.2 (34.6–50.1)		209	109	52.9 (45.1–60.5)	
other	2	1	24.8 (0.0–100.0)		2	1	24.8 (0.0–100.0)	

4. Sexual Behavior

Table 4.1. Prevalence of Sexual Practice by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had sex: ever										
yes	470	94.4	(91.9–96.1)	183	94.0	(90.1–96.5)	287	94.7	(91.0–96.9)	0.7694
N	500			198			302			
Had sex: in the past 12 months										
yes	408	86.4	(82.4–89.6)	157	85.1	(78.0–90.2)	251	87.3	(82.1–91.1)	0.5667
N	469			182			287			
Had sex: in the past 30 days										
yes	264	58.0	(52.9–62.9)	117	63.9	(55.6–71.5)	147	53.8	(47.3–60.1)	0.0569
N	464			181			283			
Had a sex partner in the past 30 days: regular										
yes	219	80.7	(74.7–85.5)	93	77.1	(67.1–84.7)	126	83.7	(76.1–89.2)	0.2268
N	270			119			151			
Had a sex partner in the past 30 days: casual										
yes	60	20.9	(16.2–26.6)	26	19.8	(13.3–28.5)	34	21.8	(15.4–29.8)	0.7178
N	269			119			150			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	9	2.8	(1.4–5.7)	1	0.6	(0.1–3.9)	8	4.7	(2.2–9.7)	0.0163
N	269			119			150			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes	22	8.8	(5.5–13.8)	15	13.2	(7.4–22.5)	7	5.1	(2.3–10.9)	0.0427
N	270			119			151			
Used condom during last sex: if ever had sex										
yes	184	45.5	(40.2–51.0)	74	46.2	(37.7–54.9)	110	45.0	(38.2–52.0)	0.8339
N	415			169			246			
Used condom during last sex: if had sex in 12m										

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
yes	172	47.5	(41.8–53.2)	68	48.9	(39.7–58.1)	104	46.5	(39.4–53.7)	0.6849
N	376			149			227			
Used condom during last sex: if had sex in 30d										
yes	121	48.5	(41.7–55.4)	52	49.7	(39.3–60.1)	69	47.5	(38.5–56.6)	0.7558
N	263			117			146			



Figure 4.1. Frequency of sex in the past week by Drug Types Used (%)

Table 4.2. Sex Practices by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had same-sex sexual experience										
yes	66	15.0	(11.6–19.1)	45	26.6	(19.7–34.8)	21	6.8	(4.3–10.4)	0.0000
N	467			182			285			
Provided sex services for money										
yes	61	12.9	(9.8–16.8)	53	27.6	(20.8–35.5)	8	2.6	(1.2–5.3)	0.0000
N	468			183			285			
Paid for sex ever										
yes	101	20.8	(16.9–25.2)	3	1.3	(0.4–3.9)	98	34.5	(28.5–41.0)	0.0000
N	468			182			286			
Had sex with a sex worker in the past 6 months										
yes	24	22.9	(15.2–32.9)	0	0.0		24	23.5	(15.6–33.7)	0.3550
N	101			3			98			
Type of partner with whom had last sex										
regular	271	60.7	(55.5–65.7)	116	63.9	(55.3–71.8)	155	58.4	(51.7–64.7)	0.0000
casual	140	31.0	(26.4–36.1)	42	25.9	(19.0–34.3)	98	34.7	(28.8–41.2)	
com. sex (I paid)	15	3.3	(1.9–5.7)	1	0.4	(0.1–2.6)	14	5.5	(3.1–9.4)	
com. sex (I was paid)	21	4.9	(3.0–8.0)	17	9.8	(5.7–16.4)	4	1.4	(0.5–4.2)	
N	447			176			271			
With whom last had sex										
man	181	40.7	(35.7–45.9)	172	94.0	(88.3–97.0)	9	2.8	(1.4–5.4)	0.0000
woman	272	57.2	(52.0–62.2)	6	3.8	(1.6–8.8)	266	95.2	(92.0–97.2)	

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
men and women	9	2.1	(1.1–4.2)	3	2.3	(0.7–7.1)	6	2.0	(0.9–4.6)	
N	462			181			281			
Type of last sex contact: vaginal										
yes	352	85.9	(81.7–89.2)	147	85.8	(77.8–91.2)	205	86.0	(81.0–89.8)	0.9570
N	411			166			245			
Type of last sex contact: anal										
yes	59	14.0	(10.6–18.3)	21	12.3	(7.6–19.3)	38	15.3	(10.8–21.1)	0.4594
N	411			166			245			
Type of last sex contact: oral										
yes	125	30.4	(25.6–35.8)	49	31.0	(23.4–39.8)	76	30.0	(24.0–36.8)	0.8556
N	411			166			245			

Table 4.3. Sex Partners by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had a sex partner in the past 30 days: regular										
yes	219	80.7	(74.7–85.5)	93	77.1	(67.1–84.7)	126	83.7	(76.1–89.2)	0.2268
N	270			119			151			
Had a sex partner in the past 30 days: casual										
yes	60	20.9	(16.2–26.6)	26	19.8	(13.3–28.5)	34	21.8	(15.4–29.8)	0.7178
N	269			119			150			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	9	2.8	(1.4–5.7)	1	0.6	(0.1–3.9)	8	4.7	(2.2–9.7)	0.0163
N	269			119			150			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes	22	8.8	(5.5–13.8)	15	13.2	(7.4–22.5)	7	5.1	(2.3–10.9)	0.0427
N	270			119			151			
Number of sex partners in the past 30 days: regular										
1	199	93.2	(89.0–95.9)	85	94.2	(88.1–97.3)	114	92.4	(85.9–96.1)	0.4354
2-4	16	6.5	(3.9–10.7)	6	5.1	(2.3–11.2)	10	7.6	(3.9–14.1)	
5+	1	0.3	(0.0–1.9)	1	0.6	(0.1–4.3)	0	0.0		
N	216			92			124			
Number of sex partners in the past 30 days: casual										
1	26	44.5	(31.6–58.3)	11	44.0	(25.5–64.4)	15	44.9	(27.9–63.3)	0.9888
2-4	23	36.7	(24.8–50.4)	10	36.3	(19.9–56.7)	13	37.0	(21.5–55.9)	
5+	10	18.8	(9.9–32.8)	5	19.7	(7.7–41.7)	5	18.0	(7.2–38.5)	
N	59			26			33			
Number of sex partners in the past 30 days: commercial (buying - I paid)										
1	5	44.5	(16.8–76.2)	0	0.0		5	49.0	(17.6–81.1)	0.5614
2-4	1	15.0	(2.1–59.2)	0	0.0		1	16.5	(2.3–62.5)	
5+	3	40.5	(13.1–75.4)	1	100.0		2	34.6	(8.6–74.8)	
N	9			1			8			
Number of sex partners in the past 30 days: commercial (selling - I was paid)										
1	4	17.5	(6.0–41.6)	0	0.0		4	62.2	(20.5–91.3)	
2-4	0	0.0		0	0.0		0	0.0		
5+	17	82.5	(58.4–94.0)	15	100.0		2	37.8	(8.7–79.5)	
N	21			15			6			
Number of sex partners in the past 30 days: total										
1	192	72.9	(66.6–78.4)	83	72.1	(62.1–80.3)	109	73.6	(65.2–80.7)	0.0158
2-4	45	15.1	(11.1–20.0)	14	10.1	(5.9–16.7)	31	19.2	(13.4–26.9)	

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
5+	30	12.0	(8.1–17.5)	21	17.9	(11.1–27.5)	9	7.1	(3.5–13.9)	
N	267			118			149			



Figure 4.2. Condom Use During Last Sexual Encounter by Type of Partner (%)



Figure 4.3. Trends in Condom Use During Last Sexual Encounter by Survey Round (%)

Table 4.4. Condom Use During Last Sexual Encounter by Sociodemographic Characteristics

			Used condom during last sex: if ever had sex				
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
Total							
	All	415	231	54.5 (49.0–59.8)	184	45.5 (40.2–51.0)	1.0000
Sex							

		Used condom during last sex: if ever had sex			
	N	no		yes	
		n	% (CI)	n	% (CI)	p-value
male	246	136	55.0 (48.0–61.8)	110	45.0 (38.2–52.0)	0.8339
female	169	95	53.8 (45.1–62.3)	74	46.2 (37.7–54.9)	
Age						
<25	18	8	42.3 (20.7–67.3)	10	57.7 (32.7–79.3)	0.0387
25-34	119	56	47.6 (37.7–57.6)	63	52.4 (42.4–62.3)	
35-44	208	118	54.1 (46.3–61.8)	90	45.9 (38.2–53.7)	
45+	70	49	69.9 (56.7–80.4)	21	30.1 (19.6–43.3)	
Years since the start of injecting drug use						
≤2	17	8	43.3 (20.7–69.0)	9	56.7 (31.0–79.3)	0.3391
3-5	55	25	44.5 (30.1–59.8)	30	55.5 (40.2–69.9)	
6-10	81	44	52.9 (41.4–64.2)	37	47.1 (35.8–58.6)	
≥11	261	153	57.4 (50.3–64.2)	108	42.6 (35.8–49.7)	
Partnership status						
live alone	166	84	51.0 (42.6–59.4)	82	49.0 (40.6–57.4)	0.3177
live with partner	249	147	56.7 (49.5–63.6)	102	43.3 (36.4–50.5)	
Current employment status						
full-time	165	92	51.7 (43.2–60.1)	73	48.3 (39.9–56.8)	0.0664
part-time or temporary	144	79	52.3 (43.3–61.1)	65	47.7 (38.9–56.7)	
unemployed	48	34	70.2 (52.8–83.2)	14	29.8 (16.8–47.2)	
disabled	17	11	74.2 (46.3–90.6)	6	25.8 (9.4–53.7)	
other	40	15	42.7 (26.0–61.2)	25	57.3 (38.8–74.0)	
Monthly income category						
<3K	29	18	68.1 (46.9–83.7)	11	31.9 (16.3–53.1)	0.2148
3-10K	107	62	56.3 (45.6–66.5)	45	43.7 (33.5–54.4)	
10-20K	145	79	51.7 (42.6–60.7)	66	48.3 (39.3–57.4)	
≥20K	70	33	44.0 (31.8–57.1)	37	56.0 (42.9–68.2)	
Ever incarcerated						
no	360	200	54.7 (48.8–60.5)	160	45.3 (39.5–51.2)	0.7680
yes	55	31	52.4 (38.1–66.3)	24	47.6 (33.7–61.9)	

Table 4.5. Condom Use During Last Sexual Encounter by Selected Subgroups

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	340	203	58.7 (52.6–64.5)	137	41.3 (35.5–47.4)	0.0007
yes	74	28	35.3 (24.6–47.7)	46	64.7 (52.3–75.4)	
Treated with MAT currently (of all)						
no	384	212	53.8 (48.1–59.4)	172	46.2 (40.6–51.9)	0.4123
yes	30	18	62.0 (42.3–78.5)	12	38.0 (21.5–57.7)	
HIV test result						
positive	76	39	53.0 (40.0–65.6)	37	47.0 (34.4–60.0)	0.7983
negative	339	192	54.8 (48.8–60.7)	147	45.2 (39.3–51.2)	
Past 30 days injecting 4 categories						
opioids	222	124	53.5 (46.1–60.8)	98	46.5 (39.2–53.9)	
stimulants	159	86	53.2 (44.3–61.9)	73	46.8 (38.1–55.7)	
opi+stimul	34	21	68.8 (51.1–82.3)	13	31.2 (17.7–48.9)	
other	0	0		0		
Injecting drug type of choice						
opioids	238	137	55.6 (48.3–62.6)	101	44.4 (37.4–51.7)	0.5236
stimulants	176	94	53.4 (45.0–61.6)	82	46.6 (38.4–55.0)	
other	1	0	0.0	1	100.0	

Table 4.6. Condom use by type of partner by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Used condom during last sex: regular partner										
yes	93	44.5	(37.1–52.3)	37	44.7	(33.2–56.9)	56	44.4	(34.9–54.3)	0.9630
N	217			93			124			
Used condom during last sex: casual partner										
yes	38	67.1	(53.8–78.1)	11	46.4	(27.4–66.5)	27	83.0	(67.1–92.1)	0.0034
N	60			26			34			
Used condom during last sex: commercial (I paid) partner										
yes	6	74.0	(40.3–92.3)	0	0.0		6	81.4	(45.7–95.8)	0.0654
N	9			1			8			
Used condom during last sex: commercial (I was paid) partner										
yes	17	89.8	(71.2–96.9)	13	100.0		4	70.1	(33.4–91.7)	0.0292
N	20			13			7			
Condom use frequency: regular partner										
always	40	23.9	(17.3–31.9)	15	25.4	(15.0–39.5)	25	22.7	(15.1–32.6)	0.2302
often	31	12.6	(8.7–17.9)	12	11.0	(6.0–19.3)	19	13.9	(8.7–21.5)	

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
half	21	8.0	(5.1–12.3)	6	4.6	(2.0–10.3)	15	10.5	(6.1–17.3)	
sometimes	18	6.7	(4.2–10.6)	9	7.3	(3.7–14.0)	9	6.2	(3.2–11.8)	
rarely	25	12.0	(8.0–17.6)	16	17.7	(10.7–27.9)	9	7.6	(3.8–14.6)	
never	83	36.9	(29.9–44.5)	34	34.0	(23.9–45.7)	49	39.1	(29.9–49.1)	
N	218			92			126			
Condom use frequency: casual partner										
always	28	48.3	(35.0–61.8)	8	29.4	(14.7–50.1)	20	62.4	(44.3–77.7)	0.0035
often	7	13.9	(6.5–27.3)	3	18.0	(5.8–43.6)	4	10.8	(3.9–26.4)	
half	5	7.7	(2.9–18.8)	1	2.9	(0.4–18.3)	4	11.3	(3.7–29.3)	
sometimes	7	11.8	(5.7–23.1)	6	24.0	(10.9–44.9)	1	2.7	(0.4–17.1)	
rarely	3	4.5	(1.4–13.7)	0	0.0		3	7.9	(2.4–22.8)	
never	9	13.8	(7.0–25.6)	7	25.8	(11.9–47.1)	2	4.9	(1.2–17.9)	
N	59			25			34			
Condom use frequency: commercial (I paid) partner										
always	5	60.7	(29.7–85.0)	0	0.0		5	66.3	(33.3–88.6)	
often	3	23.8	(7.2–55.9)	1	100.0		2	16.9	(3.9–50.5)	
half	0	0.0		0	0.0		0	0.0		
sometimes	0	0.0		0	0.0		0	0.0		
rarely	0	0.0		0	0.0		0	0.0		
never	2	15.5	(3.6–47.2)	0	0.0		2	16.9	(3.9–50.5)	
N	10			1			9			
Condom use frequency: commercial (I was paid) partner										
always	11	61.5	(38.8–80.1)	7	57.5	(29.6–81.3)	4	70.1	(33.4–91.7)	
often	8	29.1	(13.7–51.5)	8	42.5	(18.7–70.4)	0	0.0		
half	0	0.0		0	0.0		0	0.0		
sometimes	0	0.0		0	0.0		0	0.0		
rarely	0	0.0		0	0.0		0	0.0		
never	3	9.4	(2.9–26.8)	0	0.0		3	29.9	(8.3–66.6)	
N	22			15			7			



Figure 4.4. Frequency of condom use by type of partner by Sex (%)



Figure 4.5. Frequency of condom use among men during the last sexual encounter by the riskiest type of partner in the past 30 days (%)

5. HIV, HCV, and Syphilis Testing Results

Table 5.1. HIV Prevalence by Sociodemographic Characteristics

			HIV test result			
	N	positive		negative		
		n	% (CI)	n	% (CI)	p-value
Total						
All	500	85	17.5 (13.9–21.8)	415	82.5 (78.2–86.1)	1.0000
Sex						
male	302	42	14.2 (10.1–19.6)	260	85.8 (80.4–89.9)	0.0518
female	198	43	22.1 (16.1–29.6)	155	77.9 (70.4–83.9)	
Age						
<25	23	4	17.2 (6.1–39.9)	19	82.8 (60.1–93.9)	0.0001
25-34	143	13	8.7 (4.8–15.1)	130	91.3 (84.9–95.2)	
35-44	246	42	16.2 (11.7–21.9)	204	83.8 (78.1–88.3)	
45+	88	26	34.9 (23.5–48.3)	62	65.1 (51.7–76.5)	
Years since the start of injecting drug use						
≤2	23	3	11.7 (3.5–32.9)	20	88.3 (67.1–96.5)	0.0090
3-5	65	6	7.4 (3.1–16.3)	59	92.6 (83.7–96.9)	
6-10	102	12	11.2 (6.2–19.4)	90	88.8 (80.6–93.8)	
≥11	306	63	21.8 (16.7–28.0)	243	78.2 (72.0–83.3)	
Partnership status						
live alone	234	40	16.4 (11.7–22.3)	194	83.6 (77.7–88.3)	0.5911

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
live with partner	266	45	18.5 (13.4–24.9)	221	81.5 (75.1–86.6)	
Current employment status						
full-time	192	31	16.6 (11.4–23.7)	161	83.4 (76.3–88.6)	0.0258
part-time or temporary	175	32	18.2 (12.5–25.6)	143	81.8 (74.4–87.5)	
unemployed	64	11	13.9 (7.3–24.8)	53	86.1 (75.2–92.7)	
disabled	17	5	49.0 (20.5–78.1)	12	51.0 (21.9–79.5)	
other	51	6	11.9 (5.0–25.7)	45	88.1 (74.3–95.0)	
Monthly income category						
<3K	32	13	48.1 (27.9–68.9)	19	51.9 (31.1–72.1)	0.0002
3-10K	147	24	16.6 (10.7–24.9)	123	83.4 (75.1–89.3)	
10-20K	162	24	14.5 (9.6–21.3)	138	85.5 (78.7–90.4)	
≥20K	74	11	12.2 (6.7–21.4)	63	87.8 (78.6–93.3)	
Ever incarcerated						
no	437	74	17.5 (13.7–22.2)	363	82.5 (77.8–86.3)	0.9974
yes	63	11	17.5 (9.5–29.9)	52	82.5 (70.1–90.5)	

Table 5.2. HIV Prevalence by Selected Subgroups

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	416	59	14.8 (11.1–19.3)	357	85.2 (80.7–88.9)	0.0034
yes	83	25	30.2 (20.1–42.6)	58	69.8 (57.4–79.9)	
Treated with MAT currently (of all)						
no	461	69	15.4 (11.9–19.6)	392	84.6 (80.4–88.1)	0.0010
yes	35	14	38.6 (23.0–56.9)	21	61.4 (43.1–77.0)	
Past 30 days injecting 4 categories						
opioids	267	52	19.2 (14.5–25.1)	215	80.8 (74.9–85.5)	
stimulants	193	24	15.0 (9.4–23.0)	169	85.0 (77.0–90.6)	
opi+stimul	40	9	18.3 (9.3–33.0)	31	81.7 (67.0–90.7)	
other	0	0		0		
Injecting drug type of choice						

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
opioids	288	58	19.6 (15.1–25.2)	230	80.4 (74.8–84.9)	0.4838
stimulants	210	26	14.5 (9.3–22.0)	184	85.5 (78.0–90.7)	
other	2	1	24.8 (0.0–100.0)	1	75.2 (0.0–100.0)	



Figure 5.1. HIV Test Result (%)



Figure 5.2. Trends in HIV Prevalence by Survey Round (%)



Figure 5.3. Anti-HCV Testing Coverage In the Survey (%)



Figure 5.4. Anti-HCV Test Results (%)



Figure 5.5. Anti-HCV Test Results by Sex (%)



Figure 5.6. Trends in Anti-HCV Prevalence by Survey Round (%)



Figure 5.7. Syphilis Test Results (%)

6. HIV Prevention

Table 6.1. Being a Client of NGO by Sociodemographic Characteristics

			Client of NGO working with PWID			
		N	no		yes	
			n	% (CI)	n	% (CI)	p-value
Total							
	All	499	416	83.2 (79.1–86.6)	83	16.8 (13.4–20.9)	1.0000
Sex							
	male	301	252	84.2 (79.3–88.1)	49	15.8 (11.9–20.7)	0.5273
	female	198	164	81.7 (74.4–87.3)	34	18.3 (12.7–25.6)	
Age							

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
<25	23	19	82.8 (60.1–93.9)	4	17.2 (6.1–39.9)	0.0711
25-34	143	122	85.1 (77.7–90.3)	21	14.9 (9.7–22.3)	
35-44	246	211	85.8 (80.1–90.1)	35	14.2 (9.9–19.9)	
45+	87	64	72.8 (60.4–82.4)	23	27.2 (17.6–39.6)	
Years since the start of injecting drug use						
≤2	23	20	87.1 (64.7–96.1)	3	12.9 (3.9–35.3)	0.3353
3-5	65	58	90.6 (81.0–95.6)	7	9.4 (4.4–19.0)	
6-10	102	84	79.9 (69.8–87.3)	18	20.1 (12.7–30.2)	
≥11	305	250	82.1 (76.6–86.6)	55	17.9 (13.4–23.4)	
Partnership status						
live alone	234	192	81.3 (74.6–86.5)	42	18.7 (13.5–25.4)	0.3607
live with partner	265	224	84.8 (79.5–88.8)	41	15.2 (11.2–20.5)	
Current employment status						
full-time	192	158	81.8 (74.6–87.3)	34	18.2 (12.7–25.4)	0.8387
part-time or temporary	175	147	82.6 (75.1–88.3)	28	17.4 (11.7–24.9)	
unemployed	64	56	86.9 (74.9–93.6)	8	13.1 (6.4–25.1)	
disabled	16	11	77.4 (49.2–92.3)	5	22.6 (7.7–50.8)	
other	51	43	86.1 (72.6–93.5)	8	13.9 (6.5–27.4)	
Monthly income category						
<3K	31	22	74.2 (54.5–87.4)	9	25.8 (12.6–45.5)	0.0654
3-10K	147	129	89.4 (83.3–93.4)	18	10.6 (6.6–16.7)	
10-20K	162	135	82.2 (74.8–87.8)	27	17.8 (12.2–25.2)	
≥20K	74	58	75.8 (61.6–86.0)	16	24.2 (14.0–38.4)	
Ever incarcerated						
no	436	367	83.9 (79.5–87.4)	69	16.1 (12.6–20.5)	0.2566
yes	63	49	77.7 (64.8–86.9)	14	22.3 (13.1–35.2)	

Table 6.2. Being a Client of NGO by Selected Subgroups

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Treated with MAT currently (of all)						
no	460	392	85.0 (81.0–88.3)	68	15.0 (11.7–19.0)	0.0046
yes	35	22	66.2 (48.4–80.3)	13	33.8 (19.7–51.6)	
HIV test result						
positive	84	59	70.7 (58.2–80.7)	25	29.3 (19.3–41.8)	0.0034
negative	415	357	85.8 (81.6–89.1)	58	14.2 (10.9–18.4)	
Past 30 days injecting 4 categories						
opioids	267	219	82.6 (76.9–87.1)	48	17.4 (12.9–23.1)	
stimulants	192	161	82.7 (75.5–88.0)	31	17.3 (12.0–24.5)	
opi+stimul	40	36	90.4 (75.8–96.6)	4	9.6 (3.4–24.2)	
other	0	0		0		
Injecting drug type of choice						
opioids	288	238	83.0 (77.6–87.3)	50	17.0 (12.7–22.4)	0.7618
stimulants	209	176	83.1 (76.3–88.2)	33	16.9 (11.8–23.7)	
other	2	2	100.0	0	0.0	



Figure 6.1. Injecting and Sex Risk Perception Among HIV-negative PWID (%)



Figure 6.2. Received HIV Prevention Services in the Past 12 Months and 30 days (%)



Figure 6.3. Receiving Package of Prevention Services in the Past 12 Months (%)



Figure 6.4. Trends in Receiving HIV Prevention Services in the Past 12 Months (%)



Figure 6.5. Perceived changes in access to HIV prevention since February 2022 (%)

Table 6.3. Percentage of correct responses to knowledge questions by HIV status

	Total	HIV test result		
	All	negative	positive	
	%	%	%	p-value
HIV knowledge				
HIV may be avoided	82.1	80.8	88.4	0.1165
proper condom use may prevent HIV	64.5	61.8	77.2	0.0211
undetectable=untransmittable	58.9	56.4	70.8	0.0305
PEP reduces the risk of HIV	60.0	57.9	70.2	0.0793
ART should be started immediately	78.5	76.5	88.0	0.0190

	Total	HIV test result		
	All %	negative %	positive %	p-value
ART may be postponed if one feels healthy	49.6	45.4	69.5	0.0002
ART may be stopped if one feels healthy	47.2	43.0	67.1	0.0002
HIV is transmitted through blood and sex	81.2	79.1	91.1	0.0080
HIV is transmitted via air, food, or skin	45.1	42.5	57.2	0.0317
HBV knowledge				
proper condom use may prevent HBV	73.1	72.3	76.6	0.5333
treatment should be started immediately	72.3	69.8	84.2	0.0102
treatment may be postponed if one feels healthy	41.4	38.9	53.5	0.0333
HBV is 100% transmitted from mother to child	14.6	13.9	18.0	0.4257
HBV is transmitted through blood and sex	72.7	70.4	83.4	0.0395
HBV is transmitted via air, food, or skin	40.8	40.1	44.3	0.5308
treatment may be stopped if one feels healthy	45.7	43.9	53.9	0.1516
HCV knowledge				
proper condom use may prevent HCV	7.1	7.5	4.9	0.3768
treatment should be started immediately	74.0	73.2	77.4	0.4533
treatment may be postponed if one feels healthy	41.5	39.5	51.3	0.0822
HCV is 100% transmitted from mother to child	15.4	15.8	13.1	0.6084
HCV is transmitted through blood and sex	74.3	73.1	80.4	0.1856
there is no treatment for HCV	42.3	41.3	46.9	0.4097
HCV is transmitted via air, food, or skin	68.2	68.1	68.7	0.9312
treatment may be stopped if one feels healthy	40.7	41.1	38.5	0.7018

7. HIV Testing

Table 7.1. HIV Testing Knowledge and Uptake

	n	%	CI
Know where to get HIV test			
yes	308	63.7	(58.9–68.3)
Tested for HIV ever			
yes	331	67.9	(63.1–72.3)
Tested for HIV in the past 12 months			
yes	98	36.2	(30.0–42.9)
Tested for HIV in the past 6 months			
yes	29	10.5	(7.0–15.4)
Received the result of HIV test (of those tested)			
yes	323	98.7	(96.8–99.5)
Willing to disclose HIV test result (of those who got result)			
yes	319	99.1	(97.2–99.7)
Self-reported HIV status (of all tested)			
positive	69	22.0	(17.1–27.7)
negative	255	78.0	(72.3–82.9)
HIV testing and status awareness (GAM)			
yes	135	49.3	(42.7–55.9)
Ever did a HIV self-test			
yes	4	1.3	(0.4–4.2)
Regular sex partner tested for HIV			
yes	126	52.5	(45.2–59.7)
Regular sex partner HIV test result			
positive	23	18.2	(11.6–27.4)
negative	100	79.3	(69.9–86.3)
cannot disclose	3	2.6	(0.8–7.7)



Figure 7.1. HIV Testing Uptake (%)



Figure 7.2. Testing for HIV, HCV, syphilis since February 2022 (%)



Figure 7.3. HIV Testing Since February 2022 (%)

Table 7.2. Testing for HIV in the past 12 months (among all) by Sociodemographic Characteristics

	N	Tested for HIV in the past 12 months			
		no		yes	
		n	% (CI)	n	% (CI)	p-value
Total						
All	291	193	63.8 (57.1–70.0)	98	36.2 (30.0–42.9)	1.0000
Sex						
male	166	110	66.5 (58.0–74.1)	56	33.5 (25.9–42.0)	0.3620
female	125	83	60.4 (49.7–70.3)	42	39.6 (29.7–50.3)	
Age						
<25	10	8	81.8 (46.4–95.9)	2	18.2 (4.1–53.6)	0.6628
25-34	76	51	66.4 (54.2–76.8)	25	33.6 (23.2–45.8)	
35-44	154	101	61.7 (52.1–70.4)	53	38.3 (29.6–47.9)	
45+	51	33	63.6 (46.8–77.6)	18	36.4 (22.4–53.2)	
Years since the start of injecting drug use						
≤2	9	5	48.5 (18.2–79.9)	4	51.5 (20.1–81.8)	0.2256
3-5	32	24	76.6 (57.4–88.8)	8	23.4 (11.2–42.6)	
6-10	57	44	71.0 (55.8–82.6)	13	29.0 (17.4–44.2)	
≥11	193	120	60.8 (52.4–68.7)	73	39.2 (31.3–47.6)	
Partnership status						
live alone	119	81	67.0 (56.2–76.4)	38	33.0 (23.6–43.8)	0.4204
live with partner	172	112	61.6 (52.8–69.6)	60	38.4 (30.4–47.2)	

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Current employment status						
full-time	118	81	64.6 (54.2–73.8)	37	35.4 (26.2–45.8)	0.8114
part-time or temporary	101	66	60.1 (48.4–70.8)	35	39.9 (29.2–51.6)	
unemployed	30	19	61.6 (39.4–79.9)	11	38.4 (20.1–60.6)	
disabled	13	8	75.1 (44.0–92.0)	5	24.9 (8.0–56.0)	
other	29	19	70.1 (50.0–84.6)	10	29.9 (15.4–50.0)	
Monthly income category						
<3K	21	12	62.6 (37.2–82.6)	9	37.4 (17.4–62.8)	0.9630
3-10K	78	54	65.7 (52.0–77.2)	24	34.3 (22.8–48.0)	
10-20K	111	80	68.0 (57.6–76.8)	31	32.0 (23.2–42.4)	
≥20K	51	33	64.1 (47.3–78.1)	18	35.9 (21.9–52.7)	
Ever incarcerated						
no	249	168	63.8 (56.4–70.6)	81	36.2 (29.4–43.6)	0.9699
yes	42	25	64.1 (47.9–77.6)	17	35.9 (22.4–52.1)	

Table 7.3. Testing for HIV in the past 12 months (among all) by Selected Subgroups

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	224	169	73.2 (65.7–79.6)	55	26.8 (20.4–34.3)	0.0000
yes	66	23	32.2 (21.3–45.3)	43	67.8 (54.7–78.7)	
Treated with MAT currently (of all)						
no	262	182	67.4 (60.3–73.7)	80	32.6 (26.3–39.7)	0.0020
yes	27	11	36.0 (19.6–56.5)	16	64.0 (43.5–80.4)	
HIV test result						
positive	72	44	58.8 (44.7–71.6)	28	41.2 (28.4–55.3)	0.3849
negative	219	149	65.6 (57.9–72.5)	70	34.4 (27.5–42.1)	
Past 30 days injecting 4 categories						
opioids	152	96	57.9 (48.4–66.8)	56	42.1 (33.2–51.6)	
stimulants	110	78	71.6 (61.1–80.2)	32	28.4 (19.8–38.9)	
opi+stimul	29	19	67.2 (46.5–82.8)	10	32.8 (17.2–53.5)	

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
other	0	0		0		
Injecting drug type of choice						
opioids	166	107	60.7 (51.7–69.0)	59	39.3 (31.0–48.3)	0.0698
stimulants	123	86	70.5 (60.6–78.8)	37	29.5 (21.2–39.4)	
other	2	0	0.0	2	100.0	

8. HIV Treatment

Figure 8.1. HIV Status Awareness Among HIV+ (%)



Figure 8.2. HIV Treatment Cascade - Four-stage (%)



Figure 8.3. HIV Treatment Cascade - Conditional (%)



Figure 8.4. HIV Treatment Cascade - Proportions (%)



Figure 8.5. Trends in HIV Treatment Cascade (Conditional, 95-95-95) by Survey Round (%)

Table 8.1. HIV Treatment Cascade (Conditional, 95-95-95) by Sociodemographic Characteristics

		Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
		N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Total											
	All	85	81.0 (69.2–89.0)	1.0000	68	96.9 (90.6–99.0)	1.0000	65	52	81.5 (69.4–89.5)	1.0000
Sex											
	male	42	65.4 (46.6–80.4)	0.0003	28	100.0	0.1950	28	20	71.2 (50.1–85.9)	0.1044
	female	43	95.0 (85.2–98.5)		40	95.0 (85.0–98.5)		37	32	88.2 (72.6–95.5)	
Age											
	<25	4	78.5 (24.9–97.6)	0.7707	3	100.0	0.5741	3	3	100.0	0.5558

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
25-34	13	84.5 (52.8–96.4)		11	93.1 (62.4–99.1)		10	8	85.4 (53.2–96.8)	
35-44	42	75.9 (60.8–86.5)		30	95.2 (81.8–98.9)		28	24	85.5 (65.1–94.9)	
45+	26	86.4 (52.2–97.4)		24	100.0		24	17	73.6 (50.7–88.3)	
Years since the start of injecting drug use										
≤2	3	70.0 (15.4–96.8)	0.5808	2	100.0	0.8857	2	2	100.0	0.3034
3-5	6	58.9 (19.5–89.5)		4	100.0		4	2	41.0 (8.5–83.8)	
6-10	12	85.3 (54.9–96.5)		10	100.0		10	8	75.5 (34.8–94.7)	
≥11	63	82.0 (67.5–90.9)		51	96.1 (88.2–98.8)		48	39	83.5 (69.9–91.7)	
Partnership status										
live alone	40	85.4 (71.4–93.2)	0.3975	33	93.2 (80.2–97.9)	0.0679	30	28	91.3 (69.3–98.0)	0.1198
live with partner	45	77.6 (59.3–89.2)		35	100.0		35	24	73.9 (56.3–86.2)	
Current employment status										
full-time	31	86.3 (69.6–94.5)	0.5182	26	97.7 (85.0–99.7)	0.7987	25	20	78.2 (55.4–91.2)	0.1037
part-time or temporary	32	76.5 (58.9–88.1)		23	93.4 (76.2–98.4)		21	20	96.9 (80.1–99.6)	
unemployed	11	93.1 (62.1–99.1)		10	100.0		10	8	85.4 (53.2–96.8)	
disabled	5	62.9 (12.0–95.4)		4	100.0		4	1	59.0 (11.0–94.4)	
other	6	85.7 (39.2–98.2)		5	100.0		5	3	50.1 (12.8–87.3)	
Monthly income category										
<3K	13	78.0 (28.9–96.9)	0.6522	12	94.4 (65.7–99.3)	0.6001	11	9	85.2 (51.8–96.9)	0.3327
3-10K	24	87.2 (68.9–95.4)		20	93.2 (74.7–98.4)		18	11	67.1 (41.1–85.7)	
10-20K	24	71.4 (50.7–85.9)		16	100.0		16	14	84.5 (53.1–96.4)	
≥20K	11	71.6 (39.3–90.8)		8	100.0		8	8	100.0	
Ever incarcerated										
no	74	80.3 (67.3–89.0)	0.6455	59	96.5 (89.4–98.9)	0.5472	56	44	80.8 (67.6–89.5)	0.7177

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
yes	11	85.9 (55.6–96.7)		9	100.0		9	8	86.3 (42.7–98.2)	

Table 8.2. HIV Treatment Cascade (Conditional, 95-95-95) by Selected Subgroups

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID										
no	59	75.2 (59.9–86.0)	0.0294	44	95.3 (85.8–98.5)	0.2375	41	32	79.1 (62.4–89.6)	0.3095
yes	25	94.2 (78.2–98.7)		23	100.0		23	20	89.0 (69.6–96.6)	
Treated with MAT currently (of all)										
no	69	81.1 (67.3–90.0)	0.5312	56	96.2 (88.6–98.8)	0.5188	53	42	79.9 (65.8–89.1)	0.3213
yes	14	73.3 (44.4–90.4)		10	100.0		10	9	92.1 (57.3–99.0)	
HIV test result										
positive	85	81.0 (69.0–89.0)		68	96.9 (90.5–99.1)		65	52	81.5 (69.2–89.6)	
negative	0	0.0		0	0.0		0	0	0.0	
Past 30 days injecting 4 categories										
opioids	52	84.8 (72.4–92.2)		43	100.0		43	37	83.7 (66.9–92.8)	
stimulants	24	75.5 (48.0–91.2)		18	93.4 (75.2–98.5)		16	11	80.7 (57.2–92.9)	
opi+stimul	9	75.8 (37.9–94.2)		7	85.8 (40.3–98.2)		6	4	62.9 (22.3–90.9)	
other	0			0			0	0		
Injecting drug type of choice										
opioids	58	83.0 (71.0–90.6)	0.7454	47	98.5 (89.7–99.8)	0.5152	46	40	85.3 (69.4–93.7)	0.0862
stimulants	26	76.7 (49.9–91.6)		20	93.8 (76.7–98.6)		18	12	78.1 (55.0–91.2)	
other	1	100.0		1	100.0		1	0	0.0	

Table 8.3. ART adherence (among those on ART)

		n	%	CI
When did you last miss ART dose				
	last week	5	6.2	(2.5–14.7)
	1-2 weeks ago	3	3.7	(1.2–11.1)
	3-4 weeks ago	5	7.1	(2.9–16.4)
	1-3 months ago	4	5.7	(2.1–14.6)
	never	48	77.3	(65.4–86.0)
What was the reason for missing the last ART dose				
	forgot	8	42.5	(20.0–68.6)
	did not have meds	6	44.9	(20.2–72.4)

		n	%	CI
	was under influence	3	12.6	(3.7–35.1)
	did not want others to see	0	0.0	
	other	0	0.0	
Reasons for not taking ART				
	not sure it is needed	2	10.6	(2.5–35.7)
	no time to visit clinic	1	3.2	(0.4–20.2)
	no motivation to visit clinic	4	36.8	(12.8–69.7)
	missed a visit, hard to come back	1	3.6	(0.5–22.5)
	too sick to visit clinic	1	6.6	(0.9–35.4)
	drug use	6	44.3	(19.5–72.2)
	side effects or complications	1	6.2	(0.9–33.5)
	no understanding of how to take it	0	0.0	
	lost or sold all ARVs	0	0.0	
	alcohol use	1	5.0	(0.7–28.8)
	waited too long and left	0	0.0	
Time on ART				
	≤3m	1	4.2	(0.6–25.4)
	4-24m	7	55.2	(28.5–79.2)
	25-60m	7	35.4	(15.4–62.3)
	5y+	1	5.2	(0.7–30.1)

9. PrEP



Figure 9.1. PrEP Uptake in the Past 12 Months (%)



Figure 9.2. Change in PrEP Awareness and Uptake from 2020 to 2023 (%)



Figure 9.3. Change in PrEP Uptake from 2020 to 2023 (%)

Table 9.1. PrEP Awareness by Sociodemographic Characteristics

			PrEP uptake in the past 12 months								
		N	use now		used in the past		never used		not aware		
			n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total											
	All	500	42	9.4 (6.7–13.0)	18	4.8 (2.7–8.4)	109	20.0 (16.4–24.0)	331	65.9 (60.9–70.5)	1.0000
Sex											
	male	302	28	10.1 (6.7–15.0)	8	3.5 (1.5–7.9)	54	16.2 (12.4–20.9)	212	70.3 (64.1–75.7)	0.0925
	female	198	14	8.3 (4.5–14.6)	10	6.7 (3.1–13.9)	55	25.3 (19.1–32.7)	119	59.7 (51.5–67.4)	
Age											
	<25	23	2	7.4 (1.7–27.2)	0	0.0	5	19.7 (7.7–42.0)	16	72.9 (50.6–87.7)	0.0555
	25-34	143	20	14.4 (9.2–21.9)	2	1.3 (0.3–5.5)	27	16.2 (11.0–23.1)	94	68.1 (59.5–75.7)	

	N	PrEP uptake in the past 12 months								
		use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
35-44	246	18	9.0 (5.2–15.2)	14	8.0 (4.2–14.7)	56	20.9 (15.9–27.0)	158	62.1 (54.7–69.0)	
45+	88	2	2.9 (0.7–11.9)	2	2.7 (0.6–11.7)	21	23.3 (14.5–35.2)	63	71.0 (58.8–80.9)	
Years since the start of injecting drug use										
≤2	23	3	11.7 (3.5–32.9)	0	0.0	2	8.2 (1.8–29.8)	18	80.1 (57.9–92.2)	0.0417
3-5	65	5	9.4 (3.6–22.1)	1	1.1 (0.2–8.0)	7	8.5 (3.9–17.5)	52	81.0 (68.4–89.4)	
6-10	102	12	13.7 (7.7–23.3)	2	2.1 (0.5–8.4)	25	22.6 (15.3–32.0)	63	61.6 (51.1–71.0)	
≥11	306	22	7.9 (4.8–12.9)	15	6.8 (3.7–12.4)	74	22.3 (17.6–27.9)	195	62.9 (56.3–69.1)	
Partnership status										
live alone	234	25	11.9 (7.7–17.9)	6	4.8 (1.9–11.8)	42	16.8 (12.1–22.8)	161	66.5 (59.0–73.2)	0.3571
live with partner	266	17	7.2 (4.1–12.1)	12	4.9 (2.4–9.5)	67	22.6 (17.7–28.5)	170	65.3 (58.6–71.5)	
Current employment status										
full-time	192	16	6.8 (4.1–11.0)	8	4.2 (2.0–8.6)	53	28.0 (21.3–35.9)	115	61.1 (53.1–68.5)	0.0792
part-time or temporary	175	11	7.9 (4.0–15.1)	6	4.3 (1.5–11.6)	29	15.3 (10.6–21.6)	129	72.5 (64.2–79.5)	
unemployed	64	7	15.6 (6.9–31.4)	2	9.7 (2.5–31.1)	11	12.4 (6.5–22.2)	44	62.4 (46.8–75.8)	
disabled	17	0	0.0	1	4.5 (0.5–30.4)	5	21.6 (7.4–48.7)	11	73.9 (46.1–90.3)	
other	51	8	18.3 (8.8–34.1)	1	2.3 (0.3–15.1)	10	15.5 (8.0–27.9)	32	64.0 (48.2–77.2)	
Monthly income category										
<3K	32	0	0.0	0	0.0	9	23.7 (11.5–42.5)	23	76.3 (57.5–88.5)	0.4382
3-10K	147	11	9.2 (4.7–17.4)	3	3.5 (0.8–13.2)	30	16.8 (11.7–23.6)	103	70.5 (61.4–78.2)	
10-20K	162	13	7.5 (4.2–13.2)	9	4.9 (2.4–9.8)	36	22.9 (16.4–31.0)	104	64.6 (56.1–72.4)	
≥20K	74	10	15.0 (7.8–26.9)	2	7.2 (1.5–27.7)	20	23.1 (14.7–34.2)	42	54.8 (41.8–67.2)	
Ever incarcerated										
no	437	40	10.1 (7.1–14.1)	13	4.5 (2.3–8.5)	95	19.7 (16.0–24.1)	289	65.7 (60.4–70.6)	0.4002
yes	63	2	3.6 (0.9–13.8)	5	7.5 (2.7–18.8)	14	21.6 (12.6–34.4)	42	67.4 (53.8–78.5)	

Table 9.2. PrEP Current Use by Sociodemographic Characteristics

	N	PrEP uptake in the past 12 months								
		use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										
no	416	22	6.5 (4.0–10.5)	12	3.6 (1.7–7.3)	74	15.6 (12.3–19.7)	308	74.2 (69.0–78.8)	0.0000
yes	83	20	23.4 (14.8–34.8)	6	10.9 (4.4–24.8)	35	41.5 (30.2–53.7)	22	24.2 (15.8–35.3)	
Treated with MAT currently (of all)										
no	461	39	9.5 (6.7–13.3)	18	5.2 (2.9–9.1)	95	18.6 (15.1–22.6)	309	66.7 (61.6–71.5)	0.3563
yes	35	3	9.3 (2.9–26.3)	0	0.0	12	30.0 (16.9–47.5)	20	60.7 (42.8–76.1)	

		PrEP uptake in the past 12 months								
	N	use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
HIV test result										
positive	85	0	0.0	0	0.0	40	45.4 (33.5–57.9)	45	54.6 (42.1–66.5)	0.0000
negative	415	42	11.3 (8.1–15.6)	18	5.8 (3.3–10.1)	69	14.6 (11.4–18.5)	286	68.3 (62.9–73.2)	
Past 30 days injecting 4 categories										
opioids	267	24	11.4 (7.3–17.4)	10	6.1 (2.8–12.6)	59	19.6 (15.2–24.9)	174	62.9 (56.0–69.4)	
stimulants	193	15	6.9 (4.0–11.6)	6	3.1 (1.3–7.2)	40	20.5 (14.7–28.0)	132	69.5 (61.6–76.3)	
opi+stimul	40	3	7.7 (2.3–22.4)	2	4.9 (1.1–19.5)	10	19.4 (10.1–34.1)	25	68.0 (51.5–80.9)	
other	0	0		0		0		0		
Injecting drug type of choice										
opioids	288	25	10.3 (6.7–15.5)	11	6.0 (2.8–12.1)	64	19.8 (15.5–24.9)	188	64.0 (57.4–70.1)	0.0167
stimulants	210	16	6.7 (3.9–11.1)	7	3.4 (1.6–7.4)	44	20.1 (14.6–27.1)	143	69.8 (62.4–76.3)	
other	2	1	75.2 (0.0–100.0)	0	0.0	1	24.8 (0.0–100.0)	0	0.0	

Table 9.3. PrEP Awareness and Uptake

	n	%	CI
PrEP uptake in the past 12 months			
use now	42	9.4	(6.7–13.0)
used in the past	18	4.8	(2.7–8.4)
never used	109	20.0	(16.4–24.0)
not aware	331	65.9	(60.9–70.5)
Aware of PrEP			
no	331	65.9	(60.9–70.5)
yes	169	34.1	(29.5–39.1)
PrEP use current			
no	458	90.6	(87.0–93.3)
yes	42	9.4	(6.7–13.0)
PrEP use current (of those aware)			
no	127	72.6	(63.8–79.9)
yes	42	27.4	(20.1–36.2)

10. MAT



Figure 10.1. MAT Awareness (%)



Figure 10.2. MAT Current Uptake (%)



Figure 10.3. Trends in MAT Lifetime and Current Uptake by Survey Round (%)

Table 10.1. MAT experience

	n	%	CI
Reason for MAT discontinuation			
moved to another city	1	6.6	(0.9–35.6)
clinic closed after Feb 2022	0	0.0	
weak or no effect	3	21.9	(6.8–51.9)
side effects	9	78.7	(49.2–93.3)
do not want to visit clinic	2	13.1	(3.1–41.3)
do not want to quit drugs	4	39.3	(15.4–69.7)
hard to get to the clinic	1	6.6	(0.9–35.6)
do not need it	1	6.6	(0.9–35.6)
do not like the attitude of physician	4	26.9	(9.7–55.8)
How did the injection frequency change during MAT			
intensified	1	10.9	(1.5–49.1)
did not change	6	44.3	(19.6–72.1)
decreased	5	44.8	(19.4–73.3)
Whether bought bupr. or methadone while not being a patient in the past 12 months			
yes, methadone	103	19.0	(15.6–22.9)
yes, buprenorphine	4	0.7	(0.2–1.9)
did not buy	384	80.4	(76.4–83.8)
Where bought bupr. or methadone while not being a patient in the past 12 months			
did not buy	384	80.4	(76.4–83.8)
bought from black market	105	19.4	(16.0–23.3)
bought from private clinic	2	0.3	(0.1–1.2)
Way of using bupr. or methaone bought from others			
injecting	78	73.2	(63.3–81.2)
injecting mixed	25	24.2	(16.5–34.1)
swallow or subling.	3	2.6	(0.8–7.7)
snort	0	0.0	

Table 10.2. MAT Awareness and Uptake by Sociodemographic Characteristics

	N	MAT uptake (of all)								
		take it now		took in the past		never took but plan to		unaware or do not plan to		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	496	35	6.3 (4.5–8.9)	12	2.2 (1.2–3.9)	85	17.5 (14.0–21.6)	364	74.0 (69.5–78.0)	1.0000
Sex										
male	300	24	7.0 (4.6–10.5)	7	2.1 (1.0–4.4)	46	15.6 (11.5–20.8)	223	75.3 (69.6–80.3)	0.5877
female	196	11	5.4 (2.9–9.9)	5	2.3 (0.9–5.9)	39	20.3 (14.6–27.5)	141	72.1 (64.5–78.6)	
Age										
<25	23	0	0.0	0	0.0	1	3.7 (0.5–24.3)	22	96.3 (75.7–99.5)	0.2204
25-34	143	9	5.8 (2.9–11.4)	2	1.1 (0.3–4.3)	25	17.7 (11.8–25.6)	107	75.4 (67.0–82.3)	
35-44	245	20	7.5 (4.7–11.7)	5	2.0 (0.8–5.0)	45	19.3 (14.1–25.9)	175	71.2 (64.3–77.2)	
45+	85	6	5.6 (2.5–12.3)	5	5.2 (2.1–12.2)	14	15.7 (9.0–25.9)	60	73.5 (62.4–82.2)	
Years since the start of injecting drug use										
≤2	23	0	0.0	0	0.0	2	7.0 (1.6–26.2)	21	93.0 (73.8–98.4)	0.5147
3-5	65	3	3.0 (0.9–9.6)	1	2.8 (0.4–18.0)	10	18.6 (9.8–32.4)	51	75.6 (61.5–85.7)	
6-10	102	6	7.0 (3.1–15.2)	1	0.9 (0.1–6.4)	17	15.5 (9.5–24.3)	78	76.6 (66.7–84.2)	
≥11	303	26	7.4 (5.0–10.9)	10	2.6 (1.4–4.9)	56	18.9 (14.3–24.6)	211	71.0 (65.0–76.4)	
Partnership status										
live alone	231	17	6.0 (3.7–9.6)	4	1.9 (0.7–5.3)	38	16.6 (11.8–22.9)	172	75.5 (68.9–81.2)	0.9118
live with partner	265	18	6.7 (4.1–10.7)	8	2.4 (1.2–4.9)	47	18.3 (13.6–24.1)	192	72.7 (66.3–78.2)	
Current employment status										
full-time	190	12	5.8 (3.2–10.3)	5	3.0 (1.2–7.3)	32	16.2 (11.4–22.5)	141	75.0 (67.9–81.0)	0.7283
part-time or temporary	175	15	8.1 (4.7–13.5)	4	2.0 (0.7–5.4)	33	19.7 (13.8–27.4)	123	70.2 (62.1–77.2)	
unemployed	62	2	2.3 (0.5–10.1)	2	1.8 (0.4–7.3)	12	20.9 (11.0–36.0)	46	75.0 (60.2–85.7)	
disabled	17	3	12.6 (3.3–37.6)	1	3.6 (0.4–25.7)	2	8.1 (1.6–31.7)	11	75.7 (48.6–91.1)	
other	51	3	5.7 (1.8–16.9)	0	0.0	6	13.9 (5.8–29.8)	42	80.4 (64.6–90.2)	
Monthly income category										

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
<3K	32	3	6.7 (1.9–20.8)	3	7.7 (2.2–23.3)	3	7.7 (2.2–23.3)	23	77.9 (59.6–89.4)	0.2971
3-10K	146	10	6.7 (3.5–12.4)	2	1.8 (0.4–7.4)	29	19.9 (13.5–28.5)	105	71.6 (62.6–79.1)	
10-20K	162	13	7.6 (4.2–13.2)	2	1.0 (0.2–3.9)	30	18.2 (12.6–25.5)	117	73.3 (65.3–80.0)	
≥20K	74	9	10.3 (5.2–19.3)	2	2.7 (0.7–10.4)	7	11.2 (5.1–23.0)	56	75.8 (63.6–84.9)	
Ever incarcerated										
no	434	28	5.9 (4.0–8.6)	8	1.6 (0.8–3.4)	78	18.7 (14.8–23.2)	320	73.8 (69.0–78.2)	0.0107
yes	62	7	10.1 (4.7–20.2)	4	6.5 (2.4–16.7)	7	8.4 (3.9–17.2)	44	75.0 (62.7–84.3)	

Table 10.3. MAT Awareness and Uptake by Selected Subgroups

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
Client of NGO working with PWID										
no	414	22	5.0 (3.2–7.8)	7	1.5 (0.7–3.4)	70	17.5 (13.6–22.1)	315	76.0 (71.0–80.3)	0.0052
yes	81	13	13.3 (7.7–22.1)	5	5.4 (2.2–12.8)	15	17.9 (10.5–28.8)	48	63.4 (51.6–73.7)	
Treated with MAT currently (of all)										
no	461	0	0.0	12	2.3 (1.3–4.2)	85	18.7 (15.0–23.1)	364	79.0 (74.5–82.9)	0.0000
yes	35	35	100.0	0	0.0	0	0.0	0	0.0	
HIV test result										
positive	83	14	14.5 (8.3–24.2)	5	4.7 (1.9–11.0)	10	12.6 (6.5–23.0)	54	68.2 (56.3–78.1)	0.0028
negative	413	21	4.7 (3.0–7.3)	7	1.7 (0.8–3.6)	75	18.5 (14.6–23.2)	310	75.1 (70.2–79.5)	
Past 30 days injecting 4 categories										
opioids	264	29	10.3 (7.0–14.7)	5	1.6 (0.7–4.0)	54	22.1 (16.8–28.6)	176	66.0 (59.2–72.1)	
stimulants	192	1	0.3 (0.0–1.9)	5	2.6 (1.0–6.5)	26	12.1 (8.1–17.7)	160	85.0 (79.0–89.5)	
opi+stimul	40	5	10.3 (4.0–24.3)	2	3.6 (0.8–14.1)	5	12.6 (5.0–28.2)	28	73.5 (57.0–85.2)	
other	0	0		0		0		0		
Injecting drug type of choice										
opioids	285	33	10.7 (7.6–15.1)	6	1.8 (0.8–4.0)	57	20.9 (16.0–26.8)	189	66.5 (60.2–72.3)	0.0003
stimulants	209	2	0.7 (0.2–2.8)	6	2.7 (1.1–6.3)	27	11.7 (7.9–17.0)	174	84.9 (79.2–89.3)	
other	2	0	0.0	0	0.0	1	75.2 (0.0–100.0)	1	24.8 (0.0–100.0)	



Figure 10.4. Buying MAT medications while not being a patient (%)



Figure 10.5. Source of buying MAT medications while not being a patient (%)



Figure 10.6. Route of administration of MAT medications bought from others (%)

11. Overdose and Naloxone



Figure 11.1. Overdose Experience Ever and in the Past 12 Months (%)



Figure 11.2. Trends in Overdose Experience in the Past 12 Months by Survey Round (%)



Figure 11.3. Drugs causing overdoses (if used only one drug) (%)



Figure 11.4. Naloxone Use (%)

Table 11.1. Overdose Experience

	n	%	CI
Experienced overdose ever			
yes	146	25.9	(22.1–30.1)
Number of overdoses in lifetime			
1	46	35.8	(27.7–44.8)
2-4	63	43.0	(34.6–51.8)
5+	31	21.2	(14.9–29.3)
Experienced overdose in the past 12 months			
yes	36	5.7	(4.0–8.0)
Experienced overdose in the past 12 months (of those ever)			
yes	36	22.2	(16.0–29.9)
Number of overdoses in the past 12 months			
1	27	74.3	(56.7–86.5)
2-4	9	25.7	(13.5–43.3)
5+	0	0.0	
Drug overdosed with (if used only one drug)			
methadone	6	39.3	(18.4–65.0)
other opioid	4	24.2	(9.1–50.4)
stimulant	7	36.6	(17.5–61.0)
other	0	0.0	
Drugs overdosed with (if used a combination)			
methadone+stimulant	1	36.4	(4.9–86.5)
methadone+barbit. or dimedr.	0	0.0	
methadone+other	1	36.4	(4.9–86.5)
other	1	27.1	(3.2–80.6)
Drug overdosed with (if combined drug with alcohol)			
methadone	7	37.9	(17.8–63.3)
other opioid	2	16.7	(4.2–47.7)
stimulant	6	40.6	(18.4–67.4)
other	1	4.8	(0.7–28.1)
Naloxone knowledge and experience			
never heard	245	51.6	(46.7–56.5)
aware but not used	152	29.3	(25.1–33.9)
used myself	45	7.6	(5.6–10.3)
my friends used	52	10.2	(7.6–13.6)

	n	%	CI
me and my friends used	6	1.2	(0.5–2.8)

Table 11.2. Overdose Experience in the Past 12 Months by Sociodemographic Characteristics

		Experienced overdose in the past 12 months			
	N	no		yes	
		n	% (CI)	n	% (CI)	p-value
Total						
All	494	458	94.3 (92.0–96.0)	36	5.7 (4.0–8.0)	1.0000
Sex						
male	297	271	92.8 (89.3–95.2)	26	7.2 (4.8–10.7)	0.0600
female	197	187	96.4 (93.3–98.1)	10	3.6 (1.9–6.7)	
Age						
<25	21	18	90.6 (72.1–97.3)	3	9.4 (2.7–27.9)	0.5159
25-34	140	132	96.0 (91.9–98.0)	8	4.0 (2.0–8.1)	
35-44	246	229	94.4 (90.7–96.7)	17	5.6 (3.3–9.3)	
45+	87	79	92.3 (85.0–96.3)	8	7.7 (3.7–15.0)	
Years since the start of injecting drug use						
≤2	21	19	93.7 (75.3–98.6)	2	6.3 (1.4–24.7)	0.5445
3-5	64	56	90.8 (81.9–95.6)	8	9.2 (4.4–18.1)	
6-10	101	95	95.6 (90.2–98.1)	6	4.4 (1.9–9.8)	
≥11	304	284	94.6 (91.4–96.6)	20	5.4 (3.4–8.6)	
Partnership status						
live alone	231	212	92.9 (88.7–95.6)	19	7.1 (4.4–11.3)	0.1726
live with partner	263	246	95.5 (92.8–97.3)	17	4.5 (2.7–7.2)	
Current employment status						
full-time	189	173	93.5 (89.4–96.1)	16	6.5 (3.9–10.6)	0.3626
part-time or temporary	173	162	94.7 (90.2–97.2)	11	5.3 (2.8–9.8)	
unemployed	63	61	97.8 (91.3–99.5)	2	2.2 (0.5–8.7)	
disabled	17	16	96.4 (74.3–99.6)	1	3.6 (0.4–25.7)	
other	51	45	90.0 (77.0–96.1)	6	10.0 (3.9–23.0)	
Monthly income category						
<3K	32	30	95.3 (81.6–98.9)	2	4.7 (1.1–18.4)	0.8871
3-10K	143	133	93.8 (88.4–96.8)	10	6.2 (3.2–11.6)	

		Experienced overdose in the past 12 months					
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
	10-20K	162	152	94.8 (90.1–97.4)	10	5.2 (2.6–9.9)	
	≥20K	73	65	92.6 (85.2–96.4)	8	7.4 (3.6–14.8)	
Ever incarcerated							
	no	432	408	95.8 (93.7–97.3)	24	4.2 (2.7–6.3)	0.0000
	yes	62	50	82.6 (70.3–90.5)	12	17.4 (9.5–29.7)	

Table 11.3. Overdose Experience in the Past 12 Months by Selected Subgroups

		Experienced overdose in the past 12 months				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	411	381	94.3 (91.7–96.1)	30	5.7 (3.9–8.3)	0.9500
yes	82	76	94.4 (87.8–97.6)	6	5.6 (2.4–12.2)	
Treated with MAT currently (of all)						
no	456	423	94.4 (91.9–96.1)	33	5.6 (3.9–8.1)	0.6701
yes	35	32	92.7 (78.6–97.8)	3	7.3 (2.2–21.4)	
HIV test result						
positive	83	77	93.9 (86.7–97.4)	6	6.1 (2.6–13.3)	0.8663
negative	411	381	94.4 (91.8–96.2)	30	5.6 (3.8–8.2)	
Past 30 days injecting 4 categories						
opioids	262	242	93.8 (90.3–96.1)	20	6.2 (3.9–9.7)	
stimulants	192	180	96.0 (92.8–97.8)	12	4.0 (2.2–7.2)	
opi+stimul	40	36	89.0 (71.6–96.3)	4	11.0 (3.7–28.4)	
other	0	0		0		
Injecting drug type of choice						
opioids	283	262	93.9 (90.5–96.1)	21	6.1 (3.9–9.5)	0.8285
stimulants	209	194	94.8 (91.1–97.0)	15	5.2 (3.0–8.9)	
other	2	2	100.0	0	0.0	

Table 11.4. Naloxone Experience by Sociodemographic Characteristics

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total								

	N	Naloxone knowledge and experience (3 categories)						
		unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
All	500	245	51.6 (46.7–56.5)	204	39.6 (34.9–44.4)	51	8.8 (6.6–11.6)	1.0000
Sex								
male	302	137	47.4 (41.2–53.7)	129	41.6 (35.6–47.8)	36	11.0 (7.9–15.2)	0.0451
female	198	108	57.6 (49.6–65.1)	75	36.7 (29.4–44.6)	15	5.7 (3.4–9.6)	
Age								
<25	23	17	78.6 (57.1–91.0)	6	21.4 (9.0–42.9)	0	0.0	0.0113
25-34	143	82	60.9 (52.0–69.1)	52	33.4 (25.7–42.0)	9	5.7 (2.9–11.0)	
35-44	246	112	47.4 (40.3–54.5)	105	42.4 (35.5–49.5)	29	10.3 (7.0–14.8)	
45+	88	34	41.9 (30.4–54.4)	41	46.2 (34.6–58.3)	13	11.9 (6.8–20.2)	
Years since the start of injecting drug use								
≤2	23	18	83.1 (62.9–93.5)	5	16.9 (6.5–37.1)	0	0.0	0.0011
3-5	65	39	61.9 (48.1–73.9)	21	31.4 (20.3–45.1)	5	6.7 (2.7–15.9)	
6-10	102	62	60.6 (50.1–70.1)	31	31.0 (22.2–41.4)	9	8.5 (4.3–15.9)	
≥11	306	123	44.0 (37.6–50.6)	146	45.8 (39.5–52.3)	37	10.2 (7.2–14.1)	
Partnership status								
live alone	234	124	52.4 (45.2–59.5)	90	39.8 (32.9–47.2)	20	7.8 (4.9–12.2)	0.7743
live with partner	266	121	51.0 (44.2–57.7)	114	39.3 (33.1–45.9)	31	9.7 (6.8–13.7)	
Current employment status								
full-time	192	89	48.9 (41.0–56.8)	83	41.6 (34.1–49.5)	20	9.5 (6.1–14.6)	0.9468
part-time or temporary	175	86	50.7 (42.5–58.8)	71	40.3 (32.6–48.5)	18	9.0 (5.6–14.3)	
unemployed	64	37	57.6 (43.2–70.8)	22	35.5 (23.1–50.2)	5	6.9 (2.8–16.3)	
disabled	17	7	56.2 (27.2–81.5)	9	40.2 (16.7–69.3)	1	3.6 (0.4–25.7)	
other	51	26	55.6 (40.0–70.2)	18	33.9 (21.1–49.6)	7	10.5 (4.4–22.9)	
Monthly income category								
<3K	32	16	55.8 (35.3–74.5)	13	36.1 (19.7–56.5)	3	8.2 (2.4–24.4)	0.0041
3-10K	147	78	53.9 (44.9–62.7)	61	40.9 (32.4–50.0)	8	5.2 (2.6–10.3)	
10-20K	162	66	45.3 (36.8–54.1)	68	38.9 (31.1–47.3)	28	15.8 (10.8–22.5)	
≥20K	74	25	31.7 (21.5–44.0)	41	60.7 (48.2–72.0)	8	7.6 (3.7–15.0)	
Ever incarcerated								
no	437	226	54.6 (49.3–59.7)	173	38.0 (33.0–43.2)	38	7.5 (5.4–10.3)	0.0002

			Naloxone knowledge and experience (3 categories)						
		N	unaware		aware but did not use		used myself		
			n	% (CI)	n	% (CI)	n	% (CI)	p-value
	yes	63	19	28.8 (18.4–42.0)	31	52.0 (38.8–65.0)	13	19.2 (11.0–31.5)	

Table 11.5. Naloxone Experience by Selected Subgroups

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID								
no	416	208	53.3 (47.9–58.6)	167	38.2 (33.2–43.5)	41	8.5 (6.2–11.6)	0.2600
yes	83	36	42.9 (31.6–55.0)	37	46.5 (34.6–58.8)	10	10.6 (5.6–19.1)	
Treated with MAT currently (of all)								
no	461	235	53.8 (48.6–58.8)	184	38.4 (33.6–43.4)	42	7.8 (5.7–10.7)	0.0002
yes	35	7	21.6 (9.9–40.7)	19	53.4 (35.6–70.4)	9	25.0 (12.9–43.0)	
HIV test result								
positive	85	37	50.4 (38.1–62.8)	34	36.0 (25.3–48.4)	14	13.5 (7.8–22.4)	0.2815
negative	415	208	51.9 (46.5–57.2)	170	40.3 (35.2–45.6)	37	7.8 (5.6–10.9)	
Past 30 days injecting 4 categories								
opioids	267	123	48.0 (41.3–54.8)	114	42.0 (35.5–48.7)	30	10.0 (6.9–14.2)	
stimulants	193	110	60.3 (52.3–67.7)	67	33.2 (26.2–41.0)	16	6.5 (3.8–10.9)	
opi+stimul	40	12	31.1 (17.6–48.6)	23	56.4 (39.4–72.0)	5	12.6 (5.0–28.2)	
other	0	0		0		0		
Injecting drug type of choice								
opioids	288	130	47.1 (40.7–53.6)	125	42.4 (36.3–48.9)	33	10.5 (7.4–14.6)	0.4022
stimulants	210	114	57.1 (49.4–64.4)	78	36.1 (29.2–43.6)	18	6.9 (4.2–11.1)	
other	2	1	75.2 (0.0–100.0)	1	24.8 (0.0–100.0)	0	0.0	

12. Physical and Mental Health

Table 12.1. Disease and treatment history

		n	%	CI
Had a disease				
	hepatitis B	27	5.5	(3.7–8.2)
	hepatitis C	59	13.0	(9.8–17.0)
	syphilis	17	3.5	(2.1–5.7)
	gonorrhea	29	6.3	(4.3–9.1)
	chlamydia	47	11.4	(8.3–15.5)
	herpes	75	15.4	(12.2–19.4)

		n	%	CI
	human papillomavirus	6	1.2	(0.5–2.6)
	tuberculosis	17	3.8	(2.2–6.6)
Treated for: hepatitis B				
	treated successfully	15	54.4	(34.7–72.8)
	treated unsuccessfully	4	18.1	(6.7–40.4)
	did not complete	5	18.8	(7.9–38.6)
	treated now	3	8.7	(2.7–24.3)
	never treated	0	0.0	
Treated for: hepatitis C				
	treated successfully	20	36.6	(23.4–52.2)
	treated unsuccessfully	4	6.7	(2.3–18.0)
	did not complete	2	3.4	(0.8–13.0)
	treated now	8	11.8	(5.6–23.3)
	never treated	23	41.4	(27.3–57.2)
Treated for: syphilis				
	treated successfully	6	35.2	(15.8–61.0)
	treated unsuccessfully	1	7.0	(1.0–36.4)
	did not complete	2	15.6	(3.8–46.8)
	treated now	1	5.2	(0.7–29.7)
	never treated	7	37.0	(17.6–61.6)
Treated for: tuberculosis				
	treated successfully	16	95.2	(71.6–99.3)
	treated unsuccessfully	1	4.8	(0.7–28.4)
	did not complete	0	0.0	
	treated now	0	0.0	
	never treated	0	0.0	

Table 12.2. Mental health screening scores

	n	Mean	CI	Median	IQR
AUDIT-C alcohol risk score ≥5	4,874	1.2	(1.2–1.2)	1	(1–1)
PHQ-9 depression result	5,002	2.2	(2.2–2.3)	2	(1–3)
GAD-7 anxiety result	5,002	1.9	(1.9–1.9)	2	(1–2)

Table 12.3. Health care utilization

		n	%	CI
Had problems with health besides drugs which required medical attention in the past 12 months				
	yes	149	28.6	(24.4–33.2)
Referred to a health care facility for treatment in the past 12 months				
	yes	116	23.5	(19.4–28.0)
Referred to a health care facility				
	primary care	66	54.1	(43.6–64.3)
	hospital, HIV clinic	33	34.0	(24.2–45.4)
	private clinic	8	6.2	(2.9–12.6)
	private lab	2	2.3	(0.5–9.3)
	TB dispensary	0	0.0	
	drug clinic	0	0.0	
	STI clinic	9	7.7	(3.9–14.6)
	ambulance	23	16.4	(10.7–24.2)
	mobile clinic	0	0.0	
	other	3	2.8	(0.9–8.4)
Last health care facility referred to				

	n	%	CI
primary care	61	51.0	(40.6–61.3)
hospital, HIV clinic	20	21.8	(13.6–33.1)
private clinic	7	5.6	(2.5–12.0)
private lab	0	0.0	
TB dispensary	0	0.0	
drug clinic	1	1.0	(0.1–6.9)
STI clinic	9	7.7	(3.9–14.6)
ambulance	18	13.0	(8.0–20.3)
mobile clinic	0	0.0	
other	0	0.0	
Received necessary care in health care facility			
yes	106	92.3	(85.6–96.0)
Signed a declaration with primary care physician			
yes	211	45.1	(40.1–50.2)
How frequently saw the primary care physician			
twice per month or more	2	1.0	(0.2–3.8)
once per month	24	11.9	(7.6–18.1)
3-4 times in 12 months	104	51.0	(43.1–58.9)
only once	76	36.1	(28.9–44.1)



Figure 12.1. Risky alcohol use (AUDIT-C score > 5) (%)



Figure 12.2. Depression symptoms severity (PHQ-9) (%)



Figure 12.3. Anxiety symptoms severity (GAD-7) (%)

Table 12.4. Risky alcohol use (AUDIT-C score > 5) by Sociodemographic Characteristics

			AUDIT-C alcohol risk score ≥5				
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
Total							
	All	493	357	73.3 (68.8–77.3)	136	26.7 (22.7–31.2)	1.0000
Sex							
	male	297	213	72.1 (66.1–77.3)	84	27.9 (22.7–33.9)	0.5025
	female	196	144	75.0 (68.0–80.9)	52	25.0 (19.1–32.0)	
Age							
	<25	23	14	60.7 (37.7–79.7)	9	39.3 (20.3–62.3)	0.4492

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
25-34	142	107	77.0 (69.0–83.5)	35	23.0 (16.5–31.0)	
35-44	242	176	73.0 (66.3–78.7)	66	27.0 (21.3–33.7)	
45+	86	60	71.7 (60.3–80.9)	26	28.3 (19.1–39.7)	
Years since the start of injecting drug use						
≤2	23	12	55.5 (33.4–75.6)	11	44.5 (24.4–66.6)	0.1090
3-5	65	42	67.7 (54.4–78.6)	23	32.3 (21.4–45.6)	
6-10	101	74	70.5 (59.9–79.3)	27	29.5 (20.7–40.1)	
≥11	301	226	76.4 (70.8–81.3)	75	23.6 (18.7–29.2)	
Partnership status						
live alone	231	156	67.0 (59.9–73.4)	75	33.0 (26.6–40.1)	0.0065
live with partner	262	201	78.7 (73.1–83.4)	61	21.3 (16.6–26.9)	
Current employment status						
full-time	188	149	80.8 (74.3–86.0)	39	19.2 (14.0–25.7)	0.0443
part-time or temporary	174	118	68.9 (61.1–75.7)	56	31.1 (24.3–38.9)	
unemployed	63	41	63.3 (48.5–76.0)	22	36.7 (24.0–51.5)	
disabled	17	13	83.2 (56.8–94.9)	4	16.8 (5.1–43.2)	
other	50	35	71.5 (56.2–83.1)	15	28.5 (16.9–43.8)	
Monthly income category						
<3K	32	23	73.7 (53.6–87.2)	9	26.3 (12.8–46.4)	0.0008
3-10K	145	92	63.6 (54.4–71.8)	53	36.4 (28.2–45.6)	
10-20K	160	124	79.9 (72.8–85.5)	36	20.1 (14.5–27.2)	
≥20K	74	65	88.4 (78.5–94.1)	9	11.6 (5.9–21.5)	
Ever incarcerated						
no	431	315	74.1 (69.4–78.3)	116	25.9 (21.7–30.6)	0.2764
yes	62	42	67.0 (53.2–78.4)	20	33.0 (21.6–46.8)	

Table 12.5. Risky alcohol use (AUDIT-C score > 5) by Selected Subgroups

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
	n		% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	410	295	72.5 (67.6–77.0)	115	27.5 (23.0–32.4)	0.4604
yes	82	61	76.7 (65.8–84.9)	21	23.3 (15.1–34.2)	
Treated with MAT currently (of all)						
no	456	328	72.9 (68.2–77.1)	128	27.1 (22.9–31.8)	0.5511
yes	33	26	77.9 (59.1–89.5)	7	22.1 (10.5–40.9)	
HIV test result						
positive	82	69	87.5 (78.7–93.0)	13	12.5 (7.0–21.3)	0.0011
negative	411	288	70.3 (65.3–74.9)	123	29.7 (25.1–34.7)	
Past 30 days injecting 4 categories						
opioids	261	190	73.9 (67.6–79.3)	71	26.1 (20.7–32.4)	
stimulants	192	140	74.1 (66.9–80.2)	52	25.9 (19.8–33.1)	
opi+stimul	40	27	64.7 (47.2–79.0)	13	35.3 (21.0–52.8)	
other	0	0		0		
Injecting drug type of choice						
opioids	282	205	73.5 (67.6–78.8)	77	26.5 (21.2–32.4)	0.6047
stimulants	209	150	72.4 (65.3–78.5)	59	27.6 (21.5–34.7)	
other	2	2	100.0	0	0.0	

Table 12.6. Depression symptoms severity (PHQ-9) by Sociodemographic Characteristics

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	120	24.7 (20.6–29.4)	141	29.9 (25.5–34.7)	107	20.8 (17.1–25.1)	132	24.6 (20.8–28.8)	1.0000
Sex										
male	302	76	25.2 (20.2–31.0)	79	28.7 (23.1–35.0)	67	20.9 (16.4–26.3)	80	25.2 (20.3–30.8)	0.9384
female	198	44	24.1 (17.6–32.1)	62	31.6 (24.7–39.5)	40	20.6 (14.7–28.0)	52	23.7 (18.0–30.5)	
Age										
<25	23	5	27.4 (11.2–53.0)	3	12.3 (3.6–34.8)	9	34.4 (17.5–56.6)	6	25.8 (10.9–49.6)	0.2336
25-34	143	42	32.0 (23.7–41.7)	40	27.7 (20.5–36.3)	25	17.3 (11.6–25.0)	36	22.9 (16.6–30.8)	
35-44	246	57	23.2 (17.7–29.9)	74	32.0 (25.6–39.2)	49	19.1 (14.1–25.5)	66	25.6 (20.2–31.9)	
45+	88	16	16.9 (10.0–26.9)	24	32.0 (21.2–45.1)	24	27.1 (17.7–39.2)	24	24.0 (15.9–34.7)	
Years since the start of injecting drug use										
≤2	23	5	26.2 (10.6–51.6)	4	17.6 (5.9–42.0)	6	24.6 (10.4–47.9)	8	31.7 (15.1–54.7)	0.4440

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
3-5	65	21	37.0 (24.3–51.8)	14	19.1 (11.2–30.9)	16	23.3 (13.9–36.3)	14	20.6 (11.7–33.6)	
6-10	102	26	25.6 (17.6–35.7)	29	29.1 (20.6–39.5)	21	21.4 (14.0–31.2)	26	23.9 (16.5–33.3)	
≥11	306	68	22.3 (17.3–28.2)	91	32.6 (26.6–39.1)	64	20.1 (15.4–25.8)	83	25.1 (20.2–30.6)	
Partnership status										
live alone	234	52	22.9 (17.3–29.6)	61	26.3 (20.4–33.2)	45	18.3 (13.3–24.7)	76	32.6 (26.3–39.4)	0.0083
live with partner	266	68	26.4 (20.7–33.0)	80	33.0 (26.7–39.9)	62	22.9 (17.8–29.0)	56	17.8 (13.6–22.9)	
Current employment status										
full-time	192	44	22.9 (16.8–30.3)	58	30.8 (23.9–38.6)	44	23.1 (17.0–30.6)	46	23.3 (17.5–30.2)	0.4886
part-time or temporary	175	40	25.2 (18.5–33.2)	44	27.2 (20.1–35.5)	44	22.5 (16.8–29.4)	47	25.2 (19.0–32.6)	
unemployed	64	17	25.7 (15.1–40.3)	17	27.1 (16.7–40.9)	10	19.9 (9.7–36.5)	20	27.2 (17.1–40.4)	
disabled	17	3	13.5 (3.6–39.4)	8	61.6 (32.7–84.1)	1	6.0 (0.7–37.1)	5	18.9 (6.4–44.3)	
other	51	16	33.3 (19.7–50.4)	14	28.6 (16.7–44.4)	8	14.2 (6.7–27.8)	13	23.9 (13.4–39.0)	
Monthly income category										
<3K	32	6	15.5 (6.5–32.8)	9	38.7 (19.3–62.5)	5	13.2 (5.0–30.5)	12	32.6 (17.3–52.8)	0.0227
3-10K	147	34	23.1 (16.2–31.7)	51	34.7 (26.6–43.8)	28	19.2 (12.9–27.6)	34	23.0 (16.4–31.1)	
10-20K	162	26	17.7 (11.5–26.3)	49	32.8 (25.1–41.5)	42	24.0 (17.7–31.6)	45	25.5 (19.1–33.2)	
≥20K	74	31	42.5 (30.6–55.3)	13	19.4 (10.2–33.8)	9	10.5 (5.3–19.7)	21	27.6 (17.8–40.0)	
Ever incarcerated										
no	437	106	25.0 (20.6–30.0)	117	28.9 (24.2–34.1)	95	21.3 (17.2–26.0)	119	24.8 (20.8–29.3)	0.6111
yes	63	14	22.9 (13.5–36.1)	24	37.5 (25.7–51.1)	12	16.9 (9.5–28.3)	13	22.7 (13.0–36.6)	

Table 12.7. Depression symptoms severity (PHQ-9) by Selected Subgroups

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	120	24.7 (20.6–29.4)	141	29.9 (25.5–34.7)	107	20.8 (17.1–25.1)	132	24.6 (20.8–28.8)	1.0000
Sex										
male	302	76	25.2 (20.2–31.0)	79	28.7 (23.1–35.0)	67	20.9 (16.4–26.3)	80	25.2 (20.3–30.8)	0.9384
female	198	44	24.1 (17.6–32.1)	62	31.6 (24.7–39.5)	40	20.6 (14.7–28.0)	52	23.7 (18.0–30.5)	
Age										
<25	23	5	27.4 (11.2–53.0)	3	12.3 (3.6–34.8)	9	34.4 (17.5–56.6)	6	25.8 (10.9–49.6)	0.2336
25-34	143	42	32.0 (23.7–41.7)	40	27.7 (20.5–36.3)	25	17.3 (11.6–25.0)	36	22.9 (16.6–30.8)	
35-44	246	57	23.2 (17.7–29.9)	74	32.0 (25.6–39.2)	49	19.1 (14.1–25.5)	66	25.6 (20.2–31.9)	
45+	88	16	16.9 (10.0–26.9)	24	32.0 (21.2–45.1)	24	27.1 (17.7–39.2)	24	24.0 (15.9–34.7)	

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Years since the start of injecting drug use										
≤2	23	5	26.2 (10.6–51.6)	4	17.6 (5.9–42.0)	6	24.6 (10.4–47.9)	8	31.7 (15.1–54.7)	0.4440
3-5	65	21	37.0 (24.3–51.8)	14	19.1 (11.2–30.9)	16	23.3 (13.9–36.3)	14	20.6 (11.7–33.6)	
6-10	102	26	25.6 (17.6–35.7)	29	29.1 (20.6–39.5)	21	21.4 (14.0–31.2)	26	23.9 (16.5–33.3)	
≥11	306	68	22.3 (17.3–28.2)	91	32.6 (26.6–39.1)	64	20.1 (15.4–25.8)	83	25.1 (20.2–30.6)	
Partnership status										
live alone	234	52	22.9 (17.3–29.6)	61	26.3 (20.4–33.2)	45	18.3 (13.3–24.7)	76	32.6 (26.3–39.4)	0.0083
live with partner	266	68	26.4 (20.7–33.0)	80	33.0 (26.7–39.9)	62	22.9 (17.8–29.0)	56	17.8 (13.6–22.9)	
Current employment status										
full-time	192	44	22.9 (16.8–30.3)	58	30.8 (23.9–38.6)	44	23.1 (17.0–30.6)	46	23.3 (17.5–30.2)	0.4886
part-time or temporary	175	40	25.2 (18.5–33.2)	44	27.2 (20.1–35.5)	44	22.5 (16.8–29.4)	47	25.2 (19.0–32.6)	
unemployed	64	17	25.7 (15.1–40.3)	17	27.1 (16.7–40.9)	10	19.9 (9.7–36.5)	20	27.2 (17.1–40.4)	
disabled	17	3	13.5 (3.6–39.4)	8	61.6 (32.7–84.1)	1	6.0 (0.7–37.1)	5	18.9 (6.4–44.3)	
other	51	16	33.3 (19.7–50.4)	14	28.6 (16.7–44.4)	8	14.2 (6.7–27.8)	13	23.9 (13.4–39.0)	
Monthly income category										
<3K	32	6	15.5 (6.5–32.8)	9	38.7 (19.3–62.5)	5	13.2 (5.0–30.5)	12	32.6 (17.3–52.8)	0.0227
3-10K	147	34	23.1 (16.2–31.7)	51	34.7 (26.6–43.8)	28	19.2 (12.9–27.6)	34	23.0 (16.4–31.1)	
10-20K	162	26	17.7 (11.5–26.3)	49	32.8 (25.1–41.5)	42	24.0 (17.7–31.6)	45	25.5 (19.1–33.2)	
≥20K	74	31	42.5 (30.6–55.3)	13	19.4 (10.2–33.8)	9	10.5 (5.3–19.7)	21	27.6 (17.8–40.0)	
Ever incarcerated										
no	437	106	25.0 (20.6–30.0)	117	28.9 (24.2–34.1)	95	21.3 (17.2–26.0)	119	24.8 (20.8–29.3)	0.6111
yes	63	14	22.9 (13.5–36.1)	24	37.5 (25.7–51.1)	12	16.9 (9.5–28.3)	13	22.7 (13.0–36.6)	

Table 12.8. Anxiety symptoms severity (GAD-7) by Sociodemographic Characteristics

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	183	37.8 (33.1–42.8)	152	30.8 (26.4–35.6)	121	23.4 (19.6–27.8)	44	8.0 (5.9–10.7)	1.0000
Sex										
male	302	105	35.8 (29.9–42.0)	92	31.1 (25.5–37.3)	79	25.5 (20.5–31.2)	26	7.7 (5.2–11.3)	0.6242
female	198	78	40.7 (33.1–48.8)	60	30.4 (23.5–38.4)	42	20.5 (15.0–27.5)	18	8.4 (5.2–13.3)	
Age										
<25	23	8	38.5 (19.4–62.0)	9	38.1 (19.6–60.9)	5	19.7 (7.8–41.6)	1	3.7 (0.5–24.3)	0.6563

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
25-34	143	58	43.4 (34.5–52.8)	43	28.7 (21.4–37.3)	28	18.3 (12.7–25.7)	14	9.6 (5.6–16.1)	
35-44	246	92	36.5 (30.0–43.5)	71	31.3 (24.8–38.6)	60	24.1 (18.6–30.6)	23	8.2 (5.3–12.3)	
45+	88	25	32.5 (22.0–45.2)	29	30.7 (20.9–42.7)	28	30.6 (20.7–42.7)	6	6.1 (2.7–13.5)	
Years since the start of injecting drug use										
≤2	23	9	41.4 (21.6–64.5)	7	29.3 (13.4–52.6)	4	14.1 (4.9–34.2)	3	15.2 (4.5–40.6)	0.7630
3-5	65	19	34.6 (22.1–49.6)	25	35.7 (24.0–49.3)	18	26.5 (16.5–39.7)	3	3.2 (1.0–9.9)	
6-10	102	42	41.7 (32.0–52.2)	28	27.3 (19.1–37.4)	24	23.2 (15.7–33.0)	8	7.7 (3.8–15.1)	
≥11	306	112	36.9 (30.9–43.4)	91	31.2 (25.4–37.7)	73	23.4 (18.4–29.2)	30	8.5 (5.9–12.2)	
Partnership status										
live alone	234	77	32.5 (26.2–39.6)	68	28.9 (22.8–36.0)	64	28.8 (22.6–35.9)	25	9.8 (6.5–14.3)	0.0299
live with partner	266	106	42.3 (35.7–49.2)	84	32.4 (26.3–39.2)	57	18.9 (14.5–24.1)	19	6.5 (4.0–10.2)	
Current employment status										
full-time	192	64	34.8 (27.6–42.7)	66	32.7 (25.9–40.4)	46	23.9 (17.8–31.4)	16	8.6 (5.2–13.8)	0.7806
part-time or temporary	175	61	36.1 (28.6–44.3)	51	30.0 (22.7–38.3)	51	27.7 (21.3–35.2)	12	6.2 (3.4–11.1)	
unemployed	64	26	40.7 (27.7–55.2)	17	27.9 (16.8–42.6)	13	22.3 (12.2–37.0)	8	9.1 (4.3–18.1)	
disabled	17	7	44.3 (17.6–74.8)	4	30.8 (8.8–67.3)	3	13.2 (3.4–39.5)	3	11.7 (3.1–35.6)	
other	51	25	48.5 (33.3–64.1)	14	31.5 (18.8–47.8)	7	11.0 (4.7–23.6)	5	9.0 (3.6–20.8)	
Monthly income category										
<3K	32	8	28.2 (12.3–52.3)	14	44.5 (25.1–65.7)	5	16.3 (6.2–36.5)	5	11.0 (4.2–25.7)	0.5295
3-10K	147	60	40.4 (31.9–49.5)	41	28.1 (20.6–37.0)	33	23.4 (16.5–32.1)	13	8.1 (4.7–13.8)	
10-20K	162	46	31.0 (23.3–39.9)	52	33.2 (25.6–41.8)	51	27.9 (21.3–35.7)	13	7.9 (4.4–13.6)	
≥20K	74	33	44.6 (32.5–57.4)	20	27.2 (16.8–41.0)	17	22.9 (14.0–35.1)	4	5.3 (1.9–13.8)	
Ever incarcerated										
no	437	166	39.3 (34.2–44.7)	125	29.2 (24.5–34.3)	107	23.4 (19.3–28.1)	39	8.1 (5.9–11.1)	0.1264
yes	63	17	26.0 (16.1–39.1)	27	43.4 (30.8–56.9)	14	23.6 (14.0–37.2)	5	6.9 (2.7–16.4)	

Table 12.9. Anxiety symptoms severity (GAD-7) by Selected Subgroups

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
no	416	151	37.8 (32.6–43.3)	121	29.4 (24.6–34.7)	103	23.7 (19.6–28.5)	41	9.0 (6.6–12.3)	0.2682
yes	83	32	38.2 (27.4–50.3)	30	36.8 (25.9–49.3)	18	22.1 (13.2–34.5)	3	2.9 (0.9–8.9)	
Treated with MAT currently (of all)										
no	461	164	37.3 (32.4–42.5)	142	31.6 (26.9–36.6)	112	22.8 (18.9–27.1)	43	8.4 (6.2–11.3)	0.1582
yes	35	19	53.3 (35.5–70.3)	9	22.7 (11.5–39.9)	7	24.0 (11.1–44.2)	0	0.0	
HIV test result										
positive	85	31	41.4 (29.5–54.4)	28	28.6 (19.0–40.6)	20	23.3 (14.3–35.5)	6	6.8 (3.0–14.8)	0.9019
negative	415	152	37.0 (32.0–42.4)	124	31.3 (26.4–36.6)	101	23.5 (19.3–28.2)	38	8.2 (5.9–11.3)	
Past 30 days injecting 4 categories										
opioids	267	95	38.6 (32.2–45.4)	88	31.1 (25.2–37.7)	68	25.2 (19.9–31.4)	16	5.1 (3.1–8.3)	
stimulants	193	72	36.5 (29.1–44.7)	53	31.1 (23.9–39.3)	47	22.6 (16.7–29.7)	21	9.8 (6.3–15.0)	
opi+stimul	40	16	39.3 (24.5–56.5)	11	26.5 (14.3–43.8)	6	14.6 (6.4–29.9)	7	19.6 (9.0–37.5)	
other	0	0		0		0		0		
Injecting drug type of choice										
opioids	288	104	39.2 (33.0–45.7)	93	29.9 (24.4–36.0)	71	24.6 (19.5–30.5)	20	6.4 (4.0–9.9)	0.5141
stimulants	210	78	36.3 (29.2–44.1)	58	31.0 (24.1–38.8)	50	22.4 (16.7–29.2)	24	10.3 (6.8–15.3)	
other	2	1	24.8 (0.0–100.0)	1	75.2 (0.0–100.0)	0	0.0	0	0.0	

13. Detention and Incarceration

Table 13.1. Police Detention and Incarceration Experience

	n	%	CI
Detained by police in 2022 for			
drug use	31	5.4	(3.8–7.8)
drug dealing	26	3.9	(2.6–5.8)
drug storing	47	8.4	(6.3–11.3)
Detained by police in 2023 for			
drug use	23	4.6	(2.8–7.3)
drug dealing	16	2.8	(1.7–4.8)
drug storing	46	8.5	(6.3–11.4)
Stopped, detained, or arrested by police ever			
yes	259	49.9	(45.0–54.8)
Ever incarcerated			
yes	63	11.4	(8.8–14.6)
Duration of incarceration			
≤6m	8	12.0	(5.7–23.3)
6m-2y	15	27.0	(16.6–40.8)
2-4y	20	29.5	(19.3–42.3)
4y+	20	31.5	(20.6–44.8)

	n	%	CI
Time since last incarceration			
≤1y	2	2.6	(0.6–10.2)
1-3y	7	11.6	(5.4–23.4)
3-5y	18	28.8	(18.4–42.0)
5-10y	16	25.7	(15.6–39.3)
10y+	19	31.2	(20.4–44.5)
Used injecting drugs during incarceration			
yes	40	62.9	(49.4–74.7)



Figure 13.1. Incarceration Lifetime Experience (%)

14. Negative experience

Table 14.1. Negative experience

	n	%	CI
Felt excluded from family activities due to drug use			
no	245	51.0	(46.1–56.0)
yes, in the past 6m	101	19.3	(15.8–23.3)
yes, but 6m+ ago	154	29.7	(25.5–34.3)
Was scolded because of drug use			
no	175	38.2	(33.3–43.3)
yes, in the past 6m	136	26.3	(22.3–30.7)
yes, but 6m+ ago	189	35.5	(31.1–40.2)
Was blackmailed for drug use			
no	273	54.9	(50.0–59.8)
yes, in the past 6m	112	22.9	(19.0–27.3)
yes, but 6m+ ago	115	22.2	(18.4–26.5)
Negative experience in the past 6 months (GAM 6.5)			
no	337	68.2	(63.5–72.6)
yes	163	31.8	(27.4–36.5)
Ever experienced physical violence			
no	253	53.0	(48.0–57.9)
yes	233	47.0	(42.1–52.0)
Experienced physical violence in the past 12 months (of those who had ever)			
no	138	58.1	(50.8–65.1)

		n	%	CI
	yes	94	41.9	(34.9–49.2)
Witnessed physical violence in the past 12 months				
	no	350	71.5	(66.8–75.8)
	yes	142	28.5	(24.2–33.2)



Figure 14.1. Negative Experience Related to Drug Use in the past 6 Months or Physical Violence in the past 12 months (%)

Table 14.2. Negative Experience Related to Drug Use by Sociodemographic Characteristics

		Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	500	163	31.8 (27.4–36.5)	1.0000	232	94	41.9 (34.9–49.2)	1.0000
Sex									
	male	302	102	34.0 (28.4–40.2)	0.2498	147	57	38.7 (30.7–47.4)	0.3095
	female	198	61	28.6 (22.2–36.0)		85	37	46.4 (34.5–58.8)	
Age									
	<25	23	17	74.9 (51.2–89.5)	0.0002	8	4	39.4 (12.7–74.5)	0.9838
	25-34	143	44	30.8 (23.2–39.6)		61	25	40.4 (28.1–54.0)	
	35-44	246	78	30.8 (24.7–37.8)		118	48	43.2 (33.3–53.7)	
	45+	88	24	24.4 (16.1–35.1)		45	17	40.8 (25.5–58.1)	
Years since the start of injecting drug use									
	≤2	23	12	53.8 (31.8–74.5)	0.0648	10	7	64.9 (29.3–89.2)	0.5100
	3-5	65	21	30.4 (19.8–43.7)		23	10	36.2 (18.7–58.4)	
	6-10	102	35	36.2 (26.9–46.8)		47	19	41.1 (27.1–56.7)	

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
≥11	306	92	28.3 (23.0–34.3)		152	58	41.3 (32.5–50.6)	
Partnership status								
live alone	234	85	35.8 (29.3–42.9)	0.1017	102	45	48.3 (37.7–59.2)	0.1152
live with partner	266	78	28.3 (22.7–34.6)		130	49	36.8 (28.1–46.5)	
Current employment status								
full-time	192	69	36.6 (29.3–44.5)	0.3517	88	31	37.1 (26.4–49.1)	0.0976
part-time or temporary	175	56	30.6 (23.8–38.3)		78	35	48.4 (36.1–60.8)	
unemployed	64	20	32.7 (20.7–47.5)		25	7	22.2 (9.5–43.6)	
disabled	17	6	25.8 (9.4–53.7)		10	4	40.0 (14.1–72.9)	
other	51	12	20.4 (11.1–34.6)		31	17	55.3 (35.9–73.2)	
Monthly income category								
<3K	32	8	23.1 (10.6–43.1)	0.3428	18	8	44.5 (22.9–68.4)	0.6867
3-10K	147	52	36.2 (28.0–45.3)		69	29	45.0 (32.3–58.3)	
10-20K	162	54	32.9 (25.4–41.4)		77	30	38.6 (27.8–50.6)	
≥20K	74	20	25.2 (16.2–37.0)		37	17	51.3 (32.9–69.3)	
Ever incarcerated								
no	437	151	33.6 (28.8–38.7)	0.0136	185	73	40.0 (32.2–48.3)	0.2334
yes	63	12	17.8 (10.1–29.6)		47	21	50.4 (35.3–65.4)	

Table 14.3. Negative Experience Related to Drug Use by Selected Subgroups

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	416	138	32.8 (28.0–38.1)	0.3050	181	76	42.2 (34.5–50.4)	0.8771
yes	83	25	26.8 (18.0–37.9)		51	18	40.8 (25.9–57.6)	
Treated with MAT currently (of all)								
no	461	148	31.4 (26.9–36.2)	0.2384	212	86	41.2 (34.1–48.8)	0.6023
yes	35	14	41.7 (25.4–60.1)		18	6	34.4 (15.1–60.8)	
HIV test result								
positive	85	28	28.5 (19.4–39.9)	0.5093	36	10	34.3 (17.3–56.7)	0.4278
negative	415	135	32.5 (27.7–37.7)		196	84	43.5 (36.0–51.2)	

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Past 30 days injecting 4 categories								
opioids	267	92	33.6 (27.6–40.1)		127	43	35.4 (26.4–45.6)	
stimulants	193	61	31.1 (24.2–38.8)		85	45	53.2 (41.5–64.5)	
opi+stimul	40	10	22.1 (11.6–38.0)		20	6	34.1 (15.3–59.9)	
other	0	0			0	0		
Injecting drug type of choice								
opioids	288	98	33.3 (27.6–39.6)	0.4948	134	44	34.8 (26.0–44.7)	0.0391
stimulants	210	65	30.4 (23.9–37.8)		97	50	52.3 (41.4–63.0)	
other	2	0	0.0		1	0	0.0	

15. The Impact of the Full-scale War

Table 15.1. Migration Since February 2022

	n	%	CI
Changed place of residence since Feb 2022			
yes, because of the war	34	7.0	(4.9–9.9)
yes, for other reasons	56	11.3	(8.5–15.0)
no	400	81.7	(77.5–85.2)
Where migrated since Feb 2022			
unknown	10	20.1	(10.8–34.2)
other country	4	14.9	(5.8–33.4)
other oblast	6	17.0	(7.6–33.7)
other city	13	29.8	(17.5–45.9)
other district	8	12.9	(6.3–24.5)
other house	3	5.3	(1.7–15.6)
Where lived before Feb 2022 (if changed residence)			
same oblast	83	92.1	(83.6–96.4)
other oblast	7	7.9	(3.6–16.4)
other country	0	0.0	



Figure 15.1. Change of Residence Since February 2022 (%)



Figure 15.2. Migration Destination by Survey Site (%)



Figure 15.3. Residence Before February 2022 (%)



Figure 15.4. Changes Since February 2022 (%)

City-level Results: Zaporizhzhia



Figure A. RDS recruitment tree in Zaporizhzhia

1. Sociodemographic Information

Table 1.1. Sociodemographic Characteristics

	n	Mean	CI	Median	IQR
Age, years	500	41.1	(40.5–41.7)	40	(37–45)
Age of first non-injecting drug use	354	17.2	(16.8–17.6)	17	(15–18)
Years since the start of non-injecting drug use	354	23.7	(22.9–24.5)	23	(19–28)
Age of first injecting drug use	483	19.2	(18.8–19.5)	18	(17–20)
Years since the start of injecting drug use	483	22.0	(21.4–22.7)	22	(18–26)
Personal monthly income, UAH	472	6,977.6	(6604.8–7350.3)	6,000	(5000–9000)

Table 1.2. Descriptive Statistics for Sociodemographics

	Site	n	%	CI
Sex				
male	Zaporizhzhia	415	83.2	(79.4–86.5)
female	Zaporizhzhia	85	16.8	(13.5–20.6)
Age				
<25	Zaporizhzhia	4	0.8	(0.3–2.1)
25-34	Zaporizhzhia	60	12.2	(9.3–15.9)
35-44	Zaporizhzhia	287	57.3	(52.5–61.9)
45+	Zaporizhzhia	149	29.7	(25.5–34.3)
Family status				
married or living together	Zaporizhzhia	83	16.3	(13.0–20.1)
married but have another partner	Zaporizhzhia	45	9.7	(7.0–13.1)
not married but have a partner	Zaporizhzhia	144	28.4	(24.3–32.8)
married but not living together	Zaporizhzhia	31	6.1	(4.2–8.7)
not married and do not have a partner	Zaporizhzhia	197	39.6	(35.1–44.3)
Partnership status				
live alone	Zaporizhzhia	228	45.7	(41.0–50.4)
live with partner	Zaporizhzhia	272	54.3	(49.6–59.0)
Education				
incompl. high school	Zaporizhzhia	258	53.2	(48.4–57.9)
high school	Zaporizhzhia	137	27.2	(23.2–31.6)
>high school	Zaporizhzhia	105	19.6	(16.3–23.5)
Current occupation				
school student	Zaporizhzhia	0	0.0	
college/uni student	Zaporizhzhia	0	0.0	
permanent job	Zaporizhzhia	61	11.0	(8.5–14.0)
sporadic jobs	Zaporizhzhia	297	61.3	(56.6–65.8)
unemployed	Zaporizhzhia	113	23.0	(19.2–27.3)
housewife	Zaporizhzhia	2	0.4	(0.1–1.5)
disabled	Zaporizhzhia	22	3.8	(2.5–5.8)
military	Zaporizhzhia	3	0.4	(0.1–1.4)
other	Zaporizhzhia	1	0.1	(0.0–0.8)
Homelessness				
never	Zaporizhzhia	400	83.5	(79.8–86.6)
yes, 12m+ ago	Zaporizhzhia	84	15.8	(12.7–19.3)
yes, in the past 12m	Zaporizhzhia	3	0.8	(0.3–2.5)
Homeless in 12 months (of those ever)				
no	Zaporizhzhia	84	95.2	(86.1–98.5)
yes	Zaporizhzhia	3	4.8	(1.5–13.9)
Monthly income category				
<3K	Zaporizhzhia	33	6.1	(4.3–8.6)
3-10K	Zaporizhzhia	347	75.3	(71.0–79.1)
10-20K	Zaporizhzhia	84	17.2	(13.9–21.0)

	Site	n	%	CI
≥20K	Zaporizhzhia	8	1.4	(0.7–3.0)
Monthly income relative to 2023 subsistence minimum				
<2684	Zaporizhzhia	31	5.7	(4.0–8.2)
≥2684	Zaporizhzhia	441	94.3	(91.8–96.0)
Years since the start of injecting drug use				
≤2	Zaporizhzhia	2	0.4	(0.1–1.7)
3-5	Zaporizhzhia	7	1.6	(0.7–3.3)
6-10	Zaporizhzhia	18	3.4	(2.1–5.4)
≥11	Zaporizhzhia	456	94.7	(92.2–96.4)

Table 1.3. Accommodation in the past 12 months

	Site	n	%	CI
own place	Zaporizhzhia	146	28.0	(24.0–32.4)
friends or relatives	Zaporizhzhia	183	37.0	(32.5–41.7)
renting	Zaporizhzhia	99	20.3	(16.7–24.5)
varying	Zaporizhzhia	96	19.4	(15.9–23.5)
on the street (homeless)	Zaporizhzhia	3	0.8	(0.2–2.4)
in a refugee shelter	Zaporizhzhia	0	0.0	



Figure 1.1. Distribution of Age by Sex (%)



Figure 1.2. Trend in Sex Distribution by Survey Round (%)



Figure 1.3. Trend in Age Groups by Survey Round (%)

2. Drug Use



Figure 2.1. Injecting Drug Use in the Past 12 Months and 30 Days (%)



Figure 2.2. Non-injecting Drug Use in the Past 12 Months (%)



Figure 2.3. Trends in Injecting Drugs Types in the Past 30 Days by Survey Round (%)



Figure 2.4. Trends in Injecting Opioids in the Past 30 Days by Survey Round (%)



Figure 2.5. Trends in Injecting Stimulants in the Past 30 Days by Survey Round (%)

Figure 2.6. Trends in Injecting Other Drugs in the Past 30 Days by Survey Round (%)



Figure 2.7. Injecting Drug Preference (%)

Table 2.1. Types of Injecting Drugs in the Past 30 Days by Sociodemographic Characteristics

			Past 30 days injecting 4 categories								
		N	n	opioids % (CI)	n	stimulants % (CI)	n	opi+stimul % (CI)	n	other % (CI)	p-value
Total											
	All	500	330	66.2 (61.4–70.6)	20	3.9 (2.4–6.2)	146	28.5 (24.4–33.0)	4	1.4 (0.4–4.8)	1.0000
Sex											
	male	415	274	66.9 (61.7–71.6)	17	4.1 (2.4–6.8)	120	27.4 (23.0–32.2)	4	1.7 (0.5–5.7)	0.5900
	female	85	56	62.6 (50.1–73.7)	3	3.1 (1.0–9.6)	26	34.3 (23.4–47.0)	0	0.0	
Age											
	<25	4	3	63.4 (4.2–98.6)	1	36.6 (1.4–95.8)	0	0.0	0	0.0	0.0462

	N	Past 30 days injecting 4 categories								
		opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
25-34	60	38	66.1 (52.1–77.8)	6	7.9 (3.4–17.4)	16	26.0 (15.7–39.7)	0	0.0	
35-44	287	200	70.8 (64.8–76.2)	8	2.7 (1.2–5.6)	77	24.7 (19.9–30.1)	2	1.8 (0.4–8.7)	
45+	149	89	57.3 (48.0–66.0)	5	3.9 (1.5–9.7)	53	37.7 (29.2–47.1)	2	1.1 (0.3–4.5)	
Years since the start of injecting drug use										
≤2	2	1	50.0 (0.0–100.0)	1	50.0 (0.0–100.0)	0	0.0	0	0.0	
3-5	7	6	81.3 (23.4–98.4)	1	18.7 (1.6–76.6)	0	0.0	0	0.0	
6-10	18	14	79.1 (52.3–92.9)	0	0.0	4	20.9 (7.1–47.7)	0	0.0	
≥11	456	297	65.3 (60.3–70.0)	16	3.4 (2.0–5.8)	139	29.8 (25.4–34.6)	4	1.5 (0.4–5.3)	
Partnership status										
live alone	228	175	78.3 (72.2–83.3)	3	1.0 (0.3–3.1)	48	19.9 (15.1–25.8)	2	0.8 (0.2–3.3)	0.0000
live with partner	272	155	56.0 (49.3–62.4)	17	6.4 (3.8–10.5)	98	35.8 (29.7–42.3)	2	1.9 (0.4–9.2)	
Current employment status										
full-time	61	44	71.7 (58.4–82.0)	3	6.0 (1.9–17.8)	14	22.3 (13.4–34.8)	0	0.0	0.7072
part-time or temporary	297	196	67.2 (61.0–72.8)	8	2.5 (1.2–5.4)	90	28.3 (23.2–34.2)	3	1.9 (0.5–7.8)	
unemployed	113	73	62.0 (51.4–71.5)	6	5.7 (2.4–12.9)	33	31.5 (22.4–42.1)	1	0.9 (0.1–6.4)	
disabled	22	13	61.8 (39.1–80.3)	3	10.8 (3.1–31.2)	6	27.5 (12.1–51.1)	0	0.0	
other	6	3	49.9 (10.4–89.6)	0	0.0	3	50.1 (10.4–89.6)	0	0.0	
Monthly income category										
<3K	33	26	78.4 (60.1–89.7)	0	0.0	6	17.9 (7.9–35.7)	1	3.7 (0.5–23.2)	0.4233
3-10K	347	225	65.1 (59.2–70.5)	12	3.5 (1.9–6.5)	107	29.8 (24.7–35.4)	3	1.7 (0.4–6.8)	
10-20K	84	57	68.5 (57.4–77.8)	4	4.7 (1.7–12.1)	23	26.8 (18.2–37.7)	0	0.0	
≥20K	8	5	59.8 (19.0–90.4)	1	20.6 (2.0–76.9)	2	19.6 (3.3–63.6)	0	0.0	
Ever incarcerated										
no	362	259	72.0 (66.6–76.9)	15	4.1 (2.4–6.9)	87	23.7 (19.1–29.0)	1	0.2 (0.0–1.7)	0.8069
yes	45	33	73.0 (57.1–84.6)	4	6.7 (2.4–17.3)	8	20.3 (10.2–36.4)	0	0.0	

Table 2.2. Types of Injecting Drugs in the Past 30 Days by Selected Subgroups

	N	Past 30 days injecting 4 categories								
		opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										

	N	Past 30 days injecting 4 categories								
		opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
no	385	262	69.3 (64.1–74.0)	12	2.8 (1.5–5.2)	110	27.7 (23.1–32.7)	1	0.2 (0.0–1.6)	0.0000
yes	96	59	58.9 (47.4–69.5)	7	8.3 (3.8–17.4)	27	26.4 (18.2–36.7)	3	6.4 (1.6–22.7)	
Treated with MAT currently (of all)										
no	407	277	68.9 (63.9–73.5)	17	4.2 (2.5–6.9)	112	26.7 (22.4–31.6)	1	0.2 (0.0–1.5)	0.0000
yes	56	37	61.0 (44.9–75.0)	3	4.8 (1.5–14.6)	13	22.9 (13.2–36.8)	3	11.2 (2.8–35.7)	
HIV test result										
positive	21	17	78.5 (50.2–93.0)	2	13.8 (2.8–47.0)	2	7.7 (1.7–28.6)	0	0.0	0.1294
negative	479	313	65.6 (60.8–70.2)	18	3.5 (2.1–5.7)	144	29.4 (25.1–34.1)	4	1.5 (0.4–5.0)	
Injecting drug type of choice										
opioids	458	321	70.7 (65.9–75.0)	2	0.7 (0.2–2.9)	134	28.4 (24.1–33.1)	1	0.2 (0.0–1.3)	0.0000
stimulants	34	6	15.3 (6.5–31.8)	17	49.8 (32.0–67.6)	11	34.9 (19.4–54.3)	0	0.0	
other	3	1	31.6 (0.2–99.0)	1	21.6 (0.1–98.2)	0	0.0	1	46.8 (0.4–99.4)	

Table 2.3. Injecting frequency

	Past 30 days injecting 4 categories								
	opioids		stimulants		opi+stimul		other		
	n	%	n	%	n	%	n	%	p-value
Injecting frequency: last 24 hrs									
0 times	11	3.1	2	10.8	3	2.2	0	0.0	0.1621
1 time	255	80.0	13	67.9	130	90.5	4	100.0	
2-3 times	58	15.2	4	17.7	12	6.8	0	0.0	
4+ times	6	1.6	1	3.6	1	0.4	0	0.0	
N	330		20		146		4		
Injecting frequency: last 24 hrs (among those who did)									
1 time	255	82.6	13	76.1	130	92.6	4	100.0	0.1706
2-3 times	58	15.7	4	19.9	12	7.0	0	0.0	
4+ times	6	1.7	1	4.1	1	0.4	0	0.0	
N	319		18		143		4		
Injecting frequency: last week									
0 times	2	0.5	0	0.0	0	0.0	0	0.0	0.0000
1-6 times	51	15.2	14	75.1	38	23.8	3	87.8	
every day	277	84.3	6	24.9	108	76.2	1	12.2	
N	330		20		146		4		
Injecting frequency: last 30 days									
1-9 times	5	1.2	1	4.3	1	0.7	0	0.0	0.0000
10-19 times	12	3.6	3	15.1	5	3.0	0	0.0	
20-29 times	48	14.4	12	65.4	39	24.8	3	87.8	
every day	265	80.8	4	15.2	101	71.4	1	12.2	
N	330		20		146		4		
Injecting frequency: main drug last 30 days									
0-9 times	6	1.5	1	5.4	1	0.5	0	0.0	0.0000
10-19 times	9	2.6	3	18.8	4	2.6	0	0.0	

	Past 30 days injecting 4 categories								
	opioids		stimulants		opi+stimul		other		
	n	%	n	%	n	%	n	%	p-value
20-29 times	55	16.7	9	56.9	38	24.6	2	86.0	
every day	257	79.2	4	18.9	101	72.3	1	14.0	
N	327		17		144		3		

Table 2.4. Injecting drug type of choice by Income Category

	Injecting drug type of choice					
	opioids		stimulants		other	
	n	%	n	%	n	%
Monthly income category						
<3K	31	6.2	0	0.0	1	100.0
3-10K	325	76.2	19	62.1	0	0.0
10-20K	73	16.5	11	31.4	0	0.0
≥20K	6	1.1	2	6.6	0	0.0
N	435		32		1	

Table 2.5. Sources of drugs by Drug Type of Choice

Total		Injecting drug type of choice						
All		opioids		stimulants		other		
n	%	n	%	n	%	n	%	p-value
prepare myself								
106	17.9	97	17.8	8	21.5	1	21.6	0.8148
prepared by friends								
50	10.2	50	11.0	0	0.0	0	0.0	0.1145
from a dealer								
296	63.3	269	62.6	24	73.0	1	31.6	0.2886
buy on Internet								
181	40.0	174	41.2	6	24.1	1	46.8	0.1998
from a pharmacy								
4	0.7	3	0.6	1	2.3	0	0.0	0.4534
N								
637		593		39		3		
from MAT program								
		0	0.0	0	0.0	0	0.0	
other								
		0	0.0	0	0.0	0	0.0	



Figure 2.8. Change in the price, quality, and access of drugs by Drug Type of Choice (%)

3. Injecting Risk Behavior

Table 3.1. Prevalence of Injection Risk Practices

	n	%	CI
Used clean syringe for last injection			
yes	381	78.6	(74.6–82.1)
Source of syringe for last injection			
bought in pharmacy	201	38.9	(34.4–43.6)
got in pharmacy	64	13.2	(10.3–16.7)
got from NGO	196	41.4	(36.8–46.2)
got from friend	24	4.6	(3.0–6.9)
got used from friend	4	0.7	(0.3–1.9)
used one used by myself	7	1.2	(0.6–2.6)
got pre-loaded	0	0.0	
other	0	0.0	
Used shared syringe in the past 30 days			
yes	88	17.4	(14.2–21.2)
Used pre-filled syringe in the past 30 days			
yes	33	6.3	(4.4–9.0)
Used front-/back-loaded syringe in the past 30 days			
yes	39	7.9	(5.7–10.8)
Used shared container in the past 30 days			
yes	43	8.5	(6.3–11.4)
Used own previously used syringe in the past 30 days			
yes	43	9.5	(7.0–12.7)
Gave someone a used syringe in the past 30 days			
yes	87	17.4	(14.0–21.3)
Any inj. risk (shared syringe, pre-filled, front-/back-load, container) in the past 30 days			
yes	140	32.4	(27.8–37.4)

Table 3.2. Frequency of risky injection practices

	n	%	CI
Frequency of injecting with a syringe used by others in the past 30 days			
always	1	1.7	(0.2–11.1)

	n	%	CI
often	24	27.3	(18.8–37.8)
half	6	6.6	(2.9–14.1)
sometimes	10	12.4	(6.7–21.8)
rarely	40	45.3	(34.9–56.1)
never	6	6.7	(2.9–14.7)
Frequency of injecting with others in the same place in the past 30 days			
always	9	1.6	(0.8–3.2)
often	207	46.3	(41.4–51.3)
half	49	9.0	(6.8–11.9)
sometimes	29	6.0	(4.0–8.8)
rarely	80	16.0	(12.9–19.7)
never	96	21.0	(17.3–25.4)
Number of syringes used repeatedly in the past 30 days			
1-9	23	56.5	(40.2–71.6)
10-29	9	26.2	(14.1–43.4)
30+	7	17.3	(8.3–32.5)
Number of times one syringe used repeatedly in the past 30 days			
1	1	3.4	(0.5–20.7)
2-3	23	68.1	(50.2–81.8)
4-9	5	13.1	(5.3–28.9)
10+	5	15.4	(6.4–32.9)
How the pre-filled syringe was obtained			
from dealer	6	22.1	(9.5–43.3)
from friends	23	70.9	(50.9–85.1)
from stash	3	7.0	(2.2–20.3)
Someone used one syringe for injection before front-/back-loading			
no	406	94.0	(91.5–95.9)
yes	30	6.0	(4.1–8.5)



Figure 3.1. Prevalence of Key Injection Risk Practices (%)



Figure 3.2. Trends in Key Injection Risk Practices by Survey Round (%)



Figure 3.3. With whom injected drugs in the same place (%)



Figure 3.4. With whom injected drugs in the same place by sex (%)



Figure 3.5. With whom injected drugs in the same place by age (%)

Table 3.3. Prevalence of Shared and Pre-filled Syringe Use by Sociodemographic Characteristics

		Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	481	88	17.4 (14.2–21.2)	1.0000	446	33	6.3 (4.4–9.0)	1.0000
Sex									
	male	399	73	17.3 (13.8–21.4)	0.8520	366	31	7.3 (5.0–10.4)	0.0773
	female	82	15	18.2 (11.0–28.6)		80	2	2.1 (0.5–8.7)	
Age									
	<25	4	0	0.0	0.7230	4	1	36.6 (1.4–95.8)	0.0983

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
25-34	58	12	19.4 (10.9–32.2)		55	5	8.4 (3.3–19.9)	
35-44	280	52	18.2 (14.0–23.3)		261	18	5.9 (3.6–9.5)	
45+	139	24	15.7 (10.5–22.8)		126	9	5.5 (2.8–10.5)	
Years since the start of injecting drug use								
≤2	2	1	50.0 (0.0–100.0)	0.1057	2	0	0.0	0.4687
3-5	7	0	0.0		7	1	18.7 (1.6–76.6)	
6-10	17	0	0.0		18	1	3.4 (0.4–23.4)	
≥11	440	82	17.7 (14.3–21.6)		403	29	6.0 (4.1–8.7)	
Partnership status								
live alone	219	28	11.8 (8.1–16.7)	0.0029	210	10	3.9 (2.1–7.3)	0.0402
live with partner	262	60	22.2 (17.4–27.9)		236	23	8.5 (5.5–13.0)	
Current employment status								
full-time	60	8	14.2 (7.1–26.5)	0.9540	61	7	12.1 (5.6–24.0)	0.3370
part-time or temporary	288	55	17.8 (13.8–22.8)		260	16	5.2 (3.1–8.7)	
unemployed	106	21	18.2 (11.9–26.9)		98	8	6.5 (3.1–13.0)	
disabled	21	3	14.5 (4.4–38.9)		20	2	7.0 (1.5–26.7)	
other	6	1	22.8 (1.7–83.3)		6	0	0.0	
Monthly income category								
<3K	32	5	18.2 (7.5–38.2)	0.9926	30	1	2.7 (0.4–18.3)	0.0000
3-10K	335	60	16.7 (13.0–21.1)		306	20	5.8 (3.6–9.0)	
10-20K	82	13	16.8 (9.9–27.3)		77	4	4.7 (1.7–12.3)	
≥20K	8	2	19.6 (3.3–63.6)		8	5	59.8 (19.0–90.4)	
Ever incarcerated								
no	349	66	18.0 (14.3–22.6)	0.4654	339	20	4.9 (3.1–7.6)	0.0014
yes	45	10	22.7 (12.3–38.0)		42	8	17.3 (8.5–32.1)	

Table 3.4. Prevalence of Shared and Pre-filled Syringe Use by Selected Subgroups

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	373	59	15.1 (11.8–19.2)	0.0075	350	17	4.0 (2.4–6.5)	0.0003

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
yes	92	26	27.5 (18.9–38.2)		81	13	14.9 (8.3–25.3)	
Treated with MAT currently (of all)								
no	397	71	17.1 (13.7–21.3)	0.3096	367	26	6.2 (4.1–9.3)	0.7273
yes	52	12	23.2 (13.0–37.9)		52	5	7.4 (3.0–17.3)	
HIV test result								
positive	21	5	21.6 (8.4–45.2)	0.6043	20	2	7.3 (1.6–27.4)	0.8339
negative	460	83	17.3 (14.0–21.1)		426	31	6.3 (4.3–9.1)	
Past 30 days injecting 4 categories								
opioids	321	49	14.9 (11.3–19.3)	0.2608	309	13	4.1 (2.3–7.3)	0.0044
stimulants	20	6	26.7 (11.2–51.5)		19	5	23.8 (8.9–49.9)	
opi+stimul	137	33	23.0 (16.5–31.2)		114	14	9.4 (5.4–15.7)	
other	3	0	0.0		4	1	12.2 (0.3–87.7)	
Injecting drug type of choice								
opioids	441	78	16.9 (13.6–20.8)	0.1266	406	26	5.6 (3.8–8.4)	0.0268
stimulants	34	9	26.7 (13.8–45.3)		33	6	15.7 (6.6–33.0)	
other	2	1	59.4 (0.3–99.8)		3	1	21.6 (0.1–98.2)	

Table 3.5. Prevalence of Front-/back-loading and Container Sharing by Sociodemographic Characteristics

		Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	432	39	7.9 (5.7–10.8)	1.0000	451	43	8.5 (6.3–11.4)	1.0000
Sex									
	male	352	34	8.5 (6.0–11.8)	0.3123	371	39	9.2 (6.7–12.5)	0.2785
	female	80	5	5.3 (2.1–12.6)		80	4	5.2 (1.9–13.8)	
Age									
	<25	3	0	0.0	0.9503	3	0	0.0	0.0430
	25-34	52	5	9.0 (3.6–21.1)		54	11	18.0 (9.7–30.7)	
	35-44	253	23	7.8 (5.2–11.7)		258	19	6.3 (4.0–9.9)	
	45+	124	11	7.7 (4.2–13.8)		136	13	8.9 (5.1–15.0)	
Years since the start of injecting drug use									

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
≤2	2	0	0.0	0.5433	2	1	50.0 (0.0–100.0)	0.0910
3-5	7	0	0.0		7	0	0.0	
6-10	17	0	0.0		16	0	0.0	
≥11	393	37	8.2 (5.9–11.2)		414	41	8.8 (6.5–11.9)	
Partnership status								
live alone	194	16	7.0 (4.2–11.3)	0.4949	212	18	7.0 (4.3–11.0)	0.2652
live with partner	238	23	8.7 (5.7–13.0)		239	25	9.8 (6.6–14.4)	
Current employment status								
full-time	58	11	19.4 (10.8–32.4)	0.0009	58	16	27.2 (16.9–40.7)	0.0000
part-time or temporary	253	17	5.7 (3.5–9.1)		267	17	5.5 (3.4–8.7)	
unemployed	95	9	7.8 (3.9–15.0)		98	9	8.3 (4.2–15.7)	
disabled	20	0	0.0		22	1	3.7 (0.5–24.7)	
other	6	2	34.5 (5.0–84.1)		5	0	0.0	
Monthly income category								
<3K	31	2	5.8 (1.3–22.9)	0.0081	32	1	3.1 (0.4–20.1)	0.0002
3-10K	294	23	6.6 (4.4–10.0)		306	21	6.2 (4.0–9.5)	
10-20K	75	8	11.5 (5.7–21.6)		80	14	16.2 (9.5–26.1)	
≥20K	8	4	39.2 (10.3–78.4)		8	4	39.2 (10.3–78.4)	
Ever incarcerated								
no	330	21	5.8 (3.7–8.9)	0.0000	337	23	6.1 (4.0–9.1)	0.0000
yes	40	15	33.5 (20.4–49.8)		43	12	25.0 (14.1–40.2)	

Table 3.6. Prevalence of Front-/back-loading and Container Sharing by Selected Subgroups

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	345	23	6.0 (4.0–9.0)	0.0020	357	21	5.1 (3.3–7.8)	0.0000
yes	73	14	16.7 (9.7–27.3)		81	19	21.9 (13.9–32.7)	
Treated with MAT currently (of all)								
no	360	30	7.3 (5.1–10.5)	0.2146	369	31	7.3 (5.1–10.3)	0.0093

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
yes	48	7	12.3 (5.7–24.6)		52	10	18.3 (9.7–32.0)	
HIV test result								
positive	21	4	16.4 (5.7–39.1)	0.1261	21	4	15.7 (5.4–38.0)	0.1999
negative	411	35	7.5 (5.3–10.4)		430	39	8.1 (5.9–11.1)	
Past 30 days injecting 4 categories								
opioids	295	23	7.1 (4.7–10.6)	0.4493	302	22	6.3 (4.1–9.6)	0.0278
stimulants	18	4	18.6 (6.3–43.8)		18	6	31.6 (13.4–58.1)	
opi+stimul	115	12	8.9 (5.0–15.5)		127	15	11.0 (6.6–17.9)	
other	4	0	0.0		4	0	0.0	
Injecting drug type of choice								
opioids	396	31	7.1 (4.9–10.0)	0.0104	411	34	7.5 (5.3–10.5)	0.0049
stimulants	30	8	21.7 (10.4–40.0)		33	9	23.3 (11.8–41.1)	
other	3	0	0.0		3	0	0.0	

4. Sexual Behavior

Table 4.1. Prevalence of Sexual Practice by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had sex: ever										
yes	415	91.4	(88.5–93.7)	71	87.8	(77.7–93.7)	344	92.2	(89.1–94.4)	0.2303
N	458			80			378			
Had sex: in the past 12 months										
yes	367	89.2	(85.5–92.0)	64	90.9	(81.4–95.8)	303	88.8	(84.6–92.0)	0.6125
N	410			71			339			
Had sex: in the past 30 days										
yes	216	50.8	(45.5–56.1)	52	75.3	(62.9–84.6)	164	46.1	(40.4–51.8)	0.0000
N	410			69			341			
Had a sex partner in the past 30 days: regular										
yes	140	86.0	(79.9–90.5)	47	96.5	(86.1–99.2)	93	81.4	(73.3–87.5)	0.0090
N	165			49			116			
Had a sex partner in the past 30 days: casual										
yes	41	26.0	(19.5–33.9)	6	13.7	(5.7–29.3)	35	31.9	(23.6–41.5)	0.0349
N	155			48			107			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	1	0.7	(0.1–4.8)	0	0.0		1	1.0	(0.1–7.0)	0.4880
N	160			50			110			
Used condom during last sex: if ever had sex										
yes	125	39.0	(33.4–44.9)	41	67.2	(54.0–78.1)	84	32.0	(26.4–38.3)	0.0000
N	320			64			256			

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Used condom during last sex: if had sex in 12m										
yes	118	40.0	(34.1–46.1)	41	72.2	(58.8–82.6)	77	31.9	(26.0–38.4)	0.0000
N	296			59			237			
Used condom during last sex: if had sex in 30d										
yes	96	50.5	(42.8–58.1)	36	77.4	(63.4–87.1)	60	41.2	(33.0–50.0)	0.0000
N	193			49			144			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes				0	0.0		0	0.0		
N				49			108			



Figure 4.1. Frequency of sex in the past week by Drug Types Used (%)

Table 4.2. Sex Practices by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had same-sex sexual experience										
yes	47	10.0	(7.5–13.2)	12	15.4	(8.7–25.9)	35	8.9	(6.4–12.3)	0.0931
N	408			71			337			
Provided sex services for money										
yes	32	7.3	(5.2–10.3)	11	14.2	(7.8–24.4)	21	5.9	(3.8–9.0)	0.0154
N	389			70			319			
Paid for sex ever										
yes	64	14.8	(11.6–18.8)	2	2.8	(0.7–11.0)	62	17.4	(13.6–22.1)	0.0022
N	374			69			305			
Had sex with a sex worker in the past 6 months										
yes	16	24.6	(15.4–36.9)	1	44.7	(4.6–93.1)	15	23.9	(14.7–36.3)	0.5004
N	64			2			62			
Type of partner with whom had last sex										
regular	193	48.0	(42.6–53.3)	53	74.7	(61.9–84.3)	140	42.5	(36.8–48.5)	
casual	199	50.5	(45.2–55.9)	17	25.3	(15.7–38.1)	182	55.7	(49.7–61.5)	
com. sex (I paid)	8	1.5	(0.7–3.1)	0	0.0		8	1.8	(0.9–3.7)	
com. sex (I was paid)	0	0.0		0	0.0		0	0.0		

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
N	400			70			330			
With whom last had sex										
man	71	17.9	(14.1–22.5)	63	89.7	(79.4–95.2)	8	2.8	(1.4–5.6)	
woman	316	82.1	(77.5–85.9)	7	10.3	(4.8–20.6)	309	97.2	(94.4–98.6)	
men and women	0	0.0		0	0.0		0	0.0		
N	387			70			317			
Type of last sex contact: vaginal										
yes	386	95.6	(93.2–97.2)	70	98.8	(91.5–99.8)	316	95.0	(92.2–96.8)	0.1319
N	407			71			336			
Type of last sex contact: anal										
yes	11	2.8	(1.5–5.1)	1	0.9	(0.1–6.3)	10	3.1	(1.6–6.0)	0.2006
N	407			71			336			
Type of last sex contact: oral										
yes	40	8.5	(6.2–11.5)	4	4.6	(1.7–12.0)	36	9.3	(6.7–12.8)	0.1657
N	407			71			336			

Table 4.3. Sex Partners by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had a sex partner in the past 30 days: regular										
yes	140	86.0	(79.9–90.5)	47	96.5	(86.1–99.2)	93	81.4	(73.3–87.5)	0.0090
N	165			49			116			
Had a sex partner in the past 30 days: casual										
yes	41	26.0	(19.5–33.9)	6	13.7	(5.7–29.3)	35	31.9	(23.6–41.5)	0.0349
N	155			48			107			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	1	0.7	(0.1–4.8)	0	0.0		1	1.0	(0.1–7.0)	0.4880
N	160			50			110			
Number of sex partners in the past 30 days: regular										
1	70	97.6	(90.1–99.4)	12	100.0		58	97.1	(88.5–99.3)	
2-4	2	2.4	(0.6–9.9)	0	0.0		2	2.9	(0.7–11.5)	
5+	0	0.0		0	0.0		0	0.0		
N	72			12			60			
Number of sex partners in the past 30 days: casual										
1	19	67.1	(47.5–82.1)	2	75.7	(21.3–97.3)	17	66.1	(45.2–82.2)	
2-4	9	32.9	(17.9–52.5)	1	24.3	(2.7–78.7)	8	33.9	(17.8–54.8)	
5+	0	0.0		0	0.0		0	0.0		
N	28			3			25			
Number of sex partners in the past 30 days: total										
1	63	78.2	(67.4–86.2)	9	73.8	(42.0–91.6)	54	79.0	(67.2–87.3)	0.8130
2-4	16	20.3	(12.6–30.9)	3	26.2	(8.4–58.0)	13	19.3	(11.4–30.9)	
5+	1	1.5	(0.2–9.9)	0	0.0		1	1.7	(0.2–11.4)	
N	80			12			68			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes				0	0.0		0	0.0		
N				49			108			



Figure 4.2. Condom Use During Last Sexual Encounter by Type of Partner (%)



Figure 4.3. Trends in Condom Use During Last Sexual Encounter by Survey Round (%)

Table 4.4. Condom Use During Last Sexual Encounter by Sociodemographic Characteristics

			Used condom during last sex: if ever had sex				
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
Total							
	All	320	195	61.0 (55.1–66.6)	125	39.0 (33.4–44.9)	1.0000
Sex							
	male	256	172	68.0 (61.7–73.6)	84	32.0 (26.4–38.3)	0.0000
	female	64	23	32.8 (21.9–46.0)	41	67.2 (54.0–78.1)	
Age							
	<25	4	2	44.7 (3.0–95.5)	2	55.3 (4.5–97.0)	0.6432

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
25-34	39	26	63.8 (46.2–78.4)	13	36.2 (21.6–53.8)	
35-44	191	118	63.0 (55.6–69.9)	73	37.0 (30.1–44.4)	
45+	86	49	55.8 (43.9–67.1)	37	44.2 (32.9–56.1)	
Years since the start of injecting drug use						
≤2	2	2	100.0	0	0.0	0.1333
3-5	6	2	26.6 (4.1–75.4)	4	73.4 (24.6–95.9)	
6-10	13	9	73.8 (43.6–91.1)	4	26.2 (8.9–56.4)	
≥11	287	174	60.5 (54.2–66.4)	113	39.5 (33.6–45.8)	
Partnership status						
live alone	148	105	71.2 (63.0–78.2)	43	28.8 (21.8–37.0)	0.0015
live with partner	172	90	52.6 (44.4–60.7)	82	47.4 (39.3–55.6)	
Current employment status						
full-time	47	25	49.9 (35.2–64.5)	22	50.1 (35.5–64.8)	0.2096
part-time or temporary	192	113	59.9 (52.2–67.2)	79	40.1 (32.8–47.8)	
unemployed	68	46	67.0 (54.2–77.6)	22	33.0 (22.4–45.8)	
disabled	11	9	80.4 (44.2–95.5)	2	19.6 (4.5–55.8)	
other	2	2	100.0	0	0.0	
Monthly income category						
<3K	22	21	94.2 (66.9–99.3)	1	5.8 (0.7–33.1)	0.0012
3-10K	220	140	64.3 (57.1–70.9)	80	35.7 (29.1–42.9)	
10-20K	56	25	43.8 (30.7–57.9)	31	56.2 (42.1–69.3)	
≥20K	8	4	47.8 (13.3–84.6)	4	52.2 (15.4–86.7)	
Ever incarcerated						
no	245	136	55.5 (48.7–62.0)	109	44.5 (38.0–51.3)	0.0585
yes	33	25	73.9 (54.8–86.8)	8	26.1 (13.2–45.2)	

Table 4.5. Condom Use During Last Sexual Encounter by Selected Subgroups

	N	Used condom during last sex: if ever had sex				
		no		yes		
	n		% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	253	153	61.3 (54.9–67.3)	100	38.7 (32.7–45.1)	0.2504
yes	52	36	70.3 (55.4–81.9)	16	29.7 (18.1–44.6)	
Treated with MAT currently (of all)						
no	268	162	61.1 (54.9–67.0)	106	38.9 (33.0–45.1)	0.4926
yes	32	21	67.9 (48.0–82.9)	11	32.1 (17.1–52.0)	
HIV test result						
positive	17	10	63.6 (37.7–83.5)	7	36.4 (16.5–62.3)	0.8235
negative	303	185	60.8 (54.8–66.6)	118	39.2 (33.4–45.2)	
Past 30 days injecting 4 categories						
opioids	223	138	62.0 (55.1–68.4)	85	38.0 (31.6–44.9)	0.4763
stimulants	11	7	68.7 (35.2–89.9)	4	31.3 (10.1–64.8)	
opi+stimul	83	48	55.3 (43.1–66.8)	35	44.7 (33.2–56.9)	
other	3	2	85.6 (8.3–99.7)	1	14.4 (0.3–91.7)	
Injecting drug type of choice						
opioids	296	178	60.0 (53.9–65.8)	118	40.0 (34.2–46.1)	
stimulants	21	14	63.3 (38.4–82.7)	7	36.7 (17.3–61.6)	
other	0	0	0.0	0	0.0	

Table 4.6. Condom use by type of partner by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Used condom during last sex: regular partner										
yes	80	60.2	(51.4–68.4)	35	80.0	(65.8–89.2)	45	50.1	(39.7–60.5)	0.0008
N	139			46			93			
Used condom during last sex: casual partner										
yes	15	34.3	(21.5–50.0)	4	60.1	(23.1–88.3)	11	29.2	(16.8–45.7)	0.1292
N	47			7			40			
Used condom during last sex: commercial (I paid) partner										
yes	1	31.4	(4.4–81.9)	0	0.0		1	31.4	(4.4–81.9)	
N	4			0			4			
Condom use frequency: regular partner										
always	3	2.0	(0.6–6.2)	1	1.9	(0.3–12.7)	2	2.1	(0.5–8.1)	0.0017
often	67	51.1	(42.2–60.0)	33	75.8	(61.0–86.3)	34	38.1	(28.4–48.9)	
half	5	4.1	(1.6–9.7)	0	0.0		5	6.2	(2.5–14.5)	
sometimes	4	3.4	(1.1–9.8)	0	0.0		4	5.1	(1.7–14.5)	
rarely	22	15.5	(10.2–22.8)	2	3.7	(0.9–14.6)	20	21.8	(14.3–31.8)	
never	36	23.9	(17.4–31.8)	10	18.6	(9.7–32.6)	26	26.7	(18.6–36.8)	
N	137			46			91			

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Condom use frequency: casual partner										
always	4	7.6	(2.8–19.1)	0	0.0		4	9.2	(3.4–22.6)	0.1300
often	7	17.6	(8.3–33.6)	3	51.9	(17.6–84.5)	4	10.5	(4.0–25.2)	
half	3	6.2	(2.0–18.2)	1	8.3	(1.0–44.1)	2	5.8	(1.5–20.6)	
sometimes	5	12.5	(4.8–28.6)	0	0.0		5	15.1	(5.9–33.4)	
rarely	13	27.9	(16.5–43.1)	2	25.7	(5.8–66.0)	11	28.3	(16.0–45.0)	
never	14	28.2	(17.0–42.9)	1	14.2	(1.8–59.5)	13	31.0	(18.5–47.2)	
N	46			7			39			
Condom use frequency: commercial (I paid) partner										
always	0	0.0		0	0.0		0	0.0		
often	1	31.4	(4.4–81.9)	0	0.0		1	31.4	(4.4–81.9)	
half	1	21.2	(2.6–72.7)	0	0.0		1	21.2	(2.6–72.7)	
sometimes	1	31.4	(4.4–81.9)	0	0.0		1	31.4	(4.4–81.9)	
rarely	1	16.1	(1.9–65.1)	0	0.0		1	16.1	(1.9–65.2)	
never	0	0.0		0	0.0		0	0.0		
N	4			0			4			
Condom use frequency: commercial (I was paid) partner										
always	0	0.0		0	0.0		0	0.0		
often	0	0.0		0	0.0		0	0.0		
half	1	9.4	(1.2–47.3)	0	0.0		1	11.0	(1.4–52.5)	
sometimes	3	48.7	(15.5–83.0)	1	100.0		2	40.4	(9.1–82.1)	
rarely	3	41.9	(12.4–78.5)	0	0.0		3	48.7	(13.8–84.9)	
never	0	0.0		0	0.0		0	0.0		
N	7			1			6			
Used condom during last sex: commercial (I was paid) partner										
yes				0	0.0		0	0.0		
N				1			6			



Figure 4.4. Frequency of condom use by type of partner by Sex (%)



Figure 4.5. Frequency of condom use among men during the last sexual encounter by the riskiest type of partner in the past 30 days (%)

5. HIV, HCV, and Syphilis Testing Results

Table 5.1. HIV Prevalence by Sociodemographic Characteristics

			HIV test result			
	N	positive		negative		
		n	% (CI)	n	% (CI)	p-value
Total						
All	500	21	4.1 (2.6–6.3)	479	95.9 (93.7–97.4)	1.0000
Sex						
male	415	14	3.5 (2.0–5.9)	401	96.5 (94.1–98.0)	0.1191
female	85	7	7.1 (3.3–14.5)	78	92.9 (85.5–96.7)	
Age						
<25	4	0	0.0	4	100.0	0.6903
25-34	60	2	2.9 (0.7–11.5)	58	97.1 (88.5–99.3)	
35-44	287	16	5.0 (3.0–8.2)	271	95.0 (91.8–97.0)	
45+	149	3	2.8 (0.8–9.0)	146	97.2 (91.0–99.2)	
Years since the start of injecting drug use						
≤2	2	0	0.0	2	100.0	0.7932
3-5	7	0	0.0	7	100.0	
6-10	18	0	0.0	18	100.0	
≥11	456	19	4.1 (2.5–6.5)	437	95.9 (93.5–97.5)	
Partnership status						
live alone	228	9	3.9 (2.0–7.4)	219	96.1 (92.6–98.0)	0.8395

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
live with partner	272	12	4.2 (2.3–7.6)	260	95.8 (92.4–97.7)	
Current employment status						
full-time	61	2	3.2 (0.8–12.7)	59	96.8 (87.3–99.2)	0.2464
part-time or temporary	297	10	3.2 (1.7–6.2)	287	96.8 (93.8–98.3)	
unemployed	113	9	7.6 (3.9–14.3)	104	92.4 (85.7–96.1)	
disabled	22	0	0.0	22	100.0	
other	6	0	0.0	6	100.0	
Monthly income category						
<3K	33	1	3.7 (0.5–23.2)	32	96.3 (76.8–99.5)	0.1805
3-10K	347	17	4.7 (2.9–7.7)	330	95.3 (92.3–97.1)	
10-20K	84	0	0.0	84	100.0	
≥20K	8	1	10.5 (0.9–60.2)	7	89.5 (39.8–99.1)	
Ever incarcerated						
no	362	19	5.1 (3.2–8.0)	343	94.9 (92.0–96.8)	0.8542
yes	45	2	4.4 (1.0–17.1)	43	95.6 (82.9–99.0)	

Table 5.2. HIV Prevalence by Selected Subgroups

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	385	12	3.4 (1.9–6.0)	373	96.6 (94.0–98.1)	0.0505
yes	96	9	7.9 (4.0–14.9)	87	92.1 (85.1–96.0)	
Treated with MAT currently (of all)						
no	407	17	4.2 (2.5–6.8)	390	95.8 (93.2–97.5)	0.4857
yes	56	4	6.1 (2.2–15.9)	52	93.9 (84.1–97.8)	
Past 30 days injecting 4 categories						
opioids	330	17	4.8 (3.0–7.7)	313	95.2 (92.3–97.0)	0.1294
stimulants	20	2	14.3 (2.9–48.5)	18	85.7 (51.5–97.1)	
opi+stimul	146	2	1.1 (0.3–4.4)	144	98.9 (95.6–99.7)	
other	4	0	0.0	4	100.0	
Injecting drug type of choice						

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
opioids	458	19	3.8 (2.4–6.0)	439	96.2 (94.0–97.6)	0.4465
stimulants	34	2	8.7 (1.8–33.2)	32	91.3 (66.8–98.2)	
other	3	0	0.0	3	100.0	



Figure 5.1. HIV Test Result (%)



Figure 5.2. Trends in HIV Prevalence by Survey Round (%)



Figure 5.3. Anti-HCV Testing Coverage In the Survey (%)



Figure 5.4. Anti-HCV Test Results (%)



Figure 5.5. Anti-HCV Test Results by Sex (%)



Figure 5.6. Trends in Anti-HCV Prevalence by Survey Round (%)



Figure 5.7. Syphilis Test Results (%)

6. HIV Prevention

Table 6.1. Being a Client of NGO by Sociodemographic Characteristics

			Client of NGO working with PWID			
		N	no		yes	
			n	% (CI)	n	% (CI)	p-value
Total							
	All	481	385	80.1 (75.9–83.7)	96	19.9 (16.3–24.1)	1.0000
Sex							
	male	398	318	79.8 (75.1–83.8)	80	20.2 (16.2–24.9)	0.7110
	female	83	67	81.6 (71.4–88.8)	16	18.4 (11.2–28.6)	
Age							

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
<25	4	2	41.0 (2.7–94.7)	2	59.0 (5.3–97.3)	0.1709
25-34	59	49	84.7 (73.0–91.9)	10	15.3 (8.1–27.0)	
35-44	278	227	81.0 (75.1–85.7)	51	19.0 (14.3–24.9)	
45+	140	107	77.4 (69.4–83.8)	33	22.6 (16.2–30.6)	
Years since the start of injecting drug use						
≤2	2	2	100.0	0	0.0	0.4905
3-5	7	6	81.3 (23.4–98.4)	1	18.7 (1.6–76.6)	
6-10	18	17	94.7 (67.0–99.4)	1	5.3 (0.6–33.0)	
≥11	437	351	80.2 (75.8–84.0)	86	19.8 (16.0–24.2)	
Partnership status						
live alone	222	196	89.7 (85.1–93.1)	26	10.3 (6.9–14.9)	0.0000
live with partner	259	189	71.7 (65.2–77.4)	70	28.3 (22.6–34.8)	
Current employment status						
full-time	58	45	76.0 (62.2–85.9)	13	24.0 (14.1–37.8)	0.3574
part-time or temporary	286	238	82.7 (77.2–87.1)	48	17.3 (12.9–22.8)	
unemployed	108	78	74.5 (65.0–82.2)	30	25.5 (17.8–35.0)	
disabled	22	18	80.7 (55.9–93.3)	4	19.3 (6.7–44.1)	
other	6	5	88.3 (30.9–99.2)	1	11.7 (0.8–69.1)	
Monthly income category						
<3K	33	22	65.6 (46.8–80.6)	11	34.4 (19.4–53.2)	0.1141
3-10K	333	272	81.4 (76.3–85.7)	61	18.6 (14.3–23.7)	
10-20K	80	61	76.9 (65.9–85.2)	19	23.1 (14.8–34.1)	
≥20K	8	5	59.8 (19.0–90.4)	3	40.2 (9.6–81.0)	
Ever incarcerated						
no	349	292	84.3 (80.0–87.9)	57	15.7 (12.1–20.0)	0.1949
yes	44	33	76.5 (61.0–87.1)	11	23.5 (12.9–39.0)	

Table 6.2. Being a Client of NGO by Selected Subgroups

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Treated with MAT currently (of all)						
no	396	342	86.6 (82.7–89.8)	54	13.4 (10.2–17.3)	0.0000
yes	52	18	31.0 (19.3–45.8)	34	69.0 (54.2–80.7)	
HIV test result						
positive	21	12	63.1 (39.8–81.6)	9	36.9 (18.4–60.2)	0.0505
negative	460	373	80.9 (76.6–84.5)	87	19.1 (15.5–23.4)	
Past 30 days injecting 4 categories						
opioids	321	262	82.6 (77.9–86.5)	59	17.4 (13.5–22.1)	0.0000
stimulants	19	12	58.0 (31.9–80.3)	7	42.0 (19.7–68.1)	
opi+stimul	137	110	80.8 (73.0–86.8)	27	19.2 (13.2–27.0)	
other	4	1	12.2 (0.3–87.7)	3	87.8 (12.3–99.7)	
Injecting drug type of choice						
opioids	441	360	82.1 (78.1–85.6)	81	17.9 (14.4–21.9)	0.0629
stimulants	32	21	67.1 (47.8–82.0)	11	32.9 (18.0–52.2)	
other	3	2	53.2 (0.6–99.6)	1	46.8 (0.4–99.4)	



Figure 6.1. Injecting and Sex Risk Perception Among HIV-negative PWID (%)



Figure 6.2. Received HIV Prevention Services in the Past 12 Months and 30 days (%)



Figure 6.3. Receiving Package of Prevention Services in the Past 12 Months (%)



Figure 6.4. Trends in Receiving HIV Prevention Services in the Past 12 Months (%)



Figure 6.5. Perceived changes in access to HIV prevention since February 2022 (%)

Table 6.3. Percentage of correct responses to knowledge questions by HIV status

	Total	HIV test result		
	All	negative	positive	
	%	%	%	p-value
HIV knowledge				
HIV may be avoided	57.8	58.5	42.2	0.1523
proper condom use may prevent HIV	60.0	60.2	53.5	0.5623
undetectable=untransmittable	61.5	61.4	64.1	0.8058
PEP reduces the risk of HIV	61.0	61.3	53.8	0.5181
ART should be started immediately	47.7	47.6	51.1	0.7618

	Total	HIV test result		
	All	negative	positive	
	%	%	%	p-value
ART may be postponed if one feels healthy	25.2	25.1	26.7	0.8863
ART may be stopped if one feels healthy	40.5	41.0	27.5	0.2312
HIV is transmitted through blood and sex	62.2	62.3	58.6	0.7403
HIV is transmitted via air, food, or skin	49.4	49.9	37.6	0.2758
HBV knowledge				
proper condom use may prevent HBV	55.4	56.1	39.2	0.1396
treatment should be started immediately	58.7	58.5	63.2	0.6907
treatment may be postponed if one feels healthy	36.2	36.8	23.2	0.2769
HBV is 100% transmitted from mother to child	13.7	13.6	15.9	0.7534
HBV is transmitted through blood and sex	61.0	61.2	54.7	0.5715
HBV is transmitted via air, food, or skin	19.8	19.5	26.2	0.5022
treatment may be stopped if one feels healthy	41.2	42.2	18.8	0.0403
HCV knowledge				
proper condom use may prevent HCV	17.1	16.2	37.5	0.0208
treatment should be started immediately	53.0	52.8	57.3	0.7042
treatment may be postponed if one feels healthy	38.2	38.7	24.8	0.1911
HCV is 100% transmitted from mother to child	9.4	8.6	28.0	0.0040
HCV is transmitted through blood and sex	63.8	63.9	62.1	0.8800
there is no treatment for HCV	14.0	13.0	39.1	0.0016
HCV is transmitted via air, food, or skin	29.7	28.7	52.1	0.0298
treatment may be stopped if one feels healthy	31.8	31.1	46.0	0.1787

7. HIV Testing

Table 7.1. HIV Testing Knowledge and Uptake

	n	%	CI
Know where to get HIV test			
yes	309	65.0	(60.2–69.4)
Tested for HIV ever			
yes	330	76.5	(71.9–80.6)
Tested for HIV in the past 12 months			
yes	39	47.0	(36.1–58.2)
Tested for HIV in the past 6 months			
yes	23	28.9	(19.7–40.2)
Received the result of HIV test (of those tested)			
yes	282	89.6	(85.3–92.8)
Willing to disclose HIV test result (of those who got result)			
yes	279	99.7	(97.9–100.0)
Self-reported HIV status (of all tested)			
positive	4	1.1	(0.4–3.0)
negative	312	98.9	(97.0–99.6)
HIV testing and status awareness (GAM)			
yes	37	47.0	(35.7–58.5)
Ever did a HIV self-test			
yes	0	0.0	
Regular sex partner tested for HIV			
yes	96	41.0	(34.4–47.9)
Regular sex partner HIV test result			
positive	2	2.0	(0.5–7.7)
negative	90	96.3	(90.4–98.6)
cannot disclose	2	1.7	(0.4–6.8)



Figure 7.1. HIV Testing Uptake (%)



Figure 7.2. Testing for HIV, HCV, syphilis since February 2022 (%)



Figure 7.3. HIV Testing Since February 2022 (%)

Table 7.2. Testing for HIV in the past 12 months (among all) by Sociodemographic Characteristics

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Total						
All	82	43	53.0 (41.8–63.9)	39	47.0 (36.1–58.2)	1.0000
Sex						
male	69	38	54.6 (42.3–66.3)	31	45.4 (33.7–57.7)	0.5018
female	13	5	44.0 (19.9–71.4)	8	56.0 (28.6–80.1)	
Age						
<25	1	0	0.0	1	100.0	0.4048
25-34	14	9	64.4 (35.8–85.4)	5	35.6 (14.6–64.2)	
35-44	40	18	46.9 (31.5–62.9)	22	53.1 (37.1–68.5)	
45+	27	16	59.4 (39.6–76.5)	11	40.6 (23.5–60.4)	
Years since the start of injecting drug use						
≤2	0	0	0.0	0	0.0	
3-5	1	0	0.0	1	100.0	
6-10	5	1	18.8 (2.1–71.5)	4	81.2 (28.5–97.9)	
≥11	73	40	56.0 (44.1–67.3)	33	44.0 (32.7–55.9)	
Partnership status						
live alone	32	17	53.9 (36.2–70.7)	15	46.1 (29.3–63.8)	0.9004
live with partner	50	26	52.4 (38.2–66.3)	24	47.6 (33.7–61.8)	

	N	Tested for HIV in the past 12 months			
		no		yes	
		n	% (CI)	n	% (CI)	p-value
Current employment status						
full-time	25	15	60.8 (39.8–78.5)	10	39.2 (21.5–60.2)	0.1467
part-time or temporary	27	16	57.8 (38.0–75.4)	11	42.2 (24.6–62.0)	
unemployed	21	7	34.6 (17.1–57.5)	14	65.4 (42.5–82.9)	
disabled	7	5	74.8 (33.2–94.7)	2	25.2 (5.3–66.8)	
other	2	0	0.0	2	100.0	
Monthly income category						
<3K	16	4	25.0 (9.1–52.5)	12	75.0 (47.5–90.9)	0.0019
3-10K	42	25	59.8 (44.0–73.8)	17	40.2 (26.2–56.0)	
10-20K	15	11	77.7 (51.7–91.9)	4	22.3 (8.1–48.3)	
≥20K	6	1	11.3 (0.9–63.6)	5	88.7 (36.4–99.1)	
Ever incarcerated						
no	60	28	47.1 (34.5–60.1)	32	52.9 (39.9–65.5)	0.0791
yes	17	12	71.5 (45.7–88.2)	5	28.5 (11.8–54.3)	

Table 7.3. Testing for HIV in the past 12 months (among all) by Selected Subgroups

	N	Tested for HIV in the past 12 months			
		no		yes	
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	52	28	52.8 (38.8–66.3)	24	47.2 (33.7–61.2)	0.9180
yes	26	13	54.0 (34.2–72.7)	13	46.0 (27.3–65.8)	
Treated with MAT currently (of all)						
no	54	30	55.1 (41.2–68.2)	24	44.9 (31.8–58.8)	0.8264
yes	26	13	52.4 (32.7–71.3)	13	47.6 (28.7–67.3)	
HIV test result						
positive	6	2	35.4 (8.0–77.6)	4	64.6 (22.4–92.0)	0.3861
negative	76	41	54.4 (42.7–65.6)	35	45.6 (34.4–57.3)	
Past 30 days injecting 4 categories						
opioids	56	24	44.6 (31.7–58.3)	32	55.4 (41.7–68.3)	0.1838
stimulants	7	5	61.4 (20.8–90.5)	2	38.6 (9.5–79.2)	
opi+stimul	18	13	71.9 (46.5–88.3)	5	28.1 (11.7–53.5)	

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
other	1	1	100.0	0	0.0	
Injecting drug type of choice						
opioids	66	31	48.5 (36.3–60.9)	35	51.5 (39.1–63.7)	0.3023
stimulants	14	10	67.0 (37.1–87.5)	4	33.0 (12.5–62.9)	
other	1	1	100.0	0	0.0	

8. HIV Treatment



Figure 8.1. HIV Status Awareness Among HIV+ (%)



Figure 8.2. HIV Treatment Cascade - Four-stage (%)



Figure 8.3. HIV Treatment Cascade - Conditional (%)



Figure 8.4. HIV Treatment Cascade - Proportions (%)



Figure 8.5. Trends in HIV Treatment Cascade (Conditional, 95-95-95) by Survey Round (%)

Table 8.1. HIV Treatment Cascade (Conditional, 95-95-95) by Sociodemographic Characteristics

		Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)		Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
		N	% (CI)	p-value	n	% (CI)	N	n	% (CI)	p-value
Total										
	All	21	17.4 (6.4–39.3)	1.0000			4	3	79.8 (28.8–97.5)	1.0000
Sex										
	male	14	17.3 (5.3–43.8)	0.9771	3	100.0	3	2	71.3 (18.0–96.6)	0.4882
	female	7	17.8 (2.5–65.1)		1	100.0	1	1	100.0	
Age										
	<25	0	0.0		0	0.0	0	0	0.0	
	25-34	2	59.7 (8.0–96.2)		1	100.0	1	1	100.0	

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)		Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	n	% (CI)	N	n	% (CI)	p-value
35-44	16	17.3 (5.5–43.1)		3	100.0	3	2	71.3 (17.9–96.6)	
45+	3	0.0		0	0.0	0	0	0.0	
Years since the start of injecting drug use									
≤2	0	0.0				0	0	0.0	
3-5	0	0.0				0	0	0.0	
6-10	0	0.0				0	0	0.0	
≥11	19	19.1 (7.0–42.4)				4	3	79.8 (28.8–97.5)	
Partnership status									
live alone	9	20.1 (4.8–55.7)	0.7778	2	100.0	2	1	59.7 (8.3–96.0)	0.3038
live with partner	12	15.4 (3.6–46.6)		2	100.0	2	2	100.0	
Current employment status									
full-time	2	100.0		2	100.0	2	1	59.7 (8.0–96.2)	
part-time or temporary	10	7.2 (1.0–38.6)		1	100.0	1	1	100.0	
unemployed	9	12.2 (1.7–53.4)		1	100.0	1	1	100.0	
disabled	0	0.0		0	0.0	0	0	0.0	
other	0	0.0		0	0.0	0	0	0.0	
Monthly income category									
<3K	1	100.0		1	100.0	1	1	100.0	
3-10K	17	10.6 (2.5–34.9)		2	100.0	2	1	59.7 (8.4–96.0)	
10-20K	0	0.0		0	0.0	0	0	0.0	
≥20K	1	100.0		1	100.0	1	1	100.0	
Ever incarcerated									
no	19	19.1 (7.0–42.4)	0.5038			4	3	79.8 (28.8–97.5)	
yes	2	0.0				0	0	0.0	

Table 8.2. HIV Treatment Cascade (Conditional, 95-95-95) by Selected Subgroups

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)		Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)		
	N	% (CI)	p-value	n	% (CI)	N	n	% (CI)
Client of NGO working with PWID								
no	12	0.0	0.0025			0	0	0.0

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)		Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)		
	N	% (CI)	p-value	n	% (CI)	N	n	% (CI)
yes	9	47.3 (18.7–77.7)				4	3	79.8 (28.4–97.5)
Treated with MAT currently (of all)								
no	17	16.6 (5.3–41.8)	0.8155	3	100.0	3	2	74.7 (21.0–97.1)
yes	4	21.4 (2.6–73.5)		1	100.0	1	1	100.0
HIV test result								
positive	21	17.4 (6.0–40.9)				4	3	79.8 (26.0–97.8)
negative	0	0.0				0	0	0.0
Past 30 days injecting 4 categories								
opioids	17	17.7 (5.7–43.5)		3	100.0	3	2	74.7 (21.0–97.1)
stimulants	2	0.0		0	0.0	0	0	0.0
opi+stimul	2	45.6 (4.9–93.2)		1	100.0	1	1	100.0
other	0	0.0		0	0.0	0	0	0.0
Injecting drug type of choice								
opioids	19	20.2 (7.6–43.9)				4	3	79.8 (28.8–97.5)
stimulants	2	0.0				0	0	0.0
other	0	0.0				0	0	0.0

Table 8.3. ART adherence (among those on ART)

		n	%	CI
When did you last miss ART dose				
	last week	1	20.2	(2.5–71.2)
	1-2 weeks ago	0	0.0	
	3-4 weeks ago	0	0.0	
	1-3 months ago	0	0.0	
	never	3	79.8	(28.8–97.5)
What was the reason for missing the last ART dose				
	forgot	0	0.0	
	did not have meds	1	100.0	
	was under influence	0	0.0	
	did not want others to see	0	0.0	
	other	0	0.0	
Reasons for not taking ART				
	not sure it is needed	0	0.0	
	no time to visit clinic	0	0.0	
	no motivation to visit clinic	0	0.0	
	missed a visit, hard to come back	0	0.0	
	too sick to visit clinic	0	0.0	
	drug use	1	100.0	
	side effects or complications	0	0.0	
	no understanding of how to take it	0	0.0	

	n	%	CI
lost or sold all ARVs	0	0.0	
alcohol use	0	0.0	
waited too long and left	1	100.0	
Time on ART			
≤3m	1	100.0	
4-24m	0	0.0	
25-60m	0	0.0	
5y+	0	0.0	

9. PrEP



Figure 9.1. PrEP Uptake in the Past 12 Months (%)



Figure 9.2. Change in PrEP Awareness and Uptake from 2020 to 2023 (%)



Figure 9.3. Change in PrEP Uptake from 2020 to 2023 (%)

Table 9.1. PrEP Awareness by Sociodemographic Characteristics

		PrEP uptake in the past 12 months								
	N	use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	477	38	7.8 (5.4–11.0)	8	1.5 (0.7–3.0)	68	13.2 (10.4–16.7)	363	77.6 (73.3–81.3)	1.0000
Sex										
male	392	29	7.5 (4.9–11.2)	7	1.5 (0.7–3.2)	59	14.2 (10.9–18.2)	297	76.8 (72.0–81.1)	0.5903
female	85	9	9.0 (4.6–17.0)	1	1.3 (0.2–8.7)	9	8.8 (4.5–16.6)	66	80.9 (71.2–87.9)	
Age										
<25	3	0	0.0	0	0.0	1	24.1 (0.6–94.2)	2	75.9 (5.8–99.4)	0.9811
25-34	58	4	5.6 (2.0–15.0)	0	0.0	10	15.4 (8.1–27.3)	44	79.0 (66.3–87.8)	
35-44	272	20	8.0 (4.8–13.2)	5	1.5 (0.6–3.7)	38	13.2 (9.5–18.1)	209	77.2 (71.2–82.3)	
45+	144	14	8.3 (4.8–13.8)	3	2.0 (0.6–6.5)	19	12.1 (7.7–18.6)	108	77.6 (69.9–83.8)	
Years since the start of injecting drug use										
≤2	2	0	0.0	0	0.0	0	0.0	2	100.0	
3-5	7	0	0.0	0	0.0	0	0.0	7	100.0	
6-10	18	0	0.0	0	0.0	4	20.7 (7.2–47.0)	14	79.3 (53.0–92.8)	
≥11	434	36	8.1 (5.6–11.6)	8	1.6 (0.8–3.3)	60	12.8 (9.9–16.5)	330	77.5 (72.9–81.4)	
Partnership status										
live alone	222	12	5.0 (2.8–8.7)	1	0.3 (0.0–2.3)	32	12.8 (9.0–17.9)	177	81.9 (76.2–86.5)	0.0280
live with partner	255	26	10.2 (6.5–15.6)	7	2.5 (1.1–5.3)	36	13.6 (9.7–18.7)	186	73.7 (67.3–79.3)	
Current employment status										
full-time	60	2	3.3 (0.8–13.0)	3	4.9 (1.5–14.7)	14	19.7 (11.6–31.5)	41	72.0 (59.3–82.0)	0.1492
part-time or temporary	281	27	9.6 (6.2–14.5)	4	1.2 (0.4–3.4)	31	10.4 (7.2–14.7)	219	78.9 (73.1–83.7)	

	N	PrEP uptake in the past 12 months								
		use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
unemployed	108	7	5.5 (2.6–11.4)	1	0.8 (0.1–5.5)	21	18.7 (12.1–27.8)	79	75.0 (65.5–82.6)	
disabled	21	2	7.4 (1.6–28.5)	0	0.0	2	10.6 (2.4–36.0)	17	82.0 (58.0–93.7)	
other	6	0	0.0	0	0.0	0	0.0	6	100.0	
Monthly income category										
<3K	31	3	9.1 (2.7–26.6)	1	3.2 (0.4–21.0)	7	22.2 (10.4–41.2)	20	65.5 (46.4–80.6)	0.4255
3-10K	330	24	7.4 (4.6–11.6)	4	1.0 (0.4–2.9)	43	12.6 (9.3–16.9)	259	79.0 (73.7–83.5)	
10-20K	80	7	8.6 (4.0–17.2)	3	3.4 (1.1–10.3)	14	14.6 (8.5–24.0)	56	73.4 (62.6–82.0)	
≥20K	8	2	19.6 (3.3–63.6)	0	0.0	3	28.6 (6.4–70.3)	3	51.8 (15.4–86.3)	
Ever incarcerated										
no	354	19	4.6 (2.9–7.2)	5	1.3 (0.5–3.3)	53	13.4 (10.2–17.4)	277	80.6 (76.1–84.4)	0.6121
yes	42	4	8.9 (3.2–22.5)	1	2.0 (0.3–13.4)	6	11.5 (5.0–24.3)	31	77.6 (62.7–87.7)	

Table 9.2. PrEP Current Use by Sociodemographic Characteristics

	N	PrEP uptake in the past 12 months								
		use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										
no	369	2	0.3 (0.1–1.1)	3	0.7 (0.2–2.2)	43	10.8 (7.9–14.5)	321	88.2 (84.4–91.2)	0.0000
yes	91	35	38.9 (28.2–50.7)	5	5.0 (2.0–12.0)	23	23.9 (15.8–34.5)	28	32.2 (22.7–43.6)	
Treated with MAT currently (of all)										
no	388	12	2.6 (1.5–4.7)	6	1.4 (0.6–3.2)	50	11.6 (8.7–15.3)	320	84.3 (80.3–87.7)	0.0000
yes	53	22	45.9 (31.0–61.6)	2	3.1 (0.7–12.1)	12	21.3 (11.9–35.3)	17	29.7 (18.3–44.3)	
HIV test result										
positive	20	3	11.7 (3.4–33.2)	0	0.0	6	27.5 (11.7–52.0)	11	60.8 (37.0–80.4)	0.1853
negative	457	35	7.6 (5.2–10.9)	8	1.5 (0.7–3.1)	62	12.6 (9.8–16.1)	352	78.3 (73.9–82.1)	
Past 30 days injecting 4 categories										
opioids	316	21	5.9 (3.8–9.0)	5	1.5 (0.6–3.6)	50	14.7 (11.1–19.2)	240	78.0 (72.9–82.3)	0.0000
stimulants	20	2	9.0 (2.0–33.0)	0	0.0	3	18.1 (4.8–49.3)	15	72.9 (44.8–89.9)	
opi+stimul	137	12	7.8 (4.4–13.7)	3	1.7 (0.5–5.4)	14	9.2 (5.3–15.3)	108	81.3 (73.8–87.0)	
other	4	3	87.8 (12.3–99.7)	0	0.0	1	12.2 (0.3–87.7)	0	0.0	
Injecting drug type of choice										
opioids	437	32	6.6 (4.7–9.3)	6	1.2 (0.5–2.8)	64	13.7 (10.7–17.4)	335	78.4 (74.2–82.2)	0.1088
stimulants	32	3	6.4 (1.9–19.2)	2	5.2 (1.2–19.6)	4	11.1 (3.9–27.6)	23	77.3 (59.9–88.6)	
other	3	1	46.8 (0.4–99.4)	0	0.0	0	0.0	2	53.2 (0.6–99.6)	

Table 9.3. PrEP Awareness and Uptake

	n	%	CI
PrEP uptake in the past 12 months			
use now	38	7.8	(5.4–11.0)
used in the past	8	1.5	(0.7–3.0)
never used	68	13.2	(10.4–16.7)
not aware	363	77.6	(73.3–81.3)
Aware of PrEP			
no	363	76.8	(72.4–80.6)
yes	117	23.2	(19.4–27.6)
PrEP use current			
no	439	92.2	(89.0–94.6)
yes	38	7.8	(5.4–11.0)
PrEP use current (of those aware)			
no	76	65.5	(54.9–74.6)
yes	38	34.5	(25.4–45.1)

10. MAT



Figure 10.1. MAT Awareness (%)



Figure 10.2. MAT Current Uptake (%)



Figure 10.3. Trends in MAT Lifetime and Current Uptake by Survey Round (%)

Table 10.1. MAT experience

	n	%	CI
Reason for MAT discontinuation			
moved to another city	3	7.1	(2.3–20.2)
clinic closed after Feb 2022	6	13.8	(6.0–28.6)
weak or no effect	9	23.6	(12.6–39.8)
side effects	5	12.7	(5.3–27.3)
do not want to visit clinic	9	23.4	(12.4–40.0)
do not want to quit drugs	3	8.0	(2.4–23.4)
hard to get to the clinic	3	8.0	(2.6–22.3)
do not need it	4	8.6	(3.2–21.2)
do not like the attitude of physician	0	0.0	
How did the injection frequency change during MAT			
intensified	14	29.7	(18.0–44.8)
did not change	21	48.8	(34.1–63.8)
decreased	9	21.5	(11.4–36.9)

	n	%	CI
Whether bought bupr. or methadone while not being a patient in the past 12 months			
yes, methadone	85	16.4	(13.3–20.1)
yes, buprenorphine	17	3.8	(2.3–6.2)
did not buy	358	79.7	(75.7–83.2)
Where bought bupr. or methadone while not being a patient in the past 12 months			
did not buy	358	82.4	(78.5–85.7)
bought from black market	73	14.8	(11.8–18.4)
bought from private clinic	13	2.9	(1.6–5.0)
Way of using bupr. or methaone bought from others			
injecting	58	69.1	(57.5–78.6)
injecting mixed	4	5.0	(1.9–12.8)
swallow or subling.	11	15.8	(8.9–26.6)
snort	8	10.1	(5.1–19.2)

Table 10.2. MAT Awareness and Uptake by Sociodemographic Characteristics

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	463	56	11.7 (8.9–15.4)	36	7.3 (5.2–10.1)	97	19.3 (15.8–23.3)	274	61.7 (56.9–66.3)	1.0000
Sex										
male	382	47	12.0 (8.8–16.1)	31	7.3 (5.1–10.4)	73	18.0 (14.3–22.4)	231	62.8 (57.4–67.8)	0.4635
female	81	9	10.7 (5.5–20.0)	5	7.1 (2.9–16.2)	24	25.9 (17.6–36.5)	43	56.3 (44.9–67.0)	
Age										
<25	4	0	0.0	1	22.3 (0.7–92.2)	0	0.0	3	77.7 (7.8–99.3)	0.1767
25-34	56	7	9.6 (4.4–19.7)	7	10.6 (4.9–21.6)	14	20.8 (12.0–33.6)	28	59.0 (44.6–72.0)	
35-44	266	25	9.9 (6.3–15.1)	14	4.9 (2.9–8.3)	55	19.0 (14.6–24.4)	172	66.2 (59.8–72.0)	
45+	137	24	16.8 (11.3–24.2)	14	10.1 (5.9–16.8)	28	19.7 (13.6–27.8)	71	53.4 (44.3–62.2)	
Years since the start of injecting drug use										
≤2	2	0	0.0	0	0.0	0	0.0	2	100.0	
3-5	7	0	0.0	0	0.0	0	0.0	7	100.0	
6-10	17	2	12.3 (2.7–41.2)	0	0.0	4	20.4 (6.9–47.1)	11	67.3 (40.6–86.1)	
≥11	420	51	11.8 (8.8–15.7)	34	7.6 (5.4–10.6)	91	20.0 (16.3–24.3)	244	60.5 (55.4–65.4)	
Partnership status										
live alone	209	21	9.0 (5.8–13.6)	4	1.9 (0.7–5.0)	36	14.9 (10.7–20.4)	148	74.2 (67.7–79.8)	0.0000
live with partner	254	35	14.0 (9.8–19.8)	32	11.8 (8.3–16.4)	61	23.0 (17.9–28.9)	126	51.2 (44.6–57.9)	
Current employment status										
full-time	60	12	18.5 (10.5–30.7)	3	5.9 (1.8–17.6)	15	23.9 (14.6–36.6)	30	51.7 (38.6–64.5)	0.1327
part-time or temporary	266	22	8.9 (5.5–14.1)	19	6.6 (4.2–10.3)	62	21.5 (16.8–27.1)	163	63.0 (56.5–69.0)	

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
unemployed	110	17	14.0 (8.6–21.9)	9	7.1 (3.6–13.5)	16	12.9 (7.7–21.1)	68	66.0 (56.1–74.6)	
disabled	21	4	17.8 (6.2–41.6)	4	20.8 (7.2–47.0)	3	13.3 (4.0–36.1)	10	48.1 (26.7–70.3)	
other	6	1	22.8 (1.7–83.3)	1	13.3 (0.9–72.1)	1	11.7 (0.8–69.1)	3	52.3 (11.3–90.4)	
Monthly income category										
<3K	31	8	24.5 (11.9–43.8)	4	16.0 (5.9–36.6)	8	23.2 (11.4–41.5)	11	36.3 (20.7–55.4)	0.0868
3-10K	321	29	9.4 (6.2–13.9)	25	7.1 (4.8–10.5)	73	21.0 (16.7–26.1)	194	62.5 (56.6–68.0)	
10-20K	76	13	15.7 (9.1–25.8)	4	5.2 (1.9–13.6)	13	15.7 (9.1–25.8)	46	63.4 (51.7–73.8)	
≥20K	8	2	19.6 (3.3–63.6)	0	0.0	2	19.6 (3.3–63.6)	4	60.8 (21.6–89.7)	
Ever incarcerated										
no	344	38	9.8 (7.1–13.3)	26	7.0 (4.7–10.2)	73	19.3 (15.4–23.9)	207	64.0 (58.5–69.1)	0.1473
yes	42	7	17.0 (8.0–32.7)	3	7.2 (2.2–21.3)	13	29.6 (17.4–45.6)	19	46.2 (31.0–62.2)	

Table 10.3. MAT Awareness and Uptake by Selected Subgroups

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
Client of NGO working with PWID										
no	360	18	4.4 (2.7–6.9)	20	4.8 (3.1–7.5)	75	18.4 (14.7–22.8)	247	72.4 (67.5–76.9)	0.0000
yes	88	34	39.7 (28.8–51.7)	15	17.9 (10.8–28.2)	18	20.8 (12.9–31.8)	21	21.7 (14.1–31.9)	
Treated with MAT currently (of all)										
no	407	0	0.0	36	8.3 (5.9–11.4)	97	21.9 (18.0–26.3)	274	69.9 (65.1–74.3)	0.0000
yes	56	56	100.0	0	0.0	0	0.0	0	0.0	
HIV test result										
positive	21	4	16.4 (5.7–39.1)	0	0.0	8	40.8 (20.3–65.0)	9	42.8 (22.3–66.1)	0.0444
negative	442	52	11.5 (8.6–15.3)	36	7.6 (5.5–10.5)	89	18.3 (14.9–22.3)	265	62.6 (57.6–67.2)	
Past 30 days injecting 4 categories										
opioids	314	37	10.5 (7.6–14.4)	19	6.2 (3.9–9.6)	58	17.0 (13.1–21.8)	200	66.3 (60.6–71.5)	0.0000
stimulants	20	3	13.4 (3.9–37.2)	6	24.7 (10.0–49.1)	4	29.8 (10.7–60.1)	7	32.1 (14.3–57.3)	
opi+stimul	125	13	10.3 (5.9–17.2)	11	7.8 (4.2–14.0)	34	23.8 (17.1–32.1)	67	58.1 (48.8–66.9)	
other	4	3	87.8 (12.3–99.7)	0	0.0	1	12.2 (0.3–87.7)	0	0.0	
Injecting drug type of choice										
opioids	423	47	10.3 (7.7–13.6)	26	5.9 (4.0–8.6)	92	19.9 (16.2–24.1)	258	64.0 (59.1–68.6)	0.0002
stimulants	33	5	12.8 (5.1–28.5)	9	27.3 (14.1–46.2)	5	17.4 (6.6–38.6)	14	42.6 (25.6–61.5)	

	N	MAT uptake (of all)								
		take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
other	3	1	46.8 (0.4–99.4)	1	21.6 (0.1–98.2)	0	0.0	1	31.6 (0.2–99.0)	



Figure 10.4. Buying MAT medications while not being a patient (%)



Figure 10.5. Source of buying MAT medications while not being a patient (%)



Figure 10.6. Route of administration of MAT medications bought from others (%)

11. Overdose and Naloxone



Figure 11.1. Overdose Experience Ever and in the Past 12 Months (%)



Figure 11.2. Trends in Overdose Experience in the Past 12 Months by Survey Round (%)



Figure 11.3. Drugs causing overdoses (if used only one drug) (%)



Figure 11.4. Naloxone Use (%)

Table 11.1. Overdose Experience

		n	%	CI
Experienced overdose ever				
	yes	270	62.5	(57.6–67.2)
Number of overdoses in lifetime				
	1	64	29.3	(23.0–36.6)
	2-4	125	56.5	(49.0–63.7)
	5+	28	14.2	(9.4–20.9)
Experienced overdose in the past 12 months				
	yes	31	7.7	(5.3–10.9)
Experienced overdose in the past 12 months (of those ever)				
	yes	31	12.8	(8.9–18.0)
Number of overdoses in the past 12 months				
	1	24	85.3	(65.9–94.5)
	2-4	4	14.7	(5.5–34.1)
	5+	0	0.0	
Drug overdosed with (if used only one drug)				
	methadone	9	68.4	(38.9–88.0)
	other opioid	0	0.0	
	stimulant	3	24.0	(7.6–54.5)
	other	1	7.6	(1.0–39.3)
Drugs overdosed with (if used a combination)				
	methadone+stimulant	0	0.0	
	methadone+barbit. or dimedr.	0	0.0	
	methadone+other	0	0.0	
	other	6	100.0	
Drug overdosed with (if combined drug with alcohol)				
	methadone	3	20.9	(6.5–49.9)
	other opioid	5	36.1	(14.8–64.8)
	stimulant	1	12.8	(1.8–53.5)
	other	3	30.2	(10.2–62.4)
Naloxone knowledge and experience				
	never heard	216	47.3	(42.5–52.1)
	aware but not used	133	24.5	(20.8–28.6)
	used myself	58	11.7	(8.8–15.3)
	my friends used	61	11.6	(9.0–14.8)

	n	%	CI
me and my friends used	23	4.9	(3.3–7.4)

Table 11.2. Overdose Experience in the Past 12 Months by Sociodemographic Characteristics

		Experienced overdose in the past 12 months				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
Total						
All	416	385	92.3 (89.1–94.7)	31	7.7 (5.3–10.9)	1.0000
Sex						
male	353	325	91.9 (88.2–94.5)	28	8.1 (5.5–11.8)	0.3628
female	63	60	95.2 (85.8–98.5)	3	4.8 (1.5–14.2)	
Age						
<25	3	3	100.0	0	0.0	0.8659
25-34	51	46	89.7 (76.5–95.9)	5	10.3 (4.1–23.5)	
35-44	249	231	92.8 (88.6–95.6)	18	7.2 (4.4–11.4)	
45+	113	105	92.3 (84.4–96.4)	8	7.7 (3.6–15.6)	
Years since the start of injecting drug use						
≤2	1	1	100.0	0	0.0	0.4059
3-5	5	5	100.0	0	0.0	
6-10	15	13	80.8 (45.4–95.5)	2	19.2 (4.5–54.6)	
≥11	380	354	93.1 (89.7–95.4)	26	6.9 (4.6–10.3)	
Partnership status						
live alone	179	173	96.2 (91.2–98.4)	6	3.8 (1.6–8.8)	0.0252
live with partner	237	212	89.4 (84.5–92.9)	25	10.6 (7.1–15.5)	
Current employment status						
full-time	53	50	93.3 (80.4–97.9)	3	6.7 (2.1–19.6)	0.2797
part-time or temporary	240	224	93.9 (89.9–96.4)	16	6.1 (3.6–10.1)	
unemployed	97	88	89.6 (80.4–94.8)	9	10.4 (5.2–19.6)	
disabled	19	16	80.9 (52.2–94.2)	3	19.1 (5.8–47.8)	
other	6	6	100.0	0	0.0	
Monthly income category						
<3K	32	30	91.2 (69.8–97.9)	2	8.8 (2.1–30.2)	0.6688
3-10K	287	266	92.7 (88.6–95.3)	21	7.3 (4.7–11.4)	

		Experienced overdose in the past 12 months					
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
	10-20K	66	61	93.1 (84.1–97.2)	5	6.9 (2.8–15.9)	
	≥20K	8	7	79.4 (23.1–98.0)	1	20.6 (2.0–76.9)	
Ever incarcerated							
	no	300	276	91.6 (87.6–94.5)	24	8.4 (5.5–12.4)	0.3291
	yes	39	37	95.8 (84.0–99.0)	2	4.2 (1.0–16.0)	

Table 11.3. Overdose Experience in the Past 12 Months by Selected Subgroups

		Experienced overdose in the past 12 months					
	N		no		yes		
		n	% (CI)		n	% (CI)	p-value
Client of NGO working with PWID							
no	323	310	95.8 (92.7–97.6)		13	4.2 (2.4–7.3)	0.0000
yes	81	63	77.5 (66.0–85.9)		18	22.5 (14.1–34.0)	
Treated with MAT currently (of all)							
no	338	319	93.9 (90.4–96.2)		19	6.1 (3.8–9.6)	0.0214
yes	49	41	84.2 (70.2–92.4)		8	15.8 (7.6–29.8)	
HIV test result							
positive	19	17	90.4 (65.6–97.9)		2	9.6 (2.1–34.4)	0.7401
negative	397	368	92.4 (89.1–94.8)		29	7.6 (5.2–10.9)	
Past 30 days injecting 4 categories							
opioids	268	247	91.8 (87.5–94.8)		21	8.2 (5.2–12.5)	0.1521
stimulants	16	13	79.0 (45.3–94.5)		3	21.0 (5.5–54.7)	
opi+stimul	129	123	95.6 (90.3–98.0)		6	4.4 (2.0–9.7)	
other	3	2	86.0 (9.0–99.7)		1	14.0 (0.3–91.0)	
Injecting drug type of choice							
opioids	383	355	92.2 (88.7–94.7)		28	7.8 (5.3–11.3)	0.8845
stimulants	27	24	91.6 (75.6–97.5)		3	8.4 (2.5–24.4)	
other	3	3	100.0		0	0.0	

Table 11.4. Naloxone Experience by Sociodemographic Characteristics

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total								
All	491	216	47.3 (42.5–52.1)	194	36.1 (31.8–40.7)	81	16.6 (13.3–20.6)	1.0000
Sex								
male	406	164	43.6 (38.4–49.0)	171	38.6 (33.8–43.8)	71	17.7 (13.9–22.3)	0.0022
female	85	52	65.0 (53.7–74.9)	23	23.8 (15.8–34.2)	10	11.2 (6.0–20.0)	
Age								
<25	3	2	52.9 (2.2–98.2)	1	47.1 (1.8–97.8)	0	0.0	0.7058
25-34	59	23	48.2 (34.0–62.7)	26	37.2 (25.1–51.0)	10	14.7 (7.7–26.0)	
35-44	282	137	50.3 (44.1–56.5)	101	33.3 (27.8–39.3)	44	16.4 (11.9–22.0)	
45+	147	54	41.0 (32.2–50.4)	66	40.8 (32.5–49.5)	27	18.2 (12.5–25.8)	
Years since the start of injecting drug use								
≤2	2	2	100.0	0	0.0	0	0.0	0.3754
3-5	7	6	81.3 (23.4–98.4)	1	18.7 (1.6–76.6)	0	0.0	
6-10	17	6	34.5 (14.8–61.6)	8	46.4 (23.0–71.4)	3	19.1 (5.7–47.9)	
≥11	449	195	46.8 (41.8–51.9)	179	36.3 (31.7–41.1)	75	16.9 (13.4–21.2)	
Partnership status								
live alone	224	109	53.6 (46.6–60.5)	80	31.5 (25.6–38.1)	35	14.8 (10.6–20.4)	0.0546
live with partner	267	107	41.9 (35.5–48.6)	114	40.0 (33.8–46.4)	46	18.1 (13.3–24.1)	
Current employment status								
full-time	61	20	35.9 (24.3–49.5)	35	54.8 (41.6–67.4)	6	9.2 (4.1–19.5)	0.0019
part-time or temporary	290	148	52.7 (46.4–58.9)	100	32.0 (26.6–37.9)	42	15.3 (11.1–20.8)	
unemployed	111	41	42.8 (32.8–53.4)	46	37.0 (28.1–46.8)	24	20.2 (13.6–29.1)	
disabled	22	6	31.0 (14.0–55.5)	8	32.2 (15.6–55.1)	8	36.7 (18.4–59.8)	
other	6	0	0.0	5	81.6 (20.7–98.7)	1	18.4 (1.3–79.3)	
Monthly income category								
<3K	33	5	17.6 (7.2–37.0)	20	55.5 (37.3–72.4)	8	26.9 (13.7–46.2)	0.0046
3-10K	339	156	48.5 (42.6–54.4)	127	34.4 (29.2–39.9)	56	17.1 (13.0–22.2)	
10-20K	84	39	51.5 (40.3–62.5)	34	37.3 (27.3–48.4)	11	11.2 (6.2–19.6)	
≥20K	8	2	19.6 (3.3–63.6)	6	80.4 (36.4–96.7)	0	0.0	
Ever incarcerated								

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
no	360	198	58.8 (53.3–64.1)	128	32.3 (27.5–37.6)	34	8.9 (6.2–12.4)	0.0000
yes	45	9	23.1 (12.2–39.3)	26	53.8 (38.4–68.5)	10	23.1 (12.4–38.8)	

Table 11.5. Naloxone Experience by Selected Subgroups

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID								
no	377	195	55.6 (50.2–60.8)	134	31.7 (27.0–36.7)	48	12.8 (9.6–16.8)	0.0000
yes	95	16	17.2 (10.4–27.1)	51	53.1 (41.9–64.0)	28	29.7 (20.2–41.4)	
Treated with MAT currently (of all)								
no	399	197	52.7 (47.5–57.9)	150	34.4 (29.7–39.5)	52	12.8 (9.8–16.7)	0.0000
yes	56	7	12.6 (5.8–25.1)	30	48.9 (34.5–63.5)	19	38.5 (24.5–54.7)	
HIV test result								
positive	21	10	48.0 (26.2–70.6)	8	33.0 (15.8–56.5)	3	19.0 (5.4–49.1)	0.9411
negative	470	206	47.3 (42.4–52.2)	186	36.2 (31.8–40.9)	78	16.5 (13.1–20.5)	
Past 30 days injecting 4 categories								
opioids	327	167	54.0 (48.3–59.7)	129	36.3 (31.1–42.0)	31	9.6 (6.7–13.6)	0.0000
stimulants	20	2	16.0 (3.5–49.8)	12	52.7 (28.4–75.8)	6	31.3 (12.9–58.4)	
opi+stimul	140	47	38.0 (29.0–47.8)	52	34.2 (26.4–42.9)	41	27.8 (20.7–36.3)	
other	4	0	0.0	1	15.2 (0.3–90.4)	3	84.8 (9.6–99.7)	
Injecting drug type of choice								
opioids	450	209	49.9 (45.0–54.9)	175	35.6 (31.1–40.4)	66	14.5 (11.4–18.2)	0.0065
stimulants	33	6	20.8 (8.8–41.7)	16	47.1 (29.5–65.5)	11	32.1 (17.4–51.5)	
other	3	0	0.0	2	68.4 (1.0–99.8)	1	31.6 (0.2–99.0)	

12. Physical and Mental Health

Table 12.1. Disease and treatment history

		n	%	CI
Had a disease				
	hepatitis B	321	66.5	(61.8–70.9)
	hepatitis C	287	59.9	(55.0–64.5)
	syphilis	84	17.7	(14.3–21.7)

		n	%	CI
	gonorrhea	58	13.1	(10.1–16.8)
	chlamydia	28	6.6	(4.5–9.6)
	herpes	49	11.0	(8.3–14.5)
	human papillomavirus	18	4.3	(2.7–6.9)
	tuberculosis	110	24.7	(20.7–29.1)
Treated for: hepatitis B				
	treated successfully	252	81.2	(76.3–85.3)
	treated unsuccessfully	27	8.5	(5.7–12.4)
	did not complete	28	8.4	(5.8–12.2)
	treated now	5	1.2	(0.5–3.0)
	never treated	3	0.7	(0.2–2.2)
Treated for: hepatitis C				
	treated successfully	141	52.8	(46.3–59.2)
	treated unsuccessfully	81	30.6	(24.9–37.0)
	did not complete	26	9.0	(6.1–13.1)
	treated now	6	2.0	(0.9–4.5)
	never treated	17	5.6	(3.4–9.2)
Treated for: syphilis				
	treated successfully	65	78.4	(67.2–86.5)
	treated unsuccessfully	15	20.7	(12.7–32.0)
	did not complete	0	0.0	
	treated now	1	0.9	(0.1–6.1)
	never treated	0	0.0	
Treated for: tuberculosis				
	treated successfully	73	75.4	(65.5–83.1)
	treated unsuccessfully	15	15.1	(9.0–24.2)
	did not complete	7	6.5	(3.1–13.3)
	treated now	2	1.6	(0.4–6.2)
	never treated	1	1.4	(0.2–9.3)

Table 12.2. Mental health screening scores

	n	Mean	CI	Median	IQR
AUDIT-C alcohol risk score ≥5	4,874	1.2	(1.2–1.2)	1	(1–1)
PHQ-9 depression result	5,002	2.2	(2.2–2.3)	2	(1–3)
GAD-7 anxiety result	5,002	1.9	(1.9–1.9)	2	(1–2)

Table 12.3. Health care utilization

	n	%	CI
Had problems with health besides drugs which required medical attention in the past 12 months			
yes	185	40.7	(35.9–45.6)
Referred to a health care facility for treatment in the past 12 months			
yes	120	26.0	(21.8–30.6)
Referred to a health care facility			
primary care	90	77.8	(69.1–84.6)
hospital, HIV clinic	8	6.6	(3.2–13.0)
private clinic	9	5.9	(3.0–11.3)
private lab	8	7.5	(3.6–14.9)
TB dispensary	2	1.9	(0.5–7.6)
drug clinic	0	0.0	
STI clinic	5	3.5	(1.4–8.3)
ambulance	16	12.4	(7.5–19.7)
mobile clinic	1	0.7	(0.1–5.0)

	n	%	CI
other	1	0.9	(0.1–6.1)
Last health care facility referred to			
primary care	71	73.8	(63.9–81.8)
hospital, HIV clinic	4	3.3	(1.1–9.1)
private clinic	7	5.6	(2.6–11.7)
private lab	5	5.9	(2.3–14.3)
TB dispensary	1	0.8	(0.1–5.8)
drug clinic	0	0.0	
STI clinic	3	2.4	(0.8–7.2)
ambulance	9	8.2	(4.2–15.3)
mobile clinic	0	0.0	
other	0	0.0	
Received necessary care in health care facility			
yes	100	90.8	(83.8–95.0)
Signed a declaration with primary care physician			
yes	315	68.3	(63.6–72.6)
How frequently saw the primary care physician			
twice per month or more	36	10.9	(7.9–15.1)
once per month	145	49.6	(43.5–55.7)
3-4 times in 12 months	40	11.4	(8.2–15.4)
only once	88	28.1	(22.9–34.0)



Figure 12.1. Risky alcohol use (AUDIT-C score > 5) (%)



Figure 12.2. Depression symptoms severity (PHQ-9) (%)



Figure 12.3. Anxiety symptoms severity (GAD-7) (%)

Table 12.4. Risky alcohol use (AUDIT-C score > 5) by Sociodemographic Characteristics

			AUDIT-C alcohol risk score ≥5				
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
Total							
	All	470	440	93.8 (91.2–95.7)	30	6.2 (4.3–8.8)	1.0000
Sex							
	male	389	364	93.9 (91.0–95.9)	25	6.1 (4.1–9.0)	0.8867
	female	81	76	93.4 (84.7–97.3)	5	6.6 (2.7–15.3)	
Age							
	<25	4	4	100.0	0	0.0	0.2114

	N	AUDIT-C alcohol risk score ≥5				
		n	no % (CI)	n	yes % (CI)	p-value
25-34	56	53	94.8 (84.6–98.4)	3	5.2 (1.6–15.4)	
35-44	270	256	95.4 (92.2–97.3)	14	4.6 (2.7–7.8)	
45+	140	127	90.2 (83.6–94.3)	13	9.8 (5.7–16.4)	
Years since the start of injecting drug use						
≤2	2	2	100.0	0	0.0	0.6449
3-5	7	7	100.0	0	0.0	
6-10	17	17	100.0	0	0.0	
≥11	429	400	93.4 (90.6–95.4)	29	6.6 (4.6–9.4)	
Partnership status						
live alone	215	206	96.3 (92.9–98.1)	9	3.7 (1.9–7.1)	0.0395
live with partner	255	234	91.7 (87.5–94.6)	21	8.3 (5.4–12.5)	
Current employment status						
full-time	60	58	96.4 (86.4–99.1)	2	3.6 (0.9–13.6)	0.3754
part-time or temporary	280	262	94.1 (90.6–96.3)	18	5.9 (3.7–9.4)	
unemployed	107	100	93.3 (86.3–96.9)	7	6.7 (3.1–13.7)	
disabled	20	18	88.0 (60.7–97.2)	2	12.0 (2.8–39.3)	
other	3	2	70.1 (8.8–98.3)	1	29.9 (1.7–91.2)	
Monthly income category						
<3K	28	27	96.5 (77.8–99.6)	1	3.5 (0.4–22.2)	0.8026
3-10K	329	306	93.4 (90.1–95.6)	23	6.6 (4.4–9.9)	
10-20K	83	79	94.6 (86.0–98.0)	4	5.4 (2.0–14.0)	
≥20K	8	8	100.0	0	0.0	
Ever incarcerated						
no	345	317	92.2 (88.8–94.6)	28	7.8 (5.4–11.2)	0.0705
yes	43	43	100.0	0	0.0	

Table 12.5. Risky alcohol use (AUDIT-C score > 5) by Selected Subgroups

	N	AUDIT-C alcohol risk score ≥5				
		n	no % (CI)	n	yes % (CI)	p-value
Client of NGO working with PWID						

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	361	334	92.9 (89.8–95.2)	27	7.1 (4.8–10.2)	0.1561
yes	93	91	97.3 (89.7–99.4)	2	2.7 (0.6–10.3)	
Treated with MAT currently (of all)						
no	383	354	92.8 (89.7–95.0)	29	7.2 (5.0–10.3)	0.1559
yes	55	54	98.0 (86.8–99.7)	1	2.0 (0.3–13.2)	
HIV test result						
positive	18	18	100.0	0	0.0	0.2854
negative	452	422	93.6 (90.9–95.5)	30	6.4 (4.5–9.1)	
Past 30 days injecting 4 categories						
opioids	312	292	94.0 (90.8–96.2)	20	6.0 (3.8–9.2)	0.6328
stimulants	20	20	100.0	0	0.0	
opi+stimul	134	124	92.0 (85.6–95.7)	10	8.0 (4.3–14.4)	
other	4	4	100.0	0	0.0	
Injecting drug type of choice						
opioids	429	400	93.5 (90.6–95.5)	29	6.5 (4.5–9.4)	0.6932
stimulants	34	33	96.7 (78.7–99.6)	1	3.3 (0.4–21.3)	
other	3	3	100.0	0	0.0	

Table 12.6. Depression symptoms severity (PHQ-9) by Sociodemographic Characteristics

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	18	4.0 (2.3–6.9)	73	13.6 (10.8–17.0)	165	30.7 (26.6–35.0)	244	51.7 (47.0–56.5)	1.0000
Sex										
male	415	17	4.6 (2.6–8.0)	65	14.8 (11.6–18.7)	148	33.0 (28.4–37.9)	185	47.6 (42.4–52.9)	0.0005
female	85	1	1.0 (0.1–7.1)	8	7.7 (3.7–15.3)	17	19.2 (12.0–29.4)	59	72.1 (61.2–80.8)	
Age										
<25	4	2	55.3 (4.5–97.0)	0	0.0	0	0.0	2	44.7 (3.0–95.5)	0.0003
25-34	60	5	7.4 (3.0–17.2)	11	16.9 (9.1–29.3)	22	31.1 (20.3–44.5)	22	44.5 (30.6–59.4)	
35-44	287	9	3.9 (1.7–8.9)	44	14.1 (10.5–18.7)	86	28.5 (23.4–34.3)	148	53.4 (47.2–59.5)	
45+	149	2	1.3 (0.3–5.1)	18	11.6 (7.2–18.1)	57	35.4 (27.7–44.0)	72	51.7 (42.9–60.4)	
Years since the start of injecting drug use										

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
≤2	2	1	50.0 (0.0–100.0)	0	0.0	0	0.0	1	50.0 (0.0–100.0)	
3-5	7	3	44.3 (10.5–84.3)	0	0.0	0	0.0	4	55.7 (15.7–89.5)	
6-10	18	3	14.2 (4.1–38.8)	1	8.7 (1.1–45.6)	9	48.4 (25.1–72.4)	5	28.8 (11.3–56.2)	
≥11	456	9	2.5 (1.1–5.7)	66	13.3 (10.4–16.8)	154	31.6 (27.3–36.2)	227	52.6 (47.7–57.6)	
Partnership status										
live alone	228	8	2.9 (1.4–5.8)	30	12.9 (9.0–18.1)	64	24.9 (19.6–31.0)	126	59.3 (52.5–65.8)	0.0246
live with partner	272	10	4.9 (2.3–10.1)	43	14.2 (10.5–19.0)	101	35.5 (29.7–41.8)	118	45.4 (38.9–52.0)	
Current employment status										
full-time	61	5	8.7 (3.5–20.0)	13	21.2 (12.3–34.0)	19	28.6 (18.6–41.4)	24	41.5 (29.3–54.9)	0.1607
part-time or temporary	297	8	3.4 (1.4–8.2)	34	10.7 (7.6–14.8)	99	31.0 (25.8–36.8)	156	54.9 (48.7–61.0)	
unemployed	113	5	4.1 (1.7–9.6)	24	19.4 (13.0–28.0)	39	31.0 (22.9–40.4)	45	45.5 (35.6–55.9)	
disabled	22	0	0.0	1	2.6 (0.3–18.1)	6	29.2 (12.9–53.6)	15	68.2 (44.4–85.2)	
other	6	0	0.0	1	22.8 (1.7–83.3)	2	33.8 (5.1–83.1)	3	43.4 (8.3–86.6)	
Monthly income category										
<3K	33	2	5.9 (1.4–21.8)	4	9.9 (3.4–25.5)	18	58.2 (40.2–74.3)	9	25.9 (13.4–44.1)	0.0006
3-10K	347	10	3.6 (1.6–7.6)	50	13.4 (10.2–17.5)	113	30.1 (25.3–35.4)	174	52.9 (47.1–58.6)	
10-20K	84	4	4.1 (1.5–10.8)	13	13.7 (7.8–22.8)	23	25.3 (17.0–35.9)	44	56.9 (45.7–67.4)	
≥20K	8	2	31.2 (5.6–77.6)	2	29.7 (5.1–76.9)	3	28.6 (6.4–70.3)	1	10.5 (0.9–60.2)	
Ever incarcerated										
no	362	12	3.0 (1.7–5.2)	46	11.3 (8.5–15.0)	94	24.0 (19.7–28.8)	210	61.7 (56.3–66.9)	0.0000
yes	45	0	0.0	8	20.3 (10.2–36.4)	26	54.6 (39.1–69.2)	11	25.1 (14.0–40.9)	

Table 12.7. Depression symptoms severity (PHQ-9) by Selected Subgroups

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	18	4.0 (2.3–6.9)	73	13.6 (10.8–17.0)	165	30.7 (26.6–35.0)	244	51.7 (47.0–56.5)	1.0000
Sex										
male	415	17	4.6 (2.6–8.0)	65	14.8 (11.6–18.7)	148	33.0 (28.4–37.9)	185	47.6 (42.4–52.9)	0.0005
female	85	1	1.0 (0.1–7.1)	8	7.7 (3.7–15.3)	17	19.2 (12.0–29.4)	59	72.1 (61.2–80.8)	
Age										
<25	4	2	55.3 (4.5–97.0)	0	0.0	0	0.0	2	44.7 (3.0–95.5)	0.0003
25-34	60	5	7.4 (3.0–17.2)	11	16.9 (9.1–29.3)	22	31.1 (20.3–44.5)	22	44.5 (30.6–59.4)	
35-44	287	9	3.9 (1.7–8.9)	44	14.1 (10.5–18.7)	86	28.5 (23.4–34.3)	148	53.4 (47.2–59.5)	

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
45+	149	2	1.3 (0.3–5.1)	18	11.6 (7.2–18.1)	57	35.4 (27.7–44.0)	72	51.7 (42.9–60.4)	
Years since the start of injecting drug use										
≤2	2	1	50.0 (0.0–100.0)	0	0.0	0	0.0	1	50.0 (0.0–100.0)	
3-5	7	3	44.3 (10.5–84.3)	0	0.0	0	0.0	4	55.7 (15.7–89.5)	
6-10	18	3	14.2 (4.1–38.8)	1	8.7 (1.1–45.6)	9	48.4 (25.1–72.4)	5	28.8 (11.3–56.2)	
≥11	456	9	2.5 (1.1–5.7)	66	13.3 (10.4–16.8)	154	31.6 (27.3–36.2)	227	52.6 (47.7–57.6)	
Partnership status										
live alone	228	8	2.9 (1.4–5.8)	30	12.9 (9.0–18.1)	64	24.9 (19.6–31.0)	126	59.3 (52.5–65.8)	0.0246
live with partner	272	10	4.9 (2.3–10.1)	43	14.2 (10.5–19.0)	101	35.5 (29.7–41.8)	118	45.4 (38.9–52.0)	
Current employment status										
full-time	61	5	8.7 (3.5–20.0)	13	21.2 (12.3–34.0)	19	28.6 (18.6–41.4)	24	41.5 (29.3–54.9)	0.1607
part-time or temporary	297	8	3.4 (1.4–8.2)	34	10.7 (7.6–14.8)	99	31.0 (25.8–36.8)	156	54.9 (48.7–61.0)	
unemployed	113	5	4.1 (1.7–9.6)	24	19.4 (13.0–28.0)	39	31.0 (22.9–40.4)	45	45.5 (35.6–55.9)	
disabled	22	0	0.0	1	2.6 (0.3–18.1)	6	29.2 (12.9–53.6)	15	68.2 (44.4–85.2)	
other	6	0	0.0	1	22.8 (1.7–83.3)	2	33.8 (5.1–83.1)	3	43.4 (8.3–86.6)	
Monthly income category										
<3K	33	2	5.9 (1.4–21.8)	4	9.9 (3.4–25.5)	18	58.2 (40.2–74.3)	9	25.9 (13.4–44.1)	0.0006
3-10K	347	10	3.6 (1.6–7.6)	50	13.4 (10.2–17.5)	113	30.1 (25.3–35.4)	174	52.9 (47.1–58.6)	
10-20K	84	4	4.1 (1.5–10.8)	13	13.7 (7.8–22.8)	23	25.3 (17.0–35.9)	44	56.9 (45.7–67.4)	
≥20K	8	2	31.2 (5.6–77.6)	2	29.7 (5.1–76.9)	3	28.6 (6.4–70.3)	1	10.5 (0.9–60.2)	
Ever incarcerated										
no	362	12	3.0 (1.7–5.2)	46	11.3 (8.5–15.0)	94	24.0 (19.7–28.8)	210	61.7 (56.3–66.9)	0.0000
yes	45	0	0.0	8	20.3 (10.2–36.4)	26	54.6 (39.1–69.2)	11	25.1 (14.0–40.9)	

Table 12.8. Anxiety symptoms severity (GAD-7) by Sociodemographic Characteristics

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	18	4.1 (2.4–7.0)	178	33.8 (29.6–38.3)	129	24.6 (20.8–28.9)	175	37.5 (32.9–42.3)	1.0000
Sex										
male	415	16	4.5 (2.5–7.9)	162	37.2 (32.4–42.3)	109	25.1 (20.9–29.8)	128	33.3 (28.5–38.5)	0.0002
female	85	2	2.3 (0.6–8.9)	16	17.0 (10.3–26.8)	20	22.2 (14.4–32.7)	47	58.5 (46.9–69.2)	
Age										

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
<25	4	0	0.0	2	55.3 (4.5–97.0)	0	0.0	2	44.7 (3.0–95.5)	0.3577
25-34	60	4	6.0 (2.2–15.6)	25	37.4 (25.3–51.3)	12	17.5 (9.7–29.6)	19	39.1 (25.4–54.7)	
35-44	287	11	4.8 (2.3–9.8)	97	32.7 (27.3–38.7)	70	22.4 (17.9–27.8)	109	40.0 (34.1–46.2)	
45+	149	3	2.0 (0.6–6.1)	54	33.9 (26.3–42.4)	47	32.3 (24.4–41.3)	45	31.8 (23.9–41.0)	
Years since the start of injecting drug use										
≤2	2	0	0.0	1	50.0 (0.0–100.0)	0	0.0	1	50.0 (0.0–100.0)	0.9125
3-5	7	1	14.1 (1.1–70.1)	2	30.1 (5.0–77.9)	1	11.4 (0.9–64.7)	3	44.3 (10.5–84.3)	
6-10	18	1	5.3 (0.6–33.0)	7	35.7 (16.2–61.5)	5	30.2 (12.1–57.7)	5	28.8 (11.3–56.2)	
≥11	456	14	3.7 (1.9–6.9)	160	33.4 (29.0–38.1)	120	24.9 (20.9–29.4)	162	38.1 (33.2–43.1)	
Partnership status										
live alone	228	8	3.1 (1.5–6.3)	76	31.8 (25.8–38.4)	43	15.5 (11.5–20.6)	101	49.5 (42.6–56.5)	0.0000
live with partner	272	10	4.9 (2.3–10.2)	102	35.5 (29.7–41.8)	86	32.2 (26.4–38.6)	74	27.4 (21.9–33.6)	
Current employment status										
full-time	61	2	2.6 (0.6–10.2)	22	35.2 (23.8–48.5)	23	37.1 (25.5–50.4)	14	25.1 (15.2–38.4)	0.0359
part-time or temporary	297	9	3.9 (1.7–8.7)	100	31.7 (26.4–37.6)	66	20.8 (16.4–26.0)	122	43.5 (37.4–49.9)	
unemployed	113	7	6.1 (2.9–12.6)	48	39.8 (30.7–49.7)	27	24.9 (16.6–35.5)	31	29.2 (20.9–39.2)	
disabled	22	0	0.0	4	19.9 (6.9–45.4)	10	43.7 (23.8–66.0)	8	36.4 (18.3–59.4)	
other	6	0	0.0	4	69.9 (19.2–95.8)	2	30.1 (4.2–80.8)	0	0.0	
Monthly income category										
<3K	33	2	5.9 (1.4–21.8)	12	38.3 (22.5–57.1)	13	37.6 (22.3–55.9)	6	18.2 (8.0–36.1)	0.0871
3-10K	347	14	4.7 (2.5–8.7)	125	34.3 (29.1–39.8)	79	22.0 (17.6–27.2)	129	39.0 (33.5–44.9)	
10-20K	84	1	0.9 (0.1–6.2)	26	27.8 (19.2–38.6)	26	29.7 (20.7–40.7)	31	41.5 (30.8–53.2)	
≥20K	8	0	0.0	4	52.2 (15.4–86.7)	4	47.8 (13.3–84.6)	0	0.0	
Ever incarcerated										
no	362	9	2.4 (1.2–4.6)	103	26.1 (21.6–31.0)	84	22.4 (18.0–27.4)	166	49.2 (43.6–54.8)	0.0000
yes	45	1	1.8 (0.2–12.3)	21	50.9 (35.8–65.8)	17	34.1 (21.5–49.5)	6	13.2 (5.8–27.1)	

Table 12.9. Anxiety symptoms severity (GAD-7) by Selected Subgroups

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										
no	385	7	1.7 (0.8–3.6)	128	30.9 (26.3–35.9)	82	20.8 (16.7–25.5)	168	46.6 (41.3–52.0)	0.0000
yes	96	11	14.7 (7.3–27.4)	42	43.9 (33.4–54.9)	38	37.2 (27.5–48.1)	5	4.2 (1.7–9.9)	
Treated with MAT currently (of all)										
no	407	8	1.9 (0.9–3.7)	132	31.2 (26.7–36.1)	99	23.4 (19.2–28.1)	168	43.6 (38.4–48.8)	0.0000
yes	56	10	23.7 (11.6–42.3)	27	44.5 (30.7–59.1)	16	27.1 (16.6–41.1)	3	4.7 (1.5–14.1)	
HIV test result										
positive	21	0	0.0	8	34.0 (16.4–57.6)	6	30.9 (13.1–57.0)	7	35.1 (16.6–59.4)	0.7803
negative	479	18	4.3 (2.5–7.3)	170	33.8 (29.5–38.4)	123	24.3 (20.5–28.7)	168	37.6 (32.9–42.5)	
Past 30 days injecting 4 categories										
opioids	330	10	3.0 (1.6–5.6)	113	32.8 (27.7–38.3)	72	19.7 (15.8–24.4)	135	44.5 (38.8–50.3)	0.0000
stimulants	20	0	0.0	8	38.7 (18.6–63.7)	9	50.3 (26.8–73.7)	3	10.9 (3.1–31.7)	
opi+stimul	146	6	3.8 (1.7–8.6)	57	37.1 (29.1–45.9)	46	32.2 (24.3–41.3)	37	26.8 (19.3–36.0)	
other	4	2	72.6 (7.2–98.9)	0	0.0	2	27.4 (1.1–92.8)	0	0.0	
Injecting drug type of choice										
opioids	458	14	3.0 (1.7–5.0)	166	34.4 (30.0–39.2)	109	22.9 (19.0–27.2)	169	39.8 (34.9–44.8)	0.0119
stimulants	34	1	3.3 (0.4–21.3)	11	32.7 (18.2–51.6)	16	46.2 (29.0–64.4)	6	17.8 (7.2–37.6)	
other	3	0	0.0	0	0.0	3	100.0	0	0.0	

13. Detention and Incarceration

Table 13.1. Police Detention and Incarceration Experience

	n	%	CI
Detained by police in 2022 for			
drug use	39	7.0	(5.1–9.6)
drug dealing	37	6.6	(4.7–9.0)
drug storing	60	10.3	(8.0–13.2)
Detained by police in 2023 for			
drug use	36	6.6	(4.7–9.2)
drug dealing	32	5.3	(3.8–7.6)
drug storing	49	8.0	(6.0–10.6)
Stopped, detained, or arrested by police ever			
yes	246	56.3	(51.3–61.2)
Ever incarcerated			
yes	45	9.9	(7.3–13.1)
Duration of incarceration			
≤6m	6	18.5	(8.5–35.9)

	n	%	CI
6m-2y	1	2.0	(0.3–13.0)
2-4y	14	40.8	(25.8–57.8)
4y+	16	38.7	(24.5–55.1)
Time since last incarceration			
≤1y	3	8.0	(2.6–22.2)
1-3y	11	30.6	(17.7–47.5)
3-5y	9	19.3	(10.0–34.0)
5-10y	10	22.5	(12.2–37.6)
10y+	7	19.6	(9.6–36.1)
Used injecting drugs during incarceration			
yes	34	93.1	(80.3–97.8)



Figure 13.1. Incarceration Lifetime Experience (%)

14. Negative experience

Table 14.1. Negative experience

	n	%	CI
Felt excluded from family activities due to drug use			
no	89	15.7	(12.8–19.2)
yes, in the past 6m	203	39.8	(35.3–44.6)
yes, but 6m+ ago	204	44.4	(39.7–49.3)
Was scolded because of drug use			
no	104	21.2	(17.6–25.3)
yes, in the past 6m	165	32.1	(27.9–36.7)
yes, but 6m+ ago	197	46.7	(41.8–51.7)
Was blackmailed for drug use			
no	141	28.2	(24.1–32.6)
yes, in the past 6m	112	23.5	(19.7–27.8)
yes, but 6m+ ago	204	48.3	(43.4–53.3)
Negative experience in the past 6 months (GAM 6.5)			
no	222	54.3	(49.2–59.2)
yes	215	45.7	(40.8–50.8)
Ever experienced physical violence			
no	129	27.3	(23.2–31.9)

		n	%	CI
	yes	319	72.7	(68.1–76.8)
Experienced physical violence in the past 12 months (of those who had ever)				
	no	58	15.7	(12.1–20.2)
	yes	258	84.3	(79.8–87.9)
Witnessed physical violence in the past 12 months				
	no	126	25.3	(21.4–29.6)
	yes	343	74.7	(70.4–78.6)



Figure 14.1. Negative Experience Related to Drug Use in the past 6 Months or Physical Violence in the past 12 months (%)

Table 14.2. Negative Experience Related to Drug Use by Sociodemographic Characteristics

		Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	437	215	45.7 (40.8–50.8)	1.0000	316	258	84.3 (79.8–87.9)	1.0000
Sex									
	male	354	186	49.0 (43.4–54.6)	0.0065	253	208	84.8 (79.8–88.7)	0.6159
	female	83	29	31.7 (22.2–43.0)		63	50	82.2 (70.6–89.9)	
Age									
	<25	4	2	59.0 (5.3–97.3)	0.9053	3	1	28.8 (0.8–95.5)	0.0523
	25-34	52	27	45.9 (31.4–61.1)		39	31	80.9 (64.8–90.8)	
	35-44	253	119	44.5 (38.2–51.0)		194	163	86.2 (80.6–90.4)	
	45+	128	67	47.7 (38.2–57.3)		80	63	83.4 (73.8–89.9)	
Years since the start of injecting drug use									
	≤2	2	1	50.0 (0.0–100.0)	0.7272	2	1	50.0 (0.0–100.0)	0.0971

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
3-5	7	2	30.1 (5.0–77.9)		4	3	64.7 (9.8–96.9)	
6-10	16	9	56.3 (29.9–79.5)		15	10	64.4 (35.2–85.7)	
≥11	398	197	45.8 (40.6–51.1)		285	234	85.1 (80.5–88.7)	
Partnership status								
live alone	203	84	37.1 (30.4–44.2)	0.0015	166	145	89.7 (84.4–93.3)	0.0047
live with partner	234	131	53.3 (46.3–60.2)		150	113	78.2 (70.6–84.3)	
Current employment status								
full-time	60	39	63.5 (50.0–75.2)	0.0505	48	32	67.4 (52.3–79.6)	0.0006
part-time or temporary	257	113	41.3 (35.1–47.9)		192	167	88.8 (83.5–92.6)	
unemployed	96	51	47.0 (36.4–57.9)		59	47	84.8 (74.0–91.6)	
disabled	19	9	49.2 (26.5–72.1)		13	10	76.8 (43.5–93.4)	
other	4	2	37.7 (4.4–88.9)		3	1	30.9 (1.9–91.3)	
Monthly income category								
<3K	28	22	76.8 (56.0–89.6)	0.0028	20	10	52.2 (30.0–73.5)	0.0000
3-10K	295	138	43.6 (37.6–49.8)		211	181	88.1 (83.1–91.8)	
10-20K	81	39	43.8 (33.0–55.3)		62	52	85.1 (73.9–92.0)	
≥20K	8	6	80.4 (36.4–96.7)		7	1	11.6 (1.0–63.4)	
Ever incarcerated								
no	337	136	36.3 (31.1–41.9)	0.0000	252	205	84.3 (79.3–88.2)	0.5327
yes	41	28	71.0 (55.0–83.0)		27	21	79.7 (60.2–91.0)	

Table 14.3. Negative Experience Related to Drug Use by Selected Subgroups

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	345	148	39.2 (33.9–44.7)	0.0000	257	213	85.4 (80.7–89.2)	0.1649
yes	77	59	75.4 (63.6–84.4)		53	40	77.3 (62.9–87.3)	
Treated with MAT currently (of all)								
no	366	162	41.3 (36.1–46.7)	0.0003	268	223	85.1 (80.3–88.9)	0.0291
yes	46	33	70.6 (55.1–82.4)		31	19	69.0 (49.6–83.5)	
HIV test result								

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
positive	20	7	31.1 (14.1–55.4)	0.1846	16	12	75.8 (47.6–91.5)	0.3500
negative	417	208	46.4 (41.3–51.6)		300	246	84.7 (80.1–88.3)	
Past 30 days injecting 4 categories								
opioids	300	140	44.0 (38.1–50.0)	0.7747	231	191	84.5 (79.2–88.7)	0.5867
stimulants	19	10	49.3 (25.4–73.5)		9	6	66.9 (28.7–91.0)	
opi+stimul	116	64	49.6 (39.5–59.8)		74	59	84.5 (75.0–90.9)	
other	2	1	50.0 (1.1–98.9)		2	2	100.0	
Injecting drug type of choice								
opioids	400	197	45.6 (40.5–50.9)	0.9894	300	246	84.6 (80.1–88.3)	0.2400
stimulants	32	15	45.7 (28.1–64.4)		11	8	67.1 (32.7–89.6)	
other	2	1	40.6 (0.2–99.7)		2	1	68.4 (0.5–99.9)	

15. The Impact of the Full-scale War

Table 15.1. Migration Since February 2022

	n	%	CI
Changed place of residence since Feb 2022			
yes, because of the war	72	14.6	(11.6–18.2)
yes, for other reasons	34	7.6	(5.4–10.8)
no	370	77.8	(73.6–81.5)
Where migrated since Feb 2022			
unknown	24	28.7	(19.6–40.1)
other country	9	12.4	(6.3–22.9)
other oblast	9	10.2	(5.3–18.7)
other city	10	13.3	(7.2–23.3)
other district	7	9.4	(4.5–18.8)
other house	21	26.0	(17.3–37.0)
Where lived before Feb 2022 (if changed residence)			
same oblast	53	83.3	(72.8–90.3)
other oblast	10	12.5	(6.7–22.1)
other country	3	4.3	(1.4–12.6)



Figure 15.1. Change of Residence Since February 2022 (%)



Figure 15.2. Migration Destination by Survey Site (%)



Figure 15.3. Residence Before February 2022 (%)



Figure 15.4. Changes Since February 2022 (%)

City-level Results: Kyiv



Figure A. RDS recruitment tree in Kyiv

1. Sociodemographic Information

Table 1.1. Sociodemographic Characteristics

	n	Mean	CI	Median	IQR
Age, years	500	39.6	(38.9–40.4)	40	(36–44)
Age of first non-injecting drug use	479	16.4	(15.9–16.9)	15	(14–18)
Years since the start of non-injecting drug use	479	23.3	(22.4–24.2)	24	(20–28)
Age of first injecting drug use	496	20.4	(19.8–21.1)	19	(16–23)
Years since the start of injecting drug use	496	19.2	(18.2–20.2)	21	(12–25)
Personal monthly income, UAH	473	10,233.3	(9169.5–11297.1)	9,000	(4600–15000)

Table 1.2. Descriptive Statistics for Sociodemographics

	Site	n	%	CI
Sex				
male	Kyiv	424	85.4	(80.9–88.9)
female	Kyiv	76	14.6	(11.1–19.1)
Age				
<25	Kyiv	8	3.2	(1.4–7.1)
25-34	Kyiv	69	14.3	(11.0–18.4)
35-44	Kyiv	310	62.0	(56.5–67.2)
45+	Kyiv	113	20.5	(16.6–25.0)
Family status				
married or living together	Kyiv	85	14.6	(11.4–18.4)
married but have another partner	Kyiv	13	3.8	(1.8–7.6)
not married but have a partner	Kyiv	161	32.0	(27.0–37.5)
married but not living together	Kyiv	41	6.6	(4.6–9.4)
not married and do not have a partner	Kyiv	200	43.1	(37.5–48.8)
Partnership status				
live alone	Kyiv	241	49.7	(44.0–55.3)
live with partner	Kyiv	259	50.3	(44.7–56.0)
Education				
incompl. high school	Kyiv	57	11.8	(8.6–16.1)
high school	Kyiv	222	46.6	(41.0–52.3)
>high school	Kyiv	221	41.6	(36.2–47.2)
Current occupation				
school student	Kyiv	0	0.0	
college/uni student	Kyiv	0	0.0	
permanent job	Kyiv	90	17.1	(13.3–21.7)
sporadic jobs	Kyiv	273	54.9	(49.2–60.5)
unemployed	Kyiv	104	20.7	(16.1–26.1)
housewife	Kyiv	5	1.1	(0.4–3.3)
disabled	Kyiv	15	3.6	(1.8–7.2)
military	Kyiv	1	0.2	(0.0–1.5)
other	Kyiv	11	2.3	(1.2–4.5)
Homelessness				
never	Kyiv	382	76.9	(72.1–81.1)
yes, 12m+ ago	Kyiv	102	20.3	(16.3–24.9)
yes, in the past 12m	Kyiv	16	2.9	(1.7–4.9)
Homeless in 12 months (of those ever)				
no	Kyiv	102	87.6	(79.5–92.8)
yes	Kyiv	16	12.4	(7.2–20.5)
Monthly income category				
<3K	Kyiv	67	14.0	(10.2–18.8)
3-10K	Kyiv	179	37.7	(32.3–43.4)
10-20K	Kyiv	180	38.5	(33.0–44.4)

	Site	n	%	CI
≥20K	Kyiv	47	9.8	(7.0–13.5)
Monthly income relative to 2023 subsistence minimum				
<2684	Kyiv	65	13.5	(9.8–18.3)
≥2684	Kyiv	408	86.5	(81.7–90.2)
Years since the start of injecting drug use				
≤2	Kyiv	12	3.1	(1.7–5.8)
3-5	Kyiv	19	5.4	(3.1–9.3)
6-10	Kyiv	41	9.5	(6.8–13.2)
≥11	Kyiv	424	81.9	(77.0–85.9)

Table 1.3. Accommodation in the past 12 months

	Site	n	%	CI
own place	Kyiv	284	56.4	(50.8–61.8)
friends or relatives	Kyiv	131	25.8	(21.3–30.8)
renting	Kyiv	70	15.5	(11.9–19.9)
varying	Kyiv	19	3.4	(2.0–5.9)
on the street (homeless)	Kyiv	18	3.1	(1.8–5.1)
in a refugee shelter	Kyiv	3	0.6	(0.2–1.9)



Figure 1.1. Distribution of Age by Sex (%)



Figure 1.2. Trend in Sex Distribution by Survey Round (%)



Figure 1.3. Trend in Age Groups by Survey Round (%)

2. Drug Use



Figure 2.1. Injecting Drug Use in the Past 12 Months and 30 Days (%)



Figure 2.2. Non-injecting Drug Use in the Past 12 Months (%)



Figure 2.3. Trends in Injecting Drugs Types in the Past 30 Days by Survey Round (%)



Figure 2.4. Trends in Injecting Opioids in the Past 30 Days by Survey Round (%)



Figure 2.5. Trends in Injecting Stimulants in the Past 30 Days by Survey Round (%)



Figure 2.6. Trends in Injecting Other Drugs in the Past 30 Days by Survey Round (%)



Figure 2.7. Injecting Drug Preference (%)

Table 2.1. Types of Injecting Drugs in the Past 30 Days by Sociodemographic Characteristics

			Past 30 days injecting 4 categories								
		N	opioids		stimulants		opi+stimul		other		
			n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total											
	All	500	445	86.2 (81.6–89.8)	20	5.4 (3.3–8.7)	27	5.8 (3.8–8.7)	8	2.6 (1.0–6.7)	1.0000
Sex											
	male	424	377	85.5 (80.2–89.5)	17	5.8 (3.5–9.7)	23	5.9 (3.8–9.2)	7	2.8 (1.0–7.6)	0.7031
	female	76	68	90.5 (80.3–95.7)	3	2.7 (0.8–8.6)	4	5.0 (1.6–14.5)	1	1.9 (0.3–12.5)	
Age											
	<25	8	6	83.1 (37.3–97.6)	0	0.0	2	16.9 (2.4–62.7)	0	0.0	0.0424

	N	Past 30 days injecting 4 categories								
		opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
25-34	69	52	73.4 (59.5–83.9)	4	6.4 (2.3–16.4)	11	17.8 (9.3–31.4)	2	2.4 (0.5–11.5)	
35-44	310	281	87.5 (81.1–91.9)	13	5.3 (2.8–9.8)	12	4.0 (2.1–7.3)	4	3.3 (1.0–10.2)	
45+	113	106	91.7 (81.6–96.5)	3	5.7 (1.8–17.0)	2	1.3 (0.3–5.1)	2	1.3 (0.3–5.7)	
Years since the start of injecting drug use										
≤2	12	9	73.6 (36.9–93.0)	1	5.9 (0.6–39.1)	1	11.7 (1.3–57.6)	1	8.8 (0.9–49.8)	0.0228
3-5	19	14	75.8 (47.7–91.5)	3	14.1 (3.8–41.0)	2	10.1 (2.0–38.0)	0	0.0	
6-10	41	30	73.6 (55.3–86.2)	2	5.8 (1.3–22.4)	9	20.6 (9.7–38.5)	0	0.0	
≥11	424	390	89.1 (83.9–92.7)	14	4.8 (2.6–8.6)	14	3.4 (1.9–6.1)	6	2.7 (0.9–7.9)	
Partnership status										
live alone	241	218	88.7 (82.4–92.9)	10	5.1 (2.4–10.5)	10	5.5 (2.8–10.5)	3	0.7 (0.2–2.4)	0.1474
live with partner	259	227	83.7 (76.4–89.1)	10	5.7 (2.9–10.6)	17	6.1 (3.6–10.2)	5	4.6 (1.6–12.6)	
Current employment status										
full-time	90	80	91.3 (82.7–95.9)	3	3.1 (0.7–12.1)	5	4.0 (1.5–10.4)	2	1.6 (0.4–6.8)	0.6916
part-time or temporary	273	243	82.9 (75.4–88.4)	13	7.1 (3.9–12.7)	13	6.3 (3.5–11.2)	4	3.7 (1.1–11.5)	
unemployed	104	91	88.4 (79.6–93.7)	4	4.6 (1.6–12.4)	8	6.6 (3.1–13.7)	1	0.3 (0.0–2.5)	
disabled	15	14	92.4 (54.8–99.2)	0	0.0	1	7.6 (0.8–45.2)	0	0.0	
other	17	16	92.6 (57.9–99.1)	0	0.0	0	0.0	1	7.4 (0.9–42.1)	
Monthly income category										
<3K	67	58	81.9 (61.4–92.8)	3	3.9 (1.2–12.2)	3	4.6 (1.2–15.8)	3	9.6 (1.9–37.1)	0.2251
3-10K	179	159	85.8 (77.9–91.2)	5	4.5 (1.7–11.2)	12	8.2 (4.4–14.9)	3	1.5 (0.4–5.1)	
10-20K	180	162	87.5 (79.6–92.6)	10	7.5 (3.7–14.7)	7	3.5 (1.6–7.9)	1	1.5 (0.2–9.7)	
≥20K	47	41	86.0 (71.1–93.9)	2	4.9 (1.1–18.5)	3	6.2 (1.9–18.3)	1	2.9 (0.4–18.8)	
Ever incarcerated										
no	274	234	81.5 (74.4–87.0)	16	7.7 (4.5–13.0)	20	8.1 (5.0–12.9)	4	2.7 (0.6–10.8)	0.0858
yes	225	210	91.9 (86.0–95.5)	4	2.5 (0.8–7.5)	7	3.0 (1.3–6.7)	4	2.6 (0.9–7.8)	

Table 2.2. Types of Injecting Drugs in the Past 30 Days by Selected Subgroups

	N	Past 30 days injecting 4 categories								
		opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										

	N	Past 30 days injecting 4 categories								
		opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
no	320	279	85.5 (79.8–89.8)	15	6.1 (3.5–10.3)	19	5.0 (3.0–8.3)	7	3.4 (1.3–8.6)	0.0229
yes	174	163	90.8 (82.7–95.3)	3	1.2 (0.4–3.9)	7	7.7 (3.5–16.0)	1	0.3 (0.0–2.2)	
Treated with MAT currently (of all)										
no	262	221	84.0 (78.1–88.6)	15	6.4 (3.7–10.7)	20	6.4 (4.0–10.0)	6	3.2 (1.2–8.5)	0.0365
yes	231	217	93.2 (87.6–96.3)	5	2.0 (0.8–4.8)	7	4.1 (1.6–9.9)	2	0.7 (0.2–2.9)	
HIV test result										
positive	102	93	86.6 (74.5–93.5)	4	7.7 (2.7–20.2)	4	5.2 (1.8–14.1)	1	0.5 (0.1–3.6)	0.4692
negative	398	352	86.1 (80.9–90.1)	16	4.9 (2.8–8.4)	23	5.9 (3.7–9.3)	7	3.1 (1.2–8.0)	
Injecting drug type of choice										
opioids	470	437	92.3 (88.7–94.8)	7	1.3 (0.5–3.2)	21	5.2 (3.2–8.3)	5	1.2 (0.4–3.7)	0.0000
stimulants	20	4	27.2 (9.3–57.6)	11	59.0 (32.9–80.9)	5	13.8 (4.7–34.0)	0	0.0	
other	7	3	22.4 (3.4–70.4)	1	11.5 (0.8–68.3)	1	9.2 (0.6–62.3)	2	56.9 (11.6–93.0)	

Table 2.3. Injecting frequency

	Past 30 days injecting 4 categories								
	opioids		stimulants		opi+stimul		other		
	n	%	n	%	n	%	n	%	p-value
Injecting frequency: last 24 hrs									
0 times	41	11.1	4	25.3	3	11.0	3	37.7	0.2908
1 time	226	55.3	11	54.3	12	47.1	3	56.2	
2-3 times	156	29.4	5	20.4	12	41.9	2	6.1	
4+ times	22	4.2	0	0.0	0	0.0	0	0.0	
N	445		20		27		8		
Injecting frequency: last 24 hrs (among those who did)									
1 time	226	62.2	11	72.8	12	52.9	3	90.3	0.5913
2-3 times	156	33.1	5	27.2	12	47.1	2	9.7	
4+ times	22	4.7	0	0.0	0	0.0	0	0.0	
N	404		16		24		5		
Injecting frequency: last week									
0 times	3	1.0	0	0.0	0	0.0	2	30.8	0.0000
1-6 times	125	36.0	11	63.8	9	38.8	3	52.8	
every day	317	63.0	9	36.2	18	61.2	3	16.4	
N	445		20		27		8		
Injecting frequency: last 30 days									
1-9 times	85	20.2	6	29.2	5	21.2	4	37.3	0.2880
10-19 times	58	16.6	5	32.1	5	19.5	1	45.3	
20-29 times	67	19.4	3	9.7	7	26.0	1	5.8	
every day	235	43.9	6	29.0	10	33.3	1	11.5	
N	445		20		27		7		
Injecting frequency: main drug last 30 days									
0-9 times	30	8.5	5	33.9	0	0.0	3	37.7	0.0048
10-19 times	61	17.6	4	29.3	6	26.3	1	40.6	

	Past 30 days injecting 4 categories								
	opioids		stimulants		opi+stimul		other		
	n	%	n	%	n	%	n	%	p-value
20-29 times	69	18.7	2	3.4	4	18.8	1	5.2	
every day	280	55.2	7	33.3	16	54.9	3	16.4	
N	440		18		26		8		

Table 2.4. Injecting drug type of choice by Income Category

	Injecting drug type of choice					
	opioids		stimulants		other	
	n	%	n	%	n	%
Monthly income category						
<3K	63	13.6	2	4.8	1	45.3
3-10K	171	38.9	6	32.2	1	9.2
10-20K	170	38.9	8	44.3	2	18.2
≥20K	39	8.6	4	18.7	3	27.3
N	443		20		7	

Table 2.5. Sources of drugs by Drug Type of Choice

Total		Injecting drug type of choice						
All		opioids		stimulants		other		
n	%	n	%	n	%	n	%	p-value
prepare myself								
172	32.3	164	32.4	5	23.0	3	61.1	0.2607
prepared by friends								
20	5.8	18	5.9	1	4.3	1	6.6	0.9367
from a dealer								
139	34.4	123	32.4	11	61.4	2	23.1	0.0454
buy on Internet								
51	13.6	47	13.5	3	17.8	1	9.2	0.8082
from a pharmacy								
153	24.7	151	26.9	2	5.5	0	0.0	0.0689
from MAT program								
30	3.3	30	3.7	0	0.0	0	0.0	0.6350
other								
10	2.2	10	2.4	0	0.0	0	0.0	0.7472
N								
575		543		22		7		



Figure 2.8. Change in the price, quality, and access of drugs by Drug Type of Choice (%)

3. Injecting Risk Behavior

Table 3.1. Prevalence of Injection Risk Practices

	n	%	CI
Used clean syringe for last injection			
yes	482	96.1	(93.3–97.7)
Source of syringe for last injection			
bought in pharmacy	432	88.8	(85.4–91.5)
got in pharmacy	4	0.8	(0.3–2.5)
got from NGO	52	8.0	(5.8–10.9)
got from friend	2	0.3	(0.1–1.4)
got used from friend	3	0.6	(0.2–2.1)
used one used by myself	5	1.4	(0.6–3.4)
got pre-loaded	0	0.0	
other	1	0.1	(0.0–0.4)
Used shared syringe in the past 30 days			
yes	77	13.5	(10.4–17.4)
Used pre-filled syringe in the past 30 days			
yes	47	9.2	(6.6–12.7)
Used front-/back-loaded syringe in the past 30 days			
yes	95	16.4	(12.9–20.5)
Used shared container in the past 30 days			
yes	85	15.7	(12.3–19.8)
Used own previously used syringe in the past 30 days			
yes	198	33.5	(28.6–38.7)
Gave someone a used syringe in the past 30 days			
yes	32	5.8	(3.9–8.6)
Any inj. risk (shared syringe, pre-filled, front-/back-load, container) in the past 30 days			
yes	176	30.9	(26.3–36.0)

Table 3.2. Frequency of risky injection practices

	n	%	CI
Frequency of injecting with a syringe used by others in the past 30 days			
always	8	10.6	(4.6–22.4)

	n	%	CI
often	4	4.5	(1.5–13.1)
half	7	10.8	(4.3–24.3)
sometimes	8	14.8	(6.9–29.1)
rarely	20	27.1	(17.0–40.1)
never	27	32.2	(21.2–45.8)
Frequency of injecting with others in the same place in the past 30 days			
always	61	14.2	(10.5–19.0)
often	36	8.0	(5.2–12.1)
half	61	12.3	(9.1–16.3)
sometimes	67	13.6	(10.3–17.7)
rarely	83	17.6	(13.5–22.5)
never	160	34.3	(28.9–40.2)
Number of syringes used repeatedly in the past 30 days			
1-9	116	61.4	(52.7–69.5)
10-29	55	30.1	(22.8–38.6)
30+	17	8.5	(4.7–14.8)
Number of times one syringe used repeatedly in the past 30 days			
1	31	15.5	(10.2–23.0)
2-3	87	49.3	(40.4–58.2)
4-9	37	21.7	(15.2–29.9)
10+	25	13.5	(8.6–20.5)
How the pre-filled syringe was obtained			
from dealer	16	36.5	(21.9–54.2)
from friends	19	49.1	(32.5–65.9)
from stash	8	14.4	(6.4–29.3)
Someone used one syringe for injection before front-/back-loading			
no	432	88.4	(84.7–91.3)
yes	61	11.6	(8.7–15.3)



Figure 3.1. Prevalence of Key Injection Risk Practices (%)



Figure 3.2. Trends in Key Injection Risk Practices by Survey Round (%)



Figure 3.3. With whom injected drugs in the same place (%)



Figure 3.4. With whom injected drugs in the same place by sex (%)



Figure 3.5. With whom injected drugs in the same place by age (%)

Table 3.3. Prevalence of Shared and Pre-filled Syringe Use by Sociodemographic Characteristics

		Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	500	77	13.5 (10.4–17.4)	1.0000	496	47	9.2 (6.6–12.7)	1.0000
Sex									
	male	424	59	12.4 (9.2–16.4)	0.1322	421	40	9.1 (6.4–12.7)	0.8420
	female	76	18	20.1 (11.2–33.3)		75	7	10.0 (3.9–23.4)	
Age									
	<25	8	1	11.4 (0.9–63.5)	0.5040	8	1	6.8 (0.5–49.5)	0.9804

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
25-34	69	11	14.3 (7.5–25.5)		69	8	10.4 (4.8–21.1)	
35-44	310	54	15.2 (11.0–20.6)		307	29	9.1 (6.0–13.6)	
45+	113	11	8.3 (4.2–15.7)		112	9	9.2 (4.1–19.0)	
Years since the start of injecting drug use								
≤2	12	0	0.0	0.0426	12	0	0.0	0.6662
3-5	19	7	34.6 (13.6–64.0)		19	2	7.4 (1.4–30.7)	
6-10	41	7	14.2 (6.0–30.1)		41	7	11.2 (4.9–23.9)	
≥11	424	62	12.5 (9.3–16.5)		420	38	9.5 (6.6–13.6)	
Partnership status								
live alone	241	38	14.5 (10.1–20.4)	0.5704	238	27	10.5 (6.8–15.8)	0.4106
live with partner	259	39	12.5 (8.6–18.0)		258	20	8.0 (4.8–13.0)	
Current employment status								
full-time	90	10	7.6 (3.7–15.3)	0.2322	90	5	5.7 (2.1–14.8)	0.6651
part-time or temporary	273	48	16.2 (11.8–21.8)		270	31	10.7 (7.1–15.6)	
unemployed	104	14	10.1 (5.1–18.7)		104	7	7.4 (2.9–17.6)	
disabled	15	2	10.1 (1.6–43.0)		15	2	15.2 (3.0–51.0)	
other	17	3	24.8 (6.6–60.5)		16	2	9.0 (1.9–33.8)	
Monthly income category								
<3K	67	9	9.4 (4.0–20.5)	0.4156	67	5	9.3 (3.6–22.3)	0.5568
3-10K	179	31	17.4 (11.9–24.8)		178	19	10.3 (6.1–16.9)	
10-20K	180	30	12.9 (8.1–19.8)		178	20	10.4 (6.2–16.9)	
≥20K	47	5	10.8 (4.2–25.0)		46	2	3.1 (0.7–12.4)	
Ever incarcerated								
no	274	44	14.0 (9.9–19.6)	0.7458	272	25	10.0 (6.4–15.3)	0.5579
yes	225	33	12.9 (8.7–18.7)		223	22	8.3 (5.1–13.2)	

Table 3.4. Prevalence of Shared and Pre-filled Syringe Use by Selected Subgroups

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	320	45	12.3 (8.9–16.8)	0.3712	319	32	9.5 (6.5–13.8)	0.7583

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
yes	174	30	15.6 (10.2–23.3)		172	15	8.5 (4.6–15.2)	
Treated with MAT currently (of all)								
no	262	41	13.6 (9.9–18.5)	0.6420	260	28	9.5 (6.4–13.9)	0.6131
yes	231	33	12.1 (8.2–17.6)		229	18	8.0 (4.7–13.5)	
HIV test result								
positive	102	16	15.2 (8.8–25.0)	0.6400	102	9	11.1 (5.1–22.4)	0.5762
negative	398	61	13.2 (9.8–17.5)		394	38	8.8 (6.1–12.5)	
Past 30 days injecting 4 categories								
opioids	445	59	11.2 (8.3–15.1)	0.0150	441	38	8.7 (6.0–12.5)	0.4431
stimulants	20	7	29.2 (12.0–55.5)		20	3	11.8 (3.1–36.0)	
opi+stimul	27	9	31.1 (15.3–52.9)		27	6	18.2 (7.1–39.6)	
other	8	2	17.3 (2.3–64.7)		8	0	0.0	
Injecting drug type of choice								
opioids	470	69	12.8 (9.6–16.7)	0.5469	466	44	8.9 (6.4–12.4)	0.8392
stimulants	20	5	20.8 (7.7–45.2)		20	2	12.9 (2.8–43.8)	
other	7	2	18.2 (2.1–69.2)		7	1	11.5 (0.8–68.3)	

Table 3.5. Prevalence of Front-/back-loading and Container Sharing by Sociodemographic Characteristics

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total								
All	498	95	16.4 (12.9–20.5)	1.0000	498	85	15.7 (12.3–19.8)	1.0000
Sex								
male	422	82	16.1 (12.5–20.6)	0.7763	423	69	14.8 (11.3–19.1)	0.2566
female	76	13	17.8 (9.3–31.1)		75	16	21.1 (11.7–35.0)	
Age								
<25	8	2	12.4 (1.8–51.6)	0.2605	8	2	12.4 (1.8–51.6)	0.4836
25-34	69	18	25.6 (15.4–39.4)		69	14	21.4 (12.3–34.5)	
35-44	308	59	15.1 (11.1–20.3)		309	56	15.9 (11.7–21.3)	
45+	113	16	14.4 (8.0–24.3)		112	13	11.5 (6.0–21.1)	
Years since the start of injecting drug use								

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
≤2	12	1	5.9 (0.6–39.1)	0.4569	12	0	0.0	0.2143
3-5	19	3	9.8 (2.6–30.7)		19	2	5.8 (1.2–24.0)	
6-10	41	9	14.4 (6.9–27.8)		41	8	16.3 (7.7–31.4)	
≥11	422	82	17.6 (13.6–22.5)		422	75	17.0 (13.1–21.8)	
Partnership status								
live alone	240	49	15.9 (11.4–21.7)	0.8088	240	41	15.1 (10.7–21.0)	0.7730
live with partner	258	46	16.8 (12.0–23.2)		258	44	16.2 (11.5–22.4)	
Current employment status								
full-time	90	18	19.6 (11.2–32.1)	0.7695	90	17	19.2 (11.1–31.1)	0.4666
part-time or temporary	272	53	16.8 (12.3–22.5)		272	51	16.9 (12.4–22.6)	
unemployed	104	21	15.5 (8.9–25.5)		104	13	10.0 (4.9–19.3)	
disabled	15	1	7.6 (0.8–45.2)		15	3	22.9 (5.9–58.5)	
other	16	2	9.8 (2.1–35.9)		16	1	7.7 (0.9–43.4)	
Monthly income category								
<3K	67	11	15.1 (7.7–27.5)	0.7054	67	8	11.3 (5.1–23.0)	0.0420
3-10K	178	29	14.1 (9.1–21.2)		179	28	16.4 (10.9–23.9)	
10-20K	179	40	18.2 (12.5–25.9)		180	42	19.9 (13.9–27.7)	
≥20K	47	11	20.8 (10.0–38.3)		45	3	2.8 (0.8–9.5)	
Ever incarcerated								
no	273	55	18.7 (13.7–24.9)	0.1774	274	45	16.5 (11.8–22.5)	0.6554
yes	224	40	13.6 (9.4–19.2)		223	40	14.8 (10.3–20.7)	

Table 3.6. Prevalence of Front-/back-loading and Container Sharing by Selected Subgroups

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	320	62	16.7 (12.6–21.7)	0.7676	318	50	14.7 (10.8–19.6)	0.3374
yes	173	31	15.5 (10.1–22.9)		174	33	18.6 (12.5–26.6)	
Treated with MAT currently (of all)								
no	261	49	16.3 (12.1–21.5)	0.8363	260	46	15.7 (11.6–20.9)	0.9926

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
yes	230	45	17.0 (12.3–23.1)		231	38	15.7 (11.1–21.9)	
HIV test result								
positive	102	21	22.8 (14.2–34.6)	0.1190	102	23	26.0 (16.7–38.1)	0.0112
negative	396	74	15.0 (11.4–19.4)		396	62	13.4 (10.1–17.7)	
Past 30 days injecting 4 categories								
opioids	443	75	14.7 (11.3–19.0)	0.0127	443	69	14.1 (10.7–18.3)	0.0689
stimulants	20	7	31.4 (12.7–59.0)		20	7	33.4 (13.9–60.9)	
opi+stimul	27	12	33.5 (17.2–55.1)		27	9	29.8 (14.3–51.7)	
other	8	1	2.7 (0.2–28.0)		8	0	0.0	
Injecting drug type of choice								
opioids	468	87	15.7 (12.2–19.8)	0.1081	468	79	15.1 (11.8–19.2)	0.5796
stimulants	20	7	31.9 (13.2–59.1)		20	4	24.4 (8.2–53.8)	
other	7	1	6.6 (0.4–53.4)		7	2	18.2 (2.1–69.2)	

4. Sexual Behavior

Table 4.1. Prevalence of Sexual Practice by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had sex: ever										
yes	482	96.4	(93.9–98.0)	69	89.8	(76.2–96.1)	413	97.6	(95.3–98.8)	0.0080
N	499			76			423			
Had sex: in the past 12 months										
yes	412	87.5	(83.4–90.8)	58	81.5	(61.1–92.5)	354	88.5	(84.7–91.5)	0.2980
N	481			69			412			
Had sex: in the past 30 days										
yes	275	62.5	(56.8–67.9)	43	65.3	(48.3–79.1)	232	62.1	(55.9–67.8)	0.7103
N	477			69			408			
Had a sex partner in the past 30 days: regular										
yes	250	90.7	(85.6–94.2)	43	100.0		207	89.2	(83.2–93.2)	0.0657
N	274			43			231			
Had a sex partner in the past 30 days: casual										
yes	43	17.3	(12.4–23.7)	1	6.4	(0.9–34.3)	42	19.1	(13.6–26.2)	0.2078
N	272			42			230			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	2	0.6	(0.2–2.4)	0	0.0		2	0.7	(0.2–2.8)	0.5648
N	271			43			228			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes	2	0.9	(0.2–3.8)	1	1.8	(0.2–12.4)	1	0.7	(0.1–5.0)	0.4948
N	273			43			230			

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Used condom during last sex: if ever had sex										
yes	182	39.5	(33.8–45.5)	19	21.9	(12.5–35.5)	163	42.2	(35.9–48.8)	0.0071
N	439			62			377			
Used condom during last sex: if had sex in 12m										
yes	170	41.7	(35.6–48.0)	17	24.4	(14.0–39.0)	153	44.1	(37.4–51.1)	0.0140
N	393			55			338			
Used condom during last sex: if had sex in 30d										
yes	108	37.7	(30.8–45.1)	10	15.8	(7.5–30.2)	98	41.2	(33.4–49.4)	0.0022
N	272			42			230			



Figure 4.1. Frequency of sex in the past week by Drug Types Used (%)

Table 4.2. Sex Practices by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had same-sex sexual experience										
yes	27	4.7	(3.0–7.2)	11	11.1	(5.5–21.2)	16	3.7	(2.1–6.3)	0.0097
N	482			69			413			
Provided sex services for money										
yes	17	3.8	(2.2–6.4)	7	10.1	(4.3–21.8)	10	2.8	(1.4–5.6)	0.0145
N	480			68			412			
Paid for sex ever										
yes	78	15.9	(12.4–20.2)	3	5.9	(1.3–22.4)	75	17.4	(13.5–22.2)	0.1020
N	479			68			411			
Had sex with a sex worker in the past 6 months										
yes	20	22.0	(13.6–33.4)	1	20.7	(1.7–79.4)	19	22.0	(13.5–33.8)	0.9537
N	77			3			74			
Type of partner with whom had last sex										
regular	351	79.6	(74.4–83.9)	60	94.9	(82.0–98.7)	291	77.3	(71.6–82.2)	0.0005
casual	82	18.7	(14.5–23.8)	1	0.5	(0.1–3.8)	81	21.4	(16.6–27.1)	
com. sex (I paid)	6	1.5	(0.6–3.6)	1	3.2	(0.4–19.9)	5	1.2	(0.5–3.4)	
com. sex (I was paid)	1	0.2	(0.0–1.3)	1	1.4	(0.2–9.5)	0	0.0		

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
N	440			63			377			
With whom last had sex										
man	60	12.2	(9.0–16.3)	59	95.0	(85.1–98.5)	1	0.3	(0.0–2.5)	
woman	380	86.7	(82.5–90.0)	1	1.6	(0.2–11.1)	379	98.8	(96.4–99.6)	
men and women	4	1.1	(0.4–3.1)	2	3.3	(0.8–13.0)	2	0.8	(0.2–3.2)	
N	444			62			382			
Type of last sex contact: vaginal										
yes	429	96.8	(94.2–98.3)	61	96.3	(81.9–99.3)	368	96.9	(94.1–98.4)	0.8475
N	441			63			378			
Type of last sex contact: anal										
yes	67	15.6	(11.9–20.1)	9	16.2	(7.9–30.1)	58	15.5	(11.6–20.4)	0.9082
N	441			63			378			
Type of last sex contact: oral										
yes	108	24.1	(19.6–29.3)	14	21.5	(11.9–35.7)	94	24.5	(19.6–30.2)	0.6560
N	441			63			378			

Table 4.3. Sex Partners by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had a sex partner in the past 30 days: regular										
yes	250	90.7	(85.6–94.2)	43	100.0		207	89.2	(83.2–93.2)	0.0657
N	274			43			231			
Had a sex partner in the past 30 days: casual										
yes	43	17.3	(12.4–23.7)	1	6.4	(0.9–34.3)	42	19.1	(13.6–26.2)	0.2078
N	272			42			230			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	2	0.6	(0.2–2.4)	0	0.0		2	0.7	(0.2–2.8)	0.5648
N	271			43			228			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes	2	0.9	(0.2–3.8)	1	1.8	(0.2–12.4)	1	0.7	(0.1–5.0)	0.4948
N	273			43			230			
Number of sex partners in the past 30 days: regular										
1	176	92.1	(86.2–95.7)	29	90.7	(73.2–97.2)	147	92.4	(85.6–96.2)	0.8220
2-4	13	7.2	(3.8–13.0)	3	9.3	(2.8–26.8)	10	6.8	(3.3–13.4)	
5+	1	0.7	(0.1–4.7)	0	0.0		1	0.8	(0.1–5.6)	
N	190			32			158			
Number of sex partners in the past 30 days: casual										
1	15	50.8	(30.7–70.6)	0	0.0		15	50.8	(30.7–70.6)	
2-4	14	46.3	(27.1–66.7)	0	0.0		14	46.3	(27.1–66.7)	
5+	1	2.9	(0.4–18.3)	0	0.0		1	2.9	(0.4–18.3)	
N	30			0			30			
Number of sex partners in the past 30 days: commercial (selling - I was paid)										
1	1	69.8	(12.5–97.4)	0	0.0		1	100.0		
2-4	0	0.0		0	0.0		0	0.0		
5+	1	30.2	(2.6–87.5)	1	100.0		0	0.0		
N	2			1			1			
Number of sex partners in the past 30 days: total										
1	168	82.9	(75.5–88.4)	29	93.0	(74.3–98.4)	139	81.1	(72.7–87.4)	0.3342
2-4	26	14.3	(9.3–21.5)	2	7.0	(1.6–25.7)	24	15.6	(9.9–23.7)	
5+	5	2.8	(1.1–7.0)	0	0.0		5	3.3	(1.3–8.2)	

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
N	199			31			168			



Figure 4.2. Condom Use During Last Sexual Encounter by Type of Partner (%)



Figure 4.3. Trends in Condom Use During Last Sexual Encounter by Survey Round (%)

Table 4.4. Condom Use During Last Sexual Encounter by Sociodemographic Characteristics

			Used condom during last sex: if ever had sex				
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
Total							
	All	439	257	60.5 (54.5–66.2)	182	39.5 (33.8–45.5)	1.0000
Sex							

		Used condom during last sex: if ever had sex			
	N	no		yes	
		n	% (CI)	n	% (CI)	p-value
male	377	214	57.8 (51.2–64.1)	163	42.2 (35.9–48.8)	0.0071
female	62	43	78.1 (64.5–87.5)	19	21.9 (12.5–35.5)	
Age						
<25	6	4	70.6 (19.7–95.9)	2	29.4 (4.1–80.3)	0.6522
25-34	64	38	58.9 (44.2–72.1)	26	41.1 (27.9–55.8)	
35-44	270	151	58.3 (50.2–66.0)	119	41.7 (34.0–49.8)	
45+	99	64	67.0 (55.3–77.0)	35	33.0 (23.0–44.7)	
Years since the start of injecting drug use						
≤2	11	4	36.0 (11.4–71.2)	7	64.0 (28.8–88.6)	0.3316
3-5	17	7	48.1 (19.4–78.1)	10	51.9 (21.9–80.6)	
6-10	35	20	56.8 (37.4–74.2)	15	43.2 (25.8–62.6)	
≥11	373	224	62.6 (55.9–68.8)	149	37.4 (31.2–44.1)	
Partnership status						
live alone	196	90	47.2 (38.0–56.5)	106	52.8 (43.5–62.0)	0.0000
live with partner	243	167	71.9 (64.6–78.2)	76	28.1 (21.8–35.4)	
Current employment status						
full-time	81	46	62.1 (48.2–74.2)	35	37.9 (25.8–51.8)	0.9979
part-time or temporary	233	134	60.5 (52.6–67.8)	99	39.5 (32.2–47.4)	
unemployed	95	60	60.4 (44.9–74.1)	35	39.6 (25.9–55.1)	
disabled	14	7	58.6 (23.1–87.0)	7	41.4 (13.0–76.9)	
other	16	10	56.7 (28.6–81.0)	6	43.3 (19.0–71.4)	
Monthly income category						
<3K	59	34	60.1 (42.9–75.1)	25	39.9 (24.9–57.1)	0.4515
3-10K	151	83	55.4 (44.9–65.4)	68	44.6 (34.6–55.1)	
10-20K	162	101	66.1 (56.4–74.7)	61	33.9 (25.3–43.6)	
≥20K	43	24	57.1 (39.6–73.0)	19	42.9 (27.0–60.4)	
Ever incarcerated						
no	240	132	56.1 (48.2–63.8)	108	43.9 (36.2–51.8)	0.1170
yes	199	125	65.7 (56.3–74.1)	74	34.3 (25.9–43.7)	

Table 4.5. Condom Use During Last Sexual Encounter by Selected Subgroups

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	283	165	60.8 (53.4–67.7)	118	39.2 (32.3–46.6)	0.8796
yes	150	88	59.8 (50.1–68.9)	62	40.2 (31.1–49.9)	
Treated with MAT currently (of all)						
no	226	136	61.2 (53.6–68.3)	90	38.8 (31.7–46.4)	0.8484
yes	206	119	60.2 (52.4–67.5)	87	39.8 (32.5–47.6)	
HIV test result						
positive	87	43	45.0 (32.7–57.9)	44	55.0 (42.1–67.3)	0.0105
negative	352	214	63.5 (56.8–69.8)	138	36.5 (30.2–43.2)	
Past 30 days injecting 4 categories						
opioids	389	228	60.3 (53.8–66.5)	161	39.7 (33.5–46.2)	0.3897
stimulants	18	10	56.6 (29.5–80.3)	8	43.4 (19.7–70.5)	
opi+stimul	25	13	53.9 (31.8–74.6)	12	46.1 (25.4–68.2)	
other	7	6	88.9 (34.4–99.2)	1	11.1 (0.8–65.6)	
Injecting drug type of choice						
opioids	412	242	60.3 (54.0–66.2)	170	39.7 (33.8–46.0)	0.8802
stimulants	18	12	66.1 (37.9–86.2)	6	33.9 (13.8–62.1)	
other	7	2	54.5 (10.1–92.7)	5	45.5 (7.3–89.9)	

Table 4.6. Condom use by type of partner by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Used condom during last sex: regular partner										
yes	96	37.8	(30.5–45.7)	9	14.0	(6.4–27.8)	87	42.4	(34.0–51.3)	0.0006
N	248			43			205			
Used condom during last sex: casual partner										
yes	26	51.9	(34.6–68.7)	2	100.0		24	48.4	(31.3–65.8)	0.1793
N	44			2			42			
Used condom during last sex: commercial (I paid) partner										
yes	2	63.1	(19.9–92.2)	0	0.0		2	63.1	(19.9–92.2)	
N	5			0			5			
Used condom during last sex: commercial (I was paid) partner										
yes	1	83.6	(24.0–98.8)	0	0.0		1	83.6	(24.0–98.8)	
N	2			0			2			
Condom use frequency: regular partner										
always	57	20.3	(15.1–26.7)	6	10.1	(3.9–24.0)	51	22.2	(16.3–29.6)	0.1150

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
often	19	8.6	(5.0–14.4)	5	9.5	(3.2–24.9)	14	8.4	(4.5–15.2)	
half	14	5.8	(3.3–10.1)	0	0.0		14	7.0	(4.0–12.0)	
sometimes	14	6.5	(3.0–13.5)	2	3.2	(0.7–13.4)	12	7.1	(3.1–15.5)	
rarely	17	9.0	(5.3–14.8)	2	6.6	(1.6–23.5)	15	9.5	(5.4–16.1)	
never	117	49.8	(41.9–57.7)	26	70.5	(52.9–83.5)	91	45.8	(37.2–54.7)	
N	238			41			197			
Condom use frequency: casual partner										
always	18	32.1	(18.7–49.1)	1	22.4	(1.7–82.9)	17	32.8	(18.9–50.5)	0.0101
often	3	8.7	(2.3–27.9)	1	77.6	(17.1–98.3)	2	3.6	(0.7–16.4)	
half	6	7.6	(2.9–18.1)	0	0.0		6	8.1	(3.2–19.4)	
sometimes	1	3.5	(0.5–21.4)	0	0.0		1	3.8	(0.5–22.7)	
rarely	4	14.2	(5.3–33.1)	0	0.0		4	15.3	(5.7–35.0)	
never	12	33.9	(19.2–52.7)	0	0.0		12	36.4	(20.8–55.5)	
N	44			2			42			
Condom use frequency: commercial (I paid) partner										
always	0	0.0		0	0.0		0	0.0		
often	1	6.6	(0.8–38.6)	0	0.0		1	6.6	(0.8–38.7)	
half	2	26.7	(5.1–71.2)	0	0.0		2	26.7	(5.1–71.2)	
sometimes	1	33.5	(5.4–81.8)	0	0.0		1	33.5	(5.4–81.8)	
rarely	0	0.0		0	0.0		0	0.0		
never	2	33.2	(7.4–75.6)	0	0.0		2	33.2	(7.4–75.6)	
N	6			0			6			
Condom use frequency: commercial (I was paid) partner										
always	1	19.4	(2.2–71.7)	1	100.0		0	0.0		
often	1	8.8	(1.0–49.2)	0	0.0		1	10.9	(1.1–58.3)	
half	1	26.9	(3.3–79.9)	0	0.0		1	33.4	(3.6–86.9)	
sometimes	1	44.9	(7.4–89.2)	0	0.0		1	55.7	(9.2–93.9)	
rarely	0	0.0		0	0.0		0	0.0		
never	0	0.0		0	0.0		0	0.0		
N	4			1			3			



Figure 4.4. Frequency of condom use by type of partner by Sex (%)



Figure 4.5. Frequency of condom use among men during the last sexual encounter by the riskiest type of partner in the past 30 days (%)

5. HIV, HCV, and Syphilis Testing Results

Table 5.1. HIV Prevalence by Sociodemographic Characteristics

			HIV test result				
		N	positive		negative		
			n	% (CI)	n	% (CI)	p-value
Total							
	All	500	102	17.9 (14.3–22.2)	398	82.1 (77.8–85.7)	1.0000
Sex							
	male	424	82	17.4 (13.6–22.1)	342	82.6 (77.9–86.4)	0.5240
	female	76	20	20.9 (12.2–33.6)	56	79.1 (66.4–87.8)	
Age							
	<25	8	1	11.4 (0.9–63.5)	7	88.6 (36.5–99.1)	0.0348
	25-34	69	5	8.0 (2.9–20.1)	64	92.0 (79.9–97.1)	
	35-44	310	63	17.0 (12.6–22.4)	247	83.0 (77.6–87.4)	
	45+	113	33	28.9 (19.9–39.9)	80	71.1 (60.1–80.1)	
Years since the start of injecting drug use							
	≤2	12	0	0.0	12	100.0	0.0179
	3-5	19	1	1.3 (0.1–10.7)	18	98.7 (89.3–99.9)	
	6-10	41	4	10.4 (3.5–27.1)	37	89.6 (72.9–96.5)	
	≥11	424	97	20.8 (16.5–25.8)	327	79.2 (74.2–83.5)	
Partnership status							
	live alone	241	50	20.4 (14.8–27.4)	191	79.6 (72.6–85.2)	0.2139

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
live with partner	259	52	15.5 (11.3–20.9)	207	84.5 (79.1–88.7)	
Current employment status						
full-time	90	16	16.3 (9.2–27.2)	74	83.7 (72.8–90.8)	0.9814
part-time or temporary	273	52	18.2 (13.4–24.4)	221	81.8 (75.6–86.6)	
unemployed	104	26	18.7 (11.3–29.3)	78	81.3 (70.7–88.7)	
disabled	15	5	21.5 (6.2–53.4)	10	78.5 (46.6–93.8)	
other	17	3	14.7 (4.1–40.9)	14	85.3 (59.1–95.9)	
Monthly income category						
<3K	67	16	15.0 (8.0–26.4)	51	85.0 (73.6–92.0)	0.2393
3-10K	179	42	22.0 (15.6–30.1)	137	78.0 (69.9–84.4)	
10-20K	180	27	14.4 (9.2–21.8)	153	85.6 (78.2–90.8)	
≥20K	47	6	11.7 (4.8–25.7)	41	88.3 (74.3–95.2)	
Ever incarcerated						
no	274	49	15.7 (11.3–21.3)	225	84.3 (78.7–88.7)	0.2101
yes	225	53	20.8 (15.1–27.9)	172	79.2 (72.1–84.9)	

Table 5.2. HIV Prevalence by Selected Subgroups

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	320	61	15.8 (11.8–20.8)	259	84.2 (79.2–88.2)	0.0333
yes	174	40	25.1 (18.0–34.0)	134	74.9 (66.0–82.0)	
Treated with MAT currently (of all)						
no	262	48	16.5 (12.3–21.9)	214	83.5 (78.1–87.7)	0.1271
yes	231	52	22.6 (16.9–29.6)	179	77.4 (70.4–83.1)	
Past 30 days injecting 4 categories						
opioids	445	93	18.0 (14.2–22.6)	352	82.0 (77.4–85.8)	0.4692
stimulants	20	4	25.8 (8.7–55.8)	16	74.2 (44.2–91.3)	
opi+stimul	27	4	16.1 (5.4–39.2)	23	83.9 (60.8–94.6)	
other	8	1	3.4 (0.2–33.1)	7	96.6 (66.9–99.8)	
Injecting drug type of choice						

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
opioids	470	97	18.1 (14.4–22.6)	373	81.9 (77.4–85.6)	0.6755
stimulants	20	3	18.7 (5.4–47.9)	17	81.3 (52.1–94.6)	
other	7	1	6.6 (0.4–53.4)	6	93.4 (46.6–99.6)	



Figure 5.1. HIV Test Result (%)



Figure 5.2. Trends in HIV Prevalence by Survey Round (%)



Figure 5.3. Anti-HCV Testing Coverage In the Survey (%)



Figure 5.4. Anti-HCV Test Results (%)



Figure 5.5. Anti-HCV Test Results by Sex (%)



Figure 5.6. Trends in Anti-HCV Prevalence by Survey Round (%)



Figure 5.7. Syphilis Test Results (%)

6. HIV Prevention

Table 6.1. Being a Client of NGO by Sociodemographic Characteristics

			Client of NGO working with PWID			
		N	no		yes	
			n	% (CI)	n	% (CI)	p-value
Total							
	All	494	320	77.2 (73.0–81.0)	174	22.8 (19.0–27.0)	1.0000
Sex							
	male	418	281	79.1 (74.6–82.9)	137	20.9 (17.1–25.4)	0.0384
	female	76	39	66.6 (53.1–77.8)	37	33.4 (22.2–46.9)	
Age							

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
<25	8	8	100.0	0	0.0	0.2741
25-34	69	49	78.0 (65.6–86.9)	20	22.0 (13.1–34.4)	
35-44	304	194	77.6 (72.0–82.3)	110	22.4 (17.7–28.0)	
45+	113	69	72.1 (62.4–80.2)	44	27.9 (19.8–37.6)	
Years since the start of injecting drug use						
≤2	12	12	100.0	0	0.0	0.0093
3-5	19	18	98.3 (86.9–99.8)	1	1.7 (0.2–13.1)	
6-10	40	31	81.4 (64.7–91.3)	9	18.6 (8.7–35.3)	
≥11	419	256	74.4 (69.5–78.8)	163	25.6 (21.2–30.5)	
Partnership status						
live alone	237	149	76.7 (70.3–82.0)	88	23.3 (18.0–29.7)	0.7842
live with partner	257	171	77.8 (71.8–82.8)	86	22.2 (17.2–28.2)	
Current employment status						
full-time	90	63	85.0 (77.1–90.6)	27	15.0 (9.4–22.9)	0.4073
part-time or temporary	270	172	74.8 (68.7–80.0)	98	25.2 (20.0–31.3)	
unemployed	102	65	78.5 (68.2–86.1)	37	21.5 (13.9–31.8)	
disabled	15	8	68.3 (33.9–90.0)	7	31.7 (10.0–66.1)	
other	16	11	78.2 (49.7–92.9)	5	21.8 (7.1–50.3)	
Monthly income category						
<3K	67	39	69.7 (55.0–81.3)	28	30.3 (18.7–45.0)	0.3746
3-10K	176	113	75.8 (68.4–82.0)	63	24.2 (18.0–31.6)	
10-20K	178	120	80.8 (73.9–86.2)	58	19.2 (13.8–26.1)	
≥20K	47	31	79.1 (64.0–88.9)	16	20.9 (11.1–36.0)	
Ever incarcerated						
no	268	181	78.5 (72.7–83.4)	87	21.5 (16.6–27.3)	0.5240
yes	225	139	75.9 (69.3–81.5)	86	24.1 (18.5–30.7)	

Table 6.2. Being a Client of NGO by Selected Subgroups

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Treated with MAT currently (of all)						
no	259	226	88.5 (83.9–91.9)	33	11.5 (8.1–16.1)	0.0000
yes	228	89	37.8 (30.8–45.3)	139	62.2 (54.7–69.2)	
HIV test result						
positive	101	61	68.0 (56.8–77.5)	40	32.0 (22.5–43.2)	0.0333
negative	393	259	79.2 (74.7–83.2)	134	20.8 (16.8–25.3)	
Past 30 days injecting 4 categories						
opioids	442	279	76.2 (71.6–80.2)	163	23.8 (19.8–28.4)	0.0229
stimulants	18	15	94.4 (81.0–98.5)	3	5.6 (1.5–19.0)	
opi+stimul	26	19	69.0 (44.9–85.8)	7	31.0 (14.2–55.1)	
other	8	7	97.3 (72.0–99.8)	1	2.7 (0.2–28.0)	
Injecting drug type of choice						
opioids	464	292	75.3 (70.7–79.4)	172	24.7 (20.6–29.3)	0.0980
stimulants	20	18	94.2 (74.0–99.0)	2	5.8 (1.0–26.0)	
other	7	7	100.0	0	0.0	



Figure 6.1. Injecting and Sex Risk Perception Among HIV-negative PWID (%)



Figure 6.2. Received HIV Prevention Services in the Past 12 Months and 30 days (%)



Figure 6.3. Receiving Package of Prevention Services in the Past 12 Months (%)



Figure 6.4. Trends in Receiving HIV Prevention Services in the Past 12 Months (%)



Figure 6.5. Perceived changes in access to HIV prevention since February 2022 (%)

Table 6.3. Percentage of correct responses to knowledge questions by HIV status

	Total	HIV test result		
	All %	negative %	positive %	p-value
HIV knowledge				
HIV may be avoided	91.1	90.4	94.2	0.2186
proper condom use may prevent HIV	30.4	28.9	37.4	0.1715
undetectable=untransmittable	42.6	38.5	61.2	0.0007
PEP reduces the risk of HIV	43.9	40.2	61.0	0.0020
ART should be started immediately	75.5	72.8	88.2	0.0033

	Total	HIV test result		
	All %	negative %	positive %	p-value
ART may be postponed if one feels healthy	47.8	46.6	53.5	0.3070
ART may be stopped if one feels healthy	53.6	53.1	56.3	0.6339
HIV is transmitted through blood and sex	90.0	89.8	91.1	0.7128
HIV is transmitted via air, food, or skin	62.0	61.9	62.4	0.9373
HBV knowledge				
proper condom use may prevent HBV	82.0	81.4	84.6	0.5491
treatment should be started immediately	85.1	87.2	75.3	0.0175
treatment may be postponed if one feels healthy	64.1	63.8	65.2	0.8241
HBV is 100% transmitted from mother to child	16.6	16.5	16.7	0.9679
HBV is transmitted through blood and sex	86.5	87.8	80.5	0.1424
HBV is transmitted via air, food, or skin	50.2	52.6	39.4	0.0462
treatment may be stopped if one feels healthy	56.4	55.6	60.1	0.5030
HCV knowledge				
proper condom use may prevent HCV	10.1	9.2	14.2	0.2532
treatment should be started immediately	83.7	83.3	85.6	0.6389
treatment may be postponed if one feels healthy	55.9	54.6	62.0	0.2687
HCV is 100% transmitted from mother to child	12.5	11.5	17.2	0.2167
HCV is transmitted through blood and sex	87.9	87.3	90.3	0.5135
there is no treatment for HCV	45.8	44.0	54.0	0.1383
HCV is transmitted via air, food, or skin	69.5	66.5	83.0	0.0055
treatment may be stopped if one feels healthy	56.7	55.4	63.0	0.2532

7. HIV Testing

Table 7.1. HIV Testing Knowledge and Uptake

	n	%	CI
Know where to get HIV test			
yes	402	79.3	(73.8–83.9)
Tested for HIV ever			
yes	448	86.9	(82.0–90.6)
Tested for HIV in the past 12 months			
yes	214	51.8	(45.3–58.1)
Tested for HIV in the past 6 months			
yes	149	33.9	(28.0–40.2)
Received the result of HIV test (of those tested)			
yes	433	98.8	(97.4–99.4)
Willing to disclose HIV test result (of those who got result)			
yes	427	98.8	(96.7–99.6)
Self-reported HIV status (of all tested)			
positive	80	15.5	(12.0–19.8)
negative	357	84.5	(80.2–88.0)
HIV testing and status awareness (GAM)			
yes	242	57.9	(51.4–64.0)
Ever did a HIV self-test			
yes	6	1.7	(0.7–4.1)
Regular sex partner tested for HIV			
yes	169	73.1	(65.3–79.7)
Regular sex partner HIV test result			
positive	29	12.2	(7.9–18.5)
negative	136	86.4	(80.0–91.0)
cannot disclose	3	1.3	(0.4–4.5)



Figure 7.1. HIV Testing Uptake (%)



Figure 7.2. Testing for HIV, HCV, syphilis since February 2022 (%)



Figure 7.3. HIV Testing Since February 2022 (%)

Table 7.2. Testing for HIV in the past 12 months (among all) by Sociodemographic Characteristics

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Total						
All	393	179	48.2 (41.9–54.7)	214	51.8 (45.3–58.1)	1.0000
Sex						
male	334	150	47.4 (40.5–54.3)	184	52.6 (45.7–59.5)	0.5490
female	59	29	53.0 (36.1–69.2)	30	47.0 (30.8–63.9)	
Age						
<25	3	1	28.8 (2.1–88.6)	2	71.2 (11.4–97.9)	0.1588
25-34	49	28	58.4 (41.3–73.6)	21	41.6 (26.4–58.7)	
35-44	254	104	44.0 (36.0–52.3)	150	56.0 (47.7–64.0)	
45+	87	46	57.2 (44.9–68.7)	41	42.8 (31.3–55.1)	
Years since the start of injecting drug use						
≤2	9	6	58.4 (20.7–88.3)	3	41.6 (11.7–79.3)	0.6441
3-5	9	5	54.1 (20.7–84.2)	4	45.9 (15.8–79.3)	
6-10	25	15	59.2 (35.5–79.3)	10	40.8 (20.7–64.5)	
≥11	349	152	46.4 (39.6–53.3)	197	53.6 (46.7–60.4)	
Partnership status						
live alone	186	74	43.6 (34.5–53.1)	112	56.4 (46.9–65.5)	0.1688
live with partner	207	105	52.6 (43.8–61.3)	102	47.4 (38.7–56.2)	

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Current employment status						
full-time	76	34	49.7 (35.1–64.4)	42	50.3 (35.6–64.9)	0.7780
part-time or temporary	213	96	45.5 (37.4–53.8)	117	54.5 (46.2–62.6)	
unemployed	79	36	55.9 (40.1–70.6)	43	44.1 (29.4–59.9)	
disabled	12	7	40.3 (11.9–77.1)	5	59.7 (22.9–88.1)	
other	13	6	53.5 (23.8–80.9)	7	46.5 (19.1–76.2)	
Monthly income category						
<3K	52	21	42.6 (25.7–61.5)	31	57.4 (38.5–74.3)	0.8016
3-10K	141	64	52.3 (41.9–62.4)	77	47.7 (37.6–58.1)	
10-20K	148	75	47.4 (37.2–57.9)	73	52.6 (42.1–62.8)	
≥20K	35	13	47.8 (29.4–66.9)	22	52.2 (33.1–70.6)	
Ever incarcerated						
no	209	102	52.2 (43.6–60.6)	107	47.8 (39.4–56.4)	0.2221
yes	183	77	44.1 (34.8–53.8)	106	55.9 (46.2–65.2)	

Table 7.3. Testing for HIV in the past 12 months (among all) by Selected Subgroups

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	242	120	50.3 (42.4–58.3)	122	49.7 (41.7–57.6)	0.1968
yes	147	58	42.0 (32.5–52.0)	89	58.0 (48.0–67.5)	
Treated with MAT currently (of all)						
no	190	106	52.9 (44.7–61.1)	84	47.1 (38.9–55.3)	0.0010
yes	201	72	34.1 (27.1–41.8)	129	65.9 (58.2–72.9)	
HIV test result						
positive	82	45	53.4 (40.2–66.2)	37	46.6 (33.8–59.8)	0.4131
negative	311	134	47.2 (40.0–54.4)	177	52.8 (45.6–60.0)	
Past 30 days injecting 4 categories						
opioids	359	159	47.2 (40.6–53.9)	200	52.8 (46.1–59.4)	0.1564
stimulants	9	6	87.7 (60.2–97.1)	3	12.3 (2.9–39.8)	
opi+stimul	18	11	55.5 (28.7–79.4)	7	44.5 (20.6–71.3)	

	N	Tested for HIV in the past 12 months				
		n	no % (CI)	n	yes % (CI)	p-value
other	7	3	31.3 (4.1–82.9)	4	68.7 (17.1–95.9)	
Injecting drug type of choice						
opioids	373	167	48.2 (41.7–54.8)	206	51.8 (45.2–58.3)	0.7764
stimulants	11	7	56.4 (22.1–85.5)	4	43.6 (14.5–77.9)	
other	7	4	36.5 (5.9–84.0)	3	63.5 (16.0–94.1)	

8. HIV Treatment



Figure 8.1. HIV Status Awareness Among HIV+ (%)



Figure 8.2. HIV Treatment Cascade - Four-stage (%)



Figure 8.3. HIV Treatment Cascade - Conditional (%)



Figure 8.4. HIV Treatment Cascade - Proportions (%)



Figure 8.5. Trends in HIV Treatment Cascade (Conditional, 95-95-95) by Survey Round (%)

Table 8.1. HIV Treatment Cascade (Conditional, 95-95-95) by Sociodemographic Characteristics

		Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
		N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Total											
	All	102	61.9 (49.7–72.8)	1.0000	67	68.7 (54.0–80.5)	1.0000	50	36	65.7 (48.1–79.9)	1.0000
Sex											
	male	82	60.3 (46.7–72.5)	0.5096	52	65.6 (49.1–79.1)	0.3442	37	26	63.6 (43.8–79.6)	0.6496
	female	20	69.8 (42.5–87.8)		15	81.7 (45.2–96.0)		13	10	73.0 (32.1–93.9)	
Age											

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
<25	1	100.0	0.4289	1	100.0	0.6095	1	1	100.0	0.4286
25-34	5	62.2 (16.4–93.2)		3	61.6 (10.8–95.5)		2	1	20.3 (1.5–81.1)	
35-44	63	53.7 (38.8–68.0)		36	75.5 (53.6–89.1)		29	22	68.7 (44.9–85.5)	
45+	33	74.2 (48.2–89.9)		27	58.6 (36.7–77.5)		18	12	63.8 (35.7–84.8)	
Years since the start of injecting drug use										
≤2	0	0.0		0	0.0		0	0	0.0	
3-5	1	100.0		1	100.0		1	0	0.0	
6-10	4	64.9 (17.0–94.3)		2	57.0 (7.0–95.9)		1	1	100.0	
≥11	97	61.6 (49.0–72.8)		64	69.2 (54.0–81.1)		48	35	64.6 (46.6–79.3)	
Partnership status										
live alone	50	61.7 (44.0–76.7)	0.9624	32	65.1 (44.0–81.6)	0.5424	23	19	75.9 (50.0–90.8)	0.1860
live with partner	52	62.2 (45.8–76.3)		35	73.3 (52.7–87.1)		27	17	54.1 (31.7–75.0)	
Current employment status										
full-time	16	40.7 (17.8–68.4)	0.3617	8	45.5 (14.2–80.8)	0.5772	5	3	52.1 (14.5–87.4)	0.4887
part-time or temporary	52	70.2 (52.4–83.4)		37	70.5 (51.0–84.6)		27	17	58.6 (36.1–78.0)	
unemployed	26	58.7 (33.9–79.7)		17	73.1 (40.8–91.5)		14	12	80.4 (39.3–96.3)	
disabled	5	44.4 (9.1–86.4)		3	100.0		3	3	100.0	
other	3	66.3 (12.8–96.4)		2	49.1 (4.6–95.1)		1	1	100.0	
Monthly income category										
<3K	16	68.2 (37.6–88.4)	0.0101	11	91.4 (55.6–98.9)	0.1983	10	9	95.9 (73.3–99.5)	0.0195
3-10K	42	77.8 (58.2–89.8)		33	77.4 (57.0–89.9)		26	15	53.3 (31.1–74.3)	
10-20K	27	34.7 (17.9–56.5)		12	50.9 (21.9–79.3)		8	8	100.0	

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
≥20K	6	48.1 (13.6–84.5)		3	51.9 (7.8–93.2)		1	0	0.0	
Ever incarcerated										
no	49	63.1 (45.4–77.8)	0.8504	34	54.4 (34.1–73.3)	0.0236	24	19	65.6 (37.7–85.8)	0.9932
yes	53	60.8 (43.8–75.6)		33	82.5 (65.7–92.0)		26	17	65.8 (42.9–83.1)	

Table 8.2. HIV Treatment Cascade (Conditional, 95-95-95) by Selected Subgroups

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID										
no	61	52.2 (37.3–66.7)	0.0026	34	67.1 (46.1–83.0)	0.7846	26	18	70.7 (47.1–86.7)	0.5005
yes	40	85.0 (68.4–93.7)		33	70.8 (49.8–85.6)		24	18	59.6 (34.2–80.7)	
Treated with MAT currently (of all)										
no	48	56.8 (41.3–71.0)	0.0501	28	60.1 (40.4–76.9)	0.0318	17	9	54.9 (30.8–76.9)	0.1428
yes	52	76.5 (62.2–86.5)		38	84.5 (68.3–93.3)		32	26	79.4 (53.3–92.9)	
HIV test result										
positive	102	61.9 (49.6–72.9)		67	68.7 (53.8–80.5)		50	36	65.7 (47.9–80.0)	
negative	0	0.0		0	0.0		0	0	0.0	
Past 30 days injecting 4 categories										
opioids	93	63.8 (51.1–74.9)	0.4833	62	72.5 (57.3–83.9)	0.1562	48	35	68.5 (50.7–82.1)	
stimulants	4	34.7 (5.3–83.4)		2	0.0		0	0	0.0	
opi+stimul	4	67.0 (19.1–94.6)		2	56.1 (6.5–95.9)		1	0	0.0	
other	1	100.0		1	100.0		1	1	100.0	
Injecting drug type of choice										
opioids	97	63.6 (51.1–74.5)	0.5628	65	72.9 (58.2–83.9)		50	36	65.7 (48.1–79.9)	
stimulants	3	54.0 (8.2–93.9)		2	0.0		0	0	0.0	
other	1	0.0		0	0.0		0	0	0.0	

Table 8.3. ART adherence (among those on ART)

	n	%	CI
When did you last miss ART dose			

	n	%	CI
last week	3	6.2	(1.6–20.9)
1-2 weeks ago	2	1.9	(0.4–8.1)
3-4 weeks ago	2	5.4	(1.3–19.4)
1-3 months ago	9	21.6	(10.2–40.0)
never	34	64.9	(47.5–79.1)
What was the reason for missing the last ART dose			
forgot	9	55.7	(29.3–79.2)
did not have meds	6	25.3	(8.7–54.6)
was under influence	2	15.9	(3.8–47.3)
did not want others to see	0	0.0	
other	1	3.2	(0.4–20.2)
Reasons for not taking ART			
not sure it is needed	9	45.0	(23.2–69.0)
no time to visit clinic	6	26.5	(11.2–50.6)
no motivation to visit clinic	8	37.0	(17.6–61.7)
missed a visit, hard to come back	6	31.9	(14.2–56.9)
too sick to visit clinic	5	31.3	(13.4–57.1)
drug use	7	35.3	(16.4–60.4)
side effects or complications	5	31.8	(13.4–58.3)
no understanding of how to take it	3	18.3	(5.7–45.2)
lost or sold all ARVs	4	24.0	(9.0–50.2)
alcohol use	5	29.8	(12.5–55.6)
waited too long and left	4	23.3	(8.5–49.9)
Time on ART			
≤3m	4	26.1	(10.1–52.7)
4-24m	7	30.6	(13.5–55.6)
25-60m	5	22.2	(7.1–51.8)
5y+	7	21.1	(8.3–44.0)

9. PrEP



Figure 9.1. PrEP Uptake in the Past 12 Months (%)



Figure 9.2. Change in PrEP Awareness and Uptake from 2020 to 2023 (%)



Figure 9.3. Change in PrEP Uptake from 2020 to 2023 (%)

Table 9.1. PrEP Awareness by Sociodemographic Characteristics

			PrEP uptake in the past 12 months				
		N	use now	never used		not aware	
			n	% (CI)	n	% (CI)	n	% (CI)
Total							
	All	498	10	2.7 (1.4–5.3)	52	9.8 (6.9–13.9)	436	87.5 (83.1–90.8)
Sex							
	male	422	9	2.6 (1.3–5.1)	43	9.9 (6.6–14.4)	370	87.6 (82.8–91.2)
	female	76	1	3.7 (0.5–22.4)	9	9.6 (4.4–19.8)	66	86.7 (73.5–93.9)
Age							
	<25	8	0	0.0	1	5.5 (0.4–43.9)	7	94.5 (56.1–99.6)
	25-34	69	0	0.0	3	3.0 (0.8–10.3)	66	97.0 (89.7–99.2)

		PrEP uptake in the past 12 months					
	N	use now		never used		not aware	
		n	% (CI)	n	% (CI)	n	% (CI)
35-44	308	6	2.9 (1.2–6.8)	33	11.0 (6.9–17.1)	269	86.1 (79.7–90.7)
45+	113	4	4.4 (1.5–12.3)	15	11.7 (6.5–20.2)	94	83.9 (74.4–90.3)
Years since the start of injecting drug use							
≤2	12	0	0.0	0	0.0	12	100.0
3-5	19	1	10.0 (1.2–50.1)	4	10.8 (3.2–30.8)	14	79.2 (49.3–93.7)
6-10	41	1	2.9 (0.4–18.9)	5	11.6 (3.7–31.0)	35	85.5 (66.4–94.6)
≥11	422	8	2.4 (1.1–4.9)	43	10.0 (6.7–14.7)	371	87.6 (82.8–91.3)
Partnership status							
live alone	240	7	3.9 (1.8–8.1)	27	9.6 (6.0–14.9)	206	86.5 (80.5–90.9)
live with partner	258	3	1.6 (0.4–6.3)	25	10.1 (5.8–16.8)	230	88.4 (81.4–93.0)
Current employment status							
full-time	89	0	0.0	9	7.9 (3.6–16.6)	80	92.1 (83.4–96.4)
part-time or temporary	272	8	3.5 (1.7–7.2)	32	13.2 (8.5–20.0)	232	83.3 (76.4–88.5)
unemployed	104	1	1.3 (0.2–9.1)	10	5.7 (2.8–11.4)	93	92.9 (86.3–96.5)
disabled	15	0	0.0	0	0.0	15	100.0
other	17	1	14.7 (1.9–60.8)	1	1.6 (0.2–13.0)	15	83.7 (40.7–97.5)
Monthly income category							
<3K	67	0	0.0	8	15.1 (5.1–36.7)	59	84.9 (63.3–94.9)
3-10K	178	5	3.6 (1.5–8.7)	17	9.7 (5.6–16.3)	156	86.6 (79.4–91.6)
10-20K	179	2	1.7 (0.3–8.9)	18	8.2 (4.5–14.7)	159	90.1 (82.9–94.4)
≥20K	47	2	6.6 (1.6–23.8)	3	4.2 (1.0–16.5)	42	89.2 (73.1–96.1)
Ever incarcerated							
no	273	3	2.1 (0.7–6.7)	28	10.6 (6.4–17.1)	242	87.3 (80.4–92.0)
yes	224	7	3.5 (1.6–7.5)	24	8.9 (5.5–14.0)	193	87.7 (81.9–91.8)

Table 9.2. PrEP Current Use by Sociodemographic Characteristics

		PrEP uptake in the past 12 months					
	N	use now		never used		not aware	
		n	% (CI)	n	% (CI)	n	% (CI)
Client of NGO working with PWID							
no	318	6	2.3 (0.9–5.4)	28	8.7 (5.3–13.8)	284	89.1 (83.7–92.8)
yes	174	4	4.4 (1.5–11.8)	23	13.9 (8.7–21.3)	147	81.8 (73.3–88.0)
Treated with MAT currently (of all)							
no	261	8	3.0 (1.4–6.2)	23	9.4 (5.9–14.7)	230	87.6 (82.0–91.6)
yes	230	1	1.6 (0.2–10.5)	29	11.7 (8.0–16.8)	200	86.7 (80.7–91.1)

	N	PrEP uptake in the past 12 months					
		use now		never used		not aware	
		n	% (CI)	n	% (CI)	n	% (CI)
HIV test result							
positive	102	7	9.3 (4.3–19.1)	13	10.2 (5.5–18.1)	82	80.5 (70.1–87.9)
negative	396	3	1.3 (0.4–4.3)	39	9.7 (6.4–14.5)	354	89.0 (84.0–92.6)
Past 30 days injecting 4 categories							
opioids	444	9	2.7 (1.3–5.6)	43	8.4 (5.8–11.9)	392	88.9 (84.9–91.9)
stimulants	19	1	6.9 (0.8–39.2)	3	13.8 (2.8–46.8)	15	79.3 (48.3–94.0)
opi+stimul	27	0	0.0	5	13.5 (4.8–32.6)	22	86.5 (67.4–95.2)
other	8	0	0.0	1	40.6 (4.8–90.2)	7	59.4 (9.8–95.2)
Injecting drug type of choice							
opioids	468	9	2.6 (1.3–5.3)	50	9.0 (6.5–12.5)	409	88.4 (84.5–91.4)
stimulants	20	1	5.8 (0.7–34.7)	1	8.6 (1.1–45.0)	18	85.7 (54.4–96.8)
other	7	0	0.0	1	45.3 (5.5–92.2)	6	54.7 (7.8–94.5)

Table 9.3. PrEP Awareness and Uptake

	n	%	CI
PrEP uptake in the past 12 months			
use now	10	2.7	(1.4–5.3)
used in the past	0	0.0	
never used	52	9.8	(6.9–13.9)
not aware	436	87.5	(83.1–90.8)
Aware of PrEP			
no	436	87.1	(82.8–90.5)
yes	64	12.9	(9.5–17.2)
PrEP use current			
no	488	97.3	(94.7–98.6)
yes	10	2.7	(1.4–5.3)
PrEP use current (of those aware)			
no	52	78.3	(62.4–88.7)
yes	10	21.7	(11.3–37.6)

10. MAT



Figure 10.1. MAT Awareness (%)



Figure 10.2. MAT Current Uptake (%)



Figure 10.3. Trends in MAT Lifetime and Current Uptake by Survey Round (%)

Table 10.1. MAT experience

	n	%	CI
Reason for MAT discontinuation			
moved to another city	6	13.6	(5.4–30.3)
clinic closed after Feb 2022	3	18.8	(5.7–47.2)
weak or no effect	3	14.5	(4.5–38.0)
side effects	1	4.0	(0.6–23.8)
do not want to visit clinic	5	18.3	(7.1–39.8)
do not want to quit drugs	3	6.2	(1.5–21.7)
hard to get to the clinic	2	3.3	(0.8–12.7)
do not need it	4	16.2	(5.6–38.8)
do not like the attitude of physician	1	5.0	(0.7–28.4)
How did the injection frequency change during MAT			
intensified	7	32.5	(15.5–55.8)
did not change	14	58.3	(36.5–77.3)
decreased	7	9.2	(3.9–20.0)
Whether bought bupr. or methadone while not being a patient in the past 12 months			
yes, methadone	331	65.4	(59.7–70.6)
yes, buprenorphine	7	1.4	(0.6–3.3)
did not buy	151	33.2	(28.0–38.8)
Where bought bupr. or methadone while not being a patient in the past 12 months			
did not buy	151	33.8	(28.5–39.5)
bought from black market	253	52.2	(46.4–57.9)
bought from private clinic	75	14.1	(10.6–18.5)
Way of using bupr. or methaone bought from others			
injecting	292	87.4	(82.0–91.4)
injecting mixed	20	4.6	(2.8–7.5)
swallow or subling.	23	7.2	(4.1–12.4)
snort	2	0.8	(0.2–3.4)

Table 10.2. MAT Awareness and Uptake by Sociodemographic Characteristics

	N	MAT uptake (of all)								
		take it now		took in the past		never took but plan to		unaware or do not plan to		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	493	231	22.1 (18.8–25.9)	20	5.1 (3.2–8.0)	58	17.3 (13.0–22.6)	184	55.5 (49.9–60.9)	1.0000
Sex										
male	417	194	21.6 (18.1–25.6)	15	4.5 (2.7–7.5)	50	17.1 (12.6–22.6)	158	56.9 (50.9–62.7)	0.5473
female	76	37	25.4 (16.4–37.1)	5	8.5 (3.0–21.8)	8	18.9 (8.1–38.0)	26	47.3 (33.0–62.0)	
Age										
<25	8	1	5.5 (0.4–43.9)	0	0.0	4	38.1 (8.6–80.1)	3	56.4 (16.0–89.7)	0.5460
25-34	68	26	21.1 (12.8–32.7)	1	1.5 (0.2–10.5)	8	14.1 (6.9–26.5)	33	63.3 (49.7–75.0)	
35-44	306	153	22.5 (18.3–27.3)	13	5.9 (3.3–10.2)	33	17.9 (12.1–25.6)	107	53.8 (46.3–61.1)	
45+	111	51	24.5 (17.6–33.0)	6	6.0 (2.6–13.3)	13	14.6 (8.4–24.3)	41	54.9 (44.0–65.3)	
Years since the start of injecting drug use										
≤2	12	1	2.3 (0.2–19.3)	0	0.0	0	0.0	11	97.7 (80.7–99.8)	0.0056
3-5	18	2	3.0 (0.6–13.8)	1	4.1 (0.5–28.0)	2	9.9 (1.9–38.2)	13	83.0 (57.0–94.7)	
6-10	40	10	13.4 (6.0–27.1)	0	0.0	8	19.5 (9.3–36.3)	22	67.1 (49.8–80.8)	
≥11	419	218	25.4 (21.4–29.8)	19	6.0 (3.7–9.5)	47	18.2 (13.3–24.4)	135	50.4 (44.1–56.7)	
Partnership status										
live alone	239	112	22.1 (17.4–27.6)	10	5.3 (2.8–9.9)	29	19.0 (12.7–27.4)	88	53.6 (45.4–61.5)	0.8340
live with partner	254	119	22.2 (17.6–27.5)	10	4.9 (2.5–9.4)	29	15.6 (10.4–22.8)	96	57.3 (49.6–64.7)	
Current employment status										
full-time	90	43	21.5 (14.7–30.3)	5	7.5 (3.0–17.6)	8	10.7 (5.1–20.8)	34	60.3 (47.7–71.6)	0.1688
part-time or temporary	268	121	22.1 (17.7–27.2)	12	6.1 (3.3–10.8)	35	16.3 (11.7–22.3)	100	55.5 (48.3–62.4)	
unemployed	102	57	26.3 (18.0–36.6)	3	2.3 (0.7–7.4)	11	22.9 (11.7–39.8)	31	48.6 (34.8–62.7)	
disabled	15	5	11.4 (3.4–32.2)	0	0.0	3	45.1 (13.4–81.4)	7	43.5 (14.9–77.2)	
other	17	5	14.7 (4.7–37.7)	0	0.0	1	5.9 (0.7–36.3)	11	79.4 (53.8–92.7)	
Monthly income category										

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
<3K	66	32	22.5 (13.8–34.4)	3	3.8 (1.1–11.8)	6	17.9 (6.8–39.6)	25	55.8 (39.1–71.2)	0.7391
3-10K	176	82	20.9 (15.9–26.9)	8	5.2 (2.6–10.3)	23	19.6 (12.6–29.2)	63	54.3 (45.0–63.2)	
10-20K	179	86	23.8 (18.1–30.7)	6	5.3 (2.3–12.0)	22	17.0 (10.6–26.0)	65	53.9 (44.4–63.1)	
≥20K	46	16	16.0 (8.2–28.7)	0	0.0	4	10.6 (3.9–25.9)	26	73.4 (57.7–84.8)	
Ever incarcerated										
no	270	124	21.7 (17.4–26.7)	13	6.4 (3.6–11.2)	26	12.3 (8.3–17.8)	107	59.7 (52.6–66.4)	0.0302
yes	222	106	22.5 (17.5–28.4)	7	3.5 (1.6–7.4)	32	23.6 (16.0–33.2)	77	50.4 (41.7–59.2)	

Table 10.3. MAT Awareness and Uptake by Selected Subgroups

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
Client of NGO working with PWID										
no	315	89	10.8 (8.4–13.9)	16	5.5 (3.3–9.2)	42	17.0 (12.0–23.5)	168	66.6 (60.0–72.7)	0.0000
yes	172	139	60.7 (50.6–69.9)	4	3.9 (1.4–10.2)	16	19.2 (12.1–29.1)	13	16.3 (9.6–26.2)	
Treated with MAT currently (of all)										
no	262	0	0.0	20	6.5 (4.1–10.3)	58	22.2 (16.8–28.9)	184	71.2 (64.4–77.2)	0.0000
yes	231	231	100.0	0	0.0	0	0.0	0	0.0	
HIV test result										
positive	100	52	28.0 (19.9–37.8)	8	11.8 (5.8–22.3)	14	21.1 (12.5–33.3)	26	39.2 (27.9–51.8)	0.0066
negative	393	179	20.9 (17.3–24.9)	12	3.6 (2.0–6.7)	44	16.5 (11.8–22.6)	158	59.0 (52.7–65.0)	
Past 30 days injecting 4 categories										
opioids	438	217	24.0 (20.2–28.1)	19	5.8 (3.6–9.2)	51	18.2 (13.4–24.1)	151	52.1 (46.1–58.1)	0.0991
stimulants	20	5	8.2 (2.8–21.3)	0	0.0	1	6.7 (0.8–38.7)	14	85.1 (62.3–95.2)	
opi+stimul	27	7	15.5 (5.7–35.4)	1	2.1 (0.3–15.1)	6	22.9 (9.5–45.6)	13	59.5 (37.8–78.1)	
other	8	2	6.1 (0.8–34.1)	0	0.0	0	0.0	6	93.9 (65.9–99.2)	
Injecting drug type of choice										
opioids	463	229	24.2 (20.6–28.3)	18	5.3 (3.3–8.5)	58	19.1 (14.4–24.8)	158	51.4 (45.5–57.2)	0.0038
stimulants	20	2	2.5 (0.5–11.3)	1	1.9 (0.2–14.7)	0	0.0	17	95.5 (84.6–98.8)	
other	7	0	0.0	1	6.6 (0.4–53.4)	0	0.0	6	93.4 (46.6–99.6)	



Figure 10.4. Buying MAT medications while not being a patient (%)

Figure 10.5. Source of buying MAT medications while not being a patient (%)



Figure 10.6. Route of administration of MAT medications bought from others (%)

11. Overdose and Naloxone



Figure 11.1. Overdose Experience Ever and in the Past 12 Months (%)



Figure 11.2. Trends in Overdose Experience in the Past 12 Months by Survey Round (%)



Figure 11.3. Drugs causing overdoses (if used only one drug) (%)



Figure 11.4. Naloxone Use (%)

Table 11.1. Overdose Experience

	n	%	CI
Experienced overdose ever			
yes	214	39.1	(33.9–44.7)
Number of overdoses in lifetime			
1	45	22.5	(16.1–30.7)
2-4	99	50.4	(41.8–59.1)
5+	57	27.0	(19.7–35.8)
Experienced overdose in the past 12 months			
yes	30	6.2	(3.8–10.0)
Experienced overdose in the past 12 months (of those ever)			
yes	30	16.1	(10.2–24.6)
Number of overdoses in the past 12 months			
1	12	38.4	(18.5–63.1)
2-4	11	39.7	(17.2–67.6)
5+	5	21.9	(8.3–46.5)
Drug overdosed with (if used only one drug)			
methadone	9	79.5	(40.1–95.7)
other opioid	2	20.5	(4.3–59.9)
stimulant	0	0.0	
other	0	0.0	
Drugs overdosed with (if used a combination)			
methadone+stimulant	4	71.8	(29.1–94.1)
methadone+barbit. or dimedr.	2	19.6	(3.1–65.1)
methadone+other	1	3.2	(0.3–23.5)
other	1	5.4	(0.6–35.4)
Drug overdosed with (if combined drug with alcohol)			
methadone	6	63.2	(30.3–87.2)
other opioid	1	5.5	(0.7–32.1)
stimulant	0	0.0	
other	4	31.3	(9.9–65.3)
Naloxone knowledge and experience			
never heard	122	30.5	(25.3–36.2)
aware but not used	229	45.7	(40.1–51.4)
used myself	98	15.7	(12.4–19.7)
my friends used	44	6.9	(4.8–9.8)

	n	%	CI
me and my friends used	7	1.2	(0.5–2.9)

Table 11.2. Overdose Experience in the Past 12 Months by Sociodemographic Characteristics

	N	Experienced overdose in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Total						
All	495	465	93.8 (90.0–96.2)	30	6.2 (3.8–10.0)	1.0000
Sex						
male	419	398	94.7 (90.5–97.1)	21	5.3 (2.9–9.5)	0.1272
female	76	67	88.6 (75.9–95.0)	9	11.4 (5.0–24.1)	
Age						
<25	8	6	60.8 (13.7–93.8)	2	39.2 (6.2–86.3)	0.0038
25-34	69	64	94.3 (83.9–98.2)	5	5.7 (1.8–16.1)	
35-44	305	285	94.7 (91.3–96.8)	20	5.3 (3.2–8.7)	
45+	113	110	95.7 (85.1–98.9)	3	4.3 (1.1–14.9)	
Years since the start of injecting drug use						
≤2	11	10	91.0 (49.4–99.0)	1	9.0 (1.0–50.6)	0.1963
3-5	19	18	80.1 (31.4–97.3)	1	19.9 (2.7–68.6)	
6-10	41	40	98.1 (87.0–99.8)	1	1.9 (0.2–13.0)	
≥11	420	393	94.2 (91.0–96.3)	27	5.8 (3.7–9.0)	
Partnership status						
live alone	236	222	96.0 (92.6–97.9)	14	4.0 (2.1–7.4)	0.0882
live with partner	259	243	91.6 (84.6–95.5)	16	8.4 (4.5–15.4)	
Current employment status						
full-time	89	81	93.8 (86.5–97.3)	8	6.2 (2.7–13.5)	0.0556
part-time or temporary	271	262	96.4 (92.7–98.3)	9	3.6 (1.7–7.3)	
unemployed	103	91	85.8 (70.5–93.8)	12	14.2 (6.2–29.5)	
disabled	15	15	100.0	0	0.0	
other	16	15	92.1 (56.1–99.1)	1	7.9 (0.9–43.9)	
Monthly income category						
<3K	66	62	92.6 (77.3–97.9)	4	7.4 (2.1–22.7)	0.5326
3-10K	177	169	96.0 (91.3–98.2)	8	4.0 (1.8–8.7)	

		Experienced overdose in the past 12 months				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
	10-20K	178	165	91.5 (82.5–96.1)	13	8.5 (3.9–17.5)
	≥20K	47	45	95.4 (82.0–99.0)	2	4.6 (1.0–18.0)
Ever incarcerated						
	no	271	254	93.1 (86.7–96.6)	17	6.9 (3.4–13.3)	0.5591
	yes	223	211	94.8 (90.3–97.2)	12	5.2 (2.8–9.7)

Table 11.3. Overdose Experience in the Past 12 Months by Selected Subgroups

		Experienced overdose in the past 12 months				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	317	297	93.5 (88.6–96.4)	20	6.5 (3.6–11.4)	0.6488
yes	173	164	94.8 (89.1–97.6)	9	5.2 (2.4–10.9)	
Treated with MAT currently (of all)						
no	260	247	94.4 (89.4–97.1)	13	5.6 (2.9–10.6)	0.3009
yes	228	211	91.3 (85.2–95.0)	17	8.7 (5.0–14.8)	
HIV test result						
positive	101	99	98.5 (93.6–99.7)	2	1.5 (0.3–6.4)	0.0247
negative	394	366	92.7 (88.2–95.6)	28	7.3 (4.4–11.8)	
Past 30 days injecting 4 categories						
opioids	440	420	94.7 (90.3–97.1)	20	5.3 (2.9–9.7)	0.0398
stimulants	20	18	97.0 (86.9–99.4)	2	3.0 (0.6–13.1)	
opi+stimul	27	21	83.9 (64.8–93.6)	6	16.1 (6.4–35.2)	
other	8	6	79.3 (30.3–97.1)	2	20.7 (2.9–69.7)	
Injecting drug type of choice						
opioids	465	437	93.6 (89.5–96.1)	28	6.4 (3.9–10.5)	0.4774
stimulants	20	19	98.1 (85.3–99.8)	1	1.9 (0.2–14.7)	
other	7	6	88.5 (31.7–99.2)	1	11.5 (0.8–68.3)	

Table 11.4. Naloxone Experience by Sociodemographic Characteristics

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total								
All	500	122	30.5 (25.3–36.2)	273	52.6 (47.0–58.2)	105	16.9 (13.5–21.0)	1.0000
Sex								
male	424	107	30.8 (25.3–37.0)	233	54.1 (48.0–60.1)	84	15.0 (11.7–19.2)	0.1254
female	76	15	28.4 (15.5–46.1)	40	43.9 (30.5–58.3)	21	27.7 (16.7–42.3)	
Age								
<25	8	4	64.9 (22.3–92.3)	2	22.7 (3.6–69.8)	2	12.4 (1.8–51.6)	0.3406
25-34	69	18	32.0 (20.2–46.6)	35	52.8 (39.1–66.2)	16	15.2 (8.2–26.4)	
35-44	310	71	28.3 (21.8–35.8)	177	54.4 (46.9–61.7)	62	17.3 (12.8–22.9)	
45+	113	29	30.7 (21.3–42.1)	59	51.7 (40.7–62.5)	25	17.6 (11.2–26.5)	
Years since the start of injecting drug use								
≤2	12	7	53.7 (22.0–82.6)	5	46.3 (17.4–78.0)	0	0.0	0.0037
3-5	19	13	71.6 (41.9–89.8)	5	18.4 (6.0–44.2)	1	10.0 (1.2–50.1)	
6-10	41	13	33.0 (18.8–51.2)	22	58.4 (40.8–74.2)	6	8.5 (3.3–20.4)	
≥11	424	88	26.6 (21.2–32.9)	239	54.7 (48.4–60.8)	97	18.7 (14.8–23.4)	
Partnership status								
live alone	241	62	32.3 (24.8–40.8)	130	52.8 (44.6–60.9)	49	14.9 (10.6–20.4)	0.5640
live with partner	259	60	28.7 (21.8–36.7)	143	52.4 (44.6–60.2)	56	18.9 (13.9–25.2)	
Current employment status								
full-time	90	27	31.9 (21.1–45.2)	42	52.6 (39.3–65.5)	21	15.5 (9.1–25.2)	0.9749
part-time or temporary	273	59	28.3 (21.9–35.6)	158	55.0 (47.7–62.1)	56	16.7 (12.3–22.3)	
unemployed	104	28	32.4 (20.2–47.6)	54	49.4 (35.7–63.2)	22	18.2 (10.9–28.9)	
disabled	15	3	42.6 (11.7–80.7)	10	44.7 (15.4–78.2)	2	12.7 (2.4–46.2)	
other	17	4	29.8 (10.3–61.2)	9	46.1 (21.2–73.0)	4	24.1 (6.4–59.8)	
Monthly income category								
<3K	67	21	41.6 (26.2–58.8)	40	49.2 (33.1–65.4)	6	9.3 (3.6–21.7)	0.3312
3-10K	179	36	26.5 (18.6–36.2)	108	58.0 (48.6–66.9)	35	15.5 (10.5–22.2)	
10-20K	180	43	29.4 (21.1–39.2)	86	49.2 (39.7–58.7)	51	21.4 (15.3–29.3)	
≥20K	47	16	34.2 (20.2–51.7)	23	52.0 (35.1–68.4)	8	13.8 (5.9–29.1)	
Ever incarcerated								

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
no	274	83	37.9 (30.8–45.6)	142	46.6 (39.4–54.0)	49	15.4 (11.0–21.1)	0.0086
yes	225	39	21.3 (14.4–30.4)	131	60.1 (51.3–68.3)	55	18.5 (13.5–24.9)	

Table 11.5. Naloxone Experience by Selected Subgroups

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID								
no	320	102	36.7 (30.2–43.7)	163	49.3 (42.4–56.1)	55	14.1 (10.4–18.8)	0.0000
yes	174	19	9.8 (5.8–15.9)	107	64.2 (55.3–72.3)	48	26.0 (18.9–34.7)	
Treated with MAT currently (of all)								
no	262	86	34.6 (28.1–41.8)	136	51.1 (44.1–58.1)	40	14.3 (10.4–19.3)	0.0001
yes	231	34	15.7 (10.9–22.1)	134	58.2 (50.7–65.4)	63	26.0 (20.1–33.0)	
HIV test result								
positive	102	22	23.6 (14.6–35.8)	59	55.5 (43.5–66.8)	21	20.9 (13.0–31.9)	0.3511
negative	398	100	32.0 (26.1–38.5)	214	52.0 (45.6–58.4)	84	16.0 (12.4–20.5)	
Past 30 days injecting 4 categories								
opioids	445	99	27.9 (22.5–34.1)	251	54.6 (48.6–60.6)	95	17.4 (13.7–21.9)	0.0079
stimulants	20	12	74.9 (49.9–89.9)	6	22.1 (8.1–47.6)	2	3.0 (0.6–13.1)	
opi+stimul	27	7	24.3 (10.7–46.4)	13	50.6 (29.6–71.4)	7	25.1 (10.9–47.8)	
other	8	4	36.0 (6.0–83.3)	3	53.6 (10.9–91.6)	1	10.3 (0.8–62.7)	
Injecting drug type of choice								
opioids	470	103	27.2 (22.0–33.1)	262	54.2 (48.3–60.0)	105	18.6 (14.9–23.1)	0.0007
stimulants	20	14	77.3 (50.7–91.8)	6	22.7 (8.2–49.3)	0	0.0	
other	7	2	15.8 (1.9–64.5)	5	84.2 (35.5–98.1)	0	0.0	

12. Physical and Mental Health

Table 12.1. Disease and treatment history

		n	%	CI
Had a disease				
	hepatitis B	76	13.4	(10.2–17.4)
	hepatitis C	254	43.2	(37.7–48.9)
	syphilis	8	1.1	(0.5–2.5)

	n	%	CI
gonorrhea	13	2.4	(1.3–4.3)
chlamydia	8	1.4	(0.6–3.1)
herpes	34	6.3	(4.2–9.2)
human papillomavirus	9	1.7	(0.8–3.6)
tuberculosis	29	5.4	(3.3–8.9)
Treated for: hepatitis B			
treated successfully	25	40.5	(27.5–54.9)
treated unsuccessfully	9	15.8	(7.5–30.2)
did not complete	6	7.9	(3.0–19.2)
treated now	2	3.5	(0.7–15.6)
never treated	32	32.4	(21.3–46.0)
Treated for: hepatitis C			
treated successfully	42	17.7	(11.9–25.6)
treated unsuccessfully	26	9.9	(6.2–15.4)
did not complete	18	7.1	(4.1–12.1)
treated now	11	6.1	(3.0–11.8)
never treated	151	59.1	(51.0–66.8)
Treated for: syphilis			
treated successfully	7	100.0	
treated unsuccessfully	0	0.0	
did not complete	0	0.0	
treated now	0	0.0	
never treated	0	0.0	
Treated for: tuberculosis			
treated successfully	25	87.6	(65.7–96.3)
treated unsuccessfully	2	7.1	(1.7–26.0)
did not complete	0	0.0	
treated now	1	5.3	(0.7–30.0)
never treated	0	0.0	

Table 12.2. Mental health screening scores

	n	Mean	CI	Median	IQR
AUDIT-C alcohol risk score ≥5	4,874	1.2	(1.2–1.2)	1	(1–1)
PHQ-9 depression result	5,002	2.2	(2.2–2.3)	2	(1–3)
GAD-7 anxiety result	5,002	1.9	(1.9–1.9)	2	(1–2)

Table 12.3. Health care utilization

	n	%	CI
Had problems with health besides drugs which required medical attention in the past 12 months			
yes	178	37.5	(32.1–43.4)
Referred to a health care facility for treatment in the past 12 months			
yes	127	26.4	(21.4–32.0)
Referred to a health care facility			
primary care	64	48.6	(36.8–60.5)
hospital, HIV clinic	67	54.8	(42.7–66.3)
private clinic	1	0.6	(0.1–4.2)
private lab	1	0.2	(0.0–1.6)
TB dispensary	1	1.0	(0.1–7.1)
drug clinic	0	0.0	
STI clinic	2	1.2	(0.3–5.2)
ambulance	10	6.8	(3.1–14.2)
mobile clinic	0	0.0	

	n	%	CI
other	1	0.7	(0.1–4.9)
Last health care facility referred to			
primary care	55	41.7	(30.4–54.1)
hospital, HIV clinic	61	51.7	(39.7–63.5)
private clinic	1	0.6	(0.1–4.2)
private lab	0	0.0	
TB dispensary	1	1.1	(0.1–7.2)
drug clinic	0	0.0	
STI clinic	2	1.2	(0.3–5.3)
ambulance	5	3.0	(1.1–7.8)
mobile clinic	0	0.0	
other	1	0.7	(0.1–4.9)
Received necessary care in health care facility			
yes	116	94.4	(88.5–97.4)
Signed a declaration with primary care physician			
yes	340	65.5	(59.9–70.7)
How frequently saw the primary care physician			
twice per month or more	33	9.9	(6.6–14.7)
once per month	22	5.9	(3.5–9.7)
3-4 times in 12 months	95	29.7	(23.5–36.8)
only once	162	54.4	(47.1–61.6)



Figure 12.1. Risky alcohol use (AUDIT-C score > 5) (%)



Figure 12.2. Depression symptoms severity (PHQ-9) (%)



Figure 12.3. Anxiety symptoms severity (GAD-7) (%)

Table 12.4. Risky alcohol use (AUDIT-C score > 5) by Sociodemographic Characteristics

			AUDIT-C alcohol risk score ≥5			
		N	no		yes	
			n	% (CI)	n	% (CI)	p-value
Total							
	All	454	357	75.9 (70.4–80.7)	97	24.1 (19.3–29.6)	1.0000
Sex							
	male	384	303	75.8 (69.7–81.0)	81	24.2 (19.0–30.3)	0.9096
	female	70	54	76.6 (62.0–86.8)	16	23.4 (13.2–38.0)	
Age							
	<25	8	4	45.4 (10.6–85.4)	4	54.6 (14.6–89.4)	0.0373

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
25-34	62	40	65.7 (51.1–77.8)	22	34.3 (22.2–48.9)	
35-44	282	225	77.4 (70.3–83.2)	57	22.6 (16.8–29.7)	
45+	102	88	84.4 (74.2–91.1)	14	15.6 (8.9–25.8)	
Years since the start of injecting drug use						
≤2	9	8	87.5 (39.3–98.7)	1	12.5 (1.3–60.7)	0.2314
3-5	17	12	60.6 (27.2–86.4)	5	39.4 (13.6–72.8)	
6-10	39	26	64.8 (46.7–79.5)	13	35.2 (20.5–53.3)	
≥11	385	308	78.0 (72.2–82.9)	77	22.0 (17.1–27.8)	
Partnership status						
live alone	210	166	78.3 (71.0–84.2)	44	21.7 (15.8–29.0)	0.3814
live with partner	244	191	73.8 (65.5–80.7)	53	26.2 (19.3–34.5)	
Current employment status						
full-time	84	68	81.2 (69.2–89.2)	16	18.8 (10.8–30.8)	0.4289
part-time or temporary	253	200	76.4 (69.5–82.1)	53	23.6 (17.9–30.5)	
unemployed	87	67	68.3 (50.8–81.9)	20	31.7 (18.1–49.2)	
disabled	15	13	87.3 (53.8–97.6)	2	12.7 (2.4–46.2)	
other	14	8	66.0 (35.6–87.2)	6	34.0 (12.8–64.4)	
Monthly income category						
<3K	57	50	90.7 (79.6–96.1)	7	9.3 (3.9–20.4)	0.0968
3-10K	161	129	75.5 (66.3–82.8)	32	24.5 (17.2–33.7)	
10-20K	167	126	73.8 (63.6–82.0)	41	26.2 (18.0–36.4)	
≥20K	43	31	67.8 (49.4–81.9)	12	32.2 (18.1–50.6)	
Ever incarcerated						
no	252	193	75.5 (68.2–81.6)	59	24.5 (18.4–31.8)	0.8547
yes	201	163	76.5 (67.5–83.6)	38	23.5 (16.4–32.5)	

Table 12.5. Risky alcohol use (AUDIT-C score > 5) by Selected Subgroups

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
	n		% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	298	225	73.6 (66.8–79.4)	73	26.4 (20.6–33.2)	0.0539
yes	151	127	83.5 (75.0–89.5)	24	16.5 (10.5–25.0)	
Treated with MAT currently (of all)						
no	238	174	73.6 (66.7–79.5)	64	26.4 (20.5–33.3)	0.0131
yes	209	179	84.8 (78.1–89.7)	30	15.2 (10.3–21.9)	
HIV test result						
positive	93	73	71.9 (58.9–82.1)	20	28.1 (17.9–41.1)	0.4381
negative	361	284	76.8 (70.6–82.1)	77	23.2 (17.9–29.4)	
Past 30 days injecting 4 categories						
opioids	405	328	77.3 (71.3–82.3)	77	22.7 (17.7–28.7)	0.4266
stimulants	19	12	67.9 (41.1–86.5)	7	32.1 (13.5–58.9)	
opi+stimul	23	13	61.2 (37.2–80.7)	10	38.8 (19.3–62.8)	
other	7	4	78.9 (31.2–96.9)	3	21.1 (3.1–68.8)	
Injecting drug type of choice						
opioids	426	340	77.1 (71.3–82.0)	86	22.9 (18.0–28.7)	0.7599
stimulants	18	13	70.8 (42.5–88.8)	5	29.2 (11.2–57.5)	
other	7	4	67.7 (18.5–95.1)	3	32.3 (4.9–81.5)	

Table 12.6. Depression symptoms severity (PHQ-9) by Sociodemographic Characteristics

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	159	36.0 (30.6–41.9)	186	34.0 (28.9–39.5)	100	21.1 (17.0–25.8)	55	8.9 (6.6–11.9)	1.0000
Sex										
male	424	140	36.8 (31.0–43.1)	158	34.6 (28.9–40.6)	82	20.6 (16.3–25.7)	44	8.0 (5.7–11.1)	0.4791
female	76	19	31.4 (18.3–48.3)	28	30.8 (19.8–44.7)	18	23.5 (13.2–38.3)	11	14.2 (7.3–25.8)	
Age										
<25	8	4	63.2 (20.8–91.8)	2	19.9 (3.1–66.2)	2	16.9 (2.4–62.7)	0	0.0	0.3781
25-34	69	22	33.7 (21.9–48.0)	22	27.8 (17.1–41.8)	15	22.6 (13.1–36.1)	10	15.9 (8.2–28.4)	
35-44	310	94	34.1 (27.1–41.8)	119	37.0 (30.0–44.5)	59	19.8 (14.8–25.9)	38	9.2 (6.4–13.1)	
45+	113	39	39.4 (29.0–50.8)	43	31.7 (23.0–41.8)	24	24.4 (15.8–35.7)	7	4.6 (1.8–11.0)	
Years since the start of injecting drug use										

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
≤2	12	5	35.0 (11.7–68.7)	4	42.1 (14.3–76.0)	1	8.8 (0.9–49.8)	2	14.0 (2.1–55.3)	0.0906
3-5	19	10	67.6 (40.5–86.5)	8	30.0 (12.1–57.1)	1	2.4 (0.3–17.9)	0	0.0	
6-10	41	14	35.4 (20.3–54.1)	11	24.6 (13.1–41.4)	12	33.0 (18.4–51.8)	4	7.0 (2.4–19.1)	
≥11	424	130	34.4 (28.5–40.8)	162	35.2 (29.4–41.4)	85	21.4 (16.9–26.7)	47	9.0 (6.5–12.3)	
Partnership status										
live alone	241	75	37.1 (29.1–45.8)	88	30.5 (23.8–38.2)	49	22.4 (16.6–29.5)	29	9.9 (6.6–14.8)	0.5674
live with partner	259	84	35.0 (27.8–42.9)	98	37.4 (30.1–45.4)	51	19.7 (14.3–26.4)	26	7.9 (5.0–12.1)	
Current employment status										
full-time	90	37	38.2 (26.4–51.6)	28	40.0 (27.1–54.4)	15	14.8 (8.2–25.4)	10	7.0 (3.4–13.8)	0.3708
part-time or temporary	273	75	32.4 (25.9–39.7)	108	35.7 (29.1–43.0)	63	24.2 (18.5–30.9)	27	7.7 (4.9–11.8)	
unemployed	104	40	44.8 (31.2–59.2)	37	26.4 (16.3–39.7)	15	17.8 (9.9–29.9)	12	11.1 (5.7–20.4)	
disabled	15	4	43.6 (12.4–80.8)	7	34.3 (11.3–68.1)	4	22.2 (5.6–57.9)	0	0.0	
other	17	3	26.1 (6.9–62.8)	6	25.1 (9.3–52.2)	3	22.0 (6.3–54.2)	5	26.8 (9.8–55.0)	
Monthly income category										
<3K	67	14	23.2 (11.0–42.5)	30	42.2 (27.1–59.0)	14	22.2 (11.8–37.7)	9	12.4 (5.6–25.2)	0.5305
3-10K	179	60	40.6 (31.5–50.5)	71	32.2 (24.7–40.7)	32	19.7 (13.6–27.7)	16	7.4 (4.3–12.6)	
10-20K	180	60	38.9 (29.9–48.6)	62	33.2 (24.6–43.2)	36	19.1 (13.0–27.3)	22	8.8 (5.3–14.0)	
≥20K	47	19	35.0 (20.9–52.2)	13	31.4 (17.6–49.6)	12	30.6 (16.8–49.0)	3	3.1 (0.8–10.6)	
Ever incarcerated										
no	274	85	34.7 (27.8–42.2)	102	35.7 (28.9–43.1)	52	19.5 (14.3–25.9)	35	10.1 (6.9–14.6)	0.6083
yes	225	74	37.8 (29.4–47.1)	83	31.8 (24.3–40.3)	48	23.0 (16.9–30.6)	20	7.4 (4.5–11.9)	

Table 12.7. Depression symptoms severity (PHQ-9) by Selected Subgroups

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	159	36.0 (30.6–41.9)	186	34.0 (28.9–39.5)	100	21.1 (17.0–25.8)	55	8.9 (6.6–11.9)	1.0000
Sex										
male	424	140	36.8 (31.0–43.1)	158	34.6 (28.9–40.6)	82	20.6 (16.3–25.7)	44	8.0 (5.7–11.1)	0.4791
female	76	19	31.4 (18.3–48.3)	28	30.8 (19.8–44.7)	18	23.5 (13.2–38.3)	11	14.2 (7.3–25.8)	
Age										
<25	8	4	63.2 (20.8–91.8)	2	19.9 (3.1–66.2)	2	16.9 (2.4–62.7)	0	0.0	0.3781
25-34	69	22	33.7 (21.9–48.0)	22	27.8 (17.1–41.8)	15	22.6 (13.1–36.1)	10	15.9 (8.2–28.4)	
35-44	310	94	34.1 (27.1–41.8)	119	37.0 (30.0–44.5)	59	19.8 (14.8–25.9)	38	9.2 (6.4–13.1)	

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
45+	113	39	39.4 (29.0–50.8)	43	31.7 (23.0–41.8)	24	24.4 (15.8–35.7)	7	4.6 (1.8–11.0)	
Years since the start of injecting drug use										
≤2	12	5	35.0 (11.7–68.7)	4	42.1 (14.3–76.0)	1	8.8 (0.9–49.8)	2	14.0 (2.1–55.3)	0.0906
3-5	19	10	67.6 (40.5–86.5)	8	30.0 (12.1–57.1)	1	2.4 (0.3–17.9)	0	0.0	
6-10	41	14	35.4 (20.3–54.1)	11	24.6 (13.1–41.4)	12	33.0 (18.4–51.8)	4	7.0 (2.4–19.1)	
≥11	424	130	34.4 (28.5–40.8)	162	35.2 (29.4–41.4)	85	21.4 (16.9–26.7)	47	9.0 (6.5–12.3)	
Partnership status										
live alone	241	75	37.1 (29.1–45.8)	88	30.5 (23.8–38.2)	49	22.4 (16.6–29.5)	29	9.9 (6.6–14.8)	0.5674
live with partner	259	84	35.0 (27.8–42.9)	98	37.4 (30.1–45.4)	51	19.7 (14.3–26.4)	26	7.9 (5.0–12.1)	
Current employment status										
full-time	90	37	38.2 (26.4–51.6)	28	40.0 (27.1–54.4)	15	14.8 (8.2–25.4)	10	7.0 (3.4–13.8)	0.3708
part-time or temporary	273	75	32.4 (25.9–39.7)	108	35.7 (29.1–43.0)	63	24.2 (18.5–30.9)	27	7.7 (4.9–11.8)	
unemployed	104	40	44.8 (31.2–59.2)	37	26.4 (16.3–39.7)	15	17.8 (9.9–29.9)	12	11.1 (5.7–20.4)	
disabled	15	4	43.6 (12.4–80.8)	7	34.3 (11.3–68.1)	4	22.2 (5.6–57.9)	0	0.0	
other	17	3	26.1 (6.9–62.8)	6	25.1 (9.3–52.2)	3	22.0 (6.3–54.2)	5	26.8 (9.8–55.0)	
Monthly income category										
<3K	67	14	23.2 (11.0–42.5)	30	42.2 (27.1–59.0)	14	22.2 (11.8–37.7)	9	12.4 (5.6–25.2)	0.5305
3-10K	179	60	40.6 (31.5–50.5)	71	32.2 (24.7–40.7)	32	19.7 (13.6–27.7)	16	7.4 (4.3–12.6)	
10-20K	180	60	38.9 (29.9–48.6)	62	33.2 (24.6–43.2)	36	19.1 (13.0–27.3)	22	8.8 (5.3–14.0)	
≥20K	47	19	35.0 (20.9–52.2)	13	31.4 (17.6–49.6)	12	30.6 (16.8–49.0)	3	3.1 (0.8–10.6)	
Ever incarcerated										
no	274	85	34.7 (27.8–42.2)	102	35.7 (28.9–43.1)	52	19.5 (14.3–25.9)	35	10.1 (6.9–14.6)	0.6083
yes	225	74	37.8 (29.4–47.1)	83	31.8 (24.3–40.3)	48	23.0 (16.9–30.6)	20	7.4 (4.5–11.9)	

Table 12.8. Anxiety symptoms severity (GAD-7) by Sociodemographic Characteristics

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	238	49.8 (44.2–55.5)	177	33.9 (28.8–39.5)	65	13.5 (10.1–17.8)	20	2.7 (1.6–4.5)	1.0000
Sex										
male	424	212	51.7 (45.6–57.8)	149	33.9 (28.3–40.0)	47	11.9 (8.4–16.6)	16	2.6 (1.4–4.6)	0.1297
female	76	26	39.1 (25.2–54.9)	28	34.4 (22.2–49.0)	18	22.8 (13.2–36.5)	4	3.8 (1.3–10.6)	
Age										

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
<25	8	2	22.7 (3.6–69.8)	6	77.3 (30.2–96.4)	0	0.0	0	0.0	0.0145
25-34	69	27	39.2 (26.7–53.3)	27	38.1 (25.7–52.2)	15	22.7 (13.2–36.1)	0	0.0	
35-44	310	143	49.7 (42.3–57.2)	110	32.8 (26.3–40.1)	44	14.6 (10.0–20.8)	13	2.9 (1.5–5.3)	
45+	113	66	61.8 (50.7–71.8)	34	27.8 (19.0–38.6)	6	5.7 (2.3–13.3)	7	4.7 (1.9–11.2)	
Years since the start of injecting drug use										
≤2	12	6	46.7 (17.7–78.2)	5	51.0 (20.2–81.0)	0	0.0	1	2.3 (0.2–19.3)	0.5835
3-5	19	9	47.7 (21.5–75.3)	9	49.9 (22.8–77.1)	1	2.4 (0.3–17.9)	0	0.0	
6-10	41	20	51.9 (34.6–68.7)	14	33.7 (19.7–51.3)	6	12.1 (4.7–27.7)	1	2.3 (0.3–15.6)	
≥11	424	202	50.2 (43.9–56.4)	148	32.4 (26.9–38.5)	57	14.6 (10.6–19.6)	17	2.8 (1.6–5.0)	
Partnership status										
live alone	241	112	52.0 (43.9–60.0)	87	34.0 (26.8–42.0)	33	11.2 (7.6–16.2)	9	2.9 (1.3–6.2)	0.6146
live with partner	259	126	47.7 (40.0–55.5)	90	33.9 (26.7–42.0)	32	15.7 (10.4–23.1)	11	2.6 (1.4–4.9)	
Current employment status										
full-time	90	47	52.3 (38.8–65.4)	31	37.8 (25.2–52.2)	10	9.0 (4.2–18.1)	2	0.9 (0.2–3.9)	0.7251
part-time or temporary	273	124	48.5 (41.3–55.8)	104	36.0 (29.3–43.3)	35	13.5 (9.3–19.3)	10	2.0 (1.0–3.9)	
unemployed	104	52	50.0 (36.2–63.7)	33	29.9 (18.8–44.0)	13	15.0 (7.0–29.5)	6	5.1 (1.9–12.8)	
disabled	15	8	63.1 (28.6–88.0)	3	14.7 (3.3–46.8)	4	22.2 (5.6–57.9)	0	0.0	
other	17	7	47.7 (21.8–74.8)	6	29.8 (11.0–59.3)	3	16.6 (4.6–45.2)	1	5.9 (0.7–36.3)	
Monthly income category										
<3K	67	25	39.3 (24.5–56.4)	33	51.1 (34.9–67.2)	4	3.9 (1.2–12.2)	5	5.6 (1.8–16.0)	0.0654
3-10K	179	93	57.1 (48.0–65.7)	58	28.0 (21.0–36.4)	23	13.4 (8.6–20.2)	5	1.5 (0.6–4.1)	
10-20K	180	86	48.8 (39.4–58.3)	62	33.3 (24.6–43.2)	25	15.6 (9.4–24.7)	7	2.3 (1.0–5.2)	
≥20K	47	25	53.2 (36.1–69.6)	12	31.1 (16.9–50.1)	9	14.9 (6.9–29.4)	1	0.8 (0.1–5.6)	
Ever incarcerated										
no	274	127	49.0 (41.7–56.4)	95	33.8 (26.9–41.4)	38	13.6 (9.4–19.2)	14	3.6 (1.9–6.7)	0.7322
yes	225	110	50.7 (42.0–59.4)	82	34.3 (26.7–42.7)	27	13.3 (8.2–20.9)	6	1.7 (0.7–3.9)	

Table 12.9. Anxiety symptoms severity (GAD-7) by Selected Subgroups

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										
no	320	154	50.6 (43.7–57.4)	118	34.7 (28.4–41.5)	38	12.9 (8.9–18.2)	10	1.9 (0.9–3.7)	0.3723
yes	174	82	47.5 (38.6–56.6)	58	32.8 (24.7–42.0)	25	14.8 (9.3–22.9)	9	4.8 (2.1–10.5)	
Treated with MAT currently (of all)										
no	262	125	49.5 (42.6–56.5)	90	33.8 (27.5–40.8)	37	14.1 (9.9–19.6)	10	2.6 (1.3–4.9)	0.7212
yes	231	110	50.8 (43.4–58.3)	85	34.9 (28.2–42.3)	26	10.7 (6.8–16.5)	10	3.5 (1.9–6.6)	
HIV test result										
positive	102	52	54.9 (43.1–66.1)	34	29.4 (20.2–40.7)	14	14.8 (8.4–24.9)	2	0.9 (0.2–4.2)	0.4531
negative	398	186	48.7 (42.4–55.1)	143	34.9 (29.0–41.3)	51	13.2 (9.4–18.2)	18	3.1 (1.8–5.3)	
Past 30 days injecting 4 categories										
opioids	445	216	50.7 (44.7–56.7)	162	34.6 (29.1–40.5)	51	12.1 (8.6–16.8)	16	2.6 (1.4–4.6)	0.0321
stimulants	20	9	56.2 (30.7–78.8)	5	22.3 (7.4–50.7)	6	21.6 (7.8–47.1)	0	0.0	
opi+stimul	27	10	43.5 (23.5–65.9)	5	15.6 (5.4–37.5)	8	32.0 (15.5–54.6)	4	8.9 (2.9–24.1)	
other	8	3	22.5 (3.7–68.6)	5	77.5 (31.4–96.3)	0	0.0	0	0.0	
Injecting drug type of choice										
opioids	470	225	50.7 (44.9–56.6)	166	32.5 (27.3–38.1)	62	14.1 (10.4–18.7)	17	2.7 (1.6–4.7)	0.3710
stimulants	20	10	51.0 (26.5–75.0)	6	40.2 (18.0–67.2)	1	4.3 (0.5–28.3)	3	4.5 (1.2–15.4)	
other	7	2	15.8 (1.9–64.5)	3	66.0 (18.2–94.5)	2	18.2 (2.1–69.2)	0	0.0	

13. Detention and Incarceration

Table 13.1. Police Detention and Incarceration Experience

	n	%	CI
Detained by police in 2022 for			
drug use	60	10.1	(7.5–13.4)
drug dealing	7	1.6	(0.7–3.5)
drug storing	29	6.0	(3.6–9.7)
Detained by police in 2023 for			
drug use	48	8.0	(5.7–11.0)
drug dealing	3	0.5	(0.2–1.6)
drug storing	22	5.0	(2.9–8.8)
Stopped, detained, or arrested by police ever			
yes	363	72.6	(67.5–77.1)
Ever incarcerated			
yes	225	44.9	(39.3–50.6)
Duration of incarceration			
≤6m	27	12.2	(7.8–18.6)

	n	%	CI
6m-2y	50	22.7	(16.2–30.8)
2-4y	68	31.6	(23.6–40.8)
4y+	75	33.5	(25.8–42.2)
Time since last incarceration			
≤1y	13	6.6	(3.5–12.1)
1-3y	31	12.2	(8.1–18.1)
3-5y	30	12.0	(7.8–18.2)
5-10y	59	24.1	(18.0–31.5)
10y+	88	45.0	(36.2–54.1)
Used injecting drugs during incarceration			
yes	130	50.2	(41.5–59.0)



Figure 13.1. Incarceration Lifetime Experience (%)

14. Negative experience

Table 14.1. Negative experience

	n	%	CI
Felt excluded from family activities due to drug use			
no	290	61.9	(56.4–67.1)
yes, in the past 6m	92	17.0	(13.4–21.3)
yes, but 6m+ ago	113	21.1	(17.1–25.8)
Was scolded because of drug use			
no	200	45.1	(39.5–50.9)
yes, in the past 6m	136	24.5	(20.0–29.6)
yes, but 6m+ ago	158	30.4	(25.6–35.7)
Was blackmailed for drug use			
no	369	76.4	(71.4–80.7)
yes, in the past 6m	51	10.7	(7.5–15.0)
yes, but 6m+ ago	76	13.0	(10.0–16.6)
Negative experience in the past 6 months (GAM 6.5)			
no	338	70.0	(64.4–75.0)
yes	154	30.0	(25.0–35.6)
Ever experienced physical violence			
no	336	70.2	(65.1–75.0)

		n	%	CI
	yes	160	29.8	(25.0–34.9)
Experienced physical violence in the past 12 months (of those who had ever)				
	no	67	45.0	(35.6–54.7)
	yes	93	55.0	(45.3–64.4)
Witnessed physical violence in the past 12 months				
	no	333	67.3	(61.8–72.4)
	yes	161	32.7	(27.6–38.2)



Figure 14.1. Negative Experience Related to Drug Use in the past 6 Months or Physical Violence in the past 12 months (%)

Table 14.2. Negative Experience Related to Drug Use by Sociodemographic Characteristics

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total								
All	492	154	30.0 (25.0–35.6)	1.0000	160	93	55.0 (45.3–64.4)	1.0000
Sex								
male	418	126	29.8 (24.3–36.0)	0.8636	132	78	56.6 (46.5–66.2)	0.5782
female	74	28	31.1 (19.5–45.6)		28	15	48.6 (24.4–73.5)	
Age								
<25	8	5	71.8 (27.2–94.5)	0.0019	2	2	100.0	0.3359
25-34	68	27	40.1 (27.3–54.5)		22	13	55.1 (31.0–77.0)	
35-44	304	97	29.7 (23.3–37.1)		103	62	58.5 (45.5–70.5)	
45+	112	25	17.2 (10.9–26.3)		33	16	41.7 (24.5–61.2)	
Years since the start of injecting drug use								
≤2	12	5	39.0 (12.7–73.8)	0.0409	2	2	100.0	0.3102

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
3-5	18	7	57.1 (28.9–81.4)		5	3	73.3 (28.0–95.1)	
6-10	41	18	39.4 (24.2–57.0)		14	9	65.8 (37.3–86.1)	
≥11	418	122	26.4 (21.2–32.4)		139	79	51.7 (41.1–62.1)	
Partnership status								
live alone	235	78	32.0 (24.6–40.5)	0.4660	75	45	54.8 (40.4–68.4)	0.9588
live with partner	257	76	28.1 (21.5–35.7)		85	48	55.3 (42.2–67.7)	
Current employment status								
full-time	89	24	25.4 (15.5–38.7)	0.2388	23	10	32.2 (15.2–55.7)	0.4083
part-time or temporary	269	85	28.1 (22.2–34.9)		93	58	60.9 (48.6–72.0)	
unemployed	102	34	38.3 (24.9–53.7)		30	16	51.5 (31.6–70.9)	
disabled	15	4	14.1 (3.3–44.0)		6	4	44.2 (7.1–89.1)	
other	16	6	45.4 (19.3–74.3)		7	4	57.0 (18.9–88.3)	
Monthly income category								
<3K	65	22	24.6 (14.1–39.3)	0.8384	20	10	38.1 (15.2–68.0)	0.2655
3-10K	177	53	31.8 (23.3–41.8)		56	36	67.0 (51.3–79.7)	
10-20K	177	60	30.1 (21.9–39.7)		63	36	50.3 (35.9–64.6)	
≥20K	47	10	27.3 (14.2–45.9)		15	8	57.0 (27.6–82.2)	
Ever incarcerated								
no	267	88	32.2 (25.5–39.7)	0.4018	77	44	56.5 (42.9–69.1)	0.7722
yes	224	66	27.5 (20.2–36.3)		83	49	53.6 (39.7–67.0)	

Table 14.3. Negative Experience Related to Drug Use by Selected Subgroups

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	316	94	28.1 (22.2–35.0)	0.2525	100	59	53.0 (41.2–64.5)	0.5028
yes	171	57	34.5 (26.1–44.0)		57	32	59.7 (43.6–73.9)	
Treated with MAT currently (of all)								
no	256	69	28.8 (22.6–35.9)	0.2984	85	51	55.6 (43.4–67.1)	0.8771
yes	229	83	33.9 (27.3–41.3)		71	40	54.1 (40.5–67.2)	
HIV test result								

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
positive	101	32	28.5 (19.3–39.9)	0.7638	29	11	37.5 (19.8–59.4)	0.0863
negative	391	122	30.3 (24.6–36.8)		131	82	58.4 (47.4–68.7)	
Past 30 days injecting 4 categories								
opioids	440	134	30.0 (24.5–36.1)	0.6457	140	81	54.1 (43.6–64.2)	0.2817
stimulants	18	7	28.8 (11.4–55.9)		6	3	35.8 (7.6–79.0)	
opi+stimul	27	11	38.3 (20.0–60.6)		11	7	77.5 (45.7–93.4)	
other	7	2	14.0 (1.5–64.0)		3	2	79.4 (15.3–98.8)	
Injecting drug type of choice								
opioids	464	147	31.1 (25.8–36.9)	0.4060	151	88	55.2 (45.2–64.8)	
stimulants	20	4	17.0 (4.9–44.8)		7	3	46.8 (13.1–83.7)	
other	7	2	20.7 (2.6–72.3)		0	0	0.0	

15. The Impact of the Full-scale War

Table 15.1. Migration Since February 2022

	n	%	CI
Changed place of residence since Feb 2022			
yes, because of the war	56	12.3	(9.1–16.4)
yes, for other reasons	24	5.5	(3.3–9.2)
no	418	82.2	(77.4–86.1)
Where migrated since Feb 2022			
unknown	2	4.5	(1.1–17.4)
other country	2	1.3	(0.3–5.2)
other oblast	34	66.0	(49.8–79.1)
other city	8	19.2	(9.0–36.4)
other district	2	3.1	(0.6–13.5)
other house	5	5.9	(2.2–15.2)
Where lived before Feb 2022 (if changed residence)			
same oblast	40	55.5	(41.9–68.4)
other oblast	35	44.5	(31.6–58.1)
other country	0	0.0	



Figure 15.1. Change of Residence Since February 2022 (%)



Figure 15.2. Migration Destination by Survey Site (%)



Figure 15.3. Residence Before February 2022 (%)



Figure 15.4. Changes Since February 2022 (%)

City-level Results: Lviv



Figure A. RDS recruitment tree in Lviv

1. Sociodemographic Information

Table 1.1. Sociodemographic Characteristics

	n	Mean	CI	Median	IQR
Age, years	500	39.3	(38.5–40.1)	39	(34–44)
Age of first non-injecting drug use	483	16.3	(16.0–16.6)	16	(15–18)
Years since the start of non-injecting drug use	483	22.9	(22.1–23.8)	23	(17–29)
Age of first injecting drug use	500	21.0	(20.5–21.5)	19	(18–23)
Years since the start of injecting drug use	500	18.2	(17.3–19.1)	18	(11–24)
Personal monthly income, UAH	487	12,495.0	(10898.6–14091.5)	10,000	(7000–15000)

Table 1.2. Descriptive Statistics for Sociodemographics

	Site	n	%	CI
Sex				
male	Lviv	473	95.1	(92.8–96.7)
female	Lviv	27	4.9	(3.3–7.2)
Age				
<25	Lviv	17	3.6	(2.1–5.9)
25-34	Lviv	115	24.6	(20.5–29.1)
35-44	Lviv	243	47.5	(42.8–52.2)
45+	Lviv	125	24.4	(20.6–28.6)
Family status				
married or living together	Lviv	69	14.2	(11.2–17.8)
married but have another partner	Lviv	11	2.7	(1.4–4.9)
not married but have a partner	Lviv	81	15.5	(12.5–19.2)
married but not living together	Lviv	52	10.6	(8.0–13.9)
not married and do not have a partner	Lviv	287	57.0	(52.3–61.6)
Partnership status				
live alone	Lviv	339	67.6	(63.1–71.8)
live with partner	Lviv	161	32.4	(28.2–36.9)
Education				
incompl. high school	Lviv	91	18.9	(15.5–22.9)
high school	Lviv	113	21.8	(18.3–25.8)
>high school	Lviv	296	59.3	(54.6–63.8)
Current occupation				
school student	Lviv	0	0.0	
college/uni student	Lviv	2	0.4	(0.1–1.8)
permanent job	Lviv	105	22.8	(18.8–27.3)
sporadic jobs	Lviv	309	60.2	(55.5–64.8)
unemployed	Lviv	39	7.6	(5.5–10.5)
housewife	Lviv	7	1.3	(0.6–2.7)
disabled	Lviv	32	6.4	(4.5–9.1)
military	Lviv	2	0.4	(0.1–1.5)
other	Lviv	4	0.9	(0.3–2.6)
Homelessness				
never	Lviv	454	90.9	(87.8–93.3)
yes, 12m+ ago	Lviv	46	9.1	(6.7–12.2)
yes, in the past 12m	Lviv	0	0.0	
Homeless in 12 months (of those ever)				
no	Lviv	46	100.0	
yes	Lviv	0	0.0	
Monthly income category				
<3K	Lviv	27	6.1	(4.1–9.0)
3-10K	Lviv	191	37.8	(33.3–42.4)
10-20K	Lviv	213	43.2	(38.5–48.0)

	Site	n	%	CI
≥20K	Lviv	56	13.0	(10.0–16.8)
Monthly income relative to 2023 subsistence minimum				
<2684	Lviv	27	6.1	(4.1–9.0)
≥2684	Lviv	460	93.9	(91.0–95.9)
Years since the start of injecting drug use				
≤2	Lviv	14	3.1	(1.8–5.5)
3-5	Lviv	31	7.2	(4.7–10.9)
6-10	Lviv	52	10.0	(7.6–13.0)
≥11	Lviv	403	79.7	(75.4–83.5)

Table 1.3. Accommodation in the past 12 months

	Site	n	%	CI
own place	Lviv	275	56.5	(51.8–61.0)
friends or relatives	Lviv	215	42.2	(37.7–46.9)
renting	Lviv	32	6.3	(4.4–8.9)
varying	Lviv	8	1.5	(0.7–3.0)
on the street (homeless)	Lviv	0	0.0	
in a refugee shelter	Lviv	1	0.2	(0.0–1.6)



Figure 1.1. Distribution of Age by Sex (%)



Figure 1.2. Trend in Sex Distribution by Survey Round (%)



Figure 1.3. Trend in Age Groups by Survey Round (%)

2. Drug Use



Figure 2.1. Injecting Drug Use in the Past 12 Months and 30 Days (%)



Figure 2.2. Non-injecting Drug Use in the Past 12 Months (%)



Figure 2.3. Trends in Injecting Drugs Types in the Past 30 Days by Survey Round (%)



Figure 2.4. Trends in Injecting Opioids in the Past 30 Days by Survey Round (%)



Figure 2.5. Trends in Injecting Stimulants in the Past 30 Days by Survey Round (%)



Figure 2.6. Trends in Injecting Other Drugs in the Past 30 Days by Survey Round (%)



Figure 2.7. Injecting Drug Preference (%)

Table 2.1. Types of Injecting Drugs in the Past 30 Days by Sociodemographic Characteristics

			Past 30 days injecting 4 categories					
		N	opioids		stimulants		opi+stimul	
			n	% (CI)	n	% (CI)	n	% (CI)
Total								
	All	500	383	76.5 (72.3–80.2)	46	9.9 (7.3–13.2)	71	13.7 (10.8–17.1)
Sex								
	male	473	365	77.0 (72.7–80.9)	44	9.8 (7.2–13.2)	64	13.2 (10.3–16.7)
	female	27	18	66.1 (44.8–82.5)	2	10.4 (2.5–34.9)	7	23.4 (10.7–43.7)
Age								
	<25	17	7	45.9 (21.4–72.5)	6	35.7 (14.6–64.2)	4	18.5 (6.0–44.6)

	N	Past 30 days injecting 4 categories					
		opioids		stimulants		opi+stimul	
		n	% (CI)	n	% (CI)	n	% (CI)
25-34	115	79	69.1 (59.1–77.6)	18	17.0 (10.5–26.3)	18	13.9 (8.6–21.7)
35-44	243	193	79.2 (73.2–84.1)	15	6.0 (3.5–10.1)	35	14.8 (10.7–20.3)
45+	125	104	83.2 (75.0–89.1)	7	6.4 (2.9–13.4)	14	10.4 (6.1–17.2)
Years since the start of injecting drug use							
≤2	14	6	41.1 (16.0–71.8)	6	47.9 (20.4–76.7)	2	11.0 (2.1–41.5)
3-5	31	19	62.2 (39.9–80.3)	9	31.2 (14.9–54.0)	3	6.6 (1.9–20.3)
6-10	52	32	65.3 (51.0–77.3)	8	13.2 (6.5–25.1)	12	21.4 (12.1–35.2)
≥11	403	326	80.6 (76.1–84.4)	23	6.0 (3.9–9.1)	54	13.4 (10.3–17.4)
Partnership status							
live alone	339	258	75.5 (70.2–80.1)	33	10.7 (7.5–15.0)	48	13.8 (10.4–18.2)
live with partner	161	125	78.6 (71.2–84.5)	13	8.1 (4.6–13.9)	23	13.3 (8.7–19.7)
Current employment status							
full-time	105	86	80.8 (70.7–88.0)	8	8.9 (4.1–18.2)	11	10.3 (5.5–18.5)
part-time or temporary	309	229	73.9 (68.4–78.8)	29	9.7 (6.7–13.9)	51	16.4 (12.5–21.2)
unemployed	39	31	77.9 (59.9–89.3)	5	15.4 (6.1–34.0)	3	6.6 (2.0–19.6)
disabled	32	28	90.7 (76.2–96.7)	1	2.0 (0.3–14.2)	3	7.3 (2.2–21.7)
other	15	9	61.1 (32.3–83.9)	3	23.3 (6.8–55.9)	3	15.6 (4.1–44.5)
Monthly income category							
<3K	27	22	83.4 (63.3–93.6)	1	4.8 (0.6–29.3)	4	11.8 (4.0–29.7)
3-10K	191	135	70.8 (63.5–77.1)	22	12.0 (7.9–18.0)	34	17.2 (12.3–23.5)
10-20K	213	172	81.4 (75.2–86.3)	15	6.7 (4.0–11.2)	26	11.9 (8.0–17.3)
≥20K	56	44	74.8 (59.5–85.7)	5	12.2 (4.7–28.0)	7	13.0 (6.0–25.9)
Ever incarcerated							
no	315	238	75.7 (70.3–80.4)	37	12.2 (8.7–16.8)	40	12.1 (8.8–16.4)
yes	185	145	78.0 (70.8–83.7)	9	5.5 (2.7–10.9)	31	16.5 (11.6–23.0)

Table 2.2. Types of Injecting Drugs in the Past 30 Days by Selected Subgroups

	N	Past 30 days injecting 4 categories					
		opioids		stimulants		opi+stimul	
		n	% (CI)	n	% (CI)	n	% (CI)
Client of NGO working with PWID							

	N	Past 30 days injecting 4 categories					
		opioids		stimulants		opi+stimul	
		n	% (CI)	n	% (CI)	n	% (CI)
no	457	349	76.6 (72.2–80.5)	42	9.7 (7.0–13.1)	66	13.7 (10.8–17.3)
yes	43	34	75.0 (57.3–87.0)	4	11.9 (4.2–29.4)	5	13.1 (5.1–29.6)
Treated with MAT currently (of all)							
no	480	366	75.9 (71.6–79.8)	46	10.3 (7.6–13.8)	68	13.8 (10.9–17.4)
yes	20	17	89.5 (68.8–97.1)	0	0.0	3	10.5 (2.9–31.2)
HIV test result							
positive	60	48	78.5 (64.7–88.0)	2	5.3 (1.3–19.5)	10	16.1 (8.4–28.7)
negative	440	335	76.2 (71.7–80.2)	44	10.5 (7.7–14.1)	61	13.3 (10.3–17.0)
Injecting drug type of choice							
opioids	437	379	87.0 (83.3–90.0)	0	0.0	58	13.0 (10.0–16.7)
stimulants	61	4	7.8 (2.4–23.0)	46	77.1 (63.3–86.8)	11	15.1 (8.1–26.3)
other	2	0	0.0	0	0.0	2	100.0

Table 2.3. Injecting frequency

	Past 30 days injecting 4 categories							
	opioids		stimulants		opi+stimul		other	
	n	%	n	%	n	%	n	%
Injecting frequency: last 24 hrs								
0 times	27	6.6	7	18.4	5	6.7	0	
1 time	257	67.5	24	49.0	45	66.4	0	
2-3 times	90	23.3	14	28.8	14	18.1	0	
4+ times	9	2.5	1	3.8	7	8.8	0	
N	383		46		71		0	
Injecting frequency: last 24 hrs (among those who did)								
1 time	257	72.3	24	60.1	45	71.2	0	
2-3 times	90	25.0	14	35.3	14	19.4	0	
4+ times	9	2.7	1	4.7	7	9.4	0	
N	356		39		66		0	
Injecting frequency: last week								
0 times	1	0.2	0	0.0	0	0.0	0	
1-6 times	136	37.4	24	57.7	26	37.2	0	
every day	246	62.4	22	42.3	45	62.8	0	
N	383		46		71		0	
Injecting frequency: last 30 days								
1-9 times	32	8.4	4	7.4	2	3.3	0	
10-19 times	72	19.1	14	34.0	14	18.1	0	
20-29 times	77	21.2	9	17.9	17	25.5	0	
every day	202	51.4	19	40.7	38	53.1	0	
N	383		46		71		0	
Injecting frequency: main drug last 30 days								
0-9 times	16	4.0	2	4.6	4	5.3	0	
10-19 times	75	20.0	14	34.0	11	14.3	0	
20-29 times	76	20.7	10	20.2	21	31.9	0	

	Past 30 days injecting 4 categories							
	opioids		stimulants		opi+stimul		other	
	n	%	n	%	n	%	n	%
every day	216	55.3	20	41.2	35	48.5	0	
N	383		46		71		0	

Table 2.4. Injecting drug type of choice by Income Category

	Injecting drug type of choice					
	opioids		stimulants		other	
	n	%	n	%	n	%
Monthly income category						
<3K	25	6.0	2	7.0	0	0.0
3-10K	162	36.6	28	44.8	1	66.3
10-20K	190	44.6	22	33.5	1	33.7
≥20K	50	12.8	6	14.8	0	0.0
N	427		58		2	

Table 2.5. Sources of drugs by Drug Type of Choice

Total		Injecting drug type of choice						
All		opioids		stimulants		other		
n	%	n	%	n	%	n	%	p-value
prepare myself								
186	38.1	156	36.9	29	45.7	1	66.3	0.3140
prepared by friends								
57	11.8	50	11.6	7	13.6	0	0.0	0.8263
from a dealer								
286	56.0	263	59.2	22	34.6	1	33.7	0.0016
buy on Internet								
102	20.0	84	18.6	18	30.2	0	0.0	0.1202
from MAT program								
7	1.5	5	1.3	1	2.2	1	33.7	0.0018
other								
7	1.4	6	1.4	1	1.8	0	0.0	0.9585
N								
645		564		78		3		
from a pharmacy								
		0	0.0	0	0.0	0	0.0	



Figure 2.8. Change in the price, quality, and access of drugs by Drug Type of Choice (%)

3. Injecting Risk Behavior

Table 3.1. Prevalence of Injection Risk Practices

	n	%	CI
Used clean syringe for last injection			
yes	456	91.9	(89.2–94.1)
Source of syringe for last injection			
bought in pharmacy	403	81.5	(77.7–84.7)
got in pharmacy	0	0.0	
got from NGO	32	6.0	(4.2–8.5)
got from friend	32	6.2	(4.3–8.7)
got used from friend	1	0.2	(0.0–1.4)
used one used by myself	31	5.9	(4.1–8.4)
got pre-loaded	0	0.0	
other	1	0.2	(0.0–1.4)
Used shared syringe in the past 30 days			
yes	26	4.9	(3.3–7.2)
Used pre-filled syringe in the past 30 days			
yes	18	3.6	(2.2–5.8)
Used front-/back-loaded syringe in the past 30 days			
yes	63	12.2	(9.5–15.6)
Used shared container in the past 30 days			
yes	72	13.8	(10.9–17.2)
Used own previously used syringe in the past 30 days			
yes	228	44.4	(39.8–49.1)
Gave someone a used syringe in the past 30 days			
yes	17	3.6	(2.2–5.8)
Any inj. risk (shared syringe, pre-filled, front-/back-load, container) in the past 30 days			
yes	113	21.8	(18.2–25.8)

Table 3.2. Frequency of risky injection practices

	n	%	CI
Frequency of injecting with a syringe used by others in the past 30 days			
always	0	0.0	

	n	%	CI
often	2	7.4	(1.8–26.5)
half	4	16.5	(6.1–37.3)
sometimes	9	29.3	(15.3–48.8)
rarely	8	32.7	(16.8–54.0)
never	3	14.1	(4.5–36.1)
Frequency of injecting with others in the same place in the past 30 days			
always	35	7.5	(5.3–10.5)
often	53	10.1	(7.7–13.1)
half	49	9.9	(7.4–13.0)
sometimes	39	7.9	(5.7–10.8)
rarely	113	22.5	(18.9–26.7)
never	204	42.1	(37.5–46.9)
Number of syringes used repeatedly in the past 30 days			
1-9	142	70.3	(63.4–76.4)
10-29	56	26.5	(20.7–33.3)
30+	7	3.2	(1.5–6.7)
Number of times one syringe used repeatedly in the past 30 days			
1	2	0.9	(0.2–3.4)
2-3	161	75.2	(68.8–80.6)
4-9	31	13.8	(9.7–19.2)
10+	23	10.2	(6.7–15.2)
How the pre-filled syringe was obtained			
from dealer	6	40.6	(19.0–66.5)
from friends	9	54.3	(29.5–77.1)
from stash	1	5.1	(0.7–29.3)
Someone used one syringe for injection before front-/back-loading			
no	486	97.2	(95.1–98.4)
yes	13	2.8	(1.6–4.9)



Figure 3.1. Prevalence of Key Injection Risk Practices (%)



Figure 3.2. Trends in Key Injection Risk Practices by Survey Round (%)



Figure 3.3. With whom injected drugs in the same place (%)



Figure 3.4. With whom injected drugs in the same place by sex (%)



Figure 3.5. With whom injected drugs in the same place by age (%)

Table 3.3. Prevalence of Shared and Pre-filled Syringe Use by Sociodemographic Characteristics

		Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	498	26	4.9 (3.3–7.2)	1.0000	499	18	3.6 (2.2–5.8)	1.0000
Sex									
	male	471	25	4.9 (3.3–7.3)	0.7030	473	16	3.3 (2.0–5.5)	0.1564
	female	27	1	3.4 (0.4–22.2)		26	2	9.1 (2.1–31.5)	
Age									
	<25	17	4	16.3 (5.3–40.4)	0.0678	16	3	25.3 (7.4–58.7)	0.0001

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
25-34	114	4	3.6 (1.3–9.7)		115	3	2.4 (0.7–7.6)	
35-44	242	14	5.7 (3.3–9.7)		243	6	2.3 (1.0–5.1)	
45+	125	4	2.7 (1.0–7.3)		125	6	4.5 (2.0–9.9)	
Years since the start of injecting drug use								
≤2	14	1	4.2 (0.5–29.4)	0.8628	14	0	0.0	0.2739
3-5	31	2	3.9 (0.9–16.1)		30	2	6.5 (1.4–25.3)	
6-10	52	2	3.0 (0.7–11.7)		52	3	8.1 (2.4–23.8)	
≥11	401	21	5.2 (3.3–8.0)		403	13	2.9 (1.7–5.0)	
Partnership status								
live alone	337	13	3.6 (2.0–6.3)	0.0636	339	14	3.8 (2.2–6.5)	0.7262
live with partner	161	13	7.5 (4.3–12.7)		160	4	3.1 (1.1–8.4)	
Current employment status								
full-time	105	9	8.0 (4.1–15.0)	0.3988	105	4	4.3 (1.5–11.7)	0.6896
part-time or temporary	308	13	3.6 (2.1–6.3)		309	9	3.0 (1.5–5.7)	
unemployed	39	2	5.3 (1.1–21.6)		39	3	5.9 (1.7–17.9)	
disabled	31	2	7.0 (1.5–26.5)		32	1	2.3 (0.3–15.5)	
other	15	0	0.0		14	1	8.7 (1.0–47.1)	
Monthly income category								
<3K	27	2	7.0 (1.5–27.5)	0.8899	27	3	7.5 (2.2–23.1)	0.6215
3-10K	189	11	5.2 (2.8–9.5)		190	8	3.9 (1.9–7.8)	
10-20K	213	10	4.7 (2.5–8.8)		213	5	2.6 (1.0–6.3)	
≥20K	56	2	3.3 (0.8–12.9)		56	1	3.0 (0.4–18.9)	
Ever incarcerated								
no	314	20	5.8 (3.7–9.0)	0.1710	314	8	3.0 (1.5–6.1)	0.3632
yes	184	6	3.1 (1.3–7.0)		185	10	4.6 (2.5–8.6)	

Table 3.4. Prevalence of Shared and Pre-filled Syringe Use by Selected Subgroups

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	455	24	5.0 (3.3–7.4)	0.6907	456	14	3.2 (1.8–5.4)	0.0776

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
yes	43	2	3.7 (0.9–14.4)		43	4	8.3 (3.0–21.0)	
Treated with MAT currently (of all)								
no	478	25	4.8 (3.2–7.1)	0.7301	479	18	3.7 (2.3–6.0)	0.3899
yes	20	1	6.7 (0.8–38.3)		20	0	0.0	
HIV test result								
positive	60	4	6.2 (2.2–16.0)	0.6011	60	4	5.6 (2.0–14.7)	0.3500
negative	438	22	4.7 (3.0–7.1)		439	14	3.3 (1.9–5.7)	
Past 30 days injecting 4 categories								
opioids	382	12	3.4 (1.9–6.1)		383	11	2.7 (1.4–5.0)	
stimulants	46	5	6.6 (2.6–15.8)		45	0	0.0	
opi+stimul	70	9	11.6 (5.9–21.5)		71	7	11.1 (5.3–22.0)	
other	0	0			0	0		
Injecting drug type of choice								
opioids	435	17	4.2 (2.6–6.7)	0.1667	437	16	3.6 (2.2–6.0)	0.9667
stimulants	61	9	9.6 (4.8–18.1)		60	2	3.6 (0.8–14.3)	
other	2	0	0.0		2	0	0.0	

Table 3.5. Prevalence of Front-/back-loading and Container Sharing by Sociodemographic Characteristics

		Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	500	63	12.2 (9.5–15.6)	1.0000	499	72	13.8 (10.9–17.2)	1.0000
Sex									
	male	473	58	12.1 (9.3–15.5)	0.5938	473	62	12.5 (9.7–15.9)	0.0002
	female	27	5	15.4 (6.0–34.1)		26	10	40.0 (21.7–61.6)	
Age									
	<25	17	4	22.6 (7.0–53.0)	0.0450	16	5	37.5 (14.7–67.6)	0.0160
	25-34	115	24	18.7 (12.4–27.2)		115	24	17.5 (11.6–25.6)	
	35-44	243	23	9.9 (6.5–14.7)		243	30	12.5 (8.7–17.5)	
	45+	125	12	8.8 (4.9–15.4)		125	13	9.3 (5.2–15.9)	
Years since the start of injecting drug use									
	≤2	14	1	3.7 (0.4–27.2)	0.0134	14	3	20.3 (4.9–55.6)	0.1012

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
3-5	31	5	12.5 (4.7–29.2)		30	5	11.8 (4.4–27.8)	
6-10	52	12	25.8 (14.8–41.0)		52	13	25.3 (14.7–40.0)	
≥11	403	45	10.9 (8.1–14.5)		403	51	12.2 (9.3–15.9)	
Partnership status								
live alone	339	29	8.2 (5.6–11.7)	0.0001	339	35	9.3 (6.7–13.0)	0.0001
live with partner	161	34	20.7 (14.9–28.1)		160	37	23.1 (16.8–30.7)	
Current employment status								
full-time	105	17	16.2 (9.9–25.2)	0.4028	105	19	17.4 (11.0–26.5)	0.4564
part-time or temporary	309	33	10.9 (7.7–15.1)		309	37	11.5 (8.3–15.8)	
unemployed	39	4	8.8 (3.2–22.2)		39	7	15.4 (7.1–30.2)	
disabled	32	7	17.2 (7.8–33.8)		32	7	20.1 (9.2–38.5)	
other	15	2	7.7 (1.6–30.2)		14	2	12.8 (2.5–45.5)	
Monthly income category								
<3K	27	3	8.1 (2.4–24.3)	0.7786	27	6	15.0 (6.2–32.0)	0.9711
3-10K	191	27	13.6 (9.3–19.5)		190	28	14.6 (10.1–20.6)	
10-20K	213	25	11.6 (7.8–16.9)		213	30	13.6 (9.4–19.3)	
≥20K	56	8	14.7 (7.0–28.3)		56	7	12.3 (5.6–25.0)	
Ever incarcerated								
no	315	39	12.4 (9.0–16.8)	0.8897	314	46	14.2 (10.6–18.8)	0.6794
yes	185	24	12.0 (7.9–17.6)		185	26	12.9 (8.7–18.6)	

Table 3.6. Prevalence of Front-/back-loading and Container Sharing by Selected Subgroups

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	457	55	11.8 (9.0–15.2)	0.3166	456	67	14.2 (11.2–17.9)	0.3238
yes	43	8	17.3 (8.2–32.9)		43	5	9.2 (3.7–21.2)	
Treated with MAT currently (of all)								
no	480	59	12.0 (9.3–15.4)	0.4506	479	68	13.6 (10.7–17.1)	0.6484
yes	20	4	17.7 (5.9–42.5)		20	4	17.2 (5.7–41.8)	
HIV test result								

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
positive	60	15	24.1 (14.4–37.3)	0.0042	60	14	21.2 (12.5–33.7)	0.0775
negative	440	48	10.6 (7.9–14.0)		439	58	12.7 (9.8–16.3)	
Past 30 days injecting 4 categories								
opioids	383	39	9.7 (7.0–13.2)		383	45	11.6 (8.6–15.4)	
stimulants	46	6	12.9 (5.6–27.0)		45	8	16.8 (8.1–31.5)	
opi+stimul	71	18	26.1 (16.6–38.7)		71	19	23.7 (15.1–35.2)	
other	0	0			0	0		
Injecting drug type of choice								
opioids	437	52	11.5 (8.7–15.0)	0.0392	437	56	12.6 (9.7–16.3)	0.1436
stimulants	61	10	15.6 (8.2–27.7)		60	15	20.9 (12.3–33.3)	
other	2	1	66.3 (0.0–100.0)		2	1	33.7 (0.0–100.0)	

4. Sexual Behavior

Table 4.1. Prevalence of Sexual Practice by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had sex: ever										
yes	494	98.7	(96.9–99.4)	27	100.0		467	98.6	(96.7–99.4)	0.5912
N	500			27			473			
Had sex: in the past 12 months										
yes	397	81.4	(77.6–84.7)	24	89.8	(71.0–96.9)	373	81.0	(77.0–84.4)	0.2452
N	493			27			466			
Had sex: in the past 30 days										
yes	231	47.9	(43.1–52.6)	21	80.1	(60.2–91.4)	210	46.2	(41.3–51.1)	0.0006
N	491			27			464			
Had a sex partner in the past 30 days: regular										
yes	171	71.6	(64.3–77.8)	20	94.2	(66.2–99.3)	151	69.5	(61.9–76.2)	0.0304
N	233			21			212			
Had a sex partner in the past 30 days: casual										
yes	74	33.5	(26.9–40.7)	2	10.7	(2.5–36.0)	72	35.5	(28.6–43.2)	0.0314
N	233			21			212			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	5	2.5	(1.0–6.0)	0	0.0		5	2.8	(1.1–6.5)	0.4887
N	233			21			212			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes	2	0.7	(0.2–3.1)	2	8.8	(1.9–32.5)	0	0.0		0.0000
N	233			21			212			
Used condom during last sex: if ever had sex										
yes	169	35.4	(30.9–40.2)	8	30.3	(14.8–52.2)	161	35.7	(31.0–40.6)	0.5979
N	484			26			458			
Used condom during last sex: if had sex in 12m										

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
yes	147	37.9	(32.8–43.3)	7	29.2	(13.5–52.2)	140	38.4	(33.2–44.0)	0.3932
N	397			24			373			
Used condom during last sex: if had sex in 30d										
yes	85	38.5	(31.7–45.8)	7	32.7	(15.1–57.1)	78	39.0	(31.9–46.7)	0.5934
N	231			21			210			



Figure 4.1. Frequency of sex in the past week by Drug Types Used (%)

Table 4.2. Sex Practices by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had same-sex sexual experience										
yes	11	2.4	(1.3–4.5)	4	13.4	(4.6–32.8)	7	1.9	(0.9–4.0)	0.0004
N	493			27			466			
Provided sex services for money										
yes	7	1.4	(0.7–3.1)	5	16.9	(6.6–36.8)	2	0.6	(0.2–2.4)	0.0000
N	494			27			467			
Paid for sex ever										
yes	136	27.4	(23.4–31.7)	1	2.9	(0.4–19.9)	135	28.7	(24.5–33.2)	0.0012
N	493			27			466			
Had sex with a sex worker in the past 6 months										
yes	14	10.6	(6.3–17.3)	0	0.0		14	10.6	(6.3–17.4)	0.7338
N	136			1			135			
Type of partner with whom had last sex										
regular	254	51.4	(46.6–56.1)	23	86.1	(66.1–95.1)	231	49.5	(44.7–54.4)	0.0000
casual	225	45.8	(41.1–50.5)	2	6.9	(1.6–25.5)	223	47.8	(43.0–52.7)	
com. sex (I paid)	12	2.5	(1.4–4.4)	0	0.0		12	2.6	(1.5–4.7)	
com. sex (I was paid)	2	0.4	(0.1–1.5)	2	7.0	(1.5–27.1)	0	0.0		
N	493			27			466			
With whom last had sex										
man	27	5.0	(3.4–7.3)	27	100.0		0	0.0		
woman	466	95.0	(92.7–96.6)	0	0.0		466	100.0		

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
men and women	0	0.0		0	0.0		0	0.0		
N	493			27			466			
Type of last sex contact: vaginal										
yes	454	92.6	(89.9–94.6)	27	100.0		427	92.2	(89.3–94.3)	0.1513
N	494			27			467			
Type of last sex contact: anal										
yes	42	8.4	(6.2–11.5)	5	16.3	(6.3–36.0)	37	8.0	(5.7–11.1)	0.1330
N	494			27			467			
Type of last sex contact: oral										
yes	198	41.5	(36.9–46.3)	8	30.8	(14.9–53.1)	190	42.1	(37.3–47.0)	0.2891
N	494			27			467			

Table 4.3. Sex Partners by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had a sex partner in the past 30 days: regular										
yes	171	71.6	(64.3–77.8)	20	94.2	(66.2–99.3)	151	69.5	(61.9–76.2)	0.0304
N	233			21			212			
Had a sex partner in the past 30 days: casual										
yes	74	33.5	(26.9–40.7)	2	10.7	(2.5–36.0)	72	35.5	(28.6–43.2)	0.0314
N	233			21			212			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	5	2.5	(1.0–6.0)	0	0.0		5	2.8	(1.1–6.5)	0.4887
N	233			21			212			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes	2	0.7	(0.2–3.1)	2	8.8	(1.9–32.5)	0	0.0		0.0000
N	233			21			212			
Number of sex partners in the past 30 days: regular										
1	159	95.3	(90.2–97.9)	18	96.7	(77.7–99.6)	141	95.2	(89.4–97.9)	
2-4	7	4.7	(2.1–9.8)	1	3.3	(0.4–22.3)	6	4.8	(2.1–10.6)	
5+	0	0.0		0	0.0		0	0.0		
N	166			19			147			
Number of sex partners in the past 30 days: casual										
1	27	35.7	(24.6–48.6)	0	0.0		27	36.7	(25.3–49.9)	0.4427
2-4	36	51.7	(38.5–64.7)	2	100.0		34	50.4	(37.0–63.7)	
5+	9	12.6	(6.0–24.5)	0	0.0		9	12.9	(6.2–25.1)	
N	72			2			70			
Number of sex partners in the past 30 days: commercial (buying - I paid)										
1	3	57.2	(18.1–89.0)	0	0.0		3	57.2	(18.1–89.0)	
2-4	2	42.8	(11.0–81.9)	0	0.0		2	42.8	(11.0–81.9)	
5+	0	0.0		0	0.0		0	0.0		
N	5			0			5			
Number of sex partners in the past 30 days: total										
1	165	70.8	(63.4–77.2)	17	85.7	(61.1–95.8)	148	69.4	(61.6–76.3)	0.1504
2-4	48	23.1	(17.2–30.3)	1	5.1	(0.6–31.0)	47	24.7	(18.3–32.3)	
5+	13	6.2	(3.4–11.1)	2	9.2	(2.0–33.6)	11	5.9	(3.0–11.2)	
N	226			20			206			



Figure 4.2. Condom Use During Last Sexual Encounter by Type of Partner (%)



Figure 4.3. Trends in Condom Use During Last Sexual Encounter by Survey Round (%)

Table 4.4. Condom Use During Last Sexual Encounter by Sociodemographic Characteristics

			Used condom during last sex: if ever had sex				
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
Total							
	All	484	315	64.6 (59.8–69.1)	169	35.4 (30.9–40.2)	1.0000
Sex							
	male	458	297	64.3 (59.4–69.0)	161	35.7 (31.0–40.6)	0.5979
	female	26	18	69.7 (47.8–85.2)	8	30.3 (14.8–52.2)	
Age							
	<25	13	6	51.5 (22.8–79.2)	7	48.5 (20.8–77.2)	0.0024

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
25-34	114	72	60.8 (49.8–70.8)	42	39.2 (29.2–50.2)	
35-44	234	141	59.2 (52.4–65.6)	93	40.8 (34.4–47.6)	
45+	123	96	80.1 (71.9–86.4)	27	19.9 (13.6–28.1)	
Years since the start of injecting drug use						
≤2	12	8	76.6 (44.4–93.0)	4	23.4 (7.0–55.6)	0.1612
3-5	30	18	48.8 (27.3–70.7)	12	51.2 (29.3–72.7)	
6-10	50	27	56.8 (42.1–70.4)	23	43.2 (29.6–57.9)	
≥11	392	262	66.6 (61.5–71.3)	130	33.4 (28.7–38.5)	
Partnership status						
live alone	324	201	61.5 (55.5–67.2)	123	38.5 (32.8–44.5)	0.0635
live with partner	160	114	70.7 (62.7–77.7)	46	29.3 (22.3–37.3)	
Current employment status						
full-time	103	71	64.4 (52.4–74.8)	32	35.6 (25.2–47.6)	0.0442
part-time or temporary	304	199	66.5 (60.8–71.8)	105	33.5 (28.2–39.2)	
unemployed	34	25	74.2 (55.6–86.9)	9	25.8 (13.1–44.4)	
disabled	29	12	37.2 (21.0–56.9)	17	62.8 (43.1–79.0)	
other	14	8	57.0 (28.0–81.9)	6	43.0 (18.1–72.0)	
Monthly income category						
<3K	27	18	65.9 (44.0–82.6)	9	34.1 (17.4–56.0)	0.4524
3-10K	184	110	60.2 (52.6–67.3)	74	39.8 (32.7–47.4)	
10-20K	206	145	68.9 (61.1–75.8)	61	31.1 (24.2–38.9)	
≥20K	56	38	67.0 (52.2–79.1)	18	33.0 (20.9–47.8)	
Ever incarcerated						
no	307	198	64.0 (57.9–69.8)	109	36.0 (30.2–42.1)	0.7565
yes	177	117	65.5 (57.8–72.6)	60	34.5 (27.4–42.2)	

Table 4.5. Condom Use During Last Sexual Encounter by Selected Subgroups

	N	Used condom during last sex: if ever had sex				
		no		yes		
	n		% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	441	282	63.7 (58.6–68.4)	159	36.3 (31.6–41.4)	0.2097
yes	43	33	74.1 (57.1–86.1)	10	25.9 (13.9–42.9)	
Treated with MAT currently (of all)						
no	464	304	65.1 (60.2–69.7)	160	34.9 (30.3–39.8)	0.2515
yes	20	11	51.9 (28.7–74.3)	9	48.1 (25.7–71.3)	
HIV test result						
positive	57	29	50.0 (36.1–63.8)	28	50.0 (36.2–63.9)	0.0219
negative	427	286	66.6 (61.5–71.3)	141	33.4 (28.7–38.5)	
Past 30 days injecting 4 categories						
opioids	371	242	64.8 (59.3–70.0)	129	35.2 (30.0–40.7)	
stimulants	43	25	58.6 (41.8–73.6)	18	41.4 (26.4–58.2)	
opi+stimul	70	48	67.2 (54.3–78.0)	22	32.8 (22.0–45.7)	
other	0	0		0		
Injecting drug type of choice						
opioids	425	281	65.3 (60.2–70.1)	144	34.7 (29.9–39.8)	0.3811
stimulants	57	32	58.2 (43.7–71.4)	25	41.8 (28.6–56.3)	
other	2	2	100.0	0	0.0	

Table 4.6. Condom use by type of partner by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Used condom during last sex: regular partner										
yes	56	32.5	(25.5–40.3)	6	28.6	(12.1–53.7)	50	32.9	(25.5–41.3)	0.7088
N	171			20			151			
Used condom during last sex: casual partner										
yes	30	45.0	(32.1–58.6)	1	54.2	(6.1–95.6)	29	44.7	(31.6–58.6)	0.7915
N	74			2			72			
Used condom during last sex: commercial (I paid) partner										
yes	4	76.2	(26.2–96.7)	0	0.0		4	76.2	(26.2–96.7)	
N	5			0			5			
Condom use frequency: regular partner										
always	45	27.5	(20.9–35.2)	4	22.2	(7.9–48.7)	41	28.1	(21.1–36.4)	0.7493
often	7	2.8	(1.3–5.9)	2	6.4	(1.4–24.1)	5	2.4	(1.0–5.7)	
half	2	1.3	(0.3–5.4)	0	0.0		2	1.5	(0.4–6.1)	
sometimes	5	2.9	(1.2–7.2)	1	3.9	(0.5–25.3)	4	2.8	(1.0–7.6)	
rarely	6	4.2	(1.8–9.5)	2	8.7	(2.0–31.5)	4	3.7	(1.4–9.6)	
never	106	61.2	(53.3–68.7)	11	58.8	(34.9–79.1)	95	61.5	(53.0–69.4)	
N	171			20			151			
Condom use frequency: casual partner										

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
always	27	40.7	(28.0–54.8)	1	54.2	(6.1–95.6)	26	40.3	(27.4–54.8)	0.0900
often	2	2.7	(0.6–11.0)	0	0.0		2	2.8	(0.6–11.3)	
half	4	5.0	(1.8–12.8)	0	0.0		4	5.1	(1.9–13.1)	
sometimes	3	4.1	(1.3–12.1)	1	45.8	(4.4–93.9)	2	3.0	(0.7–11.2)	
rarely	6	7.7	(3.4–16.7)	0	0.0		6	7.9	(3.5–17.1)	
never	32	39.8	(28.3–52.6)	0	0.0		32	40.9	(29.0–53.9)	
N	74			2			72			



Figure 4.4. Frequency of condom use by type of partner by Sex (%)



Figure 4.5. Frequency of condom use among men during the last sexual encounter by the riskiest type of partner in the past 30 days (%)

5. HIV, HCV, and Syphilis Testing Results

Table 5.1. HIV Prevalence by Sociodemographic Characteristics

		HIV test result				
	N	positive		negative		
		n	% (CI)	n	% (CI)	p-value
Total						
All	500	60	12.4 (9.6–15.9)	440	87.6 (84.1–90.4)	1.0000
Sex						
male	473	53	11.8 (9.0–15.4)	420	88.2 (84.6–91.0)	0.0896
female	27	7	22.9 (10.5–42.8)	20	77.1 (57.2–89.5)	
Age						
<25	17	0	0.0	17	100.0	0.0745
25-34	115	10	7.1 (3.7–13.2)	105	92.9 (86.8–96.3)	
35-44	243	32	14.1 (10.0–19.6)	211	85.9 (80.4–90.0)	
45+	125	18	16.1 (10.0–25.0)	107	83.9 (75.0–90.0)	
Years since the start of injecting drug use						
≤2	14	0	0.0	14	100.0	0.4392
3-5	31	3	8.6 (2.4–26.0)	28	91.4 (74.0–97.6)	
6-10	52	6	11.2 (4.9–23.6)	46	88.8 (76.4–95.1)	
≥11	403	51	13.4 (10.1–17.5)	352	86.6 (82.5–89.9)	
Partnership status						
live alone	339	41	12.4 (9.0–16.7)	298	87.6 (83.3–91.0)	0.9710
live with partner	161	19	12.5 (7.9–19.2)	142	87.5 (80.8–92.1)	
Current employment status						
full-time	105	5	4.2 (1.7–10.0)	100	95.8 (90.0–98.3)	0.0000
part-time or temporary	309	34	12.2 (8.6–16.9)	275	87.8 (83.1–91.4)	
unemployed	39	7	17.6 (8.2–34.0)	32	82.4 (66.0–91.8)	
disabled	32	14	42.9 (25.9–61.7)	18	57.1 (38.3–74.1)	
other	15	0	0.0	15	100.0	
Monthly income category						
<3K	27	8	34.3 (16.6–57.7)	19	65.7 (42.3–83.4)	0.0082
3-10K	191	22	11.0 (7.3–16.4)	169	89.0 (83.6–92.7)	
10-20K	213	22	9.6 (6.2–14.4)	191	90.4 (85.6–93.8)	

		N	HIV test result				
			positive		negative		
			n	% (CI)	n	% (CI)	p-value
	≥20K	56	6	14.0 (6.2–28.5)	50	86.0 (71.5–93.8)	
Ever incarcerated							
	no	315	25	8.3 (5.5–12.4)	290	91.7 (87.6–94.5)	0.0006
	yes	185	35	19.9 (14.3–26.9)	150	80.1 (73.1–85.7)	

Table 5.2. HIV Prevalence by Selected Subgroups

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	457	50	11.4 (8.6–15.0)	407	88.6 (85.0–91.4)	0.0397
yes	43	10	23.0 (12.1–39.4)	33	77.0 (60.6–87.9)	
Treated with MAT currently (of all)						
no	480	55	11.9 (9.1–15.4)	425	88.1 (84.6–90.9)	0.1186
yes	20	5	23.9 (9.3–49.1)	15	76.1 (50.9–90.7)	
Past 30 days injecting 4 categories						
opioids	383	48	12.7 (9.5–16.8)	335	87.3 (83.2–90.5)	
stimulants	46	2	6.7 (1.6–23.9)	44	93.3 (76.1–98.4)	
opi+stimul	71	10	14.6 (7.7–26.1)	61	85.4 (73.9–92.3)	
other	0	0		0		
Injecting drug type of choice						
opioids	437	57	12.9 (9.9–16.5)	380	87.1 (83.5–90.1)	0.7398
stimulants	61	3	9.5 (3.0–26.4)	58	90.5 (73.6–97.0)	
other	2	0	0.0	2	100.0	



Figure 5.1. HIV Test Result (%)



Figure 5.2. Trends in HIV Prevalence by Survey Round (%)



Figure 5.3. Anti-HCV Testing Coverage In the Survey (%)



Figure 5.4. Anti-HCV Test Results (%)



Figure 5.5. Anti-HCV Test Results by Sex (%)



Figure 5.6. Trends in Anti-HCV Prevalence by Survey Round (%)



Figure 5.7. Syphilis Test Results (%)

6. HIV Prevention

Table 6.1. Being a Client of NGO by Sociodemographic Characteristics

			Client of NGO working with PWID			
	N		no		yes	
		n	% (CI)	n	% (CI)	p-value
Total						
All	500	457	91.6 (88.7–93.8)	43	8.4 (6.2–11.3)	1.0000
Sex						
male	473	433	91.8 (88.8–94.0)	40	8.2 (6.0–11.2)	0.6207
female	27	24	88.9 (67.3–96.9)	3	11.1 (3.1–32.7)	
Age						
<25	17	14	86.6 (62.0–96.2)	3	13.4 (3.8–38.0)	0.0963
25-34	115	104	91.4 (84.6–95.4)	11	8.6 (4.6–15.4)	
35-44	243	229	94.5 (90.6–96.8)	14	5.5 (3.2–9.4)	
45+	125	110	87.0 (79.1–92.2)	15	13.0 (7.8–20.9)	
Years since the start of injecting drug use						
≤2	14	14	100.0	0	0.0	0.6186
3-5	31	28	93.4 (79.7–98.1)	3	6.6 (1.9–20.3)	
6-10	52	47	89.4 (76.1–95.7)	5	10.6 (4.3–23.9)	
≥11	403	368	91.4 (88.1–93.9)	35	8.6 (6.1–11.9)	
Partnership status						
live alone	339	303	89.8 (86.0–92.7)	36	10.2 (7.3–14.0)	0.0549

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
live with partner	161	154	95.4 (90.1–97.9)	7	4.6 (2.1–9.9)	
Current employment status						
full-time	105	102	97.4 (92.1–99.2)	3	2.6 (0.8–7.9)	0.0236
part-time or temporary	309	283	91.3 (87.2–94.1)	26	8.7 (5.9–12.8)	
unemployed	39	32	82.4 (65.7–92.0)	7	17.6 (8.0–34.3)	
disabled	32	26	84.6 (68.1–93.4)	6	15.4 (6.6–31.9)	
other	15	14	93.4 (60.2–99.2)	1	6.6 (0.8–39.8)	
Monthly income category						
<3K	27	21	77.0 (55.3–90.0)	6	23.0 (10.0–44.7)	0.0186
3-10K	191	173	90.5 (85.1–94.1)	18	9.5 (5.9–14.9)	
10-20K	213	200	94.9 (91.2–97.1)	13	5.1 (2.9–8.8)	
≥20K	56	51	90.1 (77.3–96.1)	5	9.9 (3.9–22.7)	
Ever incarcerated						
no	315	291	93.0 (89.6–95.4)	24	7.0 (4.6–10.4)	0.1434
yes	185	166	89.1 (83.0–93.1)	19	10.9 (6.9–17.0)	

Table 6.2. Being a Client of NGO by Selected Subgroups

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Treated with MAT currently (of all)						
no	480	443	92.5 (89.7–94.7)	37	7.5 (5.3–10.3)	0.0012
yes	20	14	71.3 (46.1–87.9)	6	28.7 (12.1–53.9)	
HIV test result						
positive	60	50	84.5 (72.1–92.0)	10	15.5 (8.0–27.9)	0.0397
negative	440	407	92.6 (89.7–94.8)	33	7.4 (5.2–10.3)	
Past 30 days injecting 4 categories						
opioids	383	349	91.8 (88.6–94.2)	34	8.2 (5.8–11.4)	
stimulants	46	42	89.9 (74.3–96.5)	4	10.1 (3.5–25.7)	
opi+stimul	71	66	92.0 (81.0–96.9)	5	8.0 (3.1–19.0)	
other	0	0		0		
Injecting drug type of choice						

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
opioids	437	401	92.2 (89.1–94.4)	36	7.8 (5.6–10.9)	0.5187
stimulants	61	54	87.8 (75.4–94.4)	7	12.2 (5.6–24.6)	
other	2	2	100.0	0	0.0	



Figure 6.1. Injecting and Sex Risk Perception Among HIV-negative PWID (%)



Figure 6.2. Received HIV Prevention Services in the Past 12 Months and 30 days (%)



Figure 6.3. Receiving Package of Prevention Services in the Past 12 Months (%)



Figure 6.4. Trends in Receiving HIV Prevention Services in the Past 12 Months (%)



Figure 6.5. Perceived changes in access to HIV prevention since February 2022 (%)

Table 6.3. Percentage of correct responses to knowledge questions by HIV status

	Total	HIV test result		
	All %	negative %	positive %	p-value
HIV knowledge				
HIV may be avoided	91.2	90.8	94.0	0.3998
proper condom use may prevent HIV	51.4	49.8	62.7	0.0753
undetectable=untransmittable	53.3	51.8	63.3	0.1075
PEP reduces the risk of HIV	52.5	51.6	58.7	0.3213
ART should be started immediately	85.5	85.0	88.7	0.4369
ART may be postponed if one feels healthy	67.7	67.5	69.3	0.7883
ART may be stopped if one feels healthy	66.2	66.0	68.1	0.7552
HIV is transmitted through blood and sex	91.1	90.9	92.1	0.7572
HIV is transmitted via air, food, or skin	96.1	96.7	92.0	0.1111
HBV knowledge				
proper condom use may prevent HBV	91.0	91.6	86.9	0.2511
treatment should be started immediately	86.3	85.3	93.4	0.1021
treatment may be postponed if one feels healthy	67.6	67.9	65.3	0.7045
HBV is 100% transmitted from mother to child	29.2	30.4	20.3	0.0991
HBV is transmitted through blood and sex	88.3	88.3	88.3	0.9994
HBV is transmitted via air, food, or skin	92.1	92.5	89.5	0.4177
treatment may be stopped if one feels healthy	70.3	69.4	76.2	0.2952
HCV knowledge				
proper condom use may prevent HCV	2.7	2.7	3.0	0.8963
treatment should be started immediately	87.2	86.0	95.7	0.0264
treatment may be postponed if one feels healthy	68.6	68.9	66.3	0.7018
HCV is 100% transmitted from mother to child	27.7	27.8	27.0	0.8925
HCV is transmitted through blood and sex	85.8	85.7	86.7	0.8494
there is no treatment for HCV	65.6	65.3	68.2	0.6705
HCV is transmitted via air, food, or skin	62.0	62.0	62.1	0.9801
treatment may be stopped if one feels healthy	91.3	91.8	88.4	0.4103

7. HIV Testing

Table 7.1. HIV Testing Knowledge and Uptake

		n	%	CI
Know where to get HIV test				
	yes	372	75.6	(71.4–79.3)
Tested for HIV ever				
	yes	351	69.7	(65.2–73.9)
Tested for HIV in the past 12 months				
	yes	89	25.4	(20.8–30.6)
Tested for HIV in the past 6 months				
	yes	46	12.9	(9.6–17.1)
Received the result of HIV test (of those tested)				
	yes	347	99.0	(97.4–99.6)
Willing to disclose HIV test result (of those who got result)				
	yes	322	93.8	(90.6–96.0)
Self-reported HIV status (of all tested)				
	positive	29	8.4	(5.8–12.1)
	negative	294	91.6	(87.9–94.2)
HIV testing and status awareness (GAM)				
	yes	96	29.7	(24.6–35.3)
Ever did a HIV self-test				
	yes	0	0.0	
Regular sex partner tested for HIV				
	yes	92	60.0	(51.9–67.6)
Regular sex partner HIV test result				
	positive	3	3.1	(0.9–9.7)
	negative	82	91.2	(83.9–95.4)
	cannot disclose	7	5.7	(2.6–11.8)



Figure 7.1. HIV Testing Uptake (%)



Figure 7.2. Testing for HIV, HCV, syphilis since February 2022 (%)



Figure 7.3. HIV Testing Since February 2022 (%)

Table 7.2. Testing for HIV in the past 12 months (among all) by Sociodemographic Characteristics

			Tested for HIV in the past 12 months			
		N	no		yes	
			n	% (CI)	n	% (CI)	p-value
Total							
	All	341	252	74.6 (69.4–79.2)	89	25.4 (20.8–30.6)	1.0000
Sex							
	male	317	237	75.4 (70.1–80.1)	80	24.6 (19.9–29.9)	0.1976
	female	24	15	62.7 (39.9–81.0)	9	37.3 (19.0–60.1)	
Age							
	<25	6	3	45.8 (11.6–84.6)	3	54.2 (15.4–88.4)	0.0081

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
25-34	66	42	66.1 (52.4–77.5)	24	33.9 (22.5–47.6)	
35-44	181	133	72.7 (65.3–79.1)	48	27.3 (20.9–34.7)	
45+	88	74	87.6 (79.5–92.7)	14	12.4 (7.3–20.5)	
Years since the start of injecting drug use						
≤2	10	5	46.1 (15.8–79.6)	5	53.9 (20.4–84.2)	0.0946
3-5	16	9	67.9 (38.0–87.9)	7	32.1 (12.1–62.0)	
6-10	31	19	63.3 (44.4–78.7)	12	36.7 (21.3–55.6)	
≥11	284	219	77.4 (71.8–82.1)	65	22.6 (17.9–28.2)	
Partnership status						
live alone	226	169	76.3 (70.0–81.6)	57	23.7 (18.4–30.0)	0.3472
live with partner	115	83	71.3 (61.5–79.4)	32	28.7 (20.6–38.5)	
Current employment status						
full-time	66	52	79.8 (67.5–88.3)	14	20.2 (11.7–32.5)	0.0605
part-time or temporary	215	164	77.0 (70.5–82.4)	51	23.0 (17.6–29.5)	
unemployed	29	19	63.7 (42.9–80.4)	10	36.3 (19.6–57.1)	
disabled	22	11	50.5 (28.9–71.9)	11	49.5 (28.1–71.1)	
other	9	6	71.3 (33.5–92.5)	3	28.7 (7.5–66.5)	
Monthly income category						
<3K	22	16	80.0 (58.8–91.8)	6	20.0 (8.2–41.2)	0.8472
3-10K	134	101	76.4 (68.1–83.1)	33	23.6 (16.9–31.9)	
10-20K	135	100	74.7 (66.0–81.8)	35	25.3 (18.2–34.0)	
≥20K	43	32	70.9 (54.1–83.4)	11	29.1 (16.6–45.9)	
Ever incarcerated						
no	189	148	78.7 (71.8–84.3)	41	21.3 (15.7–28.2)	0.0582
yes	152	104	69.1 (60.9–76.3)	48	30.9 (23.7–39.1)	

Table 7.3. Testing for HIV in the past 12 months (among all) by Selected Subgroups

	N	Tested for HIV in the past 12 months				
		no		yes		
	n		% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	306	232	76.9 (71.5–81.5)	74	23.1 (18.5–28.5)	0.0055
yes	35	20	53.9 (36.2–70.7)	15	46.1 (29.3–63.8)	
Treated with MAT currently (of all)						
no	322	245	77.0 (71.8–81.5)	77	23.0 (18.5–28.2)	0.0001
yes	19	7	36.3 (16.8–61.6)	12	63.7 (38.4–83.2)	
HIV test result						
positive	52	33	66.0 (51.2–78.2)	19	34.0 (21.8–48.8)	0.1392
negative	289	219	76.2 (70.6–81.0)	70	23.8 (19.0–29.4)	
Past 30 days injecting 4 categories						
opioids	266	196	74.5 (68.5–79.7)	70	25.5 (20.3–31.5)	
stimulants	18	13	72.0 (46.4–88.5)	5	28.0 (11.5–53.6)	
opi+stimul	57	43	76.0 (62.3–85.9)	14	24.0 (14.1–37.7)	
other	0	0		0		
Injecting drug type of choice						
opioids	315	233	74.6 (69.1–79.3)	82	25.4 (20.7–30.9)	0.8653
stimulants	25	18	74.3 (53.1–88.0)	7	25.7 (12.0–46.9)	
other	1	1	100.0	0	0.0	

8. HIV Treatment



Figure 8.1. HIV Status Awareness Among HIV+ (%)



Figure 8.2. HIV Treatment Cascade - Four-stage (%)



Figure 8.3. HIV Treatment Cascade - Conditional (%)



Figure 8.4. HIV Treatment Cascade - Proportions (%)



Figure 8.5. Trends in HIV Treatment Cascade (Conditional, 95-95-95) by Survey Round (%)

Table 8.1. HIV Treatment Cascade (Conditional, 95-95-95) by Sociodemographic Characteristics

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Total										
All	60	40.0 (28.0–53.3)	1.0000	27	89.7 (71.4–96.8)	1.0000	24	16	69.5 (48.8–84.5)	1.0000
Sex										
male	53	38.4 (26.0–52.6)	0.4032	23	90.9 (69.5–97.8)	0.5296	21	13	65.6 (43.5–82.6)	0.2309
female	7	55.2 (20.1–85.8)		4	81.0 (28.4–97.9)		3	3	100.0	
Age										
<25	0	0.0		0	0.0		0	0	0.0	
25-34	10	71.1 (37.3–91.0)		7	77.1 (38.2–94.8)		5	5	100.0	
35-44	32	38.2 (23.0–56.1)		14	100.0		14	8	60.7 (34.3–82.0)	
45+	18	29.2 (12.5–54.3)		6	80.1 (31.1–97.3)		5	3	62.4 (19.8–91.8)	
Years since the start of injecting drug use										
≤2	0	0.0		0	0.0		0	0	0.0	
3-5	3	26.9 (2.8–82.2)		1	0.0		0	0	0.0	
6-10	6	38.5 (10.7–76.5)		3	72.5 (18.3–96.9)		2	2	100.0	
≥11	51	40.9 (27.8–55.4)		23	94.8 (70.7–99.3)		22	14	67.2 (45.6–83.4)	
Partnership status										
live alone	41	31.6 (19.1–47.6)	0.0765	15	85.1 (55.5–96.3)	0.3426	13	8	64.3 (36.1–85.2)	0.5792
live with partner	19	57.1 (33.2–78.1)		12	94.9 (70.1–99.3)		11	8	74.8 (43.5–92.0)	
Current employment status										
full-time	5	15.1 (1.9–62.1)		1	100.0		1	0	0.0	
part-time or temporary	34	36.1 (21.5–53.9)		14	85.1 (55.3–96.4)		12	10	84.1 (53.1–96.1)	
unemployed	7	49.9 (17.1–82.8)		4	82.4 (31.1–98.0)		3	2	70.0 (16.3–96.5)	

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
disabled	14	54.0 (26.7–79.1)		8	100.0		8	4	54.0 (20.8–84.0)	
other	0	0.0		0	0.0		0	0	0.0	
Monthly income category										
<3K	8	36.0 (10.7–72.5)	0.9928	4	100.0	0.7094	4	3	77.4 (23.9–97.4)	0.4364
3-10K	22	39.1 (21.1–60.6)		9	85.6 (42.1–98.0)		8	4	49.4 (19.1–80.2)	
10-20K	22	41.6 (22.8–63.1)		10	93.0 (62.1–99.1)		9	6	67.6 (33.3–89.7)	
≥20K	6	41.5 (11.8–79.0)		3	77.5 (22.8–97.6)		2	2	100.0	
Ever incarcerated										
no	25	31.3 (16.2–51.9)	0.2473	9	83.3 (50.0–96.1)	0.4446	7	4	59.9 (24.3–87.4)	0.4942
yes	35	46.7 (30.2–63.9)		18	93.0 (63.3–99.0)		17	12	74.0 (49.3–89.3)	

Table 8.2. HIV Treatment Cascade (Conditional, 95-95-95) by Selected Subgroups

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID										
no	50	37.5 (24.9–52.0)	0.3798	21	89.9 (67.0–97.5)	0.9145	19	12	67.1 (43.8–84.2)	0.6201
yes	10	53.5 (22.3–82.2)		6	88.6 (45.6–98.6)		5	4	78.9 (27.7–97.3)	
Treated with MAT currently (of all)										
no	55	38.1 (25.9–51.9)	0.3208	24	88.2 (68.0–96.3)	0.5102	21	14	69.6 (47.3–85.3)	0.9837
yes	5	61.2 (18.3–91.8)		3	100.0		3	2	69.0 (14.1–96.8)	
HIV test result										
positive	60	40.0 (27.8–53.5)		27	89.7 (70.9–96.9)		24	16	69.5 (48.4–84.7)	
negative	0	0.0		0	0.0		0	0	0.0	
Past 30 days injecting 4 categories										
opioids	48	47.7 (33.3–62.5)		25	92.5 (73.0–98.3)		23	15	68.5 (47.3–84.0)	
stimulants	2	0.0		0	0.0		0	0	0.0	
opi+stimul	10	15.5 (3.6–47.7)		2	46.7 (4.9–93.6)		1	1	100.0	
other	0			0			0	0		

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Injecting drug type of choice										
opioids	57	44.3 (31.6–57.8)		27	89.7 (71.4–96.8)		24	16	69.5 (48.8–84.5)	
stimulants	3	0.0		0	0.0		0	0	0.0	
other	0	0.0		0	0.0		0	0	0.0	

Table 8.3. ART adherence (among those on ART)

	n	%	CI
When did you last miss ART dose			
last week	1	6.2	(0.9–33.2)
1-2 weeks ago	0	0.0	
3-4 weeks ago	0	0.0	
1-3 months ago	3	14.7	(4.7–37.2)
never	20	79.1	(55.8–91.9)
What was the reason for missing the last ART dose			
forgot	1	23.7	(3.0–75.4)
did not have meds	3	76.3	(24.6–97.0)
was under influence	0	0.0	
did not want others to see	0	0.0	
other	0	0.0	
Reasons for not taking ART			
not sure it is needed	0	0.0	
no time to visit clinic	2	19.6	(4.5–55.5)
no motivation to visit clinic	3	27.3	(8.0–61.9)
missed a visit, hard to come back	1	8.6	(1.1–43.9)
too sick to visit clinic	1	9.9	(1.3–48.2)
drug use	1	21.6	(3.1–70.0)
side effects or complications	0	0.0	
no understanding of how to take it	1	8.6	(1.1–43.9)
lost or sold all ARVs	0	0.0	
alcohol use	0	0.0	
waited too long and left	0	0.0	
Time on ART			
≤3m	1	12.7	(1.7–54.8)
4-24m	2	29.7	(7.4–69.2)
25-60m	2	16.4	(3.7–49.8)
5y+	3	41.1	(13.5–75.8)

9. PrEP



Figure 9.1. PrEP Uptake in the Past 12 Months (%)



Figure 9.2. Change in PrEP Awareness and Uptake from 2020 to 2023 (%)



Figure 9.3. Change in PrEP Uptake from 2020 to 2023 (%)

Table 9.1. PrEP Awareness by Sociodemographic Characteristics

		PrEP uptake in the past 12 months					
	N	use now		never used		not aware	
		n	% (CI)	n	% (CI)	n	% (CI)
Total							
All	500	1	0.1 (0.0–0.8)	45	9.1 (6.8–12.1)	454	90.8 (87.8–93.1)
Sex							
male	473	1	0.1 (0.0–0.9)	43	9.2 (6.8–12.3)	429	90.7 (87.6–93.1)
female	27	0	0.0	2	7.6 (1.7–28.0)	25	92.4 (72.0–98.3)
Age							
<25	17	0	0.0	2	8.7 (1.9–32.6)	15	91.3 (67.4–98.1)
25-34	115	0	0.0	13	11.6 (6.6–19.7)	102	88.4 (80.3–93.4)
35-44	243	1	0.2 (0.0–1.8)	18	7.0 (4.4–11.1)	224	92.7 (88.6–95.4)
45+	125	0	0.0	12	10.6 (6.0–18.0)	113	89.4 (82.0–94.0)
Years since the start of injecting drug use							
≤2	14	0	0.0	1	12.0 (1.4–56.6)	13	88.0 (43.4–98.6)
3-5	31	0	0.0	3	7.5 (2.2–22.9)	28	92.5 (77.1–97.8)
6-10	52	0	0.0	4	7.0 (2.5–18.1)	48	93.0 (81.9–97.5)
≥11	403	1	0.1 (0.0–1.1)	37	9.4 (6.8–12.8)	365	90.5 (87.0–93.1)
Partnership status							
live alone	339	1	0.2 (0.0–1.2)	21	6.0 (3.9–9.1)	317	93.8 (90.7–96.0)
live with partner	161	0	0.0	24	15.6 (10.4–22.6)	137	84.4 (77.4–89.6)
Current employment status							
full-time	105	0	0.0	15	14.6 (8.6–23.6)	90	85.4 (76.4–91.4)
part-time or temporary	309	1	0.2 (0.0–1.4)	24	7.5 (5.0–11.1)	284	92.3 (88.7–94.8)

		PrEP uptake in the past 12 months					
	N	use now		never used		not aware	
		n	% (CI)	n	% (CI)	n	% (CI)
unemployed	39	0	0.0	3	8.2 (2.5–24.1)	36	91.8 (75.9–97.5)
disabled	32	0	0.0	1	3.0 (0.4–19.8)	31	97.0 (80.2–99.6)
other	15	0	0.0	2	14.5 (3.1–46.8)	13	85.5 (53.2–96.9)
Monthly income category							
<3K	27	0	0.0	2	5.7 (1.3–22.0)	25	94.3 (78.0–98.7)
3-10K	191	0	0.0	9	4.9 (2.5–9.4)	182	95.1 (90.6–97.5)
10-20K	213	1	0.3 (0.0–2.0)	27	12.4 (8.5–17.9)	185	87.3 (81.8–91.3)
≥20K	56	0	0.0	6	11.7 (5.1–24.6)	50	88.3 (75.4–94.9)
Ever incarcerated							
no	315	0	0.0	33	10.2 (7.2–14.3)	282	89.8 (85.7–92.8)
yes	185	1	0.3 (0.0–2.4)	12	7.0 (3.9–12.2)	172	92.7 (87.5–95.8)

Table 9.2. PrEP Current Use by Sociodemographic Characteristics

		PrEP uptake in the past 12 months							
	N	use now		used in the past	never used		not aware	
		n	% (CI)	% (CI)	n	% (CI)	n	% (CI)
Client of NGO working with PWID								
no	457	0	0.0	0.0	35	7.8 (5.5–10.8)	422	92.2 (89.2–94.5)
yes	43	1	1.4 (0.2–10.0)	0.0	10	23.4 (12.6–39.2)	32	75.2 (59.4–86.3)
Treated with MAT currently (of all)								
no	480	1	0.1 (0.0–0.9)	0.0	42	8.7 (6.4–11.7)	437	91.2 (88.1–93.5)
yes	20	0	0.0	0.0	3	17.9 (5.4–45.5)	17	82.1 (54.5–94.6)
HIV test result								
positive	60	1	1.0 (0.1–6.8)	0.0	4	7.5 (2.8–18.9)	55	91.5 (80.3–96.6)
negative	440	0	0.0	0.0	41	9.3 (6.8–12.6)	399	90.7 (87.4–93.2)
Past 30 days injecting 4 categories								
opioids	383	1	0.2 (0.0–1.1)	0.0	38	9.7 (7.1–13.3)	344	90.1 (86.5–92.8)
stimulants	46	0	0.0	0.0	3	8.1 (2.4–23.7)	43	91.9 (76.3–97.6)
opi+stimul	71	0	0.0	0.0	4	6.1 (2.2–15.9)	67	93.9 (84.1–97.8)
other	0	0			0		0	
Injecting drug type of choice								
opioids	437	1	0.1 (0.0–1.0)	0.0	40	9.1 (6.6–12.3)	396	90.8 (87.5–93.2)
stimulants	61	0	0.0	0.0	5	9.3 (3.7–21.5)	56	90.7 (78.5–96.3)
other	2	0	0.0	0.0	0	0.0	2	100.0

Table 9.3. PrEP Awareness and Uptake

	n	%	CI
PrEP uptake in the past 12 months			
use now	1	0.1	(0.0–0.8)
used in the past	0	0.0	
never used	45	9.1	(6.8–12.1)
not aware	454	90.8	(87.8–93.1)
Aware of PrEP			
no	454	90.8	(87.8–93.1)
yes	46	9.2	(6.9–12.2)
PrEP use current			
no	499	99.9	(99.2–100.0)
yes	1	0.1	(0.0–0.8)
PrEP use current (of those aware)			
no	45	98.7	(91.3–99.8)
yes	1	1.3	(0.2–8.7)

10. MAT



Figure 10.1. MAT Awareness (%)



Figure 10.2. MAT Current Uptake (%)



Figure 10.3. Trends in MAT Lifetime and Current Uptake by Survey Round (%)

Table 10.1. MAT experience

	n	%	CI
Reason for MAT discontinuation			
moved to another city	1	19.0	(2.3–69.9)
clinic closed after Feb 2022	0	0.0	
weak or no effect	0	0.0	
side effects	0	0.0	
do not want to visit clinic	1	17.4	(2.1–67.6)
do not want to quit drugs	0	0.0	
hard to get to the clinic	1	26.7	(3.5–78.6)
do not need it	0	0.0	
do not like the attitude of physician	1	36.9	(5.6–85.1)
How did the injection frequency change during MAT			
intensified	0	0.0	
did not change	4	100.0	
decreased	0	0.0	

	n	%	CI
Whether bought bupr. or methadone while not being a patient in the past 12 months			
yes, methadone	186	37.6	(33.1–42.3)
yes, buprenorphine	63	12.2	(9.5–15.5)
did not buy	248	50.2	(45.5–54.9)
Where bought bupr. or methadone while not being a patient in the past 12 months			
did not buy	248	50.2	(45.5–54.9)
bought from black market	247	49.5	(44.8–54.3)
bought from private clinic	2	0.3	(0.1–1.0)
Way of using bupr. or methaone bought from others			
injecting	234	94.6	(90.8–96.8)
injecting mixed	6	2.3	(1.0–5.3)
swallow or subling.	7	2.6	(1.1–5.7)
snort	2	0.6	(0.1–2.3)

Table 10.2. MAT Awareness and Uptake by Sociodemographic Characteristics

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
Total										
All	500	20	4.3 (2.7–6.6)	3	0.4 (0.1–1.2)	164	30.4 (26.4–34.7)	313	65.0 (60.5–69.2)	1.0000
Sex										
male	473	19	4.4 (2.7–6.9)	3	0.4 (0.1–1.3)	157	30.8 (26.6–35.2)	294	64.5 (59.8–68.9)	0.6330
female	27	1	2.2 (0.3–15.5)	0	0.0	7	22.9 (10.5–42.9)	19	74.9 (54.9–88.0)	
Age										
<25	17	0	0.0	0	0.0	2	9.3 (2.0–34.1)	15	90.7 (65.9–98.0)	0.1563
25-34	115	4	3.5 (1.2–9.7)	1	0.7 (0.1–4.7)	33	24.2 (17.1–33.0)	77	71.6 (62.3–79.3)	
35-44	243	13	5.4 (3.1–9.4)	2	0.5 (0.1–1.9)	78	30.7 (25.0–37.0)	150	63.4 (56.9–69.4)	
45+	125	3	3.3 (1.0–9.8)	0	0.0	51	39.0 (30.4–48.3)	71	57.7 (48.4–66.6)	
Years since the start of injecting drug use										
≤2	14	0	0.0	0	0.0	2	9.0 (1.8–35.1)	12	91.0 (64.9–98.2)	0.0260
3-5	31	3	8.3 (2.3–25.5)	0	0.0	6	14.2 (5.8–30.8)	22	77.5 (58.4–89.4)	
6-10	52	2	2.5 (0.6–10.2)	1	1.2 (0.2–8.4)	9	16.7 (8.5–30.1)	40	79.6 (66.2–88.6)	
≥11	403	15	4.3 (2.5–7.1)	2	0.3 (0.1–1.4)	147	34.4 (29.7–39.3)	239	61.0 (55.9–65.9)	
Partnership status										
live alone	339	13	4.1 (2.3–7.0)	3	0.6 (0.2–1.8)	115	31.3 (26.4–36.7)	208	64.0 (58.5–69.2)	0.6729
live with partner	161	7	4.6 (2.1–9.9)	0	0.0	49	28.4 (21.8–36.1)	105	67.0 (59.0–74.1)	
Current employment status										
full-time	105	3	3.1 (1.0–9.4)	0	0.0	30	24.6 (17.0–34.1)	72	72.3 (62.5–80.4)	0.2208

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
part-time or temporary	309	9	3.3 (1.7–6.5)	3	0.6 (0.2–2.1)	112	34.8 (29.5–40.5)	185	61.2 (55.4–66.7)	
unemployed	39	4	11.6 (4.1–28.6)	0	0.0	9	19.5 (9.8–35.0)	26	68.9 (51.7–82.1)	
disabled	32	3	8.8 (2.7–25.5)	0	0.0	9	24.6 (12.4–43.0)	20	66.6 (47.9–81.2)	
other	15	1	3.7 (0.4–26.3)	0	0.0	4	24.6 (8.3–54.0)	10	71.7 (42.9–89.5)	
Monthly income category										
<3K	27	1	3.3 (0.4–21.6)	0	0.0	4	10.9 (3.8–27.7)	22	85.8 (68.0–94.5)	0.2756
3-10K	191	8	4.3 (2.0–8.9)	0	0.0	75	36.8 (30.0–44.1)	108	58.9 (51.5–66.0)	
10-20K	213	8	4.4 (2.2–8.7)	3	0.9 (0.3–2.9)	65	28.9 (23.0–35.7)	137	65.7 (58.7–72.2)	
≥20K	56	2	3.8 (0.9–14.6)	0	0.0	18	29.3 (18.5–43.2)	36	66.9 (52.8–78.5)	
Ever incarcerated										
no	315	8	2.3 (1.1–4.7)	2	0.4 (0.1–1.7)	92	26.7 (22.0–32.0)	213	70.6 (65.1–75.5)	0.0006
yes	185	12	7.8 (4.4–13.6)	1	0.3 (0.0–2.4)	72	37.1 (30.1–44.6)	100	54.7 (47.1–62.2)	

Table 10.3. MAT Awareness and Uptake by Selected Subgroups

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
Client of NGO working with PWID										
no	457	14	3.3 (1.9–5.7)	2	0.3 (0.1–1.3)	148	30.0 (25.9–34.6)	293	66.3 (61.7–70.7)	0.0021
yes	43	6	14.6 (6.3–30.1)	1	1.3 (0.2–9.2)	16	33.9 (20.9–49.9)	20	50.2 (34.5–65.9)	
Treated with MAT currently (of all)										
no	480	0	0.0	3	0.4 (0.1–1.3)	164	31.7 (27.6–36.2)	313	67.9 (63.4–72.0)	0.0000
yes	20	20	100.0	0	0.0	0	0.0	0	0.0	
HIV test result										
positive	60	5	8.2 (3.3–19.0)	0	0.0	20	28.8 (18.6–41.8)	35	63.0 (49.5–74.7)	0.3714
negative	440	15	3.7 (2.2–6.2)	3	0.4 (0.1–1.4)	144	30.6 (26.3–35.2)	278	65.3 (60.5–69.8)	
Past 30 days injecting 4 categories										
opioids	383	17	5.0 (3.0–8.0)	3	0.5 (0.2–1.6)	134	32.6 (27.9–37.7)	229	61.9 (56.7–66.9)	
stimulants	46	0	0.0	0	0.0	7	11.7 (5.4–23.7)	39	88.3 (76.3–94.6)	
opi+stimul	71	3	3.3 (1.0–10.2)	0	0.0	23	31.4 (21.1–43.8)	45	65.4 (52.9–76.0)	
other	0	0		0		0		0		

	N	MAT uptake (of all) take it now n	% (CI)	took in the past n	% (CI)	never took but plan to n	% (CI)	unaware or do not plan to n	% (CI)	p-value
Injecting drug type of choice										
opioids	437	20	4.9 (3.1–7.6)	3	0.5 (0.1–1.4)	154	33.2 (28.7–37.9)	260	61.5 (56.6–66.2)	
stimulants	61	0	0.0	0	0.0	10	12.4 (6.5–22.4)	51	87.6 (77.6–93.5)	
other	2	0	0.0	0	0.0	0	0.0	2	100.0	



Figure 10.4. Buying MAT medications while not being a patient (%)



Figure 10.5. Source of buying MAT medications while not being a patient (%)



Figure 10.6. Route of administration of MAT medications bought from others (%)

11. Overdose and Naloxone



Figure 11.1. Overdose Experience Ever and in the Past 12 Months (%)



Figure 11.2. Trends in Overdose Experience in the Past 12 Months by Survey Round (%)



Figure 11.3. Drugs causing overdoses (if used only one drug) (%)



Figure 11.4. Naloxone Use (%)

Table 11.1. Overdose Experience

	n	%	CI
Experienced overdose ever			
yes	211	42.0	(37.4–46.7)
Number of overdoses in lifetime			
1	56	28.2	(22.1–35.3)
2-4	92	45.8	(38.6–53.2)
5+	51	26.0	(20.0–33.0)
Experienced overdose in the past 12 months			
yes	31	6.4	(4.4–9.3)
Experienced overdose in the past 12 months (of those ever)			
yes	31	15.3	(10.7–21.5)
Number of overdoses in the past 12 months			
1	18	61.6	(41.5–78.4)
2-4	10	35.6	(19.4–56.0)
5+	1	2.8	(0.4–17.7)
Drug overdosed with (if used only one drug)			
methadone	16	82.4	(60.0–93.6)
other opioid	2	10.3	(2.5–33.7)
stimulant	1	4.3	(0.6–25.4)
other	1	3.1	(0.4–19.3)
Drugs overdosed with (if used a combination)			
methadone+stimulant	2	63.3	(13.3–95.1)
methadone+barbit. or dimedr.	0	0.0	
methadone+other	0	0.0	
other	1	36.7	(4.9–86.7)
Drug overdosed with (if combined drug with alcohol)			
methadone	5	45.5	(15.0–79.7)
other opioid	1	15.1	(2.0–60.5)
stimulant	2	39.4	(10.0–79.2)
other	0	0.0	
Naloxone knowledge and experience			
never heard	148	31.5	(27.1–36.2)
aware but not used	301	58.1	(53.3–62.7)
used myself	37	7.7	(5.5–10.7)
my friends used	13	2.5	(1.4–4.4)

	n	%	CI
me and my friends used	1	0.2	(0.0–1.2)

Table 11.2. Overdose Experience in the Past 12 Months by Sociodemographic Characteristics

		Experienced overdose in the past 12 months			
	N	no		yes	
		n	% (CI)	n	% (CI)	p-value
Total						
All	494	463	93.6 (90.7–95.6)	31	6.4 (4.4–9.3)	1.0000
Sex						
male	467	436	93.2 (90.3–95.3)	31	6.8 (4.7–9.7)	0.1990
female	27	27	100.0	0	0.0	
Age						
<25	17	17	100.0	0	0.0	0.2421
25-34	114	105	90.8 (82.1–95.5)	9	9.2 (4.5–17.9)	
35-44	238	221	92.9 (88.6–95.7)	17	7.1 (4.3–11.4)	
45+	125	120	96.7 (91.9–98.7)	5	3.3 (1.3–8.1)	
Years since the start of injecting drug use						
≤2	14	13	88.0 (43.4–98.6)	1	12.0 (1.4–56.6)	0.3611
3-5	31	28	86.0 (60.3–96.2)	3	14.0 (3.8–39.7)	
6-10	50	48	96.1 (84.8–99.1)	2	3.9 (0.9–15.2)	
≥11	399	374	94.2 (91.4–96.1)	25	5.8 (3.9–8.6)	
Partnership status						
live alone	335	314	93.7 (90.2–96.0)	21	6.3 (4.0–9.8)	0.8626
live with partner	159	149	93.3 (87.5–96.5)	10	6.7 (3.5–12.5)	
Current employment status						
full-time	104	98	93.7 (84.8–97.6)	6	6.3 (2.4–15.2)	0.4524
part-time or temporary	305	284	93.1 (89.5–95.5)	21	6.9 (4.5–10.5)	
unemployed	39	35	89.1 (71.4–96.4)	4	10.9 (3.6–28.6)	
disabled	31	31	100.0	0	0.0	
other	15	15	100.0	0	0.0	
Monthly income category						
<3K	26	25	96.6 (77.6–99.6)	1	3.4 (0.4–22.4)	0.1157
3-10K	188	182	96.8 (92.9–98.6)	6	3.2 (1.4–7.1)	

		Experienced overdose in the past 12 months					
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
	10-20K	211	195	92.0 (87.0–95.2)	16	8.0 (4.8–13.0)	
	≥20K	56	50	88.6 (74.2–95.5)	6	11.4 (4.5–25.8)	
Ever incarcerated							
	no	312	296	94.1 (90.2–96.5)	16	5.9 (3.5–9.8)	0.5298
	yes	182	167	92.6 (87.8–95.6)	15	7.4 (4.4–12.2)	

Table 11.3. Overdose Experience in the Past 12 Months by Selected Subgroups

		Experienced overdose in the past 12 months				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	452	422	93.2 (90.1–95.3)	30	6.8 (4.7–9.9)	0.1440
yes	42	41	98.2 (87.7–99.8)	1	1.8 (0.2–12.3)	
Treated with MAT currently (of all)						
no	474	444	93.4 (90.5–95.5)	30	6.6 (4.5–9.5)	0.5039
yes	20	19	96.6 (76.7–99.6)	1	3.4 (0.4–23.3)	
HIV test result						
positive	59	53	91.5 (81.7–96.3)	6	8.5 (3.7–18.3)	0.4861
negative	435	410	93.9 (90.7–96.0)	25	6.1 (4.0–9.3)	
Past 30 days injecting 4 categories						
opioids	379	356	94.0 (90.9–96.1)	23	6.0 (3.9–9.1)	
stimulants	45	43	92.3 (70.5–98.4)	2	7.7 (1.6–29.5)	
opi+stimul	70	64	92.1 (82.5–96.6)	6	7.9 (3.4–17.5)	
other	0	0		0		
Injecting drug type of choice						
opioids	432	403	93.5 (90.6–95.5)	29	6.5 (4.5–9.4)	0.9339
stimulants	60	58	94.1 (76.4–98.7)	2	5.9 (1.3–23.6)	
other	2	2	100.0	0	0.0	

Table 11.4. Naloxone Experience by Sociodemographic Characteristics

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total								

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
All	500	148	31.5 (27.1–36.2)	314	60.6 (55.8–65.2)	38	7.9 (5.7–10.8)	1.0000
Sex								
male	473	141	31.5 (27.0–36.4)	297	60.7 (55.8–65.5)	35	7.7 (5.5–10.8)	0.8699
female	27	7	31.1 (14.7–54.3)	17	58.2 (36.9–76.8)	3	10.7 (3.2–29.9)	
Age								
<25	17	11	68.1 (39.6–87.4)	5	21.4 (7.8–46.6)	1	10.6 (1.3–51.6)	0.0043
25-34	115	37	37.3 (27.3–48.4)	69	54.4 (43.8–64.6)	9	8.3 (4.2–15.9)	
35-44	243	57	23.3 (18.1–29.3)	163	67.5 (61.1–73.4)	23	9.2 (6.1–13.7)	
45+	125	43	36.4 (27.8–46.0)	77	59.1 (49.6–68.0)	5	4.5 (1.7–11.2)	
Years since the start of injecting drug use								
≤2	14	7	54.5 (25.1–81.1)	7	45.5 (18.9–74.9)	0	0.0	0.0224
3-5	31	14	57.7 (36.3–76.6)	16	40.0 (21.9–61.3)	1	2.3 (0.3–16.1)	
6-10	52	16	29.8 (18.5–44.3)	32	60.4 (45.6–73.5)	4	9.8 (3.5–24.7)	
≥11	403	111	28.4 (24.0–33.4)	259	63.1 (58.0–68.0)	33	8.5 (6.0–11.9)	
Partnership status								
live alone	339	113	35.3 (29.8–41.2)	207	59.2 (53.3–64.8)	19	5.5 (3.4–8.7)	0.0048
live with partner	161	35	23.5 (17.1–31.4)	107	63.7 (55.3–71.3)	19	12.8 (8.1–19.7)	
Current employment status								
full-time	105	23	26.4 (16.8–38.9)	77	68.8 (56.6–78.8)	5	4.8 (1.9–11.8)	0.3888
part-time or temporary	309	95	31.6 (26.4–37.4)	191	60.2 (54.3–65.8)	23	8.2 (5.4–12.2)	
unemployed	39	17	46.0 (29.8–63.1)	16	41.9 (26.2–59.5)	6	12.1 (5.1–25.9)	
disabled	32	7	27.7 (13.4–48.7)	22	63.5 (43.6–79.6)	3	8.8 (2.7–25.5)	
other	15	6	39.3 (16.5–68.0)	8	47.8 (22.2–74.6)	1	12.9 (1.6–57.8)	
Monthly income category								
<3K	27	11	49.1 (28.8–69.7)	14	45.8 (26.4–66.6)	2	5.1 (1.1–20.6)	0.0313
3-10K	191	47	25.4 (19.4–32.4)	131	67.8 (60.5–74.4)	13	6.8 (3.9–11.6)	
10-20K	213	70	34.5 (27.6–42.1)	130	58.9 (51.3–66.1)	13	6.7 (3.8–11.5)	
≥20K	56	12	24.3 (13.6–39.7)	35	58.9 (44.1–72.3)	9	16.7 (8.4–30.4)	
Ever incarcerated								
no	315	97	32.9 (27.3–39.1)	204	62.1 (56.0–67.9)	14	4.9 (2.9–8.4)	0.0090

		Naloxone knowledge and experience (3 categories)						
		N	unaware		aware but did not use		used myself	
			n	% (CI)	n	% (CI)	n	% (CI)	p-value
	yes	185	51	28.9 (22.4–36.4)	110	57.8 (50.1–65.2)	24	13.3 (8.8–19.5)	

Table 11.5. Naloxone Experience by Selected Subgroups

	Naloxone knowledge and experience (3 categories)							
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID								
no	457	137	31.9 (27.3–36.9)	283	59.7 (54.7–64.5)	37	8.4 (6.0–11.6)	0.2522
yes	43	11	26.9 (15.0–43.5)	31	70.8 (54.2–83.2)	1	2.3 (0.3–15.5)	
Treated with MAT currently (of all)								
no	480	141	31.2 (26.7–36.0)	302	60.8 (55.9–65.5)	37	8.0 (5.8–11.1)	0.7183
yes	20	7	38.6 (18.3–63.9)	12	56.8 (32.6–78.2)	1	4.5 (0.5–29.1)	
HIV test result								
positive	60	16	33.0 (20.9–48.0)	37	55.7 (41.6–68.8)	7	11.3 (5.3–22.6)	0.5551
negative	440	132	31.3 (26.7–36.3)	277	61.3 (56.2–66.2)	31	7.4 (5.1–10.6)	
Past 30 days injecting 4 categories								
opioids	383	115	32.2 (27.2–37.7)	238	59.4 (53.9–64.7)	30	8.4 (5.8–12.0)	
stimulants	46	15	37.7 (23.4–54.6)	31	62.3 (45.4–76.6)	0	0.0	
opi+stimul	71	18	23.2 (14.6–34.8)	45	66.3 (54.0–76.7)	8	10.5 (5.0–20.6)	
other	0	0		0		0		
Injecting drug type of choice								
opioids	437	126	29.9 (25.4–34.9)	275	61.3 (56.2–66.2)	36	8.7 (6.3–12.1)	0.0508
stimulants	61	21	40.9 (27.7–55.5)	39	58.0 (43.5–71.2)	1	1.1 (0.2–8.0)	
other	2	1	66.3 (0.0–100.0)	0	0.0	1	33.7 (0.0–100.0)	

12. Physical and Mental Health

Table 12.1. Disease and treatment history

		n	%	CI
Had a disease				
	hepatitis B	94	18.3	(15.0–22.1)
	hepatitis C	117	23.6	(19.8–27.8)
	syphilis	3	0.6	(0.2–1.9)
	gonorrhea	10	2.0	(1.0–3.9)
	chlamydia	12	2.0	(1.1–3.6)
	herpes	47	8.5	(6.3–11.3)

		n	%	CI
	human papillomavirus	15	2.8	(1.6–4.7)
	tuberculosis	35	7.3	(5.2–10.1)
Treated for: hepatitis B				
	treated successfully	35	40.3	(30.3–51.1)
	treated unsuccessfully	30	29.5	(21.0–39.7)
	did not complete	4	3.8	(1.4–9.8)
	treated now	0	0.0	
	never treated	25	26.5	(18.2–37.0)
Treated for: hepatitis C				
	treated successfully	45	39.0	(30.2–48.6)
	treated unsuccessfully	9	6.6	(3.3–12.8)
	did not complete	10	7.4	(3.9–13.4)
	treated now	4	4.2	(1.5–11.5)
	never treated	49	42.7	(33.6–52.3)
Treated for: syphilis				
	treated successfully	3	100.0	
	treated unsuccessfully	0	0.0	
	did not complete	0	0.0	
	treated now	0	0.0	
	never treated	0	0.0	
Treated for: tuberculosis				
	treated successfully	29	85.5	(70.4–93.6)
	treated unsuccessfully	0	0.0	
	did not complete	2	4.3	(1.0–15.9)
	treated now	4	10.2	(3.7–25.1)
	never treated	0	0.0	

Table 12.2. Mental health screening scores

	n	Mean	CI	Median	IQR
AUDIT-C alcohol risk score ≥5	4,874	1.2	(1.2–1.2)	1	(1–1)
PHQ-9 depression result	5,002	2.2	(2.2–2.3)	2	(1–3)
GAD-7 anxiety result	5,002	1.9	(1.9–1.9)	2	(1–2)

Table 12.3. Health care utilization

		n	%	CI
Had problems with health besides drugs which required medical attention in the past 12 months				
	yes	101	19.2	(15.8–23.0)
Referred to a health care facility for treatment in the past 12 months				
	yes	74	14.2	(11.3–17.7)
Referred to a health care facility				
	primary care	55	73.4	(61.4–82.7)
	hospital, HIV clinic	16	24.0	(15.0–36.1)
	private clinic	2	2.4	(0.5–9.8)
	private lab	0	0.0	
	TB dispensary	2	2.4	(0.6–9.9)
	drug clinic	1	0.9	(0.1–6.3)
	STI clinic	0	0.0	
	ambulance	2	2.4	(0.6–9.2)
	mobile clinic	0	0.0	
	other	0	0.0	
Last health care facility referred to				

	n	%	CI
primary care	54	72.0	(60.0–81.6)
hospital, HIV clinic	13	19.8	(11.6–31.8)
private clinic	2	2.4	(0.5–9.8)
private lab	0	0.0	
TB dispensary	2	2.4	(0.6–9.9)
drug clinic	1	0.9	(0.1–6.3)
STI clinic	0	0.0	
ambulance	2	2.4	(0.6–9.2)
mobile clinic	0	0.0	
other	0	0.0	
Received necessary care in health care facility			
yes	71	95.3	(83.0–98.8)
Signed a declaration with primary care physician			
yes	364	73.3	(68.9–77.2)
How frequently saw the primary care physician			
twice per month or more	4	1.2	(0.4–3.1)
once per month	22	5.9	(3.8–8.9)
3-4 times in 12 months	88	23.6	(19.4–28.5)
only once	248	69.3	(64.1–74.1)



Figure 12.1. Risky alcohol use (AUDIT-C score > 5) (%)



Figure 12.2. Depression symptoms severity (PHQ-9) (%)



Figure 12.3. Anxiety symptoms severity (GAD-7) (%)

Table 12.4. Risky alcohol use (AUDIT-C score > 5) by Sociodemographic Characteristics

			AUDIT-C alcohol risk score ≥5			
		N	no		yes	
			n	% (CI)	n	% (CI)	p-value
Total							
	All	494	442	88.0 (83.9–91.2)	52	12.0 (8.8–16.1)	1.0000
Sex							
	male	467	416	87.5 (83.2–90.8)	51	12.5 (9.2–16.8)	0.0551
	female	27	26	97.6 (83.3–99.7)	1	2.4 (0.3–16.7)	
Age							
	<25	16	13	70.0 (36.5–90.5)	3	30.0 (9.5–63.5)	0.0002

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
25-34	115	94	77.6 (65.6–86.3)	21	22.4 (13.7–34.4)	
35-44	238	215	90.4 (85.6–93.7)	23	9.6 (6.3–14.4)	
45+	125	120	96.4 (91.5–98.5)	5	3.6 (1.5–8.5)	
Years since the start of injecting drug use						
≤2	14	9	65.1 (33.4–87.4)	5	34.9 (12.6–66.6)	0.0025
3-5	29	26	71.2 (38.0–90.9)	3	28.8 (9.1–62.0)	
6-10	52	41	76.3 (61.2–86.8)	11	23.7 (13.2–38.8)	
≥11	399	366	91.8 (88.5–94.2)	33	8.2 (5.8–11.5)	
Partnership status						
live alone	334	295	87.0 (81.6–91.0)	39	13.0 (9.0–18.4)	0.3919
live with partner	160	147	90.2 (83.3–94.4)	13	9.8 (5.6–16.7)	
Current employment status						
full-time	105	94	83.3 (69.5–91.6)	11	16.7 (8.4–30.5)	0.1922
part-time or temporary	303	270	89.5 (85.3–92.5)	33	10.5 (7.5–14.7)	
unemployed	39	33	83.9 (65.9–93.3)	6	16.1 (6.7–34.1)	
disabled	32	32	100.0	0	0.0	
other	15	13	79.3 (41.6–95.4)	2	20.7 (4.6–58.4)	
Monthly income category						
<3K	27	22	84.8 (65.7–94.2)	5	15.2 (5.8–34.3)	0.5675
3-10K	188	171	90.7 (85.3–94.3)	17	9.3 (5.7–14.7)	
10-20K	210	190	88.6 (80.9–93.4)	20	11.4 (6.6–19.1)	
≥20K	56	49	83.6 (67.6–92.5)	7	16.4 (7.5–32.4)	
Ever incarcerated						
no	313	285	88.2 (82.5–92.3)	28	11.8 (7.7–17.5)	0.8483
yes	181	157	87.6 (81.6–91.8)	24	12.4 (8.2–18.4)	

Table 12.5. Risky alcohol use (AUDIT-C score > 5) by Selected Subgroups

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
	n		% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	451	404	87.9 (83.5–91.2)	47	12.1 (8.8–16.5)	0.7919
yes	43	38	89.3 (75.8–95.7)	5	10.7 (4.3–24.2)	
Treated with MAT currently (of all)						
no	475	426	88.2 (84.0–91.4)	49	11.8 (8.6–16.0)	0.5577
yes	19	16	83.2 (54.1–95.4)	3	16.8 (4.6–45.9)	
HIV test result						
positive	59	51	87.2 (75.4–93.8)	8	12.8 (6.2–24.6)	0.8506
negative	435	391	88.1 (83.6–91.5)	44	11.9 (8.5–16.4)	
Past 30 days injecting 4 categories						
opioids	378	345	90.3 (85.7–93.6)	33	9.7 (6.4–14.3)	
stimulants	46	40	81.0 (62.2–91.7)	6	19.0 (8.3–37.8)	
opi+stimul	70	57	80.0 (67.8–88.3)	13	20.0 (11.7–32.2)	
other	0	0		0		
Injecting drug type of choice						
opioids	431	389	89.2 (85.0–92.4)	42	10.8 (7.6–15.0)	0.1333
stimulants	61	51	79.3 (64.2–89.1)	10	20.7 (10.9–35.8)	
other	2	2	100.0	0	0.0	

Table 12.6. Depression symptoms severity (PHQ-9) by Sociodemographic Characteristics

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	187	38.6 (34.1–43.3)	218	43.4 (38.8–48.1)	66	12.6 (9.9–16.0)	29	5.4 (3.7–7.7)	1.0000
Sex										
male	473	177	38.7 (34.0–43.6)	209	43.9 (39.2–48.8)	61	12.2 (9.5–15.6)	26	5.2 (3.5–7.7)	0.4386
female	27	10	36.9 (19.8–58.0)	9	33.3 (17.2–54.6)	5	21.3 (8.3–44.6)	3	8.5 (2.5–25.2)	
Age										
<25	17	8	41.5 (18.8–68.5)	8	48.0 (23.1–73.9)	1	10.6 (1.3–51.6)	0	0.0	0.5447
25-34	115	45	43.1 (33.0–53.8)	41	35.7 (26.6–45.9)	22	16.0 (10.3–23.9)	7	5.2 (2.4–11.2)	
35-44	243	83	34.5 (28.5–41.0)	116	48.1 (41.5–54.7)	28	10.8 (7.4–15.5)	16	6.7 (4.0–10.8)	
45+	125	51	41.6 (32.8–51.1)	53	41.4 (32.6–50.9)	15	13.2 (7.9–21.2)	6	3.7 (1.6–8.3)	
Years since the start of injecting drug use										
≤2	14	8	57.8 (27.4–83.3)	3	13.6 (3.6–40.1)	1	12.0 (1.4–56.6)	2	16.6 (3.2–54.8)	0.2389

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
3-5	31	14	49.8 (28.2–71.5)	14	43.8 (24.0–65.9)	3	6.4 (1.8–20.2)	0	0.0	
6-10	52	23	44.1 (30.5–58.5)	20	39.4 (26.3–54.1)	6	10.9 (4.8–23.0)	3	5.7 (1.7–17.3)	
≥11	403	142	36.1 (31.3–41.2)	181	45.0 (40.0–50.2)	56	13.5 (10.3–17.3)	24	5.4 (3.6–8.0)	
Partnership status										
live alone	339	121	36.6 (31.1–42.4)	161	47.9 (42.2–53.6)	41	11.2 (8.2–15.0)	16	4.4 (2.7–7.1)	0.0337
live with partner	161	66	42.8 (34.9–51.0)	57	34.1 (26.9–42.1)	25	15.8 (10.6–22.8)	13	7.4 (4.1–12.8)	
Current employment status										
full-time	105	44	45.8 (35.1–56.9)	45	42.2 (32.0–53.0)	12	9.1 (5.0–16.0)	4	2.9 (1.1–7.9)	0.0327
part-time or temporary	309	115	37.0 (31.6–42.9)	141	46.2 (40.4–52.0)	37	12.0 (8.6–16.4)	16	4.8 (2.9–7.9)	
unemployed	39	11	29.5 (16.1–47.7)	17	43.3 (27.5–60.6)	6	13.1 (5.6–27.8)	5	14.0 (5.5–31.6)	
disabled	32	8	29.4 (14.8–50.0)	11	30.4 (16.6–49.0)	10	30.8 (16.5–50.0)	3	9.4 (2.8–26.8)	
other	15	9	58.2 (29.3–82.4)	4	25.2 (8.2–55.8)	1	12.9 (1.6–57.8)	1	3.7 (0.4–26.3)	
Monthly income category										
<3K	27	9	34.9 (17.8–57.1)	10	42.3 (23.0–64.4)	3	7.3 (2.2–22.0)	5	15.4 (6.0–34.2)	0.0852
3-10K	191	56	30.3 (23.9–37.6)	92	48.1 (40.7–55.5)	31	15.8 (11.1–21.9)	12	5.8 (3.3–10.2)	
10-20K	213	92	44.4 (37.1–51.9)	86	39.6 (32.8–46.9)	25	11.2 (7.5–16.5)	10	4.8 (2.5–9.0)	
≥20K	56	24	42.2 (29.0–56.6)	26	45.7 (32.0–60.0)	5	10.6 (4.3–23.9)	1	1.5 (0.2–10.5)	
Ever incarcerated										
no	315	129	41.3 (35.5–47.4)	136	44.0 (38.1–50.0)	35	10.0 (7.1–13.9)	15	4.7 (2.8–7.9)	0.0642
yes	185	58	33.5 (26.6–41.2)	82	42.4 (35.1–50.0)	31	17.5 (12.3–24.3)	14	6.6 (3.9–11.0)	

Table 12.7. Depression symptoms severity (PHQ-9) by Selected Subgroups

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	187	38.6 (34.1–43.3)	218	43.4 (38.8–48.1)	66	12.6 (9.9–16.0)	29	5.4 (3.7–7.7)	1.0000
Sex										
male	473	177	38.7 (34.0–43.6)	209	43.9 (39.2–48.8)	61	12.2 (9.5–15.6)	26	5.2 (3.5–7.7)	0.4386
female	27	10	36.9 (19.8–58.0)	9	33.3 (17.2–54.6)	5	21.3 (8.3–44.6)	3	8.5 (2.5–25.2)	
Age										
<25	17	8	41.5 (18.8–68.5)	8	48.0 (23.1–73.9)	1	10.6 (1.3–51.6)	0	0.0	0.5447
25-34	115	45	43.1 (33.0–53.8)	41	35.7 (26.6–45.9)	22	16.0 (10.3–23.9)	7	5.2 (2.4–11.2)	
35-44	243	83	34.5 (28.5–41.0)	116	48.1 (41.5–54.7)	28	10.8 (7.4–15.5)	16	6.7 (4.0–10.8)	
45+	125	51	41.6 (32.8–51.1)	53	41.4 (32.6–50.9)	15	13.2 (7.9–21.2)	6	3.7 (1.6–8.3)	

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Years since the start of injecting drug use										
≤2	14	8	57.8 (27.4–83.3)	3	13.6 (3.6–40.1)	1	12.0 (1.4–56.6)	2	16.6 (3.2–54.8)	0.2389
3-5	31	14	49.8 (28.2–71.5)	14	43.8 (24.0–65.9)	3	6.4 (1.8–20.2)	0	0.0	
6-10	52	23	44.1 (30.5–58.5)	20	39.4 (26.3–54.1)	6	10.9 (4.8–23.0)	3	5.7 (1.7–17.3)	
≥11	403	142	36.1 (31.3–41.2)	181	45.0 (40.0–50.2)	56	13.5 (10.3–17.3)	24	5.4 (3.6–8.0)	
Partnership status										
live alone	339	121	36.6 (31.1–42.4)	161	47.9 (42.2–53.6)	41	11.2 (8.2–15.0)	16	4.4 (2.7–7.1)	0.0337
live with partner	161	66	42.8 (34.9–51.0)	57	34.1 (26.9–42.1)	25	15.8 (10.6–22.8)	13	7.4 (4.1–12.8)	
Current employment status										
full-time	105	44	45.8 (35.1–56.9)	45	42.2 (32.0–53.0)	12	9.1 (5.0–16.0)	4	2.9 (1.1–7.9)	0.0327
part-time or temporary	309	115	37.0 (31.6–42.9)	141	46.2 (40.4–52.0)	37	12.0 (8.6–16.4)	16	4.8 (2.9–7.9)	
unemployed	39	11	29.5 (16.1–47.7)	17	43.3 (27.5–60.6)	6	13.1 (5.6–27.8)	5	14.0 (5.5–31.6)	
disabled	32	8	29.4 (14.8–50.0)	11	30.4 (16.6–49.0)	10	30.8 (16.5–50.0)	3	9.4 (2.8–26.8)	
other	15	9	58.2 (29.3–82.4)	4	25.2 (8.2–55.8)	1	12.9 (1.6–57.8)	1	3.7 (0.4–26.3)	
Monthly income category										
<3K	27	9	34.9 (17.8–57.1)	10	42.3 (23.0–64.4)	3	7.3 (2.2–22.0)	5	15.4 (6.0–34.2)	0.0852
3-10K	191	56	30.3 (23.9–37.6)	92	48.1 (40.7–55.5)	31	15.8 (11.1–21.9)	12	5.8 (3.3–10.2)	
10-20K	213	92	44.4 (37.1–51.9)	86	39.6 (32.8–46.9)	25	11.2 (7.5–16.5)	10	4.8 (2.5–9.0)	
≥20K	56	24	42.2 (29.0–56.6)	26	45.7 (32.0–60.0)	5	10.6 (4.3–23.9)	1	1.5 (0.2–10.5)	
Ever incarcerated										
no	315	129	41.3 (35.5–47.4)	136	44.0 (38.1–50.0)	35	10.0 (7.1–13.9)	15	4.7 (2.8–7.9)	0.0642
yes	185	58	33.5 (26.6–41.2)	82	42.4 (35.1–50.0)	31	17.5 (12.3–24.3)	14	6.6 (3.9–11.0)	

Table 12.8. Anxiety symptoms severity (GAD-7) by Sociodemographic Characteristics

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	249	51.3 (46.6–56.0)	177	34.4 (30.1–38.9)	65	12.8 (10.0–16.2)	9	1.6 (0.8–3.1)	1.0000
Sex										
male	473	240	52.2 (47.4–57.0)	164	33.7 (29.4–38.3)	62	12.7 (9.9–16.1)	7	1.4 (0.6–3.0)	0.1802
female	27	9	33.5 (17.3–54.9)	13	47.0 (27.8–67.0)	3	14.4 (4.1–39.6)	2	5.1 (1.2–20.1)	
Age										
<25	17	11	62.9 (34.1–84.8)	4	23.2 (7.3–53.6)	2	13.9 (2.6–49.2)	0	0.0	0.1232

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
25-34	115	57	54.3 (44.1–64.2)	38	29.7 (21.7–39.1)	15	12.7 (7.5–20.7)	5	3.3 (1.3–8.3)	
35-44	243	109	44.6 (38.1–51.2)	96	40.4 (34.0–47.0)	37	14.6 (10.6–19.8)	1	0.5 (0.1–3.4)	
45+	125	72	59.8 (50.4–68.4)	39	29.0 (21.5–37.9)	11	9.1 (4.9–16.2)	3	2.2 (0.7–6.6)	
Years since the start of injecting drug use										
≤2	14	10	75.1 (41.8–92.7)	1	4.6 (0.5–31.7)	2	15.7 (2.8–54.4)	1	4.6 (0.5–31.7)	0.0094
3-5	31	21	76.9 (58.2–88.8)	9	21.7 (10.2–40.3)	1	1.4 (0.2–10.3)	0	0.0	
6-10	52	29	53.4 (39.0–67.2)	13	27.0 (15.8–42.1)	9	18.6 (9.7–32.6)	1	1.1 (0.1–7.7)	
≥11	403	189	47.8 (42.7–53.0)	154	37.6 (32.8–42.7)	53	12.9 (9.9–16.8)	7	1.6 (0.8–3.5)	
Partnership status										
live alone	339	172	52.5 (46.7–58.2)	125	35.8 (30.6–41.4)	36	10.0 (7.1–13.7)	6	1.7 (0.8–3.9)	0.0580
live with partner	161	77	48.9 (40.8–57.0)	52	31.4 (24.4–39.3)	29	18.6 (12.9–26.0)	3	1.2 (0.4–3.7)	
Current employment status										
full-time	105	56	58.1 (47.4–68.1)	31	27.4 (19.3–37.5)	16	13.3 (8.0–21.2)	2	1.2 (0.3–4.8)	0.0481
part-time or temporary	309	154	50.4 (44.6–56.2)	112	35.5 (30.1–41.3)	39	13.0 (9.5–17.6)	4	1.1 (0.4–3.0)	
unemployed	39	16	40.8 (25.3–58.4)	15	39.9 (24.6–57.5)	7	15.5 (7.2–30.5)	1	3.7 (0.5–23.3)	
disabled	32	11	35.6 (19.9–55.2)	19	57.2 (38.3–74.3)	1	3.6 (0.5–22.7)	1	3.6 (0.5–22.7)	
other	15	12	79.4 (44.0–95.0)	0	0.0	2	16.9 (3.2–55.7)	1	3.7 (0.4–26.3)	
Monthly income category										
<3K	27	12	50.8 (30.3–71.0)	8	29.0 (13.7–51.1)	7	20.3 (9.0–39.4)	0	0.0	0.0004
3-10K	191	74	39.4 (32.4–46.8)	92	48.3 (40.9–55.7)	19	9.6 (6.1–15.0)	6	2.7 (1.2–6.1)	
10-20K	213	129	61.8 (54.6–68.6)	51	22.5 (17.2–28.9)	30	14.3 (10.0–20.1)	3	1.3 (0.4–4.4)	
≥20K	56	28	51.2 (37.1–65.1)	20	33.9 (22.0–48.3)	8	14.8 (7.2–28.0)	0	0.0	
Ever incarcerated										
no	315	169	55.1 (49.1–60.9)	98	30.8 (25.7–36.5)	44	13.2 (9.8–17.6)	4	0.9 (0.3–2.4)	0.0384
yes	185	80	44.4 (37.0–52.1)	79	40.9 (33.7–48.5)	21	11.9 (7.6–18.1)	5	2.8 (1.1–6.8)	

Table 12.9. Anxiety symptoms severity (GAD-7) by Selected Subgroups

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
no	457	222	50.1 (45.2–55.1)	163	34.6 (30.2–39.4)	63	13.5 (10.6–17.2)	9	1.7 (0.9–3.4)	0.1759
yes	43	27	64.3 (47.9–78.0)	14	31.5 (18.7–48.0)	2	4.1 (0.9–16.7)	0	0.0	
Treated with MAT currently (of all)										
no	480	236	50.9 (46.1–55.7)	173	35.0 (30.6–39.6)	64	12.9 (10.1–16.4)	7	1.2 (0.6–2.6)	0.0566
yes	20	13	61.4 (36.1–81.7)	4	20.5 (7.2–46.3)	1	8.8 (1.1–45.5)	2	9.2 (1.8–35.9)	
HIV test result										
positive	60	26	46.8 (33.5–60.6)	26	41.7 (29.1–55.5)	7	10.1 (4.7–20.5)	1	1.3 (0.2–9.3)	0.6137
negative	440	223	52.0 (46.9–56.9)	151	33.3 (28.8–38.1)	58	13.1 (10.1–16.9)	8	1.6 (0.8–3.3)	
Past 30 days injecting 4 categories										
opioids	383	196	52.4 (47.0–57.7)	128	32.5 (27.7–37.6)	52	13.4 (10.2–17.4)	7	1.7 (0.8–3.7)	
stimulants	46	35	76.9 (61.7–87.3)	8	16.2 (7.9–30.4)	3	6.9 (2.1–20.3)	0	0.0	
opi+stimul	71	18	26.8 (17.1–39.4)	41	58.1 (45.6–69.7)	10	13.3 (7.0–23.8)	2	1.7 (0.4–7.0)	
other	0	0		0		0		0		
Injecting drug type of choice										
opioids	437	204	47.8 (42.8–52.8)	164	36.8 (32.2–41.7)	61	13.7 (10.7–17.5)	8	1.7 (0.8–3.4)	0.0122
stimulants	61	44	74.8 (61.9–84.4)	12	17.7 (9.9–29.7)	4	6.4 (2.3–16.8)	1	1.0 (0.1–7.2)	
other	2	1	66.3 (0.0–100.0)	1	33.7 (0.0–100.0)	0	0.0	0	0.0	

13. Detention and Incarceration

Table 13.1. Police Detention and Incarceration Experience

	n	%	CI
Detained by police in 2022 for			
drug use	21	3.8	(2.5–5.9)
drug dealing	1	0.1	(0.0–0.8)
drug storing	21	4.2	(2.6–6.6)
Detained by police in 2023 for			
drug use	17	3.4	(2.1–5.5)
drug dealing	2	0.4	(0.1–1.8)
drug storing	17	3.4	(2.0–5.8)
Stopped, detained, or arrested by police ever			
yes	385	77.9	(73.8–81.4)
Ever incarcerated			
yes	185	35.1	(30.9–39.7)
Duration of incarceration			
≤6m	18	9.2	(5.8–14.4)
6m-2y	38	20.3	(14.9–27.2)
2-4y	90	49.4	(41.8–57.0)
4y+	39	21.1	(15.5–28.0)

	n	%	CI
Time since last incarceration			
≤1y	11	6.5	(3.5–11.6)
1-3y	21	11.2	(7.2–16.9)
3-5y	28	14.0	(9.7–19.9)
5-10y	75	39.9	(32.7–47.5)
10y+	50	28.5	(22.0–35.9)
Used injecting drugs during incarceration			
yes	115	61.5	(53.8–68.6)



Figure 13.1. Incarceration Lifetime Experience (%)

14. Negative experience

Table 14.1. Negative experience

	n	%	CI
Felt excluded from family activities due to drug use			
no	215	43.4	(38.8–48.1)
yes, in the past 6m	66	13.5	(10.5–17.1)
yes, but 6m+ ago	214	43.2	(38.5–47.9)
Was scolded because of drug use			
no	179	36.9	(32.5–41.6)
yes, in the past 6m	91	18.1	(14.8–22.1)
yes, but 6m+ ago	229	44.9	(40.3–49.7)
Was blackmailed for drug use			
no	344	69.4	(64.9–73.5)
yes, in the past 6m	28	5.7	(3.8–8.4)
yes, but 6m+ ago	126	24.9	(21.1–29.1)
Negative experience in the past 6 months (GAM 6.5)			
no	390	79.2	(75.1–82.7)
yes	104	20.8	(17.3–24.9)
Ever experienced physical violence			
no	291	60.3	(55.7–64.7)
yes	209	39.7	(35.3–44.3)
Experienced physical violence in the past 12 months (of those who had ever)			
no	133	62.6	(55.3–69.3)

		n	%	CI
	yes	76	37.4	(30.7–44.7)
Witnessed physical violence in the past 12 months				
	no	332	66.5	(62.0–70.8)
	yes	168	33.5	(29.2–38.0)



Figure 14.1. Negative Experience Related to Drug Use in the past 6 Months or Physical Violence in the past 12 months (%)

Table 14.2. Negative Experience Related to Drug Use by Sociodemographic Characteristics

		Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	494	104	20.8 (17.3–24.9)	1.0000	209	76	37.4 (30.7–44.7)	1.0000
Sex									
	male	469	97	20.5 (16.9–24.7)	0.4280	198	74	38.7 (31.8–46.2)	0.0656
	female	25	7	27.7 (12.4–51.0)		11	2	13.5 (2.9–44.7)	
Age									
	<25	15	2	25.2 (6.2–63.1)	0.6855	4	1	14.6 (1.4–67.9)	0.0502
	25-34	115	30	24.3 (17.0–33.5)		48	21	48.0 (33.2–63.1)	
	35-44	239	51	20.5 (15.7–26.4)		107	41	39.9 (30.6–50.1)	
	45+	125	21	17.4 (11.2–26.1)		50	13	23.3 (13.5–37.0)	
Years since the start of injecting drug use									
	≤2	14	4	32.3 (10.4–66.2)	0.0314	6	3	44.3 (10.0–85.0)	0.2507
	3-5	29	2	5.4 (1.2–21.1)		11	6	67.0 (34.8–88.5)	
	6-10	50	16	33.1 (20.7–48.4)		20	6	31.7 (14.5–55.9)	

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
≥11	401	82	20.2 (16.4–24.7)		172	61	35.8 (28.6–43.6)	
Partnership status								
live alone	336	58	16.2 (12.5–20.8)	0.0006	132	53	40.2 (31.6–49.3)	0.3120
live with partner	158	46	30.6 (23.4–38.9)		77	23	32.7 (22.5–44.8)	
Current employment status								
full-time	105	25	21.5 (14.4–31.0)	0.4706	42	19	46.1 (30.6–62.5)	0.0480
part-time or temporary	307	60	20.3 (15.9–25.7)		135	52	39.7 (31.4–48.7)	
unemployed	37	8	22.6 (11.0–40.8)		18	4	24.3 (8.0–54.0)	
disabled	31	10	28.3 (14.9–47.1)		12	0	0.0	
other	14	1	4.1 (0.5–28.6)		2	1	34.0 (2.4–91.5)	
Monthly income category								
<3K	27	9	32.0 (15.4–54.9)	0.4031	10	4	39.4 (14.2–71.9)	0.0766
3-10K	187	36	19.1 (13.9–25.7)		90	26	29.6 (20.5–40.6)	
10-20K	212	45	20.4 (15.3–26.7)		83	35	42.0 (31.4–53.4)	
≥20K	56	14	26.3 (15.6–41.0)		20	11	59.6 (35.5–79.8)	
Ever incarcerated								
no	311	63	20.3 (15.9–25.6)	0.7220	119	48	41.5 (32.5–51.2)	0.1622
yes	183	41	21.8 (16.1–28.7)		90	28	31.5 (22.2–42.5)	

Table 14.3. Negative Experience Related to Drug Use by Selected Subgroups

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	451	96	21.2 (17.4–25.5)	0.5867	197	75	38.9 (31.9–46.4)	0.0826
yes	43	8	17.4 (8.3–33.2)		12	1	10.7 (1.4–50.2)	
Treated with MAT currently (of all)								
no	474	96	20.1 (16.5–24.3)	0.0806	200	74	38.3 (31.3–45.7)	0.2355
yes	20	8	37.1 (17.7–61.8)		9	2	19.3 (4.2–56.8)	
HIV test result								
positive	59	18	30.9 (19.4–45.3)	0.0624	23	8	33.3 (16.8–55.2)	0.6728
negative	435	86	19.4 (15.8–23.7)		186	68	37.9 (30.8–45.7)	

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Past 30 days injecting 4 categories								
opioids	379	83	21.6 (17.5–26.4)		155	48	31.8 (24.6–40.0)	
stimulants	44	6	14.0 (6.1–28.8)		17	6	48.0 (23.7–73.3)	
opi+stimul	71	15	21.2 (12.6–33.3)		37	22	54.8 (37.3–71.1)	
other	0	0			0	0		
Injecting drug type of choice								
opioids	433	93	21.1 (17.4–25.5)	0.7701	187	68	36.4 (29.5–44.0)	0.4724
stimulants	59	11	19.5 (10.2–34.0)		21	8	48.2 (26.0–71.1)	
other	2	0	0.0		1	0	0.0	

15. The Impact of the Full-scale War

Table 15.1. Migration Since February 2022

	n	%	CI
Changed place of residence since Feb 2022			
yes, because of the war	13	2.4	(1.3–4.2)
yes, for other reasons	30	6.3	(4.3–9.1)
no	457	91.4	(88.3–93.7)
Where migrated since Feb 2022			
unknown	0	0.0	
other country	1	9.6	(1.3–45.3)
other oblast	6	51.7	(25.3–77.1)
other city	0	0.0	
other district	4	26.6	(9.7–55.0)
other house	2	12.2	(2.9–38.9)
Where lived before Feb 2022 (if changed residence)			
same oblast	29	70.1	(54.1–82.3)
other oblast	12	26.0	(14.6–41.9)
other country	2	3.9	(1.0–14.7)



Figure 15.1. Change of Residence Since February 2022 (%)



Figure 15.2. Migration Destination by Survey Site (%)



Figure 15.3. Residence Before February 2022 (%)



Figure 15.4. Changes Since February 2022 (%)

City-level Results: Odesa



Figure A. RDS recruitment tree in Odesa

1. Sociodemographic Information

Table 1.1. Sociodemographic Characteristics

	n	Mean	CI	Median	IQR
Age, years	500	39.9	(39.2–40.6)	40	(35–44)
Age of first non-injecting drug use	486	17.0	(16.6–17.5)	16	(14–18)
Years since the start of non-injecting drug use	486	22.8	(22.0–23.6)	23	(17–29)
Age of first injecting drug use	500	21.3	(20.7–21.9)	19	(17–25)
Years since the start of injecting drug use	500	18.7	(17.7–19.6)	19	(10–26)
Personal monthly income, UAH	479	8,150.8	(7611.5–8690.1)	7,000	(4000–10000)

Table 1.2. Descriptive Statistics for Sociodemographics

	Site	n	%	CI
Sex				
male	Odesa	408	81.2	(77.3–84.5)
female	Odesa	92	18.8	(15.5–22.7)
Age				
<25	Odesa	9	1.7	(0.9–3.2)
25-34	Odesa	117	22.0	(18.6–26.0)
35-44	Odesa	248	52.4	(47.8–56.9)
45+	Odesa	126	23.9	(20.3–28.0)
Family status				
married or living together	Odesa	59	11.9	(9.2–15.3)
married but have another partner	Odesa	19	4.0	(2.5–6.3)
not married but have a partner	Odesa	133	26.5	(22.7–30.7)
married but not living together	Odesa	16	3.4	(2.0–5.6)
not married and do not have a partner	Odesa	273	54.2	(49.6–58.7)
Partnership status				
live alone	Odesa	289	57.6	(53.0–62.0)
live with partner	Odesa	211	42.4	(38.0–47.0)
Education				
incompl. high school	Odesa	143	28.6	(24.6–32.9)
high school	Odesa	193	37.4	(33.0–41.9)
>high school	Odesa	164	34.1	(29.8–38.6)
Current occupation				
school student	Odesa	0	0.0	
college/uni student	Odesa	0	0.0	
permanent job	Odesa	74	15.2	(12.1–18.8)
sporadic jobs	Odesa	328	65.4	(60.9–69.7)
unemployed	Odesa	54	10.4	(7.9–13.6)
housewife	Odesa	4	0.7	(0.3–1.9)
disabled	Odesa	37	8.0	(5.8–11.1)
military	Odesa	1	0.1	(0.0–0.7)
other	Odesa	1	0.1	(0.0–1.0)
Homelessness				
never	Odesa	365	74.3	(70.2–78.1)
yes, 12m+ ago	Odesa	116	22.4	(18.8–26.4)
yes, in the past 12m	Odesa	17	3.3	(2.0–5.3)
Homeless in 12 months (of those ever)				
no	Odesa	116	87.3	(80.2–92.1)
yes	Odesa	17	12.7	(7.9–19.8)
Monthly income category				
<3K	Odesa	77	16.0	(12.8–19.7)
3-10K	Odesa	211	45.4	(40.7–50.1)
10-20K	Odesa	165	33.2	(28.9–37.7)

	Site	n	%	CI
≥20K	Odesa	26	5.5	(3.7–8.1)
Monthly income relative to 2023 subsistence minimum				
<2684	Odesa	76	15.7	(12.6–19.5)
≥2684	Odesa	403	84.3	(80.5–87.4)
Years since the start of injecting drug use				
≤2	Odesa	18	3.5	(2.2–5.6)
3-5	Odesa	47	9.4	(7.0–12.4)
6-10	Odesa	64	12.9	(10.1–16.3)
≥11	Odesa	371	74.2	(70.0–78.0)

Table 1.3. Accommodation in the past 12 months

	Site	n	%	CI
own place	Odesa	240	47.7	(43.1–52.3)
friends or relatives	Odesa	123	24.0	(20.3–28.2)
renting	Odesa	79	16.6	(13.4–20.4)
varying	Odesa	36	7.3	(5.2–10.2)
on the street (homeless)	Odesa	17	3.3	(2.0–5.3)
in a refugee shelter	Odesa	7	1.6	(0.7–3.4)



Figure 1.1. Distribution of Age by Sex (%)



Figure 1.2. Trend in Sex Distribution by Survey Round (%)



Figure 1.3. Trend in Age Groups by Survey Round (%)

2. Drug Use



Figure 2.1. Injecting Drug Use in the Past 12 Months and 30 Days (%)



Figure 2.2. Non-injecting Drug Use in the Past 12 Months (%)



Figure 2.3. Trends in Injecting Drugs Types in the Past 30 Days by Survey Round (%)



Figure 2.4. Trends in Injecting Opioids in the Past 30 Days by Survey Round (%)



Figure 2.5. Trends in Injecting Stimulants in the Past 30 Days by Survey Round (%)



Figure 2.6. Trends in Injecting Other Drugs in the Past 30 Days by Survey Round (%)



Figure 2.7. Injecting Drug Preference (%)

Table 2.1. Types of Injecting Drugs in the Past 30 Days by Sociodemographic Characteristics

			Past 30 days injecting 4 categories					
		N	opioids		stimulants		opi+stimul	
			n	% (CI)	n	% (CI)	n	% (CI)
Total								
	All	500	406	81.8 (78.1–85.0)	40	7.7 (5.6–10.4)	54	10.5 (8.0–13.6)
Sex								
	male	408	331	81.8 (77.7–85.3)	29	6.8 (4.7–9.7)	48	11.4 (8.6–15.0)
	female	92	75	81.7 (72.0–88.6)	11	11.7 (6.5–20.3)	6	6.6 (2.8–14.5)
Age								
	<25	9	3	33.6 (8.6–73.0)	3	34.9 (9.2–74.0)	3	31.5 (8.0–70.9)

	N	Past 30 days injecting 4 categories					
			opioids		stimulants		opi+stimul
		n	% (CI)	n	% (CI)	n	% (CI)
25-34	117	95	82.0 (73.7–88.1)	8	6.8 (3.4–13.3)	14	11.2 (6.5–18.5)
35-44	248	195	79.4 (73.7–84.1)	22	8.4 (5.5–12.7)	31	12.2 (8.6–17.0)
45+	126	113	90.2 (83.5–94.3)	7	5.0 (2.4–10.3)	6	4.8 (2.1–10.6)
Years since the start of injecting drug use							
≤2	18	11	58.0 (32.8–79.5)	5	31.6 (13.1–58.8)	2	10.4 (2.3–36.3)
3-5	47	32	71.6 (56.8–82.9)	8	15.8 (7.8–29.6)	7	12.5 (5.8–25.0)
6-10	64	50	76.3 (63.1–85.9)	7	11.9 (5.6–23.8)	7	11.7 (5.4–23.7)
≥11	371	313	85.2 (81.1–88.5)	20	4.8 (3.1–7.4)	38	10.0 (7.3–13.7)
Partnership status							
live alone	289	243	85.2 (80.6–88.9)	23	7.8 (5.1–11.5)	23	7.0 (4.6–10.6)
live with partner	211	163	77.2 (70.7–82.5)	17	7.6 (4.7–12.1)	31	15.2 (10.8–21.1)
Current employment status							
full-time	74	56	77.0 (65.6–85.4)	12	14.6 (8.1–24.8)	6	8.4 (3.7–18.0)
part-time or temporary	328	270	83.0 (78.5–86.8)	22	6.6 (4.3–9.9)	36	10.4 (7.5–14.2)
unemployed	54	44	80.0 (65.9–89.3)	5	9.2 (3.7–21.0)	5	10.8 (4.3–24.3)
disabled	37	31	85.5 (69.8–93.8)	1	3.1 (0.4–20.1)	5	11.4 (4.5–26.1)
other	6	5	89.6 (33.6–99.3)	0	0.0	1	10.4 (0.7–66.4)
Monthly income category							
<3K	77	58	76.9 (65.8–85.2)	6	7.1 (3.1–15.4)	13	16.0 (9.2–26.4)
3-10K	211	178	84.6 (78.9–89.0)	17	7.7 (4.8–12.2)	16	7.7 (4.6–12.5)
10-20K	165	134	81.7 (74.8–87.0)	13	7.6 (4.4–12.9)	18	10.7 (6.7–16.6)
≥20K	26	20	78.0 (56.2–90.8)	4	16.5 (5.7–39.3)	2	5.5 (1.2–20.9)
Ever incarcerated							
no	306	237	78.2 (73.1–82.6)	32	10.3 (7.3–14.4)	37	11.5 (8.3–15.6)
yes	190	166	87.7 (82.0–91.8)	7	3.2 (1.5–6.7)	17	9.2 (5.7–14.5)

Table 2.2. Types of Injecting Drugs in the Past 30 Days by Selected Subgroups

	N	Past 30 days injecting 4 categories					
			opioids		stimulants		opi+stimul
		n	% (CI)	n	% (CI)	n	% (CI)
Client of NGO working with PWID							

	N	Past 30 days injecting 4 categories					
		opioids		stimulants		opi+stimul	
		n	% (CI)	n	% (CI)	n	% (CI)
no	220	180	81.4 (75.4–86.2)	20	9.3 (6.0–14.2)	20	9.3 (6.0–14.1)
yes	272	220	82.1 (77.0–86.3)	19	6.3 (4.0–9.8)	33	11.6 (8.3–16.1)
Treated with MAT currently (of all)							
no	411	323	79.3 (75.0–83.0)	39	9.1 (6.7–12.4)	49	11.6 (8.8–15.2)
yes	66	63	95.7 (87.1–98.6)	1	1.3 (0.2–8.8)	2	3.0 (0.7–11.7)
HIV test result							
positive	117	98	84.0 (75.9–89.8)	8	6.3 (3.1–12.4)	11	9.7 (5.3–17.1)
negative	383	308	81.2 (76.8–84.9)	32	8.1 (5.7–11.4)	43	10.7 (8.0–14.3)
Injecting drug type of choice							
opioids	442	405	91.7 (88.6–94.0)	2	0.4 (0.1–1.6)	35	7.9 (5.7–11.0)
stimulants	55	0	0.0	38	70.9 (57.0–81.7)	17	29.1 (18.3–43.0)
other	3	1	35.7 (0.3–99.1)	0	0.0	2	64.3 (0.9–99.7)

Table 2.3. Injecting frequency

	Past 30 days injecting 4 categories							
	opioids		stimulants		opi+stimul		other	
	n	%	n	%	n	%	n	%
Injecting frequency: last 24 hrs								
0 times	39	9.8	8	21.8	0	0.0	0	
1 time	213	52.6	14	37.0	18	34.4	0	
2-3 times	140	34.8	16	37.7	24	46.0	0	
4+ times	14	2.8	2	3.5	12	19.6	0	
N	406		40		54		0	
Injecting frequency: last 24 hrs (among those who did)								
1 time	213	58.3	14	47.3	18	34.4	0	
2-3 times	140	38.6	16	48.3	24	46.0	0	
4+ times	14	3.1	2	4.5	12	19.6	0	
N	367		32		54		0	
Injecting frequency: last week								
0 times	1	0.4	1	3.2	0	0.0	0	
1-6 times	167	42.7	17	44.4	6	11.0	0	
every day	238	56.9	22	52.4	48	89.0	0	
N	406		40		54		0	
Injecting frequency: last 30 days								
1-9 times	44	11.6	4	10.9	5	10.8	0	
10-19 times	86	20.8	12	31.7	4	7.3	0	
20-29 times	71	19.4	5	12.7	4	7.0	0	
every day	205	48.1	19	44.7	41	74.9	0	
N	406		40		54		0	
Injecting frequency: main drug last 30 days								
0-9 times	16	4.1	1	3.2	0	0.0	0	
10-19 times	87	21.1	12	31.7	5	9.4	0	
20-29 times	67	18.6	5	11.3	3	4.7	0	

	Past 30 days injecting 4 categories							
	opioids		stimulants		opi+stimul		other	
	n	%	n	%	n	%	n	%
every day	236	56.2	22	53.8	45	85.9	0	
N	406		40		53		0	

Table 2.4. Injecting drug type of choice by Income Category

	Injecting drug type of choice					
	opioids		stimulants		other	
	n	%	n	%	n	%
Monthly income category						
<3K	66	15.7	11	18.5	0	0.0
3-10K	191	46.1	20	40.8	0	0.0
10-20K	146	33.3	18	30.7	1	100.0
≥20K	21	5.0	5	10.0	0	0.0
N	424		54		1	

Table 2.5. Sources of drugs by Drug Type of Choice

Total		Injecting drug type of choice						
All		opioids		stimulants		other		
n	%	n	%	n	%	n	%	p-value
prepare myself								
137	27.2	126	28.2	10	18.6	1	28.6	0.3550
prepared by friends								
10	2.0	9	2.0	1	1.9	0	0.0	0.9649
from a dealer								
180	36.7	152	35.3	26	46.0	2	71.4	0.1427
buy on Internet								
288	57.6	252	57.3	36	64.0	0	0.0	0.0787
from a pharmacy								
33	7.1	30	7.1	3	7.5	0	0.0	0.8924
from MAT program								
21	4.1	21	4.6	0	0.0	0	0.0	0.2929
N								
669		590		76		3		
other								
		0	0.0	0	0.0	0	0.0	



Figure 2.8. Change in the price, quality, and access of drugs by Drug Type of Choice (%)

3. Injecting Risk Behavior

Table 3.1. Prevalence of Injection Risk Practices

	n	%	CI
Used clean syringe for last injection			
yes	485	97.1	(95.1–98.3)
Source of syringe for last injection			
bought in pharmacy	251	49.9	(45.3–54.5)
got in pharmacy	4	0.7	(0.3–2.0)
got from NGO	238	48.0	(43.4–52.6)
got from friend	2	0.5	(0.1–2.0)
got used from friend	1	0.2	(0.0–1.4)
used one used by myself	1	0.1	(0.0–1.0)
got pre-loaded	0	0.0	
other	3	0.6	(0.2–1.9)
Used shared syringe in the past 30 days			
yes	33	6.8	(4.8–9.6)
Used pre-filled syringe in the past 30 days			
yes	15	3.0	(1.7–5.2)
Used front-/back-loaded syringe in the past 30 days			
yes	52	10.3	(7.7–13.5)
Used shared container in the past 30 days			
yes	63	12.1	(9.4–15.4)
Used own previously used syringe in the past 30 days			
yes	192	39.4	(34.9–44.0)
Gave someone a used syringe in the past 30 days			
yes	17	3.3	(2.0–5.3)
Any inj. risk (shared syringe, pre-filled, front-/back-load, container) in the past 30 days			
yes	102	20.9	(17.3–25.0)

Table 3.2. Frequency of risky injection practices

	n	%	CI
Frequency of injecting with a syringe used by others in the past 30 days			
always	3	9.5	(3.1–26.0)

	n	%	CI
often	1	3.7	(0.5–21.9)
half	2	6.6	(1.6–23.1)
sometimes	3	6.7	(2.1–19.2)
rarely	10	27.4	(14.6–45.3)
never	14	46.2	(29.1–64.2)
Frequency of injecting with others in the same place in the past 30 days			
always	72	15.2	(12.2–18.9)
often	62	12.0	(9.3–15.2)
half	74	14.0	(11.2–17.5)
sometimes	51	10.5	(7.9–13.8)
rarely	68	15.5	(12.3–19.4)
never	155	32.7	(28.5–37.3)
Number of syringes used repeatedly in the past 30 days			
1-9	144	77.5	(70.3–83.3)
10-29	36	20.0	(14.5–27.0)
30+	4	2.5	(0.9–7.0)
Number of times one syringe used repeatedly in the past 30 days			
1	12	6.0	(3.3–10.4)
2-3	126	68.8	(61.4–75.4)
4-9	36	19.3	(14.0–26.1)
10+	10	5.9	(3.1–10.8)
How the pre-filled syringe was obtained			
from dealer	4	20.4	(7.0–46.8)
from friends	7	49.0	(22.3–76.2)
from stash	2	30.6	(8.6–67.3)
Someone used one syringe for injection before front-/back-loading			
no	471	94.8	(92.6–96.5)
yes	29	5.2	(3.5–7.4)



Figure 3.1. Prevalence of Key Injection Risk Practices (%)



Figure 3.2. Trends in Key Injection Risk Practices by Survey Round (%)



Figure 3.3. With whom injected drugs in the same place (%)



Figure 3.4. With whom injected drugs in the same place by sex (%)



Figure 3.5. With whom injected drugs in the same place by age (%)

Table 3.3. Prevalence of Shared and Pre-filled Syringe Use by Sociodemographic Characteristics

		Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	499	33	6.8 (4.8–9.6)	1.0000	499	15	3.0 (1.7–5.2)	1.0000
Sex									
	male	408	28	6.9 (4.7–10.1)	0.8661	407	15	3.8 (2.2–6.4)	0.0791
	female	91	5	6.4 (2.6–14.8)		92	0	0.0	
Age									
	<25	9	0	0.0	0.1708	9	0	0.0	0.3005

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
25-34	117	13	11.5 (6.6–19.2)		116	7	5.1 (2.4–10.6)	
35-44	248	12	5.2 (2.8–9.3)		248	7	3.3 (1.5–7.3)	
45+	125	8	6.5 (3.1–13.1)		126	1	0.8 (0.1–5.8)	
Years since the start of injecting drug use								
≤2	18	1	5.7 (0.7–34.6)	0.1603	17	0	0.0	0.7764
3-5	47	5	9.3 (3.8–21.2)		47	2	3.7 (0.9–14.2)	
6-10	64	8	12.9 (6.3–24.7)		64	2	1.9 (0.4–7.6)	
≥11	370	19	5.5 (3.4–8.7)		371	11	3.3 (1.7–6.2)	
Partnership status								
live alone	289	23	8.5 (5.5–12.8)	0.0931	288	10	3.1 (1.6–5.9)	0.9290
live with partner	210	10	4.5 (2.4–8.3)		211	5	3.0 (1.1–7.6)	
Current employment status								
full-time	74	4	5.3 (1.8–14.3)	0.3604	74	2	5.4 (1.3–19.9)	0.4989
part-time or temporary	327	17	5.4 (3.3–8.5)		327	8	2.2 (1.1–4.4)	
unemployed	54	6	10.3 (4.5–21.8)		54	2	3.3 (0.8–12.9)	
disabled	37	4	12.5 (3.9–33.0)		37	2	4.3 (1.0–16.6)	
other	6	1	10.4 (0.7–66.4)		6	1	10.4 (0.7–66.4)	
Monthly income category								
<3K	77	5	5.5 (2.2–13.1)	0.9419	77	3	4.2 (1.3–12.6)	0.7854
3-10K	211	15	7.1 (4.1–12.0)		211	6	2.9 (1.2–7.3)	
10-20K	164	9	6.1 (3.1–11.5)		164	6	3.5 (1.5–8.0)	
≥20K	26	1	4.7 (0.6–29.0)		26	0	0.0	
Ever incarcerated								
no	305	21	7.5 (4.8–11.5)	0.4848	305	5	1.5 (0.6–3.8)	0.0152
yes	190	12	5.8 (3.2–10.2)		190	10	5.6 (2.9–10.8)	

Table 3.4. Prevalence of Shared and Pre-filled Syringe Use by Selected Subgroups

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	219	12	5.6 (3.1–9.8)	0.3700	219	5	2.2 (0.9–5.5)	0.4007

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
yes	272	20	7.8 (4.9–12.1)		272	9	3.6 (1.8–7.3)	
Treated with MAT currently (of all)								
no	410	28	6.9 (4.7–10.1)	0.7472	410	14	3.5 (2.0–6.1)	0.3052
yes	66	5	8.1 (3.3–18.5)		66	1	1.3 (0.2–8.8)	
HIV test result								
positive	116	7	6.1 (2.9–12.6)	0.7609	117	4	2.6 (1.0–6.8)	0.7334
negative	383	26	7.0 (4.7–10.3)		382	11	3.2 (1.7–6.0)	
Past 30 days injecting 4 categories								
opioids	405	22	5.7 (3.7–8.8)		406	9	2.4 (1.2–5.0)	
stimulants	40	3	8.3 (2.5–24.0)		40	0	0.0	
opi+stimul	54	8	13.9 (6.7–26.7)		53	6	10.2 (4.4–21.9)	
other	0	0			0	0		
Injecting drug type of choice								
opioids	441	27	6.3 (4.3–9.3)	0.4204	441	12	2.8 (1.5–5.3)	0.6895
stimulants	55	6	11.1 (4.9–23.3)		55	3	4.9 (1.5–14.7)	
other	3	0	0.0		3	0	0.0	

Table 3.5. Prevalence of Front-/back-loading and Container Sharing by Sociodemographic Characteristics

		Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	499	52	10.3 (7.7–13.5)	1.0000	496	63	12.1 (9.4–15.4)	1.0000
Sex									
	male	407	47	11.2 (8.3–15.0)	0.1909	404	55	12.7 (9.7–16.5)	0.3714
	female	92	5	6.2 (2.5–14.5)		92	8	9.2 (4.5–17.8)	
Age									
	<25	9	0	0.0	0.0408	9	0	0.0	0.0526
	25-34	117	18	14.5 (8.9–22.8)		117	21	15.4 (10.0–22.8)	
	35-44	247	27	11.6 (7.9–16.8)		246	33	13.8 (9.8–19.2)	
	45+	126	7	4.3 (2.0–9.0)		124	9	5.9 (3.0–11.2)	
Years since the start of injecting drug use									
	≤2	18	2	10.4 (2.3–36.3)	0.8438	18	3	15.1 (4.4–40.6)	0.9254

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
3-5	47	7	13.4 (6.0–27.1)		46	6	10.8 (4.7–22.9)	
6-10	64	6	8.1 (3.5–17.8)		64	8	10.4 (5.0–20.3)	
≥11	370	37	10.3 (7.3–14.2)		368	46	12.4 (9.2–16.4)	
Partnership status								
live alone	288	28	9.0 (6.1–13.0)	0.3062	287	28	8.9 (6.1–12.8)	0.0155
live with partner	211	24	12.0 (7.9–18.0)		209	35	16.3 (11.7–22.4)	
Current employment status								
full-time	74	7	11.1 (4.9–23.3)	0.9551	74	7	9.4 (4.0–20.7)	0.8529
part-time or temporary	327	32	9.6 (6.7–13.6)		324	40	11.9 (8.8–16.1)	
unemployed	54	7	12.2 (5.8–24.1)		54	8	14.6 (7.3–27.3)	
disabled	37	5	12.2 (4.7–28.1)		37	7	15.4 (6.8–31.0)	
other	6	1	10.4 (0.7–66.4)		6	1	10.4 (0.7–66.4)	
Monthly income category								
<3K	77	13	16.2 (9.4–26.7)	0.3263	77	15	18.7 (11.2–29.4)	0.3651
3-10K	210	19	9.7 (6.0–15.4)		208	24	11.4 (7.5–17.0)	
10-20K	165	16	8.2 (4.9–13.3)		164	20	10.5 (6.8–16.1)	
≥20K	26	3	12.8 (3.7–35.8)		26	3	12.4 (3.5–35.4)	
Ever incarcerated								
no	306	24	7.0 (4.6–10.5)	0.0032	302	30	8.6 (6.0–12.3)	0.0033
yes	189	28	15.9 (10.8–22.7)		190	33	17.8 (12.6–24.5)	

Table 3.6. Prevalence of Front-/back-loading and Container Sharing by Selected Subgroups

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	219	26	11.9 (8.0–17.3)	0.2156	219	32	13.4 (9.5–18.6)	0.4369
yes	272	23	8.2 (5.3–12.6)		269	30	11.0 (7.6–15.8)	
Treated with MAT currently (of all)								
no	410	44	10.6 (7.7–14.3)	0.0602	408	54	12.3 (9.4–15.9)	0.0329
yes	66	2	3.0 (0.7–12.0)		65	2	3.0 (0.7–12.2)	
HIV test result								

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
positive	116	8	6.1 (3.0–12.1)	0.0938	117	11	9.7 (5.2–17.3)	0.4053
negative	383	44	11.5 (8.4–15.4)		379	52	12.7 (9.7–16.6)	
Past 30 days injecting 4 categories								
opioids	405	37	9.4 (6.7–13.1)		404	45	10.9 (8.0–14.5)	
stimulants	40	2	4.7 (1.1–17.9)		39	6	14.5 (6.3–29.9)	
opi+stimul	54	13	21.4 (12.4–34.4)		53	12	19.7 (11.1–32.4)	
other	0	0			0	0		
Injecting drug type of choice								
opioids	441	46	10.4 (7.6–13.9)	0.8245	439	53	11.5 (8.7–15.0)	0.3683
stimulants	55	6	10.4 (4.6–21.7)		54	10	17.7 (9.5–30.6)	
other	3	0	0.0		3	0	0.0	

4. Sexual Behavior

Table 4.1. Prevalence of Sexual Practice by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had sex: ever										
yes	483	96.5	(94.3–97.9)	89	97.2	(91.4–99.1)	394	96.4	(93.7–98.0)	0.6951
N	500			92			408			
Had sex: in the past 12 months										
yes	413	85.9	(82.4–88.9)	80	91.4	(83.9–95.6)	333	84.6	(80.5–88.1)	0.0869
N	481			89			392			
Had sex: in the past 30 days										
yes	271	56.7	(52.0–61.3)	60	67.2	(56.2–76.6)	211	54.2	(49.0–59.4)	0.0332
N	479			89			390			
Had a sex partner in the past 30 days: regular										
yes	213	78.9	(73.7–83.4)	57	94.3	(83.6–98.2)	156	74.5	(68.2–79.9)	0.0019
N	275			60			215			
Had a sex partner in the past 30 days: casual										
yes	75	26.0	(21.1–31.7)	4	7.1	(2.6–17.8)	71	31.5	(25.5–38.2)	0.0003
N	271			59			212			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	5	1.6	(0.7–3.9)	0	0.0		5	2.1	(0.9–5.0)	0.2330
N	275			60			215			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes	1	0.4	(0.1–2.5)	0	0.0		1	0.5	(0.1–3.2)	0.5939
N	274			59			215			
Used condom during last sex: if ever had sex										
yes	221	48.0	(43.2–52.8)	27	31.3	(22.1–42.4)	194	52.1	(46.7–57.4)	0.0009
N	456			88			368			
Used condom during last sex: if had sex in 12m										

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
yes	197	48.4	(43.3–53.5)	25	31.9	(22.1–43.6)	172	52.7	(46.9–58.3)	0.0016
N	399			79			320			
Used condom during last sex: if had sex in 30d										
yes	126	45.6	(39.4–51.9)	17	28.2	(17.9–41.5)	109	50.8	(43.6–57.9)	0.0031
N	267			60			207			



Figure 4.1. Frequency of sex in the past week by Drug Types Used (%)

Table 4.2. Sex Practices by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had same-sex sexual experience										
yes	20	3.8	(2.4–6.0)	13	13.9	(8.0–23.1)	7	1.5	(0.7–3.2)	0.0000
N	481			88			393			
Provided sex services for money										
yes	9	1.9	(1.0–3.6)	8	8.8	(4.4–17.1)	1	0.2	(0.0–1.5)	0.0000
N	482			89			393			
Paid for sex ever										
yes	117	23.5	(19.8–27.7)	3	3.9	(1.2–11.5)	114	28.0	(23.7–32.9)	0.0000
N	481			88			393			
Had sex with a sex worker in the past 6 months										
yes	23	18.3	(12.2–26.4)	0	0.0		23	18.9	(12.7–27.2)	0.3953
N	116			3			113			
Type of partner with whom had last sex										
regular	311	65.2	(60.7–69.6)	80	90.6	(81.4–95.5)	231	59.4	(54.2–64.4)	
casual	162	33.7	(29.4–38.2)	7	9.4	(4.5–18.6)	155	39.3	(34.3–44.4)	
com. sex (I paid)	5	1.1	(0.4–2.7)	0	0.0		5	1.4	(0.5–3.4)	
com. sex (I was paid)	0	0.0		0	0.0		0	0.0		
N	478			87			391			
With whom last had sex										
man	81	17.1	(13.8–20.9)	81	91.8	(82.5–96.4)	0	0.0		
woman	399	82.9	(79.1–86.2)	6	8.2	(3.6–17.5)	393	100.0		

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
men and women	0	0.0		0	0.0		0	0.0		
N	480			87			393			
Type of last sex contact: vaginal										
yes	454	93.8	(91.0–95.7)	85	94.6	(86.3–98.0)	369	93.6	(90.5–95.7)	0.7438
N	482			89			393			
Type of last sex contact: anal										
yes	13	2.8	(1.6–4.8)	3	4.1	(1.3–12.0)	10	2.5	(1.3–4.6)	0.4359
N	482			89			393			
Type of last sex contact: oral										
yes	66	14.4	(11.3–18.0)	6	8.1	(3.6–17.2)	60	15.8	(12.3–20.1)	0.0921
N	482			89			393			

Table 4.3. Sex Partners by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had a sex partner in the past 30 days: regular										
yes	213	78.9	(73.7–83.4)	57	94.3	(83.6–98.2)	156	74.5	(68.2–79.9)	0.0019
N	275			60			215			
Had a sex partner in the past 30 days: casual										
yes	75	26.0	(21.1–31.7)	4	7.1	(2.6–17.8)	71	31.5	(25.5–38.2)	0.0003
N	271			59			212			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	5	1.6	(0.7–3.9)	0	0.0		5	2.1	(0.9–5.0)	0.2330
N	275			60			215			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes	1	0.4	(0.1–2.5)	0	0.0		1	0.5	(0.1–3.2)	0.5939
N	274			59			215			
Number of sex partners in the past 30 days: regular										
1	193	95.5	(91.9–97.6)	50	98.6	(90.7–99.8)	143	94.5	(89.7–97.1)	
2-4	11	4.5	(2.4–8.1)	1	1.4	(0.2–9.3)	10	5.5	(2.9–10.3)	
5+	0	0.0		0	0.0		0	0.0		
N	204			51			153			
Number of sex partners in the past 30 days: casual										
1	51	73.3	(61.4–82.6)	3	100.0		48	71.9	(59.6–81.6)	0.5103
2-4	18	25.4	(16.4–37.3)	0	0.0		18	26.8	(17.3–39.0)	
5+	1	1.3	(0.2–8.5)	0	0.0		1	1.3	(0.2–8.9)	
N	70			3			67			
Number of sex partners in the past 30 days: commercial (buying - I paid)										
1	3	73.9	(22.6–96.5)	0	0.0		3	73.9	(22.6–96.5)	
2-4	1	26.1	(3.5–77.4)	0	0.0		1	26.1	(3.5–77.4)	
5+	0	0.0		0	0.0		0	0.0		
N	4			0			4			
Number of sex partners in the past 30 days: total										
1	217	85.5	(80.7–89.3)	51	98.5	(89.7–99.8)	166	82.1	(76.3–86.8)	0.0081
2-4	40	13.7	(10.0–18.4)	1	1.5	(0.2–10.3)	39	16.9	(12.4–22.6)	
5+	2	0.8	(0.2–3.2)	0	0.0		2	1.0	(0.2–4.0)	
N	259			52			207			



Figure 4.2. Condom Use During Last Sexual Encounter by Type of Partner (%)



Figure 4.3. Trends in Condom Use During Last Sexual Encounter by Survey Round (%)

Table 4.4. Condom Use During Last Sexual Encounter by Sociodemographic Characteristics

			Used condom during last sex: if ever had sex			
		N	no		yes	
			n	% (CI)	n	% (CI)	p-value
Total							
	All	456	235	52.0 (47.2–56.8)	221	48.0 (43.2–52.8)	1.0000
Sex							
	male	368	174	47.9 (42.6–53.3)	194	52.1 (46.7–57.4)	0.0009
	female	88	61	68.7 (57.6–77.9)	27	31.3 (22.1–42.4)	
Age							
	<25	8	3	37.3 (9.5–77.0)	5	62.7 (23.0–90.5)	0.3281

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
25-34	110	63	59.2 (49.4–68.3)	47	40.8 (31.7–50.6)	
35-44	231	114	49.3 (42.5–56.0)	117	50.7 (44.0–57.5)	
45+	107	55	52.3 (42.4–62.1)	52	47.7 (37.9–57.6)	
Years since the start of injecting drug use						
≤2	15	11	74.1 (45.0–90.9)	4	25.9 (9.1–55.0)	0.0289
3-5	47	20	38.7 (25.4–54.0)	27	61.3 (46.0–74.6)	
6-10	60	35	63.0 (49.9–74.5)	25	37.0 (25.5–50.1)	
≥11	334	169	50.9 (45.2–56.5)	165	49.1 (43.5–54.8)	
Partnership status						
live alone	255	102	39.9 (33.8–46.4)	153	60.1 (53.6–66.2)	0.0000
live with partner	201	133	67.1 (60.0–73.5)	68	32.9 (26.5–40.0)	
Current employment status						
full-time	68	32	46.5 (34.3–59.0)	36	53.5 (41.0–65.7)	0.8008
part-time or temporary	303	158	53.0 (47.1–58.8)	145	47.0 (41.2–52.9)	
unemployed	46	22	48.6 (33.8–63.6)	24	51.4 (36.4–66.2)	
disabled	32	19	57.6 (38.5–74.7)	13	42.4 (25.3–61.5)	
other	6	3	45.4 (8.6–88.0)	3	54.6 (12.0–91.4)	
Monthly income category						
<3K	65	32	48.7 (36.2–61.4)	33	51.3 (38.6–63.8)	0.2569
3-10K	196	109	57.3 (49.9–64.4)	87	42.7 (35.6–50.1)	
10-20K	151	72	46.6 (38.4–54.9)	79	53.4 (45.1–61.6)	
≥20K	26	13	54.9 (34.5–73.8)	13	45.1 (26.2–65.5)	
Ever incarcerated						
no	279	140	50.8 (44.7–56.9)	139	49.2 (43.1–55.3)	0.4652
yes	174	94	54.5 (46.6–62.2)	80	45.5 (37.8–53.4)	

Table 4.5. Condom Use During Last Sexual Encounter by Selected Subgroups

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	200	118	60.3 (53.0–67.1)	82	39.7 (32.9–47.0)	0.0030
yes	250	115	45.5 (39.1–52.1)	135	54.5 (47.9–60.9)	
Treated with MAT currently (of all)						
no	380	200	52.9 (47.6–58.1)	180	47.1 (41.9–52.4)	0.3629
yes	57	26	46.2 (33.1–59.8)	31	53.8 (40.2–66.9)	
HIV test result						
positive	104	47	45.6 (35.9–55.7)	57	54.4 (44.3–64.1)	0.1598
negative	352	188	53.8 (48.3–59.2)	164	46.2 (40.8–51.7)	
Past 30 days injecting 4 categories						
opioids	372	186	51.0 (45.6–56.3)	186	49.0 (43.7–54.4)	
stimulants	33	19	58.3 (40.2–74.4)	14	41.7 (25.6–59.8)	
opi+stimul	51	30	55.7 (41.1–69.5)	21	44.3 (30.5–58.9)	
other	0	0		0		
Injecting drug type of choice						
opioids	406	204	50.7 (45.6–55.8)	202	49.3 (44.2–54.4)	0.3151
stimulants	47	29	62.8 (47.6–75.8)	18	37.2 (24.2–52.4)	
other	3	2	64.3 (0.9–99.7)	1	35.7 (0.3–99.1)	

Table 4.6. Condom use by type of partner by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Used condom during last sex: regular partner										
yes	78	35.1	(28.7–42.2)	14	24.5	(14.6–38.0)	64	39.0	(31.3–47.3)	0.0597
N	210			56			154			
Used condom during last sex: casual partner										
yes	52	66.9	(55.1–76.9)	5	100.0		47	64.4	(52.1–75.0)	0.0985
N	76			5			71			
Used condom during last sex: commercial (I paid) partner										
yes	2	64.7	(14.1–95.3)	0	0.0		2	64.7	(14.1–95.3)	
N	3			0			3			
Condom use frequency: regular partner										
always	53	23.4	(18.1–29.8)	9	15.0	(7.7–27.3)	44	26.5	(19.9–34.2)	0.1533
often	17	7.6	(4.7–12.1)	5	9.3	(3.8–20.8)	12	7.0	(3.9–12.2)	
half	11	4.8	(2.6–8.5)	2	3.6	(0.9–13.9)	9	5.2	(2.6–9.8)	
sometimes	9	4.0	(1.9–8.3)	1	1.7	(0.2–11.6)	8	4.8	(2.1–10.5)	
rarely	20	10.4	(6.7–15.7)	4	6.2	(2.3–15.8)	16	11.9	(7.3–18.7)	
never	101	49.8	(42.7–56.9)	35	64.2	(50.3–76.0)	66	44.6	(36.5–53.0)	
N	211			56			155			
Condom use frequency: casual partner										

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
always	40	51.5	(39.8–63.1)	2	57.9	(10.7–94.1)	38	51.2	(39.3–63.0)	0.3767
often	11	16.9	(9.6–28.1)	0	0.0		11	17.7	(10.0–29.3)	
half	6	8.4	(3.8–17.6)	1	42.1	(5.9–89.3)	5	6.9	(2.9–15.6)	
sometimes	2	2.4	(0.6–9.2)	0	0.0		2	2.5	(0.6–9.6)	
rarely	3	5.1	(1.6–14.6)	0	0.0		3	5.3	(1.7–15.2)	
never	11	15.7	(8.8–26.7)	0	0.0		11	16.4	(9.2–27.7)	
N	73			3			70			
Condom use frequency: commercial (I paid) partner										
always	3	73.9	(22.6–96.5)	0	0.0		3	73.9	(22.6–96.5)	
often	0	0.0		0	0.0		0	0.0		
half	0	0.0		0	0.0		0	0.0		
sometimes	0	0.0		0	0.0		0	0.0		
rarely	0	0.0		0	0.0		0	0.0		
never	1	26.1	(3.5–77.4)	0	0.0		1	26.1	(3.5–77.4)	
N	4			0			4			
Used condom during last sex: commercial (I was paid) partner										
yes				1	100.0		1	100.0		
N				1			1			
Condom use frequency: commercial (I was paid) partner										
always				1	100.0		1	100.0		
often				0	0.0		0	0.0		
half				0	0.0		0	0.0		
sometimes				0	0.0		0	0.0		
rarely				0	0.0		0	0.0		
never				0	0.0		0	0.0		
N				1			1			



Figure 4.4. Frequency of condom use by type of partner by Sex (%)



Figure 4.5. Frequency of condom use among men during the last sexual encounter by the riskiest type of partner in the past 30 days (%)

5. HIV, HCV, and Syphilis Testing Results

Table 5.1. HIV Prevalence by Sociodemographic Characteristics

			HIV test result				
		N	positive		negative		
			n	% (CI)	n	% (CI)	p-value
Total							
	All	500	117	22.1 (18.6–26.0)	383	77.9 (74.0–81.4)	1.0000
Sex							
	male	408	85	20.1 (16.4–24.4)	323	79.9 (75.6–83.6)	0.0279
	female	92	32	30.8 (22.0–41.1)	60	69.2 (58.9–78.0)	
Age							
	<25	9	0	0.0	9	100.0	0.0000
	25-34	117	12	10.2 (5.7–17.6)	105	89.8 (82.4–94.3)	
	35-44	248	54	20.5 (15.9–26.1)	194	79.5 (73.9–84.1)	
	45+	126	51	38.0 (29.7–47.1)	75	62.0 (52.9–70.3)	
Years since the start of injecting drug use							
	≤2	18	2	9.8 (2.1–35.0)	16	90.2 (65.0–97.9)	0.0004
	3-5	47	7	15.1 (7.0–29.3)	40	84.9 (70.7–93.0)	
	6-10	64	4	5.3 (1.9–13.8)	60	94.7 (86.2–98.1)	
	≥11	371	104	26.5 (22.1–31.4)	267	73.5 (68.6–77.9)	
Partnership status							
	live alone	289	61	20.1 (15.8–25.3)	228	79.9 (74.7–84.2)	0.2316

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
live with partner	211	56	24.7 (19.3–31.1)	155	75.3 (68.9–80.7)	
Current employment status						
full-time	74	16	19.0 (11.6–29.6)	58	81.0 (70.4–88.4)	0.0442
part-time or temporary	328	66	19.4 (15.4–24.2)	262	80.6 (75.8–84.6)	
unemployed	54	20	36.0 (23.7–50.5)	34	64.0 (49.5–76.3)	
disabled	37	13	31.4 (18.0–48.7)	24	68.6 (51.3–82.0)	
other	6	2	30.7 (4.3–81.3)	4	69.3 (18.7–95.7)	
Monthly income category						
<3K	77	23	28.8 (19.4–40.5)	54	71.2 (59.5–80.6)	0.1669
3-10K	211	50	21.8 (16.7–28.0)	161	78.2 (72.0–83.3)	
10-20K	165	29	16.4 (11.4–23.0)	136	83.6 (77.0–88.6)	
≥20K	26	7	26.6 (12.4–48.2)	19	73.4 (51.8–87.6)	
Ever incarcerated						
no	306	53	16.0 (12.3–20.6)	253	84.0 (79.4–87.7)	0.0001
yes	190	62	31.8 (25.3–39.1)	128	68.2 (60.9–74.7)	

Table 5.2. HIV Prevalence by Selected Subgroups

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	220	43	18.4 (13.8–24.2)	177	81.6 (75.8–86.2)	0.0688
yes	272	73	25.4 (20.5–31.1)	199	74.6 (68.9–79.5)	
Treated with MAT currently (of all)						
no	411	89	20.2 (16.6–24.4)	322	79.8 (75.6–83.4)	0.0584
yes	66	21	30.9 (20.5–43.7)	45	69.1 (56.3–79.5)	
Past 30 days injecting 4 categories						
opioids	406	98	22.7 (18.8–27.1)	308	77.3 (72.9–81.2)	
stimulants	40	8	18.0 (8.8–33.3)	32	82.0 (66.7–91.2)	
opi+stimul	54	11	20.4 (11.3–34.2)	43	79.6 (65.8–88.7)	
other	0	0		0		
Injecting drug type of choice						

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
opioids	442	105	22.5 (18.8–26.8)	337	77.5 (73.2–81.2)	0.5900
stimulants	55	11	17.3 (9.5–29.6)	44	82.7 (70.4–90.5)	
other	3	1	35.7 (0.3–99.1)	2	64.3 (0.9–99.7)	



Figure 5.1. HIV Test Result (%)



Figure 5.2. Trends in HIV Prevalence by Survey Round (%)



Figure 5.3. Anti-HCV Testing Coverage In the Survey (%)



Figure 5.4. Anti-HCV Test Results (%)



Figure 5.5. Anti-HCV Test Results by Sex (%)



Figure 5.6. Trends in Anti-HCV Prevalence by Survey Round (%)



Figure 5.7. Syphilis Test Results (%)

6. HIV Prevention

Table 6.1. Being a Client of NGO by Sociodemographic Characteristics

			Client of NGO working with PWID			
		N	no		yes	
			n	% (CI)	n	% (CI)	p-value
Total							
	All	492	220	45.1 (40.5–49.7)	272	54.9 (50.3–59.5)	1.0000
Sex							
	male	400	182	46.3 (41.2–51.5)	218	53.7 (48.5–58.8)	0.2765
	female	92	38	39.8 (29.9–50.6)	54	60.2 (49.4–70.1)	
Age							

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
<25	9	3	33.6 (8.6–73.0)	6	66.4 (27.0–91.4)	0.0153
25-34	115	65	58.5 (48.9–67.5)	50	41.5 (32.5–51.1)	
35-44	244	104	42.5 (36.1–49.1)	140	57.5 (50.9–63.9)	
45+	124	48	39.2 (30.6–48.5)	76	60.8 (51.5–69.4)	
Years since the start of injecting drug use						
≤2	18	14	80.1 (54.7–93.1)	4	19.9 (6.9–45.3)	0.0004
3-5	47	24	53.5 (38.4–68.0)	23	46.5 (32.0–61.6)	
6-10	62	36	58.8 (45.6–70.9)	26	41.2 (29.1–54.4)	
≥11	365	146	40.0 (34.8–45.3)	219	60.0 (54.7–65.2)	
Partnership status						
live alone	282	123	43.5 (37.6–49.7)	159	56.5 (50.3–62.4)	0.4442
live with partner	210	97	47.2 (40.2–54.3)	113	52.8 (45.7–59.8)	
Current employment status						
full-time	72	27	38.8 (27.7–51.3)	45	61.2 (48.7–72.3)	0.4024
part-time or temporary	324	154	47.5 (41.9–53.3)	170	52.5 (46.7–58.1)	
unemployed	53	24	46.4 (32.5–60.8)	29	53.6 (39.2–67.5)	
disabled	37	12	33.0 (18.9–51.0)	25	67.0 (49.0–81.1)	
other	5	2	44.0 (6.5–89.9)	3	56.0 (10.1–93.5)	
Monthly income category						
<3K	75	35	45.3 (33.7–57.3)	40	54.7 (42.7–66.3)	0.4696
3-10K	210	103	48.7 (41.6–55.8)	107	51.3 (44.2–58.4)	
10-20K	160	66	42.5 (34.7–50.7)	94	57.5 (49.3–65.3)	
≥20K	26	7	33.7 (16.5–56.7)	19	66.3 (43.3–83.5)	
Ever incarcerated						
no	301	141	47.1 (41.3–53.1)	160	52.9 (46.9–58.7)	0.3483
yes	187	79	42.6 (35.3–50.2)	108	57.4 (49.8–64.7)	

Table 6.2. Being a Client of NGO by Selected Subgroups

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Treated with MAT currently (of all)						
no	404	196	49.0 (43.9–54.1)	208	51.0 (45.9–56.1)	0.0000
yes	66	12	18.4 (10.4–30.5)	54	81.6 (69.5–89.6)	
HIV test result						
positive	116	43	37.3 (28.6–46.9)	73	62.7 (53.1–71.4)	0.0688
negative	376	177	47.3 (42.1–52.6)	199	52.7 (47.4–57.9)	
Past 30 days injecting 4 categories						
opioids	400	180	44.9 (39.8–50.1)	220	55.1 (49.9–60.2)	
stimulants	39	20	54.9 (38.5–70.3)	19	45.1 (29.7–61.5)	
opi+stimul	53	20	39.5 (26.7–54.1)	33	60.5 (45.9–73.3)	
other	0	0		0		
Injecting drug type of choice						
opioids	435	193	44.5 (39.6–49.4)	242	55.5 (50.6–60.4)	0.5387
stimulants	54	26	51.5 (37.6–65.1)	28	48.5 (34.9–62.4)	
other	3	1	28.6 (0.2–98.7)	2	71.4 (1.3–99.8)	



Figure 6.1. Injecting and Sex Risk Perception Among HIV-negative PWID (%)



Figure 6.2. Received HIV Prevention Services in the Past 12 Months and 30 days (%)



Figure 6.3. Receiving Package of Prevention Services in the Past 12 Months (%)



Figure 6.4. Trends in Receiving HIV Prevention Services in the Past 12 Months (%)



Figure 6.5. Perceived changes in access to HIV prevention since February 2022 (%)

Table 6.3. Percentage of correct responses to knowledge questions by HIV status

	Total	HIV test result		
	All	negative	positive	
	%	%	%	p-value
HIV knowledge				
HIV may be avoided	88.4	87.6	91.2	0.3076
proper condom use may prevent HIV	49.5	47.3	57.0	0.0810
undetectable=untransmittable	53.1	51.4	59.1	0.1604
PEP reduces the risk of HIV	54.3	53.1	58.7	0.3093
ART should be started immediately	87.5	87.8	86.3	0.6685

	Total	HIV test result		
	All	negative	positive	
	%	%	%	p-value
ART may be postponed if one feels healthy	74.5	74.9	73.1	0.7141
ART may be stopped if one feels healthy	79.1	77.3	85.2	0.0668
HIV is transmitted through blood and sex	92.9	92.5	94.4	0.4987
HIV is transmitted via air, food, or skin	93.8	93.0	96.6	0.1683
HBV knowledge				
proper condom use may prevent HBV	78.2	78.3	77.8	0.9096
treatment should be started immediately	83.0	83.9	79.8	0.3232
treatment may be postponed if one feels healthy	68.3	68.5	67.6	0.8603
HBV is 100% transmitted from mother to child	11.8	12.1	10.4	0.6104
HBV is transmitted through blood and sex	83.4	83.0	84.7	0.6910
HBV is transmitted via air, food, or skin	65.1	64.2	68.1	0.4658
treatment may be stopped if one feels healthy	73.3	72.6	75.8	0.5160
HCV knowledge				
proper condom use may prevent HCV	5.6	5.6	5.7	0.9806
treatment should be started immediately	83.7	83.1	85.9	0.4919
treatment may be postponed if one feels healthy	74.4	75.3	71.1	0.3836
HCV is 100% transmitted from mother to child	11.2	11.5	10.2	0.6952
HCV is transmitted through blood and sex	90.1	91.0	87.0	0.2103
there is no treatment for HCV	74.0	74.2	73.0	0.7910
HCV is transmitted via air, food, or skin	75.0	75.1	74.4	0.8718
treatment may be stopped if one feels healthy	80.5	79.7	83.3	0.4125

7. HIV Testing

Table 7.1. HIV Testing Knowledge and Uptake

	n	%	CI
Know where to get HIV test			
yes	429	88.2	(84.8–90.9)
Tested for HIV ever			
yes	462	93.7	(90.9–95.6)
Tested for HIV in the past 12 months			
yes	240	55.0	(50.1–59.9)
Tested for HIV in the past 6 months			
yes	157	36.3	(31.7–41.2)
Received the result of HIV test (of those tested)			
yes	451	98.8	(97.1–99.5)
Willing to disclose HIV test result (of those who got result)			
yes	450	100.0	
Self-reported HIV status (of all tested)			
positive	92	19.2	(15.8–23.2)
negative	364	80.8	(76.8–84.2)
HIV testing and status awareness (GAM)			
yes	289	66.1	(61.3–70.7)
Ever did a HIV self-test			
yes	2	0.4	(0.1–1.7)
Regular sex partner tested for HIV			
yes	145	72.3	(65.4–78.4)
Regular sex partner HIV test result			
positive	32	22.9	(16.4–31.2)
negative	106	75.7	(67.4–82.4)
cannot disclose	2	1.4	(0.3–5.6)



Figure 7.1. HIV Testing Uptake (%)



Figure 7.2. Testing for HIV, HCV, syphilis since February 2022 (%)



Figure 7.3. HIV Testing Since February 2022 (%)

Table 7.2. Testing for HIV in the past 12 months (among all) by Sociodemographic Characteristics

	N	Tested for HIV in the past 12 months			
		no		yes	
		n	% (CI)	n	% (CI)	p-value
Total						
All	435	195	45.0 (40.1–49.9)	240	55.0 (50.1–59.9)	1.0000
Sex						
male	357	156	44.2 (38.9–49.7)	201	55.8 (50.3–61.1)	0.5358
female	78	39	48.3 (36.8–59.9)	39	51.7 (40.1–63.2)	
Age						
<25	8	4	44.6 (13.2–80.9)	4	55.4 (19.1–86.8)	0.9963
25-34	103	45	45.9 (36.0–56.1)	58	54.1 (43.9–64.0)	
35-44	214	95	44.5 (37.6–51.6)	119	55.5 (48.4–62.4)	
45+	110	51	45.2 (35.8–55.0)	59	54.8 (45.0–64.2)	
Years since the start of injecting drug use						
≤2	11	7	64.9 (32.7–87.5)	4	35.1 (12.5–67.3)	0.3651
3-5	39	19	48.7 (32.9–64.8)	20	51.3 (35.2–67.1)	
6-10	53	18	36.8 (24.2–51.6)	35	63.2 (48.4–75.8)	
≥11	332	151	45.3 (39.7–51.0)	181	54.7 (49.0–60.3)	
Partnership status						
live alone	255	102	39.8 (33.7–46.3)	153	60.2 (53.7–66.3)	0.0166
live with partner	180	93	52.1 (44.4–59.6)	87	47.9 (40.4–55.6)	

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Current employment status						
full-time	67	26	38.7 (27.3–51.6)	41	61.3 (48.4–72.7)	0.1835
part-time or temporary	281	125	44.8 (38.8–50.9)	156	55.2 (49.1–61.2)	
unemployed	47	24	55.4 (40.2–69.7)	23	44.6 (30.3–59.8)	
disabled	34	15	38.7 (23.2–56.9)	19	61.3 (43.1–76.8)	
other	5	4	85.9 (25.4–99.1)	1	14.1 (0.9–74.6)	
Monthly income category						
<3K	66	34	54.3 (41.5–66.6)	32	45.7 (33.4–58.5)	0.4546
3-10K	180	81	43.2 (35.8–50.9)	99	56.8 (49.1–64.2)	
10-20K	148	61	42.8 (34.7–51.3)	87	57.2 (48.7–65.3)	
≥20K	26	12	43.8 (25.0–64.5)	14	56.2 (35.5–75.0)	
Ever incarcerated						
no	266	113	42.7 (36.6–49.0)	153	57.3 (51.0–63.4)	0.1741
yes	165	82	49.7 (41.7–57.8)	83	50.3 (42.2–58.3)	

Table 7.3. Testing for HIV in the past 12 months (among all) by Selected Subgroups

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	172	105	60.8 (53.0–68.1)	67	39.2 (31.9–47.0)	0.0000
yes	255	88	34.7 (28.9–41.1)	167	65.3 (58.9–71.1)	
Treated with MAT currently (of all)						
no	353	168	47.4 (42.0–52.9)	185	52.6 (47.1–58.0)	0.0430
yes	63	19	32.6 (21.3–46.3)	44	67.4 (53.7–78.7)	
HIV test result						
positive	102	67	66.9 (56.8–75.6)	35	33.1 (24.4–43.2)	0.0000
negative	333	128	38.9 (33.5–44.5)	205	61.1 (55.5–66.5)	
Past 30 days injecting 4 categories						
opioids	356	160	44.8 (39.4–50.3)	196	55.2 (49.7–60.6)	
stimulants	30	11	37.1 (21.0–56.6)	19	62.9 (43.4–79.0)	
opi+stimul	49	24	50.9 (36.4–65.3)	25	49.1 (34.7–63.6)	

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
other	0	0		0		
Injecting drug type of choice						
opioids	390	177	45.6 (40.5–50.8)	213	54.4 (49.2–59.5)	0.3657
stimulants	43	18	41.1 (26.8–57.1)	25	58.9 (42.9–73.2)	
other	2	0	0.0	2	100.0	

8. HIV Treatment



Figure 8.1. HIV Status Awareness Among HIV+ (%)



Figure 8.2. HIV Treatment Cascade - Four-stage (%)



Figure 8.3. HIV Treatment Cascade - Conditional (%)



Figure 8.4. HIV Treatment Cascade - Proportions (%)



Figure 8.5. Trends in HIV Treatment Cascade (Conditional, 95-95-95) by Survey Round (%)

Table 8.1. HIV Treatment Cascade (Conditional, 95-95-95) by Sociodemographic Characteristics

		Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
		N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Total											
	All	117	73.0 (63.9–80.5)	1.0000	86	96.2 (88.7–98.8)	1.0000	83	72	87.0 (77.7–92.8)	1.0000
Sex											
	male	85	69.3 (58.3–78.4)	0.1409	59	96.8 (87.8–99.2)	0.6977	57	51	90.7 (80.4–95.9)	0.1255
	female	32	83.5 (65.1–93.2)		27	94.9 (70.9–99.3)		26	21	78.1 (56.4–90.8)	
Age											

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
<25	0	0.0		0	0.0		0	0	0.0	
25-34	12	83.4 (50.1–96.2)		10	86.8 (44.7–98.2)		9	8	87.8 (46.6–98.3)	
35-44	54	60.7 (46.8–73.0)		32	97.5 (83.7–99.6)		31	27	89.5 (74.4–96.2)	
45+	51	85.0 (71.2–92.9)		44	97.4 (83.6–99.6)		43	37	84.7 (69.3–93.1)	
Years since the start of injecting drug use										
≤2	2	100.0	0.1272	2	100.0	0.0048	2	0	0.0	0.0034
3-5	7	41.8 (12.9–77.7)		3	57.9 (10.4–94.3)		2	2	100.0	
6-10	4	50.0 (11.6–88.4)		2	100.0		2	2	100.0	
≥11	104	75.6 (66.1–83.1)		79	97.5 (90.6–99.4)		77	68	88.4 (78.9–94.0)	
Partnership status										
live alone	61	66.6 (53.3–77.6)	0.1092	41	97.9 (86.1–99.7)	0.4381	40	38	95.7 (83.7–99.0)	0.0187
live with partner	56	80.2 (67.2–88.9)		45	94.7 (80.9–98.7)		43	34	78.7 (63.4–88.8)	
Current employment status										
full-time	16	77.8 (48.5–92.8)	0.0880	13	100.0	0.8467	13	12	91.1 (56.1–98.8)	0.2992
part-time or temporary	66	63.3 (50.7–74.2)		41	94.8 (81.0–98.7)		39	33	84.0 (68.2–92.8)	
unemployed	20	93.4 (64.0–99.1)		19	94.3 (67.6–99.2)		18	17	95.6 (73.5–99.4)	
disabled	13	83.5 (50.6–96.2)		11	100.0		11	9	86.1 (55.3–96.9)	
other	2	100.0		2	100.0		2	1	43.1 (1.9–96.6)	
Monthly income category										
<3K	23	81.6 (59.2–93.1)	0.8006	19	100.0	0.8108	19	18	96.5 (78.0–99.5)	0.1270
3-10K	50	70.6 (56.2–81.8)		35	96.3 (77.8–99.5)		34	26	76.5 (59.0–88.0)	

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
10-20K	29	70.8 (50.8–85.0)		21	95.5 (73.6–99.4)		20	18	89.4 (64.1–97.5)	
≥20K	7	72.0 (30.2–93.8)		5	100.0		5	5	100.0	
Ever incarcerated										
no	53	71.4 (57.2–82.4)	0.6861	39	96.5 (78.8–99.5)	0.9051	38	30	78.6 (62.1–89.2)	0.0508
yes	62	74.9 (62.3–84.4)		46	95.9 (84.9–99.0)		44	41	93.4 (81.3–97.9)	

Table 8.2. HIV Treatment Cascade (Conditional, 95-95-95) by Selected Subgroups

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID										
no	43	47.8 (32.9–63.0)	0.0000	21	100.0	0.3159	21	18	86.2 (64.1–95.6)	0.8965
yes	73	88.8 (78.8–94.4)		65	95.0 (85.3–98.4)		62	54	87.3 (76.1–93.7)	
Treated with MAT currently (of all)										
no	89	68.8 (58.0–77.9)	0.0162	62	96.1 (85.6–99.0)	0.9332	60	51	84.5 (72.4–91.9)	0.0638
yes	21	95.1 (71.3–99.3)		20	95.7 (74.0–99.4)		19	19	100.0	
HIV test result										
positive	117	73.0 (63.8–80.6)		86	96.2 (88.6–98.8)		83	72	87.0 (77.6–92.8)	
negative	0	0.0		0	0.0		0	0	0.0	
Past 30 days injecting 4 categories										
opioids	98	77.9 (68.1–85.3)		77	95.8 (87.4–98.7)		74	64	86.3 (76.1–92.6)	
stimulants	8	37.9 (11.8–73.5)		3	100.0		3	3	100.0	
opi+stimul	11	54.0 (25.0–80.5)		6	100.0		6	5	89.2 (47.3–98.7)	
other	0			0			0	0		
Injecting drug type of choice										
opioids	105	75.3 (65.7–82.9)	0.1173	80	95.9 (87.9–98.7)	0.8996	77	67	86.9 (77.1–92.9)	0.8791
stimulants	11	44.1 (18.5–73.4)		5	100.0		5	4	84.2 (35.8–98.1)	
other	1	100.0		1	100.0		1	1	100.0	

Table 8.3. ART adherence (among those on ART)

	n	%	CI
When did you last miss ART dose			
last week	6	7.8	(3.4–16.6)
1-2 weeks ago	12	14.7	(8.3–24.9)
3-4 weeks ago	4	4.7	(1.7–12.6)
1-3 months ago	6	7.0	(3.1–14.9)
never	56	65.8	(54.5–75.6)
What was the reason for missing the last ART dose			
forgot	19	66.8	(45.8–82.8)
did not have meds	3	12.0	(3.6–33.4)
was under influence	1	6.4	(0.9–33.6)
did not want others to see	1	3.2	(0.4–19.9)
other	3	11.6	(3.8–30.6)
Reasons for not taking ART			
not sure it is needed	6	23.9	(11.0–44.5)
no time to visit clinic	4	17.1	(6.4–38.1)
no motivation to visit clinic	6	26.2	(12.2–47.8)
missed a visit, hard to come back	3	14.3	(4.7–36.1)
too sick to visit clinic	1	3.8	(0.5–22.9)
drug use	8	33.9	(17.7–55.0)
side effects or complications	6	25.3	(11.7–46.3)
no understanding of how to take it	4	17.0	(6.3–38.3)
lost or sold all ARVs	2	7.1	(1.7–25.3)
alcohol use	6	26.5	(12.4–47.8)
waited too long and left	1	2.4	(0.3–15.6)
Time on ART			
≤3m	2	8.4	(2.1–28.3)
4-24m	6	22.2	(9.9–42.4)
25-60m	8	29.2	(14.7–49.5)
5y+	12	40.3	(23.6–59.6)

9. PrEP



Figure 9.1. PrEP Uptake in the Past 12 Months (%)



Figure 9.2. Change in PrEP Awareness and Uptake from 2020 to 2023 (%)



Figure 9.3. Change in PrEP Uptake from 2020 to 2023 (%)

Table 9.1. PrEP Awareness by Sociodemographic Characteristics

			PrEP uptake in the past 12 months								
		N	use now		used in the past		never used		not aware		
			n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total											
	All	496	8	1.6 (0.7–3.5)	8	1.7 (0.8–3.7)	121	24.9 (21.1–29.1)	359	71.9 (67.5–75.9)	1.0000
Sex											
	male	405	7	1.8 (0.8–4.2)	7	1.8 (0.8–4.2)	90	22.2 (18.3–26.7)	301	74.2 (69.4–78.5)	0.0391
	female	91	1	0.8 (0.1–5.4)	1	1.1 (0.1–7.4)	31	36.3 (26.4–47.5)	58	61.9 (50.7–71.9)	
Age											
	<25	9	0	0.0	0	0.0	3	36.9 (10.0–75.5)	6	63.1 (24.5–90.0)	0.2485
	25-34	116	0	0.0	1	0.7 (0.1–4.6)	20	17.8 (11.5–26.5)	95	81.6 (72.8–88.0)	

		PrEP uptake in the past 12 months								
	N	use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
35-44	245	6	2.5 (1.0–6.1)	4	2.0 (0.6–5.9)	58	23.9 (18.7–30.0)	177	71.6 (65.2–77.3)	
45+	126	2	1.3 (0.3–5.4)	3	2.1 (0.6–6.6)	40	32.4 (24.4–41.6)	81	64.2 (55.0–72.5)	
Years since the start of injecting drug use										
≤2	18	0	0.0	0	0.0	2	10.4 (2.3–36.3)	16	89.6 (63.7–97.7)	0.0593
3-5	46	0	0.0	2	3.7 (0.9–14.5)	3	6.7 (2.1–19.6)	41	89.6 (76.4–95.8)	
6-10	64	0	0.0	1	1.5 (0.2–10.5)	13	20.7 (12.1–33.3)	50	77.7 (65.1–86.7)	
≥11	368	8	2.2 (1.0–4.7)	5	1.5 (0.5–4.2)	103	28.5 (23.9–33.7)	252	67.8 (62.5–72.7)	
Partnership status										
live alone	286	5	1.4 (0.6–3.4)	4	1.7 (0.5–5.2)	66	23.6 (18.8–29.3)	211	73.3 (67.5–78.5)	0.8870
live with partner	210	3	1.9 (0.5–6.9)	4	1.7 (0.6–4.6)	55	26.5 (20.7–33.3)	148	69.9 (62.9–76.0)	
Current employment status										
full-time	73	3	5.4 (1.4–18.3)	1	1.3 (0.2–9.2)	23	34.1 (23.4–46.6)	46	59.2 (46.6–70.7)	
part-time or temporary	325	5	1.2 (0.5–2.9)	5	1.2 (0.5–2.9)	72	22.7 (18.2–27.9)	243	74.9 (69.7–79.6)	
unemployed	54	0	0.0	2	6.7 (1.5–25.7)	13	22.9 (13.1–36.9)	39	70.4 (55.1–82.2)	
disabled	37	0	0.0	0	0.0	12	30.0 (16.9–47.4)	25	70.0 (52.6–83.1)	
other	6	0	0.0	0	0.0	1	15.1 (1.0–75.3)	5	84.9 (24.7–99.0)	
Monthly income category										
<3K	77	1	0.7 (0.1–5.1)	3	5.5 (1.5–18.1)	16	20.9 (12.8–32.3)	57	72.9 (60.6–82.4)	0.1377
3-10K	208	3	1.9 (0.5–6.9)	2	0.7 (0.2–3.0)	58	27.6 (21.7–34.5)	145	69.7 (62.7–75.9)	
10-20K	164	3	1.6 (0.5–5.0)	1	0.4 (0.1–2.8)	35	22.4 (16.3–30.0)	125	75.5 (67.9–81.8)	
≥20K	26	1	2.7 (0.3–18.7)	1	3.8 (0.5–24.5)	6	24.7 (10.8–47.2)	18	68.7 (46.8–84.6)	
Ever incarcerated										
no	302	3	0.8 (0.3–2.6)	5	1.9 (0.7–5.1)	68	23.8 (19.0–29.3)	226	73.5 (67.8–78.5)	0.3696
yes	190	5	2.9 (1.0–7.9)	3	1.4 (0.4–4.4)	50	25.7 (19.8–32.7)	132	70.1 (62.8–76.5)	

Table 9.2. PrEP Current Use by Sociodemographic Characteristics

		PrEP uptake in the past 12 months								
	N	use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										
no	219	2	0.7 (0.2–2.9)	3	1.2 (0.4–3.8)	21	10.0 (6.5–15.1)	193	88.1 (82.8–91.9)	0.0000
yes	269	6	2.4 (0.9–5.9)	5	2.1 (0.7–5.8)	97	36.6 (30.7–42.8)	161	59.0 (52.6–65.0)	
Treated with MAT currently (of all)										
no	408	7	1.7 (0.7–4.1)	4	0.8 (0.3–2.2)	89	22.2 (18.3–26.8)	308	75.2 (70.5–79.4)	0.0000
yes	65	1	1.3 (0.2–8.9)	4	7.7 (2.5–21.7)	28	43.2 (31.0–56.3)	32	47.7 (35.2–60.6)	

		PrEP uptake in the past 12 months								
	N	n	use now % (CI)	n	used in the past % (CI)	n	never used % (CI)	n	not aware % (CI)	p-value
HIV test result										
positive	116	2	1.6 (0.4–6.3)	2	1.8 (0.4–7.1)	42	35.2 (26.8–44.7)	70	61.4 (51.8–70.1)	0.0499
negative	380	6	1.6 (0.6–4.1)	6	1.6 (0.6–4.1)	79	21.9 (17.8–26.7)	289	74.8 (69.8–79.3)	
Past 30 days injecting 4 categories										
opioids	402	4	1.1 (0.3–3.6)	7	1.9 (0.8–4.3)	102	26.1 (21.8–30.9)	289	70.9 (65.9–75.5)	
stimulants	40	2	4.7 (1.1–17.9)	0	0.0	9	19.8 (10.1–35.1)	29	75.5 (59.7–86.5)	
opi+stimul	54	2	3.3 (0.8–12.7)	1	1.4 (0.2–9.5)	10	18.8 (10.1–32.5)	41	76.5 (62.8–86.3)	
other	0	0		0		0		0		
Injecting drug type of choice										
opioids	438	6	1.4 (0.5–3.6)	8	1.9 (0.9–4.1)	111	26.1 (22.0–30.7)	313	70.6 (65.8–75.0)	0.4563
stimulants	55	2	3.5 (0.8–13.5)	0	0.0	10	15.7 (8.3–27.7)	43	80.8 (68.2–89.2)	
other	3	0	0.0	0	0.0	0	0.0	3	100.0	

Table 9.3. PrEP Awareness and Uptake

		n	%	CI
PrEP uptake in the past 12 months				
	use now	8	1.6	(0.7–3.5)
	used in the past	8	1.7	(0.8–3.7)
	never used	121	24.9	(21.1–29.1)
	not aware	359	71.9	(67.5–75.9)
Aware of PrEP				
	no	359	71.4	(67.0–75.4)
	yes	140	28.6	(24.6–33.0)
PrEP use current				
	no	488	98.4	(96.5–99.3)
	yes	8	1.6	(0.7–3.5)
PrEP use current (of those aware)				
	no	129	94.3	(87.9–97.4)
	yes	8	5.7	(2.6–12.1)

10. MAT



Figure 10.1. MAT Awareness (%)



Figure 10.2. MAT Current Uptake (%)



Figure 10.3. Trends in MAT Lifetime and Current Uptake by Survey Round (%)

Table 10.1. MAT experience

	n	%	CI
Reason for MAT discontinuation			
moved to another city	2	14.0	(3.4–43.2)
clinic closed after Feb 2022	0	0.0	
weak or no effect	2	17.8	(4.4–50.6)
side effects	1	6.7	(0.9–35.9)
do not want to visit clinic	1	8.4	(1.2–41.6)
do not want to quit drugs	2	16.7	(4.0–49.3)
hard to get to the clinic	1	5.6	(0.8–31.6)
do not need it	5	31.8	(12.7–59.9)
do not like the attitude of physician	1	5.6	(0.8–31.6)
How did the injection frequency change during MAT			
intensified	4	23.6	(8.8–49.8)
did not change	7	46.4	(23.4–71.0)
decreased	5	30.0	(12.2–57.0)
Whether bought bupr. or methadone while not being a patient in the past 12 months			
yes, methadone	212	43.7	(39.2–48.4)
yes, buprenorphine	10	1.9	(1.0–3.6)
did not buy	275	54.3	(49.7–58.9)
Where bought bupr. or methadone while not being a patient in the past 12 months			
did not buy	275	55.1	(50.4–59.7)
bought from black market	192	40.1	(35.6–44.8)
bought from private clinic	23	4.8	(3.2–7.2)
Way of using bupr. or methaone bought from others			
injecting	192	88.1	(83.0–91.8)
injecting mixed	9	4.2	(2.1–7.9)
swallow or subling.	12	5.0	(2.8–8.8)
snort	6	2.7	(1.2–6.1)

Table 10.2. MAT Awareness and Uptake by Sociodemographic Characteristics

	N	MAT uptake (of all)								
		take it now		took in the past		never took but plan to		unaware or do not plan to		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	477	66	13.7 (10.8–17.3)	13	2.8 (1.6–4.9)	143	29.7 (25.6–34.2)	255	53.8 (49.1–58.5)	1.0000
Sex										
male	388	55	14.0 (10.8–18.1)	13	3.4 (1.9–6.0)	114	29.3 (24.8–34.3)	206	53.2 (47.9–58.4)	0.3572
female	89	11	12.2 (6.7–21.1)	0	0.0	29	31.2 (22.1–42.1)	49	56.6 (45.6–67.0)	
Age										
<25	9	0	0.0	0	0.0	2	22.0 (4.2–64.6)	7	78.0 (35.4–95.8)	0.1709
25-34	112	8	7.0 (3.3–14.0)	2	1.4 (0.3–5.3)	33	28.5 (20.7–37.9)	69	63.1 (53.4–71.9)	
35-44	235	35	14.1 (10.1–19.3)	8	3.4 (1.6–7.0)	71	30.5 (24.6–37.1)	121	52.0 (45.2–58.7)	
45+	121	23	20.0 (13.4–28.7)	3	2.9 (0.9–9.1)	37	29.6 (21.8–38.7)	58	47.6 (38.4–56.9)	
Years since the start of injecting drug use										
≤2	17	0	0.0	0	0.0	4	21.7 (7.6–48.3)	13	78.3 (51.7–92.4)	0.0611
3-5	44	2	4.1 (1.0–15.8)	0	0.0	12	31.3 (18.1–48.5)	30	64.5 (47.7–78.3)	
6-10	62	7	9.6 (4.4–19.5)	1	1.1 (0.2–8.0)	16	25.9 (16.0–39.0)	38	63.4 (50.2–74.9)	
≥11	354	57	16.3 (12.6–20.8)	12	3.5 (1.9–6.3)	111	30.6 (25.8–35.8)	174	49.7 (44.2–55.1)	
Partnership status										
live alone	276	45	16.4 (12.3–21.6)	10	3.5 (1.8–6.6)	84	30.3 (24.9–36.4)	137	49.8 (43.6–56.0)	0.1128
live with partner	201	21	9.9 (6.4–15.0)	3	1.8 (0.6–5.8)	59	28.8 (22.7–35.8)	118	59.4 (52.1–66.3)	
Current employment status										
full-time	71	8	10.4 (5.1–20.1)	0	0.0	21	32.7 (21.9–45.7)	42	56.9 (44.3–68.6)	0.0590
part-time or temporary	313	39	12.2 (8.9–16.5)	10	3.2 (1.7–6.1)	100	31.7 (26.5–37.3)	164	52.9 (47.1–58.6)	
unemployed	51	12	23.1 (12.6–38.6)	1	1.7 (0.2–11.5)	12	21.9 (12.3–35.9)	26	53.3 (38.6–67.4)	
disabled	35	7	21.7 (10.3–40.0)	2	6.1 (1.3–24.1)	4	9.8 (3.5–24.8)	22	62.4 (44.1–77.7)	
other	6	0	0.0	0	0.0	5	73.8 (14.3–97.9)	1	26.2 (2.1–85.7)	
Monthly income category										
<3K	73	12	17.5 (9.6–29.7)	4	7.4 (2.7–18.8)	23	30.0 (20.2–42.1)	34	45.0 (33.4–57.2)	0.1552
3-10K	204	23	10.7 (7.0–15.9)	6	2.2 (1.0–5.0)	58	27.8 (21.8–34.7)	117	59.3 (52.1–66.1)	

		MAT uptake (of all)								
	N	take it now		took in the past		never took but plan to		unaware or do not plan to		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
10-20K	154	23	15.2 (10.2–22.2)	2	1.0 (0.3–4.1)	50	33.4 (26.0–41.8)	79	50.3 (42.1–58.5)	
≥20K	25	4	16.0 (5.7–37.6)	1	6.7 (0.9–37.0)	7	25.5 (11.5–47.3)	13	51.8 (31.3–71.8)	
Ever incarcerated										
no	291	37	12.6 (9.1–17.3)	5	1.7 (0.6–4.2)	81	27.7 (22.7–33.5)	168	58.0 (51.9–63.8)	0.0892
yes	182	28	15.1 (10.4–21.2)	8	4.6 (2.2–9.4)	60	32.8 (26.0–40.4)	86	47.5 (40.0–55.2)	

Table 10.3. MAT Awareness and Uptake by Selected Subgroups

		MAT uptake (of all)								
	N	take it now		took in the past		never took but plan to		unaware or do not plan to		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										
no	208	12	5.7 (3.2–10.0)	5	2.3 (0.9–5.8)	43	20.8 (15.5–27.3)	148	71.2 (64.3–77.2)	0.0000
yes	262	54	20.5 (15.8–26.1)	8	3.2 (1.5–6.6)	96	36.1 (30.2–42.4)	104	40.2 (34.1–46.6)	
Treated with MAT currently (of all)										
no	411	0	0.0	13	3.2 (1.8–5.6)	143	34.4 (29.8–39.4)	255	62.4 (57.3–67.2)	0.0000
yes	66	66	100.0	0	0.0	0	0.0	0	0.0	
HIV test result										
positive	110	21	19.5 (12.8–28.6)	1	1.6 (0.2–10.5)	34	30.1 (22.0–39.7)	54	48.8 (39.2–58.5)	0.2856
negative	367	45	12.1 (9.0–16.0)	12	3.1 (1.7–5.6)	109	29.6 (24.9–34.7)	201	55.2 (49.8–60.5)	
Past 30 days injecting 4 categories										
opioids	386	63	16.1 (12.6–20.3)	12	3.2 (1.7–5.7)	117	29.9 (25.3–34.9)	194	50.8 (45.6–56.1)	
stimulants	40	1	2.2 (0.3–14.6)	1	2.2 (0.3–14.6)	8	21.6 (10.8–38.7)	30	74.1 (57.1–86.0)	
opi+stimul	51	2	4.0 (1.0–15.1)	0	0.0	18	34.4 (22.2–49.1)	31	61.6 (46.9–74.4)	
other	0	0		0		0		0		
Injecting drug type of choice										
opioids	420	65	15.2 (12.0–19.2)	12	2.9 (1.6–5.3)	130	30.3 (25.9–35.1)	213	51.5 (46.5–56.5)	0.0236
stimulants	54	1	1.6 (0.2–11.2)	1	1.6 (0.2–11.2)	11	22.0 (12.3–36.1)	41	74.8 (60.6–85.1)	
other	3	0	0.0	0	0.0	2	71.4 (1.3–99.8)	1	28.6 (0.2–98.7)	



Figure 10.4. Buying MAT medications while not being a patient (%)



Figure 10.5. Source of buying MAT medications while not being a patient (%)



Figure 10.6. Route of administration of MAT medications bought from others (%)

11. Overdose and Naloxone



Figure 11.1. Overdose Experience Ever and in the Past 12 Months (%)



Figure 11.2. Trends in Overdose Experience in the Past 12 Months by Survey Round (%)



Figure 11.3. Drugs causing overdoses (if used only one drug) (%)



Figure 11.4. Naloxone Use (%)

Table 11.1. Overdose Experience

	n	%	CI
Experienced overdose ever			
yes	210	42.6	(38.1–47.3)
Number of overdoses in lifetime			
1	52	25.4	(19.7–32.0)
2-4	108	53.0	(45.7–60.1)
5+	43	21.7	(16.1–28.5)
Experienced overdose in the past 12 months			
yes	36	7.4	(5.2–10.4)
Experienced overdose in the past 12 months (of those ever)			
yes	36	17.4	(12.4–23.8)
Number of overdoses in the past 12 months			
1	17	46.4	(29.4–64.3)
2-4	14	44.1	(26.9–62.7)
5+	4	9.6	(3.5–23.7)
Drug overdosed with (if used only one drug)			
methadone	13	47.1	(26.8–68.4)
other opioid	1	9.9	(1.4–45.2)
stimulant	8	29.2	(14.0–51.0)
other	2	13.9	(3.2–43.9)
Drugs overdosed with (if used a combination)			
methadone+stimulant	4	100.0	
methadone+barbit. or dimedr.	0	0.0	
methadone+other	0	0.0	
other	0	0.0	
Drug overdosed with (if combined drug with alcohol)			
methadone	8	100.0	
other opioid	0	0.0	
stimulant	0	0.0	
other	0	0.0	
Naloxone knowledge and experience			
never heard	82	16.8	(13.6–20.5)
aware but not used	209	42.4	(37.9–47.0)
used myself	71	13.5	(10.7–16.9)
my friends used	124	24.5	(20.8–28.6)

	n	%	CI
me and my friends used	14	2.9	(1.7–4.9)

Table 11.2. Overdose Experience in the Past 12 Months by Sociodemographic Characteristics

		Experienced overdose in the past 12 months			
	N	no		yes	
		n	% (CI)	n	% (CI)	p-value
Total						
All	497	461	92.6 (89.6–94.8)	36	7.4 (5.2–10.4)	1.0000
Sex						
male	407	376	92.0 (88.4–94.5)	31	8.0 (5.5–11.6)	0.2579
female	90	85	95.3 (88.8–98.1)	5	4.7 (1.9–11.2)	
Age						
<25	9	9	100.0	0	0.0	0.0017
25-34	117	111	96.0 (91.2–98.3)	6	4.0 (1.7–8.8)	
35-44	247	221	88.5 (83.2–92.3)	26	11.5 (7.7–16.8)	
45+	124	120	97.8 (94.0–99.2)	4	2.2 (0.8–6.0)	
Years since the start of injecting drug use						
≤2	18	16	88.2 (59.8–97.4)	2	11.8 (2.6–40.2)	0.3214
3-5	47	43	87.7 (69.1–95.8)	4	12.3 (4.2–30.9)	
6-10	64	61	97.0 (90.7–99.1)	3	3.0 (0.9–9.3)	
≥11	368	341	92.6 (89.1–95.1)	27	7.4 (4.9–10.9)	
Partnership status						
live alone	289	269	93.6 (89.8–96.0)	20	6.4 (4.0–10.2)	0.3764
live with partner	208	192	91.2 (85.6–94.8)	16	8.8 (5.2–14.4)	
Current employment status						
full-time	74	71	93.5 (80.1–98.1)	3	6.5 (1.9–19.9)	0.4144
part-time or temporary	326	304	93.6 (90.0–95.9)	22	6.4 (4.1–10.0)	
unemployed	54	46	85.2 (71.9–92.8)	8	14.8 (7.2–28.1)	
disabled	36	34	92.7 (73.9–98.3)	2	7.3 (1.7–26.1)	
other	6	5	89.6 (33.6–99.3)	1	10.4 (0.7–66.4)	
Monthly income category						
<3K	77	70	92.2 (83.4–96.5)	7	7.8 (3.5–16.6)	0.5463
3-10K	210	193	91.4 (86.1–94.8)	17	8.6 (5.2–13.9)	

		Experienced overdose in the past 12 months					
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
	10-20K	163	152	92.6 (86.2–96.2)	11	7.4 (3.8–13.8)	
	≥20K	26	26	100.0	0	0.0	
Ever incarcerated							
	no	304	286	94.0 (90.2–96.3)	18	6.0 (3.7–9.8)	0.1652
	yes	189	171	90.2 (84.2–94.1)	18	9.8 (5.9–15.8)	

Table 11.3. Overdose Experience in the Past 12 Months by Selected Subgroups

		Experienced overdose in the past 12 months				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	220	197	89.0 (83.5–92.8)	23	11.0 (7.2–16.5)	0.0059
yes	269	258	96.1 (92.6–98.0)	11	3.9 (2.0–7.4)	
Treated with MAT currently (of all)						
no	409	381	92.5 (88.9–94.9)	28	7.5 (5.1–11.1)	0.6390
yes	66	58	90.9 (82.3–95.6)	8	9.1 (4.4–17.7)	
HIV test result						
positive	116	109	93.7 (86.8–97.1)	7	6.3 (2.9–13.2)	0.6271
negative	381	352	92.3 (88.6–94.8)	29	7.7 (5.2–11.4)	
Past 30 days injecting 4 categories						
opioids	403	379	93.5 (90.1–95.8)	24	6.5 (4.2–9.9)	
stimulants	40	37	93.3 (79.6–98.0)	3	6.7 (2.0–20.4)	
opi+stimul	54	45	84.8 (72.0–92.4)	9	15.2 (7.6–28.0)	
other	0	0		0		
Injecting drug type of choice						
opioids	439	410	93.0 (89.7–95.2)	29	7.0 (4.8–10.3)	0.5216
stimulants	55	48	88.9 (77.6–94.9)	7	11.1 (5.1–22.4)	
other	3	3	100.0	0	0.0	

Table 11.4. Naloxone Experience by Sociodemographic Characteristics

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total								

	N	Naloxone knowledge and experience (3 categories)						
		unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
All	500	82	16.8 (13.6–20.5)	333	66.9 (62.4–71.1)	85	16.3 (13.2–20.0)	1.0000
Sex								
male	408	62	15.5 (12.1–19.5)	279	68.8 (63.9–73.3)	67	15.7 (12.4–19.8)	0.1812
female	92	20	22.4 (14.5–33.0)	54	58.7 (47.8–68.9)	18	18.8 (11.9–28.5)	
Age								
<25	9	1	7.6 (0.7–48.7)	7	83.8 (44.7–97.1)	1	8.6 (0.8–52.3)	0.6471
25-34	117	18	14.6 (9.2–22.3)	73	64.3 (54.8–72.7)	26	21.2 (14.5–29.8)	
35-44	248	43	18.2 (13.6–24.0)	167	67.1 (60.6–73.0)	38	14.7 (10.6–19.9)	
45+	126	20	16.2 (10.5–24.2)	86	67.7 (58.6–75.7)	20	16.0 (10.3–24.0)	
Years since the start of injecting drug use								
≤2	18	7	40.2 (19.2–65.5)	10	55.1 (30.7–77.3)	1	4.7 (0.6–30.4)	0.0640
3-5	47	10	22.1 (11.8–37.5)	32	68.8 (53.4–81.0)	5	9.1 (3.6–21.0)	
6-10	64	13	19.7 (11.4–31.8)	40	65.0 (52.0–76.1)	11	15.3 (8.3–26.7)	
≥11	371	52	14.5 (11.1–18.8)	251	67.6 (62.3–72.4)	68	17.9 (14.2–22.4)	
Partnership status								
live alone	289	45	15.7 (11.8–20.7)	200	70.5 (64.7–75.7)	44	13.8 (10.2–18.3)	0.1348
live with partner	211	37	18.2 (13.3–24.4)	133	62.1 (54.9–68.7)	41	19.7 (14.6–26.1)	
Current employment status								
full-time	74	15	20.4 (12.4–31.9)	47	62.0 (49.6–73.0)	12	17.6 (9.8–29.5)	0.5706
part-time or temporary	328	48	14.9 (11.2–19.5)	225	69.4 (64.0–74.4)	55	15.7 (12.1–20.1)	
unemployed	54	8	17.1 (8.5–31.4)	33	59.8 (45.2–72.8)	13	23.1 (13.4–36.8)	
disabled	37	10	25.9 (13.8–43.3)	23	62.4 (44.7–77.2)	4	11.8 (4.3–28.3)	
other	6	1	13.2 (0.9–72.3)	4	76.3 (25.2–96.9)	1	10.4 (0.7–66.4)	
Monthly income category								
<3K	77	18	24.3 (15.5–35.8)	44	57.3 (45.3–68.4)	15	18.5 (11.1–29.1)	0.4370
3-10K	211	32	16.0 (11.4–22.2)	147	69.4 (62.4–75.6)	32	14.6 (10.2–20.3)	
10-20K	165	24	13.6 (9.1–19.9)	111	69.5 (61.8–76.2)	30	16.9 (11.9–23.5)	
≥20K	26	3	14.8 (4.5–38.7)	18	62.0 (39.8–80.0)	5	23.3 (9.6–46.5)	
Ever incarcerated								
no	306	56	18.2 (14.1–23.2)	204	67.5 (61.8–72.8)	46	14.3 (10.7–18.7)	0.2272

			Naloxone knowledge and experience (3 categories)						
		N	unaware		aware but did not use		used myself		
			n	% (CI)	n	% (CI)	n	% (CI)	p-value
	yes	190	26	14.7 (10.1–21.1)	125	65.2 (57.7–72.1)	39	20.0 (14.6–26.7)	

Table 11.5. Naloxone Experience by Selected Subgroups

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID								
no	220	55	24.9 (19.4–31.3)	133	61.1 (54.2–67.6)	32	14.0 (9.9–19.5)	0.0003
yes	272	26	10.3 (7.0–15.0)	194	71.2 (65.2–76.6)	52	18.4 (14.1–23.7)	
Treated with MAT currently (of all)								
no	411	75	18.9 (15.2–23.2)	272	66.2 (61.2–70.8)	64	14.9 (11.7–18.9)	0.0026
yes	66	4	5.2 (1.9–13.6)	43	67.0 (54.2–77.6)	19	27.8 (18.0–40.4)	
HIV test result								
positive	117	21	18.9 (12.4–27.7)	73	61.4 (51.8–70.2)	23	19.7 (13.2–28.3)	0.3867
negative	383	61	16.2 (12.6–20.5)	260	68.5 (63.4–73.1)	62	15.4 (12.0–19.5)	
Past 30 days injecting 4 categories								
opioids	406	56	14.0 (10.8–18.0)	281	69.6 (64.6–74.1)	69	16.4 (13.0–20.6)	
stimulants	40	12	34.2 (20.3–51.6)	22	51.8 (35.7–67.6)	6	13.9 (6.1–28.6)	
opi+stimul	54	14	25.6 (15.3–39.7)	30	57.3 (43.2–70.4)	10	17.0 (9.0–29.8)	
other	0	0		0		0		
Injecting drug type of choice								
opioids	442	64	14.8 (11.6–18.7)	302	68.6 (63.9–73.0)	76	16.6 (13.3–20.5)	0.0093
stimulants	55	18	34.8 (22.7–49.2)	29	52.3 (38.5–65.7)	8	12.9 (6.3–24.5)	
other	3	0	0.0	2	64.3 (0.9–99.7)	1	35.7 (0.3–99.1)	

12. Physical and Mental Health

Table 12.1. Disease and treatment history

		n	%	CI
Had a disease				
	hepatitis B	87	18.9	(15.4–23.0)
	hepatitis C	244	54.2	(49.3–59.0)
	syphilis	8	1.4	(0.7–2.8)
	gonorrhea	13	2.5	(1.4–4.3)
	chlamydia	17	3.6	(2.2–5.9)
	herpes	109	23.3	(19.6–27.6)

		n	%	CI
	human papillomavirus	17	3.9	(2.4–6.2)
	tuberculosis	77	15.3	(12.3–18.8)
Treated for: hepatitis B				
	treated successfully	55	65.5	(54.1–75.3)
	treated unsuccessfully	5	5.7	(2.3–13.3)
	did not complete	0	0.0	
	treated now	0	0.0	
	never treated	25	28.9	(19.7–40.1)
Treated for: hepatitis C				
	treated successfully	58	25.4	(19.9–31.9)
	treated unsuccessfully	13	4.7	(2.7–8.1)
	did not complete	9	4.0	(2.0–7.8)
	treated now	15	6.8	(4.0–11.5)
	never treated	144	59.0	(52.2–65.4)
Treated for: syphilis				
	treated successfully	8	100.0	
	treated unsuccessfully	0	0.0	
	did not complete	0	0.0	
	treated now	0	0.0	
	never treated	0	0.0	
Treated for: tuberculosis				
	treated successfully	67	87.9	(78.6–93.5)
	treated unsuccessfully	4	4.1	(1.5–10.7)
	did not complete	0	0.0	
	treated now	6	8.0	(3.6–16.9)
	never treated	0	0.0	

Table 12.2. Mental health screening scores

	n	Mean	CI	Median	IQR
AUDIT-C alcohol risk score ≥5	4,874	1.2	(1.2–1.2)	1	(1–1)
PHQ-9 depression result	5,002	2.2	(2.2–2.3)	2	(1–3)
GAD-7 anxiety result	5,002	1.9	(1.9–1.9)	2	(1–2)

Table 12.3. Health care utilization

		n	%	CI
Had problems with health besides drugs which required medical attention in the past 12 months				
	yes	139	28.2	(24.2–32.6)
Referred to a health care facility for treatment in the past 12 months				
	yes	101	20.5	(17.0–24.5)
Referred to a health care facility				
	primary care	74	76.2	(66.6–83.7)
	hospital, HIV clinic	25	22.7	(15.5–32.0)
	private clinic	2	1.7	(0.4–6.7)
	private lab	0	0.0	
	TB dispensary	5	5.2	(2.1–12.3)
	drug clinic	0	0.0	
	STI clinic	0	0.0	
	ambulance	2	2.0	(0.5–7.6)
	mobile clinic	1	0.5	(0.1–3.5)
	other	4	4.1	(1.4–11.3)
Last health care facility referred to				

	n	%	CI
primary care	66	68.8	(58.7–77.3)
hospital, HIV clinic	23	21.0	(14.1–30.1)
private clinic	1	1.0	(0.1–6.7)
private lab	0	0.0	
TB dispensary	5	5.2	(2.1–12.3)
drug clinic	0	0.0	
STI clinic	0	0.0	
ambulance	0	0.0	
mobile clinic	1	0.5	(0.1–3.5)
other	3	3.6	(1.1–11.1)
Received necessary care in health care facility			
yes	92	91.3	(83.2–95.7)
Signed a declaration with primary care physician			
yes	387	78.5	(74.5–82.0)
How frequently saw the primary care physician			
twice per month or more	13	3.2	(1.8–5.6)
once per month	40	10.5	(7.7–14.2)
3-4 times in 12 months	118	31.1	(26.4–36.2)
only once	213	55.1	(49.9–60.3)



Figure 12.1. Risky alcohol use (AUDIT-C score > 5) (%)



Figure 12.2. Depression symptoms severity (PHQ-9) (%)



Figure 12.3. Anxiety symptoms severity (GAD-7) (%)

Table 12.4. Risky alcohol use (AUDIT-C score > 5) by Sociodemographic Characteristics

			AUDIT-C alcohol risk score ≥5			
		N	no		yes	
			n	% (CI)	n	% (CI)	p-value
Total							
	All	496	446	89.8 (86.6–92.3)	50	10.2 (7.7–13.4)	1.0000
Sex							
	male	404	362	89.3 (85.6–92.1)	42	10.7 (7.9–14.4)	0.4345
	female	92	84	92.0 (84.5–96.1)	8	8.0 (3.9–15.5)	
Age							
	<25	8	6	75.6 (31.5–95.4)	2	24.4 (4.6–68.5)	0.0083

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
25-34	115	98	84.8 (76.5–90.6)	17	15.2 (9.4–23.5)	
35-44	247	221	89.1 (84.1–92.6)	26	10.9 (7.4–15.9)	
45+	126	121	96.9 (92.6–98.7)	5	3.1 (1.3–7.4)	
Years since the start of injecting drug use						
≤2	17	14	80.7 (51.8–94.2)	3	19.3 (5.8–48.2)	0.0026
3-5	46	38	79.2 (62.2–89.9)	8	20.8 (10.1–37.8)	
6-10	63	51	81.2 (68.9–89.4)	12	18.8 (10.6–31.1)	
≥11	370	343	93.0 (89.8–95.3)	27	7.0 (4.7–10.2)	
Partnership status						
live alone	287	260	89.9 (85.3–93.1)	27	10.1 (6.9–14.7)	0.9694
live with partner	209	186	89.8 (84.8–93.2)	23	10.2 (6.8–15.2)	
Current employment status						
full-time	73	69	95.1 (87.0–98.2)	4	4.9 (1.8–13.0)	0.3936
part-time or temporary	325	287	88.4 (84.2–91.6)	38	11.6 (8.4–15.8)	
unemployed	54	50	90.9 (77.3–96.7)	4	9.1 (3.3–22.7)	
disabled	37	35	94.4 (79.2–98.7)	2	5.6 (1.3–20.8)	
other	6	5	82.5 (21.5–98.8)	1	17.5 (1.2–78.5)	
Monthly income category						
<3K	77	66	84.6 (73.4–91.6)	11	15.4 (8.4–26.6)	0.4244
3-10K	211	192	91.1 (86.3–94.4)	19	8.9 (5.6–13.7)	
10-20K	161	147	91.2 (85.0–95.0)	14	8.8 (5.0–15.0)	
≥20K	26	23	89.7 (70.1–97.0)	3	10.3 (3.0–29.9)	
Ever incarcerated						
no	302	268	88.1 (83.6–91.6)	34	11.9 (8.4–16.4)	0.1458
yes	190	174	92.3 (87.5–95.4)	16	7.7 (4.6–12.5)	

Table 12.5. Risky alcohol use (AUDIT-C score > 5) by Selected Subgroups

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
	n		% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	217	191	86.8 (81.0–91.1)	26	13.2 (8.9–19.0)	0.0732
yes	271	247	92.0 (88.2–94.7)	24	8.0 (5.3–11.8)	
Treated with MAT currently (of all)						
no	407	362	88.8 (85.0–91.7)	45	11.2 (8.3–15.0)	0.1523
yes	66	62	94.5 (85.7–98.0)	4	5.5 (2.0–14.3)	
HIV test result						
positive	117	108	91.0 (83.4–95.3)	9	9.0 (4.7–16.6)	0.6571
negative	379	338	89.5 (85.7–92.3)	41	10.5 (7.7–14.3)	
Past 30 days injecting 4 categories						
opioids	403	379	94.0 (90.9–96.1)	24	6.0 (3.9–9.1)	
stimulants	39	33	83.6 (66.9–92.8)	6	16.4 (7.2–33.1)	
opi+stimul	54	34	61.6 (47.3–74.3)	20	38.4 (25.7–52.7)	
other	0	0		0		
Injecting drug type of choice						
opioids	439	402	91.5 (88.2–93.9)	37	8.5 (6.1–11.8)	0.0003
stimulants	54	43	79.3 (65.6–88.5)	11	20.7 (11.5–34.4)	
other	3	1	35.7 (0.3–99.1)	2	64.3 (0.9–99.7)	

Table 12.6. Depression symptoms severity (PHQ-9) by Sociodemographic Characteristics

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	142	28.7 (24.7–33.0)	196	39.6 (35.2–44.2)	93	18.1 (14.9–21.9)	69	13.6 (10.7–17.0)	1.0000
Sex										
male	408	115	28.3 (24.0–33.1)	164	40.5 (35.6–45.6)	73	17.6 (14.1–21.9)	56	13.6 (10.5–17.5)	0.8618
female	92	27	30.2 (21.1–41.2)	32	35.9 (26.3–46.8)	20	20.4 (13.2–30.2)	13	13.5 (7.7–22.5)	
Age										
<25	9	5	61.9 (25.2–88.7)	2	20.6 (3.8–63.0)	1	7.6 (0.7–48.7)	1	10.0 (0.9–56.4)	0.1132
25-34	117	36	30.3 (22.4–39.6)	54	47.8 (38.5–57.3)	13	10.7 (6.1–18.1)	14	11.2 (6.5–18.7)	
35-44	248	71	28.5 (23.0–34.9)	91	36.7 (30.7–43.3)	48	19.4 (14.7–25.2)	38	15.3 (11.1–20.6)	
45+	126	30	25.2 (18.0–34.1)	49	39.6 (31.0–48.9)	31	22.9 (16.3–31.2)	16	12.3 (7.5–19.5)	
Years since the start of injecting drug use										
≤2	18	7	40.2 (19.2–65.5)	3	16.1 (4.8–42.3)	4	24.6 (8.8–52.3)	4	19.2 (6.6–44.3)	0.3101

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
3-5	47	16	34.5 (21.7–50.0)	18	36.4 (23.4–51.6)	5	12.1 (4.3–29.3)	8	17.0 (8.3–31.7)	
6-10	64	24	38.2 (26.6–51.3)	26	39.3 (27.6–52.3)	8	12.8 (6.2–24.5)	6	9.8 (4.1–21.5)	
≥11	371	95	25.7 (21.3–30.7)	149	41.2 (36.0–46.6)	76	19.5 (15.7–24.0)	51	13.5 (10.3–17.6)	
Partnership status										
live alone	289	80	28.7 (23.5–34.6)	117	40.4 (34.6–46.5)	49	16.5 (12.5–21.5)	43	14.4 (10.7–19.1)	0.7207
live with partner	211	62	28.6 (22.7–35.3)	79	38.5 (31.8–45.7)	44	20.4 (15.3–26.6)	26	12.5 (8.5–18.0)	
Current employment status										
full-time	74	28	36.6 (25.9–48.7)	31	42.7 (31.2–55.0)	8	11.4 (5.6–21.7)	7	9.4 (4.3–19.1)	0.0148
part-time or temporary	328	92	28.8 (23.9–34.3)	133	40.5 (35.1–46.2)	67	19.8 (15.6–24.7)	36	10.9 (7.8–14.9)	
unemployed	54	14	23.6 (13.9–37.3)	14	26.1 (15.2–40.9)	10	19.9 (10.8–33.8)	16	30.4 (18.9–45.1)	
disabled	37	8	23.7 (11.5–42.7)	16	44.8 (28.6–62.2)	7	16.8 (7.7–32.8)	6	14.7 (6.2–31.0)	
other	6	0	0.0	2	43.7 (7.4–88.3)	1	13.2 (0.9–72.3)	3	43.0 (8.0–86.8)	
Monthly income category										
<3K	77	17	23.2 (14.6–34.8)	28	37.5 (26.7–49.7)	18	21.0 (13.2–31.8)	14	18.3 (10.7–29.6)	0.7013
3-10K	211	59	28.9 (22.8–35.8)	82	39.4 (32.6–46.5)	43	19.7 (14.7–25.8)	27	12.1 (8.3–17.4)	
10-20K	165	50	29.8 (23.1–37.5)	69	41.8 (34.2–49.8)	27	16.8 (11.5–24.1)	19	11.6 (7.3–17.8)	
≥20K	26	10	39.7 (21.6–61.1)	10	36.5 (19.4–57.8)	2	7.5 (1.6–28.0)	4	16.3 (5.7–38.7)	
Ever incarcerated										
no	306	96	31.9 (26.6–37.7)	118	37.9 (32.4–43.7)	51	16.6 (12.6–21.5)	41	13.6 (10.0–18.2)	0.2120
yes	190	44	23.1 (17.4–29.9)	77	42.5 (35.2–50.1)	41	20.7 (15.3–27.3)	28	13.8 (9.5–19.6)	

Table 12.7. Depression symptoms severity (PHQ-9) by Selected Subgroups

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	142	28.7 (24.7–33.0)	196	39.6 (35.2–44.2)	93	18.1 (14.9–21.9)	69	13.6 (10.7–17.0)	1.0000
Sex										
male	408	115	28.3 (24.0–33.1)	164	40.5 (35.6–45.6)	73	17.6 (14.1–21.9)	56	13.6 (10.5–17.5)	0.8618
female	92	27	30.2 (21.1–41.2)	32	35.9 (26.3–46.8)	20	20.4 (13.2–30.2)	13	13.5 (7.7–22.5)	
Age										
<25	9	5	61.9 (25.2–88.7)	2	20.6 (3.8–63.0)	1	7.6 (0.7–48.7)	1	10.0 (0.9–56.4)	0.1132
25-34	117	36	30.3 (22.4–39.6)	54	47.8 (38.5–57.3)	13	10.7 (6.1–18.1)	14	11.2 (6.5–18.7)	
35-44	248	71	28.5 (23.0–34.9)	91	36.7 (30.7–43.3)	48	19.4 (14.7–25.2)	38	15.3 (11.1–20.6)	
45+	126	30	25.2 (18.0–34.1)	49	39.6 (31.0–48.9)	31	22.9 (16.3–31.2)	16	12.3 (7.5–19.5)	

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Years since the start of injecting drug use										
≤2	18	7	40.2 (19.2–65.5)	3	16.1 (4.8–42.3)	4	24.6 (8.8–52.3)	4	19.2 (6.6–44.3)	0.3101
3-5	47	16	34.5 (21.7–50.0)	18	36.4 (23.4–51.6)	5	12.1 (4.3–29.3)	8	17.0 (8.3–31.7)	
6-10	64	24	38.2 (26.6–51.3)	26	39.3 (27.6–52.3)	8	12.8 (6.2–24.5)	6	9.8 (4.1–21.5)	
≥11	371	95	25.7 (21.3–30.7)	149	41.2 (36.0–46.6)	76	19.5 (15.7–24.0)	51	13.5 (10.3–17.6)	
Partnership status										
live alone	289	80	28.7 (23.5–34.6)	117	40.4 (34.6–46.5)	49	16.5 (12.5–21.5)	43	14.4 (10.7–19.1)	0.7207
live with partner	211	62	28.6 (22.7–35.3)	79	38.5 (31.8–45.7)	44	20.4 (15.3–26.6)	26	12.5 (8.5–18.0)	
Current employment status										
full-time	74	28	36.6 (25.9–48.7)	31	42.7 (31.2–55.0)	8	11.4 (5.6–21.7)	7	9.4 (4.3–19.1)	0.0148
part-time or temporary	328	92	28.8 (23.9–34.3)	133	40.5 (35.1–46.2)	67	19.8 (15.6–24.7)	36	10.9 (7.8–14.9)	
unemployed	54	14	23.6 (13.9–37.3)	14	26.1 (15.2–40.9)	10	19.9 (10.8–33.8)	16	30.4 (18.9–45.1)	
disabled	37	8	23.7 (11.5–42.7)	16	44.8 (28.6–62.2)	7	16.8 (7.7–32.8)	6	14.7 (6.2–31.0)	
other	6	0	0.0	2	43.7 (7.4–88.3)	1	13.2 (0.9–72.3)	3	43.0 (8.0–86.8)	
Monthly income category										
<3K	77	17	23.2 (14.6–34.8)	28	37.5 (26.7–49.7)	18	21.0 (13.2–31.8)	14	18.3 (10.7–29.6)	0.7013
3-10K	211	59	28.9 (22.8–35.8)	82	39.4 (32.6–46.5)	43	19.7 (14.7–25.8)	27	12.1 (8.3–17.4)	
10-20K	165	50	29.8 (23.1–37.5)	69	41.8 (34.2–49.8)	27	16.8 (11.5–24.1)	19	11.6 (7.3–17.8)	
≥20K	26	10	39.7 (21.6–61.1)	10	36.5 (19.4–57.8)	2	7.5 (1.6–28.0)	4	16.3 (5.7–38.7)	
Ever incarcerated										
no	306	96	31.9 (26.6–37.7)	118	37.9 (32.4–43.7)	51	16.6 (12.6–21.5)	41	13.6 (10.0–18.2)	0.2120
yes	190	44	23.1 (17.4–29.9)	77	42.5 (35.2–50.1)	41	20.7 (15.3–27.3)	28	13.8 (9.5–19.6)	

Table 12.8. Anxiety symptoms severity (GAD-7) by Sociodemographic Characteristics

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	173	35.0 (30.7–39.5)	217	43.3 (38.8–47.9)	87	17.4 (14.2–21.2)	23	4.3 (2.8–6.5)	1.0000
Sex										
male	408	142	35.1 (30.4–40.2)	177	43.3 (38.4–48.4)	70	17.0 (13.6–21.2)	19	4.5 (2.8–7.1)	0.9213
female	92	31	34.2 (24.7–45.2)	40	43.4 (33.1–54.2)	17	19.2 (11.9–29.3)	4	3.3 (1.2–8.6)	
Age										
<25	9	6	70.5 (31.2–92.6)	1	12.0 (1.2–61.3)	2	17.5 (3.2–58.0)	0	0.0	0.0785

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
25-34	117	50	44.6 (35.4–54.3)	49	41.1 (32.2–50.7)	14	11.7 (6.9–19.3)	4	2.5 (0.9–6.7)	
35-44	248	79	32.2 (26.3–38.7)	113	44.6 (38.2–51.2)	42	17.8 (13.3–23.4)	14	5.4 (3.2–9.2)	
45+	126	38	29.7 (22.1–38.7)	54	44.7 (35.8–53.9)	29	21.9 (15.4–30.2)	5	3.7 (1.4–9.1)	
Years since the start of injecting drug use										
≤2	18	7	40.2 (19.2–65.5)	7	38.3 (18.0–63.6)	3	17.5 (5.2–45.1)	1	4.1 (0.5–27.3)	0.4982
3-5	47	19	38.3 (25.0–53.6)	19	42.5 (28.3–58.1)	6	11.8 (5.1–24.8)	3	7.4 (2.2–21.9)	
6-10	64	24	37.0 (25.6–50.1)	33	52.3 (39.4–64.8)	5	8.4 (3.3–19.5)	2	2.3 (0.5–9.7)	
≥11	371	123	33.9 (29.0–39.3)	158	42.1 (36.9–47.5)	73	19.7 (15.8–24.3)	17	4.2 (2.6–6.9)	
Partnership status										
live alone	289	97	33.8 (28.3–39.8)	133	46.7 (40.7–52.8)	46	15.6 (11.7–20.4)	13	3.9 (2.2–6.9)	0.3473
live with partner	211	76	36.5 (30.0–43.6)	84	38.8 (32.2–45.8)	41	19.9 (14.9–26.2)	10	4.8 (2.5–8.8)	
Current employment status										
full-time	74	32	41.1 (29.9–53.2)	33	47.0 (35.2–59.1)	7	9.5 (4.5–19.1)	2	2.4 (0.6–9.4)	0.0787
part-time or temporary	328	111	34.2 (29.0–39.9)	143	43.3 (37.8–49.0)	63	19.1 (15.0–23.9)	11	3.4 (1.8–6.2)	
unemployed	54	20	38.6 (25.6–53.5)	18	30.7 (19.6–44.7)	9	19.8 (10.3–34.7)	7	10.8 (5.0–21.8)	
disabled	37	10	30.2 (16.3–49.0)	19	48.5 (31.8–65.6)	7	17.2 (7.9–33.4)	1	4.1 (0.5–25.1)	
other	6	0	0.0	3	61.2 (15.7–93.0)	1	13.2 (0.9–72.3)	2	25.5 (3.4–77.0)	
Monthly income category										
<3K	77	22	30.5 (20.4–42.8)	32	40.3 (29.4–52.2)	20	26.7 (17.4–38.6)	3	2.6 (0.8–8.0)	0.3516
3-10K	211	70	34.5 (27.9–41.6)	97	45.5 (38.5–52.6)	31	14.3 (10.1–19.8)	13	5.8 (3.3–10.0)	
10-20K	165	64	38.1 (30.7–46.0)	67	40.9 (33.3–48.9)	30	18.5 (13.1–25.6)	4	2.5 (0.9–7.0)	
≥20K	26	10	38.1 (20.5–59.6)	13	48.7 (28.9–68.8)	2	9.4 (2.1–33.8)	1	3.8 (0.5–24.5)	
Ever incarcerated										
no	306	104	34.7 (29.3–40.6)	137	44.3 (38.6–50.2)	57	18.5 (14.4–23.4)	8	2.5 (1.2–5.1)	0.1030
yes	190	67	35.1 (28.3–42.6)	78	41.5 (34.4–49.1)	30	16.1 (11.3–22.4)	15	7.3 (4.3–12.0)	

Table 12.9. Anxiety symptoms severity (GAD-7) by Selected Subgroups

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										

		GAD-7 anxiety result							
	N	minimal		mild		moderate		severe	
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
no	220	78	35.5 (29.2–42.5)	91	40.7 (34.1–47.6)	40	18.3 (13.5–24.2)	11	5.5 (3.0–9.9)	0.5154
yes	272	91	34.0 (28.3–40.3)	124	45.9 (39.7–52.1)	46	16.9 (12.7–22.1)	11	3.2 (1.8–5.8)	
Treated with MAT currently (of all)										
no	411	142	35.1 (30.4–40.1)	176	42.7 (37.7–47.7)	76	18.2 (14.7–22.4)	17	4.0 (2.5–6.6)	0.6055
yes	66	24	37.3 (25.7–50.6)	29	44.4 (32.2–57.3)	8	12.1 (5.9–23.4)	5	6.2 (2.5–14.5)	
HIV test result										
positive	117	36	29.3 (21.6–38.4)	46	40.7 (31.8–50.3)	27	24.2 (16.9–33.5)	8	5.8 (2.9–11.4)	0.1108
negative	383	137	36.6 (31.6–41.8)	171	44.1 (38.9–49.3)	60	15.5 (12.1–19.6)	15	3.9 (2.3–6.5)	
Past 30 days injecting 4 categories										
opioids	406	150	37.4 (32.6–42.6)	176	43.0 (38.0–48.1)	62	15.4 (12.0–19.4)	18	4.3 (2.6–6.8)	
stimulants	40	13	30.8 (18.0–47.4)	18	46.7 (31.1–62.9)	8	20.7 (10.4–37.0)	1	1.9 (0.2–12.9)	
opi+stimul	54	10	18.8 (10.2–32.2)	23	43.8 (30.5–58.0)	17	31.1 (19.6–45.4)	4	6.3 (2.2–16.5)	
other	0	0		0		0		0		
Injecting drug type of choice										
opioids	442	159	36.4 (31.8–41.2)	190	42.7 (37.9–47.6)	72	16.5 (13.2–20.5)	21	4.4 (2.8–6.9)	0.2082
stimulants	55	14	25.3 (15.1–39.2)	26	49.3 (35.7–63.0)	13	22.1 (12.8–35.3)	2	3.3 (0.8–12.9)	
other	3	0	0.0	1	35.7 (0.3–99.1)	2	64.3 (0.9–99.7)	0	0.0	

13. Detention and Incarceration

Table 13.1. Police Detention and Incarceration Experience

	n	%	CI
Detained by police in 2022 for			
drug use	40	8.0	(5.8–10.8)
drug dealing	14	2.8	(1.6–4.8)
drug storing	35	7.2	(5.1–10.0)
Detained by police in 2023 for			
drug use	37	7.3	(5.2–10.1)
drug dealing	14	2.7	(1.6–4.7)
drug storing	28	6.0	(4.0–8.7)
Stopped, detained, or arrested by police ever			
yes	286	59.0	(54.4–63.5)
Ever incarcerated			
yes	190	37.9	(33.5–42.5)
Duration of incarceration			
≤6m	19	9.4	(6.0–14.4)
6m-2y	43	22.8	(17.1–29.7)
2-4y	72	38.7	(31.7–46.3)
4y+	56	29.1	(22.9–36.2)

	n	%	CI
Time since last incarceration			
≤1y	24	13.1	(8.8–19.1)
1-3y	19	9.9	(6.3–15.3)
3-5y	30	17.1	(12.0–23.9)
5-10y	34	17.8	(12.7–24.3)
10y+	82	42.1	(34.9–49.5)
Used injecting drugs during incarceration			
yes	111	58.8	(51.2–65.9)



Figure 13.1. Incarceration Lifetime Experience (%)

14. Negative experience

Table 14.1. Negative experience

	n	%	CI
Felt excluded from family activities due to drug use			
no	311	62.0	(57.4–66.4)
yes, in the past 6m	42	9.0	(6.6–12.1)
yes, but 6m+ ago	143	29.1	(25.0–33.5)
Was scolded because of drug use			
no	246	48.6	(44.0–53.2)
yes, in the past 6m	84	17.5	(14.2–21.3)
yes, but 6m+ ago	169	33.9	(29.7–38.4)
Was blackmailed for drug use			
no	382	77.6	(73.6–81.1)
yes, in the past 6m	44	8.6	(6.4–11.5)
yes, but 6m+ ago	74	13.8	(11.0–17.2)
Negative experience in the past 6 months (GAM 6.5)			
no	400	80.2	(76.2–83.6)
yes	96	19.8	(16.4–23.8)
Ever experienced physical violence			
no	300	61.1	(56.5–65.4)
yes	197	38.9	(34.6–43.5)
Experienced physical violence in the past 12 months (of those who had ever)			
no	115	58.3	(50.9–65.3)

		n	%	CI
	yes	81	41.7	(34.7–49.1)
Witnessed physical violence in the past 12 months				
	no	369	75.0	(70.8–78.7)
	yes	129	25.0	(21.3–29.2)



Figure 14.1. Negative Experience Related to Drug Use in the past 6 Months or Physical Violence in the past 12 months (%)

Table 14.2. Negative Experience Related to Drug Use by Sociodemographic Characteristics

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total								
All	496	96	19.8 (16.4–23.8)	1.0000	196	81	41.7 (34.7–49.1)	1.0000
Sex								
male	405	76	19.7 (15.9–24.2)	0.9145	168	69	41.6 (34.0–49.6)	0.9230
female	91	20	20.2 (13.1–30.0)		28	12	42.6 (25.2–62.0)	
Age								
<25	9	2	23.6 (4.4–67.6)	0.0001	1	0	0.0	0.7025
25-34	115	37	34.1 (25.5–43.9)		53	23	41.6 (29.0–55.5)	
35-44	246	43	18.5 (13.8–24.3)		92	39	44.4 (34.0–55.3)	
45+	126	14	9.5 (5.6–15.8)		50	19	36.6 (24.2–51.2)	
Years since the start of injecting drug use								
≤2	17	7	41.0 (19.4–66.7)	0.0208	8	5	64.6 (27.4–89.8)	0.2723
3-5	46	15	31.8 (19.6–47.3)		20	9	47.8 (25.8–70.7)	
6-10	63	11	16.4 (9.1–27.8)		28	8	28.0 (14.1–47.8)	

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
≥11	370	63	18.0 (14.1–22.6)		140	59	42.1 (33.8–50.9)	
Partnership status								
live alone	287	58	19.9 (15.5–25.1)	0.9726	123	52	43.4 (34.4–52.8)	0.5547
live with partner	209	38	19.8 (14.4–26.4)		73	29	38.9 (28.1–50.9)	
Current employment status								
full-time	73	11	17.1 (9.2–29.5)	0.8193	31	9	25.3 (13.1–43.1)	
part-time or temporary	326	68	21.4 (17.1–26.5)		139	61	44.0 (35.6–52.8)	
unemployed	54	9	15.6 (8.0–28.3)		17	9	65.8 (40.9–84.3)	
disabled	37	7	18.2 (8.5–35.0)		9	2	19.5 (4.4–56.0)	
other	6	1	15.1 (1.0–75.3)		0	0	0.0	
Monthly income category								
<3K	76	16	19.4 (11.9–30.2)	0.8624	25	11	43.2 (24.0–64.7)	0.9467
3-10K	209	35	17.8 (12.8–24.2)		75	29	38.9 (28.2–50.8)	
10-20K	164	33	20.5 (14.8–27.8)		80	33	41.5 (30.7–53.2)	
≥20K	26	6	23.8 (10.3–46.0)		9	3	32.8 (9.9–68.6)	
Ever incarcerated								
no	302	60	19.0 (14.9–23.9)	0.5646	123	50	41.5 (32.7–50.9)	0.8362
yes	190	35	21.3 (15.4–28.6)		71	31	43.1 (31.6–55.3)	

Table 14.3. Negative Experience Related to Drug Use by Selected Subgroups

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	217	52	24.2 (18.7–30.7)	0.0361	86	34	40.7 (30.4–52.0)	0.9788
yes	271	43	16.2 (12.0–21.4)		107	44	40.9 (31.6–51.0)	
Treated with MAT currently (of all)								
no	407	74	18.6 (14.9–23.0)	0.8447	152	64	42.4 (34.4–50.7)	0.6148
yes	66	12	19.7 (11.2–32.1)		25	8	36.2 (17.9–59.8)	
HIV test result								
positive	117	22	18.2 (12.0–26.6)	0.6260	50	19	37.3 (24.7–52.0)	0.4853
negative	379	74	20.3 (16.3–25.0)		146	62	43.2 (35.0–51.8)	

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Past 30 days injecting 4 categories								
opioids	406	76	19.2 (15.5–23.7)		165	62	38.6 (31.0–46.7)	
stimulants	39	6	15.9 (7.0–32.2)		17	11	66.2 (40.6–84.9)	
opi+stimul	51	14	27.7 (16.8–42.2)		14	8	49.9 (24.9–75.0)	
other	0	0			0	0		
Injecting drug type of choice								
opioids	439	82	19.2 (15.5–23.4)	0.5279	174	67	39.2 (31.9–47.1)	0.1448
stimulants	54	13	24.6 (14.5–38.6)		20	13	63.5 (39.5–82.2)	
other	3	1	35.7 (0.3–99.1)		2	1	44.5 (0.2–99.7)	

15. The Impact of the Full-scale War

Table 15.1. Migration Since February 2022

	n	%	CI
Changed place of residence since Feb 2022			
yes, because of the war	42	8.5	(6.3–11.5)
yes, for other reasons	23	4.6	(3.0–6.9)
no	433	86.9	(83.4–89.7)
Where migrated since Feb 2022			
unknown	2	3.8	(0.9–14.0)
other country	1	1.6	(0.2–10.8)
other oblast	30	66.5	(50.5–79.4)
other city	6	14.1	(6.3–28.9)
other district	5	14.0	(5.9–29.8)
other house	0	0.0	
Where lived before Feb 2022 (if changed residence)			
same oblast	27	43.2	(31.2–56.0)
other oblast	38	56.8	(44.0–68.8)
other country	0	0.0	



Figure 15.1. Change of Residence Since February 2022 (%)



Figure 15.2. Migration Destination by Survey Site (%)



Figure 15.3. Residence Before February 2022 (%)



Figure 15.4. Changes Since February 2022 (%)

City-level Results: Rivne



Figure A. RDS recruitment tree in Rivne

1. Sociodemographic Information

Table 1.1. Sociodemographic Characteristics

	n	Mean	CI	Median	IQR
Age, years	502	39.1	(38.2–40.0)	39	(34–43)
Age of first non-injecting drug use	464	18.5	(17.8–19.3)	16	(15–19)
Years since the start of non-injecting drug use	464	20.1	(19.1–21.1)	21	(14–26)
Age of first injecting drug use	502	24.3	(23.4–25.3)	21	(17–29)
Years since the start of injecting drug use	502	14.8	(13.8–15.8)	15	(5–23)
Personal monthly income, UAH	426	11,029.9	(8442.4–13617.4)	8,000	(4000–12000)

Table 1.2. Descriptive Statistics for Sociodemographics

	Site	n	%	CI
Sex				
male	Rivne	409	80.9	(76.6–84.6)
female	Rivne	93	19.1	(15.4–23.4)
Age				
<25	Rivne	20	5.1	(3.2–7.9)
25-34	Rivne	114	24.3	(20.2–28.9)
35-44	Rivne	248	48.5	(43.3–53.7)
45+	Rivne	120	22.1	(18.3–26.5)
Family status				
married or living together	Rivne	81	15.8	(12.2–20.1)
married but have another partner	Rivne	30	5.6	(3.8–8.2)
not married but have a partner	Rivne	52	10.7	(8.0–14.1)
married but not living together	Rivne	23	5.8	(3.5–9.3)
not married and do not have a partner	Rivne	316	62.2	(57.0–67.1)
Partnership status				
live alone	Rivne	339	67.9	(62.9–72.5)
live with partner	Rivne	163	32.1	(27.5–37.1)
Education				
incompl. high school	Rivne	73	14.5	(11.2–18.4)
high school	Rivne	184	36.9	(32.0–42.0)
>high school	Rivne	244	48.7	(43.5–53.9)
Current occupation				
school student	Rivne	0	0.0	
college/uni student	Rivne	0	0.0	
permanent job	Rivne	115	23.8	(19.7–28.6)
sporadic jobs	Rivne	213	42.9	(37.8–48.1)
unemployed	Rivne	124	25.1	(20.9–29.7)
housewife	Rivne	10	1.4	(0.7–2.9)
disabled	Rivne	26	3.4	(2.1–5.5)
military	Rivne	9	2.5	(1.0–5.9)
other	Rivne	5	0.9	(0.3–2.3)
Homelessness				
never	Rivne	409	81.0	(76.5–84.8)
yes, 12m+ ago	Rivne	84	16.8	(13.2–21.1)
yes, in the past 12m	Rivne	8	2.2	(1.0–4.7)
Homeless in 12 months (of those ever)				
no	Rivne	84	88.3	(76.9–94.5)
yes	Rivne	8	11.7	(5.5–23.1)
Monthly income category				
<3K	Rivne	78	16.5	(12.7–21.0)
3-10K	Rivne	165	38.3	(32.9–44.0)
10-20K	Rivne	144	35.6	(30.4–41.2)

	Site	n	%	CI
≥20K	Rivne	39	9.6	(6.6–13.8)
Monthly income relative to 2023 subsistence minimum				
<2684	Rivne	75	15.9	(12.2–20.4)
≥2684	Rivne	351	84.1	(79.6–87.8)
Years since the start of injecting drug use				
≤2	Rivne	57	14.3	(11.1–18.4)
3-5	Rivne	46	11.1	(8.2–14.8)
6-10	Rivne	58	13.5	(10.1–17.7)
≥11	Rivne	341	61.1	(55.9–66.1)

Table 1.3. Accommodation in the past 12 months

	Site	n	%	CI
own place	Rivne	283	55.4	(50.2–60.5)
friends or relatives	Rivne	100	19.1	(15.5–23.3)
renting	Rivne	86	18.4	(14.7–22.9)
varying	Rivne	15	4.3	(2.5–7.2)
on the street (homeless)	Rivne	8	2.2	(1.0–4.7)
in a refugee shelter	Rivne	39	7.3	(5.1–10.2)



Figure 1.1. Distribution of Age by Sex (%)



Figure 1.2. Trend in Sex Distribution by Survey Round (%)



Figure 1.3. Trend in Age Groups by Survey Round (%)

2. Drug Use



Figure 2.1. Injecting Drug Use in the Past 12 Months and 30 Days (%)



Figure 2.2. Non-injecting Drug Use in the Past 12 Months (%)



Figure 2.3. Trends in Injecting Drugs Types in the Past 30 Days by Survey Round (%)



Figure 2.4. Trends in Injecting Opioids in the Past 30 Days by Survey Round (%)



Figure 2.5. Trends in Injecting Stimulants in the Past 30 Days by Survey Round (%)



Figure 2.6. Trends in Injecting Other Drugs in the Past 30 Days by Survey Round (%)



Figure 2.7. Injecting Drug Preference (%)

Table 2.1. Types of Injecting Drugs in the Past 30 Days by Sociodemographic Characteristics

			Past 30 days injecting 4 categories								
		N	opioids		stimulants		opi+stimul		other		
			n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total											
	All	502	354	63.8 (58.6–68.7)	82	19.8 (16.0–24.2)	54	13.5 (10.1–17.8)	12	2.9 (1.6–5.3)	1.0000
Sex											
	male	409	291	64.8 (59.0–70.2)	65	18.9 (14.9–23.7)	44	13.7 (9.9–18.6)	9	2.6 (1.3–5.3)	0.7062
	female	93	63	59.3 (47.3–70.3)	17	23.7 (14.8–35.5)	10	12.8 (6.7–23.1)	3	4.2 (1.3–12.7)	
Age											
	<25	20	11	54.0 (30.2–76.1)	6	30.2 (12.6–56.6)	2	11.6 (2.6–39.0)	1	4.1 (0.5–27.0)	0.0021

	N	Past 30 days injecting 4 categories								
		opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
25-34	114	62	49.3 (39.2–59.5)	27	27.2 (19.0–37.4)	20	17.8 (11.4–26.8)	5	5.6 (2.1–14.1)	
35-44	248	184	66.4 (58.5–73.4)	35	17.4 (12.4–23.8)	28	15.8 (10.5–23.2)	1	0.4 (0.1–3.0)	
45+	120	97	76.2 (66.3–83.9)	14	14.5 (8.6–23.5)	4	4.1 (1.4–11.0)	5	5.2 (2.1–12.3)	
Years since the start of injecting drug use										
≤2	57	32	52.8 (38.9–66.3)	17	32.3 (20.6–46.8)	3	6.4 (2.0–18.6)	5	8.5 (3.4–19.5)	0.0149
3-5	46	28	59.6 (43.7–73.8)	8	16.8 (8.3–31.2)	8	17.6 (8.7–32.3)	2	6.0 (1.3–24.1)	
6-10	58	35	61.9 (46.9–75.0)	12	21.0 (11.6–35.2)	8	12.1 (5.7–23.7)	3	5.0 (1.4–16.5)	
≥11	341	259	67.5 (60.9–73.5)	45	17.1 (12.8–22.5)	35	14.7 (10.2–20.8)	2	0.6 (0.2–2.5)	
Partnership status										
live alone	339	249	66.6 (60.2–72.5)	50	17.3 (13.1–22.5)	34	14.0 (9.7–19.7)	6	2.2 (0.9–5.0)	0.1628
live with partner	163	105	57.8 (48.7–66.4)	32	25.1 (18.1–33.9)	20	12.5 (7.9–19.3)	6	4.6 (1.9–10.6)	
Current employment status										
full-time	115	81	64.1 (53.2–73.7)	18	17.9 (11.2–27.3)	10	10.9 (5.7–19.9)	6	7.1 (3.1–15.7)	0.0333
part-time or temporary	213	159	67.7 (59.4–74.9)	35	20.4 (14.7–27.5)	17	10.7 (6.0–18.3)	2	1.3 (0.3–5.1)	
unemployed	124	79	56.0 (45.7–65.7)	22	21.4 (14.2–31.0)	22	22.3 (14.9–32.2)	1	0.3 (0.0–2.0)	
disabled	26	20	68.7 (41.2–87.3)	3	16.5 (4.2–47.1)	2	9.6 (1.8–38.3)	1	5.2 (0.7–31.6)	
other	24	15	64.9 (38.8–84.3)	4	17.9 (6.0–43.0)	3	8.0 (1.9–27.7)	2	9.2 (2.0–33.6)	
Monthly income category										
<3K	78	56	66.3 (52.0–78.1)	11	15.8 (8.0–28.6)	8	14.1 (6.5–27.9)	3	3.9 (1.1–12.8)	0.7469
3-10K	165	123	64.0 (54.2–72.8)	26	20.5 (14.0–29.0)	14	13.4 (7.4–22.9)	2	2.1 (0.5–9.1)	
10-20K	144	97	63.2 (53.9–71.6)	32	24.8 (17.8–33.4)	13	10.6 (6.0–18.3)	2	1.4 (0.3–5.4)	
≥20K	39	26	61.9 (42.4–78.3)	5	15.6 (6.2–33.9)	8	22.5 (10.7–41.2)	0	0.0	
Ever incarcerated										
no	323	221	62.4 (56.0–68.4)	63	22.3 (17.6–28.0)	30	11.9 (8.0–17.3)	9	3.4 (1.7–6.8)	0.1981
yes	179	133	66.7 (57.6–74.7)	19	14.5 (9.2–22.1)	24	16.8 (11.0–24.9)	3	2.0 (0.6–6.2)	

Table 2.2. Types of Injecting Drugs in the Past 30 Days by Selected Subgroups

	N	Past 30 days injecting 4 categories								
		opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										

	N	Past 30 days injecting 4 categories								
		opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
no	303	180	57.4 (51.0–63.5)	71	23.7 (18.9–29.3)	41	15.0 (10.9–20.4)	11	3.9 (2.1–7.2)	0.0001
yes	192	169	81.9 (73.3–88.2)	11	9.6 (5.2–16.9)	11	8.2 (4.1–15.8)	1	0.3 (0.0–1.9)	
Treated with MAT currently (of all)										
no	341	207	60.7 (55.0–66.2)	76	21.3 (17.1–26.2)	48	15.0 (11.2–19.8)	10	2.9 (1.5–5.6)	0.0000
yes	155	144	91.8 (83.8–96.0)	3	2.0 (0.6–6.2)	6	3.0 (1.3–6.8)	2	3.2 (0.6–14.3)	
HIV test result										
positive	83	70	73.5 (57.5–85.1)	5	9.0 (3.5–21.2)	7	15.1 (6.5–31.4)	1	2.4 (0.3–15.4)	0.3207
negative	419	284	62.6 (57.0–67.8)	77	21.1 (17.0–25.9)	47	13.3 (9.8–17.9)	11	3.0 (1.6–5.6)	
Injecting drug type of choice										
opioids	393	344	83.9 (78.4–88.1)	5	1.1 (0.4–2.9)	41	13.6 (9.7–18.8)	3	1.4 (0.4–4.5)	0.0000
stimulants	92	5	4.9 (1.9–11.7)	75	80.9 (70.8–88.1)	12	14.2 (8.0–24.0)	0	0.0	
other	6	3	65.2 (17.1–94.4)	2	30.3 (4.2–81.3)	0	0.0	1	4.5 (0.3–44.6)	

Table 2.3. Injecting frequency

	Past 30 days injecting 4 categories								
	opioids		stimulants		opi+stimul		other		
	n	%	n	%	n	%	n	%	p-value
Injecting frequency: last 24 hrs									
0 times	100	37.3	53	64.5	12	20.0	7	63.0	0.0001
1 time	176	45.2	23	28.3	25	49.0	4	25.6	
2-3 times	71	14.7	2	1.8	13	24.0	1	11.4	
4+ times	7	2.9	4	5.3	4	7.0	0	0.0	
N	354		82		54		12		
Injecting frequency: last 24 hrs (among those who did)									
1 time	176	72.0	23	79.9	25	61.3	4	69.3	0.1832
2-3 times	71	23.4	2	5.2	13	30.0	1	30.7	
4+ times	7	4.6	4	15.0	4	8.7	0	0.0	
N	254		29		42		5		
Injecting frequency: last week									
0 times	18	7.9	10	14.2	1	1.9	2	19.0	0.0001
1-6 times	113	40.5	56	66.3	23	39.1	5	48.2	
every day	222	51.6	16	19.5	30	59.0	4	32.7	
N	353		82		54		11		
Injecting frequency: last 30 days									
1-9 times	84	29.3	29	33.8	11	18.5	5	39.2	0.0001
10-19 times	53	19.1	32	40.5	10	15.0	3	30.9	
20-29 times	44	11.2	8	10.5	13	26.5	0	0.0	
every day	173	40.4	13	15.2	20	40.1	4	29.9	
N	354		82		54		12		
Injecting frequency: main drug last 30 days									
0-9 times	50	21.9	28	35.0	6	9.9	5	39.2	0.0000
10-19 times	54	20.3	28	37.1	9	14.7	3	30.9	

	Past 30 days injecting 4 categories								
	opioids		stimulants		opi+stimul		other		
	n	%	n	%	n	%	n	%	p-value
20-29 times	33	9.2	6	8.1	10	23.0	0	0.0	
every day	208	48.6	16	19.8	27	52.3	4	29.9	
N	345		78		52		12		

Table 2.4. Injecting drug type of choice by Income Category

	Injecting drug type of choice					
	opioids		stimulants		other	
	n	%	n	%	n	%
Monthly income category						
<3K	64	17.4	10	11.5	2	26.3
3-10K	131	38.9	31	37.7	1	21.7
10-20K	104	33.1	36	42.8	3	52.0
≥20K	32	10.6	7	8.0	0	0.0
N	331		84		6	

Table 2.5. Sources of drugs by Drug Type of Choice

Total		Injecting drug type of choice						
All		opioids		stimulants		other		
n	%	n	%	n	%	n	%	p-value
prepare myself								
112	23.3	91	24.5	19	20.3	1	21.7	0.7487
prepared by friends								
70	17.6	46	15.3	20	23.0	3	57.1	0.0166
from a dealer								
241	55.9	179	55.7	52	55.6	2	38.4	0.7297
buy on Internet								
31	8.6	15	5.3	16	20.8	0	0.0	0.0005
from a pharmacy								
31	3.0	31	4.1	0	0.0	0	0.0	0.1117
from MAT program								
77	6.1	76	8.3	0	0.0	1	4.5	0.0005
other								
3	0.8	3	1.2	0	0.0	0	0.0	0.6100
N								
565		441		107		7		



Figure 2.8. Change in the price, quality, and access of drugs by Drug Type of Choice (%)

3. Injecting Risk Behavior

Table 3.1. Prevalence of Injection Risk Practices

	n	%	CI
Used clean syringe for last injection			
yes	461	93.1	(90.1–95.2)
Source of syringe for last injection			
bought in pharmacy	255	62.2	(57.2–67.0)
got in pharmacy	4	0.8	(0.3–2.2)
got from NGO	224	32.5	(28.0–37.3)
got from friend	6	1.5	(0.7–3.4)
got used from friend	8	2.5	(1.2–5.3)
used one used by myself	1	0.0	(0.0–0.3)
got pre-loaded	2	0.4	(0.1–1.8)
other	0	0.0	
Used shared syringe in the past 30 days			
yes	22	4.1	(2.5–6.6)
Used pre-filled syringe in the past 30 days			
yes	17	4.8	(2.9–8.0)
Used front-/back-loaded syringe in the past 30 days			
yes	30	6.4	(4.3–9.4)
Used shared container in the past 30 days			
yes	21	4.1	(2.5–6.5)
Used own previously used syringe in the past 30 days			
yes	78	16.0	(12.6–20.1)
Gave someone a used syringe in the past 30 days			
yes	10	2.5	(1.3–5.0)
Any inj. risk (shared syringe, pre-filled, front-/back-load, container) in the past 30 days			
yes	60	12.7	(9.6–16.5)

Table 3.2. Frequency of risky injection practices

	n	%	CI
Frequency of injecting with a syringe used by others in the past 30 days			
always	0	0.0	

	n	%	CI
often	5	21.4	(8.3–44.9)
half	3	23.2	(7.2–54.1)
sometimes	5	22.5	(8.2–48.7)
rarely	1	1.5	(0.2–10.2)
never	7	31.5	(13.7–57.0)
Frequency of injecting with others in the same place in the past 30 days			
always	53	11.5	(8.7–15.1)
often	55	11.5	(8.6–15.2)
half	59	11.8	(8.9–15.5)
sometimes	58	11.5	(8.7–15.0)
rarely	57	10.8	(8.1–14.3)
never	211	42.9	(37.7–48.3)
Number of syringes used repeatedly in the past 30 days			
1-9	51	68.3	(55.0–79.1)
10-29	18	27.7	(17.6–40.6)
30+	2	4.1	(1.0–15.0)
Number of times one syringe used repeatedly in the past 30 days			
1	8	13.3	(6.0–26.9)
2-3	35	58.5	(44.4–71.4)
4-9	6	7.9	(3.1–18.8)
10+	12	20.3	(11.5–33.3)
How the pre-filled syringe was obtained			
from dealer	13	65.8	(37.4–86.1)
from friends	4	34.2	(13.9–62.6)
from stash	0	0.0	
Someone used one syringe for injection before front-/back-loading			
no	486	96.7	(94.0–98.2)
yes	14	3.3	(1.8–6.0)



Figure 3.1. Prevalence of Key Injection Risk Practices (%)



Figure 3.2. Trends in Key Injection Risk Practices by Survey Round (%)



Figure 3.3. With whom injected drugs in the same place (%)



Figure 3.4. With whom injected drugs in the same place by sex (%)



Figure 3.5. With whom injected drugs in the same place by age (%)

Table 3.3. Prevalence of Shared and Pre-filled Syringe Use by Sociodemographic Characteristics

		Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	501	22	4.1 (2.5–6.6)	1.0000	499	17	4.8 (2.9–8.0)	1.0000
Sex									
	male	408	15	3.1 (1.7–5.5)	0.0330	406	11	3.5 (1.8–6.7)	0.0379
	female	93	7	8.6 (3.8–18.4)		93	6	10.2 (4.4–21.9)	
Age									
	<25	20	2	13.1 (2.6–45.6)	0.2003	20	1	9.6 (1.2–47.9)	0.2983

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
25-34	114	5	3.8 (1.5–9.7)		114	6	7.7 (3.3–17.0)	
35-44	247	12	4.2 (2.2–8.0)		247	8	4.3 (2.0–8.9)	
45+	120	3	2.3 (0.7–7.5)		118	2	1.6 (0.4–6.4)	
Years since the start of injecting drug use								
≤2	57	2	3.0 (0.7–11.9)	0.6056	56	3	5.1 (1.5–15.6)	0.3545
3-5	46	2	4.2 (1.0–15.9)		46	4	10.9 (3.8–27.3)	
6-10	58	4	7.5 (2.4–21.3)		57	2	5.0 (1.1–20.7)	
≥11	340	14	3.6 (2.0–6.7)		340	8	3.6 (1.7–7.7)	
Partnership status								
live alone	338	16	4.0 (2.2–6.9)	0.8181	337	9	3.3 (1.6–6.7)	0.0827
live with partner	163	6	4.5 (1.8–10.5)		162	8	8.0 (3.8–15.9)	
Current employment status								
full-time	115	3	2.8 (0.9–8.6)	0.6118	114	4	6.0 (2.1–15.8)	0.2232
part-time or temporary	212	13	5.5 (2.9–10.4)		212	4	2.7 (0.9–7.5)	
unemployed	124	6	4.3 (1.7–10.5)		123	9	9.0 (4.4–17.4)	
disabled	26	0	0.0		26	0	0.0	
other	24	0	0.0		24	0	0.0	
Monthly income category								
<3K	78	3	6.6 (1.9–20.2)	0.4407	78	2	5.9 (1.4–21.1)	0.3608
3-10K	165	8	3.1 (1.3–7.0)		163	5	5.4 (2.2–12.9)	
10-20K	143	5	3.3 (1.3–8.6)		144	3	1.5 (0.4–5.3)	
≥20K	39	0	0.0		38	1	2.2 (0.3–15.3)	
Ever incarcerated								
no	323	12	3.3 (1.7–6.4)	0.2296	321	10	4.9 (2.5–9.3)	0.8909
yes	178	10	5.9 (3.0–11.3)		178	7	4.6 (2.1–9.9)	

Table 3.4. Prevalence of Shared and Pre-filled Syringe Use by Selected Subgroups

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	302	12	3.9 (2.1–7.2)	0.6436	301	12	5.3 (2.9–9.5)	0.4644

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
yes	192	10	4.9 (2.4–9.8)		191	4	3.5 (1.3–9.0)	
Treated with MAT currently (of all)								
no	340	15	4.2 (2.5–7.1)	0.9816	339	16	5.4 (3.2–9.0)	0.0020
yes	155	7	4.1 (1.9–8.7)		154	1	0.5 (0.1–3.2)	
HIV test result								
positive	83	5	7.1 (2.4–19.3)	0.2893	82	2	5.3 (1.3–19.3)	0.8898
negative	418	17	3.8 (2.2–6.4)		417	15	4.8 (2.7–8.2)	
Past 30 days injecting 4 categories								
opioids	354	14	3.3 (1.7–6.0)	0.4898	351	5	2.0 (0.8–5.1)	0.0245
stimulants	81	5	6.8 (2.6–16.6)		82	5	8.6 (3.4–19.9)	
opi+stimul	54	3	5.3 (1.6–16.3)		54	6	10.0 (4.1–22.4)	
other	12	0	0.0		12	1	16.7 (1.9–66.8)	
Injecting drug type of choice								
opioids	393	17	3.7 (2.2–6.3)	0.8216	390	9	3.1 (1.5–6.4)	0.0641
stimulants	91	4	4.7 (1.6–13.3)		92	7	9.6 (4.4–19.7)	
other	6	0	0.0		6	0	0.0	

Table 3.5. Prevalence of Front-/back-loading and Container Sharing by Sociodemographic Characteristics

		Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	499	30	6.4 (4.3–9.4)	1.0000	500	21	4.1 (2.5–6.5)	1.0000
Sex									
	male	407	26	6.6 (4.3–9.9)	0.7622	407	16	3.7 (2.1–6.5)	0.4525
	female	92	4	5.5 (1.8–15.7)		93	5	5.5 (2.3–12.9)	
Age									
	<25	20	2	10.6 (1.6–46.2)	0.7674	20	2	5.1 (0.9–24.8)	0.4200
	25-34	114	5	5.0 (2.0–11.9)		113	2	1.6 (0.4–6.3)	
	35-44	246	17	7.1 (4.2–11.9)		248	11	4.4 (2.2–8.6)	
	45+	119	6	5.3 (2.3–11.7)		119	6	5.9 (2.6–13.1)	
Years since the start of injecting drug use									

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
≤2	57	2	3.2 (0.8–12.5)	0.5479	57	3	5.2 (1.6–15.8)	0.9222
3-5	46	5	8.5 (3.2–20.6)		46	3	4.6 (1.2–15.7)	
6-10	58	4	9.5 (3.4–24.1)		58	3	4.8 (1.5–14.4)	
≥11	338	19	6.0 (3.6–9.9)		339	12	3.6 (1.8–6.9)	
Partnership status								
live alone	338	22	6.4 (4.0–10.1)	0.9910	337	14	3.8 (2.0–7.0)	0.6854
live with partner	161	8	6.3 (3.0–12.8)		163	7	4.6 (2.2–9.6)	
Current employment status								
full-time	115	1	0.7 (0.1–5.2)	0.0084	115	3	2.6 (0.7–8.9)	0.3711
part-time or temporary	212	13	6.8 (3.8–12.2)		211	8	3.3 (1.6–7.0)	
unemployed	123	15	12.3 (7.0–20.7)		124	9	7.3 (3.4–14.9)	
disabled	25	0	0.0		26	0	0.0	
other	24	1	3.7 (0.4–24.7)		24	1	4.3 (0.5–28.0)	
Monthly income category								
<3K	77	2	5.9 (1.4–21.3)	0.7213	76	0	0.0	0.1988
3-10K	163	10	6.7 (3.6–12.4)		165	4	3.0 (1.1–7.8)	
10-20K	144	7	3.7 (1.5–8.7)		144	10	5.7 (2.8–11.2)	
≥20K	39	2	4.0 (0.9–15.8)		39	2	3.0 (0.6–13.5)	
Ever incarcerated								
no	322	18	5.8 (3.4–9.7)	0.5294	322	14	4.3 (2.4–7.6)	0.7749
yes	177	12	7.5 (4.1–13.4)		178	7	3.7 (1.6–8.1)	

Table 3.6. Prevalence of Front-/back-loading and Container Sharing by Selected Subgroups

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	302	18	6.1 (3.7–9.9)	0.6242	302	13	3.9 (2.2–7.1)	0.7501
yes	190	12	7.4 (3.9–13.5)		191	8	4.6 (2.1–9.7)	
Treated with MAT currently (of all)								
no	341	24	6.8 (4.5–10.2)	0.1292	340	16	4.3 (2.6–7.1)	0.3845

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
yes	152	6	3.4 (1.5–7.7)		154	5	2.8 (1.1–6.6)	
HIV test result								
positive	81	6	5.7 (1.8–16.5)	0.8308	82	4	3.0 (0.9–9.6)	0.6174
negative	418	24	6.5 (4.2–9.7)		418	17	4.2 (2.5–6.9)	
Past 30 days injecting 4 categories								
opioids	351	15	4.0 (2.2–6.9)	0.0378	352	13	3.5 (1.9–6.4)	0.7348
stimulants	82	5	8.7 (3.5–20.2)		82	2	3.8 (0.9–14.8)	
opi+stimul	54	9	14.3 (7.0–26.7)		54	5	6.5 (2.4–16.0)	
other	12	1	6.0 (0.6–39.4)		12	1	7.1 (0.7–43.7)	
Injecting drug type of choice								
opioids	390	20	4.8 (3.0–7.8)	0.1788	391	18	4.3 (2.6–7.1)	0.8849
stimulants	92	8	10.2 (4.9–20.1)		92	3	4.0 (1.2–13.0)	
other	6	0	0.0		6	0	0.0	

4. Sexual Behavior

Table 4.1. Prevalence of Sexual Practice by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had sex: ever										
yes	485	95.7	(92.1–97.6)	92	98.7	(90.9–99.8)	393	95.0	(90.7–97.3)	0.1668
N	502			93			409			
Had sex: in the past 12 months										
yes	377	80.3	(75.7–84.2)	80	86.0	(74.8–92.7)	297	78.9	(73.6–83.3)	0.2044
N	481			92			389			
Had sex: in the past 30 days										
yes	250	55.0	(49.6–60.2)	61	69.9	(58.0–79.7)	189	51.3	(45.4–57.3)	0.0057
N	473			89			384			
Had a sex partner in the past 30 days: regular										
yes	200	76.8	(70.5–82.1)	55	84.2	(70.3–92.3)	145	74.3	(66.9–80.5)	0.1698
N	258			64			194			
Had a sex partner in the past 30 days: casual										
yes	74	29.3	(23.5–35.9)	13	22.8	(12.6–37.5)	61	31.5	(24.8–39.1)	0.2598
N	258			64			194			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	6	2.6	(1.1–5.8)	0	0.0		6	3.4	(1.5–7.6)	0.1596
N	258			64			194			
Used condom during last sex: if ever had sex										
yes	203	41.6	(36.4–46.9)	19	21.7	(13.5–33.1)	184	46.4	(40.5–52.4)	0.0002
N	465			88			377			

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Used condom during last sex: if had sex in 12m										
yes	160	41.7	(36.0–47.7)	18	23.6	(14.5–36.0)	142	46.6	(40.0–53.4)	0.0014
N	369			78			291			
Used condom during last sex: if had sex in 30d										
yes	98	37.0	(30.6–43.9)	14	20.2	(11.2–33.7)	84	42.7	(35.0–50.7)	0.0044
N	249			61			188			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes				0	0.0		0	0.0		
N				64			194			



Figure 4.1. Frequency of sex in the past week by Drug Types Used (%)

Table 4.2. Sex Practices by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had same-sex sexual experience										
yes	18	3.4	(2.0–5.8)	10	11.7	(5.8–22.2)	8	1.4	(0.6–2.9)	0.0000
N	484			92			392			
Provided sex services for money										
yes	21	3.7	(2.3–6.1)	11	12.3	(6.3–22.5)	10	1.6	(0.8–3.3)	0.0000
N	484			92			392			
Paid for sex ever										
yes	75	14.9	(11.4–19.2)	1	0.3	(0.0–1.9)	74	18.5	(14.3–23.6)	0.0000
N	483			92			391			
Had sex with a sex worker in the past 6 months										
yes	23	32.2	(21.1–45.7)	0	0.0		23	32.3	(21.2–45.9)	0.5098
N	75			1			74			
Type of partner with whom had last sex										
regular	331	68.2	(63.0–72.9)	72	78.2	(66.0–86.9)	259	65.8	(60.0–71.2)	
casual	139	30.4	(25.7–35.6)	17	21.8	(13.1–34.0)	122	32.5	(27.2–38.3)	
com. sex (I paid)	6	1.4	(0.6–3.2)	0	0.0		6	1.7	(0.8–3.9)	
com. sex (I was paid)	0	0.0		0	0.0		0	0.0		

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
N	476			89			387			
With whom last had sex										
man	92	19.4	(15.6–23.8)	90	96.1	(84.6–99.1)	2	0.5	(0.1–2.0)	
woman	390	80.6	(76.2–84.4)	2	3.9	(0.9–15.4)	388	99.5	(98.0–99.9)	
men and women	0	0.0		0	0.0		0	0.0		
N	482			92			390			
Type of last sex contact: vaginal										
yes	454	96.6	(94.0–98.0)	82	94.3	(83.0–98.3)	372	97.1	(94.6–98.4)	0.3139
N	470			86			384			
Type of last sex contact: anal										
yes	31	6.8	(4.6–10.1)	3	2.8	(0.8–9.0)	28	7.7	(5.1–11.6)	0.0933
N	470			86			384			
Type of last sex contact: oral										
yes	126	26.0	(21.7–30.8)	26	31.9	(21.6–44.3)	100	24.7	(20.1–29.9)	0.2339
N	470			86			384			

Table 4.3. Sex Partners by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had a sex partner in the past 30 days: regular										
yes	200	76.8	(70.5–82.1)	55	84.2	(70.3–92.3)	145	74.3	(66.9–80.5)	0.1698
N	258			64			194			
Had a sex partner in the past 30 days: casual										
yes	74	29.3	(23.5–35.9)	13	22.8	(12.6–37.5)	61	31.5	(24.8–39.1)	0.2598
N	258			64			194			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	6	2.6	(1.1–5.8)	0	0.0		6	3.4	(1.5–7.6)	0.1596
N	258			64			194			
Number of sex partners in the past 30 days: regular										
1	100	95.8	(87.6–98.6)	26	100.0		74	94.1	(83.2–98.1)	
2-4	3	4.2	(1.4–12.4)	0	0.0		3	5.9	(1.9–16.8)	
5+	0	0.0		0	0.0		0	0.0		
N	103			26			77			
Number of sex partners in the past 30 days: casual										
1	21	64.1	(46.8–78.3)	4	84.8	(36.5–98.2)	17	59.8	(41.2–76.0)	0.4885
2-4	14	30.8	(17.7–47.9)	1	15.2	(1.8–63.5)	13	34.0	(19.2–52.7)	
5+	2	5.2	(1.3–18.6)	0	0.0		2	6.2	(1.5–21.9)	
N	37			5			32			
Number of sex partners in the past 30 days: total										
1	118	85.6	(78.2–90.8)	30	97.2	(82.0–99.6)	88	81.7	(72.5–88.3)	0.0772
2-4	19	13.0	(8.1–20.2)	1	2.8	(0.4–18.0)	18	16.4	(10.1–25.5)	
5+	2	1.4	(0.3–5.5)	0	0.0		2	1.9	(0.5–7.3)	
N	139			31			108			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes				0	0.0		0	0.0		
N				64			194			



Figure 4.2. Condom Use During Last Sexual Encounter by Type of Partner (%)



Figure 4.3. Trends in Condom Use During Last Sexual Encounter by Survey Round (%)

Table 4.4. Condom Use During Last Sexual Encounter by Sociodemographic Characteristics

			Used condom during last sex: if ever had sex				
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
Total							
	All	465	262	58.4 (53.1–63.6)	203	41.6 (36.4–46.9)	1.0000
Sex							
	male	377	193	53.6 (47.6–59.5)	184	46.4 (40.5–52.4)	0.0002
	female	88	69	78.3 (66.9–86.5)	19	21.7 (13.5–33.1)	
Age							
	<25	20	11	64.3 (40.1–82.9)	9	35.7 (17.1–59.9)	0.4833

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
25-34	112	63	59.6 (49.2–69.1)	49	40.4 (30.9–50.8)	
35-44	228	119	54.5 (46.4–62.3)	109	45.5 (37.7–53.6)	
45+	105	69	64.4 (52.9–74.4)	36	35.6 (25.6–47.1)	
Years since the start of injecting drug use						
≤2	53	32	60.6 (46.1–73.5)	21	39.4 (26.5–53.9)	0.4880
3-5	46	29	61.3 (45.1–75.3)	17	38.7 (24.7–54.9)	
6-10	56	31	47.9 (33.0–63.2)	25	52.1 (36.8–67.0)	
≥11	310	170	59.8 (53.1–66.1)	140	40.2 (33.9–46.9)	
Partnership status						
live alone	308	153	52.4 (45.7–59.0)	155	47.6 (41.0–54.3)	0.0009
live with partner	157	109	70.8 (62.2–78.1)	48	29.2 (21.9–37.8)	
Current employment status						
full-time	109	67	62.7 (51.6–72.6)	42	37.3 (27.4–48.4)	0.2872
part-time or temporary	199	112	58.1 (49.7–66.1)	87	41.9 (33.9–50.3)	
unemployed	111	53	50.7 (40.1–61.2)	58	49.3 (38.8–59.9)	
disabled	24	14	69.6 (43.9–87.1)	10	30.4 (12.9–56.1)	
other	22	16	72.3 (46.8–88.6)	6	27.7 (11.4–53.2)	
Monthly income category						
<3K	66	33	47.9 (33.5–62.5)	33	52.1 (37.5–66.5)	0.0651
3-10K	158	87	56.4 (46.7–65.7)	71	43.6 (34.3–53.3)	
10-20K	137	86	65.9 (56.5–74.2)	51	34.1 (25.8–43.5)	
≥20K	36	15	42.8 (26.2–61.3)	21	57.2 (38.7–73.8)	
Ever incarcerated						
no	303	171	57.7 (51.2–63.9)	132	42.3 (36.1–48.8)	0.6910
yes	162	91	60.0 (50.2–69.0)	71	40.0 (31.0–49.8)	

Table 4.5. Condom Use During Last Sexual Encounter by Selected Subgroups

	N	Used condom during last sex: if ever had sex				
		no		yes		
	n		% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	281	169	60.0 (53.4–66.3)	112	40.0 (33.7–46.6)	0.3638
yes	178	92	55.0 (45.9–63.7)	86	45.0 (36.3–54.1)	
Treated with MAT currently (of all)						
no	317	193	60.2 (54.2–65.8)	124	39.8 (34.2–45.8)	0.0070
yes	143	67	45.7 (37.1–54.5)	76	54.3 (45.5–62.9)	
HIV test result						
positive	77	33	41.4 (27.3–57.1)	44	58.6 (42.9–72.7)	0.0198
negative	388	229	60.6 (55.0–66.0)	159	39.4 (34.0–45.0)	
Past 30 days injecting 4 categories						
opioids	329	174	53.8 (47.2–60.3)	155	46.2 (39.7–52.8)	0.1318
stimulants	76	50	69.8 (58.3–79.3)	26	30.2 (20.7–41.7)	
opi+stimul	50	31	63.3 (47.1–77.0)	19	36.7 (23.0–52.9)	
other	10	7	60.3 (22.8–88.7)	3	39.7 (11.3–77.2)	
Injecting drug type of choice						
opioids	363	196	55.8 (49.5–61.9)	167	44.2 (38.1–50.5)	0.0419
stimulants	86	58	69.7 (58.8–78.7)	28	30.3 (21.3–41.2)	
other	6	3	34.8 (5.6–82.9)	3	65.2 (17.1–94.4)	

Table 4.6. Condom use by type of partner by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Used condom during last sex: regular partner										
yes	91	45.1	(37.5–52.9)	20	34.0	(21.6–49.1)	71	49.3	(40.3–58.4)	0.0809
N	200			55			145			
Used condom during last sex: casual partner										
yes	43	55.0	(42.2–67.1)	4	27.7	(7.6–64.3)	39	61.2	(47.2–73.5)	0.0750
N	73			12			61			
Used condom during last sex: commercial (I paid) partner										
yes	2	37.6	(8.7–79.1)	0	0.0		2	37.6	(8.7–79.2)	
N	5			0			5			
Condom use frequency: regular partner										
always	55	26.4	(20.0–34.1)	10	18.9	(9.5–34.0)	45	29.3	(21.5–38.4)	0.7319
often	11	6.5	(3.6–11.5)	2	4.2	(1.0–15.8)	9	7.4	(3.8–13.7)	
half	8	3.8	(1.8–7.8)	2	4.2	(1.0–15.9)	6	3.6	(1.5–8.5)	
sometimes	5	2.3	(0.9–5.5)	2	2.7	(0.6–11.6)	3	2.1	(0.7–6.4)	
rarely	10	5.6	(2.7–11.3)	2	7.5	(1.8–25.9)	8	4.9	(2.1–11.0)	
never	109	55.5	(47.5–63.1)	36	62.5	(46.6–76.1)	73	52.8	(43.6–61.8)	
N	198			54			144			

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Condom use frequency: casual partner										
always	26	37.1	(25.5–50.3)	2	19.9	(3.4–63.6)	24	41.0	(28.2–55.1)	0.0386
often	9	13.2	(6.7–24.5)	0	0.0		9	16.3	(8.3–29.5)	
half	3	3.5	(1.0–11.4)	1	6.6	(0.8–36.7)	2	2.8	(0.6–12.6)	
sometimes	8	10.8	(5.2–21.2)	0	0.0		8	13.3	(6.4–25.6)	
rarely	5	9.0	(3.7–20.3)	1	7.7	(1.0–40.9)	4	9.3	(3.5–22.7)	
never	18	26.4	(16.5–39.4)	8	65.8	(31.0–89.2)	10	17.4	(9.2–30.3)	
N	69			12			57			
Condom use frequency: commercial (I paid) partner										
always	2	42.1	(10.6–81.7)	0	0.0		2	42.1	(10.6–81.7)	
often	0	0.0		0	0.0		0	0.0		
half	0	0.0		0	0.0		0	0.0		
sometimes	0	0.0		0	0.0		0	0.0		
rarely	1	20.3	(2.7–69.8)	0	0.0		1	20.3	(2.7–69.8)	
never	2	37.5	(9.0–78.6)	0	0.0		2	37.5	(9.0–78.6)	
N	5			0			5			



Figure 4.4. Frequency of condom use by type of partner by Sex (%)



Figure 4.5. Frequency of condom use among men during the last sexual encounter by the riskiest type of partner in the past 30 days (%)

5. HIV, HCV, and Syphilis Testing Results

Table 5.1. HIV Prevalence by Sociodemographic Characteristics

			HIV test result			
	N	positive		negative		
		n	% (CI)	n	% (CI)	p-value
Total						
All	502	83	11.2 (8.3–14.9)	419	88.8 (85.1–91.7)	1.0000
Sex						
male	409	65	11.2 (7.9–15.5)	344	88.8 (84.5–92.1)	0.9958
female	93	18	11.2 (6.2–19.4)	75	88.8 (80.6–93.8)	
Age						
<25	20	1	0.9 (0.1–7.6)	19	99.1 (92.4–99.9)	0.0005
25-34	114	9	6.1 (2.8–12.7)	105	93.9 (87.3–97.2)	
35-44	248	55	16.8 (11.6–23.6)	193	83.2 (76.4–88.4)	
45+	120	18	6.9 (4.0–11.6)	102	93.1 (88.4–96.0)	
Years since the start of injecting drug use						
≤2	57	1	0.5 (0.1–3.6)	56	99.5 (96.4–99.9)	0.0566
3-5	46	5	9.9 (3.8–23.7)	41	90.1 (76.3–96.2)	
6-10	58	6	16.7 (6.5–36.8)	52	83.3 (63.2–93.5)	
≥11	341	71	12.7 (9.4–17.0)	270	87.3 (83.0–90.6)	
Partnership status						
live alone	339	52	11.1 (7.5–16.0)	287	88.9 (84.0–92.5)	0.9008

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
live with partner	163	31	11.5 (7.4–17.4)	132	88.5 (82.6–92.6)	
Current employment status						
full-time	115	20	11.4 (6.6–18.8)	95	88.6 (81.2–93.4)	0.8892
part-time or temporary	213	34	10.8 (6.4–17.6)	179	89.2 (82.4–93.6)	
unemployed	124	19	11.6 (6.6–19.6)	105	88.4 (80.4–93.4)	
disabled	26	8	17.9 (6.5–40.7)	18	82.1 (59.3–93.5)	
other	24	2	6.9 (1.2–31.0)	22	93.1 (69.0–98.8)	
Monthly income category						
<3K	78	15	12.8 (6.2–24.5)	63	87.2 (75.5–93.8)	0.1131
3-10K	165	36	14.2 (8.5–22.7)	129	85.8 (77.3–91.5)	
10-20K	144	16	6.9 (3.8–12.1)	128	93.1 (87.9–96.2)	
≥20K	39	10	21.0 (9.8–39.5)	29	79.0 (60.5–90.2)	
Ever incarcerated						
no	323	38	6.6 (4.4–9.8)	285	93.4 (90.2–95.6)	0.0000
yes	179	45	20.7 (13.9–29.7)	134	79.3 (70.3–86.1)	

Table 5.2. HIV Prevalence by Selected Subgroups

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	303	25	8.2 (5.0–13.1)	278	91.8 (86.9–95.0)	0.0020
yes	192	56	19.5 (14.1–26.3)	136	80.5 (73.7–85.9)	
Treated with MAT currently (of all)						
no	341	26	8.5 (5.6–12.8)	315	91.5 (87.2–94.4)	0.0000
yes	155	57	35.0 (27.4–43.6)	98	65.0 (56.4–72.6)	
Past 30 days injecting 4 categories						
opioids	354	70	12.9 (9.2–17.8)	284	87.1 (82.2–90.8)	0.3207
stimulants	82	5	5.1 (2.0–12.4)	77	94.9 (87.6–98.0)	
opi+stimul	54	7	12.5 (5.2–27.0)	47	87.5 (73.0–94.8)	
other	12	1	9.0 (1.0–50.3)	11	91.0 (49.7–99.0)	
Injecting drug type of choice						

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
opioids	393	77	13.2 (9.6–17.9)	316	86.8 (82.1–90.4)	0.0197
stimulants	92	3	2.9 (0.9–9.0)	89	97.1 (91.0–99.1)	
other	6	1	16.7 (1.1–77.7)	5	83.3 (22.3–98.9)	



Figure 5.1. HIV Test Result (%)



Figure 5.2. Trends in HIV Prevalence by Survey Round (%)



Figure 5.3. Anti-HCV Testing Coverage In the Survey (%)



Figure 5.4. Anti-HCV Test Results (%)



Figure 5.5. Anti-HCV Test Results by Sex (%)



Figure 5.6. Trends in Anti-HCV Prevalence by Survey Round (%)



Figure 5.7. Syphilis Test Results (%)

6. HIV Prevention

Table 6.1. Being a Client of NGO by Sociodemographic Characteristics

			Client of NGO working with PWID			
		N	no		yes	
			n	% (CI)	n	% (CI)	p-value
Total							
	All	495	303	73.9 (69.5–77.9)	192	26.1 (22.1–30.5)	1.0000
Sex							
	male	403	246	73.8 (68.8–78.2)	157	26.2 (21.8–31.2)	0.8765
	female	92	57	74.6 (64.2–82.8)	35	25.4 (17.2–35.8)	
Age							

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
<25	20	13	66.6 (41.7–84.8)	7	33.4 (15.2–58.3)	0.5828
25-34	112	76	78.1 (69.4–84.9)	36	21.9 (15.1–30.6)	
35-44	244	135	72.0 (65.4–77.8)	109	28.0 (22.2–34.6)	
45+	119	79	75.3 (65.5–83.0)	40	24.7 (17.0–34.5)	
Years since the start of injecting drug use						
≤2	57	46	84.1 (71.8–91.7)	11	15.9 (8.3–28.2)	0.0027
3-5	45	35	82.7 (68.6–91.3)	10	17.3 (8.7–31.4)	
6-10	57	45	85.2 (73.5–92.3)	12	14.8 (7.7–26.5)	
≥11	336	177	67.5 (61.5–73.0)	159	32.5 (27.0–38.5)	
Partnership status						
live alone	336	206	73.4 (67.9–78.3)	130	26.6 (21.7–32.1)	0.7242
live with partner	159	97	75.0 (67.3–81.4)	62	25.0 (18.6–32.7)	
Current employment status						
full-time	113	67	74.1 (64.9–81.5)	46	25.9 (18.5–35.1)	0.1950
part-time or temporary	213	127	72.6 (65.6–78.7)	86	27.4 (21.3–34.4)	
unemployed	121	78	75.3 (66.0–82.7)	43	24.7 (17.3–34.0)	
disabled	24	11	55.4 (30.1–78.2)	13	44.6 (21.8–69.9)	
other	24	20	90.4 (69.8–97.4)	4	9.6 (2.6–30.2)	
Monthly income category						
<3K	77	40	64.4 (50.6–76.2)	37	35.6 (23.8–49.4)	0.1831
3-10K	164	90	70.8 (62.6–77.8)	74	29.2 (22.2–37.4)	
10-20K	142	99	79.2 (71.6–85.2)	43	20.8 (14.8–28.4)	
≥20K	36	22	73.1 (53.9–86.3)	14	26.9 (13.7–46.1)	
Ever incarcerated						
no	319	212	77.1 (71.9–81.6)	107	22.9 (18.4–28.1)	0.0330
yes	176	91	67.3 (58.9–74.7)	85	32.7 (25.3–41.1)	

Table 6.2. Being a Client of NGO by Selected Subgroups

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Treated with MAT currently (of all)						
no	338	265	79.9 (75.1–84.0)	73	20.1 (16.0–24.9)	0.0000
yes	151	34	23.8 (16.9–32.5)	117	76.2 (67.5–83.1)	
HIV test result						
positive	81	25	54.4 (39.3–68.7)	56	45.6 (31.3–60.7)	0.0020
negative	414	278	76.4 (71.7–80.5)	136	23.6 (19.5–28.3)	
Past 30 days injecting 4 categories						
opioids	349	180	66.5 (60.6–71.9)	169	33.5 (28.1–39.4)	0.0001
stimulants	82	71	87.5 (78.1–93.3)	11	12.5 (6.7–21.9)	
opi+stimul	52	41	83.8 (69.7–92.1)	11	16.2 (7.9–30.3)	
other	12	11	97.6 (80.3–99.8)	1	2.4 (0.2–19.7)	
Injecting drug type of choice						
opioids	386	208	68.3 (62.8–73.4)	178	31.7 (26.6–37.2)	0.0003
stimulants	92	81	89.2 (80.9–94.1)	11	10.8 (5.9–19.1)	
other	6	4	78.8 (23.9–97.8)	2	21.2 (2.2–76.1)	



Figure 6.1. Injecting and Sex Risk Perception Among HIV-negative PWID (%)



Figure 6.2. Received HIV Prevention Services in the Past 12 Months and 30 days (%)



Figure 6.3. Receiving Package of Prevention Services in the Past 12 Months (%)



Figure 6.4. Trends in Receiving HIV Prevention Services in the Past 12 Months (%)



Figure 6.5. Perceived changes in access to HIV prevention since February 2022 (%)

Table 6.3. Percentage of correct responses to knowledge questions by HIV status

	Total	HIV test result		
	All	negative	positive	
	%	%	%	p-value
HIV knowledge				
HIV may be avoided	93.0	92.5	97.4	0.0272
proper condom use may prevent HIV	35.1	34.0	43.4	0.2506
undetectable=untransmittable	34.9	34.4	39.1	0.5341
PEP reduces the risk of HIV	36.0	36.0	36.1	0.9935
ART should be started immediately	50.9	51.0	49.8	0.8878

	Total	HIV test result		
	All %	negative %	positive %	p-value
ART may be postponed if one feels healthy	33.7	34.2	30.1	0.5708
ART may be stopped if one feels healthy	35.6	35.7	34.8	0.9029
HIV is transmitted through blood and sex	94.6	94.6	94.5	0.9591
HIV is transmitted via air, food, or skin	75.0	74.7	76.7	0.7690
HBV knowledge				
proper condom use may prevent HBV	79.7	80.2	75.2	0.5329
treatment should be started immediately	77.7	78.0	75.9	0.7523
treatment may be postponed if one feels healthy	48.2	49.3	39.2	0.1937
HBV is 100% transmitted from mother to child	12.9	13.2	10.6	0.5487
HBV is transmitted through blood and sex	81.3	82.3	73.2	0.2405
HBV is transmitted via air, food, or skin	63.3	63.6	60.6	0.7033
treatment may be stopped if one feels healthy	54.5	55.0	50.7	0.6082
HCV knowledge				
proper condom use may prevent HCV	4.4	4.8	1.7	0.1030
treatment should be started immediately	77.9	78.3	75.1	0.6961
treatment may be postponed if one feels healthy	44.6	45.1	41.3	0.6353
HCV is 100% transmitted from mother to child	11.7	12.5	5.8	0.1325
HCV is transmitted through blood and sex	79.3	78.2	88.2	0.0854
there is no treatment for HCV	56.8	56.1	63.0	0.3891
HCV is transmitted via air, food, or skin	68.8	69.1	66.7	0.7899
treatment may be stopped if one feels healthy	65.8	65.1	71.4	0.4201

7. HIV Testing

Table 7.1. HIV Testing Knowledge and Uptake

	n	%	CI
Know where to get HIV test			
yes	388	78.7	(73.9–82.8)
Tested for HIV ever			
yes	427	83.3	(79.3–86.7)
Tested for HIV in the past 12 months			
yes	191	53.2	(46.4–59.8)
Tested for HIV in the past 6 months			
yes	131	34.0	(28.3–40.2)
Received the result of HIV test (of those tested)			
yes	408	95.0	(90.9–97.3)
Willing to disclose HIV test result (of those who got result)			
yes	399	99.5	(98.4–99.8)
Self-reported HIV status (of all tested)			
positive	51	7.4	(5.2–10.5)
negative	360	92.6	(89.5–94.8)
HIV testing and status awareness (GAM)			
yes	190	53.9	(47.2–60.6)
Ever did a HIV self-test			
yes	2	0.1	(0.0–0.4)
Regular sex partner tested for HIV			
yes	96	61.2	(51.1–70.3)
Regular sex partner HIV test result			
positive	15	12.3	(6.8–21.4)
negative	80	86.2	(76.7–92.2)
cannot disclose	1	1.5	(0.2–9.9)



Figure 7.1. HIV Testing Uptake (%)



Figure 7.2. Testing for HIV, HCV, syphilis since February 2022 (%)



Figure 7.3. HIV Testing Since February 2022 (%)

Table 7.2. Testing for HIV in the past 12 months (among all) by Sociodemographic Characteristics

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Total						
All	317	126	46.8 (40.2–53.6)	191	53.2 (46.4–59.8)	1.0000
Sex						
male	250	95	44.6 (37.1–52.4)	155	55.4 (47.6–62.9)	0.1947
female	67	31	55.0 (41.2–68.0)	36	45.0 (32.0–58.8)	
Age						
<25	11	6	58.9 (27.6–84.3)	5	41.1 (15.7–72.4)	0.1787
25-34	63	23	42.1 (29.2–56.2)	40	57.9 (43.8–70.8)	
35-44	167	61	42.8 (33.4–52.7)	106	57.2 (47.3–66.6)	
45+	76	36	59.6 (46.7–71.3)	40	40.4 (28.7–53.3)	
Years since the start of injecting drug use						
≤2	35	20	52.6 (35.1–69.5)	15	47.4 (30.5–64.9)	0.8805
3-5	24	9	41.4 (22.4–63.4)	15	58.6 (36.6–77.6)	
6-10	30	13	48.5 (27.7–69.8)	17	51.5 (30.2–72.3)	
≥11	228	84	46.1 (37.9–54.4)	144	53.9 (45.6–62.1)	
Partnership status						
live alone	212	81	45.5 (37.4–53.9)	131	54.5 (46.1–62.6)	0.5717
live with partner	105	45	49.6 (38.3–61.0)	60	50.4 (39.0–61.7)	

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Current employment status						
full-time	81	35	50.8 (37.8–63.7)	46	49.2 (36.3–62.2)	0.7528
part-time or temporary	135	56	48.7 (38.5–58.9)	79	51.3 (41.1–61.5)	
unemployed	69	26	42.6 (29.9–56.4)	43	57.4 (43.6–70.1)	
disabled	17	3	35.8 (11.0–71.6)	14	64.2 (28.4–89.0)	
other	15	6	34.4 (11.9–67.2)	9	65.6 (32.8–88.1)	
Monthly income category						
<3K	53	21	54.1 (37.6–69.8)	32	45.9 (30.2–62.4)	0.7984
3-10K	109	43	47.0 (35.4–58.9)	66	53.0 (41.1–64.6)	
10-20K	93	38	47.0 (35.3–59.0)	55	53.0 (41.0–64.7)	
≥20K	25	10	40.1 (20.1–64.0)	15	59.9 (36.0–79.9)	
Ever incarcerated						
no	197	85	49.2 (41.0–57.5)	112	50.8 (42.5–59.0)	0.3528
yes	120	41	42.5 (31.5–54.3)	79	57.5 (45.7–68.5)	

Table 7.3. Testing for HIV in the past 12 months (among all) by Selected Subgroups

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	179	92	56.8 (48.1–65.0)	87	43.2 (35.0–51.9)	0.0000
yes	134	33	25.0 (16.9–35.2)	101	75.0 (64.8–83.1)	
Treated with MAT currently (of all)						
no	213	102	50.0 (42.6–57.5)	111	50.0 (42.5–57.4)	0.0000
yes	103	24	23.3 (15.7–33.0)	79	76.7 (67.0–84.3)	
HIV test result						
positive	55	15	33.1 (18.2–52.4)	40	66.9 (47.6–81.8)	0.1220
negative	262	111	48.8 (41.7–56.0)	151	51.2 (44.0–58.3)	
Past 30 days injecting 4 categories						
opioids	222	77	41.7 (33.6–50.3)	145	58.3 (49.7–66.4)	0.2864
stimulants	54	30	56.8 (42.4–70.2)	24	43.2 (29.8–57.6)	
opi+stimul	34	16	53.1 (34.0–71.3)	18	46.9 (28.7–66.0)	

	N	Tested for HIV in the past 12 months				
		n	no % (CI)	n	yes % (CI)	p-value
other	7	3	55.7 (16.9–88.6)	4	44.3 (11.4–83.1)	
Injecting drug type of choice						
opioids	250	94	46.1 (38.3–54.1)	156	53.9 (45.9–61.7)	0.9136
stimulants	59	29	49.4 (36.1–62.8)	30	50.6 (37.2–63.9)	
other	3	1	50.6 (3.6–96.6)	2	49.4 (3.4–96.4)	

8. HIV Treatment



Figure 8.1. HIV Status Awareness Among HIV+ (%)



Figure 8.2. HIV Treatment Cascade - Four-stage (%)



Figure 8.3. HIV Treatment Cascade - Conditional (%)



Figure 8.4. HIV Treatment Cascade - Proportions (%)



Figure 8.5. Trends in HIV Treatment Cascade (Conditional, 95-95-95) by Survey Round (%)

Table 8.1. HIV Treatment Cascade (Conditional, 95-95-95) by Sociodemographic Characteristics

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Total										
All	83	46.2 (31.9–61.1)	1.0000	48	86.1 (64.2–95.5)	1.0000	45	32	78.0 (62.1–88.5)	1.0000
Sex										
male	65	41.0 (26.0–57.8)	0.1230	34	86.3 (57.8–96.7)	0.9722	32	26	82.1 (61.6–92.9)	0.3420
female	18	68.2 (36.3–89.0)		14	85.7 (41.8–98.0)		13	6	67.6 (36.6–88.3)	
Age										

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
<25	1	0.0	0.3158	0	0.0		0	0	0.0	
25-34	9	54.7 (20.1–85.3)		5	100.0		5	3	81.7 (39.4–96.8)	
35-44	55	40.7 (24.7–59.1)		31	83.7 (53.1–95.9)		29	24	89.2 (74.4–95.9)	
45+	18	68.4 (41.7–86.7)		12	83.1 (37.6–97.6)		11	5	38.6 (14.5–70.1)	
Years since the start of injecting drug use										
≤2	1	0.0	0.0553	0	0.0		0	0	0.0	
3-5	5	30.2 (4.2–81.2)		1	100.0		1	1	100.0	
6-10	6	11.4 (1.3–56.0)		1	100.0		1	1	100.0	
≥11	71	58.9 (42.9–73.2)		46	84.3 (60.8–94.9)		43	30	74.6 (57.3–86.6)	
Partnership status										
live alone	52	47.8 (29.2–67.0)	0.7469	32	85.8 (56.7–96.5)	0.9489	30	24	85.0 (66.7–94.1)	0.1319
live with partner	31	42.9 (23.6–64.7)		16	86.8 (44.9–98.2)		15	8	62.3 (31.3–85.7)	
Current employment status										
full-time	20	37.6 (16.5–64.8)	0.5541	9	67.4 (19.1–94.8)	0.5971	8	5	68.5 (29.4–91.9)	0.3256
part-time or temporary	34	40.7 (19.7–65.8)		17	88.9 (50.1–98.5)		16	11	71.1 (39.7–90.2)	
unemployed	19	63.3 (31.9–86.4)		14	90.4 (53.7–98.7)		13	11	92.4 (71.4–98.3)	
disabled	8	57.8 (13.0–92.6)		7	100.0		7	4	56.3 (20.5–86.5)	
other	2	20.8 (1.4–83.1)		1	100.0		1	1	100.0	
Monthly income category										
<3K	15	27.5 (10.3–55.7)	0.4082	9	100.0	0.1158	9	7	78.8 (42.4–94.9)	0.8781
3-10K	36	51.4 (26.0–76.2)		25	91.2 (57.2–98.8)		24	16	77.5 (56.4–90.1)	
10-20K	16	37.6 (14.7–67.8)		5	100.0		5	4	80.3 (29.1–97.6)	
≥20K	10	65.7 (28.1–90.4)		6	55.0 (14.8–89.6)		4	2	62.5 (13.3–94.8)	
Ever incarcerated										

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
no	38	56.2 (35.9–74.6)	0.2538	23	78.3 (43.7–94.4)	0.2683	21	14	77.5 (55.1–90.6)	0.9484
yes	45	39.6 (22.4–59.8)		25	93.4 (64.7–99.1)		24	18	78.4 (54.0–91.8)	

Table 8.2. HIV Treatment Cascade (Conditional, 95-95-95) by Selected Subgroups

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID										
no	25	32.9 (15.5–56.8)	0.0418	9	91.0 (55.0–98.8)	0.5654	8	7	90.1 (51.8–98.7)	0.2374
yes	56	62.7 (45.6–77.1)		38	82.8 (52.3–95.5)		36	25	71.1 (52.4–84.6)	
Treated with MAT currently (of all)										
no	26	40.3 (22.3–61.3)	0.1721	12	76.2 (45.1–92.6)	0.1082	9	7	85.6 (55.0–96.7)	0.2765
yes	57	58.2 (42.9–72.0)		36	100.0		36	25	69.8 (52.5–82.8)	
HIV test result										
positive	83	46.2 (31.7–61.3)		48	86.1 (63.8–95.6)		45	32	78.0 (61.8–88.6)	
negative	0	0.0		0	0.0		0	0	0.0	
Past 30 days injecting 4 categories										
opioids	70	46.2 (30.0–63.3)	0.7693	42	81.1 (55.2–93.8)		39	27	74.0 (56.0–86.4)	
stimulants	5	59.5 (18.0–90.8)		3	100.0		3	3	100.0	
opi+stimul	7	45.2 (12.5–82.8)		3	100.0		3	2	76.9 (22.0–97.5)	
other	1	0.0		0	0.0		0	0	0.0	
Injecting drug type of choice										
opioids	77	48.1 (32.4–64.2)	0.5420	46	84.6 (61.2–95.0)	0.8250	43	30	75.1 (57.9–86.9)	0.6879
stimulants	3	38.4 (5.1–88.0)		1	100.0		1	1	100.0	
other	1	100.0		1	100.0		1	1	100.0	

Table 8.3. ART adherence (among those on ART)

		n	%	CI
When did you last miss ART dose				
	last week	1	1.6	(0.2–10.7)
	1-2 weeks ago	4	16.9	(6.0–39.1)
	3-4 weeks ago	2	3.3	(0.8–13.2)

	n	%	CI
1-3 months ago	2	3.2	(0.7–12.8)
never	35	75.0	(54.9–88.1)
What was the reason for missing the last ART dose			
forgot	6	81.1	(49.0–95.0)
did not have meds	3	18.9	(5.0–51.0)
was under influence	0	0.0	
did not want others to see	0	0.0	
other	0	0.0	
Reasons for not taking ART			
not sure it is needed	3	25.7	(6.6–63.1)
no time to visit clinic	1	15.0	(2.0–60.5)
no motivation to visit clinic	1	15.0	(2.0–60.5)
missed a visit, hard to come back	1	9.5	(1.1–48.9)
too sick to visit clinic	1	8.0	(1.0–43.2)
drug use	1	6.5	(0.8–37.1)
side effects or complications	1	6.5	(0.8–37.1)
no understanding of how to take it	1	6.5	(0.8–37.1)
lost or sold all ARVs	0	0.0	
alcohol use	0	0.0	
waited too long and left	0	0.0	
Time on ART			
≤3m	0	0.0	
4-24m	2	9.4	(1.9–35.2)
25-60m	5	45.4	(16.0–78.4)
5y+	4	45.2	(15.7–78.5)

9. PrEP



Figure 9.1. PrEP Uptake in the Past 12 Months (%)



Figure 9.2. Change in PrEP Awareness and Uptake from 2020 to 2023 (%)



Figure 9.3. Change in PrEP Uptake from 2020 to 2023 (%)

Table 9.1. PrEP Awareness by Sociodemographic Characteristics

			PrEP uptake in the past 12 months								
		N	use now		used in the past		never used		not aware		
			n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total											
	All	502	9	0.9 (0.4–1.9)	2	0.3 (0.1–1.6)	34	5.4 (3.7–8.0)	457	93.3 (90.6–95.3)	1.0000
Sex											
	male	409	7	0.9 (0.4–2.0)	1	0.1 (0.0–0.5)	21	4.4 (2.7–7.3)	380	94.6 (91.7–96.5)	0.0137
	female	93	2	1.2 (0.3–5.1)	1	1.3 (0.2–9.1)	13	9.7 (5.1–17.8)	77	87.8 (79.2–93.1)	
Age											
	<25	20	0	0.0	0	0.0	3	14.8 (4.3–40.2)	17	85.2 (59.8–95.7)	0.3295
	25-34	114	2	1.0 (0.2–4.2)	0	0.0	9	6.4 (3.2–12.5)	103	92.6 (86.4–96.1)	

		PrEP uptake in the past 12 months								
	N	use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
35-44	248	4	0.8 (0.3–2.6)	1	0.1 (0.0–0.8)	12	3.7 (1.7–7.7)	231	95.3 (91.4–97.5)	
45+	120	3	1.2 (0.3–4.4)	1	1.2 (0.2–7.9)	10	6.0 (2.8–12.4)	106	91.6 (84.7–95.5)	
Years since the start of injecting drug use										
≤2	57	0	0.0	0	0.0	3	5.6 (1.7–16.5)	54	94.4 (83.5–98.3)	
3-5	46	0	0.0	0	0.0	2	2.2 (0.5–10.0)	44	97.8 (90.0–99.5)	
6-10	58	1	1.1 (0.2–8.1)	0	0.0	7	11.1 (4.6–24.3)	50	87.7 (74.7–94.6)	
≥11	341	8	1.3 (0.6–2.8)	2	0.5 (0.1–2.6)	22	4.8 (2.9–7.8)	309	93.5 (90.2–95.7)	
Partnership status										
live alone	339	5	0.6 (0.3–1.7)	2	0.5 (0.1–2.4)	19	4.7 (2.7–7.9)	313	94.2 (90.9–96.4)	0.3860
live with partner	163	4	1.5 (0.5–4.5)	0	0.0	15	7.1 (4.0–12.5)	144	91.4 (85.9–94.9)	
Current employment status										
full-time	115	3	1.3 (0.4–4.3)	0	0.0	11	5.7 (2.8–11.4)	101	93.0 (87.2–96.3)	0.8542
part-time or temporary	213	3	0.6 (0.2–2.3)	1	0.1 (0.0–0.9)	14	6.0 (3.3–10.8)	195	93.2 (88.5–96.1)	
unemployed	124	2	1.1 (0.2–5.2)	1	1.0 (0.1–7.0)	6	3.8 (1.4–9.7)	115	94.1 (87.7–97.3)	
disabled	26	1	2.1 (0.2–15.0)	0	0.0	2	11.9 (2.1–45.5)	23	86.1 (55.2–96.9)	
other	24	0	0.0	0	0.0	1	2.8 (0.3–20.0)	23	97.2 (80.0–99.7)	
Monthly income category										
<3K	78	0	0.0	0	0.0	3	4.3 (0.9–19.1)	75	95.7 (80.9–99.1)	0.6808
3-10K	165	7	2.2 (0.9–5.0)	0	0.0	14	6.6 (3.6–12.0)	144	91.2 (85.7–94.7)	
10-20K	144	1	0.5 (0.1–3.6)	1	0.2 (0.0–1.4)	8	3.5 (1.6–7.7)	134	95.8 (91.5–97.9)	
≥20K	39	1	0.7 (0.1–5.2)	0	0.0	4	8.4 (2.8–22.8)	34	90.9 (76.8–96.8)	
Ever incarcerated										
no	323	3	0.5 (0.1–1.5)	1	0.4 (0.1–2.7)	22	6.0 (3.7–9.6)	297	93.1 (89.5–95.6)	0.2128
yes	179	6	1.9 (0.7–4.7)	1	0.2 (0.0–1.3)	12	4.3 (2.2–8.2)	160	93.7 (89.4–96.3)	

Table 9.2. PrEP Current Use by Sociodemographic Characteristics

		PrEP uptake in the past 12 months								
	N	use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										
no	303	0	0.0	1	0.3 (0.0–2.5)	13	3.4 (1.8–6.4)	289	96.2 (93.2–97.9)	0.0000
yes	192	9	3.6 (1.7–7.3)	1	0.2 (0.0–1.6)	20	10.6 (6.3–17.2)	162	85.7 (78.8–90.5)	
Treated with MAT currently (of all)										
no	341	3	0.6 (0.2–1.8)	1	0.3 (0.0–2.0)	18	4.9 (3.0–7.8)	319	94.3 (91.2–96.3)	0.0031
yes	155	6	3.8 (1.7–8.5)	1	0.5 (0.1–3.8)	15	9.1 (5.4–14.8)	133	86.5 (80.1–91.1)	

	N	PrEP uptake in the past 12 months								
		use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
HIV test result										
positive	83	7	6.2 (2.6–14.3)	1	0.5 (0.1–3.7)	8	4.2 (2.0–8.9)	67	89.0 (80.7–94.0)	0.0000
negative	419	2	0.3 (0.1–1.1)	1	0.3 (0.0–2.0)	26	5.6 (3.6–8.5)	390	93.9 (90.9–95.9)	
Past 30 days injecting 4 categories										
opioids	354	9	1.4 (0.7–3.0)	0	0.0	29	6.8 (4.4–10.5)	316	91.7 (88.0–94.4)	0.3717
stimulants	82	0	0.0	1	1.3 (0.2–8.8)	3	3.9 (1.2–11.5)	78	94.8 (86.8–98.1)	
opi+stimul	54	0	0.0	1	0.4 (0.1–3.1)	2	2.3 (0.5–9.3)	51	97.3 (90.7–99.2)	
other	12	0	0.0	0	0.0	0	0.0	12	100.0	
Injecting drug type of choice										
opioids	393	9	1.3 (0.6–2.6)	1	0.1 (0.0–0.6)	29	5.9 (3.8–9.1)	354	92.7 (89.4–95.1)	0.5123
stimulants	92	0	0.0	1	1.1 (0.2–7.7)	5	4.9 (2.0–11.5)	86	94.0 (87.0–97.3)	
other	6	0	0.0	0	0.0	0	0.0	6	100.0	

Table 9.3. PrEP Awareness and Uptake

	n	%	CI
PrEP uptake in the past 12 months			
use now	9	0.9	(0.4–1.9)
used in the past	2	0.3	(0.1–1.6)
never used	34	5.4	(3.7–8.0)
not aware	457	93.3	(90.6–95.3)
Aware of PrEP			
no	457	93.3	(90.6–95.3)
yes	45	6.7	(4.7–9.4)
PrEP use current			
no	493	99.1	(98.1–99.6)
yes	9	0.9	(0.4–1.9)
PrEP use current (of those aware)			
no	36	86.2	(73.1–93.5)
yes	9	13.8	(6.5–26.9)

10. MAT



Figure 10.1. MAT Awareness (%)



Figure 10.2. MAT Current Uptake (%)



Figure 10.3. Trends in MAT Lifetime and Current Uptake by Survey Round (%)

Table 10.1. MAT experience

	n	%	CI
Reason for MAT discontinuation			
moved to another city	0	0.0	
clinic closed after Feb 2022	1	7.5	(1.0–40.2)
weak or no effect	1	14.1	(1.9–57.9)
side effects	2	16.5	(2.9–56.7)
do not want to visit clinic	2	25.0	(6.0–63.4)
do not want to quit drugs	1	2.0	(0.3–14.6)
hard to get to the clinic	1	20.7	(3.1–68.4)
do not need it	3	39.1	(12.6–74.1)
do not like the attitude of physician	0	0.0	
How did the injection frequency change during MAT			
intensified	3	26.6	(7.1–63.1)
did not change	6	59.7	(25.9–86.3)
decreased	1	13.7	(1.9–56.8)
Whether bought bupr. or methadone while not being a patient in the past 12 months			
yes, methadone	174	31.7	(27.2–36.7)
yes, buprenorphine	84	20.1	(16.1–24.7)
did not buy	239	48.2	(43.0–53.4)
Where bought bupr. or methadone while not being a patient in the past 12 months			
did not buy	239	49.1	(43.9–54.4)
bought from black market	239	49.9	(44.7–55.2)
bought from private clinic	6	0.9	(0.3–2.5)
Way of using bupr. or methaone bought from others			
injecting	204	83.0	(77.6–87.4)
injecting mixed	35	10.9	(7.5–15.6)
swallow or subling.	9	2.7	(1.3–5.6)
snort	9	3.4	(1.7–6.8)

Table 10.2. MAT Awareness and Uptake by Sociodemographic Characteristics

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
Total										
All	496	155	10.7 (8.9–12.8)	9	2.9 (1.5–5.6)	55	14.1 (10.8–18.1)	277	72.4 (67.9–76.4)	1.0000
Sex										
male	404	129	10.7 (8.8–13.1)	9	3.6 (1.8–6.8)	46	14.3 (10.7–18.7)	220	71.4 (66.4–76.0)	0.3847
female	92	26	10.5 (6.5–16.4)	0	0.0	9	13.3 (6.8–24.3)	57	76.2 (65.7–84.3)	
Age										
<25	19	1	1.0 (0.1–8.0)	0	0.0	3	22.4 (6.8–53.1)	15	76.6 (46.6–92.5)	0.4982
25-34	112	24	7.7 (4.8–12.3)	2	2.5 (0.6–9.5)	13	12.2 (7.0–20.2)	73	77.7 (68.9–84.5)	
35-44	246	92	13.0 (10.1–16.5)	5	3.6 (1.5–8.6)	30	15.5 (10.9–21.6)	119	67.9 (60.9–74.1)	
45+	119	38	11.0 (7.6–15.6)	2	2.3 (0.5–9.5)	9	11.2 (5.7–20.9)	70	75.5 (66.2–82.9)	
Years since the start of injecting drug use										
≤2	55	3	1.7 (0.5–5.3)	1	1.8 (0.2–12.4)	6	11.1 (4.9–23.4)	45	85.4 (73.1–92.6)	0.0107
3-5	46	4	2.5 (0.9–7.0)	2	7.4 (1.8–26.1)	5	10.2 (4.2–23.1)	35	79.9 (64.1–89.8)	
6-10	56	10	6.6 (2.9–14.2)	0	0.0	9	18.7 (9.5–33.5)	37	74.7 (60.2–85.3)	
≥11	339	138	15.1 (12.4–18.4)	6	2.9 (1.3–6.4)	35	14.5 (10.4–19.7)	160	67.5 (61.6–72.9)	
Partnership status										
live alone	334	107	11.0 (8.8–13.7)	6	2.8 (1.2–6.0)	35	13.7 (9.9–18.8)	186	72.5 (67.0–77.4)	0.9645
live with partner	162	48	10.0 (7.2–13.8)	3	3.1 (0.9–10.0)	20	14.8 (9.5–22.2)	91	72.1 (64.0–78.9)	
Current employment status										
full-time	115	29	8.0 (5.2–11.9)	2	2.5 (0.6–9.6)	19	19.8 (12.7–29.5)	65	69.8 (59.8–78.2)	0.0120
part-time or temporary	210	65	10.3 (7.8–13.6)	3	2.4 (0.7–7.6)	19	12.0 (7.6–18.4)	123	75.4 (68.5–81.1)	
unemployed	121	36	10.4 (7.2–15.0)	2	2.4 (0.6–9.4)	14	14.1 (8.4–22.8)	69	73.0 (64.0–80.5)	
disabled	26	17	29.9 (15.1–50.5)	2	19.6 (4.9–53.6)	1	7.5 (1.0–40.7)	6	42.9 (20.5–68.6)	
other	24	8	15.0 (5.5–35.1)	0	0.0	2	8.7 (1.9–31.6)	14	76.3 (52.9–90.2)	
Monthly income category										
<3K	78	37	18.4 (12.1–27.1)	0	0.0	9	19.8 (10.3–34.6)	32	61.8 (48.2–73.7)	0.0644
3-10K	163	56	11.6 (8.5–15.6)	2	2.1 (0.5–8.0)	20	15.7 (10.2–23.5)	85	70.6 (62.4–77.7)	
10-20K	141	31	7.0 (4.7–10.4)	3	3.6 (1.1–11.1)	14	11.8 (7.0–19.2)	93	77.5 (69.3–84.1)	
≥20K	39	10	8.2 (3.8–16.6)	3	10.3 (3.1–29.2)	5	11.8 (4.6–27.1)	21	69.7 (51.5–83.3)	
Ever incarcerated										

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
no	319	78	7.6 (5.9–9.6)	3	1.4 (0.4–4.3)	27	10.1 (6.9–14.5)	211	81.0 (76.2–85.0)	0.0000
yes	177	77	17.2 (13.0–22.4)	6	6.0 (2.6–13.1)	28	22.4 (15.6–30.9)	66	54.5 (45.4–63.4)	

Table 10.3. MAT Awareness and Uptake by Selected Subgroups

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
Client of NGO working with PWID										
no	299	34	3.4 (2.3–5.0)	6	2.5 (1.1–5.8)	36	13.0 (9.4–17.7)	223	81.1 (76.0–85.3)	0.0000
yes	190	117	30.8 (24.6–37.7)	2	2.6 (0.7–9.9)	19	17.8 (11.5–26.5)	52	48.8 (40.0–57.7)	
Treated with MAT currently (of all)										
no	341	0	0.0	9	3.2 (1.6–6.2)	55	15.8 (12.1–20.2)	277	81.0 (76.2–85.0)	0.0000
yes	155	155	100.0	0	0.0	0	0.0	0	0.0	
HIV test result										
positive	83	57	33.0 (22.4–45.6)	2	4.5 (1.0–17.7)	5	11.9 (4.9–26.3)	19	50.5 (35.4–65.6)	0.0000
negative	413	98	7.8 (6.3–9.7)	7	2.7 (1.3–5.6)	50	14.4 (10.9–18.7)	258	75.2 (70.4–79.3)	
Past 30 days injecting 4 categories										
opioids	351	144	15.3 (12.6–18.5)	4	2.2 (0.8–6.0)	33	12.8 (9.1–17.7)	170	69.7 (64.1–74.7)	0.0008
stimulants	79	3	1.1 (0.3–3.6)	2	3.5 (0.9–13.1)	7	9.7 (4.4–19.9)	67	85.7 (74.9–92.3)	
opi+stimul	54	6	2.4 (1.0–5.6)	3	5.7 (1.7–17.1)	14	27.6 (16.4–42.7)	31	64.3 (49.1–77.1)	
other	12	2	11.4 (1.8–47.5)	0	0.0	1	7.1 (0.7–43.7)	9	81.5 (47.0–95.6)	
Injecting drug type of choice										
opioids	390	152	14.0 (11.6–16.9)	7	3.0 (1.4–6.4)	41	14.0 (10.3–18.7)	190	69.0 (63.6–73.8)	0.0168
stimulants	89	1	0.2 (0.0–1.6)	2	3.0 (0.7–11.4)	12	14.5 (8.2–24.5)	74	82.3 (71.8–89.4)	
other	6	1	4.5 (0.3–44.6)	0	0.0	0	0.0	5	95.5 (55.4–99.7)	



Figure 10.4. Buying MAT medications while not being a patient (%)



Figure 10.5. Source of buying MAT medications while not being a patient (%)



Figure 10.6. Route of administration of MAT medications bought from others (%)

11. Overdose and Naloxone



Figure 11.1. Overdose Experience Ever and in the Past 12 Months (%)



Figure 11.2. Trends in Overdose Experience in the Past 12 Months by Survey Round (%)



Figure 11.3. Drugs causing overdoses (if used only one drug) (%)



Figure 11.4. Naloxone Use (%)

Table 11.1. Overdose Experience

	n	%	CI
Experienced overdose ever			
yes	142	26.5	(22.2–31.3)
Number of overdoses in lifetime			
1	51	36.9	(27.9–47.0)
2-4	58	44.9	(35.1–55.2)
5+	25	18.1	(10.7–29.0)
Experienced overdose in the past 12 months			
yes	31	6.0	(4.0–8.9)
Experienced overdose in the past 12 months (of those ever)			
yes	31	22.9	(15.7–32.2)
Number of overdoses in the past 12 months			
1	19	74.2	(48.6–89.7)
2-4	5	25.8	(10.3–51.4)
5+	0	0.0	
Drug overdosed with (if used only one drug)			
methadone	4	30.8	(9.7–64.7)
other opioid	1	9.5	(1.3–45.3)
stimulant	7	54.4	(25.6–80.6)
other	2	5.3	(1.2–21.1)
Drugs overdosed with (if used a combination)			
methadone+stimulant	1	7.5	(0.8–44.7)
methadone+barbit. or dimedr.	1	7.5	(0.8–44.7)
methadone+other	3	85.0	(46.0–97.4)
other	0	0.0	
Drug overdosed with (if combined drug with alcohol)			
methadone	7	60.9	(31.7–84.0)
other opioid	0	0.0	
stimulant	4	32.2	(11.9–62.4)
other	1	6.9	(0.9–36.9)
Naloxone knowledge and experience			
never heard	287	65.7	(60.8–70.2)
aware but not used	161	25.9	(21.8–30.3)
used myself	34	5.1	(3.4–7.8)
my friends used	19	3.3	(2.0–5.5)

	n	%	CI
me and my friends used	0	0.0	

Table 11.2. Overdose Experience in the Past 12 Months by Sociodemographic Characteristics

		Experienced overdose in the past 12 months			
	N	no		yes	
		n	% (CI)	n	% (CI)	p-value
Total						
All	499	468	94.0 (91.1–96.0)	31	6.0 (4.0–8.9)	1.0000
Sex						
male	406	380	94.2 (91.0–96.2)	26	5.8 (3.8–9.0)	0.7800
female	93	88	93.2 (83.0–97.5)	5	6.8 (2.5–17.0)	
Age						
<25	20	18	83.8 (51.3–96.2)	2	16.2 (3.8–48.7)	0.1824
25-34	114	106	92.7 (85.5–96.4)	8	7.3 (3.6–14.5)	
35-44	246	230	94.4 (90.1–96.9)	16	5.6 (3.1–9.9)	
45+	119	114	96.9 (91.6–98.9)	5	3.1 (1.1–8.4)	
Years since the start of injecting drug use						
≤2	57	56	97.7 (84.8–99.7)	1	2.3 (0.3–15.2)	0.4885
3-5	45	41	91.8 (78.3–97.2)	4	8.2 (2.8–21.7)	
6-10	58	53	90.6 (76.9–96.5)	5	9.4 (3.5–23.1)	
≥11	339	318	94.2 (90.6–96.5)	21	5.8 (3.5–9.4)	
Partnership status						
live alone	338	320	94.8 (91.5–96.9)	18	5.2 (3.1–8.5)	0.3006
live with partner	161	148	92.1 (85.5–95.9)	13	7.9 (4.1–14.5)	
Current employment status						
full-time	114	112	98.7 (93.3–99.8)	2	1.3 (0.2–6.7)	0.0152
part-time or temporary	213	203	95.2 (90.4–97.7)	10	4.8 (2.3–9.6)	
unemployed	123	107	87.5 (79.3–92.8)	16	12.5 (7.2–20.7)	
disabled	26	24	91.5 (61.2–98.6)	2	8.5 (1.4–38.8)	
other	23	22	95.4 (70.3–99.4)	1	4.6 (0.6–29.7)	
Monthly income category						
<3K	78	71	87.4 (73.5–94.5)	7	12.6 (5.5–26.5)	0.0573
3-10K	164	156	97.4 (94.0–98.9)	8	2.6 (1.1–6.0)	

		Experienced overdose in the past 12 months				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
10-20K	142	135	95.0 (89.4–97.7)	7	5.0 (2.3–10.6)	
≥20K	39	37	92.8 (74.2–98.3)	2	7.2 (1.7–25.8)	
Ever incarcerated						
no	322	305	94.9 (91.2–97.0)	17	5.1 (3.0–8.8)	0.2928
yes	177	163	92.1 (86.1–95.7)	14	7.9 (4.3–13.9)	

Table 11.3. Overdose Experience in the Past 12 Months by Selected Subgroups

		Experienced overdose in the past 12 months				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	301	285	94.4 (90.9–96.7)	16	5.6 (3.3–9.1)	0.7754
yes	192	178	93.7 (88.1–96.8)	14	6.3 (3.2–11.9)	
Treated with MAT currently (of all)						
no	339	319	93.9 (90.6–96.1)	20	6.1 (3.9–9.4)	0.8348
yes	154	143	93.4 (88.1–96.5)	11	6.6 (3.5–11.9)	
HIV test result						
positive	83	76	92.4 (80.5–97.3)	7	7.6 (2.7–19.5)	0.6216
negative	416	392	94.2 (91.1–96.2)	24	5.8 (3.8–8.9)	
Past 30 days injecting 4 categories						
opioids	351	331	95.1 (91.8–97.1)	20	4.9 (2.9–8.2)	0.3864
stimulants	82	77	92.6 (82.6–97.1)	5	7.4 (2.9–17.4)	
opi+stimul	54	48	89.6 (76.9–95.7)	6	10.4 (4.3–23.1)	
other	12	12	100.0	0	0.0	
Injecting drug type of choice						
opioids	390	366	94.6 (91.4–96.6)	24	5.4 (3.4–8.6)	0.6650
stimulants	92	86	92.5 (83.6–96.7)	6	7.5 (3.3–16.4)	
other	6	6	100.0	0	0.0	

Table 11.4. Naloxone Experience by Sociodemographic Characteristics

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total								
All	501	287	65.7 (60.8–70.2)	180	29.2 (24.9–33.8)	34	5.1 (3.4–7.8)	1.0000
Sex								
male	408	229	65.1 (59.7–70.2)	148	29.6 (24.8–34.9)	31	5.2 (3.4–8.0)	0.9057
female	93	58	67.9 (56.6–77.5)	32	27.4 (18.9–38.0)	3	4.7 (1.3–15.9)	
Age								
<25	20	10	42.3 (21.5–66.2)	6	28.4 (12.1–53.3)	4	29.3 (11.1–57.9)	0.0000
25-34	114	65	63.3 (53.2–72.4)	39	30.1 (21.8–40.0)	10	6.5 (3.1–13.3)	
35-44	247	134	66.4 (59.2–72.8)	96	29.9 (23.7–36.8)	17	3.8 (2.1–6.7)	
45+	120	78	72.1 (62.5–80.1)	39	26.9 (19.1–36.6)	3	0.9 (0.3–3.0)	
Years since the start of injecting drug use								
≤2	56	47	84.3 (71.2–92.1)	6	10.5 (4.5–22.3)	3	5.2 (1.4–17.3)	0.0200
3-5	46	31	71.1 (55.7–82.8)	14	27.1 (15.8–42.4)	1	1.9 (0.2–12.8)	
6-10	58	41	70.5 (55.2–82.2)	14	22.8 (12.9–37.0)	3	6.8 (1.8–21.9)	
≥11	341	168	59.4 (53.0–65.4)	146	35.3 (29.6–41.5)	27	5.3 (3.3–8.5)	
Partnership status								
live alone	339	192	65.6 (59.6–71.1)	124	29.3 (24.2–35.1)	23	5.1 (3.1–8.3)	0.9961
live with partner	162	95	65.9 (57.3–73.6)	56	28.9 (21.9–37.1)	11	5.2 (2.3–11.2)	
Current employment status								
full-time	115	64	64.4 (53.9–73.6)	45	31.2 (22.5–41.4)	6	4.4 (1.7–11.3)	0.4398
part-time or temporary	212	123	66.2 (58.5–73.1)	75	28.9 (22.5–36.2)	14	4.9 (2.4–9.8)	
unemployed	124	71	66.7 (57.0–75.1)	42	27.8 (20.0–37.3)	11	5.5 (2.6–11.0)	
disabled	26	10	42.3 (20.2–67.9)	13	40.6 (19.7–65.6)	3	17.1 (4.8–46.2)	
other	24	19	78.7 (53.9–92.1)	5	21.3 (7.9–46.1)	0	0.0	
Monthly income category								
<3K	78	42	59.2 (45.2–71.9)	30	31.2 (20.1–45.0)	6	9.6 (3.5–23.4)	0.3337
3-10K	165	85	63.9 (55.1–71.8)	73	34.3 (26.6–43.0)	7	1.8 (0.7–4.7)	
10-20K	144	89	66.6 (57.6–74.5)	44	27.4 (20.1–36.1)	11	6.0 (3.0–11.8)	
≥20K	39	21	61.3 (42.1–77.6)	14	30.7 (16.6–49.6)	4	8.0 (2.3–24.3)	
Ever incarcerated								

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
no	322	204	69.6 (63.7–74.9)	105	26.4 (21.5–32.0)	13	4.0 (2.1–7.5)	0.0475
yes	179	83	57.6 (48.6–66.1)	75	35.0 (27.1–43.7)	21	7.4 (4.3–12.5)	

Table 11.5. Naloxone Experience by Selected Subgroups

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID								
no	302	215	74.1 (68.4–79.1)	76	22.4 (17.8–27.9)	11	3.5 (1.8–6.7)	0.0000
yes	192	69	42.3 (33.7–51.4)	101	47.8 (39.2–56.6)	22	9.9 (5.8–16.2)	
Treated with MAT currently (of all)								
no	340	230	69.3 (63.9–74.2)	98	26.7 (22.1–31.9)	12	4.0 (2.2–7.1)	0.0000
yes	155	52	32.8 (25.2–41.4)	82	53.8 (45.3–62.2)	21	13.4 (8.6–20.1)	
HIV test result								
positive	83	37	56.2 (41.1–70.2)	34	36.6 (23.8–51.7)	12	7.2 (3.5–14.3)	0.2719
negative	418	250	66.9 (61.7–71.7)	146	28.3 (23.8–33.2)	22	4.9 (3.0–7.8)	
Past 30 days injecting 4 categories								
opioids	353	184	61.7 (55.5–67.5)	138	31.2 (25.9–37.0)	31	7.1 (4.6–10.8)	0.0382
stimulants	82	61	76.4 (65.3–84.7)	20	21.2 (13.5–31.5)	1	2.5 (0.3–15.8)	
opi+stimul	54	31	62.6 (47.1–75.8)	21	36.6 (23.5–52.1)	2	0.8 (0.2–3.3)	
other	12	11	94.0 (60.6–99.4)	1	6.0 (0.6–39.4)	0	0.0	
Injecting drug type of choice								
opioids	392	208	62.6 (56.7–68.0)	151	31.1 (26.0–36.6)	33	6.4 (4.2–9.6)	0.2040
stimulants	92	65	72.5 (61.9–81.0)	26	25.4 (17.4–35.5)	1	2.1 (0.3–13.9)	
other	6	6	100.0	0	0.0	0	0.0	

12. Physical and Mental Health

Table 12.1. Disease and treatment history

		n	%	CI
Had a disease				
	hepatitis B	47	7.1	(4.9–10.1)
	hepatitis C	172	27.8	(23.4–32.8)
	syphilis	13	1.8	(1.0–3.3)

	n	%	CI
gonorrhea	10	1.9	(1.0–3.7)
chlamydia	14	2.7	(1.5–4.7)
herpes	73	13.2	(10.3–16.8)
human papillomavirus	19	4.0	(2.5–6.4)
tuberculosis	12	2.3	(1.2–4.6)
Treated for: hepatitis B			
treated successfully	26	50.8	(33.0–68.3)
treated unsuccessfully	1	0.9	(0.1–6.0)
did not complete	0	0.0	
treated now	4	7.6	(2.0–25.1)
never treated	16	40.7	(24.4–59.4)
Treated for: hepatitis C			
treated successfully	54	30.4	(22.4–39.8)
treated unsuccessfully	14	9.2	(5.1–16.2)
did not complete	9	4.5	(2.1–9.4)
treated now	21	9.9	(5.9–16.1)
never treated	72	46.0	(36.4–55.9)
Treated for: syphilis			
treated successfully	10	88.6	(49.1–98.4)
treated unsuccessfully	0	0.0	
did not complete	0	0.0	
treated now	0	0.0	
never treated	1	11.4	(1.6–50.9)
Treated for: tuberculosis			
treated successfully	11	100.0	
treated unsuccessfully	0	0.0	
did not complete	0	0.0	
treated now	0	0.0	
never treated	0	0.0	

Table 12.2. Mental health screening scores

	n	Mean	CI	Median	IQR
AUDIT-C alcohol risk score ≥5	4,874	1.2	(1.2–1.2)	1	(1–1)
PHQ-9 depression result	5,002	2.2	(2.2–2.3)	2	(1–3)
GAD-7 anxiety result	5,002	1.9	(1.9–1.9)	2	(1–2)

Table 12.3. Health care utilization

	n	%	CI
Had problems with health besides drugs which required medical attention in the past 12 months			
yes	193	40.7	(35.6–46.0)
Referred to a health care facility for treatment in the past 12 months			
yes	165	34.2	(29.4–39.3)
Referred to a health care facility			
primary care	131	78.4	(69.4–85.3)
hospital, HIV clinic	49	32.0	(24.0–41.2)
private clinic	4	2.7	(1.0–7.1)
private lab	1	0.8	(0.1–5.2)
TB dispensary	1	0.6	(0.1–4.3)
drug clinic	3	2.4	(0.7–7.2)
STI clinic	0	0.0	
ambulance	1	0.8	(0.1–5.2)
mobile clinic	1	0.2	(0.0–1.2)

	n	%	CI
other	0	0.0	
Last health care facility referred to			
primary care	118	70.1	(60.9–77.9)
hospital, HIV clinic	37	23.4	(16.3–32.5)
private clinic	4	2.7	(1.0–7.1)
private lab	1	0.8	(0.1–5.2)
TB dispensary	1	0.6	(0.1–4.3)
drug clinic	3	2.4	(0.7–7.2)
STI clinic	0	0.0	
ambulance	0	0.0	
mobile clinic	0	0.0	
other	0	0.0	
Received necessary care in health care facility			
yes	160	96.8	(91.9–98.8)
Signed a declaration with primary care physician			
yes	406	78.4	(73.5–82.7)
How frequently saw the primary care physician			
twice per month or more	28	5.6	(3.6–8.7)
once per month	71	16.5	(12.6–21.3)
3-4 times in 12 months	153	42.3	(36.5–48.3)
only once	130	35.6	(30.1–41.6)

Figure 12.1. Risky alcohol use (AUDIT-C score > 5) (%)



Figure 12.2. Depression symptoms severity (PHQ-9) (%)



Figure 12.3. Anxiety symptoms severity (GAD-7) (%)

Table 12.4. Risky alcohol use (AUDIT-C score > 5) by Sociodemographic Characteristics

			AUDIT-C alcohol risk score ≥5				
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
Total							
	All	482	356	70.9 (65.8–75.5)	126	29.1 (24.5–34.2)	1.0000
Sex							
	male	392	278	67.9 (62.2–73.2)	114	32.1 (26.8–37.8)	0.0177
	female	90	78	83.1 (71.6–90.5)	12	16.9 (9.5–28.4)	
Age							
	<25	19	11	55.6 (31.2–77.6)	8	44.4 (22.4–68.8)	0.1816

		AUDIT-C alcohol risk score ≥5				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
25-34	108	83	76.7 (66.9–84.3)	25	23.3 (15.7–33.1)	
35-44	237	175	67.8 (59.9–74.9)	62	32.2 (25.1–40.1)	
45+	118	87	74.7 (65.0–82.5)	31	25.3 (17.5–35.0)	
Years since the start of injecting drug use						
≤2	56	40	73.5 (60.0–83.7)	16	26.5 (16.3–40.0)	0.9748
3-5	42	31	69.8 (52.6–82.7)	11	30.2 (17.3–47.4)	
6-10	55	40	71.0 (55.7–82.7)	15	29.0 (17.3–44.3)	
≥11	329	245	70.4 (63.9–76.3)	84	29.6 (23.7–36.1)	
Partnership status						
live alone	326	241	71.5 (65.2–77.0)	85	28.5 (23.0–34.8)	0.7380
live with partner	156	115	69.7 (60.7–77.5)	41	30.3 (22.5–39.3)	
Current employment status						
full-time	113	80	68.1 (57.5–77.1)	33	31.9 (22.9–42.5)	0.8373
part-time or temporary	202	149	70.2 (61.8–77.4)	53	29.8 (22.6–38.2)	
unemployed	119	91	73.8 (63.9–81.8)	28	26.2 (18.2–36.1)	
disabled	25	20	67.1 (38.8–86.8)	5	32.9 (13.2–61.2)	
other	23	16	78.7 (55.5–91.6)	7	21.3 (8.4–44.5)	
Monthly income category						
<3K	78	62	77.5 (64.1–86.9)	16	22.5 (13.1–35.9)	0.1519
3-10K	159	129	75.1 (65.1–82.9)	30	24.9 (17.1–34.9)	
10-20K	137	88	64.0 (54.6–72.5)	49	36.0 (27.5–45.4)	
≥20K	37	28	79.4 (60.5–90.7)	9	20.6 (9.3–39.5)	
Ever incarcerated						
no	310	234	72.2 (65.9–77.8)	76	27.8 (22.2–34.1)	0.4218
yes	172	122	68.1 (59.2–75.8)	50	31.9 (24.2–40.8)	

Table 12.5. Risky alcohol use (AUDIT-C score > 5) by Selected Subgroups

		AUDIT-C alcohol risk score ≥5				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	287	199	68.7 (62.4–74.4)	88	31.3 (25.6–37.6)	0.0969
yes	189	154	77.2 (68.7–84.0)	35	22.8 (16.0–31.3)	
Treated with MAT currently (of all)						
no	326	226	69.7 (64.0–74.8)	100	30.3 (25.2–36.0)	0.0009
yes	151	128	84.7 (77.6–89.9)	23	15.3 (10.1–22.4)	
HIV test result						
positive	79	69	80.7 (65.3–90.3)	10	19.3 (9.7–34.7)	0.1532
negative	403	287	69.8 (64.3–74.7)	116	30.2 (25.3–35.7)	
Past 30 days injecting 4 categories						
opioids	340	263	74.9 (69.0–80.0)	77	25.1 (20.0–31.0)	0.0289
stimulants	79	50	63.9 (52.1–74.3)	29	36.1 (25.7–47.9)	
opi+stimul	52	33	58.3 (41.8–73.2)	19	41.7 (26.8–58.2)	
other	11	10	92.0 (52.7–99.2)	1	8.0 (0.8–47.3)	
Injecting drug type of choice						
opioids	377	290	73.4 (67.4–78.6)	87	26.6 (21.4–32.6)	0.1393
stimulants	90	55	62.9 (51.9–72.7)	35	37.1 (27.3–48.1)	
other	5	4	82.6 (20.2–98.9)	1	17.4 (1.1–79.8)	

Table 12.6. Depression symptoms severity (PHQ-9) by Sociodemographic Characteristics

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	502	120	22.6 (18.6–27.3)	215	44.1 (39.0–49.4)	108	20.8 (17.1–25.1)	59	12.4 (9.5–16.2)	1.0000
Sex										
male	409	106	25.4 (20.7–30.7)	178	44.3 (38.6–50.3)	77	17.6 (13.8–22.1)	48	12.7 (9.4–17.0)	0.0040
female	93	14	11.1 (5.7–20.6)	37	43.1 (32.0–55.0)	31	34.5 (24.4–46.2)	11	11.2 (5.6–21.1)	
Age										
<25	20	3	13.6 (4.0–37.5)	8	44.9 (22.9–69.1)	4	12.7 (4.0–33.8)	5	28.9 (11.7–55.3)	0.4268
25-34	114	25	22.4 (15.0–32.1)	53	44.0 (34.2–54.3)	24	21.9 (14.6–31.5)	12	11.7 (6.3–20.6)	
35-44	248	56	22.0 (16.1–29.3)	115	47.5 (39.8–55.4)	48	19.1 (14.0–25.5)	29	11.4 (7.6–16.7)	
45+	120	36	26.4 (18.5–36.1)	39	36.6 (27.0–47.5)	32	25.3 (17.6–34.9)	13	11.7 (6.4–20.4)	
Years since the start of injecting drug use										

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
≤2	57	13	21.5 (12.5–34.5)	24	44.9 (31.5–59.0)	12	17.9 (10.0–29.9)	8	15.7 (7.7–29.5)	0.9849
3-5	46	8	22.6 (11.4–39.8)	22	42.9 (28.6–58.6)	12	25.0 (13.8–40.9)	4	9.5 (3.4–23.5)	
6-10	58	12	19.6 (10.7–33.1)	27	49.9 (35.0–64.8)	12	17.9 (9.5–31.4)	7	12.6 (5.8–25.0)	
≥11	341	87	23.6 (18.4–29.6)	142	42.9 (36.5–49.6)	72	21.4 (16.7–26.9)	40	12.2 (8.6–16.9)	
Partnership status										
live alone	339	82	22.4 (17.7–27.8)	146	45.4 (39.1–51.9)	67	18.2 (14.0–23.3)	44	14.0 (10.2–18.9)	0.2259
live with partner	163	38	23.2 (16.0–32.5)	69	41.4 (32.9–50.4)	41	26.3 (19.3–34.7)	15	9.1 (5.1–15.7)	
Current employment status										
full-time	115	34	26.5 (18.3–36.7)	43	40.5 (30.2–51.7)	25	21.4 (14.1–31.2)	13	11.6 (6.4–20.0)	0.0712
part-time or temporary	213	52	23.6 (17.7–30.8)	108	50.1 (42.1–58.1)	35	15.9 (11.1–22.3)	18	10.4 (6.4–16.3)	
unemployed	124	22	14.5 (9.1–22.4)	47	42.3 (32.7–52.7)	34	25.9 (18.2–35.4)	21	17.2 (10.8–26.4)	
disabled	26	6	21.2 (7.1–48.8)	13	51.2 (27.2–74.7)	4	16.9 (5.2–42.9)	3	10.7 (2.3–37.7)	
other	24	6	38.1 (14.3–69.6)	4	13.2 (4.0–35.6)	10	37.6 (17.0–63.9)	4	11.0 (3.1–32.2)	
Monthly income category										
<3K	78	15	17.9 (9.9–30.2)	42	54.6 (40.9–67.6)	11	14.5 (7.1–27.3)	10	12.9 (6.5–24.3)	0.7430
3-10K	165	43	22.4 (15.9–30.5)	71	44.5 (35.3–54.1)	36	21.8 (15.2–30.1)	15	11.3 (6.5–18.9)	
10-20K	144	37	27.0 (19.5–36.1)	59	43.0 (33.9–52.6)	32	19.3 (13.4–26.9)	16	10.7 (6.3–17.8)	
≥20K	39	13	35.5 (18.0–57.9)	16	37.3 (21.5–56.5)	5	14.5 (5.4–33.2)	5	12.8 (4.7–30.3)	
Ever incarcerated										
no	323	73	22.7 (17.8–28.6)	141	44.4 (38.2–50.8)	66	18.9 (14.6–24.0)	43	14.0 (10.2–18.9)	0.4043
yes	179	47	22.4 (16.0–30.5)	74	43.5 (34.5–53.0)	42	24.8 (18.0–33.2)	16	9.2 (5.3–15.6)	

Table 12.7. Depression symptoms severity (PHQ-9) by Selected Subgroups

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	502	120	22.6 (18.6–27.3)	215	44.1 (39.0–49.4)	108	20.8 (17.1–25.1)	59	12.4 (9.5–16.2)	1.0000
Sex										
male	409	106	25.4 (20.7–30.7)	178	44.3 (38.6–50.3)	77	17.6 (13.8–22.1)	48	12.7 (9.4–17.0)	0.0040
female	93	14	11.1 (5.7–20.6)	37	43.1 (32.0–55.0)	31	34.5 (24.4–46.2)	11	11.2 (5.6–21.1)	
Age										
<25	20	3	13.6 (4.0–37.5)	8	44.9 (22.9–69.1)	4	12.7 (4.0–33.8)	5	28.9 (11.7–55.3)	0.4268
25-34	114	25	22.4 (15.0–32.1)	53	44.0 (34.2–54.3)	24	21.9 (14.6–31.5)	12	11.7 (6.3–20.6)	
35-44	248	56	22.0 (16.1–29.3)	115	47.5 (39.8–55.4)	48	19.1 (14.0–25.5)	29	11.4 (7.6–16.7)	

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
45+	120	36	26.4 (18.5–36.1)	39	36.6 (27.0–47.5)	32	25.3 (17.6–34.9)	13	11.7 (6.4–20.4)	
Years since the start of injecting drug use										
≤2	57	13	21.5 (12.5–34.5)	24	44.9 (31.5–59.0)	12	17.9 (10.0–29.9)	8	15.7 (7.7–29.5)	0.9849
3-5	46	8	22.6 (11.4–39.8)	22	42.9 (28.6–58.6)	12	25.0 (13.8–40.9)	4	9.5 (3.4–23.5)	
6-10	58	12	19.6 (10.7–33.1)	27	49.9 (35.0–64.8)	12	17.9 (9.5–31.4)	7	12.6 (5.8–25.0)	
≥11	341	87	23.6 (18.4–29.6)	142	42.9 (36.5–49.6)	72	21.4 (16.7–26.9)	40	12.2 (8.6–16.9)	
Partnership status										
live alone	339	82	22.4 (17.7–27.8)	146	45.4 (39.1–51.9)	67	18.2 (14.0–23.3)	44	14.0 (10.2–18.9)	0.2259
live with partner	163	38	23.2 (16.0–32.5)	69	41.4 (32.9–50.4)	41	26.3 (19.3–34.7)	15	9.1 (5.1–15.7)	
Current employment status										
full-time	115	34	26.5 (18.3–36.7)	43	40.5 (30.2–51.7)	25	21.4 (14.1–31.2)	13	11.6 (6.4–20.0)	0.0712
part-time or temporary	213	52	23.6 (17.7–30.8)	108	50.1 (42.1–58.1)	35	15.9 (11.1–22.3)	18	10.4 (6.4–16.3)	
unemployed	124	22	14.5 (9.1–22.4)	47	42.3 (32.7–52.7)	34	25.9 (18.2–35.4)	21	17.2 (10.8–26.4)	
disabled	26	6	21.2 (7.1–48.8)	13	51.2 (27.2–74.7)	4	16.9 (5.2–42.9)	3	10.7 (2.3–37.7)	
other	24	6	38.1 (14.3–69.6)	4	13.2 (4.0–35.6)	10	37.6 (17.0–63.9)	4	11.0 (3.1–32.2)	
Monthly income category										
<3K	78	15	17.9 (9.9–30.2)	42	54.6 (40.9–67.6)	11	14.5 (7.1–27.3)	10	12.9 (6.5–24.3)	0.7430
3-10K	165	43	22.4 (15.9–30.5)	71	44.5 (35.3–54.1)	36	21.8 (15.2–30.1)	15	11.3 (6.5–18.9)	
10-20K	144	37	27.0 (19.5–36.1)	59	43.0 (33.9–52.6)	32	19.3 (13.4–26.9)	16	10.7 (6.3–17.8)	
≥20K	39	13	35.5 (18.0–57.9)	16	37.3 (21.5–56.5)	5	14.5 (5.4–33.2)	5	12.8 (4.7–30.3)	
Ever incarcerated										
no	323	73	22.7 (17.8–28.6)	141	44.4 (38.2–50.8)	66	18.9 (14.6–24.0)	43	14.0 (10.2–18.9)	0.4043
yes	179	47	22.4 (16.0–30.5)	74	43.5 (34.5–53.0)	42	24.8 (18.0–33.2)	16	9.2 (5.3–15.6)	

Table 12.8. Anxiety symptoms severity (GAD-7) by Sociodemographic Characteristics

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	502	153	29.4 (24.7–34.5)	251	51.0 (45.8–56.2)	81	16.2 (12.8–20.3)	17	3.4 (2.0–5.7)	1.0000
Sex										
male	409	134	31.9 (26.6–37.7)	198	49.4 (43.6–55.2)	63	15.0 (11.5–19.4)	14	3.7 (2.1–6.4)	0.0886
female	93	19	18.7 (11.2–29.6)	53	57.7 (45.8–68.8)	18	21.5 (13.1–33.2)	3	2.1 (0.5–7.9)	
Age										

	N	GAD-7 anxiety result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
<25	20	5	25.2 (9.9–50.8)	11	52.5 (29.0–74.9)	3	18.2 (5.5–45.7)	1	4.1 (0.5–27.0)	0.2966
25-34	114	24	18.4 (12.0–27.1)	70	62.7 (52.3–71.9)	18	16.9 (10.3–26.5)	2	2.1 (0.5–8.2)	
35-44	248	78	33.1 (25.8–41.3)	117	45.9 (38.3–53.7)	44	17.3 (12.4–23.6)	9	3.7 (1.8–7.6)	
45+	120	46	34.3 (25.3–44.6)	53	49.0 (38.7–59.3)	16	12.8 (7.6–20.6)	5	4.0 (1.5–10.1)	
Years since the start of injecting drug use										
≤2	57	18	30.3 (19.4–44.1)	22	40.3 (27.5–54.5)	13	23.9 (13.7–38.3)	4	5.5 (1.9–15.0)	0.7808
3-5	46	10	27.0 (14.8–44.0)	29	56.3 (40.3–71.1)	6	14.4 (6.3–29.3)	1	2.3 (0.3–15.4)	
6-10	58	14	25.9 (13.7–43.4)	33	55.1 (39.6–69.7)	8	13.9 (6.4–27.7)	3	5.1 (1.6–15.4)	
≥11	341	111	30.3 (24.5–36.9)	167	51.6 (45.0–58.1)	54	15.3 (11.4–20.3)	9	2.8 (1.3–5.7)	
Partnership status										
live alone	339	107	30.4 (24.8–36.8)	168	50.4 (44.0–56.7)	53	15.8 (11.8–20.8)	11	3.4 (1.8–6.3)	0.9250
live with partner	163	46	27.1 (19.6–36.3)	83	52.3 (43.2–61.2)	28	17.2 (11.5–24.9)	6	3.5 (1.4–8.2)	
Current employment status										
full-time	115	33	24.7 (16.9–34.6)	59	55.1 (44.4–65.4)	17	14.8 (8.8–23.8)	6	5.3 (2.2–12.2)	0.3450
part-time or temporary	213	66	31.3 (24.0–39.6)	113	52.1 (44.0–60.0)	29	14.3 (9.6–20.8)	5	2.3 (0.9–5.9)	
unemployed	124	37	27.8 (19.7–37.6)	59	50.2 (40.2–60.2)	26	20.0 (13.2–29.2)	2	2.0 (0.5–7.9)	
disabled	26	10	33.0 (13.9–59.9)	10	36.0 (16.3–61.8)	4	15.9 (4.7–42.2)	2	15.1 (3.6–45.8)	
other	24	7	41.3 (16.8–70.9)	10	35.0 (15.7–60.9)	5	20.8 (7.2–47.0)	2	2.9 (0.6–12.6)	
Monthly income category										
<3K	78	26	30.3 (19.5–43.8)	38	55.1 (41.5–68.0)	12	11.0 (5.4–21.0)	2	3.6 (0.9–13.7)	0.5599
3-10K	165	56	31.4 (22.9–41.2)	83	51.2 (41.8–60.5)	24	16.1 (10.3–24.3)	2	1.3 (0.3–5.4)	
10-20K	144	36	26.6 (19.2–35.6)	76	51.3 (42.0–60.6)	23	16.0 (10.4–23.6)	9	6.1 (3.0–12.0)	
≥20K	39	14	37.3 (19.5–59.3)	20	50.6 (31.4–69.6)	4	11.6 (4.0–29.0)	1	0.5 (0.1–3.9)	
Ever incarcerated										
no	323	93	28.7 (23.1–35.0)	162	50.2 (43.9–56.5)	58	17.8 (13.5–23.1)	10	3.3 (1.7–6.2)	0.6904
yes	179	60	30.8 (22.9–40.1)	89	52.5 (43.3–61.5)	23	13.0 (8.2–19.9)	7	3.7 (1.6–8.5)	

Table 12.9. Anxiety symptoms severity (GAD-7) by Selected Subgroups

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										
no	303	87	29.4 (23.7–35.9)	150	50.2 (43.8–56.5)	56	17.3 (13.1–22.4)	10	3.1 (1.6–5.8)	0.7796
yes	192	64	30.0 (22.8–38.3)	96	51.6 (42.9–60.3)	25	13.9 (8.8–21.3)	7	4.5 (1.9–10.1)	
Treated with MAT currently (of all)										
no	341	90	28.0 (22.8–33.7)	179	51.8 (46.0–57.6)	60	16.9 (13.1–21.5)	12	3.3 (1.9–5.8)	0.1037
yes	155	60	39.0 (31.2–47.5)	70	45.7 (37.4–54.2)	21	12.9 (8.3–19.5)	4	2.4 (0.9–6.3)	
HIV test result										
positive	83	36	41.7 (27.1–58.0)	32	42.3 (28.3–57.7)	13	13.0 (6.2–25.5)	2	2.9 (0.6–13.5)	0.2862
negative	419	117	27.8 (23.0–33.2)	219	52.1 (46.5–57.6)	68	16.6 (13.0–21.1)	15	3.5 (2.0–5.9)	
Past 30 days injecting 4 categories										
opioids	354	113	29.3 (23.6–35.7)	176	52.7 (46.2–59.1)	52	14.4 (10.6–19.2)	13	3.6 (2.0–6.6)	0.2537
stimulants	82	22	25.2 (16.7–36.0)	39	45.9 (34.8–57.5)	19	25.9 (16.7–38.0)	2	3.0 (0.7–11.4)	
opi+stimul	54	16	39.4 (24.9–56.1)	28	45.4 (30.9–60.7)	8	11.4 (5.1–23.6)	2	3.8 (0.9–14.4)	
other	12	2	13.1 (2.6–46.2)	8	73.7 (41.1–91.9)	2	13.1 (2.6–46.2)	0	0.0	
Injecting drug type of choice										
opioids	393	122	29.3 (23.9–35.4)	195	52.1 (46.0–58.2)	62	15.0 (11.4–19.5)	14	3.5 (2.0–6.2)	0.7337
stimulants	92	26	28.8 (20.0–39.7)	46	46.1 (35.6–56.9)	17	21.4 (13.4–32.4)	3	3.7 (1.2–11.1)	
other	6	2	43.4 (7.2–88.5)	4	56.6 (11.5–92.8)	0	0.0	0	0.0	

13. Detention and Incarceration

Table 13.1. Police Detention and Incarceration Experience

	n	%	CI
Detained by police in 2022 for			
drug use	27	4.5	(2.9–6.9)
drug dealing	11	1.9	(1.0–3.7)
drug storing	24	4.8	(3.0–7.5)
Detained by police in 2023 for			
drug use	25	4.4	(2.8–6.8)
drug dealing	7	1.3	(0.5–3.0)
drug storing	15	2.6	(1.4–4.6)
Stopped, detained, or arrested by police ever			
yes	390	75.5	(70.4–79.9)
Ever incarcerated			
yes	179	32.6	(27.9–37.7)
Duration of incarceration			
≤6m	16	9.0	(5.2–15.1)

	n	%	CI
6m-2y	31	14.5	(9.5–21.6)
2-4y	60	33.8	(25.8–42.8)
4y+	67	42.7	(33.6–52.3)
Time since last incarceration			
≤1y	25	15.3	(9.9–22.8)
1-3y	23	16.3	(10.5–24.5)
3-5y	21	12.4	(7.6–19.5)
5-10y	36	22.2	(14.4–32.5)
10y+	68	33.8	(26.0–42.6)
Used injecting drugs during incarceration			
yes	105	61.6	(52.6–69.9)



Figure 13.1. Incarceration Lifetime Experience (%)

14. Negative experience

Table 14.1. Negative experience

	n	%	CI
Felt excluded from family activities due to drug use			
no	288	57.8	(52.6–62.8)
yes, in the past 6m	97	19.3	(15.5–23.8)
yes, but 6m+ ago	111	22.9	(18.9–27.5)
Was scolded because of drug use			
no	231	47.9	(42.8–53.2)
yes, in the past 6m	128	24.7	(20.6–29.4)
yes, but 6m+ ago	142	27.3	(23.1–32.0)
Was blackmailed for drug use			
no	430	86.7	(83.0–89.7)
yes, in the past 6m	26	5.0	(3.2–7.6)
yes, but 6m+ ago	45	8.3	(6.0–11.5)
Negative experience in the past 6 months (GAM 6.5)			
no	356	72.4	(67.6–76.8)
yes	139	27.6	(23.2–32.4)
Ever experienced physical violence			
no	247	49.9	(44.7–55.1)

		n	%	CI
	yes	254	50.1	(44.9–55.3)
Experienced physical violence in the past 12 months (of those who had ever)				
	no	166	63.2	(55.9–69.9)
	yes	88	36.8	(30.1–44.1)
Witnessed physical violence in the past 12 months				
	no	313	61.3	(56.1–66.3)
	yes	183	38.7	(33.7–43.9)



Figure 14.1. Negative Experience Related to Drug Use in the past 6 Months or Physical Violence in the past 12 months (%)

Table 14.2. Negative Experience Related to Drug Use by Sociodemographic Characteristics

		Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	495	139	27.6 (23.2–32.4)	1.0000	254	88	36.8 (30.1–44.1)	1.0000
Sex									
	male	403	120	29.6 (24.6–35.1)	0.0645	209	73	37.4 (29.9–45.6)	0.7290
	female	92	19	19.0 (11.7–29.4)		45	15	34.2 (20.1–51.8)	
Age									
	<25	20	7	27.8 (11.9–52.2)	0.0057	10	6	52.1 (21.3–81.4)	0.2825
	25-34	111	31	25.8 (17.9–35.6)		52	25	46.9 (32.5–61.8)	
	35-44	245	82	34.7 (27.7–42.4)		138	41	32.9 (24.0–43.3)	
	45+	119	19	14.3 (8.5–23.0)		54	16	31.3 (18.7–47.5)	
Years since the start of injecting drug use									
	≤2	56	17	28.3 (17.7–41.9)	0.3285	27	12	44.4 (26.0–64.5)	0.1123

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
3-5	45	13	23.6 (13.2–38.6)		26	15	57.8 (37.2–76.0)	
6-10	56	9	17.4 (8.4–32.7)		27	11	31.8 (16.2–53.0)	
≥11	338	100	30.2 (24.5–36.6)		174	50	32.0 (24.0–41.3)	
Partnership status								
live alone	333	95	28.5 (23.1–34.7)	0.5441	174	60	36.9 (28.8–45.9)	0.9657
live with partner	162	44	25.6 (18.9–33.7)		80	28	36.6 (25.2–49.7)	
Current employment status								
full-time	113	26	22.9 (15.3–32.9)	0.6814	52	19	40.5 (26.4–56.5)	0.8768
part-time or temporary	209	60	28.9 (22.0–36.8)		110	39	37.3 (27.2–48.7)	
unemployed	124	43	31.3 (22.9–41.1)		69	22	36.5 (24.5–50.5)	
disabled	25	5	21.4 (7.5–47.9)		12	4	24.6 (6.9–59.0)	
other	24	5	23.5 (8.7–49.8)		11	4	26.4 (7.1–63.0)	
Monthly income category								
<3K	77	25	29.4 (18.5–43.2)	0.9921	47	12	31.7 (17.2–51.1)	0.7573
3-10K	164	45	27.9 (20.2–37.2)		76	26	37.4 (24.8–51.9)	
10-20K	144	41	27.4 (20.1–36.2)		69	31	43.6 (31.4–56.7)	
≥20K	36	9	26.5 (13.1–46.3)		23	10	42.2 (20.7–67.1)	
Ever incarcerated								
no	319	99	30.5 (24.9–36.6)	0.0604	150	57	38.5 (29.9–47.9)	0.5449
yes	176	40	21.4 (15.1–29.3)		104	31	34.0 (23.6–46.1)	

Table 14.3. Negative Experience Related to Drug Use by Selected Subgroups

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	299	78	26.5 (21.2–32.5)	0.2993	144	57	37.1 (28.8–46.3)	0.7825
yes	189	60	31.6 (24.1–40.2)		107	29	35.0 (24.2–47.7)	
Treated with MAT currently (of all)								
no	337	97	27.8 (22.9–33.2)	0.7267	164	69	39.5 (31.8–47.9)	0.0052
yes	152	42	29.5 (22.3–37.8)		87	19	21.3 (13.7–31.7)	
HIV test result								

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
positive	82	21	26.3 (15.9–40.2)	0.8298	48	12	33.2 (17.0–54.7)	0.6992
negative	413	118	27.7 (23.0–32.9)		206	76	37.4 (30.2–45.3)	
Past 30 days injecting 4 categories								
opioids	350	95	27.2 (22.0–33.1)	0.4886	175	52	30.7 (23.1–39.6)	0.1839
stimulants	82	21	23.3 (15.1–34.2)		43	18	41.8 (27.3–57.9)	
opi+stimul	52	19	36.1 (22.1–52.9)		33	16	50.3 (31.1–69.5)	
other	11	4	26.7 (7.8–61.3)		3	2	51.2 (5.9–94.6)	
Injecting drug type of choice								
opioids	388	113	29.5 (24.3–35.3)	0.0875	196	63	34.7 (26.9–43.4)	0.5748
stimulants	91	21	21.9 (14.3–32.0)		52	22	42.7 (29.3–57.3)	
other	6	1	4.5 (0.3–44.6)		4	2	32.1 (3.0–88.0)	

15. The Impact of the Full-scale War

Table 15.1. Migration Since February 2022

		n	%	CI
Changed place of residence since Feb 2022				
	yes, because of the war	72	14.9	(11.4–19.1)
	yes, for other reasons	9	2.2	(1.1–4.3)
	no	420	83.0	(78.6–86.6)
Where migrated since Feb 2022				
	unknown	1	1.8	(0.3–11.9)
	other country	0	0.0	
	other oblast	63	86.8	(75.9–93.2)
	other city	6	8.8	(3.9–18.7)
	other district	1	1.4	(0.2–9.5)
	other house	1	1.2	(0.2–8.2)
Where lived before Feb 2022 (if changed residence)				
	same oblast	14	18.5	(10.8–29.8)
	other oblast	65	81.5	(70.2–89.2)
	other country	0	0.0	



Figure 15.1. Change of Residence Since February 2022 (%)



Figure 15.2. Migration Destination by Survey Site (%)



Figure 15.3. Residence Before February 2022 (%)



Figure 15.4. Changes Since February 2022 (%)

City-level Results: Kharkiv



Figure A. RDS recruitment tree in Kharkiv

1. Sociodemographic Information

Table 1.1. Sociodemographic Characteristics

	n	Mean	CI	Median	IQR
Age, years	500	39.6	(38.7–40.5)	40	(35–45)
Age of first non-injecting drug use	481	16.7	(16.4–17.1)	16	(14–18)
Years since the start of non-injecting drug use	481	23.0	(22.1–24.0)	23	(18–29)
Age of first injecting drug use	500	20.6	(20.1–21.1)	19	(17–24)
Years since the start of injecting drug use	500	18.9	(18.0–19.9)	19	(12–25)
Personal monthly income, UAH	453	8,696.0	(7985.6–9406.5)	7,000	(4000–12000)

Table 1.2. Descriptive Statistics for Sociodemographics

	Site	n	%	CI
Sex				
male	Kharkiv	435	87.9	(84.5–90.7)
female	Kharkiv	65	12.1	(9.3–15.5)
Age				
<25	Kharkiv	25	6.1	(3.8–9.4)
25-34	Kharkiv	95	18.9	(15.4–22.9)
35-44	Kharkiv	253	49.4	(44.5–54.3)
45+	Kharkiv	127	25.6	(21.5–30.2)
Family status				
married or living together	Kharkiv	90	16.9	(13.7–20.7)
married but have another partner	Kharkiv	13	3.1	(1.6–5.8)
not married but have a partner	Kharkiv	175	37.2	(32.5–42.1)
married but not living together	Kharkiv	23	3.8	(2.5–5.7)
not married and do not have a partner	Kharkiv	199	39.1	(34.5–43.9)
Partnership status				
live alone	Kharkiv	222	42.8	(38.1–47.7)
live with partner	Kharkiv	278	57.2	(52.3–61.9)
Education				
incompl. high school	Kharkiv	66	13.5	(10.5–17.1)
high school	Kharkiv	216	42.2	(37.5–47.1)
>high school	Kharkiv	218	44.3	(39.5–49.3)
Current occupation				
school student	Kharkiv	0	0.0	
college/uni student	Kharkiv	1	0.2	(0.0–1.8)
permanent job	Kharkiv	94	18.5	(15.0–22.4)
sporadic jobs	Kharkiv	273	53.1	(48.2–58.0)
unemployed	Kharkiv	104	22.1	(18.2–26.6)
housewife	Kharkiv	8	2.0	(0.8–4.6)
disabled	Kharkiv	10	2.4	(1.1–5.1)
military	Kharkiv	4	0.9	(0.3–2.3)
other	Kharkiv	5	0.8	(0.3–1.9)
Homelessness				
never	Kharkiv	452	89.7	(86.0–92.5)
yes, 12m+ ago	Kharkiv	48	10.3	(7.5–14.0)
yes, in the past 12m	Kharkiv	0	0.0	
Homeless in 12 months (of those ever)				
no	Kharkiv	48	100.0	
yes	Kharkiv	0	0.0	
Monthly income category				
<3K	Kharkiv	70	16.5	(12.8–21.0)
3-10K	Kharkiv	203	44.9	(39.9–50.1)
10-20K	Kharkiv	140	29.7	(25.3–34.5)

	Site	n	%	CI
≥20K	Kharkiv	40	8.9	(6.3–12.4)
Monthly income relative to 2023 subsistence minimum				
<2684	Kharkiv	68	15.9	(12.3–20.3)
≥2684	Kharkiv	385	84.1	(79.7–87.7)
Years since the start of injecting drug use				
≤2	Kharkiv	18	4.4	(2.5–7.6)
3-5	Kharkiv	24	4.7	(3.1–7.2)
6-10	Kharkiv	53	10.8	(8.2–14.3)
≥11	Kharkiv	405	80.1	(75.7–83.8)

Table 1.3. Accommodation in the past 12 months

	Site	n	%	CI
own place	Kharkiv	289	57.5	(52.6–62.3)
friends or relatives	Kharkiv	166	33.1	(28.7–37.8)
renting	Kharkiv	47	10.1	(7.4–13.7)
varying	Kharkiv	8	1.5	(0.7–2.9)
on the street (homeless)	Kharkiv	0	0.0	
in a refugee shelter	Kharkiv	8	1.4	(0.7–2.9)



Figure 1.1. Distribution of Age by Sex (%)



Figure 1.2. Trend in Sex Distribution by Survey Round (%)



Figure 1.3. Trend in Age Groups by Survey Round (%)

2. Drug Use



Figure 2.1. Injecting Drug Use in the Past 12 Months and 30 Days (%)



Figure 2.2. Non-injecting Drug Use in the Past 12 Months (%)



Figure 2.3. Trends in Injecting Drugs Types in the Past 30 Days by Survey Round (%)



Figure 2.4. Trends in Injecting Opioids in the Past 30 Days by Survey Round (%)



Figure 2.5. Trends in Injecting Stimulants in the Past 30 Days by Survey Round (%)



Figure 2.6. Trends in Injecting Other Drugs in the Past 30 Days by Survey Round (%)



Figure 2.7. Injecting Drug Preference (%)

Table 2.1. Types of Injecting Drugs in the Past 30 Days by Sociodemographic Characteristics

			Past 30 days injecting 4 categories					
		N	opioids		stimulants		opi+stimul	
			n	% (CI)	n	% (CI)	n	% (CI)
Total								
	All	500	449	89.5 (85.9–92.2)	18	3.9 (2.3–6.6)	33	6.6 (4.5–9.6)
Sex								
	male	435	394	89.8 (85.9–92.8)	12	3.4 (1.8–6.5)	29	6.8 (4.5–10.1)
	female	65	55	86.9 (76.5–93.1)	6	7.4 (3.2–16.2)	4	5.7 (2.1–14.8)
Age								
	<25	25	20	72.6 (44.0–90.0)	3	17.1 (4.0–50.3)	2	10.2 (2.3–35.6)

	N	Past 30 days injecting 4 categories					
			opioids		stimulants		opi+stimul
		n	% (CI)	n	% (CI)	n	% (CI)
25-34	95	79	84.9 (76.3–90.8)	6	5.3 (2.3–11.8)	10	9.8 (5.2–17.6)
35-44	253	229	91.0 (86.6–94.1)	8	3.3 (1.6–6.7)	16	5.7 (3.4–9.4)
45+	127	121	93.8 (84.1–97.7)	1	1.0 (0.1–6.7)	5	5.3 (1.7–15.3)
Years since the start of injecting drug use							
≤2	18	15	75.7 (37.4–94.2)	3	24.3 (5.8–62.6)	0	0.0
3-5	24	16	66.7 (43.1–84.0)	5	16.2 (6.1–36.7)	3	17.1 (5.2–44.0)
6-10	53	45	87.0 (75.1–93.7)	3	5.4 (1.7–16.3)	5	7.6 (3.0–17.7)
≥11	405	373	91.9 (88.2–94.5)	7	1.9 (0.8–4.0)	25	6.2 (4.0–9.7)
Partnership status							
live alone	222	190	86.0 (80.0–90.4)	11	5.8 (2.8–11.5)	21	8.2 (5.3–12.6)
live with partner	278	259	92.1 (87.1–95.2)	7	2.5 (1.1–5.4)	12	5.4 (2.8–10.2)
Current employment status							
full-time	94	89	95.5 (89.3–98.2)	4	3.5 (1.3–9.2)	1	1.0 (0.1–7.1)
part-time or temporary	273	241	87.3 (81.9–91.3)	8	4.0 (1.7–9.0)	24	8.7 (5.7–13.0)
unemployed	104	96	91.6 (81.1–96.5)	1	0.7 (0.1–4.9)	7	7.8 (3.0–18.4)
disabled	10	10	100.0	0	0.0	0	0.0
other	18	12	71.3 (44.1–88.7)	5	25.4 (9.3–52.9)	1	3.3 (0.4–23.3)
Monthly income category							
<3K	70	65	90.9 (75.0–97.1)	1	1.0 (0.1–7.2)	4	8.0 (2.3–24.8)
3-10K	203	178	87.4 (80.9–91.9)	8	4.7 (2.0–10.9)	17	7.9 (4.8–12.9)
10-20K	140	128	91.1 (84.3–95.1)	7	5.7 (2.6–12.0)	5	3.3 (1.3–8.0)
≥20K	40	36	91.0 (77.3–96.8)	2	4.3 (1.0–16.5)	2	4.7 (1.1–17.9)
Ever incarcerated							
no	329	289	87.5 (82.8–91.0)	18	6.1 (3.5–10.2)	22	6.5 (4.2–9.9)
yes	169	158	93.0 (86.2–96.6)	0	0.0	11	7.0 (3.4–13.8)

Table 2.2. Types of Injecting Drugs in the Past 30 Days by Selected Subgroups

	N	Past 30 days injecting 4 categories					
			opioids		stimulants		opi+stimul
		n	% (CI)	n	% (CI)	n	% (CI)
Client of NGO working with PWID							

	N	Past 30 days injecting 4 categories					
		opioids		stimulants		opi+stimul	
		n	% (CI)	n	% (CI)	n	% (CI)
no	264	233	88.3 (82.7–92.2)	16	6.3 (3.5–11.0)	15	5.4 (2.9–9.8)
yes	231	211	90.8 (85.8–94.1)	2	0.9 (0.2–3.8)	18	8.3 (5.1–13.1)
Treated with MAT currently (of all)							
no	429	383	89.4 (85.7–92.3)	18	4.5 (2.6–7.6)	28	6.1 (4.1–8.9)
yes	63	59	94.3 (85.1–97.9)	0	0.0	4	5.7 (2.1–14.9)
HIV test result							
positive	77	66	82.1 (67.7–90.9)	3	7.9 (2.0–26.3)	8	10.0 (4.9–19.3)
negative	423	383	90.7 (87.0–93.4)	15	3.3 (1.9–5.5)	25	6.1 (3.9–9.4)
Injecting drug type of choice							
opioids	475	443	93.1 (89.9–95.3)	3	0.5 (0.2–1.7)	29	6.4 (4.3–9.5)
stimulants	23	4	13.5 (4.5–34.3)	15	74.9 (52.6–88.9)	4	11.6 (3.8–30.3)
other	2	2	100.0	0	0.0	0	0.0

Table 2.3. Injecting frequency

	Past 30 days injecting 4 categories							
	opioids		stimulants		opi+stimul		other	
	n	%	n	%	n	%	n	%
Injecting frequency: last 24 hrs								
0 times	12	2.9	2	14.3	0	0.0	0	
1 time	296	65.4	12	64.2	15	49.5	0	
2-3 times	131	29.2	3	15.1	17	47.7	0	
4+ times	10	2.5	1	6.4	1	2.8	0	
N	449		18		33		0	
Injecting frequency: last 24 hrs (among those who did)								
1 time	296	67.4	12	75.0	15	49.5	0	
2-3 times	131	30.0	3	17.6	17	47.7	0	
4+ times	10	2.6	1	7.4	1	2.8	0	
N	437		16		33		0	
Injecting frequency: last week								
0 times	0	0.0	0	0.0	0	0.0	0	
1-6 times	140	33.1	13	77.1	11	30.3	0	
every day	309	66.9	5	22.9	22	69.7	0	
N	449		18		33		0	
Injecting frequency: last 30 days								
1-9 times	30	6.5	2	23.3	4	14.1	0	
10-19 times	62	14.2	7	33.9	1	2.8	0	
20-29 times	90	21.1	5	23.8	11	27.6	0	
every day	267	58.2	4	19.0	17	55.5	0	
N	449		18		33		0	
Injecting frequency: main drug last 30 days								
0-9 times	13	3.4	2	23.3	1	5.6	0	
10-19 times	65	14.9	6	24.4	5	12.7	0	
20-29 times	82	18.9	5	29.4	11	29.0	0	

	Past 30 days injecting 4 categories							
	opioids		stimulants		opi+stimul		other	
	n	%	n	%	n	%	n	%
every day	288	62.8	5	22.9	16	52.7	0	
N	448		18		33		0	

Table 2.4. Injecting drug type of choice by Income Category

	Injecting drug type of choice					
	opioids		stimulants		other	
	n	%	n	%	n	%
Monthly income category						
<3K	66	16.7	2	6.7	2	100.0
3-10K	190	44.4	13	58.8	0	0.0
10-20K	133	29.7	7	31.2	0	0.0
≥20K	39	9.2	1	3.3	0	0.0
N	428		23		2	

Table 2.5. Sources of drugs by Drug Type of Choice

Total		Injecting drug type of choice						
All		opioids		stimulants		other		
n	%	n	%	n	%	n	%	p-value
prepare myself								
118	22.6	114	22.9	2	11.0	2	100.0	0.0398
prepared by friends								
55	10.8	51	10.8	4	12.7	0	0.0	0.8492
from a dealer								
145	29.5	140	30.3	5	15.5	0	0.0	0.1621
buy on Internet								
289	58.0	273	57.3	15	72.1	1	54.3	0.3310
from a pharmacy								
2	0.3	1	0.1	0	0.0	1	54.3	0.0000
from MAT program								
12	2.2	12	2.3	0	0.0	0	0.0	0.7228
other								
2	0.5	2	0.5	0	0.0	0	0.0	0.9293
N								
623		593		26		4		



Figure 2.8. Change in the price, quality, and access of drugs by Drug Type of Choice (%)

3. Injecting Risk Behavior

Table 3.1. Prevalence of Injection Risk Practices

	n	%	CI
Used clean syringe for last injection			
yes	487	97.6	(95.6–98.7)
Source of syringe for last injection			
bought in pharmacy	303	63.4	(58.7–67.8)
got in pharmacy	2	0.3	(0.1–1.1)
got from NGO	182	33.9	(29.6–38.5)
got from friend	9	1.7	(0.9–3.4)
got used from friend	0	0.0	
used one used by myself	2	0.3	(0.1–1.4)
got pre-loaded	2	0.3	(0.1–1.4)
other	0	0.0	
Used shared syringe in the past 30 days			
yes	12	2.2	(1.2–4.1)
Used pre-filled syringe in the past 30 days			
yes	42	8.2	(5.9–11.3)
Used front-/back-loaded syringe in the past 30 days			
yes	161	31.4	(27.1–36.1)
Used shared container in the past 30 days			
yes	137	25.8	(21.8–30.2)
Used own previously used syringe in the past 30 days			
yes	264	51.0	(46.2–55.9)
Gave someone a used syringe in the past 30 days			
yes	23	4.7	(2.9–7.5)
Any inj. risk (shared syringe, pre-filled, front-/back-load, container) in the past 30 days			
yes	233	44.1	(39.4–49.0)

Table 3.2. Frequency of risky injection practices

	n	%	CI
Frequency of injecting with a syringe used by others in the past 30 days			
always	0	0.0	

	n	%	CI
often	0	0.0	
half	2	13.5	(3.2–42.5)
sometimes	3	20.8	(6.3–50.6)
rarely	3	29.8	(9.1–64.5)
never	4	35.8	(12.8–67.9)
Frequency of injecting with others in the same place in the past 30 days			
always	57	10.8	(8.2–14.2)
often	62	12.2	(9.4–15.8)
half	51	10.3	(7.7–13.8)
sometimes	72	15.3	(12.1–19.2)
rarely	133	27.1	(22.9–31.8)
never	114	24.1	(20.1–28.6)
Number of syringes used repeatedly in the past 30 days			
1-9	182	72.2	(65.9–77.7)
10-29	69	25.6	(20.3–31.7)
30+	7	2.2	(1.1–4.7)
Number of times one syringe used repeatedly in the past 30 days			
1	10	3.9	(2.0–7.4)
2-3	167	64.5	(58.0–70.5)
4-9	59	23.0	(17.8–29.1)
10+	25	8.6	(5.8–12.6)
How the pre-filled syringe was obtained			
from dealer	6	13.6	(6.0–28.0)
from friends	24	59.9	(43.0–74.8)
from stash	11	26.4	(14.5–43.2)
Someone used one syringe for injection before front-/back-loading			
no	420	85.2	(81.5–88.2)
yes	78	14.8	(11.8–18.5)



Figure 3.1. Prevalence of Key Injection Risk Practices (%)



Figure 3.2. Trends in Key Injection Risk Practices by Survey Round (%)



Figure 3.3. With whom injected drugs in the same place (%)



Figure 3.4. With whom injected drugs in the same place by sex (%)



Figure 3.5. With whom injected drugs in the same place by age (%)

Table 3.3. Prevalence of Shared and Pre-filled Syringe Use by Sociodemographic Characteristics

		Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	499	12	2.2 (1.2–4.1)	1.0000	500	42	8.2 (5.9–11.3)	1.0000
Sex									
	male	434	8	1.8 (0.8–3.9)	0.0778	435	34	7.6 (5.2–10.8)	0.1883
	female	65	4	5.3 (1.9–13.8)		65	8	12.9 (6.1–25.0)	
Age									
	<25	25	1	2.5 (0.3–17.7)	0.9414	25	5	12.6 (4.6–30.0)	0.2437

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
25-34	95	3	2.5 (0.8–7.6)		95	13	12.7 (7.2–21.4)	
35-44	252	5	1.9 (0.7–4.9)		253	15	7.1 (4.0–12.3)	
45+	127	3	2.8 (0.8–9.1)		127	9	6.1 (3.1–11.6)	
Years since the start of injecting drug use								
≤2	18	1	3.5 (0.4–24.6)	0.8422	18	5	17.3 (5.9–40.8)	0.2258
3-5	24	0	0.0		24	3	14.6 (4.0–40.8)	
6-10	53	1	1.7 (0.2–11.9)		53	7	10.7 (4.9–21.6)	
≥11	404	10	2.4 (1.2–4.7)		405	27	7.0 (4.6–10.5)	
Partnership status								
live alone	221	1	0.4 (0.1–3.1)	0.0168	222	15	6.2 (3.6–10.4)	0.1831
live with partner	278	11	3.6 (1.9–6.8)		278	27	9.7 (6.4–14.5)	
Current employment status								
full-time	94	4	4.5 (1.5–12.6)	0.5642	94	4	3.9 (1.4–10.4)	0.3573
part-time or temporary	273	5	1.7 (0.6–4.6)		273	26	10.3 (6.7–15.4)	
unemployed	104	2	1.5 (0.4–6.1)		104	10	8.0 (4.2–14.7)	
disabled	10	0	0.0		10	0	0.0	
other	17	1	4.1 (0.5–27.6)		18	2	7.2 (1.5–28.1)	
Monthly income category								
<3K	69	0	0.0	0.2581	70	5	5.7 (2.2–13.8)	0.5972
3-10K	203	6	3.3 (1.3–7.8)		203	21	9.7 (6.2–14.9)	
10-20K	140	2	1.1 (0.3–4.5)		140	5	5.8 (2.0–15.4)	
≥20K	40	2	3.5 (0.8–13.9)		40	4	8.5 (3.0–21.8)	
Ever incarcerated								
no	328	9	2.7 (1.3–5.6)	0.3195	329	33	10.4 (7.2–14.9)	0.0144
yes	169	3	1.4 (0.4–4.3)		169	9	4.2 (2.1–8.1)	

Table 3.4. Prevalence of Shared and Pre-filled Syringe Use by Selected Subgroups

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	264	8	2.7 (1.3–5.5)	0.5310	264	24	8.8 (5.6–13.6)	0.6312

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
yes	230	4	1.7 (0.6–5.3)		231	18	7.5 (4.7–12.0)	
Treated with MAT currently (of all)								
no	428	12	2.6 (1.4–4.8)	0.2351	429	41	9.3 (6.7–12.9)	0.0180
yes	63	0	0.0		63	1	1.3 (0.2–9.0)	
HIV test result								
positive	77	0	0.0	0.1974	77	2	2.3 (0.5–9.1)	0.0347
negative	422	12	2.6 (1.4–4.8)		423	40	9.2 (6.5–12.7)	
Past 30 days injecting 4 categories								
opioids	449	10	1.9 (1.0–3.7)		449	35	7.7 (5.4–11.0)	
stimulants	17	1	5.0 (0.6–32.3)		18	4	15.9 (5.1–39.9)	
opi+stimul	33	1	5.6 (0.7–32.2)		33	3	10.4 (2.9–31.1)	
other	0	0			0	0		
Injecting drug type of choice								
opioids	475	11	2.2 (1.1–4.1)	0.7613	475	37	7.8 (5.5–11.0)	0.2542
stimulants	22	1	4.3 (0.5–27.7)		23	5	16.4 (6.1–37.3)	
other	2	0	0.0		2	0	0.0	

Table 3.5. Prevalence of Front-/back-loading and Container Sharing by Sociodemographic Characteristics

		Used front-/back-loaded syringe in the past 30 days			Used shared container in the past 30 days			
		n	% (CI)	p-value	N	n	% (CI)	p-value
Total								
	All	161	31.4 (27.1–36.1)	1.0000	500	137	25.8 (21.8–30.2)	1.0000
Sex								
	male	137	30.5 (26.0–35.5)	0.2869	435	108	23.5 (19.4–28.1)	0.0027
	female	24	37.7 (25.8–51.4)		65	29	42.5 (30.1–56.0)	
Age								
	<25	7	20.5 (8.8–40.9)	0.3304	25	7	20.5 (8.8–40.9)	0.0007
	25-34	33	35.9 (25.9–47.3)		95	40	41.3 (30.9–52.4)	
	35-44	84	33.3 (27.2–39.9)		253	67	25.8 (20.4–32.2)	
	45+	37	27.0 (19.2–36.6)		127	23	15.5 (10.1–23.1)	
Years since the start of injecting drug use								
	≤2	4	15.6 (4.9–39.7)	0.3251	18	6	22.5 (8.4–47.9)	0.3179

	Used front-/back-loaded syringe in the past 30 days			Used shared container in the past 30 days			
	n	% (CI)	p-value	N	n	% (CI)	p-value
3-5	5	25.1 (10.0–50.3)		24	10	39.8 (20.8–62.3)	
6-10	13	26.2 (14.3–43.0)		53	17	32.3 (19.4–48.5)	
≥11	139	33.3 (28.5–38.6)		405	104	24.3 (20.0–29.0)	
Partnership status							
live alone	70	29.9 (23.9–36.6)	0.5603	222	56	22.6 (17.4–28.7)	0.1786
live with partner	91	32.5 (26.6–39.1)		278	81	28.2 (22.7–34.5)	
Current employment status							
full-time	26	29.1 (19.6–40.8)	0.6494	94	25	26.0 (17.1–37.4)	0.6667
part-time or temporary	90	33.0 (27.2–39.4)		273	75	27.9 (22.4–34.2)	
unemployed	37	32.3 (23.2–43.1)		104	29	22.4 (15.4–31.5)	
disabled	3	19.6 (4.2–57.5)		10	2	11.8 (1.9–48.4)	
other	4	18.4 (5.9–44.7)		18	6	24.6 (9.6–50.1)	
Monthly income category							
<3K	23	31.5 (20.1–45.6)	0.0958	70	23	27.4 (17.6–39.9)	0.9070
3-10K	70	33.2 (26.6–40.4)		203	61	28.5 (22.4–35.5)	
10-20K	40	28.3 (20.7–37.4)		140	36	25.1 (17.9–34.0)	
≥20K	20	52.3 (34.7–69.4)		40	12	30.7 (15.9–50.9)	
Ever incarcerated							
no	94	29.1 (24.1–34.8)	0.1653	329	90	26.8 (21.9–32.3)	0.4938
yes	67	35.9 (28.2–44.5)		169	46	23.7 (17.4–31.5)	

Table 3.6. Prevalence of Front-/back-loading and Container Sharing by Selected Subgroups

	Used front-/back-loaded syringe in the past 30 days			Used shared container in the past 30 days			
	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID							
no	83	30.7 (24.7–37.3)	0.6903	264	79	27.5 (21.9–33.9)	0.3243
yes	77	32.5 (26.4–39.2)		231	56	23.3 (18.1–29.6)	
Treated with MAT currently (of all)							
no	138	30.7 (26.1–35.6)	0.8290	429	126	27.6 (23.3–32.5)	0.0644
yes	20	32.1 (21.1–45.5)		63	11	16.3 (8.9–28.1)	
HIV test result							

	Used front-/back-loaded syringe in the past 30 days			Used shared container in the past 30 days			
	n	% (CI)	p-value	N	n	% (CI)	p-value
positive	25	30.4 (20.7–42.1)	0.8416	77	19	20.6 (13.0–30.9)	0.2571
negative	136	31.6 (26.9–36.7)		423	118	26.6 (22.3–31.5)	
Past 30 days injecting 4 categories							
opioids	145	31.0 (26.5–35.9)		449	120	25.4 (21.3–30.1)	
stimulants	5	24.7 (8.9–52.4)		18	5	18.7 (6.6–42.8)	
opi+stimul	11	40.6 (22.2–62.0)		33	12	34.5 (18.9–54.4)	
other	0			0	0		
Injecting drug type of choice							
opioids	153	31.6 (27.1–36.4)	0.7219	475	127	25.6 (21.5–30.1)	0.7693
stimulants	7	26.9 (11.5–50.9)		23	9	29.1 (13.5–52.0)	
other	1	54.3 (0.0–100.0)		2	1	45.7 (0.0–100.0)	

4. Sexual Behavior

Table 4.1. Prevalence of Sexual Practice by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had sex: ever										
yes	494	98.8	(97.4–99.5)	65	100.0		429	98.7	(97.1–99.4)	0.3701
N	500			65			435			
Had sex: in the past 12 months										
yes	427	86.0	(82.2–89.1)	60	92.0	(81.7–96.8)	367	85.1	(81.0–88.5)	0.1551
N	494			65			429			
Had sex: in the past 30 days										
yes	322	65.9	(61.1–70.3)	54	81.6	(68.8–90.0)	268	63.6	(58.5–68.5)	0.0095
N	491			65			426			
Had a sex partner in the past 30 days: regular										
yes	280	87.7	(83.7–90.9)	51	95.4	(86.1–98.6)	229	86.3	(81.7–90.0)	0.0477
N	325			54			271			
Had a sex partner in the past 30 days: casual										
yes	53	15.2	(11.5–20.0)	4	5.9	(2.1–15.3)	49	16.9	(12.6–22.3)	0.0270
N	325			54			271			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	14	4.4	(2.6–7.4)	0	0.0		14	5.2	(3.0–8.7)	0.1185
N	324			54			270			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes	1	0.2	(0.0–1.4)	1	1.3	(0.2–9.0)	0	0.0		0.0186
N	325			54			271			
Used condom during last sex: if ever had sex										
yes	267	54.7	(49.7–59.6)	27	36.0	(24.8–49.0)	240	57.3	(51.9–62.5)	0.0023
N	484			65			419			
Used condom during last sex: if had sex in 12m										

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
yes	242	56.1	(50.8–61.4)	27	39.2	(26.9–52.9)	215	58.7	(52.9–64.3)	0.0082
N	424			60			364			
Used condom during last sex: if had sex in 30d										
yes	177	54.0	(47.8–60.1)	25	40.9	(27.8–55.6)	152	56.4	(49.5–63.0)	0.0552
N	322			54			268			



Figure 4.1. Frequency of sex in the past week by Drug Types Used (%)

Table 4.2. Sex Practices by Sex

	Total				Sex						
	All				female			male			
	n	%	CI		n	%	CI	n	%	CI	p-value
Had same-sex sexual experience											
yes	13	2.3	(1.3–4.1)		8	12.2	(5.7–24.2)	5	0.9	(0.4–2.3)	0.0000
N	493				65			428			
Provided sex services for money											
yes	23	3.9	(2.6–5.8)		15	19.6	(11.8–31.0)	8	1.7	(0.8–3.4)	0.0000
N	494				65			429			
Paid for sex ever											
yes	211	43.4	(38.6–48.4)		1	1.3	(0.2–8.7)	210	49.3	(44.0–54.6)	0.0000
N	494				65			429			
Had sex with a sex worker in the past 6 months											
yes	41	22.1	(16.0–29.7)		0	0.0		41	22.1	(16.0–29.8)	0.5974
N	210				1			209			
Type of partner with whom had last sex											
regular	365	76.0	(71.6–80.0)		58	92.1	(80.3–97.1)	307	73.8	(68.9–78.2)	0.0055
casual	103	20.8	(17.1–25.0)		4	6.8	(2.2–18.9)	99	22.8	(18.7–27.4)	
com. sex (I paid)	12	3.0	(1.6–5.8)		0	0.0		12	3.4	(1.8–6.5)	
com. sex (I was paid)	1	0.1	(0.0–0.9)		1	1.1	(0.1–7.6)	0	0.0		
N	481				63			418			
With whom last had sex											
man	64	12.1	(9.3–15.5)		63	96.9	(80.4–99.6)	1	0.2	(0.0–1.3)	
woman	420	87.9	(84.5–90.7)		1	3.1	(0.4–19.6)	419	99.8	(98.7–100.0)	

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
men and women	0	0.0		0	0.0		0	0.0		
N	484			64			420			
Type of last sex contact: vaginal										
yes	465	96.6	(94.5–97.8)	63	98.7	(91.1–99.8)	402	96.3	(94.0–97.7)	0.2672
N	483			64			419			
Type of last sex contact: anal										
yes	23	4.7	(3.1–7.1)	3	4.7	(1.4–14.5)	20	4.7	(2.9–7.3)	0.9797
N	483			64			419			
Type of last sex contact: oral										
yes	111	22.8	(18.9–27.2)	9	12.2	(6.1–22.6)	102	24.2	(20.0–29.1)	0.0304
N	483			64			419			

Table 4.3. Sex Partners by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had a sex partner in the past 30 days: regular										
yes	280	87.7	(83.7–90.9)	51	95.4	(86.1–98.6)	229	86.3	(81.7–90.0)	0.0477
N	325			54			271			
Had a sex partner in the past 30 days: casual										
yes	53	15.2	(11.5–20.0)	4	5.9	(2.1–15.3)	49	16.9	(12.6–22.3)	0.0270
N	325			54			271			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	14	4.4	(2.6–7.4)	0	0.0		14	5.2	(3.0–8.7)	0.1185
N	324			54			270			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes	1	0.2	(0.0–1.4)	1	1.3	(0.2–9.0)	0	0.0		0.0186
N	325			54			271			
Number of sex partners in the past 30 days: regular										
1	235	97.8	(95.3–99.0)	42	100.0		193	97.3	(94.4–98.8)	0.5183
2-4	6	1.9	(0.9–4.3)	0	0.0		6	2.3	(1.0–5.1)	
5+	1	0.3	(0.0–2.1)	0	0.0		1	0.4	(0.0–2.5)	
N	242			42			200			
Number of sex partners in the past 30 days: casual										
1	25	54.8	(39.2–69.6)	3	81.0	(29.6–97.7)	22	53.0	(36.7–68.7)	0.5618
2-4	21	43.0	(28.6–58.7)	1	19.0	(2.3–70.4)	20	44.7	(29.4–61.1)	
5+	1	2.1	(0.3–13.8)	0	0.0		1	2.3	(0.3–14.7)	
N	47			4			43			
Number of sex partners in the past 30 days: commercial (buying - I paid)										
1	5	51.1	(22.5–79.0)	0	0.0		5	51.1	(22.5–79.0)	
2-4	5	48.9	(21.0–77.5)	0	0.0		5	48.9	(21.0–77.5)	
5+	0	0.0		0	0.0		0	0.0		
N	10			0			10			
Number of sex partners in the past 30 days: total										
1	240	85.5	(80.4–89.5)	43	97.2	(89.0–99.3)	197	83.5	(77.7–88.1)	0.0280
2-4	41	13.9	(10.0–19.0)	2	2.8	(0.7–11.0)	39	15.8	(11.3–21.6)	
5+	2	0.6	(0.1–2.4)	0	0.0		2	0.7	(0.2–2.8)	
N	283			45			238			



Figure 4.2. Condom Use During Last Sexual Encounter by Type of Partner (%)



Figure 4.3. Trends in Condom Use During Last Sexual Encounter by Survey Round (%)

Table 4.4. Condom Use During Last Sexual Encounter by Sociodemographic Characteristics

			Used condom during last sex: if ever had sex				
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
Total							
	All	484	217	45.3 (40.4–50.3)	267	54.7 (49.7–59.6)	1.0000
Sex							
	male	419	179	42.7 (37.5–48.1)	240	57.3 (51.9–62.5)	0.0023
	female	65	38	64.0 (51.0–75.2)	27	36.0 (24.8–49.0)	
Age							
	<25	25	9	37.9 (17.8–63.1)	16	62.1 (36.9–82.2)	0.8722

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
25-34	92	39	44.4 (33.6–55.7)	53	55.6 (44.3–66.4)	
35-44	247	113	45.5 (38.8–52.4)	134	54.5 (47.6–61.2)	
45+	120	56	47.6 (37.4–57.9)	64	52.4 (42.1–62.6)	
Years since the start of injecting drug use						
≤2	18	8	42.4 (17.4–72.1)	10	57.6 (27.9–82.6)	0.6302
3-5	24	10	45.3 (24.8–67.5)	14	54.7 (32.5–75.2)	
6-10	53	17	35.7 (22.1–52.0)	36	64.3 (48.0–77.9)	
≥11	389	182	46.9 (41.4–52.4)	207	53.1 (47.6–58.6)	
Partnership status						
live alone	210	76	35.3 (28.7–42.6)	134	64.7 (57.4–71.3)	0.0006
live with partner	274	141	52.5 (45.8–59.2)	133	47.5 (40.8–54.2)	
Current employment status						
full-time	91	44	52.5 (41.4–63.4)	47	47.5 (36.6–58.6)	0.1126
part-time or temporary	265	109	40.9 (34.6–47.5)	156	59.1 (52.5–65.4)	
unemployed	101	46	45.0 (34.2–56.4)	55	55.0 (43.6–65.8)	
disabled	9	5	43.8 (11.2–82.7)	4	56.2 (17.3–88.8)	
other	18	13	73.7 (45.9–90.2)	5	26.3 (9.8–54.1)	
Monthly income category						
<3K	68	33	49.2 (35.5–63.0)	35	50.8 (37.0–64.5)	0.8478
3-10K	196	97	48.7 (41.1–56.4)	99	51.3 (43.6–58.9)	
10-20K	139	58	44.3 (35.3–53.6)	81	55.7 (46.4–64.7)	
≥20K	38	15	42.6 (25.4–61.9)	23	57.4 (38.1–74.6)	
Ever incarcerated						
no	320	147	46.8 (40.9–52.8)	173	53.2 (47.2–59.1)	0.5022
yes	162	70	43.1 (34.5–52.2)	92	56.9 (47.8–65.5)	

Table 4.5. Condom Use During Last Sexual Encounter by Selected Subgroups

	N	Used condom during last sex: if ever had sex				
		no		yes		
	n		% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	255	115	45.5 (38.6–52.6)	140	54.5 (47.4–61.4)	0.8596
yes	225	99	44.6 (37.7–51.7)	126	55.4 (48.3–62.3)	
Treated with MAT currently (of all)						
no	415	189	45.7 (40.4–51.1)	226	54.3 (48.9–59.6)	0.2142
yes	62	23	36.9 (25.2–50.3)	39	63.1 (49.7–74.8)	
HIV test result						
positive	73	26	32.5 (22.4–44.6)	47	67.5 (55.4–77.6)	0.0251
negative	411	191	47.3 (42.0–52.8)	220	52.7 (47.2–58.0)	
Past 30 days injecting 4 categories						
opioids	433	189	44.2 (39.1–49.5)	244	55.8 (50.5–60.9)	
stimulants	18	11	55.5 (26.9–80.9)	7	44.5 (19.1–73.1)	
opi+stimul	33	17	54.2 (34.7–72.5)	16	45.8 (27.5–65.3)	
other	0	0		0		
Injecting drug type of choice						
opioids	459	203	44.9 (39.9–50.1)	256	55.1 (49.9–60.1)	0.7255
stimulants	23	13	53.0 (28.4–76.2)	10	47.0 (23.8–71.6)	
other	2	1	54.3 (0.0–100.0)	1	45.7 (0.0–100.0)	

Table 4.6. Condom use by type of partner by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Used condom during last sex: regular partner										
yes	135	47.8	(41.2–54.5)	21	36.8	(24.0–51.7)	114	49.9	(42.5–57.3)	0.1115
N	279			51			228			
Used condom during last sex: casual partner										
yes	44	86.8	(75.2–93.4)	4	100.0		40	86.0	(73.7–93.1)	0.4499
N	52			4			48			
Used condom during last sex: commercial (I paid) partner										
yes	13	93.4	(64.7–99.1)	0	0.0		13	93.4	(64.7–99.1)	
N	14			0			14			
Condom use frequency: regular partner										
always	78	28.8	(23.0–35.3)	10	18.3	(9.7–31.8)	68	30.9	(24.3–38.3)	0.1564
often	39	12.2	(8.9–16.5)	8	14.2	(7.0–26.7)	31	11.8	(8.2–16.6)	
half	14	4.0	(2.3–6.8)	5	7.3	(2.9–17.0)	9	3.4	(1.7–6.5)	
sometimes	15	6.6	(3.7–11.4)	1	4.0	(0.5–23.7)	14	7.1	(3.9–12.6)	
rarely	28	9.5	(6.4–13.9)	3	4.1	(1.3–12.6)	25	10.6	(7.0–15.7)	
never	105	38.9	(32.5–45.7)	24	52.2	(37.0–66.9)	81	36.3	(29.4–43.9)	
N	279			51			228			
Condom use frequency: casual partner										

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
always	37	75.7	(62.5–85.4)	3	77.9	(25.7–97.3)	34	75.6	(61.7–85.6)	0.0159
often	4	6.9	(2.6–17.4)	0	0.0		4	7.4	(2.7–18.4)	
half	2	3.0	(0.7–12.0)	0	0.0		2	3.2	(0.8–12.7)	
sometimes	1	1.3	(0.2–8.8)	1	22.1	(2.7–74.3)	0	0.0		
rarely	1	1.5	(0.2–10.3)	0	0.0		1	1.6	(0.2–10.9)	
never	7	11.4	(5.4–22.7)	0	0.0		7	12.2	(5.7–24.0)	
N	52			4			48			
Condom use frequency: commercial (I paid) partner										
always	9	69.8	(42.7–87.8)	0	0.0		9	69.8	(42.7–87.8)	
often	3	19.7	(6.1–48.0)	0	0.0		3	19.7	(6.1–48.0)	
half	1	3.8	(0.5–23.5)	0	0.0		1	3.8	(0.5–23.6)	
sometimes	0	0.0		0	0.0		0	0.0		
rarely	0	0.0		0	0.0		0	0.0		
never	1	6.6	(0.9–35.3)	0	0.0		1	6.6	(0.9–35.3)	
N	14			0			14			



Figure 4.4. Frequency of condom use by type of partner by Sex (%)



Figure 4.5. Frequency of condom use among men during the last sexual encounter by the riskiest type of partner in the past 30 days (%)

5. HIV, HCV, and Syphilis Testing Results

Table 5.1. HIV Prevalence by Sociodemographic Characteristics

			HIV test result			
	N	positive		negative		
		n	% (CI)	n	% (CI)	p-value
Total						
All	500	77	13.9 (11.0–17.4)	423	86.1 (82.6–89.0)	1.0000
Sex						
male	435	69	14.4 (11.3–18.2)	366	85.6 (81.8–88.7)	0.3657
female	65	8	10.4 (5.0–20.1)	57	89.6 (79.9–95.0)	
Age						
<25	25	1	11.9 (1.6–53.0)	24	88.1 (47.0–98.4)	0.6014
25-34	95	10	9.2 (4.9–16.7)	85	90.8 (83.3–95.1)	
35-44	253	44	16.0 (11.9–21.1)	209	84.0 (78.9–88.1)	
45+	127	22	13.8 (8.9–20.7)	105	86.2 (79.3–91.1)	
Years since the start of injecting drug use						
≤2	18	2	20.0 (3.6–62.4)	16	80.0 (37.6–96.4)	0.6896
3-5	24	4	15.2 (5.2–36.8)	20	84.8 (63.2–94.8)	
6-10	53	5	8.7 (3.5–20.0)	48	91.3 (80.0–96.5)	
≥11	405	66	14.2 (11.2–17.9)	339	85.8 (82.1–88.8)	
Partnership status						
live alone	222	50	20.9 (15.7–27.2)	172	79.1 (72.8–84.3)	0.0002

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
live with partner	278	27	8.7 (5.9–12.6)	251	91.3 (87.4–94.1)	
Current employment status						
full-time	94	15	14.5 (8.7–23.3)	79	85.5 (76.7–91.3)	0.2803
part-time or temporary	273	30	10.8 (7.3–15.8)	243	89.2 (84.2–92.7)	
unemployed	104	23	17.4 (11.4–25.7)	81	82.6 (74.3–88.6)	
disabled	10	4	27.2 (6.9–65.2)	6	72.8 (34.8–93.1)	
other	18	4	19.3 (6.3–46.1)	14	80.7 (53.9–93.7)	
Monthly income category						
<3K	70	22	22.5 (14.3–33.4)	48	77.5 (66.6–85.7)	0.0286
3-10K	203	30	14.7 (10.0–21.1)	173	85.3 (78.9–90.0)	
10-20K	140	17	11.6 (7.2–18.3)	123	88.4 (81.7–92.8)	
≥20K	40	2	3.5 (0.8–13.9)	38	96.5 (86.1–99.2)	
Ever incarcerated						
no	329	39	11.7 (8.4–16.2)	290	88.3 (83.8–91.6)	0.0653
yes	169	38	18.0 (13.0–24.4)	131	82.0 (75.6–87.0)	

Table 5.2. HIV Prevalence by Selected Subgroups

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	264	26	8.5 (5.4–13.0)	238	91.5 (87.0–94.6)	0.0003
yes	231	50	20.7 (15.8–26.6)	181	79.3 (73.4–84.2)	
Treated with MAT currently (of all)						
no	429	57	12.0 (9.1–15.7)	372	88.0 (84.3–90.9)	0.0006
yes	63	19	28.8 (18.6–41.6)	44	71.2 (58.4–81.4)	
Past 30 days injecting 4 categories						
opioids	449	66	12.8 (10.0–16.1)	383	87.2 (83.9–90.0)	
stimulants	18	3	28.1 (7.4–65.9)	15	71.9 (34.1–92.6)	
opi+stimul	33	8	21.0 (9.9–39.0)	25	79.0 (61.0–90.1)	
other	0	0		0		
Injecting drug type of choice						

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
opioids	475	74	13.4 (10.7–16.7)	401	86.6 (83.3–89.3)	0.3958
stimulants	23	3	24.7 (6.7–60.1)	20	75.3 (39.9–93.3)	
other	2	0	0.0	2	100.0	



Figure 5.1. HIV Test Result (%)



Figure 5.2. Trends in HIV Prevalence by Survey Round (%)



Figure 5.3. Anti-HCV Testing Coverage In the Survey (%)



Figure 5.4. Anti-HCV Test Results (%)



Figure 5.5. Anti-HCV Test Results by Sex (%)



Figure 5.6. Trends in Anti-HCV Prevalence by Survey Round (%)



Figure 5.7. Syphilis Test Results (%)

6. HIV Prevention

Table 6.1. Being a Client of NGO by Sociodemographic Characteristics

		Client of NGO working with PWID					
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
Total							
	All	495	264	56.0 (51.1–60.7)	231	44.0 (39.3–48.9)	1.0000
Sex							
	male	431	226	55.1 (49.9–60.2)	205	44.9 (39.8–50.1)	0.2970
	female	64	38	62.5 (49.1–74.2)	26	37.5 (25.8–50.9)	
Age							

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
<25	25	20	82.7 (60.1–93.8)	5	17.3 (6.2–39.9)	0.0266
25-34	93	57	60.6 (49.5–70.8)	36	39.4 (29.2–50.5)	
35-44	252	127	53.7 (47.0–60.3)	125	46.3 (39.7–53.0)	
45+	125	60	50.5 (40.5–60.5)	65	49.5 (39.5–59.5)	
Years since the start of injecting drug use						
≤2	18	13	77.7 (49.3–92.6)	5	22.3 (7.4–50.7)	0.0288
3-5	23	17	72.3 (47.7–88.2)	6	27.7 (11.8–52.3)	
6-10	52	34	66.9 (51.8–79.2)	18	33.1 (20.8–48.2)	
≥11	402	200	52.4 (47.0–57.7)	202	47.6 (42.3–53.0)	
Partnership status						
live alone	220	111	52.8 (45.7–59.9)	109	47.2 (40.1–54.3)	0.2604
live with partner	275	153	58.3 (51.7–64.7)	122	41.7 (35.3–48.3)	
Current employment status						
full-time	93	63	66.9 (55.8–76.4)	30	33.1 (23.6–44.2)	0.2487
part-time or temporary	269	138	53.1 (46.6–59.5)	131	46.9 (40.5–53.4)	
unemployed	104	49	51.9 (41.0–62.7)	55	48.1 (37.3–59.0)	
disabled	10	5	68.8 (31.1–91.5)	5	31.2 (8.5–68.9)	
other	18	8	56.1 (29.5–79.6)	10	43.9 (20.4–70.5)	
Monthly income category						
<3K	69	24	39.6 (26.6–54.3)	45	60.4 (45.7–73.4)	0.0238
3-10K	200	104	53.6 (46.0–61.0)	96	46.4 (39.0–54.0)	
10-20K	139	84	64.7 (55.9–72.6)	55	35.3 (27.4–44.1)	
≥20K	40	22	55.4 (37.5–72.0)	18	44.6 (28.0–62.5)	
Ever incarcerated						
no	325	178	57.6 (51.8–63.3)	147	42.4 (36.7–48.2)	0.3862
yes	168	85	53.1 (44.4–61.6)	83	46.9 (38.4–55.6)	

Table 6.2. Being a Client of NGO by Selected Subgroups

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Treated with MAT currently (of all)						
no	424	250	61.5 (56.3–66.4)	174	38.5 (33.6–43.7)	0.0000
yes	63	8	11.6 (5.6–22.4)	55	88.4 (77.6–94.4)	
HIV test result						
positive	76	26	34.3 (23.2–47.4)	50	65.7 (52.6–76.8)	0.0003
negative	419	238	59.5 (54.2–64.5)	181	40.5 (35.5–45.8)	
Past 30 days injecting 4 categories						
opioids	444	233	55.3 (50.2–60.3)	211	44.7 (39.7–49.8)	
stimulants	18	16	89.7 (62.4–97.9)	2	10.3 (2.1–37.6)	
opi+stimul	33	15	45.4 (26.7–65.5)	18	54.6 (34.5–73.3)	
other	0	0		0		
Injecting drug type of choice						
opioids	471	247	55.0 (50.1–59.9)	224	45.0 (40.1–49.9)	0.0517
stimulants	23	17	77.5 (54.4–90.9)	6	22.5 (9.1–45.6)	
other	1	0	0.0	1	100.0	



Figure 6.1. Injecting and Sex Risk Perception Among HIV-negative PWID (%)



Figure 6.2. Received HIV Prevention Services in the Past 12 Months and 30 days (%)



Figure 6.3. Receiving Package of Prevention Services in the Past 12 Months (%)



Figure 6.4. Trends in Receiving HIV Prevention Services in the Past 12 Months (%)



Figure 6.5. Perceived changes in access to HIV prevention since February 2022 (%)

Table 6.3. Percentage of correct responses to knowledge questions by HIV status

	Total	HIV test result		
	All %	negative %	positive %	p-value
HIV knowledge				
HIV may be avoided	93.0	94.1	86.8	0.0953
proper condom use may prevent HIV	40.1	39.1	46.3	0.2836
undetectable=untransmittable	59.3	57.4	71.0	0.0600
PEP reduces the risk of HIV	59.0	56.8	72.6	0.0134
ART should be started immediately	89.1	87.8	97.1	0.0068

	Total	HIV test result		
	All %	negative %	positive %	p-value
ART may be postponed if one feels healthy	74.0	73.0	80.3	0.1800
ART may be stopped if one feels healthy	78.7	77.3	87.3	0.0408
HIV is transmitted through blood and sex	93.5	93.4	94.1	0.8998
HIV is transmitted via air, food, or skin	82.6	80.3	97.0	0.0001
HBV knowledge				
proper condom use may prevent HBV	87.6	88.1	84.3	0.4738
treatment should be started immediately	91.3	90.5	96.2	0.1008
treatment may be postponed if one feels healthy	76.5	75.1	85.5	0.0454
HBV is 100% transmitted from mother to child	20.1	20.1	20.1	0.9995
HBV is transmitted through blood and sex	92.5	92.4	92.9	0.8994
HBV is transmitted via air, food, or skin	72.8	71.9	77.9	0.3034
treatment may be stopped if one feels healthy	77.7	77.5	79.4	0.7568
HCV knowledge				
proper condom use may prevent HCV	4.3	4.7	1.8	0.3278
treatment should be started immediately	91.4	91.1	93.0	0.5983
treatment may be postponed if one feels healthy	81.3	79.9	89.8	0.0379
HCV is 100% transmitted from mother to child	18.1	19.0	12.3	0.1683
HCV is transmitted through blood and sex	95.1	94.8	96.4	0.5649
there is no treatment for HCV	83.8	82.1	94.4	0.0064
HCV is transmitted via air, food, or skin	88.5	87.2	96.9	0.0091
treatment may be stopped if one feels healthy	80.4	79.4	87.0	0.1371

7. HIV Testing

Table 7.1. HIV Testing Knowledge and Uptake

	n	%	CI
Know where to get HIV test			
yes	433	86.2	(81.9–89.6)
Tested for HIV ever			
yes	440	88.1	(84.6–90.9)
Tested for HIV in the past 12 months			
yes	218	55.7	(50.1–61.2)
Tested for HIV in the past 6 months			
yes	129	34.5	(29.3–40.0)
Received the result of HIV test (of those tested)			
yes	430	97.5	(94.5–98.8)
Willing to disclose HIV test result (of those who got result)			
yes	410	97.0	(94.6–98.3)
Self-reported HIV status (of all tested)			
positive	58	12.9	(9.8–16.7)
negative	358	87.1	(83.3–90.2)
HIV testing and status awareness (GAM)			
yes	227	60.7	(54.8–66.2)
Ever did a HIV self-test			
yes	0	0.0	
Regular sex partner tested for HIV			
yes	168	66.0	(58.7–72.5)
Regular sex partner HIV test result			
positive	11	7.6	(3.7–14.9)
negative	147	87.3	(79.9–92.3)
cannot disclose	9	5.1	(2.6–9.7)



Figure 7.1. HIV Testing Uptake (%)



Figure 7.2. Testing for HIV, HCV, syphilis since February 2022 (%)



Figure 7.3. HIV Testing Since February 2022 (%)

Table 7.2. Testing for HIV in the past 12 months (among all) by Sociodemographic Characteristics

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Total						
All	386	168	44.3 (38.8–49.9)	218	55.7 (50.1–61.2)	1.0000
Sex						
male	340	148	44.1 (38.2–50.1)	192	55.9 (49.9–61.8)	0.8005
female	46	20	46.3 (30.6–62.7)	26	53.7 (37.3–69.4)	
Age						
<25	11	5	47.9 (16.7–80.9)	6	52.1 (19.1–83.3)	0.8708
25-34	72	30	45.7 (33.4–58.5)	42	54.3 (41.5–66.6)	
35-44	200	87	41.9 (34.6–49.5)	113	58.1 (50.5–65.4)	
45+	103	46	47.4 (36.6–58.5)	57	52.6 (41.5–63.4)	
Years since the start of injecting drug use						
≤2	8	3	48.4 (13.0–85.5)	5	51.6 (14.5–87.0)	0.5879
3-5	13	9	66.4 (34.0–88.4)	4	33.6 (11.6–66.0)	
6-10	37	12	38.6 (22.0–58.3)	25	61.4 (41.7–78.0)	
≥11	328	144	44.0 (38.1–50.0)	184	56.0 (50.0–61.9)	
Partnership status						
live alone	174	79	45.1 (37.2–53.2)	95	54.9 (46.8–62.8)	0.8139
live with partner	212	89	43.7 (36.2–51.6)	123	56.3 (48.4–63.8)	

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Current employment status						
full-time	76	33	45.7 (33.7–58.3)	43	54.3 (41.7–66.3)	0.3583
part-time or temporary	206	91	44.0 (36.7–51.5)	115	56.0 (48.5–63.3)	
unemployed	82	33	42.0 (30.4–54.6)	49	58.0 (45.4–69.6)	
disabled	6	2	16.8 (2.4–62.7)	4	83.2 (37.3–97.6)	
other	15	8	63.5 (34.3–85.3)	7	36.5 (14.7–65.7)	
Monthly income category						
<3K	60	20	33.7 (21.6–48.4)	40	66.3 (51.6–78.4)	0.4179
3-10K	158	65	40.2 (32.2–48.9)	93	59.8 (51.1–67.8)	
10-20K	111	51	46.3 (36.3–56.7)	60	53.7 (43.3–63.7)	
≥20K	35	16	49.6 (30.9–68.3)	19	50.4 (31.7–69.1)	
Ever incarcerated						
no	239	109	46.0 (39.1–53.0)	130	54.0 (47.0–60.9)	0.4983
yes	146	59	42.0 (33.1–51.5)	87	58.0 (48.5–66.9)	

Table 7.3. Testing for HIV in the past 12 months (among all) by Selected Subgroups

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	188	112	59.9 (51.5–67.8)	76	40.1 (32.2–48.5)	0.0000
yes	195	53	26.7 (20.6–33.9)	142	73.3 (66.1–79.4)	
Treated with MAT currently (of all)						
no	324	151	47.4 (41.3–53.5)	173	52.6 (46.5–58.7)	0.0020
yes	57	14	24.0 (14.1–37.6)	43	76.0 (62.4–85.9)	
HIV test result						
positive	71	29	37.3 (26.3–49.9)	42	62.7 (50.1–73.7)	0.2285
negative	315	139	45.7 (39.6–52.0)	176	54.3 (48.0–60.4)	
Past 30 days injecting 4 categories						
opioids	351	151	44.3 (38.6–50.2)	200	55.7 (49.8–61.4)	
stimulants	9	7	59.9 (17.3–91.4)	2	40.1 (8.6–82.7)	
opi+stimul	26	10	37.2 (20.1–58.3)	16	62.8 (41.7–79.9)	

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
other	0	0		0		
Injecting drug type of choice						
opioids	372	162	44.5 (38.9–50.2)	210	55.5 (49.8–61.1)	0.7333
stimulants	13	6	42.5 (15.6–74.6)	7	57.5 (25.4–84.4)	
other	1	0	0.0	1	100.0	

8. HIV Treatment



Figure 8.1. HIV Status Awareness Among HIV+ (%)



Figure 8.2. HIV Treatment Cascade - Four-stage (%)



Figure 8.3. HIV Treatment Cascade - Conditional (%)



Figure 8.4. HIV Treatment Cascade - Proportions (%)



Figure 8.5. Trends in HIV Treatment Cascade (Conditional, 95-95-95) by Survey Round (%)

Table 8.1. HIV Treatment Cascade (Conditional, 95-95-95) by Sociodemographic Characteristics

		Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
		N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Total											
	All	77	73.6 (62.3–82.5)	1.0000	55	98.9 (92.7–99.9)	1.0000	54	46	86.7 (75.0–93.4)	1.0000
Sex											
	male	69	74.4 (62.3–83.5)	0.6147	50	98.8 (92.1–99.8)	0.7755	49	41	85.5 (72.9–92.8)	0.3780
	female	8	66.0 (30.3–89.6)		5	100.0		5	5	100.0	
Age											
	<25	1	100.0	0.6090	1	100.0	0.9011	1	1	100.0	0.6713

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
25-34	10	84.0 (52.1–96.2)		8	100.0		8	6	76.9 (39.4–94.4)	
35-44	44	72.2 (57.0–83.6)		31	98.1 (87.3–99.7)		30	27	90.1 (72.6–96.9)	
45+	22	66.3 (43.3–83.5)		15	100.0		15	12	80.6 (53.5–93.8)	
Years since the start of injecting drug use										
≤2	2	100.0	0.5594	2	100.0	0.9766	2	2	100.0	0.5248
3-5	4	61.0 (16.3–92.6)		2	100.0		2	1	57.0 (6.6–96.1)	
6-10	5	86.4 (40.2–98.4)		4	100.0		4	4	100.0	
≥11	66	71.3 (58.8–81.2)		47	98.6 (90.9–99.8)		46	39	85.5 (72.1–93.1)	
Partnership status										
live alone	50	67.9 (52.9–80.0)	0.1346	33	98.2 (87.9–99.8)	0.4177	32	27	85.7 (68.6–94.2)	0.7815
live with partner	27	83.9 (65.2–93.5)		22	100.0		22	19	88.2 (68.5–96.2)	
Current employment status										
full-time	15	62.8 (36.5–83.2)	0.2692	9	100.0	0.9340	9	9	100.0	0.6000
part-time or temporary	30	82.2 (64.8–92.1)		23	97.7 (84.6–99.7)		22	18	83.9 (62.4–94.2)	
unemployed	23	81.4 (58.7–93.1)		19	100.0		19	15	80.6 (57.5–92.7)	
disabled	4	42.6 (7.1–87.8)		2	100.0		2	2	100.0	
other	4	58.1 (14.0–92.2)		2	100.0		2	2	100.0	
Monthly income category										
<3K	22	80.1 (58.6–92.0)	0.8566	17	100.0	0.8215	17	16	94.3 (67.8–99.2)	0.2085
3-10K	30	74.8 (56.2–87.3)		21	97.5 (83.7–99.7)		20	18	90.8 (67.9–97.8)	
10-20K	17	75.1 (51.1–89.8)		12	100.0		12	9	78.9 (49.8–93.4)	
≥20K	2	100.0		2	100.0		2	1	45.7 (4.6–93.6)	
Ever incarcerated										
no	39	79.1 (63.6–89.1)	0.2445	29	98.2 (87.7–99.8)	0.4103	28	26	94.2 (79.0–98.6)	0.0495
yes	38	67.1 (50.1–80.6)		26	100.0		26	20	76.3 (55.7–89.2)	

Table 8.2. HIV Treatment Cascade (Conditional, 95-95-95) by Selected Subgroups

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID										
no	26	66.0 (44.3–82.6)	0.2568	16	96.5 (77.6–99.5)	0.1466	15	10	71.5 (42.9–89.3)	0.0363
yes	50	78.8 (65.0–88.1)		39	100.0		39	36	93.1 (80.4–97.8)	
Treated with MAT currently (of all)										
no	57	71.4 (57.9–82.0)	0.5122	39	100.0	0.1013	39	32	83.9 (68.9–92.5)	0.3006
yes	19	79.3 (54.4–92.5)		15	95.9 (74.7–99.5)		14	13	94.1 (66.6–99.2)	
HIV test result										
positive	77	73.6 (62.1–82.6)		55	98.9 (92.5–99.9)		54	46	86.7 (74.8–93.5)	
negative	0	0.0		0	0.0		0	0	0.0	
Past 30 days injecting 4 categories										
opioids	66	71.7 (59.3–81.5)		47	100.0		47	40	85.9 (72.7–93.3)	
stimulants	3	88.4 (34.1–99.1)		2	100.0		2	2	100.0	
opi+stimul	8	77.3 (38.4–94.9)		6	89.8 (48.4–98.8)		5	4	80.5 (29.6–97.6)	
other	0			0			0	0		
Injecting drug type of choice										
opioids	74	71.3 (59.7–80.7)		52	98.8 (91.8–99.8)		51	43	85.0 (72.4–92.5)	
stimulants	3	100.0		3	100.0		3	3	100.0	
other	0	0.0		0	0.0		0	0	0.0	

Table 8.3. ART adherence (among those on ART)

	n	%	CI
When did you last miss ART dose			
last week	1	1.8	(0.3–11.8)
1-2 weeks ago	2	3.3	(0.8–12.3)
3-4 weeks ago	4	7.4	(2.8–18.6)
1-3 months ago	5	8.2	(3.3–18.8)
never	44	79.3	(66.3–88.2)
What was the reason for missing the last ART dose			
forgot	8	64.6	(37.0–85.0)
did not have meds	5	35.4	(15.0–63.0)
was under influence	0	0.0	
did not want others to see	0	0.0	
other	0	0.0	
Reasons for not taking ART			
not sure it is needed	2	17.4	(4.4–49.3)
no time to visit clinic	2	16.0	(4.0–46.5)
no motivation to visit clinic	2	14.5	(3.6–43.7)
missed a visit, hard to come back	2	14.0	(3.4–43.0)
too sick to visit clinic	0	0.0	

	n	%	CI
drug use	2	17.4	(4.4–49.3)
side effects or complications	0	0.0	
no understanding of how to take it	0	0.0	
lost or sold all ARVs	0	0.0	
alcohol use	0	0.0	
waited too long and left	0	0.0	
Time on ART			
≤3m	2	16.0	(4.0–46.5)
4-24m	5	40.6	(17.9–68.2)
25-60m	3	20.9	(6.7–49.4)
5y+	3	22.5	(7.3–51.7)

9. PrEP



Figure 9.1. PrEP Uptake in the Past 12 Months (%)



Figure 9.2. Change in PrEP Awareness and Uptake from 2020 to 2023 (%)



Figure 9.3. Change in PrEP Uptake from 2020 to 2023 (%)

Table 9.1. PrEP Awareness by Sociodemographic Characteristics

		PrEP uptake in the past 12 months								
	N	use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	496	6	1.0 (0.4–2.4)	3	0.5 (0.2–1.7)	130	26.5 (22.3–31.2)	357	71.9 (67.2–76.2)	1.0000
Sex										
male	432	5	1.1 (0.4–2.6)	3	0.6 (0.2–1.9)	116	27.3 (22.8–32.4)	308	71.0 (65.9–75.7)	0.6095
female	64	1	0.9 (0.1–6.5)	0	0.0	14	20.9 (12.2–33.7)	49	78.1 (65.4–87.1)	
Age										
<25	25	0	0.0	0	0.0	4	19.9 (5.6–50.9)	21	80.1 (49.1–94.4)	
25-34	95	0	0.0	0	0.0	22	21.7 (14.1–31.7)	73	78.3 (68.3–85.9)	
35-44	250	5	1.6 (0.6–4.0)	3	1.1 (0.3–3.3)	69	27.9 (22.0–34.6)	173	69.5 (62.7–75.5)	
45+	126	1	1.0 (0.1–6.7)	0	0.0	35	29.2 (20.9–39.2)	90	69.8 (59.8–78.3)	
Years since the start of injecting drug use										
≤2	18	0	0.0	0	0.0	5	31.1 (9.9–65.1)	13	68.9 (34.9–90.1)	
3-5	24	1	5.3 (0.7–31.7)	0	0.0	6	18.4 (7.7–37.9)	17	76.3 (55.0–89.5)	
6-10	53	0	0.0	0	0.0	8	14.4 (6.9–27.8)	45	85.6 (72.2–93.1)	
≥11	401	5	1.0 (0.4–2.5)	3	0.7 (0.2–2.1)	111	28.4 (23.7–33.7)	282	69.9 (64.6–74.7)	
Partnership status										
live alone	219	3	1.1 (0.3–3.7)	1	0.4 (0.0–2.5)	54	25.0 (19.2–31.9)	161	73.5 (66.6–79.4)	0.8751
live with partner	277	3	1.0 (0.3–3.2)	2	0.7 (0.2–2.6)	76	27.7 (22.0–34.2)	196	70.7 (64.1–76.5)	
Current employment status										
full-time	94	1	1.0 (0.1–7.1)	0	0.0	26	28.0 (19.2–39.0)	67	70.9 (59.9–79.9)	
part-time or temporary	271	2	0.7 (0.2–3.0)	1	0.4 (0.0–2.5)	71	27.0 (21.3–33.5)	197	72.0 (65.4–77.7)	

		PrEP uptake in the past 12 months								
	N	use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
unemployed	102	3	2.2 (0.6–7.2)	2	1.6 (0.4–6.2)	23	24.7 (16.1–35.8)	74	71.6 (60.5–80.6)	
disabled	10	0	0.0	0	0.0	2	14.1 (2.4–52.1)	8	85.9 (47.9–97.6)	
other	18	0	0.0	0	0.0	8	33.6 (14.6–60.1)	10	66.4 (39.9–85.4)	
Monthly income category										
<3K	70	1	0.7 (0.1–5.3)	1	1.3 (0.2–8.8)	21	31.2 (19.8–45.4)	47	66.8 (52.6–78.5)	0.8545
3-10K	201	2	0.7 (0.2–3.1)	2	0.9 (0.2–3.4)	53	26.2 (20.0–33.5)	144	72.2 (64.9–78.5)	
10-20K	139	1	0.9 (0.1–6.5)	0	0.0	38	29.6 (21.4–39.4)	100	69.5 (59.6–77.8)	
≥20K	40	1	1.6 (0.2–11.3)	0	0.0	8	18.3 (8.5–35.0)	31	80.1 (63.4–90.4)	
Ever incarcerated										
no	326	3	1.0 (0.3–3.1)	3	0.8 (0.3–2.6)	84	26.1 (21.0–31.9)	236	72.1 (66.3–77.3)	0.6752
yes	168	3	1.2 (0.4–3.9)	0	0.0	45	27.1 (20.1–35.4)	120	71.7 (63.3–78.8)	

Table 9.2. PrEP Current Use by Sociodemographic Characteristics

		PrEP uptake in the past 12 months								
	N	use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										
no	263	1	0.2 (0.0–1.4)	0	0.0	46	18.4 (13.4–24.8)	216	81.4 (75.0–86.4)	0.0000
yes	228	5	2.1 (0.8–5.3)	3	1.2 (0.4–3.8)	83	37.1 (30.5–44.1)	137	59.6 (52.5–66.3)	
Treated with MAT currently (of all)										
no	428	6	1.2 (0.5–2.8)	3	0.6 (0.2–1.9)	114	27.6 (23.0–32.7)	305	70.6 (65.4–75.3)	0.5161
yes	60	0	0.0	0	0.0	15	21.5 (12.9–33.6)	45	78.5 (66.4–87.1)	
HIV test result										
positive	73	4	6.0 (2.1–15.7)	0	0.0	23	34.0 (22.6–47.6)	46	60.0 (46.7–71.9)	0.0001
negative	423	2	0.3 (0.1–1.1)	3	0.6 (0.2–1.9)	107	25.4 (21.0–30.4)	311	73.7 (68.7–78.2)	
Past 30 days injecting 4 categories										
opioids	445	4	0.8 (0.3–2.1)	3	0.6 (0.2–1.8)	123	27.8 (23.3–32.7)	315	70.9 (65.9–75.4)	
stimulants	18	1	6.4 (0.7–38.0)	0	0.0	3	25.2 (5.8–64.8)	14	68.4 (33.2–90.4)	
opi+stimul	33	1	1.7 (0.2–11.9)	0	0.0	4	10.8 (3.7–27.5)	28	87.5 (71.1–95.3)	
other	0	0		0		0		0		
Injecting drug type of choice										
opioids	471	5	0.8 (0.3–2.1)	3	0.6 (0.2–1.7)	124	26.4 (22.2–31.1)	339	72.2 (67.5–76.5)	0.5472
stimulants	23	1	5.5 (0.7–33.1)	0	0.0	6	31.0 (11.1–61.7)	16	63.5 (35.0–84.9)	
other	2	0	0.0	0	0.0	0	0.0	2	100.0	

Table 9.3. PrEP Awareness and Uptake

	n	%	CI
PrEP uptake in the past 12 months			
use now	6	1.0	(0.4–2.4)
used in the past	3	0.5	(0.2–1.7)
never used	130	26.5	(22.3–31.2)
not aware	357	71.9	(67.2–76.2)
Aware of PrEP			
no	357	71.5	(66.9–75.8)
yes	142	28.5	(24.2–33.1)
PrEP use current			
no	490	99.0	(97.6–99.6)
yes	6	1.0	(0.4–2.4)
PrEP use current (of those aware)			
no	133	96.3	(91.6–98.4)
yes	6	3.7	(1.6–8.4)

10. MAT



Figure 10.1. MAT Awareness (%)



Figure 10.2. MAT Current Uptake (%)



Figure 10.3. Trends in MAT Lifetime and Current Uptake by Survey Round (%)

Table 10.1. MAT experience

	n	%	CI
Reason for MAT discontinuation			
moved to another city	1	3.8	(0.5–22.9)
clinic closed after Feb 2022	2	7.7	(1.8–27.5)
weak or no effect	10	43.3	(25.3–63.2)
side effects	2	7.7	(1.9–26.1)
do not want to visit clinic	13	42.9	(25.6–62.1)
do not want to quit drugs	4	13.3	(5.0–31.3)
hard to get to the clinic	2	5.7	(1.4–20.5)
do not need it	1	2.6	(0.4–16.6)
do not like the attitude of physician	0	0.0	
How did the injection frequency change during MAT			
intensified	3	12.1	(3.9–32.2)
did not change	12	48.8	(29.8–68.1)
decreased	11	39.1	(22.2–59.1)

	n	%	CI
Whether bought bupr. or methadone while not being a patient in the past 12 months			
yes, methadone	326	65.6	(60.8–70.1)
yes, buprenorphine	0	0.0	
did not buy	170	34.4	(29.9–39.2)
Where bought bupr. or methadone while not being a patient in the past 12 months			
did not buy	170	34.5	(29.9–39.3)
bought from black market	317	63.9	(59.0–68.5)
bought from private clinic	8	1.6	(0.8–3.4)
Way of using bupr. or methaone bought from others			
injecting	224	69.5	(63.7–74.7)
injecting mixed	63	18.6	(14.4–23.7)
swallow or subling.	37	11.8	(8.5–16.1)
snort	1	0.2	(0.0–1.2)

Table 10.2. MAT Awareness and Uptake by Sociodemographic Characteristics

	N	take it now		took in the past		MAT uptake (of all) never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
Total										
All	492	63	12.0 (9.3–15.2)	27	5.0 (3.4–7.3)	135	27.1 (23.0–31.7)	267	55.9 (51.0–60.7)	1.0000
Sex										
male	428	55	12.1 (9.3–15.7)	26	5.5 (3.7–8.1)	120	27.8 (23.3–32.8)	227	54.6 (49.3–59.7)	0.2557
female	64	8	11.0 (5.3–21.4)	1	1.3 (0.2–8.8)	15	22.1 (13.1–34.7)	40	65.6 (52.3–76.9)	
Age										
<25	25	1	4.1 (0.5–26.4)	0	0.0	4	10.2 (3.4–26.9)	20	85.7 (66.6–94.7)	0.0515
25-34	94	9	9.6 (4.8–18.2)	2	1.7 (0.4–6.8)	29	34.1 (24.1–45.7)	54	54.6 (43.4–65.3)	
35-44	249	34	12.0 (8.6–16.6)	19	6.8 (4.3–10.6)	66	25.9 (20.4–32.4)	130	55.2 (48.4–61.8)	
45+	124	19	15.6 (9.8–23.8)	6	5.2 (2.2–11.7)	36	28.3 (20.3–38.0)	63	50.9 (41.0–60.7)	
Years since the start of injecting drug use										
≤2	18	0	0.0	0	0.0	2	12.8 (2.6–44.8)	16	87.2 (55.2–97.4)	0.0606
3-5	23	2	6.6 (1.5–25.0)	0	0.0	2	8.8 (1.9–31.9)	19	84.6 (62.7–94.7)	
6-10	53	7	13.9 (6.4–27.8)	4	5.8 (2.1–15.3)	16	33.0 (19.9–49.5)	26	47.2 (32.9–62.0)	
≥11	398	54	12.7 (9.7–16.4)	23	5.5 (3.6–8.3)	115	28.2 (23.6–33.3)	206	53.7 (48.3–59.0)	
Partnership status										

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
live alone	217	31	13.6 (9.5–19.0)	15	6.3 (3.8–10.3)	65	28.6 (22.6–35.3)	106	51.6 (44.4–58.7)	0.3618
live with partner	275	32	10.8 (7.5–15.1)	12	4.0 (2.2–7.3)	70	26.1 (20.5–32.5)	161	59.1 (52.5–65.5)	
Current employment status										
full-time	93	13	13.0 (7.4–21.6)	5	6.1 (2.4–14.7)	28	32.5 (22.6–44.3)	47	48.4 (37.5–59.5)	0.9250
part-time or temporary	268	31	11.6 (8.1–16.4)	12	4.3 (2.4–7.5)	71	25.0 (19.8–30.9)	154	59.2 (52.7–65.4)	
unemployed	102	16	13.2 (8.0–21.1)	8	6.1 (3.0–12.1)	26	27.3 (18.4–38.6)	52	53.3 (42.3–64.0)	
disabled	10	1	7.8 (0.7–49.6)	0	0.0	3	18.1 (3.9–54.8)	6	74.1 (36.2–93.5)	
other	18	2	8.7 (1.8–32.6)	2	7.2 (1.5–28.1)	6	30.5 (12.2–58.1)	8	53.6 (27.1–78.2)	
Monthly income category										
<3K	69	10	14.2 (7.4–25.5)	8	9.2 (4.5–18.2)	19	24.4 (15.3–36.6)	32	52.2 (38.8–65.3)	0.7107
3-10K	200	29	13.5 (9.4–19.2)	12	5.8 (3.2–10.3)	62	27.5 (21.6–34.2)	97	53.2 (45.6–60.6)	
10-20K	137	14	9.6 (5.6–15.8)	5	3.7 (1.5–8.9)	37	29.3 (21.3–38.7)	81	57.5 (48.1–66.3)	
≥20K	40	6	14.2 (5.7–31.1)	0	0.0	9	30.2 (14.9–51.7)	25	55.6 (36.9–72.8)	
Ever incarcerated										
no	325	39	10.9 (8.0–14.9)	17	5.0 (3.1–8.1)	88	26.4 (21.6–31.9)	181	57.6 (51.7–63.3)	0.7675
yes	165	23	13.5 (8.8–20.0)	10	5.0 (2.6–9.4)	47	28.7 (21.4–37.3)	85	52.8 (44.1–61.3)	

Table 10.3. MAT Awareness and Uptake by Selected Subgroups

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
Client of NGO working with PWID										
no	258	8	2.5 (1.2–5.1)	11	4.2 (2.3–7.7)	70	26.1 (20.5–32.7)	169	67.1 (60.4–73.3)	0.0000
yes	229	55	23.9 (18.6–30.3)	15	5.6 (3.4–9.3)	62	27.9 (22.1–34.5)	97	42.6 (35.8–49.6)	
Treated with MAT currently (of all)										
no	429	0	0.0	27	5.7 (3.8–8.3)	135	30.8 (26.2–35.9)	267	63.5 (58.3–68.4)	0.0000

	N	MAT uptake (of all)								
		take it now		took in the past		never took but plan to		unaware or do not plan to		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
yes	63	63	100.0	0	0.0	0	0.0	0	0.0	
HIV test result										
positive	76	19	24.5 (15.8–36.1)	5	6.7 (2.7–15.9)	23	28.9 (19.4–40.7)	29	39.8 (28.2–52.7)	0.0026
negative	416	44	9.9 (7.3–13.3)	22	4.7 (3.1–7.2)	112	26.8 (22.3–31.9)	238	58.5 (53.2–63.6)	
Past 30 days injecting 4 categories										
opioids	442	59	12.5 (9.7–16.1)	25	5.2 (3.5–7.8)	120	27.3 (22.9–32.2)	238	54.9 (49.8–60.0)	
stimulants	18	0	0.0	1	3.9 (0.4–26.7)	2	10.3 (2.1–37.6)	15	85.9 (59.6–96.2)	
opi+stimul	32	4	11.4 (4.0–28.2)	1	2.2 (0.3–14.9)	13	35.6 (20.5–54.3)	14	50.8 (32.6–68.8)	
other	0	0		0		0		0		
Injecting drug type of choice										
opioids	467	62	12.4 (9.6–15.8)	24	4.8 (3.2–7.2)	126	27.1 (22.8–31.8)	255	55.7 (50.7–60.6)	0.1040
stimulants	23	1	4.1 (0.5–26.9)	2	6.1 (1.3–23.9)	8	27.0 (12.0–50.1)	12	62.7 (38.9–81.6)	
other	2	0	0.0	1	54.3 (0.0–100.0)	1	45.7 (0.0–100.0)	0	0.0	



Figure 10.4. Buying MAT medications while not being a patient (%)



Figure 10.5. Source of buying MAT medications while not being a patient (%)



Figure 10.6. Route of administration of MAT medications bought from others (%)

11. Overdose and Naloxone



Figure 11.1. Overdose Experience Ever and in the Past 12 Months (%)



Figure 11.2. Trends in Overdose Experience in the Past 12 Months by Survey Round (%)



Figure 11.3. Drugs causing overdoses (if used only one drug) (%)



Figure 11.4. Naloxone Use (%)

Table 11.1. Overdose Experience

		n	%	CI
Experienced overdose ever				
	yes	224	46.0	(41.1–50.9)
Number of overdoses in lifetime				
	1	79	33.8	(27.3–40.9)
	2-4	111	52.5	(45.1–59.8)
	5+	30	13.7	(9.3–19.8)
Experienced overdose in the past 12 months				
	yes	28	5.7	(3.9–8.3)
Experienced overdose in the past 12 months (of those ever)				
	yes	28	12.4	(8.5–17.8)
Number of overdoses in the past 12 months				
	1	18	69.9	(49.6–84.5)
	2-4	8	27.8	(13.7–48.3)
	5+	1	2.3	(0.3–15.0)

	n	%	CI
Drug overdosed with (if used only one drug)			
methadone	12	80.0	(51.5–93.8)
other opioid	0	0.0	
stimulant	3	20.0	(6.2–48.5)
other	0	0.0	
Drugs overdosed with (if used a combination)			
methadone+stimulant	1	14.8	(1.9–60.6)
methadone+barbit. or dimedr.	4	63.1	(22.5–90.9)
methadone+other	1	22.1	(3.1–71.5)
other	0	0.0	
Drug overdosed with (if combined drug with alcohol)			
methadone	5	75.4	(36.3–94.3)
other opioid	1	14.7	(2.0–59.3)
stimulant	1	10.0	(1.3–48.3)
other	0	0.0	
Naloxone knowledge and experience			
never heard	79	17.0	(13.5–21.2)
aware but not used	331	63.9	(58.9–68.5)
used myself	49	10.4	(7.7–14.1)
my friends used	31	6.3	(4.3–9.0)
me and my friends used	10	2.4	(1.2–4.6)

Table 11.2. Overdose Experience in the Past 12 Months by Sociodemographic Characteristics

		Experienced overdose in the past 12 months				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
Total						
All	499	471	94.3 (91.7–96.1)	28	5.7 (3.9–8.3)	1.0000
Sex						
male	434	408	93.9 (90.9–95.9)	26	6.1 (4.1–9.1)	0.2034
female	65	63	97.5 (89.9–99.4)	2	2.5 (0.6–10.1)	
Age						
<25	25	25	100.0	0	0.0	0.1451
25-34	95	85	90.7 (83.0–95.1)	10	9.3 (4.9–17.0)	
35-44	252	238	93.5 (89.0–96.3)	14	6.5 (3.7–11.0)	
45+	127	123	97.1 (92.2–98.9)	4	2.9 (1.1–7.8)	
Years since the start of injecting drug use						
≤2	18	18	100.0	0	0.0	0.6938
3-5	24	22	93.7 (75.3–98.6)	2	6.3 (1.4–24.7)	
6-10	53	49	94.7 (86.1–98.1)	4	5.3 (1.9–13.9)	
≥11	404	382	94.0 (90.8–96.1)	22	6.0 (3.9–9.2)	
Partnership status						

	N	Experienced overdose in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
live alone	222	208	92.9 (88.0–95.9)	14	7.1 (4.1–12.0)	0.2729
live with partner	277	263	95.4 (92.1–97.3)	14	4.6 (2.7–7.9)	
Current employment status						
full-time	94	90	95.5 (87.4–98.5)	4	4.5 (1.5–12.6)	0.5062
part-time or temporary	273	260	95.2 (91.7–97.3)	13	4.8 (2.7–8.3)	
unemployed	104	95	91.1 (83.1–95.5)	9	8.9 (4.5–16.9)	
disabled	10	10	100.0	0	0.0	
other	17	15	89.7 (61.4–97.9)	2	10.3 (2.1–38.6)	
Monthly income category						
<3K	70	67	97.0 (90.6–99.1)	3	3.0 (0.9–9.4)	0.0552
3-10K	203	186	90.5 (84.8–94.2)	17	9.5 (5.8–15.2)	
10-20K	140	134	96.0 (90.9–98.3)	6	4.0 (1.7–9.1)	
≥20K	40	39	97.6 (84.0–99.7)	1	2.4 (0.3–16.0)	
Ever incarcerated						
no	328	312	95.2 (92.0–97.1)	16	4.8 (2.9–8.0)	0.2874
yes	169	157	92.7 (87.0–96.0)	12	7.3 (4.0–13.0)	

Table 11.3. Overdose Experience in the Past 12 Months by Selected Subgroups

	N	Experienced overdose in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	264	252	95.3 (91.5–97.4)	12	4.7 (2.6–8.5)	0.3008
yes	230	214	92.9 (88.5–95.7)	16	7.1 (4.3–11.5)	
Treated with MAT currently (of all)						
no	428	403	94.0 (91.1–96.1)	25	6.0 (3.9–8.9)	0.7197
yes	63	60	95.2 (85.8–98.5)	3	4.8 (1.5–14.2)	
HIV test result						
positive	76	71	93.6 (85.1–97.4)	5	6.4 (2.6–14.9)	0.7725
negative	423	400	94.4 (91.5–96.4)	23	5.6 (3.6–8.5)	
Past 30 days injecting 4 categories						
opioids	448	428	95.5 (92.9–97.2)	20	4.5 (2.8–7.1)	

	N	Experienced overdose in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
stimulants	18	16	90.8 (63.9–98.2)	2	9.2 (1.8–36.1)	
opi+stimul	33	27	80.2 (60.0–91.6)	6	19.8 (8.4–40.0)	
other	0	0		0		
Injecting drug type of choice						
opioids	474	449	94.5 (91.8–96.4)	25	5.5 (3.6–8.2)	0.5008
stimulants	23	20	89.3 (67.3–97.1)	3	10.7 (2.9–32.7)	
other	2	2	100.0	0	0.0	

Table 11.4. Naloxone Experience by Sociodemographic Characteristics

	N	Naloxone knowledge and experience (3 categories)						
		unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total								
All	500	79	17.0 (13.5–21.2)	362	70.1 (65.3–74.6)	59	12.9 (9.8–16.7)	1.0000
Sex								
male	435	68	17.1 (13.3–21.7)	313	69.2 (63.9–74.0)	54	13.7 (10.3–18.0)	0.2495
female	65	11	16.2 (8.9–27.8)	49	77.2 (65.0–86.1)	5	6.5 (2.6–15.3)	
Age								
<25	25	10	39.8 (19.3–64.6)	15	60.2 (35.4–80.7)	0	0.0	0.0809
25-34	95	13	16.4 (8.8–28.3)	70	71.2 (59.5–80.7)	12	12.4 (6.9–21.3)	
35-44	253	41	16.5 (12.1–21.9)	177	68.2 (61.5–74.3)	35	15.3 (10.8–21.3)	
45+	127	15	13.2 (7.4–22.4)	100	75.3 (64.8–83.5)	12	11.5 (6.0–20.9)	
Years since the start of injecting drug use								
≤2	18	10	54.4 (25.6–80.5)	8	45.6 (19.5–74.4)	0	0.0	0.0013
3-5	24	6	22.9 (9.2–46.5)	18	77.1 (53.5–90.8)	0	0.0	
6-10	53	11	23.0 (11.7–40.2)	38	68.4 (51.7–81.4)	4	8.6 (3.0–22.5)	
≥11	405	52	13.8 (10.4–18.1)	298	71.3 (66.0–76.1)	55	14.9 (11.2–19.5)	
Partnership status								
live alone	222	35	18.6 (13.3–25.5)	163	71.0 (63.8–77.3)	24	10.3 (6.9–15.3)	0.3808
live with partner	278	44	15.8 (11.4–21.4)	199	69.5 (62.7–75.5)	35	14.8 (10.3–20.7)	
Current employment status								
full-time	94	17	21.5 (12.9–33.5)	61	60.4 (48.7–70.9)	16	18.2 (11.0–28.4)	0.7604

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
part-time or temporary	273	39	15.0 (10.8–20.6)	207	73.3 (66.8–78.9)	27	11.6 (7.8–17.1)	
unemployed	104	16	17.4 (10.2–28.1)	76	70.3 (58.6–79.8)	12	12.3 (6.3–22.9)	
disabled	10	3	19.6 (4.2–57.5)	6	72.6 (34.2–93.1)	1	7.8 (0.7–49.6)	
other	18	4	19.9 (6.6–46.9)	11	68.7 (41.9–87.0)	3	11.4 (3.1–34.1)	
Monthly income category								
<3K	70	9	10.3 (5.1–19.7)	50	71.6 (57.5–82.4)	11	18.1 (9.1–32.7)	0.7143
3-10K	203	21	12.1 (7.6–18.8)	157	74.5 (67.1–80.8)	25	13.3 (9.0–19.4)	
10-20K	140	25	18.4 (12.4–26.6)	101	69.5 (60.0–77.5)	14	12.1 (6.7–21.1)	
≥20K	40	4	18.0 (5.9–43.4)	30	69.4 (48.4–84.6)	6	12.6 (5.3–27.1)	
Ever incarcerated								
no	329	51	16.1 (12.2–21.1)	247	72.7 (66.9–77.8)	31	11.2 (7.7–16.0)	0.2824
yes	169	28	18.8 (12.5–27.3)	113	65.1 (56.2–73.1)	28	16.1 (10.7–23.5)	

Table 11.5. Naloxone Experience by Selected Subgroups

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID								
no	264	63	24.8 (19.2–31.4)	182	66.5 (59.5–72.9)	19	8.6 (5.1–14.2)	0.0000
yes	231	15	7.0 (4.1–11.8)	176	74.5 (67.9–80.2)	40	18.5 (13.6–24.6)	
Treated with MAT currently (of all)								
no	429	71	18.1 (14.1–22.8)	307	69.5 (64.2–74.2)	51	12.5 (9.3–16.5)	0.1012
yes	63	5	7.4 (3.0–17.0)	51	80.9 (68.8–89.0)	7	11.7 (5.6–23.0)	
HIV test result								
positive	77	10	16.4 (7.9–30.9)	57	72.0 (58.7–82.4)	10	11.6 (6.1–20.7)	0.9265
negative	423	69	17.1 (13.4–21.6)	305	69.8 (64.5–74.6)	49	13.1 (9.7–17.4)	
Past 30 days injecting 4 categories								
opioids	449	65	15.2 (11.8–19.4)	332	72.6 (67.7–77.0)	52	12.2 (9.1–16.0)	
stimulants	18	9	59.9 (32.7–82.1)	9	40.1 (17.9–67.3)	0	0.0	
opi+stimul	33	5	15.9 (6.0–36.1)	21	54.3 (34.0–73.3)	7	29.8 (13.2–54.1)	
other	0	0		0		0		
Injecting drug type of choice								

	N	Naloxone knowledge and experience (3 categories)						
		unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
opioids	475	71	15.6 (12.3–19.8)	346	71.0 (66.1–75.4)	58	13.4 (10.2–17.4)	0.0062
stimulants	23	8	46.7 (23.3–71.6)	14	50.5 (26.7–74.2)	1	2.8 (0.3–19.7)	
other	2	0	0.0	2	100.0	0	0.0	

12. Physical and Mental Health

Table 12.1. Disease and treatment history

		n	%	CI
Had a disease				
	hepatitis B	79	16.3	(13.0–20.3)
	hepatitis C	229	47.9	(42.9–52.9)
	syphilis	14	2.2	(1.3–3.8)
	gonorrhea	61	11.2	(8.5–14.5)
	chlamydia	29	5.0	(3.4–7.3)
	herpes	84	16.4	(13.1–20.2)
	human papillomavirus	14	3.2	(1.7–5.9)
	tuberculosis	33	7.4	(5.0–10.8)
Treated for: hepatitis B				
	treated successfully	50	64.4	(52.3–74.9)
	treated unsuccessfully	4	6.3	(2.3–16.5)
	did not complete	6	9.0	(4.1–18.9)
	treated now	3	3.1	(1.0–9.3)
	never treated	15	17.1	(10.1–27.5)
Treated for: hepatitis C				
	treated successfully	72	30.0	(24.1–36.7)
	treated unsuccessfully	21	10.2	(6.3–16.0)
	did not complete	14	6.7	(3.6–12.0)
	treated now	16	6.5	(3.9–10.7)
	never treated	106	46.6	(39.5–53.8)
Treated for: syphilis				
	treated successfully	14	100.0	
	treated unsuccessfully	0	0.0	
	did not complete	0	0.0	
	treated now	0	0.0	
	never treated	0	0.0	
Treated for: tuberculosis				
	treated successfully	29	83.1	(57.3–94.8)
	treated unsuccessfully	2	12.3	(2.6–42.5)
	did not complete	0	0.0	
	treated now	2	4.6	(1.1–17.2)
	never treated	0	0.0	

Table 12.2. Mental health screening scores

	n	Mean	CI	Median	IQR
AUDIT-C alcohol risk score ≥5	4,874	1.2	(1.2–1.2)	1	(1–1)
PHQ-9 depression result	5,002	2.2	(2.2–2.3)	2	(1–3)
GAD-7 anxiety result	5,002	1.9	(1.9–1.9)	2	(1–2)

Table 12.3. Health care utilization

	n	%	CI
Had problems with health besides drugs which required medical attention in the past 12 months			
yes	171	34.1	(29.6–38.8)
Referred to a health care facility for treatment in the past 12 months			
yes	135	28.3	(23.9–33.0)
Referred to a health care facility			
primary care	72	53.4	(43.7–62.8)
hospital, HIV clinic	58	43.7	(34.5–53.3)
private clinic	14	7.7	(4.5–12.9)
private lab	2	1.1	(0.3–4.5)
TB dispensary	2	3.2	(0.7–14.4)
drug clinic	0	0.0	
STI clinic	1	0.5	(0.1–3.7)
ambulance	8	6.0	(2.8–12.3)
mobile clinic	0	0.0	
other	1	0.5	(0.1–3.7)
Last health care facility referred to			
primary care	63	47.6	(38.1–57.3)
hospital, HIV clinic	51	39.3	(30.4–49.1)
private clinic	13	7.1	(4.0–12.1)
private lab	2	1.1	(0.3–4.5)
TB dispensary	1	2.6	(0.4–16.0)
drug clinic	0	0.0	
STI clinic	1	0.5	(0.1–3.8)
ambulance	3	1.7	(0.6–5.4)
mobile clinic	0	0.0	
other	0	0.0	
Received necessary care in health care facility			
yes	124	91.4	(83.2–95.8)
Signed a declaration with primary care physician			
yes	413	83.3	(79.5–86.5)
How frequently saw the primary care physician			
twice per month or more	8	2.4	(1.2–4.9)
once per month	54	12.5	(9.5–16.2)
3-4 times in 12 months	84	20.5	(16.4–25.3)
only once	245	64.6	(59.2–69.6)



Figure 12.1. Risky alcohol use (AUDIT-C score > 5) (%)



Figure 12.2. Depression symptoms severity (PHQ-9) (%)



Figure 12.3. Anxiety symptoms severity (GAD-7) (%)

Table 12.4. Risky alcohol use (AUDIT-C score > 5) by Sociodemographic Characteristics

		AUDIT-C alcohol risk score ≥5					
	N		no		yes	
		n	% (CI)	n	% (CI)	p-value
Total						
All	490	438	89.0 (85.3–91.8)	52	11.0 (8.2–14.7)	1.0000
Sex						
male	425	379	89.3 (85.7–92.2)	46	10.7 (7.8–14.3)	0.5957
female	65	59	86.2 (68.8–94.7)	6	13.8 (5.3–31.2)	
Age						
<25	24	23	86.5 (43.5–98.1)	1	13.5 (1.9–56.5)	0.4111
25-34	94	80	83.2 (71.5–90.7)	14	16.8 (9.3–28.5)	
35-44	247	220	89.6 (85.0–92.9)	27	10.4 (7.1–15.0)	
45+	125	115	92.6 (86.4–96.1)	10	7.4 (3.9–13.6)	
Years since the start of injecting drug use						
≤2	17	14	65.8 (29.8–89.7)	3	34.2 (10.3–70.2)	0.0139
3-5	24	24	100.0	0	0.0	
6-10	52	43	81.0 (63.2–91.4)	9	19.0 (8.6–36.8)	
≥11	397	357	90.5 (87.1–93.0)	40	9.5 (7.0–12.9)	
Partnership status						
live alone	218	195	89.5 (84.4–93.1)	23	10.5 (6.9–15.6)	0.7586
live with partner	272	243	88.5 (83.0–92.4)	29	11.5 (7.6–17.0)	
Current employment status						

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
full-time	94	81	83.8 (72.1–91.2)	13	16.2 (8.8–27.9)	0.1399
part-time or temporary	266	242	91.5 (87.5–94.3)	24	8.5 (5.7–12.5)	
unemployed	103	91	89.1 (81.0–94.0)	12	10.9 (6.0–19.0)	
disabled	9	9	100.0	0	0.0	
other	17	14	72.6 (33.0–93.4)	3	27.4 (6.6–67.0)	
Monthly income category						
<3K	69	60	89.6 (80.3–94.8)	9	10.4 (5.2–19.7)	0.4264
3-10K	198	177	88.5 (82.1–92.9)	21	11.5 (7.1–17.9)	
10-20K	138	126	91.4 (85.2–95.2)	12	8.6 (4.8–14.8)	
≥20K	40	35	80.5 (56.1–93.0)	5	19.5 (7.0–43.9)	
Ever incarcerated						
no	321	286	88.7 (84.1–92.1)	35	11.3 (7.9–15.9)	0.8593
yes	167	150	89.3 (82.3–93.8)	17	10.7 (6.2–17.7)	

Table 12.5. Risky alcohol use (AUDIT-C score > 5) by Selected Subgroups

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	261	228	86.5 (80.7–90.7)	33	13.5 (9.3–19.3)	0.0429
yes	224	207	92.7 (88.3–95.5)	17	7.3 (4.5–11.7)	
Treated with MAT currently (of all)						
no	420	372	88.0 (83.9–91.2)	48	12.0 (8.8–16.1)	0.1786
yes	62	58	93.8 (84.3–97.7)	4	6.2 (2.3–15.7)	
HIV test result						
positive	74	70	94.6 (86.3–98.0)	4	5.4 (2.0–13.7)	0.1024
negative	416	368	88.1 (84.0–91.3)	48	11.9 (8.7–16.0)	
Past 30 days injecting 4 categories						
opioids	441	403	90.5 (86.6–93.3)	38	9.5 (6.7–13.4)	
stimulants	17	13	78.6 (51.8–92.7)	4	21.4 (7.3–48.2)	
opi+stimul	32	22	73.7 (54.9–86.6)	10	26.3 (13.4–45.1)	
other	0	0		0		

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Injecting drug type of choice						
opioids	466	421	89.6 (85.9–92.5)	45	10.4 (7.5–14.1)	0.0287
stimulants	22	16	74.9 (51.8–89.2)	6	25.1 (10.8–48.2)	
other	2	1	54.3 (0.0–100.0)	1	45.7 (0.0–100.0)	

Table 12.6. Depression symptoms severity (PHQ-9) by Sociodemographic Characteristics

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	222	44.0 (39.3–48.9)	210	42.0 (37.3–46.9)	53	11.1 (8.3–14.7)	15	2.9 (1.7–4.9)	1.0000
Sex										
male	435	190	42.9 (37.8–48.2)	186	42.9 (37.8–48.2)	45	11.0 (8.0–15.0)	14	3.1 (1.8–5.4)	0.4764
female	65	32	52.1 (38.8–65.2)	24	35.3 (23.9–48.7)	8	11.3 (5.5–21.9)	1	1.3 (0.2–8.7)	
Age										
<25	25	17	62.9 (37.3–82.9)	8	37.1 (17.1–62.7)	0	0.0	0	0.0	0.1816
25-34	95	45	44.8 (34.3–55.7)	35	39.6 (29.2–50.9)	9	10.1 (5.1–18.9)	6	5.6 (2.4–12.3)	
35-44	253	116	46.5 (39.9–53.3)	104	40.3 (34.0–47.1)	28	10.6 (7.3–15.3)	5	2.5 (1.0–6.3)	
45+	127	44	34.2 (25.5–44.1)	63	48.2 (38.4–58.1)	16	15.3 (8.6–25.8)	4	2.3 (0.8–6.2)	
Years since the start of injecting drug use										
≤2	18	12	60.2 (29.2–84.7)	5	31.3 (10.0–65.1)	1	8.5 (1.0–45.9)	0	0.0	0.5997
3-5	24	15	56.6 (33.9–76.8)	7	36.7 (17.8–60.8)	1	2.7 (0.3–18.8)	1	4.0 (0.5–25.7)	
6-10	53	28	52.0 (37.0–66.5)	20	39.2 (25.4–54.9)	3	5.4 (1.7–16.3)	2	3.5 (0.8–14.2)	
≥11	405	167	41.3 (36.1–46.7)	178	43.3 (38.1–48.7)	48	12.5 (9.2–16.8)	12	2.9 (1.6–5.3)	
Partnership status										
live alone	222	85	36.1 (29.7–43.1)	99	47.0 (40.0–54.2)	28	12.4 (8.5–17.7)	10	4.4 (2.3–8.4)	0.0267
live with partner	278	137	50.0 (43.3–56.6)	111	38.2 (32.1–44.8)	25	10.1 (6.4–15.5)	5	1.7 (0.7–4.5)	
Current employment status										
full-time	94	56	57.9 (46.5–68.4)	32	35.2 (25.2–46.7)	4	4.7 (1.7–12.2)	2	2.2 (0.5–8.8)	0.0008
part-time or temporary	273	120	43.7 (37.3–50.2)	120	44.8 (38.5–51.4)	25	8.3 (5.6–12.2)	8	3.2 (1.5–6.7)	
unemployed	104	36	35.4 (25.6–46.6)	47	44.7 (34.1–55.9)	17	16.9 (9.8–27.4)	4	3.0 (1.1–7.9)	
disabled	10	3	21.9 (4.9–60.4)	4	24.9 (6.2–62.5)	3	53.2 (17.0–86.3)	0	0.0	
other	18	7	48.7 (22.8–75.4)	6	27.1 (10.7–53.5)	4	20.9 (6.8–48.7)	1	3.3 (0.4–23.3)	
Monthly income category										

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
<3K	70	15	20.9 (12.3–33.3)	37	56.3 (42.5–69.1)	14	18.6 (9.8–32.3)	4	4.3 (1.5–11.4)	0.0390
3-10K	203	87	43.1 (35.9–50.7)	89	42.7 (35.4–50.2)	23	11.7 (7.4–17.9)	4	2.5 (0.9–7.2)	
10-20K	140	72	51.9 (42.7–60.9)	56	39.0 (30.6–48.1)	9	7.3 (3.7–13.9)	3	1.8 (0.6–5.7)	
≥20K	40	19	41.7 (25.8–59.5)	16	43.8 (26.9–62.4)	3	9.4 (2.8–27.5)	2	5.0 (1.1–19.5)	
Ever incarcerated										
no	329	167	50.4 (44.6–56.3)	125	38.0 (32.5–43.9)	26	8.0 (5.4–11.7)	11	3.5 (1.9–6.5)	0.0005
yes	169	54	32.2 (24.8–40.7)	84	49.2 (40.6–57.9)	27	16.8 (10.9–24.9)	4	1.8 (0.6–4.7)	

Table 12.7. Depression symptoms severity (PHQ-9) by Selected Subgroups

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	222	44.0 (39.3–48.9)	210	42.0 (37.3–46.9)	53	11.1 (8.3–14.7)	15	2.9 (1.7–4.9)	1.0000
Sex										
male	435	190	42.9 (37.8–48.2)	186	42.9 (37.8–48.2)	45	11.0 (8.0–15.0)	14	3.1 (1.8–5.4)	0.4764
female	65	32	52.1 (38.8–65.2)	24	35.3 (23.9–48.7)	8	11.3 (5.5–21.9)	1	1.3 (0.2–8.7)	
Age										
<25	25	17	62.9 (37.3–82.9)	8	37.1 (17.1–62.7)	0	0.0	0	0.0	0.1816
25-34	95	45	44.8 (34.3–55.7)	35	39.6 (29.2–50.9)	9	10.1 (5.1–18.9)	6	5.6 (2.4–12.3)	
35-44	253	116	46.5 (39.9–53.3)	104	40.3 (34.0–47.1)	28	10.6 (7.3–15.3)	5	2.5 (1.0–6.3)	
45+	127	44	34.2 (25.5–44.1)	63	48.2 (38.4–58.1)	16	15.3 (8.6–25.8)	4	2.3 (0.8–6.2)	
Years since the start of injecting drug use										
≤2	18	12	60.2 (29.2–84.7)	5	31.3 (10.0–65.1)	1	8.5 (1.0–45.9)	0	0.0	0.5997
3-5	24	15	56.6 (33.9–76.8)	7	36.7 (17.8–60.8)	1	2.7 (0.3–18.8)	1	4.0 (0.5–25.7)	
6-10	53	28	52.0 (37.0–66.5)	20	39.2 (25.4–54.9)	3	5.4 (1.7–16.3)	2	3.5 (0.8–14.2)	
≥11	405	167	41.3 (36.1–46.7)	178	43.3 (38.1–48.7)	48	12.5 (9.2–16.8)	12	2.9 (1.6–5.3)	
Partnership status										
live alone	222	85	36.1 (29.7–43.1)	99	47.0 (40.0–54.2)	28	12.4 (8.5–17.7)	10	4.4 (2.3–8.4)	0.0267
live with partner	278	137	50.0 (43.3–56.6)	111	38.2 (32.1–44.8)	25	10.1 (6.4–15.5)	5	1.7 (0.7–4.5)	
Current employment status										
full-time	94	56	57.9 (46.5–68.4)	32	35.2 (25.2–46.7)	4	4.7 (1.7–12.2)	2	2.2 (0.5–8.8)	0.0008
part-time or temporary	273	120	43.7 (37.3–50.2)	120	44.8 (38.5–51.4)	25	8.3 (5.6–12.2)	8	3.2 (1.5–6.7)	
unemployed	104	36	35.4 (25.6–46.6)	47	44.7 (34.1–55.9)	17	16.9 (9.8–27.4)	4	3.0 (1.1–7.9)	
disabled	10	3	21.9 (4.9–60.4)	4	24.9 (6.2–62.5)	3	53.2 (17.0–86.3)	0	0.0	

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
other	18	7	48.7 (22.8–75.4)	6	27.1 (10.7–53.5)	4	20.9 (6.8–48.7)	1	3.3 (0.4–23.3)	
Monthly income category										
<3K	70	15	20.9 (12.3–33.3)	37	56.3 (42.5–69.1)	14	18.6 (9.8–32.3)	4	4.3 (1.5–11.4)	0.0390
3-10K	203	87	43.1 (35.9–50.7)	89	42.7 (35.4–50.2)	23	11.7 (7.4–17.9)	4	2.5 (0.9–7.2)	
10-20K	140	72	51.9 (42.7–60.9)	56	39.0 (30.6–48.1)	9	7.3 (3.7–13.9)	3	1.8 (0.6–5.7)	
≥20K	40	19	41.7 (25.8–59.5)	16	43.8 (26.9–62.4)	3	9.4 (2.8–27.5)	2	5.0 (1.1–19.5)	
Ever incarcerated										
no	329	167	50.4 (44.6–56.3)	125	38.0 (32.5–43.9)	26	8.0 (5.4–11.7)	11	3.5 (1.9–6.5)	0.0005
yes	169	54	32.2 (24.8–40.7)	84	49.2 (40.6–57.9)	27	16.8 (10.9–24.9)	4	1.8 (0.6–4.7)	

Table 12.8. Anxiety symptoms severity (GAD-7) by Sociodemographic Characteristics

	N	GAD-7 anxiety result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	274	54.0 (49.1–58.9)	197	39.6 (34.9–44.5)	26	5.9 (3.8–8.9)	3	0.5 (0.2–1.5)	1.0000
Sex										
male	435	238	53.4 (48.1–58.6)	173	40.3 (35.2–45.6)	22	6.0 (3.7–9.4)	2	0.4 (0.1–1.6)	0.6357
female	65	36	58.9 (45.5–71.0)	24	34.8 (23.6–48.0)	4	5.1 (1.8–13.9)	1	1.3 (0.2–8.7)	
Age										
<25	25	20	77.0 (47.6–92.5)	5	23.0 (7.5–52.4)	0	0.0	0	0.0	0.2763
25-34	95	58	60.0 (48.7–70.3)	31	33.6 (23.8–45.0)	4	4.6 (1.7–11.9)	2	1.8 (0.4–7.1)	
35-44	253	131	51.5 (44.8–58.2)	105	41.8 (35.3–48.6)	16	6.4 (3.8–10.6)	1	0.3 (0.0–2.2)	
45+	127	65	49.1 (39.2–59.0)	56	43.7 (34.1–53.8)	6	7.2 (2.8–17.2)	0	0.0	
Years since the start of injecting drug use										
≤2	18	11	57.7 (27.7–82.9)	7	42.3 (17.1–72.3)	0	0.0	0	0.0	0.1382
3-5	24	18	78.4 (56.8–90.9)	4	14.9 (5.1–36.2)	1	2.7 (0.3–18.8)	1	4.0 (0.5–25.7)	
6-10	53	33	59.6 (43.9–73.6)	18	36.9 (23.3–53.0)	2	3.5 (0.8–14.2)	0	0.0	
≥11	405	212	51.6 (46.2–57.0)	168	41.3 (36.1–46.7)	23	6.7 (4.2–10.4)	2	0.4 (0.1–1.5)	
Partnership status										
live alone	222	109	48.3 (41.2–55.4)	99	45.1 (38.0–52.3)	13	6.3 (3.6–10.9)	1	0.4 (0.0–2.5)	0.1988
live with partner	278	165	58.3 (51.6–64.8)	98	35.5 (29.4–42.2)	13	5.5 (2.9–10.3)	2	0.6 (0.1–2.4)	
Current employment status										

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
full-time	94	61	60.8 (49.1–71.3)	29	34.3 (24.2–46.2)	3	4.1 (1.3–12.0)	1	0.8 (0.1–5.8)	0.3330
part-time or temporary	273	149	54.6 (48.1–60.9)	107	38.9 (32.8–45.4)	15	5.9 (3.4–10.0)	2	0.6 (0.2–2.6)	
unemployed	104	50	49.0 (38.1–60.0)	48	46.3 (35.5–57.5)	6	4.7 (2.1–10.3)	0	0.0	
disabled	10	5	35.0 (9.7–72.9)	4	35.0 (8.8–75.1)	1	30.0 (3.7–82.6)	0	0.0	
other	18	9	58.4 (31.5–81.1)	8	35.2 (15.3–62.0)	1	6.4 (0.8–38.0)	0	0.0	
Monthly income category										
<3K	70	26	34.5 (23.2–47.8)	40	59.9 (46.3–72.1)	4	5.7 (1.9–15.8)	0	0.0	0.0083
3-10K	203	121	60.0 (52.3–67.1)	67	30.9 (24.5–38.2)	14	8.7 (4.8–15.3)	1	0.4 (0.1–2.7)	
10-20K	140	85	60.2 (51.1–68.8)	48	35.0 (26.9–44.1)	5	3.5 (1.4–8.5)	2	1.3 (0.3–5.1)	
≥20K	40	22	49.7 (32.3–67.3)	16	45.2 (28.1–63.6)	2	5.0 (1.1–19.5)	0	0.0	
Ever incarcerated										
no	329	189	57.7 (51.8–63.3)	121	36.5 (31.0–42.3)	16	5.1 (3.0–8.4)	3	0.8 (0.2–2.4)	0.1436
yes	169	84	47.5 (39.0–56.1)	75	45.2 (36.7–54.0)	10	7.3 (3.5–14.6)	0	0.0	

Table 12.9. Anxiety symptoms severity (GAD-7) by Selected Subgroups

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										
no	264	145	53.7 (46.8–60.5)	107	41.5 (34.8–48.4)	11	4.6 (2.2–9.1)	1	0.3 (0.0–1.9)	0.4772
yes	231	124	53.7 (46.7–60.5)	90	38.0 (31.5–44.9)	15	7.6 (4.5–12.6)	2	0.8 (0.2–3.1)	
Treated with MAT currently (of all)										
no	429	228	52.6 (47.3–57.8)	179	41.8 (36.7–47.1)	20	5.2 (3.2–8.6)	2	0.4 (0.1–1.6)	0.0203
yes	63	42	67.0 (53.7–78.0)	15	21.6 (13.1–33.7)	5	10.1 (4.1–22.9)	1	1.3 (0.2–9.0)	
HIV test result										
positive	77	31	40.0 (28.9–52.1)	41	54.4 (42.3–66.1)	3	3.2 (1.0–9.8)	2	2.4 (0.6–9.6)	0.0011
negative	423	243	56.3 (50.9–61.5)	156	37.2 (32.2–42.5)	23	6.3 (4.0–9.8)	1	0.2 (0.0–1.3)	
Past 30 days injecting 4 categories										
opioids	449	254	56.2 (51.1–61.3)	174	38.5 (33.7–43.6)	19	4.9 (2.9–8.1)	2	0.3 (0.1–1.4)	
stimulants	18	11	48.8 (22.9–75.4)	5	41.5 (16.5–71.9)	2	9.6 (1.9–36.7)	0	0.0	
opi+stimul	33	9	27.2 (13.6–47.1)	18	53.0 (33.5–71.7)	5	17.0 (6.5–37.3)	1	2.8 (0.4–18.9)	
other	0	0		0		0		0		

	N	GAD-7 anxiety result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Injecting drug type of choice										
opioids	475	262	54.7 (49.7–59.6)	187	39.2 (34.4–44.2)	23	5.6 (3.6–8.8)	3	0.5 (0.2–1.6)	0.2491
stimulants	23	11	41.2 (20.7–65.3)	10	50.9 (27.2–74.3)	2	7.9 (1.6–31.2)	0	0.0	
other	2	1	45.7 (0.0–100.0)	0	0.0	1	54.3 (0.0–100.0)	0	0.0	

13. Detention and Incarceration

Table 13.1. Police Detention and Incarceration Experience

	n	%	CI
Detained by police in 2022 for			
drug use	83	15.5	(12.5–19.0)
drug dealing	4	0.8	(0.3–2.2)
drug storing	41	7.9	(5.8–10.8)
Detained by police in 2023 for			
drug use	70	12.7	(10.0–15.9)
drug dealing	3	0.7	(0.2–2.5)
drug storing	32	6.3	(4.4–8.9)
Stopped, detained, or arrested by police ever			
yes	374	75.7	(71.3–79.6)
Ever incarcerated			
yes	169	35.4	(30.7–40.3)
Duration of incarceration			
≤6m	19	9.7	(6.2–15.0)
6m-2y	37	21.7	(15.2–29.9)
2-4y	73	43.4	(35.1–52.1)
4y+	40	25.2	(18.2–33.9)
Time since last incarceration			
≤1y	12	8.1	(4.1–15.2)
1-3y	25	14.4	(9.6–21.1)
3-5y	18	10.0	(6.2–15.9)
5-10y	40	26.6	(19.2–35.5)
10y+	73	41.0	(32.8–49.6)
Used injecting drugs during incarceration			
yes	91	53.8	(45.1–62.3)



Figure 13.1. Incarceration Lifetime Experience (%)

14. Negative experience

Table 14.1. Negative experience

	n	%	CI
Felt excluded from family activities due to drug use			
no	291	57.2	(52.2–61.9)
yes, in the past 6m	39	8.4	(6.0–11.7)
yes, but 6m+ ago	170	34.5	(29.9–39.3)
Was scolded because of drug use			
no	191	37.7	(33.1–42.5)
yes, in the past 6m	70	14.2	(11.2–18.0)
yes, but 6m+ ago	237	48.1	(43.2–53.0)
Was blackmailed for drug use			
no	445	88.5	(84.9–91.3)
yes, in the past 6m	11	2.5	(1.4–4.7)
yes, but 6m+ ago	43	9.0	(6.5–12.3)
Negative experience in the past 6 months (GAM 6.5)			
no	423	84.2	(80.2–87.5)
yes	75	15.8	(12.5–19.8)
Ever experienced physical violence			
no	307	62.4	(57.7–67.0)
yes	193	37.6	(33.0–42.3)
Experienced physical violence in the past 12 months (of those who had ever)			
no	108	57.2	(49.5–64.5)
yes	85	42.8	(35.5–50.5)
Witnessed physical violence in the past 12 months			
no	332	69.1	(64.7–73.3)
yes	167	30.9	(26.7–35.3)

Figure 14.1. Negative Experience Related to Drug Use in the past 6 Months or Physical Violence in the past 12 months (%)

Table 14.2. Negative Experience Related to Drug Use by Sociodemographic Characteristics

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total								
All	498	75	15.8 (12.5–19.8)	1.0000	193	85	42.8 (35.5–50.5)	1.0000
Sex								
male	433	67	16.5 (12.8–20.9)	0.2599	167	73	42.3 (34.5–50.5)	0.6669
female	65	8	11.0 (5.4–21.2)		26	12	47.0 (28.3–66.5)	
Age								
<25	25	10	42.7 (21.5–67.0)	0.0013	7	5	77.9 (37.2–95.5)	0.0001
25-34	95	18	17.4 (10.9–26.5)		39	24	63.0 (46.2–77.2)	
35-44	252	35	15.3 (10.8–21.3)		94	43	45.3 (34.9–56.1)	
45+	126	12	9.1 (5.1–15.8)		53	13	19.7 (11.1–32.6)	
Years since the start of injecting drug use								
≤2	18	6	35.6 (12.8–67.6)	0.1351	4	2	37.8 (6.5–84.2)	0.0639
3-5	24	4	22.4 (8.2–48.4)		3	3	100.0	
6-10	53	11	16.4 (8.9–28.3)		21	13	61.6 (38.0–80.8)	
≥11	403	54	14.2 (10.8–18.6)		165	67	39.2 (31.6–47.5)	
Partnership status								
live alone	222	33	17.0 (11.7–24.1)	0.5677	78	35	43.3 (32.1–55.2)	0.9199
live with partner	276	42	14.9 (10.9–19.9)		115	50	42.5 (33.1–52.5)	
Current employment status								

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
full-time	94	12	13.9 (7.7–23.8)	0.7141	34	10	28.9 (15.5–47.2)	0.0307
part-time or temporary	272	43	16.7 (12.2–22.4)		115	59	53.0 (43.3–62.5)	
unemployed	104	17	17.2 (10.1–27.6)		32	12	33.3 (18.6–52.2)	
disabled	10	0	0.0		5	0	0.0	
other	18	3	14.5 (4.0–41.1)		7	4	51.2 (17.0–84.3)	
Monthly income category								
<3K	70	11	19.7 (10.2–34.5)	0.0640	19	8	40.4 (20.3–64.3)	0.0542
3-10K	203	42	21.8 (16.0–28.9)		76	42	55.8 (43.4–67.5)	
10-20K	139	17	10.7 (6.6–17.0)		65	23	34.6 (23.5–47.8)	
≥20K	40	2	7.0 (1.6–26.4)		21	8	31.6 (15.3–54.1)	
Ever incarcerated								
no	327	48	15.0 (11.2–19.9)	0.5585	115	61	51.6 (42.0–61.2)	0.0062
yes	169	27	17.4 (11.6–25.2)		78	24	30.1 (20.2–42.3)	

Table 14.3. Negative Experience Related to Drug Use by Selected Subgroups

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	262	38	15.3 (10.8–21.3)	0.7286	110	51	43.7 (34.0–54.0)	0.7355
yes	231	37	16.6 (12.1–22.5)		81	33	41.1 (30.3–52.8)	
Treated with MAT currently (of all)								
no	427	70	17.3 (13.6–21.8)	0.0236	170	76	42.8 (35.0–51.0)	0.8860
yes	63	4	6.0 (2.2–15.6)		21	8	41.0 (21.3–64.1)	
HIV test result								
positive	76	10	18.3 (9.2–33.2)	0.6262	20	10	49.5 (28.3–70.8)	0.5450
negative	422	65	15.4 (12.0–19.6)		173	75	42.2 (34.5–50.3)	
Past 30 days injecting 4 categories								
opioids	447	62	14.0 (10.8–18.0)		173	73	40.9 (33.3–49.0)	
stimulants	18	3	28.7 (7.7–66.1)		6	4	67.7 (23.4–93.5)	
opi+stimul	33	10	32.2 (16.7–52.9)		14	8	57.4 (30.4–80.6)	
other	0	0			0	0		

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Injecting drug type of choice								
opioids	473	69	15.0 (11.8–18.9)	0.1080	183	80	42.3 (34.8–50.2)	0.4806
stimulants	23	6	33.3 (12.7–63.2)		9	5	57.6 (23.1–86.0)	
other	2	0	0.0		1	0	0.0	

15. The Impact of the Full-scale War

Table 15.1. Migration Since February 2022

	n	%	CI
Changed place of residence since Feb 2022			
yes, because of the war	163	33.5	(29.1–38.3)
yes, for other reasons	3	0.5	(0.2–1.5)
no	334	66.0	(61.2–70.4)
Where migrated since Feb 2022			
unknown	0	0.0	
other country	10	6.3	(3.2–11.8)
other oblast	52	34.5	(26.7–43.2)
other city	41	23.4	(17.3–30.8)
other district	54	32.0	(24.7–40.3)
other house	6	3.9	(1.6–8.8)
Where lived before Feb 2022 (if changed residence)			
same oblast	144	84.7	(76.2–90.6)
other oblast	20	15.3	(9.4–23.8)
other country	0	0.0	



Figure 15.1. Change of Residence Since February 2022 (%)



Figure 15.2. Migration Destination by Survey Site (%)



Figure 15.3. Residence Before February 2022 (%)



Figure 15.4. Changes Since February 2022 (%)

City-level Results: Cherkasy



Figure A. RDS recruitment tree in Cherkasy

1. Sociodemographic Information

Table 1.1. Sociodemographic Characteristics

	n	Mean	CI	Median	IQR
Age, years	500	39.8	(39.1–40.5)	40	(35–46)
Age of first non-injecting drug use	462	16.4	(16.2–16.7)	16	(15–18)
Years since the start of non-injecting drug use	462	23.4	(22.6–24.2)	24	(17–29)
Age of first injecting drug use	500	20.6	(20.2–20.9)	20	(18–22)
Years since the start of injecting drug use	500	19.2	(18.4–20.0)	19	(12–26)
Personal monthly income, UAH	499	7,053.3	(6290.6–7815.9)	5,000	(1500–10000)

Table 1.2. Descriptive Statistics for Sociodemographics

	Site	n	%	CI
Sex				
male	Cherkasy	343	67.5	(62.9–71.8)
female	Cherkasy	157	32.5	(28.2–37.1)
Age				
<25	Cherkasy	8	1.7	(0.8–3.5)
25-34	Cherkasy	126	23.3	(19.6–27.4)
35-44	Cherkasy	227	46.2	(41.4–51.0)
45+	Cherkasy	139	28.8	(24.7–33.4)
Family status				
married or living together	Cherkasy	78	15.4	(12.3–19.2)
married but have another partner	Cherkasy	43	9.1	(6.7–12.3)
not married but have a partner	Cherkasy	188	35.9	(31.5–40.5)
married but not living together	Cherkasy	59	11.7	(8.9–15.3)
not married and do not have a partner	Cherkasy	132	27.8	(23.6–32.4)
Partnership status				
live alone	Cherkasy	191	39.5	(34.9–44.4)
live with partner	Cherkasy	309	60.5	(55.6–65.1)
Education				
incompl. high school	Cherkasy	15	2.8	(1.5–5.4)
high school	Cherkasy	228	47.4	(42.6–52.2)
>high school	Cherkasy	257	49.8	(45.0–54.6)
Current occupation				
school student	Cherkasy	0	0.0	
college/uni student	Cherkasy	5	0.8	(0.3–2.0)
permanent job	Cherkasy	103	19.7	(16.3–23.7)
sporadic jobs	Cherkasy	277	57.2	(52.4–61.8)
unemployed	Cherkasy	31	5.5	(3.9–7.9)
housewife	Cherkasy	21	3.9	(2.5–6.2)
disabled	Cherkasy	20	3.9	(2.3–6.6)
military	Cherkasy	3	0.7	(0.2–2.3)
other	Cherkasy	40	8.2	(5.9–11.2)
Homelessness				
never	Cherkasy	459	92.6	(89.9–94.6)
yes, 12m+ ago	Cherkasy	41	7.4	(5.4–10.1)
yes, in the past 12m	Cherkasy	0	0.0	
Homeless in 12 months (of those ever)				
no	Cherkasy	41	100.0	
yes	Cherkasy	0	0.0	
Monthly income category				
<3K	Cherkasy	156	34.7	(30.2–39.5)
3-10K	Cherkasy	189	36.2	(31.8–40.9)
10-20K	Cherkasy	128	24.6	(20.8–28.8)

	Site	n	%	CI
≥20K	Cherkasy	26	4.5	(3.0–6.7)
Monthly income relative to 2023 subsistence minimum				
<2684	Cherkasy	153	34.2	(29.7–39.0)
≥2684	Cherkasy	346	65.8	(61.0–70.3)
Years since the start of injecting drug use				
≤2	Cherkasy	10	1.9	(1.0–3.5)
3-5	Cherkasy	18	3.4	(2.1–5.4)
6-10	Cherkasy	69	13.2	(10.4–16.6)
≥11	Cherkasy	403	81.6	(77.7–84.8)

Table 1.3. Accommodation in the past 12 months

	Site	n	%	CI
own place	Cherkasy	261	52.6	(47.8–57.3)
friends or relatives	Cherkasy	171	33.9	(29.5–38.6)
renting	Cherkasy	58	12.0	(9.2–15.5)
varying	Cherkasy	11	1.8	(1.0–3.4)
on the street (homeless)	Cherkasy	0	0.0	
in a refugee shelter	Cherkasy	1	0.2	(0.0–1.2)



Figure 1.1. Distribution of Age by Sex (%)



Figure 1.2. Trend in Sex Distribution by Survey Round (%)



Figure 1.3. Trend in Age Groups by Survey Round (%)

2. Drug Use



Figure 2.1. Injecting Drug Use in the Past 12 Months and 30 Days (%)



Figure 2.2. Non-injecting Drug Use in the Past 12 Months (%)



Figure 2.3. Trends in Injecting Drugs Types in the Past 30 Days by Survey Round (%)



Figure 2.4. Trends in Injecting Opioids in the Past 30 Days by Survey Round (%)



Figure 2.5. Trends in Injecting Stimulants in the Past 30 Days by Survey Round (%)



Figure 2.6. Trends in Injecting Other Drugs in the Past 30 Days by Survey Round (%)



Figure 2.7. Injecting Drug Preference (%)

Table 2.1. Types of Injecting Drugs in the Past 30 Days by Sociodemographic Characteristics

			Past 30 days injecting 4 categories								
		N	opioids		stimulants		opi+stimul		other		
			n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total											
	All	500	305	58.6 (53.7–63.3)	45	8.5 (6.2–11.4)	148	32.7 (28.2–37.5)	2	0.3 (0.1–1.2)	1.0000
Sex											
	male	343	214	59.3 (53.3–64.9)	27	7.9 (5.3–11.6)	101	32.7 (27.2–38.6)	1	0.2 (0.0–1.3)	0.8201
	female	157	91	57.2 (48.6–65.3)	18	9.7 (5.9–15.5)	47	32.7 (25.1–41.3)	1	0.5 (0.1–3.6)	
Age											
	<25	8	7	84.2 (29.2–98.6)	1	15.8 (1.4–70.8)	0	0.0	0	0.0	0.1204

	N	Past 30 days injecting 4 categories								
		opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
25-34	126	65	49.9 (40.5–59.4)	17	11.4 (7.0–18.1)	44	38.6 (29.5–48.6)	0	0.0	
35-44	227	141	57.9 (50.5–64.9)	23	9.9 (6.4–15.1)	62	31.8 (25.3–39.2)	1	0.4 (0.0–2.5)	
45+	139	92	65.2 (56.2–73.3)	4	3.3 (1.2–8.6)	42	31.1 (23.3–40.0)	1	0.4 (0.1–3.0)	
Years since the start of injecting drug use										
≤2	10	6	51.0 (18.7–82.5)	1	14.4 (1.5–64.9)	3	34.6 (9.3–73.2)	0	0.0	0.2083
3-5	18	13	68.5 (40.9–87.2)	2	11.5 (2.3–41.2)	3	20.0 (6.1–49.1)	0	0.0	
6-10	69	45	63.8 (51.0–75.0)	12	16.4 (9.3–27.5)	12	19.7 (11.2–32.3)	0	0.0	
≥11	403	241	57.5 (52.0–62.8)	30	6.9 (4.7–10.1)	130	35.2 (30.2–40.7)	2	0.4 (0.1–1.4)	
Partnership status										
live alone	191	108	54.2 (46.1–62.0)	21	9.1 (5.7–14.0)	60	36.1 (28.5–44.4)	2	0.7 (0.2–2.9)	0.2240
live with partner	309	197	61.5 (55.4–67.2)	24	8.1 (5.3–12.1)	88	30.4 (25.1–36.3)	0	0.0	
Current employment status										
full-time	103	67	63.9 (53.3–73.2)	10	9.6 (5.1–17.5)	25	25.9 (17.7–36.2)	1	0.6 (0.1–4.3)	0.0093
part-time or temporary	277	171	59.2 (52.6–65.5)	15	5.2 (3.0–9.0)	91	35.5 (29.5–42.1)	0	0.0	
unemployed	31	20	65.0 (45.8–80.4)	7	22.1 (10.2–41.3)	4	12.9 (4.6–31.0)	0	0.0	
disabled	20	17	73.8 (34.2–93.9)	0	0.0	3	26.2 (6.1–65.8)	0	0.0	
other	69	30	41.3 (29.6–54.2)	13	17.2 (9.6–28.8)	25	40.3 (28.4–53.4)	1	1.2 (0.2–8.4)	
Monthly income category										
<3K	156	69	44.1 (35.8–52.8)	7	4.8 (2.2–10.0)	80	51.1 (42.6–59.6)	0	0.0	0.0000
3-10K	189	126	64.7 (56.5–72.1)	19	8.6 (5.3–13.7)	42	25.9 (19.0–34.2)	2	0.8 (0.2–3.2)	
10-20K	128	92	69.4 (59.9–77.6)	12	9.5 (5.2–16.8)	24	21.1 (14.1–30.2)	0	0.0	
≥20K	26	17	60.5 (38.8–78.8)	7	30.4 (14.5–53.0)	2	9.0 (2.0–32.7)	0	0.0	
Ever incarcerated										
no	426	253	57.3 (52.1–62.3)	37	8.2 (5.9–11.5)	134	34.2 (29.3–39.3)	2	0.3 (0.1–1.3)	0.3311
yes	74	52	67.3 (53.1–78.9)	8	10.0 (4.8–19.7)	14	22.8 (12.5–38.0)	0	0.0	

Table 2.2. Types of Injecting Drugs in the Past 30 Days by Selected Subgroups

	N	Past 30 days injecting 4 categories								
		opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										

		Past 30 days injecting 4 categories								
	N	opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
no	190	110	55.2 (47.5–62.7)	28	15.0 (10.2–21.5)	52	29.8 (23.2–37.4)	0	0.0	0.0006
yes	310	195	60.7 (54.4–66.6)	17	4.5 (2.7–7.3)	96	34.4 (28.6–40.7)	2	0.5 (0.1–1.9)	
Treated with MAT currently (of all)										
no	405	233	54.9 (49.6–60.2)	42	9.8 (7.1–13.3)	130	35.2 (30.2–40.6)	0	0.0	0.0002
yes	94	71	74.7 (62.8–83.8)	3	2.5 (0.8–7.8)	18	21.2 (12.7–33.4)	2	1.6 (0.4–6.4)	
HIV test result										
positive	87	58	66.9 (54.6–77.2)	6	5.5 (2.4–12.1)	22	26.9 (17.2–39.5)	1	0.7 (0.1–5.1)	0.2580
negative	413	247	56.9 (51.6–62.0)	39	9.1 (6.5–12.5)	126	33.8 (28.9–39.1)	1	0.2 (0.0–1.4)	
Injecting drug type of choice										
opioids	433	299	66.1 (60.9–71.0)	3	0.8 (0.2–2.9)	130	32.8 (28.0–38.0)	1	0.2 (0.0–1.4)	0.0000
stimulants	64	4	6.4 (2.0–18.2)	42	60.8 (46.8–73.3)	18	32.8 (21.2–47.0)	0	0.0	
other	2	1	62.8 (0.0–100.0)	0	0.0	0	0.0	1	37.2 (0.0–100.0)	

Table 2.3. Injecting frequency

	Past 30 days injecting 4 categories								
	opioids		stimulants		opi+stimul		other		
	n	%	n	%	n	%	n	%	p-value
Injecting frequency: last 24 hrs									
0 times	85	28.8	20	44.6	34	26.2	2	100.0	0.2403
1 time	186	61.4	20	43.3	103	66.0	0	0.0	
2-3 times	32	9.3	5	12.0	11	7.8	0	0.0	
4+ times	2	0.5	0	0.0	0	0.0	0	0.0	
N	305		45		148		2		
Injecting frequency: last 24 hrs (among those who did)									
1 time	186	86.2	20	78.2	103	89.5	0	0.0	
2-3 times	32	13.1	5	21.8	11	10.5	0	0.0	
4+ times	2	0.7	0	0.0	0	0.0	0	0.0	
N	220		25		114		0		
Injecting frequency: last week									
0 times	0	0.0	1	2.5	1	0.5	2	100.0	0.0000
1-6 times	226	75.1	34	74.5	121	81.0	0	0.0	
every day	79	24.9	9	23.0	26	18.5	0	0.0	
N	305		44		148		2		
Injecting frequency: last 30 days									
1-9 times	26	8.4	3	8.0	3	1.8	0	0.0	
10-19 times	66	20.5	19	39.7	28	19.5	0	0.0	
20-29 times	104	35.1	12	23.3	52	36.6	0	0.0	
every day	109	36.0	11	29.0	65	42.1	0	0.0	
N	305		45		148		0		
Injecting frequency: main drug last 30 days									
0-9 times	28	9.1	2	5.6	5	2.7	0	0.0	0.0552
10-19 times	71	22.7	21	43.5	35	25.2	1	57.7	

	Past 30 days injecting 4 categories								
	opioids		stimulants		opi+stimul		other		
	n	%	n	%	n	%	n	%	p-value
20-29 times	96	32.3	11	20.1	41	29.2	0	0.0	
every day	110	35.9	11	30.7	67	42.8	1	42.3	
N	305		45		148		2		

Table 2.4. Injecting drug type of choice by Income Category

	Injecting drug type of choice					
	opioids		stimulants		other	
	n	%	n	%	n	%
Monthly income category						
<3K	149	38.2	7	12.4	0	0.0
3-10K	163	36.6	24	32.8	2	100.0
10-20K	103	22.1	24	40.7	0	0.0
≥20K	17	3.2	9	14.0	0	0.0
N	432		64		2	

Table 2.5. Sources of drugs by Drug Type of Choice

Total		Injecting drug type of choice						
All		opioids		stimulants		other		
n	%	n	%	n	%	n	%	p-value
prepare myself								
14	2.7	12	2.7	2	2.9	0	0.0	0.9688
prepared by friends								
13	2.7	10	2.4	3	5.3	0	0.0	0.4029
from a dealer								
378	78.6	342	81.3	33	59.7	2	100.0	0.0004
buy on Internet								
160	30.6	128	29.0	32	42.6	0	0.0	0.0640
from MAT program								
1	0.2	1	0.2	0	0.0	0	0.0	0.9212
other								
3	0.6	1	0.3	2	2.4	0	0.0	0.1252
N								
569		494		72		2		
from a pharmacy								
		0	0.0	0	0.0	0	0.0	



Figure 2.8. Change in the price, quality, and access of drugs by Drug Type of Choice (%)

3. Injecting Risk Behavior

Table 3.1. Prevalence of Injection Risk Practices

	n	%	CI
Used clean syringe for last injection			
yes	492	98.7	(97.3–99.4)
Source of syringe for last injection			
bought in pharmacy	199	40.4	(35.8–45.1)
got in pharmacy	3	0.6	(0.2–2.0)
got from NGO	268	54.0	(49.2–58.7)
got from friend	23	3.6	(2.4–5.4)
got used from friend	5	1.0	(0.4–2.5)
used one used by myself	1	0.3	(0.0–1.9)
got pre-loaded	0	0.0	
other	1	0.2	(0.0–1.2)
Used shared syringe in the past 30 days			
yes	92	20.6	(16.8–24.9)
Used pre-filled syringe in the past 30 days			
yes	113	25.4	(21.3–30.0)
Used front-/back-loaded syringe in the past 30 days			
yes	112	25.0	(21.0–29.6)
Used shared container in the past 30 days			
yes	113	24.6	(20.5–29.2)
Used own previously used syringe in the past 30 days			
yes	98	21.2	(17.4–25.6)
Gave someone a used syringe in the past 30 days			
yes	143	31.6	(27.3–36.4)
Any inj. risk (shared syringe, pre-filled, front-/back-load, container) in the past 30 days			
yes	224	47.6	(42.8–52.4)

Table 3.2. Frequency of risky injection practices

	n	%	CI
Frequency of injecting with a syringe used by others in the past 30 days			
always	0	0.0	

	n	%	CI
often	16	21.6	(13.4–32.9)
half	53	57.6	(46.3–68.2)
sometimes	13	12.3	(6.9–21.0)
rarely	3	3.1	(1.0–9.4)
never	7	5.3	(2.5–11.1)
Frequency of injecting with others in the same place in the past 30 days			
always	55	11.5	(8.8–15.0)
often	82	18.4	(14.9–22.6)
half	133	30.8	(26.2–35.7)
sometimes	64	14.4	(11.1–18.5)
rarely	29	6.9	(4.7–9.9)
never	85	18.0	(14.6–22.1)
Number of syringes used repeatedly in the past 30 days			
1-9	88	91.8	(79.7–97.0)
10-29	4	3.5	(1.2–9.4)
30+	2	4.7	(1.0–20.1)
Number of times one syringe used repeatedly in the past 30 days			
1	40	40.5	(30.2–51.7)
2-3	47	49.9	(38.8–61.1)
4-9	5	5.1	(2.1–12.1)
10+	2	4.4	(0.8–20.3)
How the pre-filled syringe was obtained			
from dealer	67	61.7	(51.7–70.8)
from friends	41	34.9	(26.1–44.8)
from stash	5	3.5	(1.4–8.2)
Someone used one syringe for injection before front-/back-loading			
no	411	80.9	(76.7–84.5)
yes	87	19.1	(15.5–23.3)



Figure 3.1. Prevalence of Key Injection Risk Practices (%)



Figure 3.2. Trends in Key Injection Risk Practices by Survey Round (%)



Figure 3.3. With whom injected drugs in the same place (%)



Figure 3.4. With whom injected drugs in the same place by sex (%)



Figure 3.5. With whom injected drugs in the same place by age (%)

Table 3.3. Prevalence of Shared and Pre-filled Syringe Use by Sociodemographic Characteristics

		Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	500	92	20.6 (16.8–24.9)	1.0000	499	113	25.4 (21.3–30.0)	1.0000
Sex									
	male	343	55	18.4 (14.0–23.7)	0.1243	343	74	24.9 (19.9–30.5)	0.7002
	female	157	37	25.1 (18.3–33.4)		156	39	26.7 (19.7–35.1)	
Age									
	<25	8	2	35.6 (6.8–80.7)	0.1170	8	3	43.8 (10.9–83.2)	0.3988

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
25-34	126	26	23.6 (15.8–33.7)		125	32	26.5 (19.0–35.6)	
35-44	227	33	15.3 (10.8–21.3)		227	42	22.2 (16.4–29.3)	
45+	139	31	25.6 (18.2–34.6)		139	36	28.8 (21.1–37.9)	
Years since the start of injecting drug use								
≤2	10	0	0.0	0.0278	10	3	34.2 (9.4–72.3)	0.6704
3-5	18	0	0.0		18	3	18.0 (5.3–46.6)	
6-10	69	9	14.1 (7.1–26.0)		68	13	20.9 (12.0–33.8)	
≥11	403	83	22.9 (18.5–28.0)		403	94	26.3 (21.7–31.5)	
Partnership status								
live alone	191	35	21.0 (14.9–28.7)	0.8737	191	36	21.2 (15.2–28.9)	0.1364
live with partner	309	57	20.3 (15.7–25.7)		308	77	28.2 (22.9–34.1)	
Current employment status								
full-time	103	11	11.6 (6.1–20.8)	0.0013	103	18	19.3 (12.0–29.5)	0.1018
part-time or temporary	277	60	25.0 (19.6–31.5)		277	74	29.9 (24.2–36.3)	
unemployed	31	1	3.0 (0.4–19.8)		31	2	6.0 (1.4–22.1)	
disabled	20	0	0.0		20	3	28.3 (7.3–66.4)	
other	69	20	27.7 (18.1–40.0)		68	16	22.5 (13.8–34.5)	
Monthly income category								
<3K	156	64	41.1 (33.0–49.8)	0.0000	156	60	40.3 (32.2–49.0)	0.0000
3-10K	189	16	10.4 (5.9–17.5)		188	32	19.7 (13.7–27.5)	
10-20K	128	10	8.9 (4.5–16.7)		128	18	15.4 (9.6–23.7)	
≥20K	26	2	8.2 (1.9–29.2)		26	3	12.3 (3.6–34.7)	
Ever incarcerated								
no	426	88	22.6 (18.4–27.4)	0.0136	425	105	26.9 (22.5–31.9)	0.1511
yes	74	4	7.1 (2.4–19.0)		74	8	15.5 (6.6–32.2)	

Table 3.4. Prevalence of Shared and Pre-filled Syringe Use by Selected Subgroups

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	190	19	10.2 (6.4–15.8)	0.0000	189	37	21.5 (15.7–28.6)	0.1537

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
yes	310	73	26.9 (21.6–33.0)		310	76	27.9 (22.5–34.0)	
Treated with MAT currently (of all)								
no	405	79	22.0 (17.7–27.0)	0.1187	404	102	28.0 (23.4–33.2)	0.0293
yes	94	13	14.1 (8.0–23.7)		94	11	13.9 (6.9–26.1)	
HIV test result								
positive	87	14	15.7 (9.0–25.7)	0.2516	87	10	13.2 (6.2–26.1)	0.0301
negative	413	78	21.6 (17.3–26.5)		412	103	27.9 (23.4–33.0)	
Past 30 days injecting 4 categories								
opioids	305	36	12.7 (9.1–17.5)	0.0000	305	47	16.5 (12.4–21.7)	0.0000
stimulants	45	0	0.0		44	3	5.6 (1.7–17.0)	
opi+stimul	148	56	40.1 (31.6–49.3)		148	63	46.7 (37.9–55.8)	
other	2	0	0.0		2	0	0.0	
Injecting drug type of choice								
opioids	433	92	23.7 (19.4–28.6)	0.0001	433	106	27.5 (23.0–32.5)	0.0390
stimulants	64	0	0.0		63	7	12.4 (5.6–25.2)	
other	2	0	0.0		2	0	0.0	

Table 3.5. Prevalence of Front-/back-loading and Container Sharing by Sociodemographic Characteristics

		Used front-/back-loaded syringe in the past 30 days			Used shared container in the past 30 days			
		n	% (CI)	p-value	N	n	% (CI)	p-value
Total								
	All	112	25.0 (21.0–29.6)	1.0000	500	113	24.6 (20.5–29.2)	1.0000
Sex								
	male	80	25.3 (20.5–30.9)	0.8440	343	75	23.6 (18.8–29.2)	0.5266
	female	32	24.4 (17.5–33.0)		157	38	26.6 (19.6–35.1)	
Age								
	<25	1	23.5 (2.4–79.6)	0.4894	8	1	23.5 (2.4–79.6)	0.8653
	25-34	26	22.6 (15.0–32.5)		126	29	25.3 (17.4–35.4)	
	35-44	44	22.8 (17.1–29.7)		227	45	22.6 (16.9–29.7)	
	45+	41	30.7 (23.0–39.6)		139	38	27.2 (19.9–35.9)	
Years since the start of injecting drug use								

	Used front-/back-loaded syringe in the past 30 days			Used shared container in the past 30 days			
	n	% (CI)	p-value	N	n	% (CI)	p-value
≤2	1	8.9 (0.9–51.7)	0.0095	10	2	23.3 (4.6–65.8)	0.8659
3-5	0	0.0		18	3	17.5 (5.0–46.1)	
6-10	9	15.3 (7.7–28.1)		69	13	22.0 (12.7–35.2)	
≥11	102	28.0 (23.3–33.3)		403	95	25.3 (20.8–30.5)	
Partnership status							
live alone	46	26.9 (20.2–34.8)	0.5044	191	41	23.1 (16.7–31.2)	0.6093
live with partner	66	23.8 (18.9–29.5)		309	72	25.5 (20.5–31.3)	
Current employment status							
full-time	19	20.1 (12.7–30.4)	0.0827	103	16	15.5 (9.3–24.9)	0.2874
part-time or temporary	69	28.1 (22.4–34.5)		277	66	26.8 (21.2–33.3)	
unemployed	4	13.4 (4.9–31.8)		31	6	20.7 (9.2–40.4)	
disabled	2	7.1 (1.5–27.5)		20	5	34.0 (11.2–67.7)	
other	18	29.3 (18.8–42.6)		69	20	27.2 (17.7–39.4)	
Monthly income category							
<3K	63	40.9 (32.8–49.5)	0.0000	156	43	27.1 (20.2–35.3)	0.5851
3-10K	34	21.4 (15.1–29.3)		189	43	25.6 (18.7–33.9)	
10-20K	12	10.8 (6.0–18.8)		128	22	20.4 (13.5–29.5)	
≥20K	3	11.3 (3.4–31.5)		26	4	18.1 (6.5–41.1)	
Ever incarcerated							
no	106	27.5 (23.0–32.5)	0.0032	426	101	25.0 (20.7–29.9)	0.6468
yes	6	8.8 (3.6–20.0)		74	12	21.7 (11.4–37.4)	

Table 3.6. Prevalence of Front-/back-loading and Container Sharing by Selected Subgroups

	Used front-/back-loaded syringe in the past 30 days			Used shared container in the past 30 days			
	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID							
no	33	19.8 (14.2–26.9)	0.0586	190	33	18.2 (13.0–24.9)	0.0194
yes	79	28.3 (22.9–34.3)		310	80	28.5 (23.0–34.7)	
Treated with MAT currently (of all)							
no	96	27.0 (22.3–32.2)	0.0376	405	92	25.0 (20.5–30.1)	0.7256

	Used front-/back-loaded syringe in the past 30 days			Used shared container in the past 30 days			
	n	% (CI)	p-value	N	n	% (CI)	p-value
yes	16	16.3 (10.0–25.5)		94	21	23.0 (14.3–34.7)	
HIV test result							
positive	15	16.5 (9.9–26.2)	0.0524	87	15	19.6 (11.0–32.4)	0.3398
negative	97	26.8 (22.2–32.0)		413	98	25.6 (21.1–30.6)	
Past 30 days injecting 4 categories							
opioids	41	14.7 (10.8–19.6)	0.0000	305	50	17.6 (13.3–22.8)	0.0000
stimulants	2	6.1 (1.2–25.4)		45	5	8.9 (3.5–20.6)	
opi+stimul	69	48.8 (39.9–57.7)		148	56	40.6 (31.9–49.9)	
other	0	0.0		2	2	100.0	
Injecting drug type of choice							
opioids	107	27.7 (23.2–32.8)	0.0038	433	100	25.5 (21.1–30.5)	0.4144
stimulants	5	7.8 (2.9–19.6)		64	12	18.3 (10.1–31.0)	
other	0	0.0		2	1	37.2 (0.0–100.0)	

4. Sexual Behavior

Table 4.1. Prevalence of Sexual Practice by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had sex: ever										
yes	473	93.8	(90.7–95.9)	150	96.5	(92.5–98.4)	323	92.6	(88.1–95.4)	0.0933
N	500			157			343			
Had sex: in the past 12 months										
yes	452	96.3	(94.2–97.6)	147	98.2	(94.4–99.4)	305	95.3	(92.5–97.1)	0.1154
N	473			150			323			
Had sex: in the past 30 days										
yes	320	67.0	(62.3–71.5)	111	71.7	(63.1–79.1)	209	64.7	(58.8–70.1)	0.1674
N	473			150			323			
Had a sex partner in the past 30 days: regular										
yes	266	84.5	(79.7–88.3)	82	72.0	(62.0–80.3)	184	91.6	(87.1–94.6)	0.0000
N	315			111			204			
Had a sex partner in the past 30 days: casual										
yes	25	6.4	(4.3–9.5)	4	2.8	(1.0–7.3)	21	8.5	(5.5–12.9)	0.0296
N	315			111			204			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	7	1.8	(0.8–3.8)	0	0.0		7	2.8	(1.3–5.9)	0.0524
N	315			111			204			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes	41	13.8	(10.1–18.6)	40	37.5	(28.3–47.7)	1	0.4	(0.0–2.5)	0.0000
N	315			111			204			

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Used condom during last sex: if ever had sex										
yes	320	69.1	(64.4–73.4)	98	67.1	(58.6–74.6)	222	70.1	(64.4–75.2)	0.5470
N	469			149			320			
Used condom during last sex: if had sex in 12m										
yes	317	70.7	(66.0–75.0)	98	67.9	(59.4–75.4)	219	72.1	(66.4–77.2)	0.3940
N	452			147			305			
Used condom during last sex: if had sex in 30d										
yes	232	73.0	(67.4–77.9)	77	69.6	(59.7–77.9)	155	74.8	(68.0–80.6)	0.3468
N	320			111			209			



Figure 4.1. Frequency of sex in the past week by Drug Types Used (%)

Table 4.2. Sex Practices by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had same-sex sexual experience										
yes	37	7.4	(5.3–10.2)	25	15.1	(10.1–22.1)	12	3.5	(1.9–6.2)	0.0000
N	473			150			323			
Provided sex services for money										
yes	77	16.8	(13.4–20.8)	67	44.3	(36.0–53.0)	10	3.0	(1.6–5.6)	0.0000
N	473			150			323			
Paid for sex ever										
yes	64	12.8	(10.0–16.3)	7	4.7	(2.2–9.8)	57	16.9	(13.0–21.6)	0.0005
N	472			150			322			
Had sex with a sex worker in the past 6 months										
yes	15	24.8	(15.1–38.0)	5	68.0	(28.3–92.0)	10	18.7	(9.9–32.6)	0.0073
N	64			7			57			
Type of partner with whom had last sex										
regular	333	71.6	(67.0–75.9)	100	65.3	(56.6–73.2)	233	74.9	(69.4–79.6)	0.0000
casual	80	16.6	(13.3–20.5)	11	7.9	(4.2–14.4)	69	21.0	(16.7–26.2)	
com. sex (I paid)	13	2.7	(1.5–4.8)	0	0.0		13	4.1	(2.3–7.2)	
com. sex (I was paid)	39	9.1	(6.5–12.4)	39	26.8	(19.7–35.2)	0	0.0		

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
N	465			150			315			
With whom last had sex										
man	151	33.5	(29.0–38.3)	141	93.8	(87.4–97.0)	10	3.0	(1.5–5.7)	0.0000
woman	310	65.0	(60.1–69.6)	3	1.7	(0.5–5.3)	307	97.0	(94.3–98.5)	
men and women	5	1.5	(0.6–3.8)	5	4.5	(1.8–11.0)	0	0.0		
N	466			149			317			
Type of last sex contact: vaginal										
yes	333	70.1	(65.4–74.5)	105	68.9	(60.2–76.4)	228	70.7	(64.9–75.9)	0.7091
N	465			149			316			
Type of last sex contact: anal										
yes	173	40.3	(35.5–45.3)	69	48.9	(40.3–57.6)	104	35.9	(30.2–42.1)	0.0150
N	465			149			316			
Type of last sex contact: oral										
yes	120	24.0	(20.2–28.3)	45	26.7	(20.0–34.6)	75	22.7	(18.2–27.9)	0.3630
N	465			149			316			

Table 4.3. Sex Partners by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had a sex partner in the past 30 days: regular										
yes	266	84.5	(79.7–88.3)	82	72.0	(62.0–80.3)	184	91.6	(87.1–94.6)	0.0000
N	315			111			204			
Had a sex partner in the past 30 days: casual										
yes	25	6.4	(4.3–9.5)	4	2.8	(1.0–7.3)	21	8.5	(5.5–12.9)	0.0296
N	315			111			204			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	7	1.8	(0.8–3.8)	0	0.0		7	2.8	(1.3–5.9)	0.0524
N	315			111			204			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes	41	13.8	(10.1–18.6)	40	37.5	(28.3–47.7)	1	0.4	(0.0–2.5)	0.0000
N	315			111			204			
Number of sex partners in the past 30 days: regular										
1	242	95.5	(91.6–97.6)	70	89.8	(79.7–95.2)	172	98.0	(93.7–99.4)	0.0507
2-4	10	3.7	(2.0–7.0)	7	7.6	(3.5–15.8)	3	2.0	(0.6–6.3)	
5+	1	0.8	(0.1–5.5)	1	2.6	(0.4–16.3)	0	0.0		
N	253			78			175			
Number of sex partners in the past 30 days: casual										
1	11	60.4	(36.4–80.3)	2	100.0		9	55.2	(30.7–77.5)	0.4643
2-4	6	34.1	(15.7–58.8)	0	0.0		6	38.5	(17.9–64.2)	
5+	1	5.5	(0.8–30.8)	0	0.0		1	6.3	(0.9–33.9)	
N	18			2			16			
Number of sex partners in the past 30 days: commercial (buying - I paid)										
1	1	37.2	(3.5–90.5)	0	0.0		1	37.2	(3.5–90.6)	
2-4	1	62.8	(9.5–96.5)	0	0.0		1	62.8	(9.4–96.5)	
5+	0	0.0		0	0.0		0	0.0		
N	2			0			2			
Number of sex partners in the past 30 days: commercial (selling - I was paid)										
1	2	3.8	(0.9–14.3)	1	2.1	(0.3–13.8)	1	100.0		0.0000
2-4	29	82.2	(67.9–91.0)	29	83.7	(69.3–92.1)	0	0.0		
5+	7	14.0	(6.4–27.7)	7	14.2	(6.5–28.3)	0	0.0		

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
N	38			37			1			
Number of sex partners in the past 30 days: total										
1	239	78.6	(73.1–83.2)	63	56.1	(45.9–65.8)	176	91.7	(87.0–94.8)	0.0000
2-4	46	15.4	(11.5–20.4)	29	28.9	(20.5–39.2)	17	7.5	(4.6–12.1)	
5+	19	6.0	(3.7–9.6)	17	15.0	(9.1–23.7)	2	0.8	(0.2–3.2)	
N	304			109			195			



Figure 4.2. Condom Use During Last Sexual Encounter by Type of Partner (%)



Figure 4.3. Trends in Condom Use During Last Sexual Encounter by Survey Round (%)

Table 4.4. Condom Use During Last Sexual Encounter by Sociodemographic Characteristics

		Used condom during last sex: if ever had sex				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
Total						
All	469	149	30.9 (26.6–35.6)	320	69.1 (64.4–73.4)	1.0000
Sex						
male	320	98	29.9 (24.8–35.6)	222	70.1 (64.4–75.2)	0.5470
female	149	51	32.9 (25.4–41.4)	98	67.1 (58.6–74.6)	
Age						
<25	8	3	32.3 (7.3–74.3)	5	67.7 (25.7–92.7)	0.5812
25-34	121	33	27.0 (19.5–36.1)	88	73.0 (63.9–80.5)	
35-44	217	74	34.0 (27.5–41.2)	143	66.0 (58.8–72.5)	
45+	123	39	28.6 (21.0–37.6)	84	71.4 (62.4–79.0)	
Years since the start of injecting drug use						
≤2	10	4	41.7 (13.5–76.6)	6	58.3 (23.4–86.5)	0.0881
3-5	16	9	59.4 (32.7–81.5)	7	40.6 (18.5–67.3)	
6-10	67	22	32.4 (21.8–45.1)	45	67.6 (54.9–78.2)	
≥11	376	114	29.3 (24.6–34.5)	262	70.7 (65.5–75.4)	
Partnership status						
live alone	171	55	31.2 (24.1–39.2)	116	68.8 (60.8–75.9)	0.9363
live with partner	298	94	30.8 (25.5–36.6)	204	69.2 (63.4–74.5)	
Current employment status						
full-time	98	29	29.3 (20.6–39.8)	69	70.7 (60.2–79.4)	0.2682
part-time or temporary	256	88	33.3 (27.4–39.8)	168	66.7 (60.2–72.6)	
unemployed	30	9	28.6 (14.9–47.9)	21	71.4 (52.1–85.1)	
disabled	19	9	45.1 (20.7–72.1)	10	54.9 (27.9–79.3)	
other	66	14	20.6 (12.0–33.2)	52	79.4 (66.8–88.0)	
Monthly income category						
<3K	145	32	20.3 (14.2–28.1)	113	79.7 (71.9–85.8)	0.0023
3-10K	175	62	37.1 (29.7–45.2)	113	62.9 (54.8–70.3)	
10-20K	124	49	38.6 (29.9–48.1)	75	61.4 (51.9–70.1)	
≥20K	24	6	22.5 (9.7–44.0)	18	77.5 (56.0–90.3)	
Ever incarcerated						

		Used condom during last sex: if ever had sex				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
no	397	116	29.0 (24.4–34.0)	281	71.0 (66.0–75.6)	0.0238
yes	72	33	43.6 (31.5–56.4)	39	56.4 (43.6–68.5)	

Table 4.5. Condom Use During Last Sexual Encounter by Selected Subgroups

		Used condom during last sex: if ever had sex				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	180	73	39.8 (32.4–47.7)	107	60.2 (52.3–67.6)	0.0021
yes	289	76	25.3 (20.4–31.1)	213	74.7 (68.9–79.6)	
Treated with MAT currently (of all)						
no	376	122	31.5 (26.7–36.7)	254	68.5 (63.3–73.3)	0.6481
yes	92	27	28.8 (19.8–39.9)	65	71.2 (60.1–80.2)	
HIV test result						
positive	80	21	26.7 (17.3–38.9)	59	73.3 (61.1–82.7)	0.4199
negative	389	128	31.8 (27.1–36.9)	261	68.2 (63.1–72.9)	
Past 30 days injecting 4 categories						
opioids	291	99	32.4 (27.0–38.3)	192	67.6 (61.7–73.0)	0.3616
stimulants	44	15	38.1 (23.5–55.2)	29	61.9 (44.8–76.5)	
opi+stimul	132	35	26.4 (19.0–35.3)	97	73.6 (64.7–81.0)	
other	2	0	0.0	2	100.0	
Injecting drug type of choice						
opioids	404	123	29.3 (24.8–34.2)	281	70.7 (65.8–75.2)	0.1361
stimulants	63	25	40.7 (28.3–54.5)	38	59.3 (45.5–71.7)	
other	1	0	0.0	1	100.0	

Table 4.6. Condom use by type of partner by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Used condom during last sex: regular partner										
yes	192	73.9	(68.0–79.1)	51	61.2	(49.5–71.9)	141	79.6	(73.0–84.8)	0.0029
N	266			82			184			
Used condom during last sex: casual partner										
yes	21	89.1	(64.0–97.4)	4	100.0		17	86.9	(58.7–96.9)	0.4771

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
N	23			4			19			
Used condom during last sex: commercial (I paid) partner										
yes	4	65.7	(25.3–91.5)	0	0.0		4	65.7	(25.2–91.6)	
N	6			0			6			
Used condom during last sex: commercial (I was paid) partner										
yes	39	98.7	(91.3–99.8)	39	98.7	(91.2–99.8)	0	0.0		
N	40			40			0			
Condom use frequency: regular partner										
always	143	55.7	(49.1–62.0)	38	45.7	(34.6–57.2)	105	60.2	(52.3–67.5)	0.0863
often	25	8.9	(6.0–13.2)	8	8.5	(4.2–16.7)	17	9.1	(5.6–14.6)	
half	18	6.3	(3.9–10.0)	4	4.0	(1.5–10.6)	14	7.3	(4.3–12.3)	
sometimes	7	2.6	(1.2–5.8)	2	3.7	(0.9–14.6)	5	2.1	(0.9–5.1)	
rarely	7	2.1	(1.0–4.6)	2	2.1	(0.5–8.4)	5	2.1	(0.8–5.4)	
never	65	24.3	(19.2–30.3)	28	35.9	(25.5–47.8)	37	19.1	(13.8–25.9)	
N	265			82			183			
Condom use frequency: casual partner										
always	19	75.1	(52.1–89.3)	3	77.7	(26.0–97.2)	16	74.6	(48.8–90.1)	
often	0	0.0		0	0.0		0	0.0		
half	2	8.9	(2.2–30.2)	1	22.3	(2.8–74.0)	1	6.4	(0.9–33.9)	
sometimes	1	7.0	(1.0–36.0)	0	0.0		1	8.4	(1.2–40.8)	
rarely	0	0.0		0	0.0		0	0.0		
never	2	8.9	(2.2–30.2)	0	0.0		2	10.7	(2.6–34.8)	
N	24			4			20			
Condom use frequency: commercial (I paid) partner										
always	4	62.0	(22.4–90.2)	0	0.0		4	62.0	(22.3–90.2)	
often	0	0.0		0	0.0		0	0.0		
half	0	0.0		0	0.0		0	0.0		
sometimes	0	0.0		0	0.0		0	0.0		
rarely	0	0.0		0	0.0		0	0.0		
never	2	38.0	(9.8–77.6)	0	0.0		2	38.0	(9.8–77.7)	
N	6			0			6			
Condom use frequency: commercial (I was paid) partner										
always	25	64.2	(47.8–77.8)	24	63.6	(47.0–77.5)	1	100.0		
often	7	17.4	(8.0–33.7)	7	17.7	(8.1–34.3)	0	0.0		
half	9	18.4	(9.5–32.6)	9	18.7	(9.7–33.2)	0	0.0		
sometimes	0	0.0		0	0.0		0	0.0		
rarely	0	0.0		0	0.0		0	0.0		
never	0	0.0		0	0.0		0	0.0		
N	41			40			1			



Figure 4.4. Frequency of condom use by type of partner by Sex (%)



Figure 4.5. Frequency of condom use among men during the last sexual encounter by the riskiest type of partner in the past 30 days (%)

5. HIV, HCV, and Syphilis Testing Results

Table 5.1. HIV Prevalence by Sociodemographic Characteristics

			HIV test result			
	N	positive		negative		
		n	% (CI)	n	% (CI)	p-value
Total						
All	500	87	17.0 (13.7–20.9)	413	83.0 (79.1–86.3)	1.0000
Sex						
male	343	69	20.5 (16.1–25.8)	274	79.5 (74.2–83.9)	0.0028
female	157	18	9.7 (6.0–15.2)	139	90.3 (84.8–94.0)	
Age						

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
<25	8	1	8.2 (0.7–53.3)	7	91.8 (46.7–99.3)	0.0103
25-34	126	11	8.3 (4.4–15.2)	115	91.7 (84.8–95.6)	
35-44	227	41	17.3 (12.4–23.7)	186	82.7 (76.3–87.6)	
45+	139	34	24.0 (17.3–32.3)	105	76.0 (67.7–82.7)	
Years since the start of injecting drug use						
≤2	10	0	0.0	10	100.0	0.0054
3-5	18	0	0.0	18	100.0	
6-10	69	5	6.4 (2.5–15.5)	64	93.6 (84.5–97.5)	
≥11	403	82	19.8 (15.8–24.4)	321	80.2 (75.6–84.2)	
Partnership status						
live alone	191	42	21.1 (15.3–28.5)	149	78.9 (71.5–84.7)	0.0722
live with partner	309	45	14.3 (10.6–18.9)	264	85.7 (81.1–89.4)	
Current employment status						
full-time	103	16	13.7 (8.1–22.0)	87	86.3 (78.0–91.9)	0.0083
part-time or temporary	277	50	17.5 (13.2–22.9)	227	82.5 (77.1–86.8)	
unemployed	31	8	25.3 (12.6–44.5)	23	74.7 (55.5–87.4)	
disabled	20	7	44.2 (19.0–72.8)	13	55.8 (27.2–81.0)	
other	69	6	8.3 (3.6–17.9)	63	91.7 (82.1–96.4)	
Monthly income category						
<3K	156	33	18.8 (13.2–26.0)	123	81.2 (74.0–86.8)	0.3944
3-10K	189	37	19.1 (13.5–26.4)	152	80.9 (73.6–86.5)	
10-20K	128	15	12.9 (7.6–21.1)	113	87.1 (78.9–92.4)	
≥20K	26	2	9.1 (2.1–31.4)	24	90.9 (68.6–97.9)	
Ever incarcerated						
no	426	68	15.3 (12.0–19.3)	358	84.7 (80.7–88.0)	0.0245
yes	74	19	28.1 (17.2–42.4)	55	71.9 (57.6–82.8)	

Table 5.2. HIV Prevalence by Selected Subgroups

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	190	16	7.7 (4.5–12.9)	174	92.3 (87.1–95.5)	0.0001
yes	310	71	22.7 (17.9–28.2)	239	77.3 (71.8–82.1)	
Treated with MAT currently (of all)						
no	405	40	8.8 (6.3–12.0)	365	91.2 (88.0–93.7)	0.0000
yes	94	47	54.5 (43.5–65.1)	47	45.5 (34.9–56.5)	
Past 30 days injecting 4 categories						
opioids	305	58	19.4 (15.0–24.7)	247	80.6 (75.3–85.0)	0.2580
stimulants	45	6	11.0 (4.7–23.5)	39	89.0 (76.5–95.3)	
opi+stimul	148	22	14.0 (8.7–21.8)	126	86.0 (78.2–91.3)	
other	2	1	42.3 (0.0–100.0)	1	57.7 (0.0–100.0)	
Injecting drug type of choice						
opioids	433	79	18.0 (14.4–22.4)	354	82.0 (77.6–85.6)	0.0014
stimulants	64	6	7.9 (3.4–17.3)	58	92.1 (82.7–96.6)	
other	2	2	100.0	0	0.0	



Figure 5.1. HIV Test Result (%)



Figure 5.2. Trends in HIV Prevalence by Survey Round (%)



Figure 5.3. Anti-HCV Testing Coverage In the Survey (%)



Figure 5.4. Anti-HCV Test Results (%)



Figure 5.5. Anti-HCV Test Results by Sex (%)



Figure 5.6. Trends in Anti-HCV Prevalence by Survey Round (%)



Figure 5.7. Syphilis Test Results (%)

6. HIV Prevention

Table 6.1. Being a Client of NGO by Sociodemographic Characteristics

		Client of NGO working with PWID					
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
Total							
	All	500	190	37.9 (33.4–42.6)	310	62.1 (57.4–66.6)	1.0000
Sex							
	male	343	129	37.1 (31.7–42.8)	214	62.9 (57.2–68.3)	0.6203
	female	157	61	39.6 (31.6–48.1)	96	60.4 (51.9–68.4)	
Age							

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
<25	8	7	76.5 (20.4–97.6)	1	23.5 (2.4–79.6)	0.0005
25-34	126	63	50.2 (40.7–59.7)	63	49.8 (40.3–59.3)	
35-44	227	87	39.1 (32.4–46.3)	140	60.9 (53.7–67.6)	
45+	139	33	23.8 (16.9–32.3)	106	76.2 (67.7–83.1)	
Years since the start of injecting drug use						
≤2	10	9	91.1 (48.3–99.1)	1	8.9 (0.9–51.7)	0.0000
3-5	18	14	77.0 (50.0–91.8)	4	23.0 (8.2–50.0)	
6-10	69	41	59.3 (46.5–70.9)	28	40.7 (29.1–53.5)	
≥11	403	126	31.6 (26.8–36.8)	277	68.4 (63.2–73.2)	
Partnership status						
live alone	191	80	40.4 (33.0–48.3)	111	59.6 (51.7–67.0)	0.3955
live with partner	309	110	36.3 (30.7–42.2)	199	63.7 (57.8–69.3)	
Current employment status						
full-time	103	53	54.0 (43.6–64.0)	50	46.0 (36.0–56.4)	0.0006
part-time or temporary	277	101	35.5 (29.7–41.8)	176	64.5 (58.2–70.3)	
unemployed	31	8	28.5 (14.5–48.6)	23	71.5 (51.4–85.5)	
disabled	20	3	8.3 (2.2–26.5)	17	91.7 (73.5–97.8)	
other	69	25	36.7 (25.3–49.9)	44	63.3 (50.1–74.7)	
Monthly income category						
<3K	156	51	32.9 (25.4–41.3)	105	67.1 (58.7–74.6)	0.0005
3-10K	189	58	30.5 (24.0–38.0)	131	69.5 (62.0–76.0)	
10-20K	128	67	52.3 (43.0–61.6)	61	47.7 (38.4–57.0)	
≥20K	26	13	55.0 (34.6–73.8)	13	45.0 (26.2–65.4)	
Ever incarcerated						
no	426	175	41.0 (36.1–46.1)	251	59.0 (53.9–63.9)	0.0001
yes	74	15	17.3 (10.2–27.7)	59	82.7 (72.3–89.8)	

Table 6.2. Being a Client of NGO by Selected Subgroups

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Treated with MAT currently (of all)						
no	405	181	44.4 (39.2–49.7)	224	55.6 (50.3–60.8)	0.0000
yes	94	9	8.7 (4.5–16.3)	85	91.3 (83.7–95.5)	
HIV test result						
positive	87	16	17.2 (10.1–27.7)	71	82.8 (72.3–89.9)	0.0001
negative	413	174	42.1 (37.1–47.4)	239	57.9 (52.6–62.9)	
Past 30 days injecting 4 categories						
opioids	305	110	35.7 (30.1–41.7)	195	64.3 (58.3–69.9)	0.0006
stimulants	45	28	67.2 (51.4–79.8)	17	32.8 (20.2–48.6)	
opi+stimul	148	52	34.6 (26.7–43.3)	96	65.4 (56.7–73.3)	
other	2	0	0.0	2	100.0	
Injecting drug type of choice						
opioids	433	146	32.7 (28.2–37.6)	287	67.3 (62.4–71.8)	0.0000
stimulants	64	43	73.2 (60.9–82.7)	21	26.8 (17.3–39.1)	
other	2	1	62.8 (0.0–100.0)	1	37.2 (0.0–100.0)	



Figure 6.1. Injecting and Sex Risk Perception Among HIV-negative PWID (%)



Figure 6.2. Received HIV Prevention Services in the Past 12 Months and 30 days (%)



Figure 6.3. Receiving Package of Prevention Services in the Past 12 Months (%)



Figure 6.4. Trends in Receiving HIV Prevention Services in the Past 12 Months (%)



Figure 6.5. Perceived changes in access to HIV prevention since February 2022 (%)

Table 6.3. Percentage of correct responses to knowledge questions by HIV status

	Total	HIV test result		
	All %	negative %	positive %	p-value
HIV knowledge				
HIV may be avoided	50.2	48.7	57.3	0.1906
proper condom use may prevent HIV	46.9	44.7	57.5	0.0479
undetectable=untransmittable	58.2	56.8	64.7	0.2160
PEP reduces the risk of HIV	54.7	53.1	62.5	0.1417
ART should be started immediately	55.3	53.8	62.9	0.1608

	Total	HIV test result		
	All %	negative %	positive %	p-value
ART may be postponed if one feels healthy	44.6	44.0	47.8	0.5548
ART may be stopped if one feels healthy	46.3	46.0	47.5	0.8270
HIV is transmitted through blood and sex	63.9	63.7	65.0	0.8402
HIV is transmitted via air, food, or skin	61.1	61.1	60.8	0.9538
HBV knowledge				
proper condom use may prevent HBV	49.2	47.4	57.9	0.1088
treatment should be started immediately	52.5	51.9	55.3	0.5966
treatment may be postponed if one feels healthy	30.5	29.6	35.0	0.3795
HBV is 100% transmitted from mother to child	22.6	22.4	23.6	0.8381
HBV is transmitted through blood and sex	58.4	56.9	65.9	0.1608
HBV is transmitted via air, food, or skin	49.2	48.3	53.5	0.4222
treatment may be stopped if one feels healthy	44.9	42.8	54.9	0.0615
HCV knowledge				
proper condom use may prevent HCV	15.0	14.8	16.2	0.7738
treatment should be started immediately	46.8	47.6	43.0	0.4863
treatment may be postponed if one feels healthy	34.7	33.8	39.4	0.3848
HCV is 100% transmitted from mother to child	18.0	17.1	22.1	0.3626
HCV is transmitted through blood and sex	66.1	64.4	74.7	0.0906
there is no treatment for HCV	47.3	46.1	53.1	0.2835
HCV is transmitted via air, food, or skin	51.9	52.0	51.3	0.9176
treatment may be stopped if one feels healthy	61.2	61.6	59.0	0.6880

7. HIV Testing

Table 7.1. HIV Testing Knowledge and Uptake

	n	%	CI
Know where to get HIV test			
yes	422	83.7	(79.9–87.0)
Tested for HIV ever			
yes	431	86.2	(82.6–89.2)
Tested for HIV in the past 12 months			
yes	203	45.7	(40.6–50.9)
Tested for HIV in the past 6 months			
yes	128	29.3	(24.9–34.1)
Received the result of HIV test (of those tested)			
yes	417	97.4	(95.5–98.5)
Willing to disclose HIV test result (of those who got result)			
yes	410	98.4	(96.2–99.3)
Self-reported HIV status (of all tested)			
positive	81	18.1	(14.4–22.4)
negative	342	81.9	(77.6–85.6)
HIV testing and status awareness (GAM)			
yes	257	58.6	(53.3–63.8)
Ever did a HIV self-test			
yes	4	0.7	(0.3–2.0)
Regular sex partner tested for HIV			
yes	233	80.3	(74.8–84.8)
Regular sex partner HIV test result			
positive	18	8.0	(4.9–12.8)
negative	207	89.1	(84.1–92.7)
cannot disclose	8	2.9	(1.4–5.7)



Figure 7.1. HIV Testing Uptake (%)



Figure 7.2. Testing for HIV, HCV, syphilis since February 2022 (%)



Figure 7.3. HIV Testing Since February 2022 (%)

Table 7.2. Testing for HIV in the past 12 months (among all) by Sociodemographic Characteristics

		Tested for HIV in the past 12 months				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
Total						
All	427	224	54.3 (49.1–59.4)	203	45.7 (40.6–50.9)	1.0000
Sex						
male	291	150	53.4 (47.0–59.6)	141	46.6 (40.4–53.0)	0.6139
female	136	74	56.2 (47.1–64.9)	62	43.8 (35.1–52.9)	
Age						
<25	7	5	61.3 (16.6–92.6)	2	38.7 (7.4–83.4)	0.3420
25-34	98	49	51.2 (40.3–61.9)	49	48.8 (38.1–59.7)	
35-44	193	107	59.3 (51.6–66.6)	86	40.7 (33.4–48.4)	
45+	129	63	48.7 (39.6–58.0)	66	51.3 (42.0–60.4)	
Years since the start of injecting drug use						
≤2	10	5	43.9 (14.9–77.7)	5	56.1 (22.3–85.1)	0.8338
3-5	13	8	63.9 (34.1–85.8)	5	36.1 (14.2–65.9)	
6-10	54	29	55.0 (40.8–68.4)	25	45.0 (31.6–59.2)	
≥11	350	182	54.1 (48.4–59.8)	168	45.9 (40.2–51.6)	
Partnership status						
live alone	160	82	54.0 (45.3–62.4)	78	46.0 (37.6–54.7)	0.9242
live with partner	267	142	54.5 (48.1–60.8)	125	45.5 (39.2–51.9)	

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Current employment status						
full-time	81	44	55.1 (43.3–66.3)	37	44.9 (33.7–56.7)	0.3525
part-time or temporary	240	131	56.8 (49.9–63.4)	109	43.2 (36.6–50.1)	
unemployed	30	17	55.6 (36.6–73.0)	13	44.4 (27.0–63.4)	
disabled	20	10	58.1 (31.5–80.6)	10	41.9 (19.4–68.5)	
other	56	22	40.8 (27.8–55.2)	34	59.2 (44.8–72.2)	
Monthly income category						
<3K	133	67	50.3 (41.0–59.5)	66	49.7 (40.5–59.0)	0.0549
3-10K	166	84	52.9 (44.6–61.1)	82	47.1 (38.9–55.4)	
10-20K	108	66	65.2 (55.2–74.0)	42	34.8 (26.0–44.8)	
≥20K	19	7	35.8 (16.9–60.5)	12	64.2 (39.5–83.1)	
Ever incarcerated						
no	357	190	54.7 (49.1–60.3)	167	45.3 (39.7–50.9)	0.6768
yes	70	34	51.7 (38.7–64.5)	36	48.3 (35.5–61.3)	

Table 7.3. Testing for HIV in the past 12 months (among all) by Selected Subgroups

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	130	86	66.1 (57.0–74.2)	44	33.9 (25.8–43.0)	0.0029
yes	297	138	49.3 (43.0–55.6)	159	50.7 (44.4–57.0)	
Treated with MAT currently (of all)						
no	337	177	54.9 (49.1–60.6)	160	45.1 (39.4–50.9)	0.7073
yes	89	47	52.5 (41.1–63.6)	42	47.5 (36.4–58.9)	
HIV test result						
positive	84	58	69.6 (57.9–79.2)	26	30.4 (20.8–42.1)	0.0040
negative	343	166	50.6 (44.9–56.4)	177	49.4 (43.6–55.1)	
Past 30 days injecting 4 categories						
opioids	272	142	52.7 (46.2–59.0)	130	47.3 (41.0–53.8)	0.5281
stimulants	32	14	47.2 (29.4–65.8)	18	52.8 (34.2–70.6)	
opi+stimul	121	67	59.1 (49.2–68.2)	54	40.9 (31.8–50.8)	

	N	Tested for HIV in the past 12 months				
		n	no % (CI)	n	yes % (CI)	p-value
other	2	1	42.3 (0.0–100.0)	1	57.7 (0.0–100.0)	
Injecting drug type of choice						
opioids	377	198	54.2 (48.7–59.7)	179	45.8 (40.3–51.3)	0.8975
stimulants	47	24	54.3 (38.9–69.0)	23	45.7 (31.0–61.1)	
other	2	1	37.2 (0.0–100.0)	1	62.8 (0.0–100.0)	

8. HIV Treatment



Figure 8.1. HIV Status Awareness Among HIV+ (%)



Figure 8.2. HIV Treatment Cascade - Four-stage (%)



Figure 8.3. HIV Treatment Cascade - Conditional (%)



Figure 8.4. HIV Treatment Cascade - Proportions (%)



Figure 8.5. Trends in HIV Treatment Cascade (Conditional, 95-95-95) by Survey Round (%)

Table 8.1. HIV Treatment Cascade (Conditional, 95-95-95) by Sociodemographic Characteristics

		Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
		N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Total											
	All	87	83.0 (72.3–90.1)	1.0000	73	77.8 (66.0–86.3)	1.0000	56	41	72.8 (58.4–83.6)	1.0000
Sex											
	male	69	81.3 (68.7–89.6)	0.3524	57	74.6 (60.7–84.9)	0.1501	42	31	74.5 (57.7–86.2)	0.6131
	female	18	90.3 (67.7–97.6)		16	90.2 (67.3–97.6)		14	10	67.0 (38.1–87.0)	
Age											

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
<25	1	100.0	0.8024	1	0.0	0.0187	0	0	0.0	
25-34	11	89.4 (50.9–98.6)		10	46.0 (18.0–76.7)		6	4	58.4 (20.1–88.7)	
35-44	41	79.3 (60.5–90.6)		34	79.1 (61.4–90.0)		26	21	84.8 (66.2–94.1)	
45+	34	85.2 (69.8–93.4)		28	87.5 (70.1–95.4)		24	16	63.3 (41.2–80.9)	
Years since the start of injecting drug use										
≤2	0	0.0		0	0.0		0	0	0.0	
3-5	0	0.0		0	0.0		0	0	0.0	
6-10	5	100.0		5	27.8 (5.6–71.3)		2	2	100.0	
≥11	82	82.1 (70.9–89.6)		68	80.9 (69.1–89.0)		54	39	72.2 (57.5–83.2)	
Partnership status										
live alone	42	83.3 (65.0–93.0)	0.9552	36	85.2 (66.3–94.4)	0.1734	31	23	76.8 (57.9–88.9)	0.4940
live with partner	45	82.8 (68.5–91.4)		37	70.5 (53.7–83.1)		25	18	68.0 (45.6–84.4)	
Current employment status										
full-time	16	80.7 (43.8–95.7)	0.7683	14	58.4 (32.0–80.7)	0.1127	8	6	70.9 (32.2–92.6)	0.3639
part-time or temporary	50	80.1 (65.5–89.5)		40	78.5 (61.4–89.4)		32	22	66.4 (47.0–81.6)	
unemployed	8	85.4 (39.6–98.1)		7	100.0		7	5	65.9 (25.6–91.6)	
disabled	7	100.0		7	94.4 (60.9–99.4)		6	5	94.6 (61.2–99.5)	
other	6	85.4 (39.3–98.1)		5	57.6 (17.4–89.7)		3	3	100.0	
Monthly income category										
<3K	33	85.0 (64.8–94.6)	0.8898	29	65.0 (44.9–80.9)	0.0725	19	14	72.7 (47.8–88.6)	0.8632
3-10K	37	79.8 (63.0–90.2)		29	92.3 (76.9–97.8)		26	19	70.9 (47.8–86.6)	
10-20K	15	83.5 (48.3–96.5)		13	70.6 (40.8–89.3)		9	6	72.0 (36.1–92.1)	

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
≥20K	2	100.0		2	100.0		2	2	100.0	
Ever incarcerated										
no	68	79.1 (66.3–87.9)	0.0190	55	70.2 (56.1–81.3)	0.0119	38	28	70.9 (53.1–84.0)	0.6803
yes	19	97.1 (80.6–99.6)		18	100.0		18	13	76.6 (50.0–91.4)	

Table 8.2. HIV Treatment Cascade (Conditional, 95-95-95) by Selected Subgroups

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID										
no	16	79.3 (44.2–94.9)	0.7309	14	86.9 (58.7–96.8)	0.3737	12	8	67.0 (35.7–88.1)	0.6533
yes	71	83.8 (72.4–91.0)		59	76.0 (62.5–85.7)		44	33	74.1 (57.6–85.7)	
Treated with MAT currently (of all)										
no	40	73.4 (56.0–85.7)	0.0780	30	78.1 (59.2–89.8)	0.9581	23	19	85.5 (65.4–94.8)	0.0958
yes	47	90.0 (74.4–96.6)		43	77.6 (61.3–88.3)		33	22	65.2 (45.5–80.7)	
HIV test result										
positive	87	83.0 (72.1–90.2)		73	77.8 (65.8–86.4)		56	41	72.8 (58.2–83.7)	
negative	0	0.0		0	0.0		0	0	0.0	
Past 30 days injecting 4 categories										
opioids	58	91.3 (77.6–96.9)	0.0055	54	83.1 (69.1–91.5)	0.0406	45	33	72.4 (56.4–84.2)	
stimulants	6	100.0		6	100.0		6	4	63.0 (22.3–91.0)	
opi+stimul	22	58.6 (34.7–79.1)		12	53.0 (21.9–81.9)		5	4	81.1 (28.0–97.9)	
other	1	100.0		1	0.0		0	0	0.0	
Injecting drug type of choice										
opioids	79	82.9 (71.5–90.3)	0.8223	66	76.7 (64.2–85.9)	0.4344	50	38	75.5 (60.2–86.2)	0.1701
stimulants	6	79.8 (30.4–97.3)		5	100.0		5	3	57.5 (17.3–89.7)	
other	2	100.0		2	62.8 (0.0–100.0)		1	0	0.0	

Table 8.3. ART adherence (among those on ART)

		n	%	CI
When did you last miss ART dose				
	last week	6	9.8	(4.3–20.9)

	n	%	CI
1-2 weeks ago	4	5.4	(1.9–14.0)
3-4 weeks ago	1	2.3	(0.3–14.7)
1-3 months ago	3	4.9	(1.6–14.4)
never	47	77.6	(64.7–86.7)
What was the reason for missing the last ART dose			
forgot	5	55.8	(26.2–81.9)
did not have meds	4	35.3	(12.9–66.9)
was under influence	0	0.0	
did not want others to see	1	8.8	(1.2–43.6)
other	0	0.0	
Reasons for not taking ART			
not sure it is needed	4	38.0	(14.1–69.6)
no time to visit clinic	4	36.4	(13.7–67.4)
no motivation to visit clinic	1	18.4	(2.6–65.2)
missed a visit, hard to come back	4	39.4	(14.9–70.7)
too sick to visit clinic	4	33.6	(12.3–64.6)
drug use	4	36.1	(13.4–67.3)
side effects or complications	0	0.0	
no understanding of how to take it	5	45.8	(20.4–73.5)
lost or sold all ARVs	4	28.9	(10.5–58.5)
alcohol use	4	38.0	(14.1–69.6)
waited too long and left	1	9.3	(1.3–44.6)
Time on ART			
≤3m	6	46.3	(22.3–72.1)
4-24m	5	36.2	(15.6–63.5)
25-60m	3	17.5	(5.3–44.8)
5y+	0	0.0	

9. PrEP



Figure 9.1. PrEP Uptake in the Past 12 Months (%)



Figure 9.2. Change in PrEP Awareness and Uptake from 2020 to 2023 (%)



Figure 9.3. Change in PrEP Uptake from 2020 to 2023 (%)

Table 9.1. PrEP Awareness by Sociodemographic Characteristics

			PrEP uptake in the past 12 months								
		N	use now		used in the past		never used		not aware		
			n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total											
	All	500	20	4.9 (3.1–7.7)	11	2.2 (1.1–4.2)	51	9.2 (6.9–12.2)	418	83.7 (79.8–86.9)	1.0000
Sex											
	male	343	0	0.0	0	0.0	29	6.7 (4.6–9.7)	314	93.3 (90.3–95.4)	0.0000
	female	157	20	15.1 (9.7–22.9)	11	6.8 (3.5–12.6)	22	14.4 (9.3–21.5)	104	63.7 (55.1–71.6)	
Age											
	<25	8	0	0.0	1	23.5 (2.4–79.6)	1	15.8 (1.4–70.8)	6	60.6 (17.7–91.7)	0.0031
	25-34	126	4	4.5 (1.6–11.9)	6	4.9 (2.0–11.6)	16	12.1 (7.2–19.7)	100	78.5 (69.3–85.5)	

		PrEP uptake in the past 12 months								
	N	use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
35-44	227	8	4.1 (1.9–8.6)	3	1.0 (0.3–3.3)	22	9.3 (6.0–14.1)	194	85.6 (79.8–89.9)	
45+	139	8	6.8 (3.3–13.7)	1	0.6 (0.1–4.0)	12	6.3 (3.5–11.1)	118	86.3 (79.1–91.3)	
Years since the start of injecting drug use										
≤2	10	0	0.0	0	0.0	1	14.4 (1.5–64.9)	9	85.6 (35.1–98.5)	
3-5	18	0	0.0	0	0.0	5	26.5 (10.2–53.3)	13	73.5 (46.7–89.8)	
6-10	69	1	2.0 (0.3–13.5)	2	4.6 (1.1–17.8)	6	8.2 (3.5–18.2)	60	85.2 (72.7–92.5)	
≥11	403	19	5.7 (3.5–9.1)	9	2.0 (0.9–4.0)	39	8.5 (6.1–11.8)	336	83.9 (79.5–87.4)	
Partnership status										
live alone	191	5	3.6 (1.5–8.5)	3	1.8 (0.5–6.3)	19	8.3 (5.1–13.1)	164	86.3 (80.1–90.8)	0.6703
live with partner	309	15	5.8 (3.4–9.8)	8	2.4 (1.1–5.1)	32	9.8 (6.8–13.9)	254	82.0 (76.8–86.2)	
Current employment status										
full-time	103	2	1.7 (0.4–6.6)	7	7.8 (3.4–16.9)	13	12.0 (6.7–20.6)	81	78.5 (68.4–86.0)	
part-time or temporary	277	5	2.9 (1.1–6.9)	1	0.2 (0.0–1.5)	22	6.4 (4.1–9.7)	249	90.6 (86.2–93.7)	
unemployed	31	0	0.0	0	0.0	4	13.2 (4.6–32.4)	27	86.8 (67.6–95.4)	
disabled	20	0	0.0	0	0.0	4	17.3 (5.7–42.1)	16	82.7 (57.9–94.3)	
other	69	13	21.6 (12.5–34.7)	3	3.9 (1.2–11.9)	8	12.9 (6.0–25.6)	45	61.6 (48.2–73.4)	
Monthly income category										
<3K	156	13	9.8 (5.6–16.5)	10	6.0 (3.0–11.5)	10	6.2 (3.2–11.6)	123	78.0 (70.1–84.4)	0.0000
3-10K	189	1	0.5 (0.1–3.2)	1	0.3 (0.0–2.4)	20	10.5 (6.6–16.3)	167	88.7 (82.8–92.8)	
10-20K	128	6	5.6 (2.2–13.1)	0	0.0	18	11.6 (7.2–18.3)	104	82.8 (74.7–88.7)	
≥20K	26	0	0.0	0	0.0	2	5.5 (1.2–21.1)	24	94.5 (78.9–98.8)	
Ever incarcerated										
no	426	20	5.7 (3.6–8.9)	9	2.2 (1.0–4.4)	34	7.7 (5.4–10.9)	363	84.5 (80.3–88.0)	0.0108
yes	74	0	0.0	2	2.5 (0.6–10.1)	17	19.1 (11.6–29.7)	55	78.5 (67.5–86.5)	

Table 9.2. PrEP Current Use by Sociodemographic Characteristics

		PrEP uptake in the past 12 months								
	N	use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										
no	190	1	1.1 (0.1–7.2)	1	1.1 (0.1–7.2)	12	7.4 (4.0–13.2)	176	90.5 (83.9–94.5)	0.0429
yes	310	19	7.3 (4.5–11.5)	10	2.9 (1.5–5.6)	39	10.3 (7.4–14.0)	242	79.6 (74.4–83.9)	
Treated with MAT currently (of all)										
no	405	18	5.5 (3.3–8.8)	11	2.7 (1.4–5.1)	43	9.7 (7.1–13.2)	333	82.1 (77.6–85.9)	0.1915
yes	94	2	2.4 (0.6–9.6)	0	0.0	8	6.8 (3.3–13.5)	84	90.8 (83.1–95.2)	

		PrEP uptake in the past 12 months								
	N	use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
HIV test result										
positive	87	1	1.6 (0.2–10.6)	2	1.6 (0.4–6.5)	10	10.1 (5.3–18.5)	74	86.6 (77.6–92.4)	0.4577
negative	413	19	5.6 (3.5–8.9)	9	2.3 (1.1–4.7)	41	9.0 (6.5–12.3)	344	83.1 (78.7–86.7)	
Past 30 days injecting 4 categories										
opioids	305	7	2.3 (1.0–5.1)	6	2.3 (0.9–5.6)	35	9.8 (7.0–13.6)	257	85.6 (80.9–89.2)	
stimulants	45	0	0.0	0	0.0	10	21.0 (10.6–37.4)	35	79.0 (62.6–89.4)	
opi+stimul	148	13	10.9 (6.3–18.4)	5	2.6 (1.0–6.2)	6	5.0 (2.2–11.2)	124	81.5 (73.2–87.6)	
other	2	0	0.0	0	0.0	0	0.0	2	100.0	
Injecting drug type of choice										
opioids	433	20	5.7 (3.6–8.9)	11	2.5 (1.3–4.8)	41	8.6 (6.2–11.7)	361	83.3 (79.0–86.8)	
stimulants	64	0	0.0	0	0.0	10	13.9 (6.9–26.0)	54	86.1 (74.0–93.1)	
other	2	0	0.0	0	0.0	0	0.0	2	100.0	

Table 9.3. PrEP Awareness and Uptake

	n	%	CI
PrEP uptake in the past 12 months			
use now	20	4.9	(3.1–7.7)
used in the past	11	2.2	(1.1–4.2)
never used	51	9.2	(6.9–12.2)
not aware	418	83.7	(79.8–86.9)
Aware of PrEP			
no	418	83.7	(79.8–86.9)
yes	82	16.3	(13.1–20.2)
PrEP use current			
no	480	95.1	(92.3–96.9)
yes	20	4.9	(3.1–7.7)
PrEP use current (of those aware)			
no	62	69.9	(57.3–80.0)
yes	20	30.1	(20.0–42.7)

10. MAT



Figure 10.1. MAT Awareness (%)



Figure 10.2. MAT Current Uptake (%)



Figure 10.3. Trends in MAT Lifetime and Current Uptake by Survey Round (%)

Table 10.1. MAT experience

	n	%	CI
Reason for MAT discontinuation			
moved to another city	3	8.1	(2.5–23.1)
clinic closed after Feb 2022	0	0.0	
weak or no effect	6	14.6	(6.3–30.2)
side effects	2	5.7	(1.4–20.7)
do not want to visit clinic	11	30.9	(17.0–49.5)
do not want to quit drugs	5	12.8	(5.3–27.8)
hard to get to the clinic	5	12.9	(5.2–28.6)
do not need it	7	27.4	(13.6–47.4)
do not like the attitude of physician	6	18.0	(7.5–37.3)
How did the injection frequency change during MAT			
intensified	5	16.7	(6.5–36.7)
did not change	15	48.0	(31.0–65.4)
decreased	15	35.3	(21.3–52.5)
Whether bought bupr. or methadone while not being a patient in the past 12 months			
yes, methadone	117	21.4	(17.9–25.4)
yes, buprenorphine	1	0.1	(0.0–1.0)
did not buy	382	78.4	(74.5–81.9)
Where bought bupr. or methadone while not being a patient in the past 12 months			
did not buy	382	78.4	(74.5–81.9)
bought from black market	111	20.4	(17.0–24.3)
bought from private clinic	7	1.2	(0.6–2.5)
Way of using bupr. or methaone bought from others			
injecting	112	95.1	(89.1–97.8)
injecting mixed	1	0.8	(0.1–5.3)
swallow or subling.	5	4.2	(1.7–10.0)
snort	0	0.0	

Table 10.2. MAT Awareness and Uptake by Sociodemographic Characteristics

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
Total										
All	499	94	18.0 (14.7–22.0)	28	4.9 (3.3–7.2)	62	11.9 (9.1–15.5)	315	65.1 (60.4–69.5)	1.0000
Sex										
male	342	77	22.2 (17.8–27.5)	22	5.7 (3.6–8.9)	44	12.0 (8.7–16.4)	199	60.0 (54.2–65.6)	0.0023
female	157	17	9.4 (5.7–14.9)	6	3.1 (1.4–7.0)	18	11.8 (7.3–18.7)	116	75.7 (67.9–82.0)	
Age										
<25	8	0	0.0	0	0.0	0	0.0	8	100.0	0.0014
25-34	126	10	8.1 (4.2–15.1)	6	3.7 (1.6–8.2)	14	11.6 (6.7–19.2)	96	76.7 (67.8–83.7)	
35-44	227	52	20.6 (15.5–27.0)	15	6.1 (3.5–10.5)	37	16.6 (11.7–23.0)	123	56.7 (49.4–63.6)	
45+	138	32	23.0 (16.5–31.2)	7	4.2 (1.9–8.8)	11	5.5 (3.0–9.9)	88	67.3 (58.7–74.9)	
Years since the start of injecting drug use										
≤2	10	0	0.0	0	0.0	2	23.3 (4.6–65.8)	8	76.7 (34.2–95.4)	0.0107
3-5	18	1	6.0 (0.7–36.1)	0	0.0	3	16.9 (5.0–44.0)	14	77.0 (50.0–91.8)	
6-10	69	7	8.7 (4.0–17.9)	1	0.7 (0.1–5.3)	15	22.1 (13.3–34.4)	46	68.5 (55.9–78.8)	
≥11	402	86	20.5 (16.5–25.1)	27	5.9 (3.9–8.7)	42	9.8 (7.0–13.7)	247	63.8 (58.5–68.8)	
Partnership status										
live alone	190	45	22.5 (16.5–29.8)	11	4.1 (2.2–7.5)	23	12.2 (7.7–18.9)	111	61.2 (53.2–68.7)	0.2452
live with partner	309	49	15.2 (11.5–19.7)	17	5.4 (3.2–8.9)	39	11.8 (8.5–16.1)	204	67.7 (61.9–72.9)	
Current employment status										
full-time	103	9	8.4 (4.3–15.7)	8	7.6 (3.6–15.5)	12	10.3 (5.8–17.8)	74	73.7 (63.9–81.6)	0.0000
part-time or temporary	276	55	18.2 (13.9–23.4)	9	2.7 (1.3–5.5)	35	13.1 (9.2–18.5)	177	66.1 (59.7–71.9)	
unemployed	31	14	42.0 (25.4–60.7)	2	8.5 (2.0–29.7)	4	12.2 (4.4–29.6)	11	37.2 (21.3–56.6)	
disabled	20	9	59.3 (33.1–81.1)	6	23.0 (8.8–48.2)	5	17.6 (6.3–40.7)	0	0.0	
other	69	7	10.1 (4.7–20.2)	3	3.6 (1.1–11.1)	6	7.6 (3.0–18.1)	53	78.7 (66.8–87.2)	
Monthly income category										
<3K	156	31	17.2 (12.0–24.1)	5	3.2 (1.2–8.1)	8	5.5 (2.2–12.9)	112	74.1 (65.9–80.9)	0.0159

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
3-10K	189	44	23.5 (17.3–31.0)	14	5.9 (3.4–10.1)	25	13.6 (9.0–19.9)	106	57.1 (49.1–64.6)	
10-20K	127	15	11.8 (7.1–19.0)	9	6.7 (3.2–13.2)	24	17.7 (11.7–25.8)	79	63.8 (54.5–72.2)	
≥20K	26	4	15.2 (5.4–36.1)	0	0.0	5	18.2 (7.2–38.8)	17	66.6 (45.4–82.7)	
Ever incarcerated										
no	425	67	14.7 (11.6–18.6)	20	4.2 (2.6–6.7)	49	11.4 (8.4–15.3)	289	69.7 (64.8–74.2)	0.0000
yes	74	27	40.0 (27.9–53.5)	8	9.5 (4.5–18.9)	13	15.4 (8.8–25.6)	26	35.0 (24.1–47.8)	

Table 10.3. MAT Awareness and Uptake by Selected Subgroups

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
Client of NGO working with PWID										
no	190	9	4.2 (2.1–7.9)	4	1.3 (0.5–3.5)	24	11.7 (7.7–17.4)	153	82.9 (76.7–87.7)	0.0000
yes	309	85	26.6 (21.5–32.3)	24	7.1 (4.6–10.7)	38	12.1 (8.5–16.9)	162	54.2 (48.1–60.3)	
Treated with MAT currently (of all)										
no	405	0	0.0	28	6.0 (4.0–8.8)	62	14.6 (11.2–18.8)	315	79.5 (74.9–83.4)	0.0000
yes	94	94	100.0	0	0.0	0	0.0	0	0.0	
HIV test result										
positive	87	47	57.8 (46.1–68.7)	10	9.5 (4.7–18.3)	9	9.0 (4.5–17.0)	21	23.7 (15.3–34.8)	0.0000
negative	412	47	9.9 (7.4–13.1)	18	3.9 (2.4–6.4)	53	12.6 (9.4–16.6)	294	73.6 (68.8–77.9)	
Past 30 days injecting 4 categories										
opioids	304	71	23.0 (18.4–28.4)	24	7.3 (4.8–11.1)	41	12.6 (9.0–17.4)	168	57.0 (51.0–62.9)	0.0001
stimulants	45	3	5.3 (1.6–16.3)	1	1.4 (0.2–10.1)	5	9.2 (3.7–21.4)	36	84.1 (70.8–92.0)	
opi+stimul	148	18	11.7 (6.8–19.5)	3	1.5 (0.4–4.7)	16	11.6 (7.0–18.7)	111	75.2 (66.5–82.3)	
other	2	2	100.0	0	0.0	0	0.0	0	0.0	
Injecting drug type of choice										
opioids	432	91	20.3 (16.5–24.7)	25	5.1 (3.3–7.7)	52	11.2 (8.3–14.9)	264	63.4 (58.3–68.2)	0.0155
stimulants	64	2	2.6 (0.6–10.4)	2	2.0 (0.5–8.1)	10	17.4 (9.1–30.9)	50	78.0 (64.6–87.3)	
other	2	1	37.2 (0.0–100.0)	0	0.0	0	0.0	1	62.8 (0.0–100.0)	



Figure 10.4. Buying MAT medications while not being a patient (%)



Figure 10.5. Source of buying MAT medications while not being a patient (%)



Figure 10.6. Route of administration of MAT medications bought from others (%)

11. Overdose and Naloxone



Figure 11.1. Overdose Experience Ever and in the Past 12 Months (%)



Figure 11.2. Trends in Overdose Experience in the Past 12 Months by Survey Round (%)



Figure 11.3. Drugs causing overdoses (if used only one drug) (%)



Figure 11.4. Naloxone Use (%)

Table 11.1. Overdose Experience

	n	%	CI
Experienced overdose ever			
yes	129	25.4	(21.4–29.9)
Number of overdoses in lifetime			
1	32	25.2	(17.5–34.8)
2-4	76	61.3	(51.5–70.3)
5+	19	13.5	(8.4–20.9)
Experienced overdose in the past 12 months			
yes	16	3.2	(1.8–5.4)
Experienced overdose in the past 12 months (of those ever)			
yes	16	12.5	(7.3–20.4)
Number of overdoses in the past 12 months			
1	10	48.5	(24.0–73.8)
2-4	6	51.5	(26.2–76.0)
5+	0	0.0	
Drug overdosed with (if used only one drug)			
methadone	5	34.9	(12.7–66.4)
other opioid	3	41.0	(14.0–74.8)
stimulant	1	7.0	(0.9–38.1)
other	1	17.0	(2.5–62.5)
Drugs overdosed with (if used a combination)			
methadone+stimulant	3	82.1	(31.7–97.8)
methadone+barbit. or dimedr.	0	0.0	
methadone+other	1	17.9	(2.2–68.3)
other	0	0.0	
Drug overdosed with (if combined drug with alcohol)			
methadone	2	100.0	
other opioid	0	0.0	
stimulant	0	0.0	
other	0	0.0	
Naloxone knowledge and experience			
never heard	151	32.5	(28.1–37.2)
aware but not used	241	46.7	(42.0–51.5)
used myself	56	11.1	(8.2–14.8)
my friends used	35	7.0	(4.9–9.8)

	n	%	CI
me and my friends used	17	2.8	(1.7–4.5)

Table 11.2. Overdose Experience in the Past 12 Months by Sociodemographic Characteristics

		Experienced overdose in the past 12 months				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
Total						
All	500	484	96.8 (94.6–98.2)	16	3.2 (1.8–5.4)	1.0000
Sex						
male	343	333	97.3 (94.8–98.6)	10	2.7 (1.4–5.2)	0.4245
female	157	151	95.8 (90.0–98.3)	6	4.2 (1.7–10.0)	
Age						
<25	8	8	100.0	0	0.0	0.4906
25-34	126	124	97.8 (89.8–99.6)	2	2.2 (0.4–10.2)	
35-44	227	216	95.4 (91.2–97.6)	11	4.6 (2.4–8.8)	
45+	139	136	98.1 (94.3–99.4)	3	1.9 (0.6–5.7)	
Years since the start of injecting drug use						
≤2	10	10	100.0	0	0.0	0.8713
3-5	18	17	95.1 (68.9–99.4)	1	4.9 (0.6–31.1)	
6-10	69	67	97.7 (90.3–99.5)	2	2.3 (0.5–9.7)	
≥11	403	390	96.7 (94.0–98.2)	13	3.3 (1.8–6.0)	
Partnership status						
live alone	191	183	95.9 (91.2–98.2)	8	4.1 (1.8–8.8)	0.4110
live with partner	309	301	97.4 (94.6–98.8)	8	2.6 (1.2–5.4)	
Current employment status						
full-time	103	96	92.0 (82.9–96.5)	7	8.0 (3.5–17.1)	0.0480
part-time or temporary	277	270	97.7 (94.8–99.0)	7	2.3 (1.0–5.2)	
unemployed	31	29	95.3 (81.9–98.9)	2	4.7 (1.1–18.1)	
disabled	20	20	100.0	0	0.0	
other	69	69	100.0	0	0.0	
Monthly income category						
<3K	156	153	97.1 (91.0–99.1)	3	2.9 (0.9–9.0)	0.7870
3-10K	189	181	96.9 (93.6–98.5)	8	3.1 (1.5–6.4)	

		Experienced overdose in the past 12 months				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
	10-20K	128	123	95.8 (89.3–98.4)	5	4.2 (1.6–10.7)
	≥20K	26	26	100.0	0	0.0
Ever incarcerated						
	no	426	414	97.0 (94.5–98.4)	12	3.0 (1.6–5.5)
	yes	74	70	95.5 (88.1–98.4)	4	4.5 (1.6–11.9)

Table 11.3. Overdose Experience in the Past 12 Months by Selected Subgroups

		Experienced overdose in the past 12 months				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	190	187	97.4 (91.8–99.2)	3	2.6 (0.8–8.2)	0.6746
yes	310	297	96.5 (93.8–98.1)	13	3.5 (1.9–6.2)	
Treated with MAT currently (of all)						
no	405	397	97.6 (94.9–98.9)	8	2.4 (1.1–5.1)	0.0380
yes	94	86	93.2 (86.4–96.7)	8	6.8 (3.3–13.6)	
HIV test result						
positive	87	83	95.5 (86.4–98.6)	4	4.5 (1.4–13.6)	0.4979
negative	413	401	97.1 (94.7–98.4)	12	2.9 (1.6–5.3)	
Past 30 days injecting 4 categories						
opioids	305	294	96.2 (92.9–98.0)	11	3.8 (2.0–7.1)	0.7553
stimulants	45	44	98.6 (89.9–99.8)	1	1.4 (0.2–10.1)	
opi+stimul	148	144	97.4 (92.4–99.2)	4	2.6 (0.8–7.6)	
other	2	2	100.0	0	0.0	
Injecting drug type of choice						
opioids	433	417	96.3 (93.8–97.9)	16	3.7 (2.1–6.2)	0.3055
stimulants	64	64	100.0	0	0.0	
other	2	2	100.0	0	0.0	

Table 11.4. Naloxone Experience by Sociodemographic Characteristics

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total								
All	500	151	32.5 (28.1–37.2)	276	53.7 (48.9–58.4)	73	13.8 (10.8–17.6)	1.0000
Sex								
male	343	83	25.7 (20.8–31.2)	200	57.1 (51.2–62.8)	60	17.2 (13.0–22.4)	0.0000
female	157	68	46.6 (38.3–55.1)	76	46.6 (38.3–55.0)	13	6.9 (3.9–11.9)	
Age								
<25	8	6	79.8 (34.9–96.7)	2	20.2 (3.3–65.1)	0	0.0	0.0111
25-34	126	38	33.4 (24.6–43.5)	74	58.1 (48.3–67.3)	14	8.5 (4.9–14.3)	
35-44	227	56	26.5 (20.6–33.4)	132	56.4 (49.0–63.4)	39	17.1 (12.0–23.9)	
45+	139	51	38.4 (30.1–47.5)	68	47.8 (39.1–56.8)	20	13.7 (8.8–20.8)	
Years since the start of injecting drug use								
≤2	10	4	33.0 (9.8–69.1)	6	67.0 (30.9–90.2)	0	0.0	0.3975
3-5	18	5	28.9 (11.5–56.0)	12	66.2 (39.8–85.3)	1	4.9 (0.6–31.1)	
6-10	69	19	31.1 (20.4–44.3)	43	60.5 (47.5–72.1)	7	8.4 (3.8–17.6)	
≥11	403	123	32.8 (27.9–38.1)	215	51.8 (46.4–57.1)	65	15.4 (11.8–19.9)	
Partnership status								
live alone	191	66	37.0 (29.6–45.0)	93	45.4 (37.8–53.3)	32	17.6 (11.8–25.4)	0.0221
live with partner	309	85	29.5 (24.3–35.4)	183	59.1 (53.1–64.8)	41	11.4 (8.3–15.4)	
Current employment status								
full-time	103	27	30.4 (21.4–41.1)	57	52.9 (42.5–63.1)	19	16.7 (10.5–25.6)	0.0000
part-time or temporary	277	90	34.0 (28.0–40.4)	149	53.1 (46.6–59.5)	38	12.9 (9.1–18.1)	
unemployed	31	4	15.2 (5.6–35.3)	23	73.9 (54.4–87.0)	4	10.9 (3.8–27.2)	
disabled	20	1	4.2 (0.5–28.1)	10	41.8 (19.3–68.5)	9	53.9 (27.6–78.2)	
other	69	29	44.3 (32.1–57.2)	37	52.6 (39.8–65.0)	3	3.2 (0.9–10.1)	
Monthly income category								
<3K	156	66	42.5 (34.3–51.1)	74	46.9 (38.5–55.5)	16	10.6 (6.0–18.1)	0.0247
3-10K	189	43	24.0 (17.7–31.6)	119	62.2 (54.1–69.6)	27	13.8 (8.9–20.8)	
10-20K	128	35	32.4 (23.8–42.3)	68	50.0 (40.7–59.3)	25	17.6 (11.8–25.5)	
≥20K	26	7	24.9 (11.5–45.9)	14	56.1 (35.5–74.8)	5	19.0 (7.5–40.4)	
Ever incarcerated								

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
no	426	145	35.8 (30.9–41.0)	228	52.6 (47.4–57.7)	53	11.7 (8.7–15.5)	0.0001
yes	74	6	10.4 (4.4–22.5)	48	61.2 (47.5–73.3)	20	28.4 (17.5–42.5)	

Table 11.5. Naloxone Experience by Selected Subgroups

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID								
no	190	70	38.4 (31.3–46.2)	107	55.8 (48.1–63.3)	13	5.7 (3.2–10.2)	0.0004
yes	310	81	28.8 (23.4–34.9)	169	52.4 (46.2–58.5)	60	18.8 (14.3–24.3)	
Treated with MAT currently (of all)								
no	405	147	38.8 (33.7–44.1)	213	51.4 (46.1–56.7)	45	9.8 (7.1–13.5)	0.0000
yes	94	4	4.1 (1.4–11.1)	62	63.7 (51.9–74.1)	28	32.2 (22.2–44.2)	
HIV test result								
positive	87	4	3.7 (1.4–9.8)	56	61.5 (49.0–72.5)	27	34.8 (24.0–47.5)	0.0000
negative	413	147	38.3 (33.3–43.6)	220	52.1 (46.8–57.3)	46	9.6 (6.9–13.0)	
Past 30 days injecting 4 categories								
opioids	305	76	27.5 (22.3–33.4)	173	54.8 (48.7–60.7)	56	17.7 (13.5–23.0)	0.0434
stimulants	45	14	34.5 (20.8–51.3)	26	57.4 (41.1–72.1)	5	8.2 (3.2–19.4)	
opi+stimul	148	61	41.1 (32.6–50.2)	75	50.4 (41.5–59.3)	12	8.5 (4.2–16.3)	
other	2	0	0.0	2	100.0	0	0.0	
Injecting drug type of choice								
opioids	433	134	33.1 (28.4–38.2)	231	51.8 (46.7–57.0)	68	15.1 (11.6–19.3)	0.1990
stimulants	64	17	29.5 (18.5–43.7)	42	64.4 (50.5–76.2)	5	6.1 (2.4–14.6)	
other	2	0	0.0	2	100.0	0	0.0	

12. Physical and Mental Health

Table 12.1. Disease and treatment history

		n	%	CI
Had a disease				
	hepatitis B	181	37.4	(32.8–42.1)
	hepatitis C	205	43.1	(38.3–47.9)
	syphilis	2	0.3	(0.1–1.4)

	n	%	CI
gonorrhea	26	4.2	(2.8–6.2)
chlamydia	27	5.1	(3.4–7.4)
herpes	124	23.9	(20.1–28.1)
human papillomavirus	20	3.7	(2.3–5.8)
tuberculosis	145	29.6	(25.4–34.1)
Treated for: hepatitis B			
treated successfully	160	89.2	(83.6–93.1)
treated unsuccessfully	10	5.4	(2.8–10.2)
did not complete	4	1.9	(0.7–5.4)
treated now	0	0.0	
never treated	7	3.5	(1.6–7.3)
Treated for: hepatitis C			
treated successfully	102	51.3	(43.7–58.8)
treated unsuccessfully	57	29.5	(22.9–37.0)
did not complete	8	3.4	(1.6–6.7)
treated now	10	3.8	(2.0–7.2)
never treated	27	12.0	(8.2–17.4)
Treated for: syphilis			
treated successfully	1	100.0	
treated unsuccessfully	0	0.0	
did not complete	0	0.0	
treated now	0	0.0	
never treated	0	0.0	
Treated for: tuberculosis			
treated successfully	132	91.1	(84.7–95.0)
treated unsuccessfully	9	6.7	(3.4–12.9)
did not complete	3	1.3	(0.4–4.0)
treated now	0	0.0	
never treated	1	0.9	(0.1–6.2)

Table 12.2. Mental health screening scores

	n	Mean	CI	Median	IQR
AUDIT-C alcohol risk score ≥5	4,874	1.2	(1.2–1.2)	1	(1–1)
PHQ-9 depression result	5,002	2.2	(2.2–2.3)	2	(1–3)
GAD-7 anxiety result	5,002	1.9	(1.9–1.9)	2	(1–2)

Table 12.3. Health care utilization

	n	%	CI
Had problems with health besides drugs which required medical attention in the past 12 months			
yes	125	25.9	(21.9–30.4)
Referred to a health care facility for treatment in the past 12 months			
yes	138	26.5	(22.6–30.8)
Referred to a health care facility			
primary care	102	74.3	(65.9–81.2)
hospital, HIV clinic	42	30.8	(23.2–39.6)
private clinic	4	3.1	(1.1–8.1)
private lab	2	1.2	(0.3–4.9)
TB dispensary	4	2.7	(1.0–7.2)
drug clinic	0	0.0	
STI clinic	2	1.1	(0.3–4.5)
ambulance	2	1.4	(0.3–5.5)
mobile clinic	0	0.0	

	n	%	CI
other	7	4.5	(2.1–9.3)
Last health care facility referred to			
primary care	97	70.2	(61.6–77.7)
hospital, HIV clinic	29	21.8	(15.3–30.1)
private clinic	3	2.3	(0.7–7.2)
private lab	0	0.0	
TB dispensary	4	2.7	(1.0–7.2)
drug clinic	0	0.0	
STI clinic	1	0.5	(0.1–3.7)
ambulance	1	0.8	(0.1–5.3)
mobile clinic	0	0.0	
other	3	1.7	(0.5–5.1)
Received necessary care in health care facility			
yes	126	91.5	(85.2–95.2)
Signed a declaration with primary care physician			
yes	446	89.9	(86.8–92.3)
How frequently saw the primary care physician			
twice per month or more	84	20.7	(16.7–25.3)
once per month	95	22.2	(18.2–26.8)
3-4 times in 12 months	118	26.5	(22.2–31.3)
only once	148	30.6	(26.3–35.3)



Figure 12.1. Risky alcohol use (AUDIT-C score > 5) (%)



Figure 12.2. Depression symptoms severity (PHQ-9) (%)



Figure 12.3. Anxiety symptoms severity (GAD-7) (%)

Table 12.4. Risky alcohol use (AUDIT-C score > 5) by Sociodemographic Characteristics

			AUDIT-C alcohol risk score ≥5			
		N	no		yes	
			n	% (CI)	n	% (CI)	p-value
Total							
	All	500	464	93.8 (91.4–95.6)	36	6.2 (4.4–8.6)	1.0000
Sex							
	male	343	313	92.4 (89.0–94.8)	30	7.6 (5.2–11.0)	0.0526
	female	157	151	96.8 (92.7–98.6)	6	3.2 (1.4–7.3)	
Age							
	<25	8	8	100.0	0	0.0	0.5111

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
25-34	126	118	95.0 (90.2–97.5)	8	5.0 (2.5–9.8)	
35-44	227	208	92.2 (87.7–95.2)	19	7.8 (4.8–12.3)	
45+	139	130	95.0 (90.4–97.4)	9	5.0 (2.6–9.6)	
Years since the start of injecting drug use						
≤2	10	9	94.2 (59.8–99.4)	1	5.8 (0.6–40.2)	0.9863
3-5	18	17	95.1 (68.9–99.4)	1	4.9 (0.6–31.1)	
6-10	69	64	93.2 (83.9–97.3)	5	6.8 (2.7–16.1)	
≥11	403	374	93.8 (91.1–95.8)	29	6.2 (4.2–8.9)	
Partnership status						
live alone	191	176	93.6 (89.2–96.3)	15	6.4 (3.7–10.8)	0.8675
live with partner	309	288	93.9 (90.7–96.1)	21	6.1 (3.9–9.3)	
Current employment status						
full-time	103	94	91.6 (83.7–95.9)	9	8.4 (4.1–16.3)	0.5007
part-time or temporary	277	258	94.2 (91.0–96.4)	19	5.8 (3.6–9.0)	
unemployed	31	29	93.8 (76.8–98.6)	2	6.2 (1.4–23.2)	
disabled	20	17	88.0 (64.3–96.8)	3	12.0 (3.2–35.7)	
other	69	66	96.8 (90.1–99.0)	3	3.2 (1.0–9.9)	
Monthly income category						
<3K	156	156	100.0	0	0.0	0.0000
3-10K	189	175	93.4 (88.8–96.1)	14	6.6 (3.9–11.2)	
10-20K	128	110	87.4 (80.2–92.3)	18	12.6 (7.7–19.8)	
≥20K	26	22	84.2 (63.0–94.3)	4	15.8 (5.7–37.0)	
Ever incarcerated						
no	426	401	94.8 (92.2–96.6)	25	5.2 (3.4–7.8)	0.0120
yes	74	63	87.2 (77.6–93.1)	11	12.8 (6.9–22.4)	

Table 12.5. Risky alcohol use (AUDIT-C score > 5) by Selected Subgroups

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
	n		% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	190	175	92.9 (88.1–95.9)	15	7.1 (4.1–11.9)	0.5202
yes	310	289	94.3 (91.3–96.4)	21	5.7 (3.6–8.7)	
Treated with MAT currently (of all)						
no	405	374	93.6 (90.8–95.6)	31	6.4 (4.4–9.2)	0.6632
yes	94	89	94.8 (87.6–97.9)	5	5.2 (2.1–12.4)	
HIV test result						
positive	87	82	92.6 (82.4–97.1)	5	7.4 (2.9–17.6)	0.6510
negative	413	382	94.1 (91.6–95.8)	31	5.9 (4.2–8.4)	
Past 30 days injecting 4 categories						
opioids	305	279	92.1 (88.4–94.7)	26	7.9 (5.3–11.6)	0.2557
stimulants	45	43	95.6 (83.4–99.0)	2	4.4 (1.0–16.6)	
opi+stimul	148	140	96.3 (92.5–98.2)	8	3.7 (1.8–7.5)	
other	2	2	100.0	0	0.0	
Injecting drug type of choice						
opioids	433	401	93.6 (90.9–95.6)	32	6.4 (4.4–9.1)	0.8832
stimulants	64	60	94.7 (86.3–98.1)	4	5.3 (1.9–13.7)	
other	2	2	100.0	0	0.0	

Table 12.6. Depression symptoms severity (PHQ-9) by Sociodemographic Characteristics

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	120	23.0 (19.3–27.1)	150	32.2 (27.8–37.0)	139	27.6 (23.6–32.1)	91	17.2 (14.0–20.9)	1.0000
Sex										
male	343	79	21.9 (17.7–26.9)	99	31.2 (25.8–37.1)	92	26.1 (21.4–31.5)	73	20.7 (16.5–25.7)	0.0433
female	157	41	25.1 (18.6–33.0)	51	34.3 (26.7–42.9)	47	30.7 (23.5–39.1)	18	9.8 (6.1–15.4)	
Age										
<25	8	2	16.3 (2.7–58.1)	3	32.3 (7.3–74.3)	3	51.4 (15.1–86.3)	0	0.0	0.1936
25-34	126	37	28.9 (21.3–38.0)	42	37.1 (28.0–47.2)	29	20.6 (14.3–28.8)	18	13.3 (8.2–20.9)	
35-44	227	58	23.9 (18.6–30.3)	60	29.8 (23.3–37.3)	67	29.2 (23.2–36.0)	42	17.0 (12.5–22.7)	
45+	139	23	17.0 (11.2–25.0)	45	32.1 (24.3–40.9)	40	29.4 (21.9–38.3)	31	21.5 (15.2–29.6)	
Years since the start of injecting drug use										

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
≤2	10	2	14.9 (2.8–51.5)	7	74.2 (36.5–93.5)	1	11.0 (1.1–57.6)	0	0.0	0.0001
3-5	18	7	36.7 (16.9–62.2)	9	51.3 (27.5–74.6)	2	12.0 (2.5–41.7)	0	0.0	
6-10	69	28	41.8 (30.0–54.5)	21	30.2 (20.0–42.8)	10	15.4 (8.1–27.5)	10	12.7 (6.7–22.7)	
≥11	403	83	19.5 (15.8–23.9)	113	30.8 (25.8–36.2)	126	30.6 (26.0–35.7)	81	19.0 (15.3–23.4)	
Partnership status										
live alone	191	44	19.8 (14.6–26.2)	53	32.1 (24.6–40.5)	50	26.2 (19.9–33.6)	44	22.0 (16.4–28.9)	0.1579
live with partner	309	76	25.1 (20.3–30.6)	97	32.3 (26.9–38.2)	89	28.6 (23.5–34.3)	47	14.0 (10.5–18.5)	
Current employment status										
full-time	103	29	29.6 (20.9–40.0)	33	30.8 (22.1–41.0)	26	27.9 (19.3–38.6)	15	11.7 (7.0–19.0)	0.4744
part-time or temporary	277	62	20.7 (16.1–26.1)	87	34.0 (28.0–40.6)	73	26.3 (21.0–32.4)	55	19.0 (14.5–24.4)	
unemployed	31	10	32.0 (17.4–51.1)	3	9.2 (2.8–26.3)	11	35.3 (19.8–54.6)	7	23.6 (11.1–43.3)	
disabled	20	5	22.5 (8.3–48.4)	5	33.1 (10.6–67.3)	8	30.6 (13.1–56.4)	2	13.8 (3.1–44.3)	
other	69	14	19.5 (11.4–31.5)	22	35.7 (24.2–49.2)	21	28.8 (19.0–41.2)	12	15.9 (8.9–26.9)	
Monthly income category										
<3K	156	16	10.1 (6.1–16.4)	44	29.6 (22.2–38.3)	65	40.9 (32.8–49.6)	31	19.3 (13.5–26.8)	0.0000
3-10K	189	54	28.4 (22.0–35.9)	53	30.4 (23.3–38.5)	51	25.9 (19.8–33.0)	31	15.3 (10.7–21.4)	
10-20K	128	45	33.5 (25.5–42.7)	45	39.5 (30.5–49.3)	17	12.3 (7.5–19.7)	21	14.6 (9.4–21.9)	
≥20K	26	5	21.2 (8.5–43.7)	7	25.1 (11.4–46.4)	6	23.5 (10.1–45.6)	8	30.2 (14.8–52.0)	
Ever incarcerated										
no	426	105	23.2 (19.3–27.7)	125	31.8 (27.0–37.0)	122	28.7 (24.3–33.6)	74	16.2 (12.9–20.2)	0.3719
yes	74	15	21.4 (12.7–33.6)	25	34.8 (23.2–48.6)	17	20.5 (12.6–31.5)	17	23.3 (14.5–35.4)	

Table 12.7. Depression symptoms severity (PHQ-9) by Selected Subgroups

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	120	23.0 (19.3–27.1)	150	32.2 (27.8–37.0)	139	27.6 (23.6–32.1)	91	17.2 (14.0–20.9)	1.0000
Sex										
male	343	79	21.9 (17.7–26.9)	99	31.2 (25.8–37.1)	92	26.1 (21.4–31.5)	73	20.7 (16.5–25.7)	0.0433
female	157	41	25.1 (18.6–33.0)	51	34.3 (26.7–42.9)	47	30.7 (23.5–39.1)	18	9.8 (6.1–15.4)	
Age										
<25	8	2	16.3 (2.7–58.1)	3	32.3 (7.3–74.3)	3	51.4 (15.1–86.3)	0	0.0	0.1936
25-34	126	37	28.9 (21.3–38.0)	42	37.1 (28.0–47.2)	29	20.6 (14.3–28.8)	18	13.3 (8.2–20.9)	
35-44	227	58	23.9 (18.6–30.3)	60	29.8 (23.3–37.3)	67	29.2 (23.2–36.0)	42	17.0 (12.5–22.7)	

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
45+	139	23	17.0 (11.2–25.0)	45	32.1 (24.3–40.9)	40	29.4 (21.9–38.3)	31	21.5 (15.2–29.6)	
Years since the start of injecting drug use										
≤2	10	2	14.9 (2.8–51.5)	7	74.2 (36.5–93.5)	1	11.0 (1.1–57.6)	0	0.0	0.0001
3-5	18	7	36.7 (16.9–62.2)	9	51.3 (27.5–74.6)	2	12.0 (2.5–41.7)	0	0.0	
6-10	69	28	41.8 (30.0–54.5)	21	30.2 (20.0–42.8)	10	15.4 (8.1–27.5)	10	12.7 (6.7–22.7)	
≥11	403	83	19.5 (15.8–23.9)	113	30.8 (25.8–36.2)	126	30.6 (26.0–35.7)	81	19.0 (15.3–23.4)	
Partnership status										
live alone	191	44	19.8 (14.6–26.2)	53	32.1 (24.6–40.5)	50	26.2 (19.9–33.6)	44	22.0 (16.4–28.9)	0.1579
live with partner	309	76	25.1 (20.3–30.6)	97	32.3 (26.9–38.2)	89	28.6 (23.5–34.3)	47	14.0 (10.5–18.5)	
Current employment status										
full-time	103	29	29.6 (20.9–40.0)	33	30.8 (22.1–41.0)	26	27.9 (19.3–38.6)	15	11.7 (7.0–19.0)	0.4744
part-time or temporary	277	62	20.7 (16.1–26.1)	87	34.0 (28.0–40.6)	73	26.3 (21.0–32.4)	55	19.0 (14.5–24.4)	
unemployed	31	10	32.0 (17.4–51.1)	3	9.2 (2.8–26.3)	11	35.3 (19.8–54.6)	7	23.6 (11.1–43.3)	
disabled	20	5	22.5 (8.3–48.4)	5	33.1 (10.6–67.3)	8	30.6 (13.1–56.4)	2	13.8 (3.1–44.3)	
other	69	14	19.5 (11.4–31.5)	22	35.7 (24.2–49.2)	21	28.8 (19.0–41.2)	12	15.9 (8.9–26.9)	
Monthly income category										
<3K	156	16	10.1 (6.1–16.4)	44	29.6 (22.2–38.3)	65	40.9 (32.8–49.6)	31	19.3 (13.5–26.8)	0.0000
3-10K	189	54	28.4 (22.0–35.9)	53	30.4 (23.3–38.5)	51	25.9 (19.8–33.0)	31	15.3 (10.7–21.4)	
10-20K	128	45	33.5 (25.5–42.7)	45	39.5 (30.5–49.3)	17	12.3 (7.5–19.7)	21	14.6 (9.4–21.9)	
≥20K	26	5	21.2 (8.5–43.7)	7	25.1 (11.4–46.4)	6	23.5 (10.1–45.6)	8	30.2 (14.8–52.0)	
Ever incarcerated										
no	426	105	23.2 (19.3–27.7)	125	31.8 (27.0–37.0)	122	28.7 (24.3–33.6)	74	16.2 (12.9–20.2)	0.3719
yes	74	15	21.4 (12.7–33.6)	25	34.8 (23.2–48.6)	17	20.5 (12.6–31.5)	17	23.3 (14.5–35.4)	

Table 12.8. Anxiety symptoms severity (GAD-7) by Sociodemographic Characteristics

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	185	37.5 (33.0–42.3)	166	35.0 (30.5–39.7)	126	23.5 (19.9–27.7)	23	4.0 (2.6–6.0)	1.0000
Sex										
male	343	121	35.3 (29.9–41.1)	111	34.2 (28.8–40.0)	93	25.8 (21.2–31.0)	18	4.7 (2.9–7.5)	0.1763
female	157	64	42.2 (34.1–50.7)	55	36.6 (28.8–45.2)	33	18.9 (13.3–26.0)	5	2.4 (0.9–5.9)	
Age										

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
<25	8	3	28.4 (6.2–70.4)	5	71.6 (29.6–93.8)	0	0.0	0	0.0	0.0214
25-34	126	50	41.1 (32.1–50.7)	40	33.1 (24.5–43.1)	30	22.1 (15.5–30.4)	6	3.7 (1.6–8.3)	
35-44	227	92	41.6 (34.7–48.9)	70	32.4 (26.0–39.5)	51	20.2 (15.2–26.3)	14	5.8 (3.4–9.7)	
45+	139	40	28.7 (21.3–37.4)	51	38.3 (30.0–47.5)	45	31.5 (24.0–40.1)	3	1.5 (0.5–4.6)	
Years since the start of injecting drug use										
≤2	10	5	51.1 (18.9–82.4)	5	48.9 (17.6–81.1)	0	0.0	0	0.0	0.0189
3-5	18	11	63.4 (37.7–83.2)	6	32.5 (13.9–58.9)	1	4.1 (0.5–27.3)	0	0.0	
6-10	69	34	51.9 (39.4–64.1)	21	29.5 (19.4–42.0)	11	14.8 (8.1–25.4)	3	3.9 (1.2–11.7)	
≥11	403	135	33.8 (28.9–39.1)	134	35.6 (30.6–41.0)	114	26.3 (22.0–31.1)	20	4.2 (2.7–6.6)	
Partnership status										
live alone	191	66	35.8 (28.5–44.0)	59	32.5 (25.4–40.6)	53	26.1 (20.0–33.3)	13	5.5 (3.1–9.6)	0.3462
live with partner	309	119	38.7 (33.0–44.6)	107	36.5 (30.9–42.6)	73	21.9 (17.5–27.0)	10	2.9 (1.5–5.5)	
Current employment status										
full-time	103	52	51.1 (40.8–61.4)	30	30.6 (21.7–41.3)	16	14.4 (8.7–22.7)	5	3.9 (1.6–9.3)	0.0483
part-time or temporary	277	99	35.6 (29.7–42.0)	100	38.1 (32.0–44.6)	66	22.5 (17.7–28.2)	12	3.8 (2.1–6.7)	
unemployed	31	9	28.3 (14.7–47.3)	7	23.2 (10.9–42.7)	14	46.3 (28.8–64.8)	1	2.2 (0.3–15.2)	
disabled	20	6	42.0 (17.2–71.6)	7	27.1 (11.0–53.0)	6	25.6 (9.8–52.1)	1	5.2 (0.6–32.8)	
other	69	19	28.5 (18.2–41.6)	22	35.1 (23.8–48.4)	24	31.4 (21.2–43.6)	4	5.1 (1.7–13.9)	
Monthly income category										
<3K	156	33	22.4 (15.8–30.7)	69	45.9 (37.5–54.5)	52	30.7 (23.6–38.8)	2	1.1 (0.3–4.3)	0.0000
3-10K	189	78	42.2 (34.6–50.1)	57	32.1 (25.1–40.0)	44	21.1 (15.7–27.7)	10	4.7 (2.4–8.8)	
10-20K	128	63	50.9 (41.6–60.2)	35	27.2 (19.7–36.4)	23	16.8 (11.1–24.8)	7	5.0 (2.3–10.5)	
≥20K	26	10	42.2 (23.5–63.4)	5	17.3 (6.8–37.5)	7	25.6 (11.8–47.2)	4	14.9 (5.2–35.8)	
Ever incarcerated										
no	426	154	36.5 (31.7–41.6)	152	37.5 (32.6–42.7)	102	22.3 (18.5–26.7)	18	3.7 (2.3–5.9)	0.0199
yes	74	31	44.4 (32.0–57.6)	14	18.2 (10.7–29.3)	24	31.6 (21.3–44.2)	5	5.7 (2.3–13.6)	

Table 12.9. Anxiety symptoms severity (GAD-7) by Selected Subgroups

		GAD-7 anxiety result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										
no	190	77	40.7 (33.5–48.4)	71	38.8 (31.6–46.6)	34	17.4 (12.4–23.8)	8	3.1 (1.5–6.3)	0.0685
yes	310	108	35.6 (29.9–41.8)	95	32.6 (27.0–38.8)	92	27.3 (22.4–32.8)	15	4.5 (2.6–7.4)	
Treated with MAT currently (of all)										
no	405	155	38.8 (33.8–44.1)	135	35.2 (30.2–40.5)	97	22.4 (18.4–27.0)	18	3.6 (2.2–5.7)	0.5346
yes	94	30	32.1 (22.3–43.7)	31	34.4 (24.6–45.6)	29	28.8 (20.2–39.3)	4	4.8 (1.7–12.6)	
HIV test result										
positive	87	31	35.6 (25.1–47.8)	33	40.2 (29.2–52.2)	17	18.4 (11.2–28.8)	6	5.7 (2.4–13.0)	0.4580
negative	413	154	37.9 (33.0–43.2)	133	33.9 (29.0–39.1)	109	24.6 (20.5–29.2)	17	3.6 (2.2–5.8)	
Past 30 days injecting 4 categories										
opioids	305	133	44.2 (38.3–50.3)	97	32.3 (26.9–38.2)	63	19.9 (15.6–24.9)	12	3.7 (2.0–6.5)	0.0002
stimulants	45	14	33.7 (20.3–50.5)	9	22.1 (11.2–38.9)	14	29.5 (17.2–45.9)	8	14.7 (6.9–28.3)	
opi+stimul	148	37	26.5 (19.1–35.4)	59	43.0 (34.3–52.1)	49	28.8 (21.8–37.0)	3	1.8 (0.6–5.4)	
other	2	1	42.3 (0.0–100.0)	1	57.7 (0.0–100.0)	0	0.0	0	0.0	
Injecting drug type of choice										
opioids	433	157	36.0 (31.2–41.1)	153	37.4 (32.5–42.6)	107	23.3 (19.4–27.8)	16	3.3 (2.0–5.4)	0.0441
stimulants	64	26	46.9 (33.8–60.4)	13	19.8 (11.2–32.6)	18	24.5 (15.1–37.1)	7	8.8 (4.0–18.4)	
other	2	1	37.2 (0.0–100.0)	0	0.0	1	62.8 (0.0–100.0)	0	0.0	

13. Detention and Incarceration

Table 13.1. Police Detention and Incarceration Experience

	n	%	CI
Detained by police in 2022 for			
drug use	31	6.4	(4.4–9.2)
drug dealing	7	2.3	(1.0–5.3)
drug storing	24	4.6	(3.1–7.0)
Detained by police in 2023 for			
drug use	29	5.8	(3.9–8.4)
drug dealing	4	0.9	(0.3–2.7)
drug storing	20	3.9	(2.5–6.1)
Stopped, detained, or arrested by police ever			
yes	144	26.7	(22.8–31.1)
Ever incarcerated			
yes	74	13.1	(10.3–16.6)
Duration of incarceration			
≤6m	12	16.8	(9.6–27.8)

	n	%	CI
6m-2y	25	34.7	(23.1–48.3)
2-4y	24	30.7	(20.7–42.7)
4y+	13	17.9	(10.3–29.3)
Time since last incarceration			
≤1y	16	21.5	(13.1–33.3)
1-3y	12	15.4	(8.6–26.1)
3-5y	18	22.9	(14.4–34.4)
5-10y	12	20.1	(10.6–35.0)
10y+	16	20.1	(12.2–31.2)
Used injecting drugs during incarceration			
yes	39	54.7	(42.2–66.7)



Figure 13.1. Incarceration Lifetime Experience (%)

14. Negative experience

Table 14.1. Negative experience

	n	%	CI
Felt excluded from family activities due to drug use			
no	372	75.2	(70.9–79.1)
yes, in the past 6m	67	13.4	(10.5–17.0)
yes, but 6m+ ago	61	11.4	(8.7–14.8)
Was scolded because of drug use			
no	235	44.5	(39.8–49.2)
yes, in the past 6m	175	37.3	(32.7–42.1)
yes, but 6m+ ago	90	18.2	(14.7–22.3)
Was blackmailed for drug use			
no	316	60.9	(56.0–65.6)
yes, in the past 6m	128	27.4	(23.2–32.0)
yes, but 6m+ ago	56	11.7	(8.8–15.3)
Negative experience in the past 6 months (GAM 6.5)			
no	281	54.3	(49.5–59.0)
yes	219	45.7	(41.0–50.5)
Ever experienced physical violence			
no	280	55.7	(50.9–60.4)

		n	%	CI
	yes	220	44.3	(39.6–49.1)
Experienced physical violence in the past 12 months (of those who had ever)				
	no	146	66.2	(59.2–72.6)
	yes	74	33.8	(27.4–40.8)
Witnessed physical violence in the past 12 months				
	no	346	67.5	(62.8–72.0)
	yes	152	32.5	(28.0–37.2)



Figure 14.1. Negative Experience Related to Drug Use in the past 6 Months or Physical Violence in the past 12 months (%)

Table 14.2. Negative Experience Related to Drug Use by Sociodemographic Characteristics

		Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	500	219	45.7 (41.0–50.5)	1.0000	220	74	33.8 (27.4–40.8)	1.0000
Sex									
	male	343	137	42.3 (36.6–48.2)	0.0428	141	39	29.3 (21.8–38.1)	0.0849
	female	157	82	52.9 (44.4–61.2)		79	35	41.6 (30.6–53.4)	
Age									
	<25	8	4	51.9 (15.3–86.6)	0.0292	5	3	44.4 (7.8–88.3)	0.0125
	25-34	126	69	58.5 (49.1–67.4)		66	29	46.5 (34.1–59.4)	
	35-44	227	89	42.5 (35.5–49.8)		88	31	35.4 (25.4–46.9)	
	45+	139	57	40.2 (31.8–49.1)		61	11	17.0 (9.4–28.7)	
Years since the start of injecting drug use									
	≤2	10	5	50.9 (18.8–82.3)	0.4708	9	2	24.0 (4.5–68.0)	0.1916

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
3-5	18	11	62.8 (37.0–82.9)		11	3	27.3 (8.1–61.8)	
6-10	69	31	48.8 (36.5–61.3)		35	19	49.5 (32.5–66.8)	
≥11	403	172	44.4 (39.1–49.8)		165	50	31.2 (24.0–39.4)	
Partnership status								
live alone	191	85	49.6 (41.6–57.5)	0.2086	88	30	34.8 (24.8–46.4)	0.7982
live with partner	309	134	43.2 (37.4–49.2)		132	44	33.0 (25.1–42.0)	
Current employment status								
full-time	103	52	51.3 (41.0–61.5)	0.0002	47	19	44.7 (30.1–60.2)	0.1138
part-time or temporary	277	123	47.6 (41.2–54.1)		121	36	30.0 (22.1–39.4)	
unemployed	31	6	17.7 (7.7–35.5)		10	2	19.4 (4.4–55.5)	
disabled	20	3	9.6 (2.6–29.6)		7	0	0.0	
other	69	35	51.5 (38.9–64.0)		35	17	44.1 (27.7–62.0)	
Monthly income category								
<3K	156	101	66.7 (58.4–74.1)	0.0000	72	24	34.0 (23.2–46.6)	0.1945
3-10K	189	63	34.2 (27.1–42.0)		77	22	28.4 (18.9–40.3)	
10-20K	128	50	38.7 (30.1–48.1)		64	24	37.1 (25.5–50.4)	
≥20K	26	5	16.7 (6.5–36.5)		6	4	72.1 (28.9–94.2)	
Ever incarcerated								
no	426	201	49.4 (44.3–54.6)	0.0000	196	71	36.3 (29.4–43.7)	0.0138
yes	74	18	21.3 (13.4–32.3)		24	3	11.1 (3.3–31.2)	

Table 14.3. Negative Experience Related to Drug Use by Selected Subgroups

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	190	82	45.7 (38.2–53.4)	0.9967	101	35	37.3 (27.8–48.0)	0.3418
yes	310	137	45.7 (39.7–51.9)		119	39	30.8 (22.7–40.3)	
Treated with MAT currently (of all)								
no	405	186	48.5 (43.2–53.8)	0.0148	192	66	35.2 (28.3–42.8)	0.2067
yes	94	33	33.6 (24.1–44.5)		28	8	23.1 (11.0–42.2)	
HIV test result								

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
positive	87	33	36.9 (26.6–48.6)	0.0960	28	3	8.4 (2.5–24.5)	0.0013
negative	413	186	47.5 (42.3–52.8)		192	71	37.6 (30.6–45.2)	
Past 30 days injecting 4 categories								
opioids	305	110	36.4 (30.7–42.4)	0.0000	120	38	31.6 (23.5–40.9)	0.8475
stimulants	45	9	25.9 (13.5–43.9)		18	6	35.9 (15.7–62.7)	
opi+stimul	148	99	67.7 (58.7–75.5)		80	29	35.7 (25.2–47.8)	
other	2	1	42.3 (0.0–100.0)		2	1	57.7 (0.0–100.0)	
Injecting drug type of choice								
opioids	433	198	47.0 (41.9–52.2)	0.1278	187	65	34.9 (27.9–42.5)	0.5856
stimulants	64	19	36.4 (24.2–50.7)		30	9	30.2 (15.5–50.5)	
other	2	2	100.0		2	0	0.0	

15. The Impact of the Full-scale War

Table 15.1. Migration Since February 2022

	n	%	CI
Changed place of residence since Feb 2022			
yes, because of the war	20	3.6	(2.3–5.6)
yes, for other reasons	21	3.6	(2.3–5.5)
no	459	92.8	(90.3–94.8)
Where migrated since Feb 2022			
unknown	0	0.0	
other country	6	27.5	(12.5–50.3)
other oblast	3	20.6	(7.0–47.4)
other city	8	38.4	(19.9–61.0)
other district	2	7.7	(1.9–26.7)
other house	1	5.7	(0.8–31.3)
Where lived before Feb 2022 (if changed residence)			
same oblast	36	89.3	(74.0–96.1)
other oblast	4	10.7	(3.9–26.0)
other country	0	0.0	



Figure 15.1. Change of Residence Since February 2022 (%)



Figure 15.2. Migration Destination by Survey Site (%)



Figure 15.3. Residence Before February 2022 (%)



Figure 15.4. Changes Since February 2022 (%)

City-level Results: Chernihiv



Figure A. RDS recruitment tree in Chernihiv

1. Sociodemographic Information

Table 1.1. Sociodemographic Characteristics

	n	Mean	CI	Median	IQR
Age, years	500	40.4	(39.4–41.4)	40	(35–45)
Age of first non-injecting drug use	478	17.1	(16.5–17.7)	16	(14–17)
Years since the start of non-injecting drug use	478	23.0	(21.9–24.2)	24	(17–29)
Age of first injecting drug use	500	20.5	(19.8–21.3)	19	(16–23)
Years since the start of injecting drug use	500	19.9	(18.6–21.1)	21	(12–26)
Personal monthly income, UAH	462	7,801.6	(6504.6–9098.6)	5,000	(3000–9000)

Table 1.2. Descriptive Statistics for Sociodemographics

	Site	n	%	CI
Sex				
male	Chernihiv	398	76.4	(70.7–81.2)
female	Chernihiv	102	23.6	(18.8–29.3)
Age				
<25	Chernihiv	9	3.1	(1.2–7.4)
25-34	Chernihiv	92	20.4	(16.3–25.2)
35-44	Chernihiv	246	47.9	(42.2–53.6)
45+	Chernihiv	153	28.7	(23.7–34.2)
Family status				
married or living together	Chernihiv	181	35.6	(30.1–41.4)
married but have another partner	Chernihiv	3	1.6	(0.3–7.3)
not married but have a partner	Chernihiv	115	26.2	(21.5–31.4)
married but not living together	Chernihiv	6	1.0	(0.4–2.6)
not married and do not have a partner	Chernihiv	195	35.6	(30.4–41.2)
Partnership status				
live alone	Chernihiv	201	36.7	(31.5–42.2)
live with partner	Chernihiv	299	63.3	(57.8–68.5)
Education				
incompl. high school	Chernihiv	34	6.5	(4.4–9.7)
high school	Chernihiv	255	50.6	(44.9–56.3)
>high school	Chernihiv	211	42.9	(37.3–48.6)
Current occupation				
school student	Chernihiv	0	0.0	
college/uni student	Chernihiv	2	0.4	(0.1–2.7)
permanent job	Chernihiv	151	24.0	(19.7–28.8)
sporadic jobs	Chernihiv	225	51.6	(45.8–57.3)
unemployed	Chernihiv	68	13.7	(10.0–18.5)
housewife	Chernihiv	7	0.8	(0.3–2.0)
disabled	Chernihiv	39	7.9	(5.0–12.2)
military	Chernihiv	5	1.2	(0.5–3.0)
other	Chernihiv	3	0.4	(0.1–2.0)
Homelessness				
never	Chernihiv	454	90.5	(86.8–93.2)
yes, 12m+ ago	Chernihiv	45	9.3	(6.6–12.9)
yes, in the past 12m	Chernihiv	1	0.2	(0.0–1.5)
Homeless in 12 months (of those ever)				
no	Chernihiv	45	97.7	(85.3–99.7)
yes	Chernihiv	1	2.3	(0.3–14.7)
Monthly income category				
<3K	Chernihiv	97	21.8	(17.2–27.3)
3-10K	Chernihiv	237	54.0	(48.0–59.8)
10-20K	Chernihiv	94	18.0	(14.1–22.7)

	Site	n	%	CI
≥20K	Chernihiv	34	6.2	(4.1–9.3)
Monthly income relative to 2023 subsistence minimum				
<2684	Chernihiv	96	21.8	(17.1–27.2)
≥2684	Chernihiv	366	78.2	(72.8–82.9)
Years since the start of injecting drug use				
≤2	Chernihiv	29	7.9	(5.3–11.7)
3-5	Chernihiv	17	5.3	(2.8–9.6)
6-10	Chernihiv	38	8.0	(5.5–11.4)
≥11	Chernihiv	416	78.8	(73.6–83.3)

Table 1.3. Accommodation in the past 12 months

	Site	n	%	CI
own place	Chernihiv	337	67.8	(62.3–72.8)
friends or relatives	Chernihiv	132	25.1	(20.6–30.3)
renting	Chernihiv	39	9.0	(6.2–12.7)
varying	Chernihiv	7	1.6	(0.7–3.5)
on the street (homeless)	Chernihiv	1	0.2	(0.0–1.5)
in a refugee shelter	Chernihiv	0	0.0	



Figure 1.1. Distribution of Age by Sex (%)



Figure 1.2. Trend in Sex Distribution by Survey Round (%)



Figure 1.3. Trend in Age Groups by Survey Round (%)

2. Drug Use



Figure 2.1. Injecting Drug Use in the Past 12 Months and 30 Days (%)



Figure 2.2. Non-injecting Drug Use in the Past 12 Months (%)



Figure 2.3. Trends in Injecting Drugs Types in the Past 30 Days by Survey Round (%)



Figure 2.4. Trends in Injecting Opioids in the Past 30 Days by Survey Round (%)



Figure 2.5. Trends in Injecting Stimulants in the Past 30 Days by Survey Round (%)

Figure 2.6. Trends in Injecting Other Drugs in the Past 30 Days by Survey Round (%)



Figure 2.7. Injecting Drug Preference (%)

Table 2.1. Types of Injecting Drugs in the Past 30 Days by Sociodemographic Characteristics

			Past 30 days injecting 4 categories								
		N	opioids		stimulants		opi+stimul		other		
			n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total											
	All	500	388	65.9 (60.0–71.3)	90	29.6 (24.3–35.5)	21	4.2 (2.6–6.9)	1	0.3 (0.0–2.2)	1.0000
Sex											
	male	398	307	65.4 (58.8–71.4)	70	29.0 (23.2–35.5)	20	5.3 (3.2–8.6)	1	0.4 (0.1–2.9)	0.3996
	female	102	81	67.5 (53.4–79.0)	20	31.6 (20.2–45.7)	1	0.9 (0.1–6.4)	0	0.0	
Age											
	<25	9	3	8.4 (1.1–42.9)	6	91.6 (57.1–98.9)	0	0.0	0	0.0	0.0000

	N	Past 30 days injecting 4 categories								
		opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
25-34	92	51	39.5 (28.6–51.6)	34	53.9 (41.8–65.6)	7	6.6 (2.9–14.2)	0	0.0	
35-44	246	199	72.7 (65.0–79.3)	38	23.2 (17.1–30.7)	9	4.0 (1.9–8.3)	0	0.0	
45+	153	135	79.3 (66.7–88.0)	12	16.2 (8.3–29.3)	5	3.4 (1.1–9.7)	1	1.1 (0.2–7.5)	
Years since the start of injecting drug use										
≤2	29	13	36.3 (18.8–58.3)	14	58.6 (37.2–77.2)	2	5.1 (1.2–19.8)	0	0.0	0.0080
3-5	17	11	51.3 (20.8–80.8)	5	44.6 (16.0–77.3)	1	4.1 (0.5–28.8)	0	0.0	
6-10	38	22	40.5 (24.1–59.3)	12	48.2 (30.0–66.9)	4	11.4 (4.0–28.2)	0	0.0	
≥11	416	342	72.4 (66.0–78.0)	59	23.8 (18.4–30.1)	14	3.4 (1.8–6.4)	1	0.4 (0.1–2.8)	
Partnership status										
live alone	201	158	70.2 (61.4–77.8)	32	24.7 (17.7–33.3)	11	5.1 (2.5–10.2)	0	0.0	0.4000
live with partner	299	230	63.4 (55.5–70.5)	58	32.4 (25.4–40.3)	10	3.7 (1.9–7.2)	1	0.5 (0.1–3.5)	
Current employment status										
full-time	151	116	61.7 (50.9–71.5)	30	35.0 (25.4–45.9)	5	3.3 (1.3–8.3)	0	0.0	0.3008
part-time or temporary	225	169	66.6 (58.2–74.1)	42	27.9 (20.7–36.3)	14	5.5 (3.0–9.9)	0	0.0	
unemployed	68	54	65.7 (48.8–79.5)	13	31.2 (18.2–48.1)	1	3.0 (0.4–19.1)	0	0.0	
disabled	39	35	71.7 (40.0–90.6)	3	24.3 (6.8–58.7)	0	0.0	1	4.0 (0.5–25.1)	
other	17	14	71.9 (36.1–92.0)	2	21.5 (4.5–61.0)	1	6.7 (0.8–39.8)	0	0.0	
Monthly income category										
<3K	97	78	76.4 (64.2–85.4)	12	16.1 (8.8–27.5)	6	5.9 (2.2–14.9)	1	1.6 (0.2–10.5)	0.0614
3-10K	237	177	59.5 (50.6–67.8)	53	37.6 (29.4–46.6)	7	2.9 (1.2–6.8)	0	0.0	
10-20K	94	75	68.4 (54.9–79.4)	14	26.4 (16.1–40.2)	5	5.2 (2.0–12.9)	0	0.0	
≥20K	34	26	64.2 (42.1–81.6)	6	27.1 (12.3–49.8)	2	8.6 (2.0–30.9)	0	0.0	
Ever incarcerated										
no	330	243	61.0 (53.8–67.8)	77	36.1 (29.4–43.4)	10	2.9 (1.4–5.8)	0	0.0	0.0001
yes	170	145	78.6 (69.2–85.7)	13	12.6 (7.2–21.1)	11	7.7 (3.9–14.7)	1	1.1 (0.2–7.7)	

Table 2.2. Types of Injecting Drugs in the Past 30 Days by Selected Subgroups

	N	Past 30 days injecting 4 categories								
		opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										

		Past 30 days injecting 4 categories								
	N	opioids		stimulants		opi+stimul		other		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
no	294	196	60.2 (53.4–66.7)	80	34.4 (28.1–41.3)	17	4.9 (2.9–8.3)	1	0.4 (0.1–2.9)	0.0117
yes	205	191	82.8 (69.2–91.2)	10	15.0 (7.1–29.2)	4	2.2 (0.6–7.2)	0	0.0	
Treated with MAT currently (of all)										
no	294	190	63.2 (56.8–69.1)	87	32.1 (26.3–38.4)	16	4.4 (2.7–7.3)	1	0.3 (0.0–2.4)	0.0004
yes	205	197	96.7 (93.4–98.4)	3	1.2 (0.4–3.8)	5	2.1 (0.9–5.1)	0	0.0	
HIV test result										
positive	118	102	73.0 (56.8–84.7)	12	23.3 (12.1–40.0)	4	3.8 (1.0–13.4)	0	0.0	0.6738
negative	382	286	64.3 (57.8–70.3)	78	31.0 (25.2–37.4)	17	4.3 (2.6–7.3)	1	0.4 (0.1–2.7)	
Injecting drug type of choice										
opioids	403	386	94.8 (91.0–97.0)	2	1.0 (0.2–4.0)	14	3.8 (2.0–7.1)	1	0.5 (0.1–3.2)	
stimulants	95	1	1.0 (0.1–7.1)	87	93.7 (87.4–97.0)	7	5.3 (2.4–11.1)	0	0.0	
other	0	0		0		0		0		

Table 2.3. Injecting frequency

	Past 30 days injecting 4 categories								
	opioids		stimulants		opi+stimul		other		
	n	%	n	%	n	%	n	%	p-value
Injecting frequency: last 24 hrs									
0 times	61	24.1	27	28.7	5	31.2	1	100.0	0.3771
1 time	257	60.8	51	55.8	11	51.2	0	0.0	
2-3 times	60	13.2	8	7.9	4	11.6	0	0.0	
4+ times	10	1.9	4	7.5	1	6.0	0	0.0	
N	388		90		21		1		
Injecting frequency: last 24 hrs (among those who did)									
1 time	257	80.1	51	78.3	11	74.3	0	0.0	
2-3 times	60	17.4	8	11.2	4	16.9	0	0.0	
4+ times	10	2.5	4	10.6	1	8.8	0	0.0	
N	327		63		16		0		
Injecting frequency: last week									
0 times	15	4.9	6	6.1	1	5.1	1	100.0	0.0010
1-6 times	138	54.5	59	66.5	10	44.7	0	0.0	
every day	235	40.6	25	27.4	10	50.2	0	0.0	
N	388		90		21		1		
Injecting frequency: last 30 days									
1-9 times	62	24.7	22	24.7	1	5.1	1	100.0	0.1229
10-19 times	62	25.0	34	39.1	6	33.3	0	0.0	
20-29 times	41	12.9	13	13.1	5	18.8	0	0.0	
every day	222	37.4	21	23.0	9	42.8	0	0.0	
N	387		90		21		1		
Injecting frequency: main drug last 30 days									
0-9 times	60	24.0	22	24.7	1	5.1	1	100.0	0.1393
10-19 times	61	25.4	34	39.1	6	33.3	0	0.0	
20-29 times	40	12.6	12	12.3	5	18.8	0	0.0	

	Past 30 days injecting 4 categories								
	opioids		stimulants		opi+stimul		other		
	n	%	n	%	n	%	n	%	p-value
every day	227	38.0	22	23.9	9	42.8	0	0.0	
N	388		90		21		1		

Table 2.4. Injecting drug type of choice by Income Category

	Injecting drug type of choice					
	opioids		stimulants		other	
	n	%	n	%	n	%
Monthly income category						
<3K	82	25.6	13	12.1	0	
3-10K	184	49.5	53	64.8	0	
10-20K	78	18.6	16	17.0	0	
≥20K	27	6.4	7	6.1	0	
N	371		89		0	

Table 2.5. Sources of drugs by Drug Type of Choice

Total		Injecting drug type of choice					
All		opioids		stimulants		other	
n	%	n	%	n	%	n	%
prepare myself							
161	26.3	146	32.4	15	13.0	0	
prepared by friends							
56	15.8	43	17.3	12	11.8	0	
from a dealer							
241	56.4	189	55.7	50	57.3	0	
buy on Internet							
109	25.7	60	14.6	49	51.2	0	
from a pharmacy							
1	0.0	1	0.0	0	0.0	0	
from MAT program							
42	2.3	42	3.3	0	0.0	0	
other							
4	1.2	3	1.2	1	1.0	0	
N							
614		484		127		0	



Figure 2.8. Change in the price, quality, and access of drugs by Drug Type of Choice (%)

3. Injecting Risk Behavior

Table 3.1. Prevalence of Injection Risk Practices

	n	%	CI
Used clean syringe for last injection			
yes	486	97.2	(94.8–98.6)
Source of syringe for last injection			
bought in pharmacy	295	74.0	(68.8–78.5)
got in pharmacy	3	0.1	(0.0–0.3)
got from NGO	197	24.6	(20.2–29.7)
got from friend	4	1.0	(0.4–2.7)
got used from friend	0	0.0	
used one used by myself	0	0.0	
got pre-loaded	0	0.0	
other	1	0.3	(0.0–2.2)
Used shared syringe in the past 30 days			
yes	16	3.2	(1.8–5.7)
Used pre-filled syringe in the past 30 days			
yes	21	5.1	(3.2–8.0)
Used front-/back-loaded syringe in the past 30 days			
yes	19	4.4	(2.2–8.4)
Used shared container in the past 30 days			
yes	11	2.7	(1.3–5.2)
Used own previously used syringe in the past 30 days			
yes	156	30.2	(25.0–35.9)
Gave someone a used syringe in the past 30 days			
yes	17	4.7	(2.7–7.9)
Any inj. risk (shared syringe, pre-filled, front-/back-load, container) in the past 30 days			
yes	47	11.1	(7.8–15.6)

Table 3.2. Frequency of risky injection practices

	n	%	CI
Frequency of injecting with a syringe used by others in the past 30 days			
always	0	0.0	

	n	%	CI
often	0	0.0	
half	0	0.0	
sometimes	2	8.8	(1.4–39.2)
rarely	10	78.3	(50.6–92.7)
never	4	12.9	(3.4–38.3)
Frequency of injecting with others in the same place in the past 30 days			
always	82	18.1	(14.2–22.8)
often	32	6.6	(4.3–10.2)
half	42	10.5	(7.5–14.4)
sometimes	21	4.9	(3.0–8.1)
rarely	41	8.5	(5.9–12.1)
never	275	51.3	(45.6–57.0)
Number of syringes used repeatedly in the past 30 days			
1-9	127	89.7	(83.0–93.9)
10-29	23	8.3	(4.7–14.3)
30+	3	2.0	(0.5–7.3)
Number of times one syringe used repeatedly in the past 30 days			
1	11	9.9	(3.9–23.0)
2-3	126	76.0	(62.9–85.6)
4-9	15	11.6	(5.3–23.6)
10+	3	2.5	(0.7–8.7)
How the pre-filled syringe was obtained			
from dealer	7	36.0	(17.3–60.1)
from friends	10	42.5	(22.5–65.3)
from stash	4	21.5	(8.2–45.8)
Someone used one syringe for injection before front-/back-loading			
no	492	98.4	(96.2–99.3)
yes	6	1.6	(0.7–3.8)



Figure 3.1. Prevalence of Key Injection Risk Practices (%)



Figure 3.2. Trends in Key Injection Risk Practices by Survey Round (%)



Figure 3.3. With whom injected drugs in the same place (%)



Figure 3.4. With whom injected drugs in the same place by sex (%)



Figure 3.5. With whom injected drugs in the same place by age (%)

Table 3.3. Prevalence of Shared and Pre-filled Syringe Use by Sociodemographic Characteristics

		Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	499	16	3.2 (1.8–5.7)	1.0000	500	21	5.1 (3.2–8.0)	1.0000
Sex									
	male	397	14	3.8 (2.1–7.0)	0.1941	398	16	5.1 (3.0–8.7)	0.9864
	female	102	2	1.2 (0.2–7.1)		102	5	5.1 (2.1–12.0)	
Age									
	<25	9	0	0.0	0.4995	9	0	0.0	0.6255

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
25-34	92	6	6.3 (2.6–14.6)		92	6	8.2 (3.6–17.7)	
35-44	245	7	2.7 (1.0–6.7)		246	11	4.6 (2.3–8.7)	
45+	153	3	2.3 (0.6–8.9)		153	4	4.4 (1.6–11.5)	
Years since the start of injecting drug use								
≤2	29	0	0.0	0.5990	29	3	10.0 (3.0–28.5)	0.5822
3-5	17	0	0.0		17	1	4.1 (0.5–28.8)	
6-10	38	2	5.9 (1.3–23.0)		38	2	7.2 (1.7–25.6)	
≥11	415	14	3.5 (1.8–6.5)		416	15	4.5 (2.6–7.8)	
Partnership status								
live alone	201	4	1.4 (0.4–5.0)	0.1126	201	5	3.0 (1.1–7.7)	0.1646
live with partner	298	12	4.2 (2.2–8.1)		299	16	6.3 (3.7–10.6)	
Current employment status								
full-time	151	2	0.7 (0.1–4.1)	0.4615	151	0	0.0	0.0573
part-time or temporary	224	12	4.7 (2.4–9.0)		225	18	8.2 (5.0–13.3)	
unemployed	68	1	3.0 (0.4–19.1)		68	3	6.4 (2.0–18.8)	
disabled	39	1	2.8 (0.4–18.6)		39	0	0.0	
other	17	0	0.0		17	0	0.0	
Monthly income category								
<3K	96	3	3.5 (0.9–12.9)	0.5309	97	5	7.0 (2.9–16.1)	0.7661
3-10K	237	6	2.3 (0.8–6.1)		237	9	4.0 (1.9–8.4)	
10-20K	94	6	6.2 (2.4–15.0)		94	5	6.6 (2.5–16.3)	
≥20K	34	1	5.4 (0.7–31.5)		34	1	5.4 (0.7–31.5)	
Ever incarcerated								
no	329	9	2.0 (0.9–4.7)	0.0434	330	14	4.8 (2.7–8.4)	0.7030
yes	170	7	6.3 (2.8–13.5)		170	7	5.8 (2.7–12.4)	

Table 3.4. Prevalence of Shared and Pre-filled Syringe Use by Selected Subgroups

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	293	12	3.8 (2.0–7.1)	0.1885	294	16	5.6 (3.4–9.2)	0.4765

	Used shared syringe in the past 30 days				Used pre-filled syringe in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
yes	205	4	1.4 (0.3–6.0)		205	5	3.6 (1.2–10.6)	
Treated with MAT currently (of all)								
no	293	10	3.2 (1.7–5.9)	0.8248	294	18	5.5 (3.4–8.6)	0.0092
yes	205	6	3.7 (1.2–10.7)		205	3	1.2 (0.4–3.9)	
HIV test result								
positive	118	3	3.8 (0.9–13.9)	0.7863	118	4	2.7 (0.8–9.0)	0.2571
negative	381	13	3.1 (1.6–5.8)		382	17	5.7 (3.5–9.1)	
Past 30 days injecting 4 categories								
opioids	388	12	3.3 (1.7–6.5)	0.0000	388	15	5.1 (2.9–8.7)	0.6081
stimulants	89	0	0.0		90	4	4.2 (1.5–11.1)	
opi+stimul	21	4	24.0 (7.7–54.3)		21	2	12.6 (2.8–41.6)	
other	1	0	0.0		1	0	0.0	
Injecting drug type of choice								
opioids	403	16	4.6 (2.6–8.2)		403	17	5.6 (3.4–9.3)	
stimulants	94	0	0.0		95	4	4.1 (1.5–10.7)	
other	0	0			0	0		

Table 3.5. Prevalence of Front-/back-loading and Container Sharing by Sociodemographic Characteristics

		Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	500	19	4.4 (2.2–8.4)	1.0000	499	11	2.7 (1.3–5.2)	1.0000
Sex									
	male	398	14	3.3 (1.8–6.2)	0.2513	397	9	2.7 (1.2–5.9)	0.8731
	female	102	5	7.7 (2.0–26.0)		102	2	2.4 (0.6–9.4)	
Age									
	<25	9	1	1.0 (0.1–11.8)	0.1205	9	0	0.0	0.6681
	25-34	92	2	1.7 (0.3–9.6)		92	4	4.8 (1.6–14.0)	
	35-44	246	14	7.0 (3.1–15.1)		246	6	2.6 (1.0–6.8)	
	45+	153	2	2.2 (0.5–9.0)		152	1	1.5 (0.2–9.8)	
Years since the start of injecting drug use									
	≤2	29	2	3.6 (0.6–20.0)	0.7070	29	0	0.0	0.1124

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
3-5	17	0	0.0		17	1	4.1 (0.5–28.8)	
6-10	38	2	7.9 (1.9–27.5)		38	3	9.6 (2.5–30.9)	
≥11	416	15	4.4 (1.9–9.6)		415	7	2.1 (0.9–5.0)	
Partnership status								
live alone	201	3	0.7 (0.2–3.1)	0.0011	200	3	2.9 (0.9–8.9)	0.8687
live with partner	299	16	6.5 (3.2–12.8)		299	8	2.5 (1.1–5.8)	
Current employment status								
full-time	151	1	0.1 (0.0–0.8)	0.1941	151	1	0.2 (0.0–1.2)	0.2030
part-time or temporary	225	13	5.3 (2.9–9.7)		224	9	4.5 (2.1–9.2)	
unemployed	68	2	9.2 (1.4–42.6)		68	1	2.3 (0.3–15.1)	
disabled	39	0	0.0		39	0	0.0	
other	17	3	11.6 (2.1–45.1)		17	0	0.0	
Monthly income category								
<3K	97	2	7.4 (1.4–30.4)	0.6936	96	0	0.0	0.2994
3-10K	237	11	3.3 (1.6–7.0)		237	8	4.1 (1.8–8.9)	
10-20K	94	5	5.2 (1.8–14.5)		94	2	1.7 (0.3–9.6)	
≥20K	34	1	5.4 (0.7–31.5)		34	1	5.4 (0.7–31.5)	
Ever incarcerated								
no	330	11	4.1 (1.6–9.9)	0.7048	330	8	2.9 (1.3–6.3)	0.6729
yes	170	8	5.1 (2.2–11.4)		169	3	2.1 (0.6–7.6)	

Table 3.6. Prevalence of Front-/back-loading and Container Sharing by Selected Subgroups

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	294	12	5.3 (2.5–10.7)	0.0629	293	8	2.9 (1.4–6.1)	0.6452
yes	205	7	1.6 (0.5–4.9)		205	3	1.9 (0.3–10.0)	
Treated with MAT currently (of all)								
no	294	12	4.5 (2.2–9.0)	0.3501	293	8	2.8 (1.4–5.6)	0.2225
yes	205	7	2.8 (1.3–5.8)		205	3	1.2 (0.4–3.9)	
HIV test result								

	Used front-/back-loaded syringe in the past 30 days				Used shared container in the past 30 days			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
positive	118	4	3.1 (0.9–10.5)	0.5890	118	1	0.1 (0.0–1.1)	0.0000
negative	382	15	4.6 (2.2–9.7)		381	10	3.2 (1.6–6.4)	
Past 30 days injecting 4 categories								
opioids	388	17	5.9 (2.8–11.9)	0.1713	387	6	1.5 (0.5–4.3)	0.3067
stimulants	90	1	0.6 (0.1–4.5)		90	4	4.6 (1.7–12.1)	
opi+stimul	21	1	7.4 (0.9–41.0)		21	1	7.4 (0.9–41.0)	
other	1	0	0.0		1	0	0.0	
Injecting drug type of choice								
opioids	403	17	5.6 (2.7–11.4)		402	7	1.9 (0.7–4.8)	
stimulants	95	2	1.6 (0.4–6.8)		95	4	4.5 (1.6–11.8)	
other	0	0			0	0		

4. Sexual Behavior

Table 4.1. Prevalence of Sexual Practice by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had sex: ever										
yes	470	93.9	(89.4–96.5)	94	86.4	(70.2–94.5)	376	96.2	(92.9–98.0)	0.0141
N	500			102			398			
Had sex: in the past 12 months										
yes	381	83.4	(78.7–87.2)	81	89.7	(80.8–94.7)	300	81.6	(76.0–86.2)	0.0925
N	467			94			373			
Had sex: in the past 30 days										
yes	286	63.8	(58.1–69.1)	70	76.3	(64.2–85.2)	216	60.2	(53.7–66.4)	0.0188
N	463			94			369			
Had a sex partner in the past 30 days: regular										
yes	257	88.9	(83.6–92.7)	68	99.5	(98.1–99.9)	189	85.2	(78.4–90.2)	0.0000
N	292			70			222			
Had a sex partner in the past 30 days: casual										
yes	40	13.2	(9.1–18.8)	3	1.8	(0.4–8.3)	37	17.2	(11.8–24.4)	0.0004
N	292			70			222			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	3	1.0	(0.3–3.7)	0	0.0		3	1.4	(0.4–4.9)	0.3781
N	292			70			222			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes	1	0.1	(0.0–0.5)	0	0.0		1	0.1	(0.0–0.6)	0.5618
N	292			70			222			
Used condom during last sex: if ever had sex										
yes	142	31.0	(25.6–36.9)	19	28.3	(16.3–44.4)	123	31.7	(26.0–38.1)	0.6641
N	463			93			370			
Used condom during last sex: if had sex in 12m										

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
yes	120	32.4	(26.5–39.0)	18	31.3	(18.2–48.3)	102	32.8	(26.5–39.8)	0.8596
N	379			81			298			
Used condom during last sex: if had sex in 30d										
yes	85	31.0	(24.2–38.8)	16	33.9	(19.3–52.4)	69	30.0	(22.8–38.3)	0.6729
N	285			70			215			



Figure 4.1. Frequency of sex in the past week by Drug Types Used (%)

Table 4.2. Sex Practices by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had same-sex sexual experience										
yes	13	1.9	(0.9–4.1)	9	8.1	(3.5–17.6)	4	0.2	(0.1–0.7)	0.0000
N	470			94			376			
Provided sex services for money										
yes	12	1.9	(0.9–4.1)	7	4.2	(1.3–12.5)	5	1.3	(0.4–3.7)	0.1150
N	470			94			376			
Paid for sex ever										
yes	30	7.3	(4.9–10.9)	0	0.0		30	9.4	(6.3–13.8)	0.0091
N	470			94			376			
Had sex with a sex worker in the past 6 months										
yes	4	11.5	(3.8–30.1)	0	0.0		4	11.5	(3.8–30.1)	
N	30			0			30			
Type of partner with whom had last sex										
regular	379	80.8	(76.0–84.9)	87	93.8	(86.0–97.4)	292	77.1	(71.3–82.1)	0.0211
casual	86	18.5	(14.5–23.3)	7	6.2	(2.6–14.0)	79	22.0	(17.1–27.7)	
com. sex (I paid)	1	0.3	(0.0–2.4)	0	0.0		1	0.4	(0.1–3.0)	
com. sex (I was paid)	1	0.3	(0.0–2.4)	0	0.0		1	0.4	(0.1–3.0)	
N	467			94			373			
With whom last had sex										
man	95	22.0	(17.4–27.5)	92	99.7	(98.7–99.9)	3	0.4	(0.1–2.1)	
woman	375	78.0	(72.5–82.6)	2	0.3	(0.1–1.3)	373	99.6	(97.9–99.9)	

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
men and women	0	0.0		0	0.0		0	0.0		
N	470			94			376			
Type of last sex contact: vaginal										
yes	462	99.4	(98.1–99.8)	91	99.5	(98.5–99.9)	371	99.4	(97.5–99.9)	0.7907
N	469			94			375			
Type of last sex contact: anal										
yes	4	0.8	(0.3–2.5)	0	0.0		4	1.1	(0.4–3.2)	0.3537
N	469			94			375			
Type of last sex contact: oral										
yes	34	8.0	(5.4–11.7)	7	7.8	(2.7–20.2)	27	8.0	(5.3–12.1)	0.9483
N	469			94			375			

Table 4.3. Sex Partners by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Had a sex partner in the past 30 days: regular										
yes	257	88.9	(83.6–92.7)	68	99.5	(98.1–99.9)	189	85.2	(78.4–90.2)	0.0000
N	292			70			222			
Had a sex partner in the past 30 days: casual										
yes	40	13.2	(9.1–18.8)	3	1.8	(0.4–8.3)	37	17.2	(11.8–24.4)	0.0004
N	292			70			222			
Had a sex partner in the past 30 days: commercial (buying - I paid)										
yes	3	1.0	(0.3–3.7)	0	0.0		3	1.4	(0.4–4.9)	0.3781
N	292			70			222			
Had a sex partner in the past 30 days: commercial (selling - I was paid)										
yes	1	0.1	(0.0–0.5)	0	0.0		1	0.1	(0.0–0.6)	0.5618
N	292			70			222			
Number of sex partners in the past 30 days: regular										
1	252	99.4	(95.9–99.9)	68	100.0		184	99.2	(94.3–99.9)	
2-4	1	0.6	(0.1–4.1)	0	0.0		1	0.8	(0.1–5.7)	
5+	0	0.0		0	0.0		0	0.0		
N	253			68			185			
Number of sex partners in the past 30 days: casual										
1	31	83.1	(65.9–92.6)	2	100.0		29	82.5	(64.8–92.3)	0.7077
2-4	7	16.5	(7.1–33.9)	0	0.0		7	17.1	(7.4–34.9)	
5+	1	0.4	(0.1–2.9)	0	0.0		1	0.4	(0.1–3.0)	
N	39			2			37			
Number of sex partners in the past 30 days: total										
1	270	94.0	(89.9–96.5)	68	98.6	(90.4–99.8)	202	92.4	(87.0–95.7)	0.0710
2-4	16	5.9	(3.4–10.1)	1	1.4	(0.2–9.6)	15	7.5	(4.2–13.0)	
5+	1	0.1	(0.0–0.4)	0	0.0		1	0.1	(0.0–0.5)	
N	287			69			218			



Figure 4.2. Condom Use During Last Sexual Encounter by Type of Partner (%)



Figure 4.3. Trends in Condom Use During Last Sexual Encounter by Survey Round (%)

Table 4.4. Condom Use During Last Sexual Encounter by Sociodemographic Characteristics

			Used condom during last sex: if ever had sex				
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
Total							
	All	463	321	69.0 (63.1–74.4)	142	31.0 (25.6–36.9)	1.0000
Sex							
	male	370	247	68.3 (61.9–74.0)	123	31.7 (26.0–38.1)	0.6641
	female	93	74	71.7 (55.6–83.7)	19	28.3 (16.3–44.4)	
Age							
	<25	9	7	81.3 (35.1–97.2)	2	18.7 (2.8–64.9)	0.2203

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
25-34	85	67	75.3 (61.8–85.1)	18	24.7 (14.9–38.2)	
35-44	230	149	63.1 (54.4–71.1)	81	36.9 (28.9–45.6)	
45+	139	98	73.7 (62.9–82.2)	41	26.3 (17.8–37.1)	
Years since the start of injecting drug use						
≤2	27	17	56.9 (34.4–76.8)	10	43.1 (23.2–65.6)	0.3073
3-5	17	14	83.5 (46.6–96.7)	3	16.5 (3.3–53.4)	
6-10	35	25	78.4 (59.1–90.1)	10	21.6 (9.9–40.9)	
≥11	384	265	68.2 (61.6–74.2)	119	31.8 (25.8–38.4)	
Partnership status						
live alone	179	103	57.5 (48.0–66.5)	76	42.5 (33.5–52.0)	0.0026
live with partner	284	218	75.4 (67.8–81.7)	66	24.6 (18.3–32.2)	
Current employment status						
full-time	142	106	75.2 (64.6–83.4)	36	24.8 (16.6–35.4)	0.1178
part-time or temporary	208	149	71.1 (62.9–78.2)	59	28.9 (21.8–37.1)	
unemployed	64	37	54.4 (36.9–70.9)	27	45.6 (29.1–63.1)	
disabled	35	19	57.1 (35.1–76.7)	16	42.9 (23.3–64.9)	
other	14	10	77.5 (42.0–94.2)	4	22.5 (5.8–58.0)	
Monthly income category						
<3K	91	59	66.8 (51.6–79.2)	32	33.2 (20.8–48.4)	0.1618
3-10K	214	161	71.9 (63.1–79.2)	53	28.1 (20.8–36.9)	
10-20K	91	55	58.7 (45.6–70.6)	36	41.3 (29.4–54.4)	
≥20K	32	23	83.7 (64.3–93.6)	9	16.3 (6.4–35.7)	
Ever incarcerated						
no	304	223	69.9 (62.5–76.4)	81	30.1 (23.6–37.5)	0.5991
yes	159	98	66.8 (57.0–75.4)	61	33.2 (24.6–43.0)	

Table 4.5. Condom Use During Last Sexual Encounter by Selected Subgroups

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						

	N	Used condom during last sex: if ever had sex				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	272	192	69.1 (62.0–75.3)	80	30.9 (24.7–38.0)	0.9994
yes	190	129	69.0 (58.2–78.2)	61	31.0 (21.8–41.8)	
Treated with MAT currently (of all)						
no	276	196	69.1 (62.7–74.8)	80	30.9 (25.2–37.3)	0.7438
yes	186	124	67.5 (59.9–74.2)	62	32.5 (25.8–40.1)	
HIV test result						
positive	103	49	49.4 (36.7–62.3)	54	50.6 (37.7–63.3)	0.0010
negative	360	272	72.6 (66.0–78.3)	88	27.4 (21.7–34.0)	
Past 30 days injecting 4 categories						
opioids	359	250	69.1 (61.9–75.5)	109	30.9 (24.5–38.1)	0.7908
stimulants	83	58	70.0 (58.2–79.6)	25	30.0 (20.4–41.8)	
opi+stimul	20	12	59.3 (32.6–81.5)	8	40.7 (18.5–67.4)	
other	1	1	100.0	0	0.0	
Injecting drug type of choice						
opioids	374	259	68.8 (61.8–75.1)	115	31.2 (24.9–38.2)	
stimulants	87	61	69.8 (58.3–79.3)	26	30.2 (20.7–41.7)	
other	0	0		0		

Table 4.6. Condom use by type of partner by Sex

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Used condom during last sex: regular partner										
yes	73	27.6	(20.8–35.7)	15	31.4	(17.1–50.4)	58	26.1	(19.1–34.6)	0.5676
N	257			68			189			
Used condom during last sex: casual partner										
yes	21	54.9	(35.2–73.2)	1	75.6	(21.3–97.3)	20	54.1	(33.9–73.0)	0.4413
N	38			3			35			
Used condom during last sex: commercial (I paid) partner										
yes	2	48.4	(6.4–92.8)	0	0.0		2	48.4	(6.4–92.8)	
N	3			0			3			
Condom use frequency: regular partner										
always	55	20.1	(14.5–27.2)	9	14.2	(6.0–30.3)	46	22.5	(15.9–31.0)	0.0027
often	6	3.9	(1.1–12.8)	4	13.0	(3.7–36.9)	2	0.2	(0.0–0.8)	
half	5	1.9	(0.5–6.9)	2	4.2	(0.7–22.6)	3	1.0	(0.2–5.0)	
sometimes	5	2.1	(0.8–5.6)	1	2.7	(0.4–17.1)	4	1.8	(0.6–5.4)	
rarely	6	2.7	(1.1–6.5)	1	1.7	(0.2–11.2)	5	3.2	(1.2–8.3)	
never	178	69.2	(61.0–76.4)	51	64.3	(46.1–79.1)	127	71.2	(62.5–78.7)	
N	255			68			187			

	Total			Sex						
	All			female			male			
	n	%	CI	n	%	CI	n	%	CI	p-value
Condom use frequency: casual partner										
always	15	39.5	(22.2–59.9)	1	75.6	(21.3–97.3)	14	38.1	(20.6–59.2)	
often	2	3.7	(0.6–19.1)	0	0.0		2	3.8	(0.6–19.7)	
half	4	11.4	(3.8–29.6)	0	0.0		4	11.9	(3.9–30.6)	
sometimes	0	0.0		0	0.0		0	0.0		
rarely	1	3.3	(0.5–20.3)	0	0.0		1	3.4	(0.5–21.0)	
never	16	42.1	(24.6–61.8)	2	24.4	(2.7–78.7)	14	42.8	(24.7–63.0)	
N	38			3			35			
Condom use frequency: commercial (I paid) partner										
always	1	86.9	(29.1–99.1)	0	0.0		1	86.9	(29.0–99.1)	
often	0	0.0		0	0.0		0	0.0		
half	0	0.0		0	0.0		0	0.0		
sometimes	0	0.0		0	0.0		0	0.0		
rarely	1	13.1	(0.9–70.9)	0	0.0		1	13.1	(0.9–71.0)	
never	0	0.0		0	0.0		0	0.0		
N	2			0			2			



Figure 4.4. Frequency of condom use by type of partner by Sex (%)



Figure 4.5. Frequency of condom use among men during the last sexual encounter by the riskiest type of partner in the past 30 days (%)

5. HIV, HCV, and Syphilis Testing Results

Table 5.1. HIV Prevalence by Sociodemographic Characteristics

			HIV test result				
		N	positive		negative		
			n	% (CI)	n	% (CI)	p-value
Total							
	All	500	118	18.4 (14.4–23.3)	382	81.6 (76.7–85.6)	1.0000
Sex							
	male	398	88	16.7 (12.7–21.6)	310	83.3 (78.4–87.3)	0.2211
	female	102	30	23.9 (14.0–37.7)	72	76.1 (62.3–86.0)	
Age							
	<25	9	1	1.3 (0.1–14.2)	8	98.7 (85.8–99.9)	0.0001
	25-34	92	2	2.3 (0.6–9.1)	90	97.7 (90.9–99.4)	
	35-44	246	66	21.5 (15.9–28.3)	180	78.5 (71.7–84.1)	
	45+	153	49	26.6 (17.4–38.2)	104	73.4 (61.8–82.6)	
Years since the start of injecting drug use							
	≤2	29	3	6.0 (1.5–20.8)	26	94.0 (79.2–98.5)	0.0072
	3-5	17	1	4.1 (0.5–28.8)	16	95.9 (71.2–99.5)	
	6-10	38	3	6.9 (1.8–23.1)	35	93.1 (76.9–98.2)	
	≥11	416	111	21.8 (16.9–27.6)	305	78.2 (72.4–83.1)	
Partnership status							
	live alone	201	64	24.7 (18.1–32.7)	137	75.3 (67.3–81.9)	0.0346

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
live with partner	299	54	14.8 (10.0–21.3)	245	85.2 (78.7–90.0)	
Current employment status						
full-time	151	37	17.5 (11.2–26.2)	114	82.5 (73.8–88.8)	0.0000
part-time or temporary	225	39	13.4 (9.1–19.4)	186	86.6 (80.6–90.9)	
unemployed	68	19	18.9 (10.0–32.6)	49	81.1 (67.4–90.0)	
disabled	39	21	56.2 (33.3–76.7)	18	43.8 (23.3–66.7)	
other	17	2	10.5 (1.6–46.1)	15	89.5 (53.9–98.4)	
Monthly income category						
<3K	97	33	25.2 (16.0–37.2)	64	74.8 (62.8–84.0)	0.0703
3-10K	237	41	13.8 (8.6–21.5)	196	86.2 (78.5–91.4)	
10-20K	94	29	26.9 (17.1–39.6)	65	73.1 (60.4–82.9)	
≥20K	34	7	14.7 (5.3–34.6)	27	85.3 (65.4–94.7)	
Ever incarcerated						
no	330	55	13.1 (8.9–19.0)	275	86.9 (81.0–91.1)	0.0001
yes	170	63	32.2 (23.9–41.8)	107	67.8 (58.2–76.1)	

Table 5.2. HIV Prevalence by Selected Subgroups

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	294	47	14.6 (10.6–19.8)	247	85.4 (80.2–89.4)	0.0034
yes	205	70	29.8 (20.4–41.3)	135	70.2 (58.7–79.6)	
Treated with MAT currently (of all)						
no	294	53	17.4 (13.1–22.8)	241	82.6 (77.2–86.9)	0.0017
yes	205	65	30.4 (24.1–37.4)	140	69.6 (62.6–75.9)	
Past 30 days injecting 4 categories						
opioids	388	102	20.4 (15.8–25.9)	286	79.6 (74.1–84.2)	0.6738
stimulants	90	12	14.5 (7.2–27.1)	78	85.5 (72.9–92.8)	
opi+stimul	21	4	16.5 (4.1–47.3)	17	83.5 (52.7–95.9)	
other	1	0	0.0	1	100.0	
Injecting drug type of choice						

	N	HIV test result				
		positive		negative		
		n	% (CI)	n	% (CI)	p-value
opioids	403	106	20.5 (15.9–25.9)	297	79.5 (74.1–84.1)	
stimulants	95	11	13.2 (6.3–25.6)	84	86.8 (74.4–93.7)	
other	0	0		0		



Figure 5.1. HIV Test Result (%)



Figure 5.2. Trends in HIV Prevalence by Survey Round (%)



Figure 5.3. Anti-HCV Testing Coverage In the Survey (%)



Figure 5.4. Anti-HCV Test Results (%)



Figure 5.5. Anti-HCV Test Results by Sex (%)



Figure 5.6. Trends in Anti-HCV Prevalence by Survey Round (%)



Figure 5.7. Syphilis Test Results (%)

6. HIV Prevention

Table 6.1. Being a Client of NGO by Sociodemographic Characteristics

			Client of NGO working with PWID			
		N	no		yes	
			n	% (CI)	n	% (CI)	p-value
Total							
	All	499	294	75.1 (70.0–79.5)	205	24.9 (20.5–30.0)	1.0000
Sex							
	male	398	243	77.5 (72.3–82.0)	155	22.5 (18.0–27.7)	0.1006
	female	101	51	67.1 (53.5–78.3)	50	32.9 (21.7–46.5)	
Age							

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
<25	9	7	97.7 (85.4–99.7)	2	2.3 (0.3–14.6)	0.0034
25-34	92	71	85.6 (75.1–92.1)	21	14.4 (7.9–24.9)	
35-44	245	134	75.1 (68.3–80.9)	111	24.9 (19.1–31.7)	
45+	153	82	65.1 (53.8–75.0)	71	34.9 (25.0–46.2)	
Years since the start of injecting drug use						
≤2	29	24	97.4 (92.6–99.1)	5	2.6 (0.9–7.4)	0.0109
3-5	17	12	71.7 (38.0–91.3)	5	28.3 (8.7–62.0)	
6-10	38	31	88.5 (72.4–95.8)	7	11.5 (4.2–27.6)	
≥11	415	227	71.7 (65.8–76.9)	188	28.3 (23.1–34.2)	
Partnership status						
live alone	201	103	73.0 (65.2–79.6)	98	27.0 (20.4–34.8)	0.5063
live with partner	298	191	76.3 (69.4–82.0)	107	23.7 (18.0–30.6)	
Current employment status						
full-time	151	80	72.4 (63.0–80.1)	71	27.6 (19.9–37.0)	0.0053
part-time or temporary	225	155	78.7 (71.7–84.3)	70	21.3 (15.7–28.3)	
unemployed	68	37	84.3 (72.7–91.5)	31	15.7 (8.5–27.3)	
disabled	38	13	47.4 (25.5–70.3)	25	52.6 (29.7–74.5)	
other	17	9	63.8 (31.9–86.9)	8	36.2 (13.1–68.1)	
Monthly income category						
<3K	96	57	80.2 (70.0–87.5)	39	19.8 (12.5–30.0)	0.4164
3-10K	237	159	75.8 (67.7–82.5)	78	24.2 (17.5–32.3)	
10-20K	94	46	69.3 (57.1–79.3)	48	30.7 (20.7–42.9)	
≥20K	34	15	67.9 (47.1–83.5)	19	32.1 (16.5–52.9)	
Ever incarcerated						
no	330	218	78.1 (71.9–83.3)	112	21.9 (16.7–28.1)	0.0297
yes	169	76	67.0 (57.8–75.0)	93	33.0 (25.0–42.2)	

Table 6.2. Being a Client of NGO by Selected Subgroups

	N	Client of NGO working with PWID				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Treated with MAT currently (of all)						
no	294	229	78.9 (73.3–83.5)	65	21.1 (16.5–26.7)	0.0000
yes	204	65	32.6 (25.9–40.2)	139	67.4 (59.8–74.1)	
HIV test result						
positive	117	47	59.5 (45.7–72.0)	70	40.5 (28.0–54.3)	0.0034
negative	382	247	78.6 (73.3–83.0)	135	21.4 (17.0–26.7)	
Past 30 days injecting 4 categories						
opioids	387	196	68.7 (62.5–74.2)	191	31.3 (25.8–37.5)	0.0117
stimulants	90	80	87.3 (74.5–94.2)	10	12.7 (5.8–25.5)	
opi+stimul	21	17	87.3 (62.1–96.6)	4	12.7 (3.4–37.9)	
other	1	1	100.0	0	0.0	
Injecting drug type of choice						
opioids	402	207	69.3 (63.3–74.7)	195	30.7 (25.3–36.7)	
stimulants	95	85	87.7 (75.2–94.4)	10	12.3 (5.6–24.8)	
other	0	0		0		



Figure 6.1. Injecting and Sex Risk Perception Among HIV-negative PWID (%)



Figure 6.2. Received HIV Prevention Services in the Past 12 Months and 30 days (%)



Figure 6.3. Receiving Package of Prevention Services in the Past 12 Months (%)



Figure 6.4. Trends in Receiving HIV Prevention Services in the Past 12 Months (%)



Figure 6.5. Perceived changes in access to HIV prevention since February 2022 (%)

Table 6.3. Percentage of correct responses to knowledge questions by HIV status

	Total	HIV test result		
	All	negative	positive	
	%	%	%	p-value
HIV knowledge				
HIV may be avoided	94.9	95.3	93.1	0.4363
proper condom use may prevent HIV	82.3	80.9	88.5	0.1261
undetectable=untransmittable	81.3	80.5	84.8	0.4239
PEP reduces the risk of HIV	73.6	71.9	81.2	0.1316
ART should be started immediately	89.6	89.2	91.6	0.5668

	Total	HIV test result		
	All %	negative %	positive %	p-value
ART may be postponed if one feels healthy	87.4	87.4	87.4	0.9913
ART may be stopped if one feels healthy	91.6	90.5	96.7	0.0691
HIV is transmitted through blood and sex	98.7	98.4	99.9	0.0036
HIV is transmitted via air, food, or skin	96.8	96.8	96.8	0.9810
HBV knowledge				
proper condom use may prevent HBV	94.6	94.7	94.1	0.8166
treatment should be started immediately	88.4	87.3	93.1	0.1918
treatment may be postponed if one feels healthy	87.1	87.3	86.1	0.8104
HBV is 100% transmitted from mother to child	32.5	31.5	36.8	0.4267
HBV is transmitted through blood and sex	96.8	96.6	97.9	0.5854
HBV is transmitted via air, food, or skin	93.1	93.2	92.7	0.8773
treatment may be stopped if one feels healthy	89.2	88.0	94.1	0.1367
HCV knowledge				
proper condom use may prevent HCV	1.4	1.3	1.7	0.7321
treatment should be started immediately	88.7	88.3	90.5	0.6094
treatment may be postponed if one feels healthy	86.9	87.0	86.3	0.8791
HCV is 100% transmitted from mother to child	30.0	28.8	35.5	0.3038
HCV is transmitted through blood and sex	97.7	97.7	97.7	0.9849
there is no treatment for HCV	86.4	84.7	93.8	0.0545
HCV is transmitted via air, food, or skin	89.7	88.7	94.0	0.2111
treatment may be stopped if one feels healthy	93.0	92.4	95.8	0.3136

7. HIV Testing

Table 7.1. HIV Testing Knowledge and Uptake

	n	%	CI
Know where to get HIV test			
yes	454	85.5	(80.5–89.4)
Tested for HIV ever			
yes	458	87.4	(82.7–91.0)
Tested for HIV in the past 12 months			
yes	197	38.9	(33.0–45.2)
Tested for HIV in the past 6 months			
yes	135	27.1	(21.8–33.2)
Received the result of HIV test (of those tested)			
yes	454	98.8	(96.9–99.6)
Willing to disclose HIV test result (of those who got result)			
yes	448	99.9	(99.6–99.9)
Self-reported HIV status (of all tested)			
positive	101	17.6	(13.3–22.9)
negative	349	82.4	(77.1–86.7)
HIV testing and status awareness (GAM)			
yes	247	49.7	(43.4–56.0)
Ever did a HIV self-test			
yes	2	0.6	(0.1–2.3)
Regular sex partner tested for HIV			
yes	147	50.2	(42.5–57.9)
Regular sex partner HIV test result			
positive	29	15.8	(9.5–24.9)
negative	114	78.7	(66.6–87.2)
cannot disclose	2	5.6	(1.1–23.1)



Figure 7.1. HIV Testing Uptake (%)



Figure 7.2. Testing for HIV, HCV, syphilis since February 2022 (%)



Figure 7.3. HIV Testing Since February 2022 (%)

Table 7.2. Testing for HIV in the past 12 months (among all) by Sociodemographic Characteristics

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Total						
All	422	225	61.1 (54.8–67.0)	197	38.9 (33.0–45.2)	1.0000
Sex						
male	333	177	59.3 (52.1–66.1)	156	40.7 (33.9–47.9)	0.3191
female	89	48	66.6 (53.4–77.7)	41	33.4 (22.3–46.6)	
Age						
<25	5	1	13.6 (0.8–74.8)	4	86.4 (25.2–99.2)	0.0824
25-34	73	39	56.2 (42.1–69.4)	34	43.8 (30.6–57.9)	
35-44	212	109	62.2 (53.6–70.1)	103	37.8 (29.9–46.4)	
45+	132	76	66.2 (54.7–76.0)	56	33.8 (24.0–45.3)	
Years since the start of injecting drug use						
≤2	23	12	57.3 (32.5–78.9)	11	42.7 (21.1–67.5)	0.0874
3-5	11	2	22.0 (3.8–66.8)	9	78.0 (33.2–96.2)	
6-10	30	14	59.1 (37.7–77.5)	16	40.9 (22.5–62.3)	
≥11	358	197	63.8 (57.1–70.0)	161	36.2 (30.0–42.9)	
Partnership status						
live alone	166	89	59.2 (49.3–68.3)	77	40.8 (31.7–50.7)	0.6376
live with partner	256	136	62.2 (53.9–69.8)	120	37.8 (30.2–46.1)	

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Current employment status						
full-time	121	55	54.8 (42.9–66.2)	66	45.2 (33.8–57.1)	0.5795
part-time or temporary	199	114	61.7 (52.8–70.0)	85	38.3 (30.0–47.2)	
unemployed	57	32	68.6 (51.6–81.8)	25	31.4 (18.2–48.4)	
disabled	32	18	57.9 (32.0–80.1)	14	42.1 (19.9–68.0)	
other	13	6	78.4 (44.8–94.2)	7	21.6 (5.8–55.2)	
Monthly income category						
<3K	82	47	58.0 (44.4–70.4)	35	42.0 (29.6–55.6)	0.5468
3-10K	211	109	59.8 (50.6–68.4)	102	40.2 (31.6–49.4)	
10-20K	74	41	68.2 (53.9–79.8)	33	31.8 (20.2–46.1)	
≥20K	24	14	72.4 (46.7–88.7)	10	27.6 (11.3–53.3)	
Ever incarcerated						
no	274	155	63.9 (56.1–71.1)	119	36.1 (28.9–43.9)	0.1176
yes	148	70	53.8 (43.4–63.9)	78	46.2 (36.1–56.6)	

Table 7.3. Testing for HIV in the past 12 months (among all) by Selected Subgroups

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	245	147	62.5 (54.9–69.5)	98	37.5 (30.5–45.1)	0.4236
yes	176	77	57.0 (45.4–67.9)	99	43.0 (32.1–54.6)	
Treated with MAT currently (of all)						
no	242	156	63.4 (56.5–69.8)	86	36.6 (30.2–43.5)	0.0000
yes	180	69	35.0 (28.0–42.6)	111	65.0 (57.4–72.0)	
HIV test result						
positive	107	62	62.4 (48.5–74.5)	45	37.6 (25.5–51.5)	0.8260
negative	315	163	60.7 (53.6–67.4)	152	39.3 (32.6–46.4)	
Past 30 days injecting 4 categories						
opioids	328	165	61.2 (54.0–68.0)	163	38.8 (32.0–46.0)	0.6783
stimulants	76	48	58.6 (45.2–70.8)	28	41.4 (29.2–54.8)	
opi+stimul	17	11	72.7 (44.2–90.0)	6	27.3 (10.0–55.8)	

	N	Tested for HIV in the past 12 months				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
other	1	1	100.0	0	0.0	
Injecting drug type of choice						
opioids	340	175	63.2 (56.2–69.7)	165	36.8 (30.3–43.8)	
stimulants	80	49	56.8 (43.8–68.9)	31	43.2 (31.1–56.2)	
other	0	0		0		

8. HIV Treatment



Figure 8.1. HIV Status Awareness Among HIV+ (%)



Figure 8.2. HIV Treatment Cascade - Four-stage (%)



Figure 8.3. HIV Treatment Cascade - Conditional (%)



Figure 8.4. HIV Treatment Cascade - Proportions (%)



Figure 8.5. Trends in HIV Treatment Cascade (Conditional, 95-95-95) by Survey Round (%)

Table 8.1. HIV Treatment Cascade (Conditional, 95-95-95) by Sociodemographic Characteristics

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Total										
All	118	77.5 (66.0–85.9)	1.0000	97	91.9 (81.6–96.7)	1.0000	89	55	60.1 (42.5–75.4)	1.0000
Sex										
male	88	75.0 (61.1–85.2)	0.4592	73	90.6 (77.2–96.5)	0.6149	66	42	68.7 (51.4–82.1)	0.1664
female	30	83.1 (60.6–94.0)		24	94.6 (67.9–99.3)		23	13	43.2 (16.4–74.7)	
Age										

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
<25	1	100.0	0.7889	1	100.0	0.8699	1	1	100.0	0.0658
25-34	2	100.0		2	100.0		2	0	0.0	
35-44	66	76.4 (61.0–87.0)		53	93.0 (77.3–98.1)		50	33	74.5 (55.8–87.2)	
45+	49	77.5 (57.3–89.8)		41	89.7 (69.3–97.1)		36	21	45.2 (19.4–73.9)	
Years since the start of injecting drug use										
≤2	3	8.2 (0.7–52.3)	0.0442	1	100.0	0.0970	1	1	100.0	0.3079
3-5	1	100.0		1	100.0		1	1	100.0	
6-10	3	100.0		3	53.5 (7.2–94.5)		2	0	0.0	
≥11	111	78.4 (66.5–86.9)		92	93.3 (83.1–97.5)		85	53	60.7 (42.4–76.4)	
Partnership status										
live alone	64	64.1 (47.3–78.0)	0.0078	49	88.9 (70.3–96.4)	0.4844	43	25	71.5 (50.3–86.1)	0.2217
live with partner	54	90.5 (75.7–96.7)		48	94.0 (78.2–98.5)		46	30	52.7 (30.1–74.3)	
Current employment status										
full-time	37	83.1 (56.1–95.0)	0.9027	33	97.9 (90.5–99.6)	0.7286	31	18	47.2 (24.7–70.9)	0.5067
part-time or temporary	39	76.7 (58.1–88.6)		30	90.3 (67.9–97.6)		28	19	74.6 (50.4–89.4)	
unemployed	19	68.9 (36.9–89.3)		15	83.5 (42.1–97.2)		13	7	59.8 (20.9–89.4)	
disabled	21	77.1 (46.1–93.0)		17	91.9 (57.7–98.9)		15	10	49.5 (12.5–87.1)	
other	2	100.0		2	100.0		2	1	86.9 (24.7–99.3)	
Monthly income category										
<3K	33	75.4 (52.0–89.7)	0.6555	27	92.4 (65.8–98.7)	0.6100	25	15	61.1 (32.9–83.4)	0.9117
3-10K	41	74.1 (52.6–88.0)		31	89.7 (65.8–97.5)		28	18	57.2 (23.5–85.3)	
10-20K	29	82.5 (56.6–94.5)		26	98.0 (90.8–99.6)		24	15	64.3 (36.6–84.9)	

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
≥20K	7	95.5 (68.0–99.5)		6	100.0		6	4	42.1 (8.1–85.8)	
Ever incarcerated										
no	55	88.4 (74.6–95.1)	0.0188	46	92.9 (78.2–98.0)	0.7267	41	24	56.9 (32.8–78.1)	0.6283
yes	63	65.9 (48.6–79.8)		51	90.4 (70.8–97.3)		48	31	64.8 (42.4–82.1)	

Table 8.2. HIV Treatment Cascade (Conditional, 95-95-95) by Selected Subgroups

	Cascade: aware of HIV status (of all HIV+, 1st 95)			Cascade: on ART (of those aware, 2nd 95)			Cascade: VL<1000 cp/ml (of those on ART, 3rd 95)			
	N	% (CI)	p-value	N	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID										
no	47	75.5 (59.7–86.5)	0.6275	35	93.8 (78.0–98.5)	0.5319	33	19	65.1 (44.9–81.1)	0.4669
yes	70	80.4 (62.3–91.1)		61	89.2 (70.1–96.7)		55	35	52.5 (25.7–77.9)	
Treated with MAT currently (of all)										
no	53	75.4 (62.2–85.1)	0.0147	37	91.5 (78.9–96.9)	0.6487	33	20	59.2 (38.8–76.9)	0.6397
yes	65	92.0 (81.7–96.7)		60	93.9 (83.8–97.9)		56	35	64.8 (51.1–76.4)	
HIV test result										
positive	118	77.5 (65.9–86.0)		97	91.9 (81.5–96.7)		89	55	60.1 (42.4–75.5)	
negative	0	0.0		0	0.0		0	0	0.0	
Past 30 days injecting 4 categories										
opioids	102	75.2 (62.1–84.9)		85	88.5 (75.1–95.2)		77	51	72.4 (56.6–84.1)	
stimulants	12	81.1 (50.5–94.7)		8	100.0		8	3	34.1 (8.6–73.9)	
opi+stimul	4	100.0		4	100.0		4	1	31.2 (2.8–87.8)	
other	0	0.0		0	0.0		0	0	0.0	
Injecting drug type of choice										
opioids	106	74.6 (61.8–84.3)		88	89.0 (76.0–95.4)		80	52	71.3 (55.3–83.4)	
stimulants	11	86.2 (55.0–97.0)		8	100.0		8	3	34.1 (8.6–73.9)	
other	0			0			0	0		

Table 8.3. ART adherence (among those on ART)

		n	%	CI
When did you last miss ART dose				
	last week	1	0.2	(0.0–1.7)

	n	%	CI
1-2 weeks ago	2	2.7	(0.5–14.3)
3-4 weeks ago	2	3.5	(0.6–18.4)
1-3 months ago	4	2.7	(0.6–11.1)
never	80	90.9	(78.1–96.6)
What was the reason for missing the last ART dose			
forgot	7	61.8	(16.3–93.1)
did not have meds	1	34.9	(5.4–83.3)
was under influence	1	3.3	(0.4–23.4)
did not want others to see	0	0.0	
other	0	0.0	
Reasons for not taking ART			
not sure it is needed	4	63.6	(22.2–91.5)
no time to visit clinic	3	6.4	(1.5–22.9)
no motivation to visit clinic	2	30.5	(5.1–78.2)
missed a visit, hard to come back	2	6.1	(1.1–27.0)
too sick to visit clinic	1	2.6	(0.3–19.0)
drug use	2	5.9	(1.1–26.0)
side effects or complications	2	6.1	(1.1–27.0)
no understanding of how to take it	2	5.9	(1.1–26.0)
lost or sold all ARVs	2	5.2	(1.0–23.1)
alcohol use	2	27.3	(4.6–74.7)
waited too long and left	1	2.2	(0.3–16.5)
Time on ART			
≤3m	1	3.3	(0.4–23.8)
4-24m	4	87.4	(62.3–96.7)
25-60m	2	3.9	(0.7–18.7)
5y+	2	5.4	(1.0–24.3)

9. PrEP



Figure 9.1. PrEP Uptake in the Past 12 Months (%)



Figure 9.2. Change in PrEP Awareness and Uptake from 2020 to 2023 (%)



Figure 9.3. Change in PrEP Uptake from 2020 to 2023 (%)

Table 9.1. PrEP Awareness by Sociodemographic Characteristics

			PrEP uptake in the past 12 months								
		N	use now		used in the past		never used		not aware		
			n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total											
	All	498	10	2.2 (0.7–7.0)	2	0.5 (0.1–1.9)	86	15.7 (11.7–20.8)	400	81.6 (76.1–86.1)	1.0000
Sex											
	male	396	8	0.9 (0.3–3.0)	1	0.3 (0.0–2.4)	70	14.6 (10.3–20.3)	317	84.2 (78.4–88.6)	0.0522
	female	102	2	6.3 (1.2–27.1)	1	0.9 (0.1–6.4)	16	19.4 (11.0–32.0)	83	73.3 (58.6–84.2)	
Age											
	<25	9	0	0.0	0	0.0	1	40.7 (5.4–89.2)	8	59.3 (10.8–94.6)	0.4664
	25-34	91	1	1.3 (0.2–8.6)	0	0.0	15	14.2 (7.1–26.3)	75	84.5 (72.5–91.9)	

		PrEP uptake in the past 12 months								
	N	use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
35-44	246	4	1.1 (0.2–5.1)	1	0.5 (0.1–3.2)	40	12.4 (8.1–18.4)	201	86.0 (79.7–90.6)	
45+	152	5	4.9 (0.9–23.5)	1	0.9 (0.1–6.2)	30	19.8 (12.4–30.1)	116	74.4 (62.1–83.7)	
Years since the start of injecting drug use										
≤2	29	0	0.0	0	0.0	1	4.0 (0.5–25.2)	28	96.0 (74.8–99.5)	
3-5	16	0	0.0	0	0.0	4	40.2 (12.4–76.2)	12	59.8 (23.8–87.6)	
6-10	38	1	3.2 (0.4–20.7)	0	0.0	6	12.1 (4.1–30.9)	31	84.7 (65.8–94.1)	
≥11	415	9	2.5 (0.7–8.8)	2	0.6 (0.1–2.4)	75	15.7 (11.6–20.9)	329	81.3 (75.3–86.1)	
Partnership status										
live alone	200	5	0.6 (0.2–1.5)	1	0.7 (0.1–4.9)	23	9.5 (5.2–16.8)	171	89.2 (81.9–93.8)	0.0189
live with partner	298	5	3.1 (0.8–11.0)	1	0.3 (0.0–2.4)	63	19.3 (13.8–26.3)	229	77.2 (69.5–83.4)	
Current employment status										
full-time	149	4	0.6 (0.2–1.5)	0	0.0	29	15.5 (9.0–25.4)	116	84.0 (74.1–90.6)	0.0088
part-time or temporary	225	2	0.6 (0.1–3.1)	0	0.0	38	16.2 (10.6–24.1)	185	83.1 (75.2–88.9)	
unemployed	68	3	3.5 (0.6–17.5)	1	1.6 (0.2–10.9)	10	17.2 (8.1–32.9)	54	77.7 (61.5–88.3)	
disabled	39	1	15.8 (2.3–59.9)	1	3.3 (0.4–21.3)	9	16.3 (5.4–39.9)	28	64.6 (36.4–85.3)	
other	17	0	0.0	0	0.0	0	0.0	17	100.0	
Monthly income category										
<3K	96	3	3.5 (0.9–12.8)	2	2.3 (0.6–9.1)	20	18.0 (9.9–30.4)	71	76.2 (63.4–85.5)	0.3548
3-10K	236	5	2.8 (0.5–14.3)	0	0.0	48	18.6 (12.4–26.9)	183	78.6 (69.4–85.6)	
10-20K	94	2	0.4 (0.1–1.6)	0	0.0	13	15.4 (8.3–26.9)	79	84.2 (72.8–91.4)	
≥20K	34	0	0.0	0	0.0	5	3.4 (1.2–9.1)	29	96.6 (90.9–98.8)	
Ever incarcerated										
no	328	6	2.3 (0.5–9.7)	1	0.3 (0.0–2.1)	60	15.7 (10.8–22.1)	261	81.7 (74.7–87.2)	0.9014
yes	170	4	1.9 (0.4–8.7)	1	0.9 (0.1–6.4)	26	16.0 (9.9–24.7)	139	81.2 (72.1–87.9)	

Table 9.2. PrEP Current Use by Sociodemographic Characteristics

		PrEP uptake in the past 12 months								
	N	use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										
no	292	4	0.7 (0.1–3.4)	2	0.6 (0.2–2.5)	54	16.6 (11.7–22.9)	232	82.1 (75.8–87.1)	0.0220
yes	205	6	6.8 (1.6–24.6)	0	0.0	32	13.3 (7.7–22.0)	167	80.0 (67.2–88.6)	
Treated with MAT currently (of all)										
no	293	3	2.1 (0.5–7.8)	2	0.5 (0.1–2.1)	40	15.2 (10.9–20.8)	248	82.2 (76.1–87.0)	0.4254
yes	204	7	3.6 (1.6–7.7)	0	0.0	46	22.7 (17.1–29.5)	151	73.8 (66.7–79.8)	

	N	PrEP uptake in the past 12 months								
		use now		used in the past		never used		not aware		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
HIV test result										
positive	118	10	11.9 (3.8–31.8)	1	1.4 (0.2–9.4)	24	18.2 (10.3–30.1)	83	68.5 (53.3–80.6)	0.0001
negative	380	0	0.0	1	0.3 (0.0–1.9)	62	15.2 (10.8–21.0)	317	84.5 (78.7–89.0)	
Past 30 days injecting 4 categories										
opioids	387	7	0.8 (0.2–2.2)	2	0.7 (0.2–2.9)	69	14.5 (10.3–20.0)	309	84.1 (78.5–88.4)	0.4074
stimulants	89	1	4.3 (0.6–24.8)	0	0.0	15	20.1 (11.5–32.7)	73	75.7 (61.7–85.7)	
opi+stimul	21	2	10.7 (1.6–46.8)	0	0.0	2	6.8 (1.0–33.9)	17	82.5 (51.5–95.5)	
other	1	0	0.0	0	0.0	0	0.0	1	100.0	
Injecting drug type of choice										
opioids	402	9	1.4 (0.5–3.8)	1	0.3 (0.0–2.2)	71	14.2 (10.2–19.6)	321	84.1 (78.6–88.4)	
stimulants	94	1	4.1 (0.6–24.1)	0	0.0	14	18.6 (10.4–31.0)	79	77.3 (63.5–87.0)	
other	0	0		0		0		0		

Table 9.3. PrEP Awareness and Uptake

	n	%	CI
PrEP uptake in the past 12 months			
use now	10	2.2	(0.7–7.0)
used in the past	2	0.5	(0.1–1.9)
never used	86	15.7	(11.7–20.8)
not aware	400	81.6	(76.1–86.1)
Aware of PrEP			
no	400	81.3	(75.8–85.8)
yes	100	18.7	(14.2–24.2)
PrEP use current			
no	488	97.8	(93.0–99.3)
yes	10	2.2	(0.7–7.0)
PrEP use current (of those aware)			
no	88	88.1	(68.0–96.2)
yes	10	11.9	(3.8–32.0)

10. MAT



Figure 10.1. MAT Awareness (%)



Figure 10.2. MAT Current Uptake (%)



Figure 10.3. Trends in MAT Lifetime and Current Uptake by Survey Round (%)

Table 10.1. MAT experience

	n	%	CI
Reason for MAT discontinuation			
moved to another city	1	12.6	(1.7–54.5)
clinic closed after Feb 2022	2	18.9	(4.4–54.4)
weak or no effect	0	0.0	
side effects	1	15.5	(2.2–60.3)
do not want to visit clinic	1	9.2	(1.2–45.6)
do not want to quit drugs	2	19.9	(4.7–55.8)
hard to get to the clinic	1	12.6	(1.7–54.5)
do not need it	1	20.4	(3.0–67.9)
do not like the attitude of physician	1	15.5	(2.2–60.3)
How did the injection frequency change during MAT			
intensified	0	0.0	
did not change	7	66.9	(36.0–87.9)
decreased	4	33.1	(12.1–64.0)
Whether bought bupr. or methadone while not being a patient in the past 12 months			
yes, methadone	306	58.3	(52.5–63.9)
yes, buprenorphine	9	1.3	(0.5–3.2)
did not buy	184	40.4	(34.9–46.2)
Where bought bupr. or methadone while not being a patient in the past 12 months			
did not buy	184	40.5	(34.9–46.3)
bought from black market	311	59.0	(53.2–64.5)
bought from private clinic	3	0.5	(0.1–2.0)
Way of using bupr. or methaone bought from others			
injecting	308	99.0	(97.3–99.6)
injecting mixed	1	0.1	(0.0–0.4)
swallow or subling.	6	0.9	(0.3–2.7)
snort	0	0.0	

Table 10.2. MAT Awareness and Uptake by Sociodemographic Characteristics

	N	MAT uptake (of all)								
		take it now		took in the past		never took but plan to		unaware or do not plan to		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	499	205	7.8 (6.5–9.3)	13	3.4 (1.9–5.8)	33	9.9 (7.0–13.8)	248	78.9 (74.6–82.6)	1.0000
Sex										
male	397	168	8.5 (7.0–10.3)	10	3.4 (1.8–6.3)	29	11.2 (7.8–15.9)	190	76.9 (71.9–81.3)	0.2834
female	102	37	5.6 (3.7–8.5)	3	3.3 (1.0–10.2)	4	5.8 (2.1–15.0)	58	85.3 (76.4–91.2)	
Age										
<25	9	2	2.3 (0.3–14.6)	0	0.0	0	0.0	7	97.7 (85.4–99.7)	0.3006
25-34	92	27	5.2 (3.2–8.5)	1	1.5 (0.2–10.4)	7	8.8 (4.1–17.7)	57	84.4 (75.5–90.5)	
35-44	246	106	8.7 (6.8–11.2)	4	2.1 (0.7–6.0)	17	10.8 (6.7–17.1)	119	78.3 (71.9–83.6)	
45+	152	70	8.7 (6.3–11.9)	8	7.1 (3.5–13.9)	9	10.3 (5.3–19.0)	65	73.9 (64.7–81.4)	
Years since the start of injecting drug use										
≤2	29	5	2.6 (0.9–7.4)	0	0.0	3	9.5 (2.8–27.5)	21	87.9 (71.2–95.5)	0.3829
3-5	17	3	2.1 (0.5–8.0)	0	0.0	2	12.0 (2.3–43.8)	12	85.9 (56.3–96.7)	
6-10	38	12	6.8 (3.1–14.4)	0	0.0	1	2.7 (0.4–18.1)	25	90.5 (79.7–95.8)	
≥11	415	185	8.8 (7.3–10.7)	13	4.3 (2.4–7.4)	27	10.6 (7.2–15.2)	190	76.3 (71.3–80.7)	
Partnership status										
live alone	201	87	9.1 (6.9–11.9)	7	4.2 (2.0–8.6)	15	12.6 (7.5–20.4)	92	74.1 (66.4–80.6)	0.3012
live with partner	298	118	7.1 (5.6–9.0)	6	2.9 (1.3–6.4)	18	8.4 (5.2–13.1)	156	81.7 (76.4–85.9)	
Current employment status										
full-time	151	77	13.1 (9.6–17.6)	4	4.2 (1.5–10.9)	12	13.5 (7.7–22.5)	58	69.2 (59.9–77.2)	0.0226
part-time or temporary	224	72	5.2 (3.9–6.9)	3	1.1 (0.3–3.3)	15	9.5 (5.6–15.5)	134	84.3 (78.4–88.8)	
unemployed	68	31	8.5 (5.2–13.5)	2	4.2 (1.0–15.8)	2	5.3 (1.3–19.6)	33	82.1 (69.7–90.1)	
disabled	39	18	7.6 (3.8–14.5)	3	12.5 (3.7–34.6)	3	9.6 (2.8–28.2)	15	70.3 (48.8–85.4)	
other	17	7	7.9 (2.9–20.0)	1	9.1 (1.1–48.2)	1	11.2 (1.3–53.9)	8	71.8 (39.5–90.8)	
Monthly income category										
<3K	97	37	6.3 (4.2–9.5)	3	4.1 (1.3–12.2)	5	7.1 (2.9–16.8)	52	82.5 (72.7–89.2)	0.4583

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
3-10K	237	97	7.5 (5.7–9.7)	3	1.2 (0.4–3.8)	15	10.2 (6.1–16.5)	122	81.1 (74.9–86.1)	
10-20K	93	39	9.3 (6.1–13.9)	3	3.7 (1.1–11.3)	8	11.6 (5.8–22.0)	43	75.4 (64.7–83.7)	
≥20K	34	15	10.0 (5.1–18.5)	1	5.4 (0.7–31.5)	4	19.0 (7.0–42.1)	14	65.6 (44.4–82.0)	
Ever incarcerated										
no	329	124	6.6 (5.2–8.2)	4	1.2 (0.4–3.4)	23	10.1 (6.7–15.1)	178	82.1 (77.1–86.2)	0.0003
yes	170	81	11.1 (8.3–14.7)	9	8.9 (4.6–16.6)	10	9.4 (5.1–16.8)	70	70.5 (61.9–77.9)	

Table 10.3. MAT Awareness and Uptake by Selected Subgroups

	N	MAT uptake (of all) take it now		took in the past		never took but plan to		unaware or do not plan to		p-value
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	
Client of NGO working with PWID										
no	294	65	3.4 (2.5–4.5)	11	3.9 (2.1–7.1)	17	6.9 (4.2–11.1)	201	85.8 (81.1–89.4)	0.0000
yes	204	139	21.2 (16.3–27.2)	2	1.6 (0.4–6.4)	16	19.1 (11.9–29.3)	47	58.0 (47.7–67.7)	
Treated with MAT currently (of all)										
no	294	0	0.0	13	3.7 (2.1–6.3)	33	10.8 (7.6–15.0)	248	85.6 (81.0–89.2)	0.0000
yes	205	205	100.0	0	0.0	0	0.0	0	0.0	
HIV test result										
positive	118	65	12.9 (9.0–18.1)	5	6.7 (2.8–15.5)	5	7.2 (2.9–16.5)	43	73.2 (62.6–81.7)	0.0526
negative	381	140	6.7 (5.4–8.3)	8	2.6 (1.3–5.3)	28	10.5 (7.2–15.1)	205	80.2 (75.4–84.2)	
Past 30 days injecting 4 categories										
opioids	387	197	11.5 (9.5–13.9)	13	5.1 (2.9–8.8)	27	12.8 (8.8–18.3)	150	70.6 (64.7–75.9)	0.0001
stimulants	90	3	0.3 (0.1–1.0)	0	0.0	4	3.6 (1.3–9.6)	83	96.1 (90.3–98.5)	
opi+stimul	21	5	3.9 (1.4–10.9)	0	0.0	2	10.3 (2.3–35.7)	14	85.8 (63.5–95.4)	
other	1	0	0.0	0	0.0	0	0.0	1	100.0	
Injecting drug type of choice										
opioids	402	202	11.2 (9.3–13.5)	12	4.5 (2.5–8.0)	28	12.5 (8.7–17.8)	160	71.7 (66.1–76.8)	
stimulants	95	3	0.3 (0.1–1.0)	0	0.0	5	4.2 (1.7–10.0)	87	95.5 (89.8–98.1)	
other	0	0		0		0		0		



Figure 10.4. Buying MAT medications while not being a patient (%)



Figure 10.5. Source of buying MAT medications while not being a patient (%)



Figure 10.6. Route of administration of MAT medications bought from others (%)

11. Overdose and Naloxone



Figure 11.1. Overdose Experience Ever and in the Past 12 Months (%)



Figure 11.2. Trends in Overdose Experience in the Past 12 Months by Survey Round (%)



Figure 11.3. Drugs causing overdoses (if used only one drug) (%)



Figure 11.4. Naloxone Use (%)

Table 11.1. Overdose Experience

	n	%	CI
Experienced overdose ever			
yes	169	28.7	(24.1–33.9)
Number of overdoses in lifetime			
1	66	42.3	(32.9–52.2)
2-4	71	35.2	(26.5–44.9)
5+	30	22.6	(15.3–32.0)
Experienced overdose in the past 12 months			
yes	18	4.8	(2.8–8.0)
Experienced overdose in the past 12 months (of those ever)			
yes	18	16.6	(10.1–26.2)
Number of overdoses in the past 12 months			
1	10	45.5	(22.2–70.9)
2-4	7	54.5	(29.1–77.8)
5+	0	0.0	
Drug overdosed with (if used only one drug)			
methadone	4	55.1	(20.2–85.6)
other opioid	1	1.8	(0.2–13.3)
stimulant	3	43.1	(13.4–78.8)
other	0	0.0	
Drugs overdosed with (if used a combination)			
methadone+stimulant	1	30.2	(4.1–81.4)
methadone+barbit. or dimedr.	1	2.8	(0.3–21.3)
methadone+other	2	60.4	(16.2–92.3)
other	2	6.5	(1.2–29.4)
Drug overdosed with (if combined drug with alcohol)			
methadone	3	75.1	(23.4–96.7)
other opioid	0	0.0	
stimulant	1	24.9	(3.3–76.6)
other	0	0.0	
Naloxone knowledge and experience			
never heard	142	39.4	(33.8–45.2)
aware but not used	324	54.2	(48.4–59.9)
used myself	20	4.5	(2.6–7.6)
my friends used	13	1.8	(0.9–3.7)

	n	%	CI
me and my friends used	1	0.2	(0.0–1.3)

Table 11.2. Overdose Experience in the Past 12 Months by Sociodemographic Characteristics

		Experienced overdose in the past 12 months			
	N	no		yes	
		n	% (CI)	n	% (CI)	p-value
Total						
All	500	482	95.2 (92.0–97.2)	18	4.8 (2.8–8.0)	1.0000
Sex						
male	398	382	94.2 (90.1–96.7)	16	5.8 (3.3–9.9)	0.1137
female	102	100	98.5 (91.6–99.8)	2	1.5 (0.2–8.4)	
Age						
<25	9	9	100.0	0	0.0	0.5122
25-34	92	90	98.6 (92.1–99.7)	2	1.4 (0.3–7.9)	
35-44	246	236	94.3 (89.0–97.1)	10	5.7 (2.9–11.0)	
45+	153	147	93.9 (85.4–97.6)	6	6.1 (2.4–14.6)	
Years since the start of injecting drug use						
≤2	29	28	96.8 (78.6–99.6)	1	3.2 (0.4–21.4)	0.7271
3-5	17	17	100.0	0	0.0	
6-10	38	36	96.3 (80.8–99.4)	2	3.7 (0.6–19.2)	
≥11	416	401	94.6 (90.7–97.0)	15	5.4 (3.0–9.3)	
Partnership status						
live alone	201	197	97.5 (91.5–99.3)	4	2.5 (0.7–8.5)	0.1838
live with partner	299	285	93.9 (89.3–96.6)	14	6.1 (3.4–10.7)	
Current employment status						
full-time	151	149	99.6 (98.5–99.9)	2	0.4 (0.1–1.5)	0.1976
part-time or temporary	225	215	93.9 (88.5–96.8)	10	6.1 (3.2–11.5)	
unemployed	68	64	92.1 (78.2–97.4)	4	7.9 (2.6–21.8)	
disabled	39	37	94.2 (70.4–99.1)	2	5.8 (0.9–29.6)	
other	17	17	100.0	0	0.0	
Monthly income category						
<3K	97	93	94.5 (84.2–98.2)	4	5.5 (1.8–15.8)	0.8784
3-10K	237	226	94.3 (89.0–97.1)	11	5.7 (2.9–11.0)	

		Experienced overdose in the past 12 months					
		N	no		yes		
			n	% (CI)	n	% (CI)	p-value
	10-20K	94	92	97.2 (85.2–99.5)	2	2.8 (0.5–14.8)	
	≥20K	34	33	94.6 (68.5–99.3)	1	5.4 (0.7–31.5)	
Ever incarcerated							
	no	330	322	96.0 (92.0–98.0)	8	4.0 (2.0–8.0)	0.3311
	yes	170	160	93.3 (85.7–97.0)	10	6.7 (3.0–14.3)	

Table 11.3. Overdose Experience in the Past 12 Months by Selected Subgroups

		Experienced overdose in the past 12 months				
	N	no		yes		
		n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						
no	294	282	94.8 (90.7–97.2)	12	5.2 (2.8–9.3)	0.5634
yes	205	199	96.3 (90.4–98.7)	6	3.7 (1.3–9.6)	
Treated with MAT currently (of all)						
no	294	281	95.0 (91.5–97.1)	13	5.0 (2.9–8.5)	0.2167
yes	205	200	97.4 (93.7–98.9)	5	2.6 (1.1–6.3)	
HIV test result						
positive	118	112	91.9 (80.8–96.8)	6	8.1 (3.2–19.2)	0.2123
negative	382	370	96.0 (92.5–97.9)	12	4.0 (2.1–7.5)	
Past 30 days injecting 4 categories						
opioids	388	374	94.9 (90.6–97.2)	14	5.1 (2.8–9.4)	0.7647
stimulants	90	87	96.7 (89.8–99.0)	3	3.3 (1.0–10.2)	
opi+stimul	21	20	90.2 (51.6–98.8)	1	9.8 (1.2–48.4)	
other	1	1	100.0	0	0.0	
Injecting drug type of choice						
opioids	403	388	94.5 (90.2–97.0)	15	5.5 (3.0–9.8)	
stimulants	95	92	96.8 (90.1–99.0)	3	3.2 (1.0–9.9)	
other	0	0		0		

Table 11.4. Naloxone Experience by Sociodemographic Characteristics

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total								

	N	Naloxone knowledge and experience (3 categories)						
		unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
All	500	142	39.4 (33.8–45.2)	337	56.0 (50.1–61.6)	21	4.7 (2.8–7.8)	1.0000
Sex								
male	398	112	38.7 (32.7–45.2)	273	57.7 (51.3–63.9)	13	3.6 (1.8–6.8)	0.2519
female	102	30	41.4 (29.0–54.9)	64	50.4 (37.3–63.4)	8	8.3 (3.4–18.8)	
Age								
<25	9	7	97.7 (85.4–99.7)	2	2.3 (0.3–14.6)	0	0.0	0.0057
25-34	92	32	41.9 (30.5–54.3)	58	56.3 (44.0–68.0)	2	1.7 (0.3–9.6)	
35-44	246	64	38.9 (31.1–47.3)	169	54.2 (45.9–62.2)	13	6.9 (3.6–12.7)	
45+	153	39	32.0 (22.9–42.8)	108	64.4 (53.5–73.9)	6	3.6 (1.2–10.0)	
Years since the start of injecting drug use								
≤2	29	17	61.7 (39.1–80.2)	11	30.5 (14.5–53.3)	1	7.7 (1.0–40.5)	0.0007
3-5	17	12	82.5 (53.0–95.2)	5	17.5 (4.8–47.0)	0	0.0	
6-10	38	16	58.8 (39.9–75.4)	21	37.2 (21.6–56.1)	1	3.9 (0.5–24.5)	
≥11	416	97	32.3 (26.5–38.6)	300	63.0 (56.5–69.0)	19	4.8 (2.7–8.2)	
Partnership status								
live alone	201	57	37.0 (28.9–45.9)	135	58.9 (50.0–67.3)	9	4.1 (1.8–9.1)	0.7125
live with partner	299	85	40.7 (33.5–48.4)	202	54.2 (46.6–61.7)	12	5.0 (2.5–9.6)	
Current employment status								
full-time	151	34	30.7 (21.9–41.2)	111	65.7 (55.2–74.9)	6	3.6 (1.3–9.6)	0.0465
part-time or temporary	225	74	42.4 (34.6–50.7)	143	53.5 (45.3–61.5)	8	4.1 (1.7–9.3)	
unemployed	68	23	52.1 (35.7–68.0)	43	41.9 (27.2–58.2)	2	6.0 (1.5–21.6)	
disabled	39	4	16.5 (5.8–38.8)	32	76.7 (54.3–90.1)	3	6.8 (1.6–24.3)	
other	17	7	58.4 (28.2–83.4)	8	29.0 (10.0–59.9)	2	12.6 (1.9–52.1)	
Monthly income category								
<3K	97	32	47.6 (34.6–60.8)	60	46.2 (33.7–59.3)	5	6.2 (2.3–15.8)	0.0917
3-10K	237	61	34.9 (27.2–43.5)	170	61.4 (52.8–69.4)	6	3.6 (1.4–9.2)	
10-20K	94	31	47.0 (34.6–59.8)	56	48.8 (36.4–61.4)	7	4.1 (1.4–11.4)	
≥20K	34	5	25.1 (10.6–48.5)	26	59.7 (37.7–78.4)	3	15.2 (4.8–39.0)	
Ever incarcerated								
no	330	109	43.8 (36.9–50.9)	213	53.3 (46.2–60.2)	8	3.0 (1.3–6.8)	0.0072

		Naloxone knowledge and experience (3 categories)						
		N	unaware		aware but did not use		used myself		
			n	% (CI)	n	% (CI)	n	% (CI)	p-value
	yes	170	33	27.9 (20.0–37.4)	124	63.0 (53.2–71.9)	13	9.1 (4.7–16.8)	

Table 11.5. Naloxone Experience by Selected Subgroups

		Naloxone knowledge and experience (3 categories)						
	N	unaware		aware but did not use		used myself		
		n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID								
no	294	123	46.6 (39.9–53.5)	162	49.6 (42.8–56.3)	9	3.8 (1.9–7.7)	0.0000
yes	205	19	17.6 (10.4–28.1)	174	75.2 (64.3–83.5)	12	7.3 (3.4–15.0)	
Treated with MAT currently (of all)								
no	294	122	41.7 (35.7–48.0)	159	53.6 (47.3–59.7)	13	4.7 (2.7–8.2)	0.0000
yes	205	19	9.9 (6.1–15.5)	178	86.0 (80.0–90.5)	8	4.1 (2.0–8.1)	
HIV test result								
positive	118	20	24.0 (14.9–36.3)	90	68.8 (55.9–79.3)	8	7.2 (2.9–16.9)	0.0239
negative	382	122	42.8 (36.6–49.3)	247	53.1 (46.6–59.4)	13	4.1 (2.1–7.7)	
Past 30 days injecting 4 categories								
opioids	388	90	35.8 (29.4–42.8)	285	60.6 (53.6–67.2)	13	3.5 (1.7–7.4)	0.0000
stimulants	90	45	48.8 (37.2–60.5)	43	49.0 (37.3–60.7)	2	2.3 (0.5–9.1)	
opi+stimul	21	7	31.4 (13.0–58.2)	9	36.8 (17.1–62.1)	5	31.9 (12.2–61.2)	
other	1	0	0.0	0	0.0	1	100.0	
Injecting drug type of choice								
opioids	403	94	34.9 (28.7–41.7)	291	59.5 (52.7–66.0)	18	5.6 (3.1–9.8)	
stimulants	95	48	50.0 (38.7–61.4)	44	47.2 (36.0–58.7)	3	2.7 (0.8–8.9)	
other	0	0		0		0		

12. Physical and Mental Health

Table 12.1. Disease and treatment history

		n	%	CI
Had a disease				
	hepatitis B	59	6.1	(4.2–8.9)
	hepatitis C	215	34.2	(29.0–39.8)
	syphilis	7	1.4	(0.5–3.6)
	gonorrhea	13	1.8	(0.8–4.2)
	chlamydia	1	0.3	(0.0–1.8)
	herpes	20	2.2	(1.2–3.9)

		n	%	CI
	human papillomavirus	2	0.4	(0.1–2.8)
	tuberculosis	26	3.1	(1.8–5.3)
Treated for: hepatitis B				
	treated successfully	33	45.6	(28.2–64.1)
	treated unsuccessfully	5	22.2	(9.0–45.1)
	did not complete	2	1.1	(0.3–4.3)
	treated now	2	1.2	(0.3–4.8)
	never treated	17	30.0	(16.0–49.1)
Treated for: hepatitis C				
	treated successfully	91	48.1	(38.7–57.7)
	treated unsuccessfully	7	4.0	(1.6–9.8)
	did not complete	2	0.3	(0.1–1.5)
	treated now	7	2.0	(0.6–5.9)
	never treated	108	45.5	(36.4–55.0)
Treated for: syphilis				
	treated successfully	6	98.4	(87.1–99.8)
	treated unsuccessfully	0	0.0	
	did not complete	0	0.0	
	treated now	0	0.0	
	never treated	1	1.6	(0.2–12.9)
Treated for: tuberculosis				
	treated successfully	25	99.0	(92.6–99.9)
	treated unsuccessfully	0	0.0	
	did not complete	0	0.0	
	treated now	1	1.0	(0.1–7.4)
	never treated	0	0.0	

Table 12.2. Mental health screening scores

	n	Mean	CI	Median	IQR
AUDIT-C alcohol risk score ≥5	4,874	1.2	(1.2–1.2)	1	(1–1)
PHQ-9 depression result	5,002	2.2	(2.2–2.3)	2	(1–3)
GAD-7 anxiety result	5,002	1.9	(1.9–1.9)	2	(1–2)

Table 12.3. Health care utilization

	n	%	CI
Had problems with health besides drugs which required medical attention in the past 12 months			
yes	137	26.1	(21.3–31.5)
Referred to a health care facility for treatment in the past 12 months			
yes	111	22.2	(17.5–27.7)
Referred to a health care facility			
primary care	88	76.6	(64.6–85.5)
hospital, HIV clinic	38	42.9	(30.1–56.7)
private clinic	1	1.5	(0.2–9.7)
private lab	1	0.1	(0.0–1.0)
TB dispensary	0	0.0	
drug clinic	0	0.0	
STI clinic	0	0.0	
ambulance	4	1.7	(0.4–6.8)
mobile clinic	1	1.2	(0.2–8.0)
other	2	0.3	(0.1–1.3)
Last health care facility referred to			

	n	%	CI
primary care	77	66.5	(53.5–77.5)
hospital, HIV clinic	27	29.3	(19.0–42.2)
private clinic	1	1.5	(0.2–9.7)
private lab	0	0.0	
TB dispensary	0	0.0	
drug clinic	0	0.0	
STI clinic	0	0.0	
ambulance	2	1.4	(0.3–7.2)
mobile clinic	1	1.2	(0.2–8.0)
other	1	0.1	(0.0–1.0)
Received necessary care in health care facility			
yes	103	92.9	(83.0–97.2)
Signed a declaration with primary care physician			
yes	439	85.1	(80.7–88.6)
How frequently saw the primary care physician			
twice per month or more	22	2.9	(1.6–5.2)
once per month	46	9.1	(6.2–13.3)
3-4 times in 12 months	141	31.6	(25.8–38.0)
only once	224	56.3	(49.9–62.6)



Figure 12.1. Risky alcohol use (AUDIT-C score > 5) (%)



Figure 12.2. Depression symptoms severity (PHQ-9) (%)



Figure 12.3. Anxiety symptoms severity (GAD-7) (%)

Table 12.4. Risky alcohol use (AUDIT-C score > 5) by Sociodemographic Characteristics

			AUDIT-C alcohol risk score ≥5			
		N	no		yes	
			n	% (CI)	n	% (CI)	p-value
Total							
	All	497	441	87.7 (83.8–90.9)	56	12.3 (9.1–16.2)	1.0000
Sex							
	male	395	346	86.1 (81.3–89.8)	49	13.9 (10.2–18.7)	0.1156
	female	102	95	93.1 (84.1–97.2)	7	6.9 (2.8–15.9)	
Age							
	<25	9	6	80.3 (34.8–96.9)	3	19.7 (3.1–65.2)	0.3363

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
25-34	92	76	82.3 (70.8–89.8)	16	17.7 (10.2–29.2)	
35-44	244	219	88.4 (82.5–92.5)	25	11.6 (7.5–17.5)	
45+	152	140	91.3 (83.9–95.5)	12	8.7 (4.5–16.1)	
Years since the start of injecting drug use						
≤2	29	22	75.6 (52.6–89.6)	7	24.4 (10.4–47.4)	0.1101
3-5	17	16	95.9 (71.2–99.5)	1	4.1 (0.5–28.8)	
6-10	38	32	82.1 (63.0–92.5)	6	17.9 (7.5–37.0)	
≥11	413	371	89.0 (84.7–92.2)	42	11.0 (7.8–15.3)	
Partnership status						
live alone	198	176	88.6 (81.6–93.2)	22	11.4 (6.8–18.4)	0.7118
live with partner	299	265	87.2 (82.0–91.1)	34	12.8 (8.9–18.0)	
Current employment status						
full-time	148	131	87.3 (79.0–92.7)	17	12.7 (7.3–21.0)	0.8299
part-time or temporary	225	200	87.9 (81.9–92.1)	25	12.1 (7.9–18.1)	
unemployed	68	60	85.1 (70.0–93.3)	8	14.9 (6.7–30.0)	
disabled	39	36	93.7 (77.4–98.5)	3	6.3 (1.5–22.6)	
other	17	14	84.4 (52.9–96.3)	3	15.6 (3.7–47.1)	
Monthly income category						
<3K	97	87	89.5 (80.0–94.7)	10	10.5 (5.3–20.0)	0.4853
3-10K	237	211	88.2 (82.0–92.5)	26	11.8 (7.5–18.0)	
10-20K	91	80	86.9 (76.2–93.2)	11	13.1 (6.8–23.8)	
≥20K	34	27	77.3 (55.6–90.2)	7	22.7 (9.8–44.4)	
Ever incarcerated						
no	328	291	87.3 (82.2–91.0)	37	12.7 (9.0–17.8)	0.6413
yes	169	150	89.0 (81.8–93.6)	19	11.0 (6.4–18.2)	

Table 12.5. Risky alcohol use (AUDIT-C score > 5) by Selected Subgroups

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
	n		% (CI)	n	% (CI)	p-value
Client of NGO working with PWID						

	N	AUDIT-C alcohol risk score ≥5				
		no		yes		
		n	% (CI)	n	% (CI)	p-value
no	293	253	86.9 (82.0–90.6)	40	13.1 (9.4–18.0)	0.3746
yes	203	187	90.4 (82.3–95.1)	16	9.6 (4.9–17.7)	
Treated with MAT currently (of all)						
no	294	253	87.5 (83.2–90.9)	41	12.5 (9.1–16.8)	0.0391
yes	202	188	93.3 (88.8–96.1)	14	6.7 (3.9–11.2)	
HIV test result						
positive	116	110	96.7 (90.2–98.9)	6	3.3 (1.1–9.8)	0.0045
negative	381	331	85.7 (81.0–89.5)	50	14.3 (10.5–19.0)	
Past 30 days injecting 4 categories						
opioids	385	348	88.9 (84.1–92.3)	37	11.1 (7.7–15.9)	0.6817
stimulants	90	77	86.2 (76.9–92.2)	13	13.8 (7.8–23.1)	
opi+stimul	21	15	80.0 (56.0–92.6)	6	20.0 (7.4–44.0)	
other	1	1	100.0	0	0.0	
Injecting drug type of choice						
opioids	400	360	89.0 (84.4–92.3)	40	11.0 (7.7–15.6)	
stimulants	95	79	84.8 (75.6–90.9)	16	15.2 (9.1–24.4)	
other	0	0		0		

Table 12.6. Depression symptoms severity (PHQ-9) by Sociodemographic Characteristics

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	213	41.9 (36.4–47.6)	186	33.6 (28.5–39.1)	49	12.7 (8.8–17.9)	52	11.9 (8.7–16.0)	1.0000
Sex										
male	398	168	41.7 (35.7–48.0)	151	34.9 (29.1–41.2)	37	10.8 (7.0–16.1)	42	12.6 (9.0–17.6)	0.3846
female	102	45	42.6 (30.2–55.9)	35	29.3 (19.5–41.6)	12	18.7 (9.3–34.3)	10	9.3 (4.3–19.1)	
Age										
<25	9	5	36.1 (7.4–79.9)	3	23.2 (3.6–70.7)	1	40.7 (5.4–89.2)	0	0.0	0.4292
25-34	92	42	47.0 (35.2–59.2)	34	35.0 (24.3–47.5)	10	9.1 (4.3–18.0)	6	8.9 (3.7–19.9)	
35-44	246	97	39.2 (31.7–47.2)	95	33.5 (26.4–41.4)	27	14.9 (9.2–23.2)	27	12.4 (8.0–18.8)	
45+	153	69	43.4 (32.9–54.6)	54	33.8 (24.4–44.7)	11	8.5 (4.0–17.1)	19	14.2 (8.3–23.4)	
Years since the start of injecting drug use										
≤2	29	15	53.1 (32.2–73.0)	8	21.9 (9.7–42.2)	3	14.5 (4.1–40.0)	3	10.5 (2.2–37.7)	0.6186

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
3-5	17	8	43.6 (17.2–74.2)	5	14.4 (4.1–39.9)	3	30.3 (6.6–73.0)	1	11.6 (1.4–55.3)	
6-10	38	17	44.2 (26.7–63.2)	13	33.6 (18.1–53.7)	5	11.9 (4.3–28.7)	3	10.4 (3.2–28.6)	
≥11	416	173	40.4 (34.4–46.8)	160	36.0 (30.2–42.3)	38	11.4 (7.5–16.9)	45	12.2 (8.7–16.8)	
Partnership status										
live alone	201	85	40.9 (32.6–49.8)	71	32.1 (24.5–40.8)	19	10.6 (6.1–18.0)	26	16.3 (10.4–24.6)	0.3250
live with partner	299	128	42.5 (35.3–49.9)	115	34.4 (27.8–41.7)	30	13.8 (8.6–21.4)	26	9.3 (6.0–14.2)	
Current employment status										
full-time	151	71	51.1 (40.7–61.4)	51	29.6 (20.8–40.2)	17	10.6 (5.8–18.5)	12	8.7 (4.4–16.4)	0.5870
part-time or temporary	225	89	39.5 (32.0–47.5)	96	38.1 (30.7–46.2)	20	12.0 (6.9–20.0)	20	10.3 (6.3–16.4)	
unemployed	68	27	34.0 (20.9–50.1)	20	26.4 (14.8–42.6)	8	18.6 (6.8–41.5)	13	21.0 (10.7–37.2)	
disabled	39	17	47.4 (25.1–70.8)	15	28.7 (13.4–51.0)	2	10.5 (2.2–38.4)	5	13.4 (4.3–34.9)	
other	17	9	30.6 (11.0–61.2)	4	32.5 (10.2–67.2)	2	19.0 (4.2–55.7)	2	17.9 (3.8–54.4)	
Monthly income category										
<3K	97	37	35.1 (24.1–47.9)	29	25.2 (16.2–37.1)	12	18.4 (8.5–35.4)	19	21.3 (12.7–33.4)	0.0281
3-10K	237	95	39.4 (31.5–47.9)	106	40.8 (32.9–49.3)	23	12.8 (7.6–20.9)	13	6.9 (3.6–13.0)	
10-20K	94	44	49.1 (36.6–61.7)	28	28.1 (17.9–41.3)	8	6.7 (2.8–15.3)	14	16.1 (8.7–27.9)	
≥20K	34	19	51.4 (31.0–71.4)	9	21.6 (9.2–42.8)	4	18.3 (6.7–41.2)	2	8.6 (2.0–30.9)	
Ever incarcerated										
no	330	143	43.6 (36.8–50.6)	133	36.2 (29.8–43.1)	32	12.4 (7.7–19.2)	22	7.9 (4.8–12.7)	0.0053
yes	170	70	37.5 (28.8–47.1)	53	26.8 (19.1–36.1)	17	13.4 (7.7–22.3)	30	22.3 (15.1–31.6)	

Table 12.7. Depression symptoms severity (PHQ-9) by Selected Subgroups

		PHQ-9 depression result								
	N	minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	213	41.9 (36.4–47.6)	186	33.6 (28.5–39.1)	49	12.7 (8.8–17.9)	52	11.9 (8.7–16.0)	1.0000
Sex										
male	398	168	41.7 (35.7–48.0)	151	34.9 (29.1–41.2)	37	10.8 (7.0–16.1)	42	12.6 (9.0–17.6)	0.3846
female	102	45	42.6 (30.2–55.9)	35	29.3 (19.5–41.6)	12	18.7 (9.3–34.3)	10	9.3 (4.3–19.1)	
Age										
<25	9	5	36.1 (7.4–79.9)	3	23.2 (3.6–70.7)	1	40.7 (5.4–89.2)	0	0.0	0.4292
25-34	92	42	47.0 (35.2–59.2)	34	35.0 (24.3–47.5)	10	9.1 (4.3–18.0)	6	8.9 (3.7–19.9)	
35-44	246	97	39.2 (31.7–47.2)	95	33.5 (26.4–41.4)	27	14.9 (9.2–23.2)	27	12.4 (8.0–18.8)	
45+	153	69	43.4 (32.9–54.6)	54	33.8 (24.4–44.7)	11	8.5 (4.0–17.1)	19	14.2 (8.3–23.4)	

	N	PHQ-9 depression result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Years since the start of injecting drug use										
≤2	29	15	53.1 (32.2–73.0)	8	21.9 (9.7–42.2)	3	14.5 (4.1–40.0)	3	10.5 (2.2–37.7)	0.6186
3-5	17	8	43.6 (17.2–74.2)	5	14.4 (4.1–39.9)	3	30.3 (6.6–73.0)	1	11.6 (1.4–55.3)	
6-10	38	17	44.2 (26.7–63.2)	13	33.6 (18.1–53.7)	5	11.9 (4.3–28.7)	3	10.4 (3.2–28.6)	
≥11	416	173	40.4 (34.4–46.8)	160	36.0 (30.2–42.3)	38	11.4 (7.5–16.9)	45	12.2 (8.7–16.8)	
Partnership status										
live alone	201	85	40.9 (32.6–49.8)	71	32.1 (24.5–40.8)	19	10.6 (6.1–18.0)	26	16.3 (10.4–24.6)	0.3250
live with partner	299	128	42.5 (35.3–49.9)	115	34.4 (27.8–41.7)	30	13.8 (8.6–21.4)	26	9.3 (6.0–14.2)	
Current employment status										
full-time	151	71	51.1 (40.7–61.4)	51	29.6 (20.8–40.2)	17	10.6 (5.8–18.5)	12	8.7 (4.4–16.4)	0.5870
part-time or temporary	225	89	39.5 (32.0–47.5)	96	38.1 (30.7–46.2)	20	12.0 (6.9–20.0)	20	10.3 (6.3–16.4)	
unemployed	68	27	34.0 (20.9–50.1)	20	26.4 (14.8–42.6)	8	18.6 (6.8–41.5)	13	21.0 (10.7–37.2)	
disabled	39	17	47.4 (25.1–70.8)	15	28.7 (13.4–51.0)	2	10.5 (2.2–38.4)	5	13.4 (4.3–34.9)	
other	17	9	30.6 (11.0–61.2)	4	32.5 (10.2–67.2)	2	19.0 (4.2–55.7)	2	17.9 (3.8–54.4)	
Monthly income category										
<3K	97	37	35.1 (24.1–47.9)	29	25.2 (16.2–37.1)	12	18.4 (8.5–35.4)	19	21.3 (12.7–33.4)	0.0281
3-10K	237	95	39.4 (31.5–47.9)	106	40.8 (32.9–49.3)	23	12.8 (7.6–20.9)	13	6.9 (3.6–13.0)	
10-20K	94	44	49.1 (36.6–61.7)	28	28.1 (17.9–41.3)	8	6.7 (2.8–15.3)	14	16.1 (8.7–27.9)	
≥20K	34	19	51.4 (31.0–71.4)	9	21.6 (9.2–42.8)	4	18.3 (6.7–41.2)	2	8.6 (2.0–30.9)	
Ever incarcerated										
no	330	143	43.6 (36.8–50.6)	133	36.2 (29.8–43.1)	32	12.4 (7.7–19.2)	22	7.9 (4.8–12.7)	0.0053
yes	170	70	37.5 (28.8–47.1)	53	26.8 (19.1–36.1)	17	13.4 (7.7–22.3)	30	22.3 (15.1–31.6)	

Table 12.8. Anxiety symptoms severity (GAD-7) by Sociodemographic Characteristics

	N	GAD-7 anxiety result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Total										
All	500	261	50.3 (44.6–56.1)	193	39.7 (34.2–45.5)	37	8.3 (5.6–12.0)	9	1.7 (0.8–3.6)	1.0000
Sex										
male	398	207	49.6 (43.3–55.9)	155	40.3 (34.3–46.7)	30	8.3 (5.4–12.5)	6	1.8 (0.8–4.3)	0.9654
female	102	54	52.6 (39.4–65.5)	38	37.8 (25.6–51.7)	7	8.2 (3.5–18.2)	3	1.4 (0.3–6.5)	
Age										
<25	9	6	77.0 (29.4–96.4)	3	23.0 (3.6–70.6)	0	0.0	0	0.0	0.5336

	N	GAD-7 anxiety result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
25-34	92	50	49.8 (37.7–61.9)	38	45.5 (33.7–57.9)	3	3.4 (1.1–10.4)	1	1.3 (0.2–8.6)	
35-44	246	129	49.0 (41.0–57.1)	91	37.9 (30.1–46.3)	22	11.6 (7.3–18.1)	4	1.4 (0.4–5.0)	
45+	153	76	50.0 (39.2–60.9)	61	40.4 (30.3–51.4)	12	6.9 (3.0–14.9)	4	2.7 (0.9–7.7)	
Years since the start of injecting drug use										
≤2	29	15	48.9 (28.8–69.4)	11	45.1 (25.4–66.4)	2	5.6 (1.3–21.6)	1	0.4 (0.0–3.1)	0.5885
3-5	17	12	74.5 (41.3–92.4)	4	13.8 (3.8–39.5)	1	11.6 (1.4–55.3)	0	0.0	
6-10	38	22	54.1 (35.2–71.9)	13	35.6 (19.7–55.5)	2	7.2 (1.7–25.6)	1	3.2 (0.4–20.7)	
≥11	416	212	48.5 (42.1–54.9)	165	41.3 (35.1–47.8)	32	8.4 (5.5–12.6)	7	1.8 (0.8–4.2)	
Partnership status										
live alone	201	110	54.2 (45.2–62.9)	72	34.7 (26.8–43.7)	15	9.5 (5.1–16.9)	4	1.6 (0.5–5.3)	0.5439
live with partner	299	151	48.1 (40.7–55.6)	121	42.6 (35.3–50.2)	22	7.5 (4.6–12.1)	5	1.8 (0.7–4.6)	
Current employment status										
full-time	151	86	58.3 (47.8–68.2)	55	33.6 (24.4–44.1)	6	4.9 (2.0–11.8)	4	3.2 (1.0–9.1)	0.1347
part-time or temporary	225	113	48.7 (40.6–56.8)	93	41.2 (33.5–49.4)	17	9.6 (5.6–15.8)	2	0.6 (0.1–3.2)	
unemployed	68	32	41.4 (26.5–57.9)	27	51.3 (34.9–67.4)	8	7.1 (2.7–17.5)	1	0.3 (0.0–2.1)	
disabled	39	22	56.3 (33.0–77.1)	11	27.3 (11.6–51.9)	5	12.4 (3.8–33.5)	1	4.0 (0.5–25.1)	
other	17	8	39.4 (15.2–70.2)	7	42.8 (16.7–73.5)	1	6.7 (0.8–39.8)	1	11.2 (1.3–53.9)	
Monthly income category										
<3K	97	46	45.0 (32.6–58.0)	33	34.7 (22.6–49.3)	13	14.8 (8.0–25.7)	5	5.5 (2.1–13.8)	0.0087
3-10K	237	117	46.9 (38.5–55.4)	106	46.9 (38.6–55.4)	12	5.8 (2.8–11.5)	2	0.5 (0.1–2.8)	
10-20K	94	54	60.6 (47.5–72.2)	32	30.1 (19.7–43.0)	7	9.2 (3.9–20.4)	1	0.2 (0.0–1.2)	
≥20K	34	23	57.9 (36.5–76.7)	9	33.4 (16.8–55.6)	1	3.2 (0.4–21.1)	1	5.4 (0.7–31.5)	
Ever incarcerated										
no	330	180	53.8 (46.8–60.8)	127	38.8 (32.1–45.9)	21	7.0 (4.2–11.5)	2	0.4 (0.1–2.3)	0.0038
yes	170	81	41.1 (32.1–50.7)	66	42.2 (32.9–52.1)	16	11.5 (6.5–19.5)	7	5.1 (2.2–11.5)	

Table 12.9. Anxiety symptoms severity (GAD-7) by Selected Subgroups

	N	GAD-7 anxiety result								
		minimal		mild		moderate		severe		
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
Client of NGO working with PWID										

		GAD-7 anxiety result							
	N	minimal		mild		moderate		severe	
		n	% (CI)	n	% (CI)	n	% (CI)	n	% (CI)	p-value
no	294	145	48.0 (41.3–54.8)	126	43.6 (36.9–50.4)	18	7.0 (4.3–11.2)	5	1.5 (0.6–3.8)	0.0637
yes	205	115	57.3 (46.6–67.4)	67	28.2 (20.0–38.1)	19	12.1 (6.5–21.5)	4	2.4 (0.7–8.2)	
Treated with MAT currently (of all)										
no	294	149	49.8 (43.6–56.0)	114	40.0 (34.1–46.3)	25	8.4 (5.6–12.5)	6	1.8 (0.8–3.9)	0.6311
yes	205	111	55.1 (47.6–62.3)	79	37.4 (30.6–44.7)	12	6.3 (3.4–11.3)	3	1.2 (0.4–3.9)	
HIV test result										
positive	118	60	50.3 (37.1–63.4)	48	40.4 (28.3–53.8)	8	6.3 (2.3–16.0)	2	3.1 (0.8–11.8)	0.7556
negative	382	201	50.3 (44.0–56.7)	145	39.6 (33.4–46.0)	29	8.7 (5.7–13.0)	7	1.4 (0.6–3.4)	
Past 30 days injecting 4 categories										
opioids	388	209	51.8 (45.0–58.6)	145	38.0 (31.5–44.9)	25	7.6 (4.5–12.4)	9	2.6 (1.2–5.5)	0.0558
stimulants	90	45	49.5 (37.8–61.2)	37	42.7 (31.7–54.6)	8	7.8 (3.8–15.4)	0	0.0	
opi+stimul	21	7	36.5 (16.1–63.3)	11	48.7 (24.9–73.1)	3	14.9 (4.3–40.2)	0	0.0	
other	1	0	0.0	0	0.0	1	100.0	0	0.0	
Injecting drug type of choice										
opioids	403	210	49.6 (43.1–56.2)	157	39.8 (33.4–46.6)	27	8.1 (5.0–12.8)	9	2.5 (1.2–5.3)	
stimulants	95	50	51.9 (40.5–63.1)	35	39.3 (28.8–50.9)	10	8.8 (4.6–16.2)	0	0.0	
other	0	0		0		0		0		

13. Detention and Incarceration

Table 13.1. Police Detention and Incarceration Experience

	n	%	CI
Detained by police in 2022 for			
drug use	5	1.1	(0.5–2.7)
drug dealing	2	0.4	(0.1–1.6)
drug storing	11	2.0	(0.9–4.0)
Detained by police in 2023 for			
drug use	8	1.3	(0.6–3.0)
drug dealing	5	0.5	(0.2–1.7)
drug storing	9	1.3	(0.5–3.1)
Stopped, detained, or arrested by police ever			
yes	233	42.3	(36.9–48.0)
Ever incarcerated			
yes	170	27.7	(23.1–32.7)
Duration of incarceration			
≤6m	16	13.2	(7.7–21.9)
6m-2y	29	13.8	(8.3–22.0)
2-4y	76	45.3	(36.0–54.9)
4y+	49	27.7	(20.0–37.1)

	n	%	CI
Time since last incarceration			
≤1y	18	12.2	(7.2–20.0)
1-3y	27	17.7	(11.0–27.1)
3-5y	21	13.2	(8.0–21.0)
5-10y	43	19.0	(12.9–27.1)
10y+	61	37.9	(29.1–47.7)
Used injecting drugs during incarceration			
yes	84	45.4	(36.0–55.1)



Figure 13.1. Incarceration Lifetime Experience (%)

14. Negative experience

Table 14.1. Negative experience

	n	%	CI
Felt excluded from family activities due to drug use			
no	318	64.1	(58.4–69.4)
yes, in the past 6m	34	7.7	(4.8–12.2)
yes, but 6m+ ago	147	28.2	(23.6–33.4)
Was scolded because of drug use			
no	291	58.3	(52.5–63.8)
yes, in the past 6m	49	11.7	(8.2–16.5)
yes, but 6m+ ago	159	30.0	(25.2–35.3)
Was blackmailed for drug use			
no	428	86.4	(82.0–89.8)
yes, in the past 6m	26	5.4	(3.3–8.8)
yes, but 6m+ ago	44	8.2	(5.6–11.7)
Negative experience in the past 6 months (GAM 6.5)			
no	433	86.6	(81.7–90.3)
yes	64	13.4	(9.7–18.3)
Ever experienced physical violence			
no	315	64.2	(58.6–69.3)
yes	185	35.8	(30.7–41.4)
Experienced physical violence in the past 12 months (of those who had ever)			
no	156	76.8	(67.8–83.8)

		n	%	CI
	yes	29	23.2	(16.2–32.2)
Witnessed physical violence in the past 12 months				
	no	438	87.2	(83.1–90.5)
	yes	61	12.8	(9.5–16.9)



Figure 14.1. Negative Experience Related to Drug Use in the past 6 Months or Physical Violence in the past 12 months (%)

Table 14.2. Negative Experience Related to Drug Use by Sociodemographic Characteristics

		Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
		N	n	% (CI)	p-value	N	n	% (CI)	p-value
Total									
	All	497	64	13.4 (9.7–18.3)	1.0000	185	29	23.2 (16.2–32.2)	1.0000
Sex									
	male	395	53	13.5 (9.6–18.7)	0.9610	146	17	20.5 (13.0–30.8)	0.2735
	female	102	11	13.2 (5.5–28.4)		39	12	30.8 (16.3–50.5)	
Age									
	<25	9	2	2.3 (0.3–14.6)	0.1216	2	2	100.0	0.1117
	25-34	92	19	19.5 (11.4–31.2)		29	5	16.7 (6.4–36.9)	
	35-44	245	32	14.6 (9.0–22.9)		101	12	19.3 (10.7–32.3)	
	45+	151	11	8.3 (3.8–17.1)		53	10	31.4 (17.5–49.6)	
Years since the start of injecting drug use									
	≤2	28	7	19.5 (7.1–43.5)	0.7101	10	4	32.3 (9.7–68.0)	0.5896
	3-5	17	2	6.7 (0.9–35.5)		5	2	40.2 (8.1–83.8)	
	6-10	38	6	12.3 (4.0–31.8)		9	1	11.2 (1.4–52.5)	

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
≥11	414	49	13.4 (9.2–19.1)		161	22	22.2 (14.6–32.3)	
Partnership status								
live alone	201	16	10.1 (5.5–17.8)	0.2269	91	13	25.3 (14.6–40.3)	0.6734
live with partner	296	48	15.4 (10.4–22.2)		94	16	21.8 (13.3–33.7)	
Current employment status								
full-time	151	15	7.7 (3.8–15.1)	0.2590	53	4	14.9 (5.7–33.8)	0.0538
part-time or temporary	223	35	14.6 (9.7–21.4)		72	18	32.2 (20.7–46.3)	
unemployed	68	9	22.4 (9.3–44.6)		37	2	13.1 (3.3–39.9)	
disabled	38	2	8.0 (1.7–30.4)		15	0	0.0	
other	17	3	11.6 (2.1–45.1)		8	5	57.2 (17.0–89.7)	
Monthly income category								
<3K	96	15	21.3 (10.8–37.5)	0.0437	35	5	23.4 (9.9–45.7)	0.0859
3-10K	235	43	15.6 (10.5–22.5)		67	17	34.6 (22.0–49.8)	
10-20K	94	4	3.5 (1.0–11.4)		41	5	13.8 (5.3–31.5)	
≥20K	34	1	5.4 (0.7–31.5)		23	1	7.3 (0.9–39.4)	
Ever incarcerated								
no	329	53	15.2 (10.4–21.5)	0.1399	110	24	29.8 (20.3–41.4)	0.0096
yes	168	11	8.8 (4.5–16.5)		75	5	8.7 (3.1–22.2)	

Table 14.3. Negative Experience Related to Drug Use by Selected Subgroups

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Client of NGO working with PWID								
no	291	51	17.0 (12.2–23.4)	0.0000	81	21	30.1 (20.4–41.9)	0.0224
yes	205	13	2.7 (1.3–5.4)		104	8	10.6 (4.1–25.0)	
Treated with MAT currently (of all)								
no	291	35	13.3 (9.3–18.7)	0.6847	109	24	24.7 (17.1–34.4)	0.0036
yes	205	29	14.9 (10.0–21.6)		75	5	7.3 (3.0–16.6)	
HIV test result								
positive	117	8	6.0 (1.8–18.2)	0.1066	37	2	1.9 (0.4–7.8)	0.0000
negative	380	56	15.1 (10.8–20.8)		148	27	26.0 (18.1–35.8)	

	Negative experience in the past 6 months (GAM 6.5)				Experienced physical violence in the past 12 months (of those who had ever)			
	N	n	% (CI)	p-value	N	n	% (CI)	p-value
Past 30 days injecting 4 categories								
opioids	386	43	10.2 (6.2–16.3)		149	22	23.4 (15.2–34.1)	
stimulants	90	17	18.4 (11.1–28.9)		25	5	21.3 (8.9–42.8)	
opi+stimul	21	4	28.3 (10.5–57.0)		11	2	27.3 (6.3–68.0)	
other	0	0	0.0		0	0	0.0	
Injecting drug type of choice								
opioids	400	45	10.6 (6.7–16.6)		157	24	24.2 (16.1–34.6)	
stimulants	95	18	19.0 (11.7–29.4)		27	5	20.4 (8.6–41.3)	
other	0	0			0	0		

15. The Impact of the Full-scale War

Table 15.1. Migration Since February 2022

	n	%	CI
Changed place of residence since Feb 2022			
yes, because of the war	88	16.1	(12.5–20.6)
yes, for other reasons	1	0.2	(0.0–1.3)
no	411	83.7	(79.2–87.3)
Where migrated since Feb 2022			
unknown	0	0.0	
other country	7	15.0	(7.1–29.2)
other oblast	31	30.7	(19.9–44.2)
other city	39	40.0	(28.0–53.3)
other district	10	13.9	(6.6–26.9)
other house	1	0.3	(0.0–2.3)
Where lived before Feb 2022 (if changed residence)			
same oblast	83	90.4	(74.6–96.8)
other oblast	4	4.3	(0.8–20.3)
other country	2	5.3	(1.2–20.5)



Figure 15.1. Change of Residence Since February 2022 (%)



Figure 15.2. Migration Destination by Survey Site (%)



Figure 15.3. Residence Before February 2022 (%)



Figure 15.4. Changes Since February 2022 (%)